"Abacavir TRIANGLE Analgesics:abacavirpossiblyreducesplasmaconcentrationofMETHADONE TRIANGLE Antibacterials:plasmaconcentrationofabacavirpossiblyreducedbyRIFAMPICIN TRIANGLE Antiepileptics:plasmaconcentrationofabacavirpossiblyreducedbyFOSPHENYTOIN,PHENOBARBITAL,PHENYTOINandPRIMIDONElAntivirals:abacavirpossiblyreduceseffectsoflRIBAVIRIN;plasmaconcentrationofabacavirreducedbylTIPRANAVIRlOrlistat:absorptionofabacavirpossiblyreducedbylORLISTATAbataceptlCytotoxics:increasedriskofside-effectswhenabataceptgivenwithADALIMUMAB;avoidconcomitantuseofabataceptwithlCERTOLIZUMABPEGOL,lGOLIMUMABorlINFLIXIMABlEtanercept:avoidconcomitantuseofabataceptwithlETANERCEPTlVaccines:riskofgeneralisedinfectionswhenabataceptgivenwithlivelVACCINES—avoidconcomitantuseAbiraterone TRIANGLE Analgesics:abirateroneincreasesplasmaconcentrationofDEXTROMETHORPHANlAntibacterials:plasmaconcentrationofabirateronepossiblyreducedbylRIFABUTIN—manufacturerofabirateroneadvisesavoidconcomitantuse;plasmaconcentrationofabirateronereducedbylRIFAMPICIN—manufacturerofabirateroneadvisesavoidconcomitantuselAntidepressants:plasmaconcentrationofabirateronepossiblyreducedbylSTJOHN’SWORT—manufacturerofabirateroneadvisesavoidconcomitantuselAntiepileptics:plasmaconcentrationofabirateronepossiblyreducedbylCARBAMAZEPINE,lFOSPHENYTOIN,lPHENOBARBITAL,lPHENYTOINandlPRIMIDONE—manufacturerofabirateroneadvisesavoidconcomitantuseAcarboseseeAntidiabeticsACEInhibitors TRIANGLE Alcohol:enhancedhypotensiveeffectwhenACEinhibitorsgivenwithALCOHOL TRIANGLE Aldesleukin:enhancedhypotensiveeffectwhenACEinhibitorsgivenwithALDESLEUKINlAliskiren:increasedriskofhyperkalaemia,hypotension,andimpairedrenalfunctionwhenACEinhibitorsgivenwithlALISKIREN—avoidconcomitantuse TRIANGLE Allopurinol:manufacturersstatepossibleincreasedriskofleucopeniaandhypersensitivityreactionswhenACEinhibitorsgivenwithALLOPURINOLespeciallyinrenalimpairment TRIANGLE Alpha-blockers:enhancedhypotensiveeffectwhenACEinhibitorsgivenwithALPHA-BLOCKERS TRIANGLE Anaesthetics,General:enhancedhypotensiveeffectwhenACEinhibitorsgivenwithGENERALANAESTHETICS TRIANGLE Analgesics:increasedriskofrenalimpairmentwhenACEinhibitorsgivenwithNSAIDS,alsohypotensiveeffectantagonisedlAngiotensin-IIReceptorAntagonists:increasedriskofhyperkalaemia,hypotension,andimpairedrenalfunctionwhenACEinhibitorsgivenwithlANGIOTENSIN-IIRECEPTORANTAGONISTS—avoidconcomitantuse TRIANGLE Antacids:absorptionofACEinhibitorspossiblyreducedbyANTACIDS;absorptionofcaptopril,enalaprilandfosinoprilreducedbyANTACIDS TRIANGLE Antibacterials:plasmaconcentrationofactivemetaboliteofimidaprilreducedbyRIFAMPICIN(reducedantihypertensiveeffect);quinapriltabletsreduceabsorptionofTETRACYCLINES(quinapriltabletscontainmagnesiumcarbonate);possibleincreasedriskofhyperkalaemiawhenACEinhibitorsgivenwithTRIMETHOPRIM TRIANGLE Anticoagulants:increasedriskofhyperkalaemiawhenACEinhibitorsgivenwithHEPARINSACEInhibitors(continued) TRIANGLE Antidepressants:hypotensiveeffectofACEinhibitorspossiblyenhancedbyMAOIS TRIANGLE Antidiabetics:ACEinhibitorspossiblyenhancehypoglycaemiceffectofINSULIN,METFORMINandSULFONYLUREAS TRIANGLE Antipsychotics:enhancedhypotensiveeffectwhenACEinhibitorsgivenwithANTIPSYCHOTICS TRIANGLE AnxiolyticsandHypnotics:enhancedhypotensiveeffectwhenACEinhibitorsgivenwithANXIOLYTICSANDHYPNOTICS TRIANGLE Avanafil:hypotensiveeffectofenalaprilpossiblyenhancedbyAVANAFIL TRIANGLE Azathioprine:increasedriskofanaemiaorleucopeniawhencaptoprilgivenwithAZATHIOPRINEespeciallyinrenalimpairment;increasedriskofanaemiawhenenalaprilgivenwithAZATHIOPRINEespeciallyinrenalimpairmentlBeeVenomExtracts:possiblesevereanaphylactoidreactionwhenACEinhibitorsgivenwithlBEEVENOMEXTRACTS TRIANGLE Beta-blockers:enhancedhypotensiveeffectwhenACEinhibitorsgivenwithBETA-BLOCKERS TRIANGLE Calcium-channelBlockers:enhancedhypotensiveeffectwhenACEinhibitorsgivenwithCALCIUM-CHANNELBLOCKERS TRIANGLE CardiacGlycosides:captoprilpossiblyincreasesplasmaconcentrationofDIGOXINlCiclosporin:increasedriskofhyperkalaemiawhenACEinhibitorsgivenwithlCICLOSPORIN TRIANGLE Clonidine:enhancedhypotensiveeffectwhenACEinhibitorsgivenwithCLONIDINE;antihypertensiveeffectofcaptoprilpossiblydelayedbyprevioustreatmentwithCLONIDINE TRIANGLE Corticosteroids:hypotensiveeffectofACEinhibitorsantagonisedbyCORTICOSTEROIDSlCytotoxics:increasedriskofangioedemawhenACEinhibitorsgivenwithlEVEROLIMUS TRIANGLE Diazoxide:enhancedhypotensiveeffectwhenACEinhibitorsgivenwithDIAZOXIDElDiuretics:enhancedhypotensiveeffectwhenACEinhibitorsgivenwithlDIURETICS;increasedriskofseverehyperkalaemiawhenACEinhibitorsgivenwithlPOTASSIUM-SPARINGDIURETICSANDALDOSTERONEANTAGONISTS TRIANGLE Dopaminergics:enhancedhypotensiveeffectwhenACEinhibitorsgivenwithCO-BENELDOPA,CO-CARELDOPAorLEVODOPAlLithium:ACEinhibitorsreduceexcretionoflLITHIUM(increasedplasmaconcentration) TRIANGLE Methyldopa:enhancedhypotensiveeffectwhenACEinhibitorsgivenwithMETHYLDOPA TRIANGLE Moxisylyte:enhancedhypotensiveeffectwhenACEinhibitorsgivenwithMOXISYLYTE TRIANGLE Moxonidine:enhancedhypotensiveeffectwhenACEinhibitorsgivenwithMOXONIDINE TRIANGLE MuscleRelaxants:enhancedhypotensiveeffectwhenACEinhibitorsgivenwithBACLOFENorTIZANIDINE TRIANGLE Nitrates:enhancedhypotensiveeffectwhenACEinhibitorsgivenwithNITRATES TRIANGLE Oestrogens:hypotensiveeffectofACEinhibitorsantagonisedbyOESTROGENSlPotassiumSalts:increasedriskofseverehyperkalaemiawhenACEinhibitorsgivenwithlPOTASSIUMSALTS TRIANGLE Prostaglandins:enhancedhypotensiveeffectwhenACEinhibitorsgivenwithALPROSTADILlSodiumAurothiomalate:flushingandhypotensionreportedwhenACEinhibitorsgivenwithlSODIUMAUROTHIOMALATE TRIANGLE VasodilatorAntihypertensives:enhancedhypotensiveeffectwhenACEinhibitorsgivenwithHYDRALAZINE,MINOXIDILorSODIUMNITROPRUSSIDElWaspVenomExtracts:possiblesevereanaphylactoidreactionwhenACEinhibitorsgivenwithlWASPVENOMEXTRACTSAcebutololseeBeta-blockersAceclofenacseeNSAIDsAcemetacinseeNSAIDsAcenocoumarolseeCoumarinsAcetazolamideseeDiureticsAciclovirNOTEInteractionsdonotapplytotopicalaciclovirpreparations TRIANGLE Aminophylline:aciclovirpossiblyincreasesplasmaconcentrationofAMINOPHYLLINE1138Appendix1InteractionsBNF70Interactions|Appendix1"
"Aciclovir(continued) TRIANGLE Ciclosporin:increasedriskofnephrotoxicitywhenaciclovirgivenwithCICLOSPORIN TRIANGLE Mycophenolate:plasmaconcentrationofaciclovirincreasedbyMYCOPHENOLATE,alsoplasmaconcentrationofinactivemetaboliteofmycophenolateincreased TRIANGLE Tacrolimus:possibleincreasedriskofnephrotoxicitywhenaciclovirgivenwithTACROLIMUS TRIANGLE Theophylline:aciclovirpossiblyincreasesplasmaconcentrationofTHEOPHYLLINEAcitretinseeRetinoidsAclidiniumseeAntimuscarinicsAcrivastineseeAntihistaminesAdalimumab TRIANGLE Abatacept:increasedriskofside-effectswhenadalimumabgivenwithABATACEPTlAnakinra:avoidconcomitantuseofadalimumabwithlANAKINRAlAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lVaccines:riskofgeneralisedinfectionswhenmonoclonalantibodiesgivenwithlivelVACCINES—avoidconcomitantuseAdefovir TRIANGLE Antivirals:avoidanceofadefoviradvisedbymanufacturerofTENOFOVIR TRIANGLE Interferons:manufacturerofadefoviradvisescautionwithPEGINTERFERONALFAAdenosineNOTEPossibilityofinteractionwithdrugstendingtoimpairmyocardialconduction TRIANGLE Aminophylline:anti-arrhythmiceffectofadenosineantagonisedbyAMINOPHYLLINE—manufacturerofadenosineadvisesavoidaminophyllinefor24hoursbeforeadenosine TRIANGLE Anaesthetics,Local:increasedmyocardialdepressionwhenanti-arrhythmicsgivenwithBUPIVACAINE,LEVOBUPIVACAINE,PRILOCAINEorROPIVACAINElAnti-arrhythmics:increasedmyocardialdepressionwhenanti-arrhythmicsgivenwithotherlANTI-ARRHYTHMICSlAntipsychotics:increasedriskofventriculararrhythmiaswhenanti-arrhythmicsthatprolongtheQTintervalgivenwithlANTIPSYCHOTICSthatprolongtheQTintervallBeta-blockers:increasedmyocardialdepressionwhenanti-arrhythmicsgivenwithlBETA-BLOCKERS TRIANGLE Caffeinecitrate:anti-arrhythmiceffectofadenosineantagonisedbyCAFFEINECITRATE—manufacturerofadenosineadvisesavoidcaffeinecitrateforatleast12hoursbeforeadenosinelDipyridamole:effectofadenosineenhancedandextendedbylDIPYRIDAMOLE(importantriskoftoxicity)—reducedoseofadenosine,seep87 TRIANGLE Nicotine:effectsofadenosinepossiblyenhancedbyNICOTINE TRIANGLE Theophylline:anti-arrhythmiceffectofadenosineantagonisedbyTHEOPHYLLINE—manufacturerofadenosineadvisesavoidtheophyllinefor24hoursbeforeadenosineAdrenaline(epinephrine)seeSympathomimeticsAdrenergicNeuroneBlockers TRIANGLE Alcohol:enhancedhypotensiveeffectwhenadrenergicneuroneblockersgivenwithALCOHOL TRIANGLE Alpha-blockers:enhancedhypotensiveeffectwhenadrenergicneuroneblockersgivenwithALPHA-BLOCKERSlAnaesthetics,General:enhancedhypotensiveeffectwhenadrenergicneuroneblockersgivenwithlGENERALANAESTHETICS TRIANGLE Analgesics:hypotensiveeffectofadrenergicneuroneblockersantagonisedbyNSAIDS TRIANGLE Angiotensin-IIReceptorAntagonists:enhancedhypotensiveeffectwhenadrenergicneuroneblockersgivenwithANGIOTENSIN-IIRECEPTORANTAGONISTS TRIANGLE Antidepressants:enhancedhypotensiveeffectwhenadrenergicneuroneblockersgivenwithMAOIS;hypotensiveeffectofadrenergicneuroneblockersantagonisedbyTRICYCLICS TRIANGLE Antipsychotics:hypotensiveeffectofadrenergicneuroneblockersantagonisedbyHALOPERIDOL;hypotensiveeffectofadrenergicneuroneblockersantagonisedbyhigherdosesofAdrenergicNeuroneBlockersAntipsychotics(continued)CHLORPROMAZINE;enhancedhypotensiveeffectwhenadrenergicneuroneblockersgivenwithPHENOTHIAZINES TRIANGLE AnxiolyticsandHypnotics:enhancedhypotensiveeffectwhenadrenergicneuroneblockersgivenwithANXIOLYTICSANDHYPNOTICS TRIANGLE Beta-blockers:enhancedhypotensiveeffectwhenadrenergicneuroneblockersgivenwithBETA-BLOCKERS TRIANGLE Calcium-channelBlockers:enhancedhypotensiveeffectwhenadrenergicneuroneblockersgivenwithCALCIUM-CHANNELBLOCKERS TRIANGLE Clonidine:enhancedhypotensiveeffectwhenadrenergicneuroneblockersgivenwithCLONIDINE TRIANGLE Corticosteroids:hypotensiveeffectofadrenergicneuroneblockersantagonisedbyCORTICOSTEROIDS TRIANGLE Diazoxide:enhancedhypotensiveeffectwhenadrenergicneuroneblockersgivenwithDIAZOXIDE TRIANGLE Diuretics:enhancedhypotensiveeffectwhenadrenergicneuroneblockersgivenwithDIURETICS TRIANGLE Dopaminergics:enhancedhypotensiveeffectwhenadrenergicneuroneblockersgivenwithCO-BENELDOPA,CO-CARELDOPAorLEVODOPA TRIANGLE Methyldopa:enhancedhypotensiveeffectwhenadrenergicneuroneblockersgivenwithMETHYLDOPA TRIANGLE Moxisylyte:enhancedhypotensiveeffectwhenadrenergicneuroneblockersgivenwithMOXISYLYTE TRIANGLE Moxonidine:enhancedhypotensiveeffectwhenadrenergicneuroneblockersgivenwithMOXONIDINE TRIANGLE MuscleRelaxants:enhancedhypotensiveeffectwhenadrenergicneuroneblockersgivenwithBACLOFENorTIZANIDINE TRIANGLE Nitrates:enhancedhypotensiveeffectwhenadrenergicneuroneblockersgivenwithNITRATES TRIANGLE Oestrogens:hypotensiveeffectofadrenergicneuroneblockersantagonisedbyOESTROGENS TRIANGLE Pizotifen:hypotensiveeffectofadrenergicneuroneblockersantagonisedbyPIZOTIFEN TRIANGLE Prostaglandins:enhancedhypotensiveeffectwhenadrenergicneuroneblockersgivenwithALPROSTADILlSympathomimetics:increasedriskofhypertensionwhenguanethidinegivenwithlADRENALINE(EPINEPHRINE);hypotensiveeffectofguanethidineantagonisedbylDEXAMFETAMINEandlLISDEXAMFETAMINE;hypotensiveeffectofadrenergicneuroneblockersantagonisedbylEPHEDRINE,lISOMETHEPTENE,lMETARAMINOL,lMETHYLPHENIDATE,lNORADRENALINE(NOREPINEPHRINE),lOXYMETAZOLINE,lPHENYLEPHRINE,lPSEUDOEPHEDRINEandlXYLOMETAZOLINE TRIANGLE VasodilatorAntihypertensives:enhancedhypotensiveeffectwhenadrenergicneuroneblockersgivenwithHYDRALAZINE,MINOXIDILorSODIUMNITROPRUSSIDEAdsorbentsseeKaolinAfatinib TRIANGLE Anti-arrhythmics:plasmaconcentrationofafatinibpossiblyincreasedbyAMIODARONE—manufacturerofafatinibadvisesseparatingadministrationofamiodaroneby6to12hours TRIANGLE Antibacterials:plasmaconcentrationofafatinibpossiblyincreasedbyERYTHROMYCIN—manufacturerofafatinibadvisesseparatingadministrationoferythromycinby6to12hours;plasmaconcentrationofafatinibreducedbyRIFAMPICIN TRIANGLE Antifungals:plasmaconcentrationofafatinibpossiblyincreasedbyITRACONAZOLEandKETOCONAZOLE—manufacturerofafatinibadvisesseparatingadministrationofitraconazoleandketoconazoleby6to12hourslAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis) TRIANGLE Antivirals:plasmaconcentrationofafatinibincreasedbyRITONAVIR—manufacturerofafatinibadvisesseparatingadministrationofritonavirby6to12hours;plasmaconcentrationofafatinibpossiblyincreasedbySAQUINAVIR—manufacturerofafatinibadvisesseparatingadministrationofsaquinavirby6to12hours TRIANGLE Calcium-channelBlockers:plasmaconcentrationofafatinibpossiblyincreasedbyVERAPAMIL—manufacturerofafatinibadvisesseparatingadministrationofverapamilby6to12hoursBNF70Appendix1Interactions1139Interactions|Appendix1"
"Afatinib(continued) TRIANGLE Ciclosporin:plasmaconcentrationofafatinibpossiblyincreasedbyCICLOSPORIN—manufacturerofafatinibadvisesseparatingadministrationofciclosporinby6to12hours TRIANGLE Tacrolimus:plasmaconcentrationofafatinibpossiblyincreasedbyTACROLIMUS—manufacturerofafatinibadvisesseparatingadministrationoftacrolimusby6to12hoursAgalsidaseAlfaandBeta TRIANGLE Anti-arrhythmics:effectsofagalsidasealfaandbetapossiblyinhibitedbyAMIODARONE(manufacturersofagalsidasealfaandbetaadviseavoidconcomitantuse) TRIANGLE Antibacterials:effectsofagalsidasealfaandbetapossiblyinhibitedbyGENTAMICIN(manufacturersofagalsidasealfaandbetaadviseavoidconcomitantuse) TRIANGLE Antimalarials:effectsofagalsidasealfaandbetapossiblyinhibitedbyCHLOROQUINEandHYDROXYCHLOROQUINE(manufacturersofagalsidasealfaandbetaadviseavoidconcomitantuse)AgomelatinelAntibacterials:manufacturerofagomelatineadvisesavoidconcomitantusewithlCIPROFLOXACINlAntidepressants:metabolismofagomelatineinhibitedbylFLUVOXAMINE(increasedplasmaconcentration)lAntimalarials:avoidanceofantidepressantsadvisedbymanufactureroflARTEMETHERWITHLUMEFANTRINEandlARTENIMOLWITHPIPERAQUINE TRIANGLE Atomoxetine:possibleincreasedriskofconvulsionswhenantidepressantsgivenwithATOMOXETINEAlbendazole TRIANGLE Anthelmintics:plasmaconcentrationofbothdrugspossiblyreducedwhenalbendazolegivenwithLEVAMISOLElAntiepileptics:plasmaconcentrationofalbendazolereducedbylCARBAMAZEPINE,lFOSPHENYTOIN,lPHENOBARBITAL,lPHENYTOINandlPRIMIDONE—considerincreasingalbendazoledosewhengivenforsystemicinfectionslAntivirals:plasmaconcentrationofactivemetaboliteofalbendazolereducedbylRITONAVIR—considerincreasingalbendazoledosewhengivenforsystemicinfections TRIANGLE Corticosteroids:plasmaconcentrationofactivemetaboliteofalbendazoleincreasedbyDEXAMETHASONE TRIANGLE GrapefruitJuice:plasmaconcentrationofactivemetaboliteofalbendazoleincreasedbyGRAPEFRUITJUICE TRIANGLE Ulcer-healingDrugs:effectsofalbendazolepossiblyenhancedbyCIMETIDINEAlcohol TRIANGLE ACEInhibitors:enhancedhypotensiveeffectwhenalcoholgivenwithACEINHIBITORS TRIANGLE AdrenergicNeuroneBlockers:enhancedhypotensiveeffectwhenalcoholgivenwithADRENERGICNEURONEBLOCKERS TRIANGLE Alpha-blockers:increasedsedativeeffectwhenalcoholgivenwithINDORAMIN;enhancedhypotensiveeffectwhenalcoholgivenwithALPHA-BLOCKERS TRIANGLE Analgesics:enhancedhypotensiveandsedativeeffectswhenalcoholgivenwithOPIOIDANALGESICS TRIANGLE Angiotensin-IIReceptorAntagonists:enhancedhypotensiveeffectwhenalcoholgivenwithANGIOTENSIN-IIRECEPTORANTAGONISTS TRIANGLE Anthelmintics:possibilityofdisulfiram-likereactionwhenalcoholgivenwithLEVAMISOLElAntibacterials:disulfiram-likereactionwhenalcoholgivenwithMETRONIDAZOLE;possibilityofdisulfiram-likereactionwhenalcoholgivenwithTINIDAZOLE;increasedriskofconvulsionswhenalcoholgivenwithlCYCLOSERINElAnticoagulants:majorchangesinconsumptionofalcoholmayaffectanticoagulantcontrolwithlCOUMARINSorlPHENINDIONElAntidepressants:somebeveragescontainingalcoholandsomedealcoholisedbeveragescontaintyraminewhichinteractswithlMAOIS(hypertensivecrisis)—ifnotyramine,enhancedhypotensiveeffect;sedativeeffectspossiblyincreasedwhenalcoholgivenwithSSRIS;increasedsedativeeffectwhenalcoholgivenwithlMIRTAZAPINE,lTRICYCLIC-RELATEDANTIDEPRESSANTSorlTRICYCLICS TRIANGLE Antidiabetics:alcoholenhanceshypoglycaemiceffectofANTIDIABETICS;increasedriskoflacticacidosiswhenalcoholgivenwithMETFORMINAlcohol(continued) TRIANGLE Antiepileptics:alcoholpossiblyincreasesCNSside-effectsofCARBAMAZEPINE;chronicheavyconsumptionofalcoholpossiblyreducesplasmaconcentrationofFOSPHENYTOINandPHENYTOIN;increasedsedativeeffectwhenalcoholgivenwithPHENOBARBITALorPRIMIDONE;increasedriskofblurredvisionwhenalcoholgivenwithRETIGABINE TRIANGLE Antifungals:possibilityofdisulfiram-likereactionwhenalcoholgivenwithKETOCONAZOLE;effectsofalcoholpossiblyenhancedbyGRISEOFULVIN TRIANGLE Antihistamines:increasedsedativeeffectwhenalcoholgivenwithANTIHISTAMINES(possiblylesseffectwithnon-sedatingantihistamines) TRIANGLE Antimuscarinics:increasedsedativeeffectwhenalcoholgivenwithHYOSCINE TRIANGLE Antipsychotics:increasedsedativeeffectwhenalcoholgivenwithANTIPSYCHOTICS TRIANGLE AnxiolyticsandHypnotics:increasedsedativeeffectwhenalcoholgivenwithANXIOLYTICSANDHYPNOTICS TRIANGLE Avanafil:possibleenhancedhypotensiveeffectwhenalcoholgivenwithAVANAFIL TRIANGLE Beta-blockers:enhancedhypotensiveeffectwhenalcoholgivenwithBETA-BLOCKERS TRIANGLE Calcium-channelBlockers:enhancedhypotensiveeffectwhenalcoholgivenwithCALCIUM-CHANNELBLOCKERS;plasmaconcentrationofalcoholpossiblyincreasedbyVERAPAMIL TRIANGLE Clonidine:enhancedhypotensiveeffectwhenalcoholgivenwithCLONIDINElCytotoxics:disulfiram-likereactionwhenalcoholgivenwithPROCARBAZINE;avoidanceofalcoholadvisedbymanufactureroflTRABECTEDINlDapoxetine:increasedsedativeeffectwhenalcoholgivenwithlDAPOXETINE TRIANGLE Diazoxide:enhancedhypotensiveeffectwhenalcoholgivenwithDIAZOXIDE TRIANGLE Disulfiram:disulfiramreactionwhenalcoholgivenwithDISULFIRAM TRIANGLE Diuretics:enhancedhypotensiveeffectwhenalcoholgivenwithDIURETICS TRIANGLE Dopaminergics:alcoholreducestolerancetoBROMOCRIPTINE TRIANGLE Lipid-regulatingDrugs:avoidanceofalcoholadvisedbymanufacturerofLOMITAPIDE TRIANGLE Lofexidine:increasedsedativeeffectwhenalcoholgivenwithLOFEXIDINE TRIANGLE Methyldopa:enhancedhypotensiveeffectwhenalcoholgivenwithMETHYLDOPA TRIANGLE Metoclopramide:absorptionofalcoholpossiblyincreasedbyMETOCLOPRAMIDE TRIANGLE Moxonidine:enhancedhypotensiveeffectwhenalcoholgivenwithMOXONIDINE TRIANGLE MuscleRelaxants:increasedsedativeeffectwhenalcoholgivenwithBACLOFEN,METHOCARBAMOLorTIZANIDINE TRIANGLE Nicorandil:alcoholpossiblyenhanceshypotensiveeffectofNICORANDIL TRIANGLE Nitrates:enhancedhypotensiveeffectwhenalcoholgivenwithNITRATESlParaldehyde:increasedsedativeeffectwhenalcoholgivenwithlPARALDEHYDElRetinoids:presenceofalcoholcausesetretinatetobeformedfromlACITRETIN(increasedriskofteratogenicityinwomenofchild-bearingpotential) TRIANGLE Sympathomimetics:alcoholpossiblyenhanceseffectsofMETHYLPHENIDATE TRIANGLE VasodilatorAntihypertensives:enhancedhypotensiveeffectwhenalcoholgivenwithHYDRALAZINE,MINOXIDILorSODIUMNITROPRUSSIDEAldesleukin TRIANGLE ACEInhibitors:enhancedhypotensiveeffectwhenaldesleukingivenwithACEINHIBITORS TRIANGLE Alpha-blockers:enhancedhypotensiveeffectwhenaldesleukingivenwithALPHA-BLOCKERS TRIANGLE Angiotensin-IIReceptorAntagonists:enhancedhypotensiveeffectwhenaldesleukingivenwithANGIOTENSIN-IIRECEPTORANTAGONISTS TRIANGLE Antivirals:aldesleukinpossiblyincreasesplasmaconcentrationofINDINAVIR1140Appendix1InteractionsBNF70Interactions|Appendix1"
"Aldesleukin(continued) TRIANGLE Beta-blockers:enhancedhypotensiveeffectwhenaldesleukingivenwithBETA-BLOCKERS TRIANGLE Calcium-channelBlockers:enhancedhypotensiveeffectwhenaldesleukingivenwithCALCIUM-CHANNELBLOCKERS TRIANGLE Clonidine:enhancedhypotensiveeffectwhenaldesleukingivenwithCLONIDINElCorticosteroids:manufacturerofaldesleukinadvisesavoidconcomitantusewithlCORTICOSTEROIDSlCytotoxics:manufacturerofaldesleukinadvisesavoidconcomitantusewithlCISPLATIN,lDACARBAZINEandlVINBLASTINE TRIANGLE Diazoxide:enhancedhypotensiveeffectwhenaldesleukingivenwithDIAZOXIDE TRIANGLE Diuretics:enhancedhypotensiveeffectwhenaldesleukingivenwithDIURETICS TRIANGLE Methyldopa:enhancedhypotensiveeffectwhenaldesleukingivenwithMETHYLDOPA TRIANGLE Moxonidine:enhancedhypotensiveeffectwhenaldesleukingivenwithMOXONIDINE TRIANGLE Nitrates:enhancedhypotensiveeffectwhenaldesleukingivenwithNITRATES TRIANGLE VasodilatorAntihypertensives:enhancedhypotensiveeffectwhenaldesleukingivenwithHYDRALAZINE,MINOXIDILorSODIUMNITROPRUSSIDEAlemtuzumablAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lVaccines:riskofgeneralisedinfectionswhenmonoclonalantibodiesgivenwithlivelVACCINES—avoidconcomitantuseAlendronicAcidseeBisphosphonatesAlfacalcidolseeVitaminsAlfentanilseeOpioidAnalgesicsAlfuzosinseeAlpha-blockersAlimemazineseeAntihistaminesAliskirenlACEInhibitors:increasedriskofhyperkalaemia,hypotension,andimpairedrenalfunctionwhenaliskirengivenwithlACEINHIBITORS—avoidconcomitantuse TRIANGLE Analgesics:hypotensiveeffectofaliskirenpossiblyantagonisedbyNSAIDSlAngiotensin-IIReceptorAntagonists:increasedriskofhyperkalaemia,hypotension,andimpairedrenalfunctionwhenaliskirengivenwithlANGIOTENSIN-IIRECEPTORANTAGONISTS—avoidconcomitantuse;plasmaconcentrationofaliskirenpossiblyreducedbyIRBESARTAN TRIANGLE Antibacterials:plasmaconcentrationofaliskirenreducedbyRIFAMPICIN TRIANGLE Anticoagulants:increasedriskofhyperkalaemiawhenaliskirengivenwithHEPARINSlAntifungals:plasmaconcentrationofaliskirenincreasedbyKETOCONAZOLE;plasmaconcentrationofaliskirenincreasedbylITRACONAZOLE—avoidconcomitantuse TRIANGLE Calcium-channelBlockers:plasmaconcentrationofaliskirenincreasedbyVERAPAMILlCiclosporin:plasmaconcentrationofaliskirenincreasedbylCICLOSPORIN—avoidconcomitantuse TRIANGLE Diuretics:aliskirenreducesplasmaconcentrationofFUROSEMIDE;increasedriskofhyperkalaemiawhenaliskirengivenwithPOTASSIUM-SPARINGDIURETICSANDALDOSTERONEANTAGONISTSlGrapefruitJuice:plasmaconcentrationofaliskirenreducedbylGRAPEFRUITJUICE—avoidconcomitantuse TRIANGLE PotassiumSalts:increasedriskofhyperkalaemiawhenaliskirengivenwithPOTASSIUMSALTSAlitretinoinseeRetinoidsAlkylatingDrugsseeBendamustine,Busulfan,Carmustine,Cyclophosphamide,Estramustine,Ifosfamide,Lomustine,Melphalan,andThiotepaAllopurinol TRIANGLE ACEInhibitors:manufacturersstatepossibleincreasedriskofleucopeniaandhypersensitivityreactionswhenallopurinolgivenwithACEINHIBITORSespeciallyinrenalimpairment TRIANGLE Aminophylline:allopurinolpossiblyincreasesplasmaconcentrationofAMINOPHYLLINEAllopurinol(continued) TRIANGLE Antibacterials:increasedriskofrashwhenallopurinolgivenwithAMOXICILLIN,AMPICILLINorCO-AMOXICLAV TRIANGLE Anticoagulants:allopurinolpossiblyenhancesanticoagulanteffectofCOUMARINSlAntivirals:allopurinolincreasesplasmaconcentrationoflDIDANOSINE(riskoftoxicity)—avoidconcomitantuselAzathioprine:allopurinolenhanceseffectsandincreasestoxicityoflAZATHIOPRINE(reducedoseofazathioprinetoonequarterofusualdose) TRIANGLE Ciclosporin:allopurinolpossiblyincreasesplasmaconcentrationofCICLOSPORIN(riskofnephrotoxicity)lCytotoxics:avoidanceofallopurinoladvisedbymanufactureroflCAPECITABINE;allopurinolenhanceseffectsandincreasestoxicityoflMERCAPTOPURINE(reducedoseofmercaptopurinetoonequarterofusualdose) TRIANGLE Diuretics:increasedriskofhypersensitivitywhenallopurinolgivenwithTHIAZIDESANDRELATEDDIURETICSespeciallyinrenalimpairment TRIANGLE Theophylline:allopurinolpossiblyincreasesplasmaconcentrationofTHEOPHYLLINEAlmotriptansee5HT1-receptorAgonists(underHT)AlogliptinseeAntidiabeticsAlpha2-adrenoceptorStimulantsseeApraclonidine,Brimonidine,Clonidine,andMethyldopaAlpha-blockers TRIANGLE ACEInhibitors:enhancedhypotensiveeffectwhenalpha-blockersgivenwithACEINHIBITORS TRIANGLE AdrenergicNeuroneBlockers:enhancedhypotensiveeffectwhenalpha-blockersgivenwithADRENERGICNEURONEBLOCKERS TRIANGLE Alcohol:enhancedhypotensiveeffectwhenalpha-blockersgivenwithALCOHOL;increasedsedativeeffectwhenindoramingivenwithALCOHOL TRIANGLE Aldesleukin:enhancedhypotensiveeffectwhenalpha-blockersgivenwithALDESLEUKINlAnaesthetics,General:enhancedhypotensiveeffectwhenalpha-blockersgivenwithlGENERALANAESTHETICS TRIANGLE Analgesics:hypotensiveeffectofalpha-blockersantagonisedbyNSAIDS TRIANGLE Angiotensin-IIReceptorAntagonists:enhancedhypotensiveeffectwhenalpha-blockersgivenwithANGIOTENSIN-IIRECEPTORANTAGONISTSlAntidepressants:manufacturerofindoraminadvisesavoidconcomitantusewithlMAOIS;enhancedhypotensiveeffectwhenalpha-blockersgivenwithMAOISlAntifungals:plasmaconcentrationofalfuzosinpossiblyincreasedbyKETOCONAZOLE;plasmaconcentrationoftamsulosinincreasedbylKETOCONAZOLE TRIANGLE Antipsychotics:enhancedhypotensiveeffectwhenalpha-blockersgivenwithANTIPSYCHOTICSlAntivirals:plasmaconcentrationofdoxazosinandtamsulosinpossiblyincreasedbyBOCEPREVIR—manufacturerofbocepreviradvisesavoidconcomitantuse;plasmaconcentrationofalfuzosinpossiblyincreasedbylRITONAVIR—avoidconcomitantuse;avoidanceofalfuzosinadvisedbymanufactureroflTELAPREVIR TRIANGLE AnxiolyticsandHypnotics:enhancedhypotensiveandsedativeeffectswhenalpha-blockersgivenwithANXIOLYTICSANDHYPNOTICSlAvanafil:enhancedhypotensiveeffectwhenalpha-blockersgivenwithlAVANAFIL—whenpatientisstableonthealphablockerinitiateavanafilatthelowestpossibledoselBeta-blockers:enhancedhypotensiveeffectwhenalpha-blockersgivenwithlBETA-BLOCKERS,alsoincreasedriskoffirst-dosehypotensionwithpost-synapticalpha-blockerssuchasprazosinlCalcium-channelBlockers:enhancedhypotensiveeffectwhenalpha-blockersgivenwithlCALCIUM-CHANNELBLOCKERS,alsoincreasedriskoffirst-dosehypotensionwithpost-synapticalpha-blockerssuchasprazosin;plasmaconcentrationoftamsulosinincreasedbyVERAPAMIL TRIANGLE CardiacGlycosides:prazosinincreasesplasmaconcentrationofDIGOXIN TRIANGLE Clonidine:enhancedhypotensiveeffectwhenalpha-blockersgivenwithCLONIDINEBNF70Appendix1Interactions1141Interactions|Appendix1"
"Alpha-blockers(continued)lCobicistat:plasmaconcentrationofalfuzosinpossiblyincreasedbylCOBICISTAT—manufacturerofcobicistatadvisesavoidconcomitantuse TRIANGLE Corticosteroids:hypotensiveeffectofalpha-blockersantagonisedbyCORTICOSTEROIDS TRIANGLE Cytotoxics:avoidanceofalfuzosinadvisedbymanufacturerofIDELALISIB TRIANGLE Diazoxide:enhancedhypotensiveeffectwhenalpha-blockersgivenwithDIAZOXIDElDiuretics:enhancedhypotensiveeffectwhenalpha-blockersgivenwithlDIURETICS,alsoincreasedriskoffirst-dosehypotensionwithpost-synapticalpha-blockerssuchasprazosin TRIANGLE Dopaminergics:enhancedhypotensiveeffectwhenalpha-blockersgivenwithCO-BENELDOPA,CO-CARELDOPAorLEVODOPA TRIANGLE Methyldopa:enhancedhypotensiveeffectwhenalpha-blockersgivenwithMETHYLDOPAlMoxisylyte:possiblesevereposturalhypotensionwhenalpha-blockersgivenwithlMOXISYLYTE TRIANGLE Moxonidine:enhancedhypotensiveeffectwhenalpha-blockersgivenwithMOXONIDINE TRIANGLE MuscleRelaxants:enhancedhypotensiveeffectwhenalpha-blockersgivenwithBACLOFENorTIZANIDINE TRIANGLE Nitrates:enhancedhypotensiveeffectwhenalpha-blockersgivenwithNITRATES TRIANGLE Oestrogens:hypotensiveeffectofalpha-blockersantagonisedbyOESTROGENS TRIANGLE Prostaglandins:enhancedhypotensiveeffectwhenalpha-blockersgivenwithALPROSTADILlSildenafil:enhancedhypotensiveeffectwhenalpha-blockersgivenwithlSILDENAFIL(avoidalpha-blockersfor4hoursaftersildenafil)—whenpatientisstableonthealphablockerinitiatesildenafilatthelowestpossibledoselSympathomimetics:avoidconcomitantuseoftolazolinewithlADRENALINE(EPINEPHRINE)orlDOPAMINElTadalafil:enhancedhypotensiveeffectwhenalpha-blockersgivenwithlTADALAFIL—whenpatientisstableonthealphablockerinitiatetadalafilatthelowestpossibledose;enhancedhypotensiveeffectwhendoxazosingivenwithlTADALAFIL—manufactureroftadalafiladvisesavoidconcomitantuselUlcer-healingDrugs:effectsoftolazolineantagonisedbylCIMETIDINEandlRANITIDINElVardenafil:enhancedhypotensiveeffectwhenalpha-blockersgivenwithlVARDENAFIL—whenpatientisstableonthealphablockerinitiatevardenafilatthelowestpossibledose—separatedosesby6hours(exceptwithtamsulosin) TRIANGLE VasodilatorAntihypertensives:enhancedhypotensiveeffectwhenalpha-blockersgivenwithHYDRALAZINE,MINOXIDILorSODIUMNITROPRUSSIDEAlpha-blockers(post-synaptic)seeAlpha-blockersAlprazolamseeAnxiolyticsandHypnoticsAlprostadilseeProstaglandinsAluminiumHydroxideseeAntacidsAmantadine TRIANGLE Antimalarials:plasmaconcentrationofamantadinepossiblyincreasedbyQUININE TRIANGLE Antipsychotics:increasedriskofextrapyramidalside-effectswhenamantadinegivenwithANTIPSYCHOTICS TRIANGLE Bupropion:increasedriskofside-effectswhenamantadinegivenwithBUPROPIONlMemantine:increasedriskofCNStoxicitywhenamantadinegivenwithlMEMANTINE(manufacturerofmemantineadvisesavoidconcomitantuse);effectsofdopaminergicspossiblyenhancedbyMEMANTINE TRIANGLE Methyldopa:increasedriskofextrapyramidalside-effectswhenamantadinegivenwithMETHYLDOPA;antiparkinsonianeffectofdopaminergicsantagonisedbyMETHYLDOPA TRIANGLE Tetrabenazine:increasedriskofextrapyramidalside-effectswhenamantadinegivenwithTETRABENAZINEAmbrisentan TRIANGLE Antibacterials:plasmaconcentrationofambrisentanpossiblyincreasedbyRIFAMPICINAmbrisentan(continued)lCiclosporin:plasmaconcentrationofambrisentanincreasedbylCICLOSPORIN(seeunderAmbrisentan,p162)AmikacinseeAminoglycosidesAmilorideseeDiureticsAminoglycosides TRIANGLE AgalsidaseAlfaandBeta:gentamicinpossiblyinhibitseffectsofAGALSIDASEALFAANDBETA(manufacturersofagalsidasealfaandbetaadviseavoidconcomitantuse) TRIANGLE Analgesics:plasmaconcentrationofamikacinandgentamicininneonatespossiblyincreasedbyINDOMETACINlAntibacterials:neomycinreducesabsorptionofPHENOXYMETHYLPENICILLIN;increasedriskofnephrotoxicitywhenaminoglycosidesgivenwithCOLISTIMETHATESODIUMorPOLYMYXINS;increasedriskofnephrotoxicityandototoxicitywhenaminoglycosidesgivenwithCAPREOMYCINorlVANCOMYCIN;possibleincreasedriskofnephrotoxicitywhenaminoglycosidesgivenwithCEPHALOSPORINSlAnticoagulants:experienceinanticoagulantclinicssuggeststhatINRpossiblyalteredwhenneomycin(givenforlocalactionongut)isgivenwithlCOUMARINSorlPHENINDIONE TRIANGLE Antidiabetics:neomycinpossiblyenhanceshypoglycaemiceffectofACARBOSE,alsoseverityofgastro-intestinaleffectsincreased TRIANGLE Antifungals:increasedriskofnephrotoxicitywhenaminoglycosidesgivenwithAMPHOTERICIN TRIANGLE Bisphosphonates:increasedriskofhypocalcaemiawhenaminoglycosidesgivenwithBISPHOSPHONATES TRIANGLE CardiacGlycosides:gentamicinpossiblyincreasesplasmaconcentrationofDIGOXIN;neomycinreducesabsorptionofDIGOXINlCiclosporin:increasedriskofnephrotoxicitywhenaminoglycosidesgivenwithlCICLOSPORINlCytotoxics:neomycinpossiblyreducesabsorptionofMETHOTREXATE;neomycinreducesbioavailabilityofSORAFENIB;increasedriskofnephrotoxicityandpossiblyofototoxicitywhenaminoglycosidesgivenwithlPLATINUMCOMPOUNDSlDiuretics:increasedriskofotoxicitywhenaminoglycosidesgivenwithlLOOPDIURETICS TRIANGLE Mannitol:manufactureroftobramycinadvisesavoidconcomitantusewithMANNITOLlMuscleRelaxants:aminoglycosidesenhanceeffectsoflNON-DEPOLARISINGMUSCLERELAXANTSandlSUXAMETHONIUMlParasympathomimetics:aminoglycosidesantagoniseeffectsoflNEOSTIGMINEandlPYRIDOSTIGMINElTacrolimus:increasedriskofnephrotoxicitywhenaminoglycosidesgivenwithlTACROLIMUS TRIANGLE Vaccines:antibacterialsinactivateORALTYPHOIDVACCINE—seeunderTyphoidVaccineinBNF TRIANGLE Vitamins:neomycinpossiblyreducesabsorptionofVITAMINAAminophylline TRIANGLE Allopurinol:plasmaconcentrationofaminophyllinepossiblyincreasedbyALLOPURINOL TRIANGLE Anaesthetics,General:increasedriskofconvulsionswhenaminophyllinegivenwithKETAMINE TRIANGLE Anti-arrhythmics:aminophyllineantagonisesanti-arrhythmiceffectofADENOSINE—manufacturerofadenosineadvisesavoidaminophyllinefor24hoursbeforeadenosine;plasmaconcentrationofaminophyllineincreasedbyPROPAFENONElAntibacterials:plasmaconcentrationofaminophyllinepossiblyincreasedbyCLARITHROMYCINandISONIAZID;plasmaconcentrationofaminophyllineincreasedbylERYTHROMYCIN(alsoaminophyllinemayreduceabsorptionoforalerythromycin);plasmaconcentrationofaminophyllineincreasedbylCIPROFLOXACINandlNORFLOXACIN;metabolismofaminophyllineacceleratedbyRIFAMPICIN(reducedplasmaconcentration);possibleincreasedriskofconvulsionswhenaminophyllinegivenwithlQUINOLONESlAntidepressants:plasmaconcentrationofaminophyllineincreasedbylFLUVOXAMINE(concomitantuseshouldusuallybeavoided,butwherenotpossiblehalveaminophyllinedoseandmonitorplasma-aminophyllineconcentration);plasmaconcentrationofaminophyllinepossiblyreducedbySTJOHN’SWORT1142Appendix1InteractionsBNF70Interactions|Appendix1"
"Aminophylline(continued)lAntiepileptics:metabolismofaminophyllineacceleratedbyCARBAMAZEPINE,lPHENOBARBITALandlPRIMIDONE(reducedeffect);plasmaconcentrationofbothdrugsreducedwhenaminophyllinegivenwithlFOSPHENYTOINandlPHENYTOINlAntifungals:plasmaconcentrationofaminophyllinepossiblyincreasedbylFLUCONAZOLEandlKETOCONAZOLElAntivirals:plasmaconcentrationofaminophyllinepossiblyincreasedbyACICLOVIRandVALACICLOVIR;metabolismofaminophyllineacceleratedbylRITONAVIR(reducedplasmaconcentration) TRIANGLE AnxiolyticsandHypnotics:aminophyllinepossiblyreduceseffectsofBENZODIAZEPINES TRIANGLE Caffeinecitrate:avoidanceofaminophyllineadvisedbymanufacturerofCAFFEINECITRATElCalcium-channelBlockers:plasmaconcentrationofaminophyllinepossiblyincreasedbylCALCIUM-CHANNELBLOCKERS(enhancedeffect);plasmaconcentrationofaminophyllineincreasedbyDILTIAZEM;plasmaconcentrationofaminophyllineincreasedbylVERAPAMIL(enhancedeffect) TRIANGLE Corticosteroids:increasedriskofhypokalaemiawhenaminophyllinegivenwithCORTICOSTEROIDS TRIANGLE Cytotoxics:plasmaconcentrationofaminophyllinepossiblyincreasedbyMETHOTREXATElDeferasirox:plasmaconcentrationofaminophyllineincreasedbylDEFERASIROX(considerreducingdoseofaminophylline) TRIANGLE Disulfiram:metabolismofaminophyllineinhibitedbyDISULFIRAM(increasedriskoftoxicity) TRIANGLE Diuretics:increasedriskofhypokalaemiawhenaminophyllinegivenwithACETAZOLAMIDE,LOOPDIURETICSorTHIAZIDESANDRELATEDDIURETICS TRIANGLE Doxapram:increasedCNSstimulationwhenaminophyllinegivenwithDOXAPRAMlInterferons:metabolismofaminophyllineinhibitedbylINTERFERONALFAandlPEGINTERFERONALFA(considerreducingdoseofaminophylline) TRIANGLE LeukotrieneReceptorAntagonists:plasmaconcentrationofaminophyllinepossiblyincreasedbyZAFIRLUKAST,alsoplasmaconcentrationofzafirlukastreduced TRIANGLE Lithium:aminophyllineincreasesexcretionofLITHIUM(reducedplasmaconcentration) TRIANGLE Oestrogens:plasmaconcentrationofaminophyllineincreasedbyOESTROGENS(considerreducingdoseofaminophylline) TRIANGLE Pentoxifylline:plasmaconcentrationofaminophyllineincreasedbyPENTOXIFYLLINE TRIANGLE Roflumilast:avoidanceofaminophyllineadvisedbymanufacturerofROFLUMILAST TRIANGLE Sulfinpyrazone:plasmaconcentrationofaminophyllinereducedbySULFINPYRAZONE TRIANGLE Sympathomimetics:manufacturerofaminophyllineadvisesavoidconcomitantusewithEPHEDRINEinchildren TRIANGLE Sympathomimetics,Beta2:increasedriskofhypokalaemiawhenaminophyllinegivenwithhighdosesofBETA2SYMPATHOMIMETICSlUlcer-healingDrugs:metabolismofaminophyllineinhibitedbylCIMETIDINE(increasedplasmaconcentration);absorptionofaminophyllinepossiblyreducedbySUCRALFATE(giveatleast2hoursapart) TRIANGLE Vaccines:plasmaconcentrationofaminophyllinepossiblyincreasedbyINFLUENZAVACCINEAminosalicylatesseeindividualdrugsAmiodaroneNOTEAmiodaronehasalonghalf-life;thereisapotentialfordruginteractionstooccurforseveralweeks(orevenmonths)aftertreatmentwithithasbeenstopped TRIANGLE AgalsidaseAlfaandBeta:amiodaronepossiblyinhibitseffectsofAGALSIDASEALFAANDBETA(manufacturersofagalsidasealfaandbetaadviseavoidconcomitantuse) TRIANGLE Anaesthetics,Local:increasedmyocardialdepressionwhenanti-arrhythmicsgivenwithBUPIVACAINE,LEVOBUPIVACAINE,PRILOCAINEorROPIVACAINElAnti-arrhythmics:increasedmyocardialdepressionwhenanti-arrhythmicsgivenwithotherlANTI-ARRHYTHMICS;increasedriskofventriculararrhythmiaswhenamiodaronegivenwithlDISOPYRAMIDEorlDRONEDARONE—avoidconcomitantuse;AmiodaronelAnti-arrhythmics(continued)amiodaroneincreasesplasmaconcentrationoflFLECAINIDE(halvedoseofflecainide)lAntibacterials:increasedriskofventriculararrhythmiaswhenamiodaronegivenwithparenterallERYTHROMYCIN—avoidconcomitantuse;increasedriskofventriculararrhythmiaswhenamiodaronegivenwithlLEVOFLOXACINorlMOXIFLOXACIN—avoidconcomitantuse;possibleincreasedriskofventriculararrhythmiaswhenamiodaronegivenwithSULFAMETHOXAZOLEandTRIMETHOPRIM(asco-trimoxazole)—manufacturerofamiodaroneadvisesavoidconcomitantuseofco-trimoxazole;increasedriskofventriculararrhythmiaswhenamiodaronegivenwithlDELAMANID;avoidanceofamiodaroneadvisedbymanufacturerofFIDAXOMICIN;possibleincreasedriskofventriculararrhythmiaswhenamiodaronegivenwithlTELITHROMYCINlAnticoagulants:amiodaroneinhibitsmetabolismoflCOUMARINSandlPHENINDIONE(enhancedanticoagulanteffect);amiodaroneincreasesplasmaconcentrationoflDABIGATRAN(seeunderDabigatranEtexilate,p117)lAntidepressants:avoidanceofamiodaroneadvisedbymanufactureroflCITALOPRAMandlESCITALOPRAM(riskofventriculararrhythmias);increasedriskofventriculararrhythmiaswhenamiodaronegivenwithlTRICYCLICS—avoidconcomitantuselAntiepileptics:amiodaroneinhibitsmetabolismoflFOSPHENYTOINandlPHENYTOIN(increasedplasmaconcentration)lAntihistamines:increasedriskofventriculararrhythmiaswhenamiodaronegivenwithlMIZOLASTINE—avoidconcomitantuselAntimalarials:avoidanceofamiodaroneadvisedbymanufactureroflARTEMETHERWITHLUMEFANTRINE(riskofventriculararrhythmias);avoidanceofamiodaroneadvisedbymanufactureroflARTENIMOLWITHPIPERAQUINE(possibleriskofventriculararrhythmias);increasedriskofventriculararrhythmiaswhenamiodaronegivenwithlCHLOROQUINE,lHYDROXYCHLOROQUINE,lMEFLOQUINEorlQUININE—avoidconcomitantuselAntimuscarinics:increasedriskofventriculararrhythmiaswhenamiodaronegivenwithlTOLTERODINElAntipsychotics:increasedriskofventriculararrhythmiaswhenanti-arrhythmicsthatprolongtheQTintervalgivenwithlANTIPSYCHOTICSthatprolongtheQTinterval;increasedriskofventriculararrhythmiaswhenamiodaronegivenwithlBENPERIDOL—manufacturerofbenperidoladvisesavoidconcomitantuse;increasedriskofventriculararrhythmiaswhenamiodaronegivenwithlAMISULPRIDE,lDROPERIDOL,lHALOPERIDOL,lPHENOTHIAZINES,lPIMOZIDEorlZUCLOPENTHIXOL—avoidconcomitantuse;increasedriskofventriculararrhythmiaswhenamiodaronegivenwithlSULPIRIDElAntivirals:plasmaconcentrationofamiodaronepossiblyincreasedbylATAZANAVIR;possibleincreasedriskofbradycardiawhenamiodaronegivenwithlDACLATASVIRandlSIMEPREVIR(withsofosbuvir)—seeunderAmiodarone,p88;plasmaconcentrationofamiodaronepossiblyincreasedbylFOSAMPRENAVIR(increasedriskofventriculararrhythmias—avoidconcomitantuse);plasmaconcentrationofamiodaronepossiblyincreasedbylINDINAVIR—avoidconcomitantuse;plasmaconcentrationofamiodaroneincreasedbylRITONAVIR(increasedriskofventriculararrhythmias—avoidconcomitantuse);increasedriskofventriculararrhythmiaswhenamiodaronegivenwithlSAQUINAVIR—avoidconcomitantuse;possibleincreasedriskofbradycardiawhenamiodaronegivenwithlSOFOSBUVIR—seeunderAmiodarone,p88;avoidanceofamiodaroneadvisedbymanufactureroflTELAPREVIR(riskofventriculararrhythmias)lAtomoxetine:increasedriskofventriculararrhythmiaswhenamiodaronegivenwithlATOMOXETINElBeta-blockers:increasedriskofbradycardia,AVblockandmyocardialdepressionwhenamiodaronegivenwithlBETA-BLOCKERS;increasedmyocardialdepressionwhenanti-BNF70Appendix1Interactions1143Interactions|Appendix1"
"AmiodaronelBeta-blockers(continued)arrhythmicsgivenwithlBETA-BLOCKERS;increasedriskofventriculararrhythmiaswhenamiodaronegivenwithlSOTALOL—avoidconcomitantuselCalcium-channelBlockers:increasedriskofbradycardia,AVblockandmyocardialdepressionwhenamiodaronegivenwithlDILTIAZEMorlVERAPAMILlCardiacGlycosides:amiodaroneincreasesplasmaconcentrationoflDIGOXIN(halvedoseofdigoxin) TRIANGLE Ciclosporin:amiodaronepossiblyincreasesplasmaconcentrationofCICLOSPORINlCobicistat:plasmaconcentrationofamiodaronepossiblyincreasedbylCOBICISTAT—manufacturerofcobicistatadvisesavoidconcomitantuselColchicine:amiodaronepossiblyincreasesriskoflCOLCHICINEtoxicitylCytotoxics:amiodaronepossiblyincreasestheplasmaconcentrationofAFATINIB—manufacturerofafatinibadvisesseparatingadministrationofamiodaroneby6to12hours;possibleincreasedriskofventriculararrhythmiaswhenamiodaronegivenwithlBOSUTINIB;amiodaronepossiblyincreasestheplasmaconcentrationoflIBRUTINIB—reducedoseofibrutinib(seeunderIbrutinib,p809);avoidanceofamiodaroneadvisedbymanufacturerofIDELALISIB;possibleincreasedriskofventriculararrhythmiaswhenamiodaronegivenwithlVANDETANIB—avoidconcomitantuse;increasedriskofventriculararrhythmiaswhenamiodaronegivenwithlARSENICTRIOXIDE TRIANGLE Diuretics:increasedcardiactoxicitywithamiodaroneifhypokalaemiaoccurswithACETAZOLAMIDE,LOOPDIURETICSorTHIAZIDESANDRELATEDDIURETICS;amiodaroneincreasesplasmaconcentrationofEPLERENONE(reducedoseofeplerenone)lFingolimod:possibleincreasedriskofbradycardiawhenamiodaronegivenwithlFINGOLIMOD TRIANGLE GrapefruitJuice:plasmaconcentrationofamiodaroneincreasedbyGRAPEFRUITJUICElIvabradine:increasedriskofventriculararrhythmiaswhenamiodaronegivenwithlIVABRADINElLipid-regulatingDrugs:increasedriskofmyopathywhenamiodaronegivenwithlSIMVASTATIN(seeunderSimvastatin,p181);separatingadministrationfromamiodaroneby12hoursadvisedbymanufacturerofLOMITAPIDElLithium:manufacturerofamiodaroneadvisesavoidconcomitantusewithlLITHIUM(riskofventriculararrhythmias) TRIANGLE Orlistat:plasmaconcentrationofamiodaronepossiblyreducedbyORLISTATlPentamidineIsetionate:increasedriskofventriculararrhythmiaswhenamiodaronegivenwithlPENTAMIDINEISETIONATE—avoidconcomitantuse TRIANGLE ThyroidHormones:amiodaronecanaffectserumconcentrationsofTHYROIDHORMONES—monitorthyroidfunctionclosely TRIANGLE Ulcer-healingDrugs:plasmaconcentrationofamiodaroneincreasedbyCIMETIDINEAmisulprideseeAntipsychoticsAmitriptylineseeAntidepressants,TricyclicAmlodipineseeCalcium-channelBlockersAmoxicillinseePenicillinsAmphotericinNOTEClosemonitoringrequiredwithconcomitantadministrationofnephrotoxicdrugsorcytotoxics TRIANGLE Antibacterials:increasedriskofnephrotoxicitywhenamphotericingivenwithAMINOGLYCOSIDESorPOLYMYXINS;possibleincreasedriskofnephrotoxicitywhenamphotericingivenwithVANCOMYCIN TRIANGLE Antifungals:amphotericinreducesrenalexcretionandincreasescellularuptakeofFLUCYTOSINE(toxicitypossiblyincreased);effectsofamphotericinpossiblyantagonisedbyIMIDAZOLESandTRIAZOLES;plasmaconcentrationofamphotericinpossiblyincreasedbyMICAFUNGINlCardiacGlycosides:hypokalaemiacausedbyamphotericinincreasescardiactoxicitywithlCARDIACGLYCOSIDESAmphotericin(continued)lCiclosporin:increasedriskofnephrotoxicitywhenamphotericingivenwithlCICLOSPORINlCorticosteroids:increasedriskofhypokalaemiawhenamphotericingivenwithlCORTICOSTEROIDS—avoidconcomitantuseunlesscorticosteroidsneededtocontrolreactionslCytotoxics:increasedriskofventriculararrhythmiaswhenamphotericingivenwithlARSENICTRIOXIDE TRIANGLE Diuretics:increasedriskofhypokalaemiawhenamphotericingivenwithLOOPDIURETICSorTHIAZIDESANDRELATEDDIURETICS TRIANGLE PentamidineIsetionate:possibleincreasedriskofnephrotoxicitywhenamphotericingivenwithPENTAMIDINEISETIONATElSodiumStibogluconate:possibleincreasedriskofarrhythmiaswhenamphotericingivenafterlSODIUMSTIBOGLUCONATE—manufacturerofsodiumstibogluconateadvisesgiving14daysapartlTacrolimus:increasedriskofnephrotoxicitywhenamphotericingivenwithlTACROLIMUSAmpicillinseePenicillinsAnabolicSteroidslAnticoagulants:anabolicsteroidsenhanceanticoagulanteffectoflCOUMARINSandlPHENINDIONE TRIANGLE Antidiabetics:anabolicsteroidspossiblyenhancehypoglycaemiceffectofANTIDIABETICSAnaesthetics,GeneralNOTESeealsoSurgeryandLong-termMedication,underGeneralAnaesthesiainBNF TRIANGLE ACEInhibitors:enhancedhypotensiveeffectwhengeneralanaestheticsgivenwithACEINHIBITORSlAdrenergicNeuroneBlockers:enhancedhypotensiveeffectwhengeneralanaestheticsgivenwithlADRENERGICNEURONEBLOCKERSlAlpha-blockers:enhancedhypotensiveeffectwhengeneralanaestheticsgivenwithlALPHA-BLOCKERS TRIANGLE Aminophylline:increasedriskofconvulsionswhenketaminegivenwithAMINOPHYLLINE TRIANGLE Analgesics:metabolismofetomidateinhibitedbyFENTANYL(considerreducingdoseofetomidate);effectsofthiopentalpossiblyenhancedbyASPIRIN;effectsofintravenousgeneralanaestheticsandvolatileliquidgeneralanaestheticspossiblyenhancedbyOPIOIDANALGESICS TRIANGLE Angiotensin-IIReceptorAntagonists:enhancedhypotensiveeffectwhengeneralanaestheticsgivenwithANGIOTENSIN-IIRECEPTORANTAGONISTS TRIANGLE Antibacterials:increasedriskofhepatotoxicitywhenisofluranegivenwithISONIAZID;effectsofthiopentalenhancedbySULFONAMIDES;hypersensitivity-likereactionscanoccurwhengeneralanaestheticsgivenwithintravenousVANCOMYCIN TRIANGLE Antidepressants:increasedriskofarrhythmiasandhypotensionwhengeneralanaestheticsgivenwithTRICYCLICSlAntipsychotics:enhancedhypotensiveeffectwhengeneralanaestheticsgivenwithlANTIPSYCHOTICS;effectsofthiopentalenhancedbyDROPERIDOL TRIANGLE AnxiolyticsandHypnotics:increasedsedativeeffectwhengeneralanaestheticsgivenwithANXIOLYTICSANDHYPNOTICS TRIANGLE Beta-blockers:enhancedhypotensiveeffectwhengeneralanaestheticsgivenwithBETA-BLOCKERSlCalcium-channelBlockers:enhancedhypotensiveeffectwhengeneralanaestheticsorisofluranegivenwithCALCIUM-CHANNELBLOCKERS;generalanaestheticsenhancehypotensiveeffectoflVERAPAMIL(alsoAVdelay) TRIANGLE Clonidine:enhancedhypotensiveeffectwhengeneralanaestheticsgivenwithCLONIDINElCytotoxics:nitrousoxideincreasesantifolateeffectoflMETHOTREXATE—avoidconcomitantuse TRIANGLE Diazoxide:enhancedhypotensiveeffectwhengeneralanaestheticsgivenwithDIAZOXIDE TRIANGLE Diuretics:enhancedhypotensiveeffectwhengeneralanaestheticsgivenwithDIURETICSlDopaminergics:increasedriskofarrhythmiaswhenvolatileliquidgeneralanaestheticsgivenwithlCO-BENELDOPA,lCO-CARELDOPAorlLEVODOPA1144Appendix1InteractionsBNF70Interactions|Appendix1"
"Anaesthetics,General(continued)lDoxapram:increasedriskofarrhythmiaswhenvolatileliquidgeneralanaestheticsgivenwithlDOXAPRAM(avoiddoxapramforatleast10minutesaftervolatileliquidgeneralanaesthetics)lMemantine:increasedriskofCNStoxicitywhenketaminegivenwithlMEMANTINE(manufacturerofmemantineadvisesavoidconcomitantuse) TRIANGLE Methyldopa:enhancedhypotensiveeffectwhengeneralanaestheticsgivenwithMETHYLDOPA TRIANGLE Metoclopramide:effectsofthiopentalenhancedbyMETOCLOPRAMIDE TRIANGLE Moxonidine:enhancedhypotensiveeffectwhengeneralanaestheticsgivenwithMOXONIDINElMuscleRelaxants:increasedriskofmyocardialdepressionandbradycardiawhenpropofolgivenwithlSUXAMETHONIUM;volatileliquidgeneralanaestheticsenhanceeffectsofNON-DEPOLARISINGMUSCLERELAXANTSandSUXAMETHONIUM;ketamineenhanceseffectsofATRACURIUM TRIANGLE Nitrates:enhancedhypotensiveeffectwhengeneralanaestheticsgivenwithNITRATES TRIANGLE Oxytocin:oxytociceffectpossiblyreduced,alsoenhancedhypotensiveeffectandriskofarrhythmiaswhenvolatileliquidgeneralanaestheticsgivenwithOXYTOCINlSympathomimetics:manufacturerofisofluraneadvisesavoidconcomitantusewithlSYMPATHOMIMETICS(riskofventriculararrhythmias);increasedriskofarrhythmiaswhenvolatileliquidgeneralanaestheticsgivenwithlADRENALINE(EPINEPHRINE)orlNORADRENALINE(NOREPINEPHRINE);increasedriskofhypertensionwhenvolatileliquidgeneralanaestheticsgivenwithlMETHYLPHENIDATE TRIANGLE Theophylline:increasedriskofconvulsionswhenketaminegivenwithTHEOPHYLLINE TRIANGLE VasodilatorAntihypertensives:enhancedhypotensiveeffectwhengeneralanaestheticsgivenwithHYDRALAZINE,MINOXIDILorSODIUMNITROPRUSSIDEAnaesthetics,General(intravenous)seeAnaesthetics,GeneralAnaesthetics,General(volatileliquids)seeAnaesthetics,GeneralAnaesthetics,LocalseeBupivacaine,Chloroprocaine,Levobupivacaine,Lidocaine,Prilocaine,andRopivacaineAnagrelidelCilostazol:manufacturerofanagrelideadvisesavoidconcomitantusewithlCILOSTAZOLlPhosphodiesteraseType-3Inhibitors:manufacturerofanagrelideadvisesavoidconcomitantusewithlENOXIMONEandlMILRINONEAnakinralCytotoxics:avoidconcomitantuseofanakinrawithlADALIMUMAB,lCERTOLIZUMABPEGOL,lGOLIMUMABorlINFLIXIMABlEtanercept:avoidconcomitantuseofanakinrawithlETANERCEPTlVaccines:riskofgeneralisedinfectionswhenanakinragivenwithlivelVACCINES—avoidconcomitantuseAnalgesicsseeAspirin,Nefopam,NSAIDs,OpioidAnalgesics,andParacetamolAngiotensin-IIReceptorAntagonistslACEInhibitors:increasedriskofhyperkalaemia,hypotension,andimpairedrenalfunctionwhenangiotensin-IIreceptorantagonistsgivenwithlACEINHIBITORS—avoidconcomitantuse TRIANGLE AdrenergicNeuroneBlockers:enhancedhypotensiveeffectwhenangiotensin-IIreceptorantagonistsgivenwithADRENERGICNEURONEBLOCKERS TRIANGLE Alcohol:enhancedhypotensiveeffectwhenangiotensin-IIreceptorantagonistsgivenwithALCOHOL TRIANGLE Aldesleukin:enhancedhypotensiveeffectwhenangiotensin-IIreceptorantagonistsgivenwithALDESLEUKINlAliskiren:increasedriskofhyperkalaemia,hypotension,andimpairedrenalfunctionwhenangiotensin-IIreceptorantagonistsgivenwithlALISKIREN—avoidconcomitantuse;irbesartanpossiblyreducesplasmaconcentrationofALISKIRENAngiotensin-IIReceptorAntagonists(continued) TRIANGLE Alpha-blockers:enhancedhypotensiveeffectwhenangiotensin-IIreceptorantagonistsgivenwithALPHA-BLOCKERS TRIANGLE Anaesthetics,General:enhancedhypotensiveeffectwhenangiotensin-IIreceptorantagonistsgivenwithGENERALANAESTHETICS TRIANGLE Analgesics:increasedriskofrenalimpairmentwhenangiotensin-IIreceptorantagonistsgivenwithNSAIDS,alsohypotensiveeffectantagonised TRIANGLE Antibacterials:plasmaconcentrationoflosartananditsactivemetabolitereducedbyRIFAMPICIN;possibleincreasedriskofhyperkalaemiawhenangiotensin-IIreceptorantagonistsgivenwithTRIMETHOPRIM TRIANGLE Anticoagulants:increasedriskofhyperkalaemiawhenangiotensin-IIreceptorantagonistsgivenwithHEPARINS TRIANGLE Antidepressants:hypotensiveeffectofangiotensin-IIreceptorantagonistspossiblyenhancedbyMAOIS TRIANGLE Antipsychotics:enhancedhypotensiveeffectwhenangiotensin-IIreceptorantagonistsgivenwithANTIPSYCHOTICS TRIANGLE AnxiolyticsandHypnotics:enhancedhypotensiveeffectwhenangiotensin-IIreceptorantagonistsgivenwithANXIOLYTICSANDHYPNOTICS TRIANGLE Beta-blockers:enhancedhypotensiveeffectwhenangiotensin-IIreceptorantagonistsgivenwithBETA-BLOCKERS TRIANGLE Calcium-channelBlockers:enhancedhypotensiveeffectwhenangiotensin-IIreceptorantagonistsgivenwithCALCIUM-CHANNELBLOCKERSlCiclosporin:increasedriskofhyperkalaemiawhenangiotensin-IIreceptorantagonistsgivenwithlCICLOSPORIN TRIANGLE Clonidine:enhancedhypotensiveeffectwhenangiotensin-IIreceptorantagonistsgivenwithCLONIDINE TRIANGLE Corticosteroids:hypotensiveeffectofangiotensin-IIreceptorantagonistsantagonisedbyCORTICOSTEROIDS TRIANGLE Diazoxide:enhancedhypotensiveeffectwhenangiotensin-IIreceptorantagonistsgivenwithDIAZOXIDElDiuretics:enhancedhypotensiveeffectwhenangiotensin-IIreceptorantagonistsgivenwithlDIURETICS;increasedriskofhyperkalaemiawhenangiotensin-IIreceptorantagonistsgivenwithlPOTASSIUM-SPARINGDIURETICSANDALDOSTERONEANTAGONISTS TRIANGLE Dopaminergics:enhancedhypotensiveeffectwhenangiotensin-IIreceptorantagonistsgivenwithCO-BENELDOPA,CO-CARELDOPAorLEVODOPAlLithium:angiotensin-IIreceptorantagonistsreduceexcretionoflLITHIUM(increasedplasmaconcentration) TRIANGLE Methyldopa:enhancedhypotensiveeffectwhenangiotensin-IIreceptorantagonistsgivenwithMETHYLDOPA TRIANGLE Moxisylyte:enhancedhypotensiveeffectwhenangiotensin-IIreceptorantagonistsgivenwithMOXISYLYTE TRIANGLE Moxonidine:enhancedhypotensiveeffectwhenangiotensin-IIreceptorantagonistsgivenwithMOXONIDINE TRIANGLE MuscleRelaxants:enhancedhypotensiveeffectwhenangiotensin-IIreceptorantagonistsgivenwithBACLOFENorTIZANIDINE TRIANGLE Nitrates:enhancedhypotensiveeffectwhenangiotensin-IIreceptorantagonistsgivenwithNITRATES TRIANGLE Oestrogens:hypotensiveeffectofangiotensin-IIreceptorantagonistsantagonisedbyOESTROGENSlPotassiumSalts:increasedriskofhyperkalaemiawhenangiotensin-IIreceptorantagonistsgivenwithlPOTASSIUMSALTS TRIANGLE Prostaglandins:enhancedhypotensiveeffectwhenangiotensin-IIreceptorantagonistsgivenwithALPROSTADIL TRIANGLE Tacrolimus:increasedriskofhyperkalaemiawhenangiotensin-IIreceptorantagonistsgivenwithTACROLIMUS TRIANGLE VasodilatorAntihypertensives:enhancedhypotensiveeffectwhenangiotensin-IIreceptorantagonistsgivenwithHYDRALAZINE,MINOXIDILorSODIUMNITROPRUSSIDEAntacidsNOTEAntacidsshouldpreferablynotbetakenatthesametimeasotherdrugssincetheymayimpairabsorption TRIANGLE ACEInhibitors:antacidspossiblyreduceabsorptionofACEINHIBITORS;antacidsreduceabsorptionofCAPTOPRIL,ENALAPRILandFOSINOPRILBNF70Appendix1Interactions1145Interactions|Appendix1"
"Antacids(continued) TRIANGLE Analgesics:antacidspossiblyreduceabsorptionofACEMETACIN;alkalineurineduetosomeantacidsincreasesexcretionofASPIRIN TRIANGLE Anthelmintics:sodiumbicarbonateincreasestheexcretionofDIETHYLCARBAMAZINE TRIANGLE Antibacterials:antacidsreduceabsorptionofAZITHROMYCIN,CEFACLOR,CIPROFLOXACIN,ISONIAZID,LEVOFLOXACIN,MOXIFLOXACIN,NORFLOXACIN,OFLOXACIN,RIFAMPICINandTETRACYCLINES;avoidconcomitantuseofantacidswithMETHENAMINE;oralmagnesiumsalts(asmagnesiumtrisilicate)reduceabsorptionofNITROFURANTOIN TRIANGLE Antiepileptics:antacidsreduceabsorptionofFOSPHENYTOIN,GABAPENTINandPHENYTOIN TRIANGLE Antifungals:antacidsreduceabsorptionofITRACONAZOLEandKETOCONAZOLE TRIANGLE Antihistamines:antacidsreduceabsorptionofFEXOFENADINE TRIANGLE Antimalarials:antacidsreduceabsorptionofCHLOROQUINEandHYDROXYCHLOROQUINE;oralmagnesiumsalts(asmagnesiumtrisilicate)reduceabsorptionofPROGUANIL TRIANGLE Antipsychotics:antacidsreduceabsorptionofPHENOTHIAZINESandSULPIRIDE TRIANGLE Antivirals:antacidsreduceabsorptionofATAZANAVIR(giveatleast2hoursbeforeor1hourafterantacids);aluminiumhydroxidereducesabsorptionofDOLUTEGRAVIR—manufacturerofdolutegraviradvisesgiveatleast2hoursbeforeor6hoursafteraluminiumhydroxide;oralmagnesiumsaltsreduceabsorptionofDOLUTEGRAVIR—manufacturerofdolutegraviradvisesgiveatleast2hoursbeforeor6hoursafteroralmagnesiumsalts;aluminiumhydroxidereducesabsorptionofELVITEGRAVIR(giveatleast4hoursapart);oralmagnesiumsaltsreduceabsorptionofELVITEGRAVIR(giveatleast4hoursapart);aluminiumhydroxidereducesplasmaconcentrationofRALTEGRAVIR—manufacturerofraltegraviradvisesavoidconcomitantuse;oralmagnesiumsaltsreduceplasmaconcentrationofRALTEGRAVIR—manufacturerofraltegraviradvisesavoidconcomitantuse;manufacturerofrilpivirineadvisesgiveantacids2hoursbeforeor4hoursafterRILPIVIRINE;antacidsreduceabsorptionofTIPRANAVIR(giveatleast2hoursapart) TRIANGLE BileAcids:antacidspossiblyreduceabsorptionofBILEACIDS TRIANGLE Bisphosphonates:antacidsreduceabsorptionofBISPHOSPHONATES TRIANGLE CardiacGlycosides:antacidspossiblyreduceabsorptionofDIGOXIN TRIANGLE Corticosteroids:antacidsreduceabsorptionofDEFLAZACORTlCytotoxics:aluminiumhydroxideandoralmagnesiumsaltspossiblyreduceabsorptionofESTRAMUSTINE—manufacturerofestramustineadvisesavoidconcomitantadministration;separatingadministrationwithantacidsbyabout12hoursadvisedbymanufacturerofBOSUTINIB;antacidspossiblyreduceplasmaconcentrationoflERLOTINIB—giveantacidsatleast4hoursbeforeor2hoursaftererlotinib TRIANGLE Deferasirox:antacidscontainingaluminiumpossiblyreduceabsorptionofDEFERASIROX(manufacturerofdeferasiroxadvisesavoidconcomitantuse) TRIANGLE Deferiprone:antacidscontainingaluminiumpossiblyreduceabsorptionofDEFERIPRONE(manufacturerofdeferiproneadvisesavoidconcomitantuse) TRIANGLE Dipyridamole:antacidspossiblyreduceabsorptionofDIPYRIDAMOLE TRIANGLE Eltrombopag:antacidsreduceabsorptionofELTROMBOPAG(giveatleast4hoursapart) TRIANGLE Folates:antacidspossiblyreduceabsorptionofFOLICACID(manufactureroffolicacidadvisesgiveatleast2hoursapart) TRIANGLE IronSalts:oralmagnesiumsalts(asmagnesiumtrisilicate)reduceabsorptionoforalIRONSALTS TRIANGLE Lipid-regulatingDrugs:antacidsreduceabsorptionofROSUVASTATIN TRIANGLE Lithium:sodiumbicarbonateincreasesexcretionofLITHIUM(reducedplasmaconcentration) TRIANGLE Mycophenolate:antacidsreduceabsorptionofMYCOPHENOLATE TRIANGLE Penicillamine:antacidsreduceabsorptionofPENICILLAMINE TRIANGLE PolystyreneSulfonateResins:riskofintestinalobstructionwhenaluminiumhydroxidegivenwithPOLYSTYRENEAntacidsPolystyreneSulfonateResins(continued)SULFONATERESINS;riskofmetabolicalkalosiswhenoralmagnesiumsaltsgivenwithPOLYSTYRENESULFONATERESINS TRIANGLE Riociguat:antacidsreduceabsorptionofRIOCIGUAT(giveatleast2hoursbeforeor1hourafterriociguat) TRIANGLE Sympathomimetics:aluminiumhydroxidepossiblyincreasesabsorptionofPSEUDOEPHEDRINE TRIANGLE ThyroidHormones:antacidspossiblyreduceabsorptionofLEVOTHYROXINE TRIANGLE Ulcer-healingDrugs:antacidspossiblyreduceabsorptionofLANSOPRAZOLEAntazolineseeAntihistaminesAnthelminticsseeindividualdrugsAnthraxVaccineseeVaccinesAnti-DImmunoglobulinsseeImmunoglobulinsAnti-arrhythmicsseeAdenosine,Amiodarone,Disopyramide,Dronedarone,Flecainide,Lidocaine,andPropafenoneAntibacterialsseeindividualdrugsAntibiotics(cytotoxic)seeBleomycin,Doxorubicin,Epirubicin,Idarubicin,Mitomycin,Mitoxantrone,andPixantroneAnticoagulantsseeApixaban,Argatroban,Bivalirudin,Coumarins,Dabigatran,Danaparoid,Fondaparinux,Heparins,Phenindione,andRivaroxabanAntidepressantsseeAgomelatine;Antidepressants,SSRI;Antidepressants,Tricyclic;Antidepressants,Tricyclic(related);MAOIs;Mirtazapine;Moclobemide;Reboxetine;StJohn’sWort;VenlafaxineAntidepressants,NoradrenalineRe-uptakeInhibitorsseeReboxetineAntidepressants,SSRINOTEseealsoDapoxetine TRIANGLE Alcohol:sedativeeffectspossiblyincreasedwhenSSRIsgivenwithALCOHOLlAminophylline:fluvoxamineincreasesplasmaconcentrationoflAMINOPHYLLINE(concomitantuseshouldusuallybeavoided,butwherenotpossiblehalveaminophyllinedoseandmonitorplasma-aminophyllineconcentration) TRIANGLE Anaesthetics,Local:fluvoxamineinhibitsmetabolismofROPIVACAINE—avoidprolongedadministrationofropivacainelAnalgesics:increasedriskofbleedingwhenSSRIsgivenwithlNSAIDSorlASPIRIN;possibleincreasedserotonergiceffectswhenSSRIsgivenwithFENTANYL;fluoxetine,fluvoxamine,paroxetineandsertralinepossiblyincreaseplasmaconcentrationofMETHADONE;increasedriskofCNStoxicitywhenSSRIsgivenwithlTRAMADOLlAnti-arrhythmics:manufacturerofcitalopramandescitalopramadvisesavoidconcomitantusewithlAMIODARONE(riskofventriculararrhythmias);manufacturerofcitalopramandescitalopramadvisesavoidconcomitantusewithlDISOPYRAMIDE(riskofventriculararrhythmias);manufacturerofcitalopramandescitalopramadvisesavoidconcomitantusewithlDRONEDARONE(riskofventriculararrhythmias);fluoxetineincreasesplasmaconcentrationofFLECAINIDE;fluoxetineandparoxetinepossiblyinhibitmetabolismofPROPAFENONElAntibacterials:manufacturerofcitalopramandescitalopramadvisesavoidconcomitantusewithintravenouslERYTHROMYCIN(riskofventriculararrhythmias);manufacturerofcitalopramandescitalopramadvisesavoidconcomitantusewithlMOXIFLOXACIN(riskofventriculararrhythmias);possibleincreasedriskofventriculararrhythmiaswhencitalopramgivenwithlTELITHROMYCINlAnticoagulants:SSRIspossiblyenhanceanticoagulanteffectoflCOUMARINS;possibleincreasedriskofbleedingwhenSSRIsgivenwithlDABIGATRANlAntidepressants:avoidanceoffluvoxamineadvisedbymanufactureroflREBOXETINE;possibleincreasedserotonergiceffectswhenSSRIsgivenwithDULOXETINE;fluvoxamineinhibitsmetabolismoflDULOXETINE—avoidconcomitantuse;citalopram,escitalopram,fluvoxamine,paroxetineorsertralineshouldnotbestarteduntil2weeksafterstoppinglMAOIS,alsoMAOIsshouldnotbestarteduntilatleast1weekafterstoppingcitalopram,escitalopram,fluvoxamine,paroxetineorsertraline;fluoxetineshouldnot1146Appendix1InteractionsBNF70Interactions|Appendix1"
"Antidepressants,SSRIlAntidepressants(continued)bestarteduntil2weeksafterstoppinglMAOIS,alsoMAOIsshouldnotbestarteduntilatleast5weeksafterstoppingfluoxetine;CNSeffectsofSSRIsincreasedbylMAOIS(riskofserioustoxicity);increasedriskofCNStoxicitywhenescitalopramgivenwithlMOCLOBEMIDE,preferablyavoidconcomitantuse;afterstoppingcitalopram,fluvoxamine,paroxetineorsertralinedonotstartlMOCLOBEMIDEforatleast1week;afterstoppingfluoxetinedonotstartlMOCLOBEMIDEfor5weeks;increasedserotonergiceffectswhenSSRIsgivenwithlSTJOHN’SWORT—avoidconcomitantuse;fluvoxamineinhibitsmetabolismoflAGOMELATINE(increasedplasmaconcentration);possibleincreasedserotonergiceffectswhenfluoxetineorfluvoxaminegivenwithMIRTAZAPINE;SSRIsincreaseplasmaconcentrationofsomelTRICYCLICS;manufacturerofcitalopramandescitalopramadvisesavoidconcomitantusewithlTRICYCLICS(riskofventriculararrhythmias)lAntiepileptics:SSRIsantagoniseanticonvulsanteffectoflANTIEPILEPTICS(convulsivethresholdlowered);fluoxetineandfluvoxamineincreaseplasmaconcentrationoflCARBAMAZEPINE;fluoxetineandfluvoxamineincreaseplasmaconcentrationoflFOSPHENYTOIN;plasmaconcentrationofsertralinepossiblyreducedbyFOSPHENYTOINandPHENYTOIN,alsoplasmaconcentrationoffosphenytoinandphenytoinpossiblyincreased;plasmaconcentrationofparoxetinereducedbyFOSPHENYTOIN,PHENOBARBITAL,PHENYTOINandPRIMIDONE;fluoxetineandfluvoxamineincreaseplasmaconcentrationoflPHENYTOIN TRIANGLE Antifungals:plasmaconcentrationofparoxetinepossiblyincreasedbyTERBINAFINElAntihistamines:manufacturerofcitalopramandescitalopramadvisesavoidconcomitantusewithlMIZOLASTINE(riskofventriculararrhythmias);antidepressanteffectofSSRIspossiblyantagonisedbyCYPROHEPTADINElAntimalarials:avoidanceofantidepressantsadvisedbymanufactureroflARTEMETHERWITHLUMEFANTRINEandlARTENIMOLWITHPIPERAQUINE;possibleincreasedriskofventriculararrhythmiaswhencitalopramorescitalopramgivenwithlARTEMETHERWITHLUMEFANTRINE—avoidconcomitantuse;possibleincreasedriskofventriculararrhythmiaswhencitalopramorescitalopramgivenwithlARTENIMOLWITHPIPERAQUINE—avoidconcomitantuse;possibleincreasedriskofventriculararrhythmiaswhencitalopramandescitalopramgivenwithlCHLOROQUINE;possibleincreasedriskofventriculararrhythmiaswhencitalopramorescitalopramgivenwithlQUININE—avoidconcomitantuse TRIANGLE Antimuscarinics:paroxetineincreasesplasmaconcentrationofDARIFENACINandPROCYCLIDINElAntipsychotics:avoidanceoffluoxetine,fluvoxamineandsertralineadvisedbymanufactureroflDROPERIDOL(riskofventriculararrhythmias);manufacturerofcitalopramandescitalopramadvisesavoidconcomitantusewithlHALOPERIDOL(riskofventriculararrhythmias);fluoxetineincreasesplasmaconcentrationoflCLOZAPINE,lHALOPERIDOLandRISPERIDONE;fluvoxaminepossiblyincreasesplasmaconcentrationofASENAPINEandHALOPERIDOL;paroxetineinhibitsmetabolismofPERPHENAZINE(reducedoseofperphenazine);fluoxetineandparoxetinepossiblyincreaseplasmaconcentrationoflARIPIPRAZOLE(reducedoseofaripiprazole—consultaripiprazoleproductliterature);plasmaconcentrationofparoxetinepossiblyincreasedbyASENAPINE;fluvoxamine,paroxetineandsertralineincreaseplasmaconcentrationoflCLOZAPINE;citaloprampossiblyincreasesplasmaconcentrationofCLOZAPINE(increasedriskoftoxicity);fluvoxamineincreasesplasmaconcentrationofOLANZAPINE;manufacturerofcitalopramandescitalopramadvisesavoidconcomitantusewithlPHENOTHIAZINES(riskofventriculararrhythmias);manufacturerofcitalopramandescitalopramadvisesavoidconcomitantusewithlPIMOZIDE(riskofventriculararrhythmias);SSRIspossiblyincreaseplasmaconcentrationoflPIMOZIDE(increasedriskofventricularAntidepressants,SSRIlAntipsychotics(continued)arrhythmias—avoidconcomitantuse);paroxetinepossiblyincreasesplasmaconcentrationofRISPERIDONE(increasedriskoftoxicity)lAntivirals:plasmaconcentrationofparoxetineandsertralinepossiblyreducedbyDARUNAVIR;plasmaconcentrationofSSRIspossiblyincreasedbylRITONAVIR;plasmaconcentrationofparoxetinepossiblyreducedbyRITONAVIRlAnxiolyticsandHypnotics:fluoxetineincreasesplasmaconcentrationofALPRAZOLAM;fluvoxamineincreasesplasmaconcentrationofsomeBENZODIAZEPINES;fluvoxamineincreasesplasmaconcentrationoflMELATONIN—avoidconcomitantuse;sedativeeffectspossiblyincreasedwhensertralinegivenwithZOLPIDEM TRIANGLE Atomoxetine:possibleincreasedriskofconvulsionswhenantidepressantsgivenwithATOMOXETINE;fluoxetineandparoxetinepossiblyinhibitmetabolismofATOMOXETINElBeta-blockers:citalopramandescitalopramincreaseplasmaconcentrationofMETOPROLOL;paroxetinepossiblyincreasestheplasmaconcentrationoflMETOPROLOL—increasedriskofAVblock(manufacturerofparoxetineadvisesavoidconcomitantuseincardiacinsufficiency);fluvoxamineincreasesplasmaconcentrationofPROPRANOLOL;increasedriskofventriculararrhythmiaswhencitalopramgivenwithlSOTALOL—avoidconcomitantuse;manufacturerofescitalopramadvisesavoidconcomitantusewithlSOTALOL(riskofventriculararrhythmias) TRIANGLE Bupropion:plasmaconcentrationofcitaloprampossiblyincreasedbyBUPROPION TRIANGLE Calcium-channelBlockers:fluoxetinepossiblyinhibitsmetabolismofNIFEDIPINE(increasedplasmaconcentration)lClopidogrel:fluoxetineandfluvoxaminepossiblyreduceantiplateleteffectoflCLOPIDOGRELlDapoxetine:possibleincreasedriskofserotonergiceffectswhenSSRIsgivenwithlDAPOXETINE(manufacturerofdapoxetineadvisesSSRIsshouldnotbestarteduntil1weekafterstoppingdapoxetine,avoiddapoxetinefor2weeksafterstoppingSSRIs)lDopaminergics:increasedriskofCNStoxicitywhenSSRIsgivenwithlRASAGILINE;fluvoxamineshouldnotbestarteduntil2weeksafterstoppinglRASAGILINE;fluoxetineshouldnotbestarteduntil2weeksafterstoppinglRASAGILINE,alsorasagilineshouldnotbestarteduntilatleast5weeksafterstoppingfluoxetine;avoidanceofcitalopramandescitalopramadvisedbymanufacturerofSELEGILINE;increasedriskofhypertensionandCNSexcitationwhenfluvoxamineorsertralinegivenwithlSELEGILINE(selegilineshouldnotbestarteduntil1weekafterstoppingfluvoxamineorsertraline,avoidfluvoxamineorsertralinefor2weeksafterstoppingselegiline);increasedriskofhypertensionandCNSexcitationwhenparoxetinegivenwithlSELEGILINE(selegilineshouldnotbestarteduntil2weeksafterstoppingparoxetine,avoidparoxetinefor2weeksafterstoppingselegiline);increasedriskofhypertensionandCNSexcitationwhenfluoxetinegivenwithlSELEGILINE(selegilineshouldnotbestarteduntil5weeksafterstoppingfluoxetine,avoidfluoxetinefor2weeksafterstoppingselegiline) TRIANGLE GrapefruitJuice:plasmaconcentrationofsertralinepossiblyincreasedbyGRAPEFRUITJUICElHormoneAntagonists:fluoxetineandparoxetinepossiblyinhibitmetabolismoflTAMOXIFENtoactivemetabolite(avoidconcomitantuse)l5HT1-receptorAgonists:increasedriskofCNStoxicitywhencitalopramgivenwithl5HT1AGONISTS(manufacturerofcitalopramadvisesavoidconcomitantuse);fluvoxamineinhibitsthemetabolismofFROVATRIPTAN;possibleincreasedserotonergiceffectswhenSSRIsgivenwithNARATRIPTAN;CNStoxicityreportedwhensertralinegivenwithSUMATRIPTAN;increasedriskofCNStoxicitywhencitalopram,escitalopram,fluoxetine,fluvoxamineorparoxetinegivenwithlSUMATRIPTAN;fluvoxaminepossiblyinhibitsmetabolismofZOLMITRIPTAN(reducedoseofzolmitriptan) TRIANGLE 5HT3-receptorAntagonists:possibleincreasedserotonergiceffectswhenSSRIsgivenwith5HT3ANTAGONISTSBNF70Appendix1Interactions1147Interactions|Appendix1"
"Antidepressants,SSRI(continued) TRIANGLE Lipid-regulatingDrugs:separatingadministrationfromfluoxetineandfluvoxamineby12hoursadvisedbymanufacturerofLOMITAPIDElLithium:IncreasedriskofCNSeffectswhenSSRIsgivenwithlLITHIUM(lithiumtoxicityreported)lMethylthioninium:riskofCNStoxicitywhenSSRIsgivenwithlMETHYLTHIONINIUM—avoidconcomitantuse(ifavoidancenotpossible,uselowestpossibledoseofmethylthioniniumandobservepatientforupto4hoursafteradministration) TRIANGLE Metoclopramide:CNStoxicityreportedwhenSSRIsgivenwithMETOCLOPRAMIDElMuscleRelaxants:fluvoxamineincreasesplasmaconcentrationoflTIZANIDINE(increasedriskoftoxicity)—avoidconcomitantuse TRIANGLE Parasympathomimetics:paroxetineincreasesplasmaconcentrationofGALANTAMINElPentamidineIsetionate:manufacturerofcitalopramandescitalopramadvisesavoidconcomitantusewithlPENTAMIDINEISETIONATE(riskofventriculararrhythmias)lPirfenidone:fluvoxamineincreasesplasmaconcentrationoflPIRFENIDONE—manufacturerofpirfenidoneadvisesavoidconcomitantuselPomalidomide:fluvoxamineincreasesplasmaconcentrationoflPOMALIDOMIDE TRIANGLE Ranolazine:paroxetineincreasesplasmaconcentrationofRANOLAZINE TRIANGLE Roflumilast:fluvoxamineinhibitsthemetabolismofROFLUMILAST TRIANGLE Sympathomimetics:metabolismofSSRIspossiblyinhibitedbyMETHYLPHENIDATElTheophylline:fluvoxamineincreasesplasmaconcentrationoflTHEOPHYLLINE(concomitantuseshouldusuallybeavoided,butwherenotpossiblehalvetheophyllinedoseandmonitorplasma-theophyllineconcentration) TRIANGLE Ticagrelor:possibleincreasedriskofbleedingwhencitalopram,paroxetineorsertralinegivenwithTICAGRELOR TRIANGLE Ulcer-healingDrugs:plasmaconcentrationofcitalopram,escitalopramandsertralineincreasedbyCIMETIDINE;fluvoxaminepossiblyincreasesplasmaconcentrationofLANSOPRAZOLE;plasmaconcentrationofescitalopramincreasedbyOMEPRAZOLEAntidepressants,SSRI(related)seeDuloxetineandVenlafaxineAntidepressants,Tricyclic TRIANGLE AdrenergicNeuroneBlockers:tricyclicsantagonisehypotensiveeffectofADRENERGICNEURONEBLOCKERSlAlcohol:increasedsedativeeffectwhentricyclicsgivenwithlALCOHOL TRIANGLE Alpha2-adrenoceptorStimulants:avoidanceoftricyclicsadvisedbymanufacturerofAPRACLONIDINEandBRIMONIDINE TRIANGLE Anaesthetics,General:increasedriskofarrhythmiasandhypotensionwhentricyclicsgivenwithGENERALANAESTHETICSlAnalgesics:increasedriskofCNStoxicitywhentricyclicsgivenwithlTRAMADOL;side-effectspossiblyincreasedwhentricyclicsgivenwithNEFOPAM;sedativeeffectspossiblyincreasedwhentricyclicsgivenwithOPIOIDANALGESICSlAnti-arrhythmics:increasedriskofventriculararrhythmiaswhentricyclicsgivenwithlAMIODARONE—avoidconcomitantuse;increasedriskofventriculararrhythmiaswhentricyclicsgivenwithlDISOPYRAMIDEorlFLECAINIDE;avoidanceoftricyclicsadvisedbymanufactureroflDRONEDARONE(riskofventriculararrhythmias);increasedriskofarrhythmiaswhentricyclicsgivenwithlPROPAFENONElAntibacterials:increasedriskofventriculararrhythmiaswhentricyclicsgivenwithlMOXIFLOXACIN—avoidconcomitantuse;possibleincreasedriskofventriculararrhythmiaswhentricyclicsthatprolongtheQTintervalgivenwithlDELAMANID;possibleincreasedriskofventriculararrhythmiaswhentricyclicsgivenwithlTELITHROMYCINlAnticoagulants:tricyclicsmayenhanceorreduceanticoagulanteffectoflCOUMARINSlAntidepressants:avoidanceoftricyclicsadvisedbymanufactureroflCITALOPRAMandlESCITALOPRAM(riskofventriculararrhythmias);possibleincreasedserotonergicAntidepressants,TricycliclAntidepressants(continued)effectswhenamitriptylineorclomipraminegivenwithDULOXETINE;increasedriskofhypertensionandCNSexcitationwhentricyclicsgivenwithlMAOIS,tricyclicsshouldnotbestarteduntil2weeksafterstoppingMAOIs(3weeksifstartingclomipramineorimipramine),alsoMAOIsshouldnotbestartedforatleast1–2weeksafterstoppingtricyclics(3weeksinthecaseofclomipramineorimipramine);afterstoppingtricyclicsdonotstartlMOCLOBEMIDEforatleast1week;plasmaconcentrationofsometricyclicsincreasedbylSSRIS;plasmaconcentrationofamitriptylinereducedbySTJOHN’SWORTlAntiepileptics:tricyclicsantagoniseanticonvulsanteffectoflANTIEPILEPTICS(convulsivethresholdlowered);metabolismoftricyclicsacceleratedbylCARBAMAZEPINE(reducedplasmaconcentrationandreducedeffect);plasmaconcentrationoftricyclicspossiblyreducedbylFOSPHENYTOINandlPHENYTOIN;metabolismoftricyclicspossiblyacceleratedbylPHENOBARBITALandlPRIMIDONE(reducedplasmaconcentration) TRIANGLE Antifungals:plasmaconcentrationofamitriptylineandnortriptylinepossiblyincreasedbyFLUCONAZOLE;plasmaconcentrationoftricyclicspossiblyincreasedbyTERBINAFINE TRIANGLE Antihistamines:increasedantimuscarinicandsedativeeffectswhentricyclicsgivenwithANTIHISTAMINESlAntimalarials:avoidanceofantidepressantsadvisedbymanufactureroflARTEMETHERWITHLUMEFANTRINEandlARTENIMOLWITHPIPERAQUINE TRIANGLE Antimuscarinics:increasedriskofantimuscarinicside-effectswhentricyclicsgivenwithANTIMUSCARINICSlAntipsychotics:avoidanceoftricyclicsadvisedbymanufactureroflDROPERIDOL,lFLUPHENAZINE,lHALOPERIDOL,lSULPIRIDEandlZUCLOPENTHIXOL(riskofventriculararrhythmias);possibleincreasedantimuscarinicside-effectswhentricyclicsgivenwithCLOZAPINE;increasedriskofantimuscarinicside-effectswhentricyclicsgivenwithPHENOTHIAZINES;possibleincreasedriskofventriculararrhythmiaswhentricyclicsgivenwithlRISPERIDONElAntivirals:plasmaconcentrationoftricyclicspossiblyincreasedbylRITONAVIR;increasedriskofventriculararrhythmiaswhentricyclicsgivenwithlSAQUINAVIR—avoidconcomitantuse TRIANGLE AnxiolyticsandHypnotics:increasedsedativeeffectwhentricyclicsgivenwithANXIOLYTICSANDHYPNOTICSlAtomoxetine:increasedriskofventriculararrhythmiaswhentricyclicsgivenwithlATOMOXETINE;possibleincreasedriskofconvulsionswhenantidepressantsgivenwithATOMOXETINElBeta-blockers:plasmaconcentrationofimipramineincreasedbyLABETALOLandPROPRANOLOL;increasedriskofventriculararrhythmiaswhentricyclicsgivenwithlSOTALOL TRIANGLE Bupropion:plasmaconcentrationoftricyclicspossiblyincreasedbyBUPROPION(possibleincreasedriskofconvulsions) TRIANGLE Calcium-channelBlockers:plasmaconcentrationofimipramineincreasedbyDILTIAZEMandVERAPAMIL;plasmaconcentrationoftricyclicspossiblyincreasedbyDILTIAZEMandVERAPAMIL TRIANGLE CannabisExtract:possibleincreasedriskofhypertensionandtachycardiawhentricyclicsgivenwithCANNABISEXTRACTlClonidine:tricyclicsantagonisehypotensiveeffectoflCLONIDINE,alsoincreasedriskofhypertensiononclonidinewithdrawallCytotoxics:increasedriskofventriculararrhythmiaswhenamitriptylineorclomipraminegivenwithlARSENICTRIOXIDElDapoxetine:possibleincreasedriskofserotonergiceffectswhentricyclicsgivenwithlDAPOXETINE(manufacturerofdapoxetineadvisestricyclicsshouldnotbestarteduntil1weekafterstoppingdapoxetine,avoiddapoxetinefor2weeksafterstoppingtricyclics) TRIANGLE Disulfiram:metabolismoftricyclicsinhibitedbyDISULFIRAM(increasedplasmaconcentration);concomitantamitriptylinereportedtoincreaseDISULFIRAMreactionwithalcohol TRIANGLE Diuretics:increasedriskofposturalhypotensionwhentricyclicsgivenwithDIURETICSlDopaminergics:cautionwithtricyclicsadvisedbymanufacturerofENTACAPONE;increasedriskofCNStoxicity1148Appendix1InteractionsBNF70Interactions|Appendix1"
"Antidepressants,TricycliclDopaminergics(continued)whentricyclicsgivenwithlRASAGILINE;CNStoxicityreportedwhentricyclicsgivenwithlSELEGILINE TRIANGLE Histamine:tricyclicstheoreticallyantagoniseeffectsofHISTAMINE—manufacturerofhistamineadvisesavoidconcomitantuse TRIANGLE Lithium:riskoftoxicitywhentricyclicsgivenwithLITHIUMlMethylthioninium:riskofCNStoxicitywhenclomipraminegivenwithlMETHYLTHIONINIUM—avoidconcomitantuse(ifavoidancenotpossible,uselowestpossibledoseofmethylthioniniumandobservepatientforupto4hoursafteradministration) TRIANGLE Moxonidine:tricyclicspossiblyantagonisehypotensiveeffectofMOXONIDINE(manufacturerofmoxonidineadvisesavoidconcomitantuse) TRIANGLE MuscleRelaxants:tricyclicsenhancemusclerelaxanteffectofBACLOFEN TRIANGLE Nicorandil:tricyclicspossiblyenhancehypotensiveeffectofNICORANDIL TRIANGLE Nitrates:tricyclicsreduceeffectsofsublingualtabletsofNITRATES(failuretodissolveundertongueowingtodrymouth) TRIANGLE Oestrogens:antidepressanteffectoftricyclicsantagonisedbyOESTROGENS(butside-effectsoftricyclicspossiblyincreasedduetoincreasedplasmaconcentration)lPentamidineIsetionate:increasedriskofventriculararrhythmiaswhentricyclicsgivenwithlPENTAMIDINEISETIONATE TRIANGLE SodiumOxybate:increasedriskofside-effectswhentricyclicsgivenwithSODIUMOXYBATElSympathomimetics:increasedriskofhypertensionandarrhythmiaswhentricyclicsgivenwithlADRENALINE(EPINEPHRINE)(butlocalanaestheticswithadrenalineappeartobesafe);metabolismoftricyclicspossiblyinhibitedbyMETHYLPHENIDATE;increasedriskofhypertensionandarrhythmiaswhentricyclicsgivenwithlNORADRENALINE(NOREPINEPHRINE)orPHENYLEPHRINE TRIANGLE ThyroidHormones:effectsoftricyclicspossiblyenhancedbyTHYROIDHORMONES;effectsofamitriptylineandimipramineenhancedbyTHYROIDHORMONES TRIANGLE Ulcer-healingDrugs:plasmaconcentrationoftricyclicspossiblyincreasedbyCIMETIDINE;metabolismofamitriptyline,doxepin,imipramineandnortriptylineinhibitedbyCIMETIDINE(increasedplasmaconcentration)Antidepressants,Tricyclic(related)lAlcohol:increasedsedativeeffectwhentricyclic-relatedantidepressantsgivenwithlALCOHOL TRIANGLE Alpha2-adrenoceptorStimulants:avoidanceoftricyclic-relatedantidepressantsadvisedbymanufacturerofAPRACLONIDINEandBRIMONIDINE TRIANGLE Antibacterials:plasmaconcentrationoftrazodonepossiblyincreasedbyCLARITHROMYCIN TRIANGLE Anticoagulants:trazodonemayenhanceorreduceanticoagulanteffectofWARFARINlAntidepressants:tricyclic-relatedantidepressantsshouldnotbestarteduntil2weeksafterstoppinglMAOIS,alsoMAOIsshouldnotbestarteduntilatleast1–2weeksafterstoppingtricyclic-relatedantidepressants;afterstoppingtricyclic-relatedantidepressantsdonotstartlMOCLOBEMIDEforatleast1weeklAntiepileptics:tricyclic-relatedantidepressantspossiblyantagoniseanticonvulsanteffectoflANTIEPILEPTICS(convulsivethresholdlowered);plasmaconcentrationofmianserinandtrazodonereducedbylCARBAMAZEPINE;plasmaconcentrationofmianserinreducedbylFOSPHENYTOINandlPHENYTOIN;metabolismofmianserinacceleratedbylPHENOBARBITALandlPRIMIDONE(reducedplasmaconcentration) TRIANGLE Antihistamines:possibleincreasedantimuscarinicandsedativeeffectswhentricyclic-relatedantidepressantsgivenwithANTIHISTAMINESlAntimalarials:avoidanceofantidepressantsadvisedbymanufactureroflARTEMETHERWITHLUMEFANTRINEandlARTENIMOLWITHPIPERAQUINEAntidepressants,Tricyclic(related)(continued) TRIANGLE Antimuscarinics:possibleincreasedantimuscarinicside-effectswhentricyclic-relatedantidepressantsgivenwithANTIMUSCARINICSlAntivirals:plasmaconcentrationoftrazodoneincreasedbylRITONAVIR(increasedriskoftoxicity);increasedriskofventriculararrhythmiaswhentrazodonegivenwithlSAQUINAVIR—avoidconcomitantuse;plasmaconcentrationoftrazodonepossiblyincreasedbyTELAPREVIR TRIANGLE AnxiolyticsandHypnotics:increasedsedativeeffectwhentricyclic-relatedantidepressantsgivenwithANXIOLYTICSANDHYPNOTICS TRIANGLE Atomoxetine:possibleincreasedriskofconvulsionswhenantidepressantsgivenwithATOMOXETINE TRIANGLE Diazoxide:enhancedhypotensiveeffectwhentricyclic-relatedantidepressantsgivenwithDIAZOXIDE TRIANGLE Nitrates:tricyclic-relatedantidepressantspossiblyreduceeffectsofsublingualtabletsofNITRATES(failuretodissolveundertongueowingtodrymouth) TRIANGLE VasodilatorAntihypertensives:enhancedhypotensiveeffectwhentricyclic-relatedantidepressantsgivenwithHYDRALAZINEorSODIUMNITROPRUSSIDEAntidiabeticsNOTEOtherdrugsadministeredorallymayneedtobetakenatleast1hourbeforeor4hoursafterlixisenatideinjection,ortakenwithamealwhenlixisenatideisnotadministered,tominimisepossibleinterferencewithabsorptionNOTEOtherdrugsadministeredorallymayneedtobetakenatleast1hourbeforeor4hoursafterexenatideinjection,ortakenwithamealwhenexenatideisnotadministered,tominimisepossibleinterferencewithabsorption TRIANGLE ACEInhibitors:hypoglycaemiceffectofinsulin,metforminandsulfonylureaspossiblyenhancedbyACEINHIBITORS TRIANGLE Alcohol:hypoglycaemiceffectofantidiabeticsenhancedbyALCOHOL;increasedriskoflacticacidosiswhenmetformingivenwithALCOHOL TRIANGLE AnabolicSteroids:hypoglycaemiceffectofantidiabeticspossiblyenhancedbyANABOLICSTEROIDSlAnalgesics:effectsofsulfonylureaspossiblyenhancedbylNSAIDS;lixisenatidepossiblyreducestheabsorptionofPARACETAMOLwhengiven1to4hoursbeforeparacetamol TRIANGLE Anti-arrhythmics:hypoglycaemiceffectofgliclazide,insulinandmetforminpossiblyenhancedbyDISOPYRAMIDElAntibacterials:hypoglycaemiceffectofacarbosepossiblyenhancedbyNEOMYCIN,alsoseverityofgastro-intestinaleffectsincreased;effectsofrepaglinideenhancedbyCLARITHROMYCIN;effectsofglibenclamidepossiblyenhancedbyNORFLOXACIN;plasmaconcentrationofcanagliflozinandnateglinidereducedbylRIFAMPICIN;effectsoflinagliptinpossiblyreducedbyRIFAMPICIN;hypoglycaemiceffectofrepaglinidepossiblyantagonisedbyRIFAMPICIN;effectsofsulfonylureasenhancedbylCHLORAMPHENICOL;metabolismoftolbutamideacceleratedbylRIFAMYCINS(reducedeffect);metabolismofsulfonylureaspossiblyacceleratedbylRIFAMYCINS(reducedeffect);effectsofsulfonylureasrarelyenhancedbySULFONAMIDESandTRIMETHOPRIM;hypoglycaemiceffectofsulfonylureaspossiblyenhancedbyTETRACYCLINES;hypoglycaemiceffectofrepaglinidepossiblyenhancedbyTRIMETHOPRIM—manufactureradvisesavoidconcomitantuselAnticoagulants:exenatidepossiblyenhancesanticoagulanteffectofWARFARIN;hypoglycaemiceffectofsulfonylureaspossiblyenhancedbylCOUMARINS,alsopossiblechangestoanticoagulanteffect TRIANGLE Antidepressants:hypoglycaemiceffectofantidiabeticspossiblyenhancedbyMAOIS;hypoglycaemiceffectofinsulin,metforminandsulfonylureasenhancedbyMAOIS TRIANGLE Antidiabetics:manufacturerofdapagliflozinadvisesavoidconcomitantusewithPIOGLITAZONE TRIANGLE Antiepileptics:tolbutamidetransientlyincreasesplasmaconcentrationofFOSPHENYTOINandPHENYTOIN(possibilityoftoxicity);plasmaconcentrationofglibenclamidepossiblyreducedbyTOPIRAMATE;plasmaconcentrationofmetforminpossiblyincreasedbyTOPIRAMATElAntifungals:plasmaconcentrationofpioglitazone,saxagliptinandtolbutamideincreasedbyKETOCONAZOLE;plasmaBNF70Appendix1Interactions1149Interactions|Appendix1"
"AntidiabeticslAntifungals(continued)concentrationofsulfonylureasincreasedbylFLUCONAZOLEandlMICONAZOLE;hypoglycaemiceffectofgliclazideandglipizideenhancedbylMICONAZOLE—avoidconcomitantuse;hypoglycaemiceffectofnateglinidepossiblyenhancedbyFLUCONAZOLE;hypoglycaemiceffectofrepaglinidepossiblyenhancedbyITRACONAZOLE;hypoglycaemiceffectofglipizidepossiblyenhancedbyPOSACONAZOLE;plasmaconcentrationofsulfonylureaspossiblyincreasedbyVORICONAZOLE TRIANGLE Antihistamines:thrombocytecountdepressedwhenmetformingivenwithKETOTIFEN(manufacturerofketotifenadvisesavoidconcomitantuse) TRIANGLE Antipsychotics:hypoglycaemiceffectofsulfonylureaspossiblyantagonisedbyPHENOTHIAZINES TRIANGLE Antivirals:plasmaconcentrationoftolbutamidepossiblyincreasedbyRITONAVIR;plasmaconcentrationofmetforminincreasedbyTELAPREVIR(considerreducingdoseofmetformin) TRIANGLE Aprepitant:plasmaconcentrationoftolbutamidereducedbyAPREPITANT TRIANGLE Beta-blockers:warningsignsofhypoglycaemia(suchastremor)withantidiabeticsmaybemaskedwhengivenwithBETA-BLOCKERS;hypoglycaemiceffectofinsulinenhancedbyBETA-BLOCKERSlBosentan:increasedriskofhepatotoxicitywhenglibenclamidegivenwithlBOSENTAN—avoidconcomitantuse TRIANGLE Calcium-channelBlockers:glucosetoleranceoccasionallyimpairedwheninsulingivenwithNIFEDIPINE TRIANGLE CardiacGlycosides:canagliflozinandsitagliptinincreaseplasmaconcentrationofDIGOXIN;acarbosepossiblyreducesplasmaconcentrationofDIGOXIN TRIANGLE Ciclosporin:hypoglycaemiceffectofrepaglinidepossiblyenhancedbyCICLOSPORIN TRIANGLE Corticosteroids:hypoglycaemiceffectofantidiabeticsantagonisedbyCORTICOSTEROIDSlCytotoxics:avoidanceofrepaglinideadvisedbymanufactureroflLAPATINIB;plasmaconcentrationofmetforminpossiblyincreasedbyVANDETANIB(considerreducingdoseofmetformin) TRIANGLE Deferasirox:plasmaconcentrationofrepaglinideincreasedbyDEFERASIROX TRIANGLE Diazoxide:hypoglycaemiceffectofantidiabeticsantagonisedbyDIAZOXIDE TRIANGLE Diuretics:canagliflozinpossiblyenhancesdiureticeffectofDIURETICS;manufacturerofcanagliflozinadvisesavoidconcomitantusewithLOOPDIURETICS;hypoglycaemiceffectofantidiabeticsantagonisedbyLOOPDIURETICSandTHIAZIDESANDRELATEDDIURETICS;dapagliflozinpossiblyenhancesdiureticeffectofLOOPDIURETICSandTHIAZIDESANDRELATEDDIURETICS TRIANGLE Fosaprepitant:plasmaconcentrationoftolbutamidereducedbyFOSAPREPITANT TRIANGLE HormoneAntagonists:requirementsforantidiabeticspossiblyreducedbyLANREOTIDE,OCTREOTIDEandPASIREOTIDE TRIANGLE Leflunomide:hypoglycaemiceffectoftolbutamidepossiblyenhancedbyLEFLUNOMIDElLipid-regulatingDrugs:absorptionofglibenclamideandglipizidereducedbyCOLESEVELAM;absorptionofglimepiridereducedbyCOLESEVELAM—manufacturerofglimepirideadvisesgiveatleast4hoursbeforecolesevelam;hypoglycaemiceffectofacarbosepossiblyenhancedbyCOLESTYRAMINE;hypoglycaemiceffectofnateglinidepossiblyenhancedbyGEMFIBROZIL;increasedriskofseverehypoglycaemiawhenrepaglinidegivenwithlGEMFIBROZIL—avoidconcomitantuse;plasmaconcentrationofglibenclamidepossiblyincreasedbyFLUVASTATIN;manufacturerofcanagliflozinadvisesgiveatleast1hourbeforeor4–6hoursafterBILEACIDSEQUESTRANTS;maybeimprovedglucosetoleranceandanadditiveeffectwheninsulinorsulfonylureasgivenwithFIBRATES;separatingadministrationfromlinagliptinby12hoursadvisedbymanufacturerofLOMITAPIDE TRIANGLE Oestrogens:hypoglycaemiceffectofantidiabeticsantagonisedbyOESTROGENSAntidiabetics(continued) TRIANGLE Orlistat:avoidanceofacarboseadvisedbymanufacturerofORLISTAT TRIANGLE Pancreatin:hypoglycaemiceffectofacarboseantagonisedbyPANCREATIN TRIANGLE Progestogens:hypoglycaemiceffectofantidiabeticsantagonisedbyPROGESTOGENSlSulfinpyrazone:effectsofsulfonylureasenhancedbylSULFINPYRAZONE TRIANGLE Teriflunomide:plasmaconcentrationofrepaglinideincreasedbyTERIFLUNOMIDE TRIANGLE Testosterone:hypoglycaemiceffectofantidiabeticspossiblyenhancedbyTESTOSTERONE TRIANGLE Ulcer-healingDrugs:excretionofmetforminreducedbyCIMETIDINE(increasedplasmaconcentration);hypoglycaemiceffectofsulfonylureasenhancedbyCIMETIDINEAntiepilepticsseeCarbamazepine,Eslicarbazepine,Ethosuximide,Fosphenytoin,Gabapentin,Lacosamide,Lamotrigine,Levetiracetam,Oxcarbazepine,Perampanel,Phenobarbital,Phenytoin,Pregabalin,Primidone,Retigabine,Rufinamide,Sodiumvalproate,Stiripentol,Tiagabine,Topiramate,Valproicacid,Vigabatrin,andZonisamideAntifungalsseeAmphotericin;Antifungals,Imidazole;Antifungals,Triazole;Caspofungin;Flucytosine;Griseofulvin;Micafungin;TerbinafineAntifungals,Imidazole TRIANGLE Alcohol:possibilityofdisulfiram-likereactionwhenketoconazolegivenwithALCOHOL TRIANGLE Aliskiren:ketoconazoleincreasesplasmaconcentrationofALISKIRENlAlpha-blockers:ketoconazolepossiblyincreasesplasmaconcentrationofALFUZOSIN;ketoconazoleincreasesplasmaconcentrationoflTAMSULOSINlAminophylline:ketoconazolepossiblyincreasesplasmaconcentrationoflAMINOPHYLLINElAnalgesics:ketoconazoleinhibitsmetabolismoflBUPRENORPHINE(reducedoseofbuprenorphine);possibleincreasedriskofventriculararrhythmiaswhenketoconazolegivenwithlMETHADONE—manufacturerofketoconazoleadvisesavoidconcomitantuse;ketoconazoleincreasesplasmaconcentrationofOXYCODONE;manufacturerofketoconazoleadvisesavoidconcomitantusewithPARACETAMOL TRIANGLE Antacids:absorptionofketoconazolereducedbyANTACIDS TRIANGLE Anthelmintics:ketoconazoleincreasesplasmaconcentrationofPRAZIQUANTELlAnti-arrhythmics:increasedriskofventriculararrhythmiaswhenketoconazolegivenwithlDISOPYRAMIDE—avoidconcomitantuse;ketoconazoleincreasesplasmaconcentrationoflDRONEDARONE—avoidconcomitantuselAntibacterials:manufacturerofketoconazoleadvisesavoidconcomitantlCLARITHROMYCINinsevererenalimpairment;metabolismofketoconazoleacceleratedbylRIFAMPICIN(reducedplasmaconcentration),alsoplasmaconcentrationofrifampicinmaybereducedbyketoconazole;ketoconazoleincreasesplasmaconcentrationofBEDAQUILINE—avoidconcomitantuseifketoconazolegivenformorethan14days;avoidanceofketoconazoleadvisedbymanufacturerofFIDAXOMICIN;plasmaconcentrationofketoconazolepossiblyreducedbyISONIAZID;ketoconazoleincreasestheplasmaconcentrationoflTELITHROMYCIN—avoidinsevererenalandhepaticimpairmentlAnticoagulants:ketoconazoleincreasesplasmaconcentrationoflAPIXABAN—manufacturerofapixabanadvisesavoidconcomitantuse;miconazoleenhancesanticoagulanteffectoflCOUMARINS(miconazoleoralgelandpossiblyvaginalandtopicalformulationsabsorbed);ketoconazoleenhancesanticoagulanteffectoflCOUMARINS;ketoconazoleincreasesplasmaconcentrationoflDABIGATRANandlRIVAROXABAN—avoidconcomitantuselAntidepressants:avoidanceofimidazolesadvisedbymanufactureroflREBOXETINE;ketoconazoleincreasesplasmaconcentrationofMIRTAZAPINElAntidiabetics:miconazoleenhanceshypoglycaemiceffectoflGLICLAZIDEandlGLIPIZIDE—avoidconcomitantuse;1150Appendix1InteractionsBNF70Interactions|Appendix1"
"Antifungals,ImidazolelAntidiabetics(continued)ketoconazoleincreasesplasmaconcentrationofPIOGLITAZONE,SAXAGLIPTINandTOLBUTAMIDE;miconazoleincreasesplasmaconcentrationoflSULFONYLUREASlAntiepileptics:miconazolepossiblyincreasesplasmaconcentrationofCARBAMAZEPINE;plasmaconcentrationofketoconazolepossiblyreducedbyCARBAMAZEPINE,alsoplasmaconcentrationofcarbamazepinepossiblyincreased;plasmaconcentrationofketoconazolereducedbylFOSPHENYTOINandlPHENYTOIN;miconazoleenhancesanticonvulsanteffectoflFOSPHENYTOINandlPHENYTOIN(plasmaconcentrationoffosphenytoinandphenytoinincreased);ketoconazoleincreasesplasmaconcentrationofPERAMPANEL TRIANGLE Antifungals:imidazolespossiblyantagoniseeffectsofAMPHOTERICINlAntihistamines:imidazolespossiblyinhibitmetabolismoflMIZOLASTINE(avoidconcomitantuse)lAntimalarials:avoidanceofimidazolesadvisedbymanufactureroflARTEMETHERWITHLUMEFANTRINE;avoidanceofimidazolesadvisedbymanufactureroflARTENIMOLWITHPIPERAQUINE(possibleriskofventriculararrhythmias);ketoconazoleincreasesplasmaconcentrationofMEFLOQUINElAntimuscarinics:absorptionofketoconazolereducedbyANTIMUSCARINICS;ketoconazoleincreasesplasmaconcentrationofDARIFENACIN—avoidconcomitantuse;manufactureroffesoterodineadvisesdosereductionwhenketoconazolegivenwithFESOTERODINE—consultfesoterodineproductliterature;ketoconazoleincreasesplasmaconcentrationofOXYBUTYNIN;ketoconazoleincreasesplasmaconcentrationoflSOLIFENACIN—seeunderSolifenacin,p670;avoidanceofketoconazoleadvisedbymanufactureroflTOLTERODINElAntipsychotics:ketoconazoleinhibitsmetabolismoflARIPIPRAZOLE(reducedoseofaripiprazole);ketoconazoleincreasesplasmaconcentrationoflLURASIDONE—avoidconcomitantuse;increasedriskofventriculararrhythmiaswhenimidazolesgivenwithlPIMOZIDE—avoidconcomitantuse;imidazolespossiblyincreaseplasmaconcentrationoflQUETIAPINE—manufacturerofquetiapineadvisesavoidconcomitantuselAntivirals:ketoconazoleincreasesplasmaconcentrationoflBOCEPREVIR;ketoconazoleincreasestheplasmaconcentrationoflDACLATASVIR—reducedoseofdaclatasvir(seeunderDaclatasvir,p544);plasmaconcentrationofbothdrugsincreasedwhenketoconazolegivenwithDARUNAVIR;plasmaconcentrationofketoconazolereducedbylEFAVIRENZ;plasmaconcentrationofketoconazoleincreasedbyFOSAMPRENAVIR(alsoplasmaconcentrationoffosamprenavirpossiblyincreased);ketoconazoleincreasesplasmaconcentrationoflINDINAVIRandlMARAVIROC(considerreducingdoseofindinavirandmaraviroc);plasmaconcentrationofketoconazolereducedbylNEVIRAPINE—avoidconcomitantuse;plasmaconcentrationofketoconazoleincreasedbylRITONAVIR(reducedoseofketoconazole);imidazolespossiblyincreaseplasmaconcentrationofSAQUINAVIR;ketoconazoleincreasesplasmaconcentrationoflSAQUINAVIR—manufacturerofketoconazoleadvisesavoidconcomitantuse;avoidanceofketoconazoleadvisedbymanufactureroflSIMEPREVIR;plasmaconcentrationofbothdrugspossiblyincreasedwhenketoconazolegivenwithTELAPREVIR(increasedriskofventriculararrhythmias)—reducedoseofketoconazolelAnxiolyticsandHypnotics:ketoconazoleincreasesplasmaconcentrationoflALPRAZOLAM—manufacturerofketoconazoleadvisesavoidconcomitantuse;ketoconazoleincreasesplasmaconcentrationoflMIDAZOLAM(riskofprolongedsedation—avoidconcomitantuseoforalmidazolam);ketoconazoleincreasesplasmaconcentrationofZOLPIDEM TRIANGLE Aprepitant:ketoconazoleincreasesplasmaconcentrationofAPREPITANTlAvanafil:ketoconazoleincreasesplasmaconcentrationoflAVANAFIL—avoidconcomitantuseAntifungals,Imidazole(continued) TRIANGLE Beta-blockers:ketoconazolepossiblyincreasesplasmaconcentrationofNADOLOL TRIANGLE Bosentan:ketoconazoleincreasesplasmaconcentrationofBOSENTANlCalcium-channelBlockers:ketoconazoleinhibitsmetabolismoflFELODIPINE(increasedplasmaconcentration)—manufacturerofketoconazoleadvisesavoidconcomitantuse;avoidanceofketoconazoleadvisedbymanufacturerofLERCANIDIPINE;ketoconazolepossiblyinhibitsmetabolismofDIHYDROPYRIDINES(increasedplasmaconcentration) TRIANGLE CannabisExtract:ketoconazoleincreasesplasmaconcentrationofCANNABISEXTRACTlCiclosporin:ketoconazoleinhibitsmetabolismoflCICLOSPORIN(increasedplasmaconcentration);miconazolepossiblyinhibitsmetabolismoflCICLOSPORIN(increasedplasmaconcentration)lCilostazol:ketoconazoleincreasesplasmaconcentrationoflCILOSTAZOL(seeunderCilostazol,p206) TRIANGLE Cinacalcet:ketoconazoleinhibitsmetabolismofCINACALCET(increasedplasmaconcentration)lClopidogrel:ketoconazolepossiblyreducesantiplateleteffectoflCLOPIDOGREL TRIANGLE Cobicistat:plasmaconcentrationofketoconazolepossiblyincreasedbyCOBICISTAT—manufacturerofcobicistatadvisesreducedoseofketoconazolelColchicine:ketoconazolepossiblyincreasesriskoflCOLCHICINEtoxicity—suspendorreducedoseofcolchicine(avoidconcomitantuseinhepaticorrenalimpairment)lCorticosteroids:ketoconazolepossiblyinhibitsmetabolismofCORTICOSTEROIDS;ketoconazoleincreasestheplasmaconcentrationofinhaledandoral(andpossiblyalsointranasalandrectal)lBUDESONIDE;ketoconazoleincreasesplasmaconcentrationofactivemetaboliteoflCICLESONIDE;ketoconazolepossiblyincreasesplasmaconcentrationofinhaledFLUTICASONE;ketoconazoleinhibitsthemetabolismofMETHYLPREDNISOLONE;ketoconazoleincreasesplasmaconcentrationofinhaledMOMETASONElCytotoxics:ketoconazoleinhibitsthemetabolismofIFOSFAMIDE;possibleincreasedriskofneutropeniawhenketoconazolegivenwithlBRENTUXIMABVEDOTIN;ketoconazolepossiblyincreasestheplasmaconcentrationofAFATINIB—manufacturerofafatinibadvisesseparatingadministrationofketoconazoleby6to12hours;ketoconazoleincreasesplasmaconcentrationofAXITINIB(reducedoseofaxitinib—consultaxitinibproductliterature);ketoconazoleincreasestheplasmaconcentrationoflBOSUTINIB—manufacturerofbosutinibadvisesavoidorconsiderreducingdoseofbosutinib;ketoconazoleincreasesplasmaconcentrationofBORTEZOMIB,CABOZANTINIB,DABRAFENIB,ETOPOSIDE,IDELALISIB,IMATINIBandPONATINIB;ketoconazoleincreasesplasmaconcentrationoflCRIZOTINIB,lLAPATINIB,lNILOTINIBandlREGORAFENIB—avoidconcomitantuse;ketoconazolepossiblyincreasesplasmaconcentrationofDASATINIB;ketoconazoleinhibitsmetabolismofERLOTINIBandSUNITINIB(increasedplasmaconcentration);ketoconazoleincreasesplasmaconcentrationoflEVEROLIMUS—manufacturerofketoconazoleadvisesavoidconcomitantuse;ketoconazoleincreasesplasmaconcentrationoflIBRUTINIB—reducedoseofibrutinib(seeunderIbrutinib,p809);ketoconazoleincreasesplasmaconcentrationoflPAZOPANIB(reducedoseofpazopanib);manufacturerofruxolitinibadvisesdosereductionwhenketoconazolegivenwithlRUXOLITINIB—consultruxolitinibproductliterature;ketoconazoleincreasesplasmaconcentrationofactivemetaboliteoflTEMSIROLIMUS—avoidconcomitantuse;avoidanceofketoconazoleadvisedbymanufactureroflCABAZITAXEL;invitrostudiessuggestapossibleinteractionbetweenketoconazoleandDOCETAXEL(consultdocetaxelproductliterature);ketoconazolereducesplasmaconcentrationoflIRINOTECAN(butconcentrationofactivemetaboliteofirinotecanincreased)—avoidconcomitantuse;ketoconazoleincreasesplasmaconcentrationoflVINFLUNINE—manufacturerofvinflunineadvisesavoidconcomitantuseBNF70Appendix1Interactions1151Interactions|Appendix1"
"Antifungals,Imidazole(continued)lDapoxetine:ketoconazoleincreasesplasmaconcentrationoflDAPOXETINE—manufacturerofdapoxetineadvisesavoidconcomitantuselDiuretics:ketoconazoleincreasesplasmaconcentrationoflEPLERENONE—avoidconcomitantuselDomperidone:manufacturerofketoconazoleadvisesavoidconcomitantusewithlDOMPERIDONE(riskofventriculararrhythmias)lErgotAlkaloids:manufacturerofketoconazoleadvisesavoidconcomitantusewithlERGOTALKALOIDS;increasedriskofergotismwhenimidazolesgivenwithlERGOTAMINE—avoidconcomitantuselFingolimod:ketoconazoleincreasesplasmaconcentrationoflFINGOLIMOD TRIANGLE Fosaprepitant:ketoconazoleincreasesplasmaconcentrationofFOSAPREPITANT TRIANGLE HormoneAntagonists:manufacturerofketoconazoleadvisesavoidconcomitantusewithPASIREOTIDEl5HT1-receptorAgonists:ketoconazoleincreasesplasmaconcentrationofALMOTRIPTAN(increasedriskoftoxicity);ketoconazoleincreasesplasmaconcentrationoflELETRIPTAN(riskoftoxicity)—avoidconcomitantuselIvabradine:ketoconazoleincreasesplasmaconcentrationoflIVABRADINE—avoidconcomitantuselIvacaftor:ketoconazoleincreasesplasmaconcentrationoflIVACAFTOR(seeunderIvacaftor,p257) TRIANGLE Lanthanum:absorptionofketoconazolepossiblyreducedbyLANTHANUM(giveatleast2hoursapart)lLenalidomide:ketoconazolepossiblyincreasesplasmaconcentrationoflLENALIDOMIDE(increasedriskoftoxicity)lLipid-regulatingDrugs:possibleincreasedriskofmyopathywhenimidazolesgivenwithATORVASTATIN;possibleincreasedriskofmyopathywhenketoconazolegivenwithlATORVASTATIN—manufacturerofketoconazoleadvisesavoidconcomitantuse;increasedriskofmyopathywhenketoconazolegivenwithlSIMVASTATIN(avoidconcomitantuse);possibleincreasedriskofmyopathywhenmiconazolegivenwithlSIMVASTATIN;ketoconazoleincreasesplasmaconcentrationoflLOMITAPIDE—avoidconcomitantuse TRIANGLE Macitentan:ketoconazoleincreasesplasmaconcentrationofMACITENTAN TRIANGLE Mirabegron:whengivenwithketoconazoleavoidorreducedoseofMIRABEGRONinhepaticorrenalimpairment—seeMirabegron,p671lNintedanib:ketoconazoleincreasesplasmaconcentrationoflNINTEDANIB TRIANGLE Oestrogens:anecdotalreportsofcontraceptivefailurewhenimidazolesgivenwithOESTROGENS TRIANGLE Parasympathomimetics:ketoconazoleincreasesplasmaconcentrationofGALANTAMINElRanolazine:ketoconazoleincreasesplasmaconcentrationoflRANOLAZINE—avoidconcomitantuselRetinoids:ketoconazoleincreasesplasmaconcentrationofALITRETINOIN;ketoconazolepossiblyincreasesriskoflTRETINOINtoxicity TRIANGLE Riociguat:avoidanceofketoconazoleadvisedbymanufacturerofRIOCIGUATlSildenafil:ketoconazoleincreasesplasmaconcentrationoflSILDENAFIL—reduceinitialdoseofsildenafilforerectiledysfunctionandavoidconcomitantuseofsildenafilforpulmonaryhypertensionlSirolimus:ketoconazoleincreasesplasmaconcentrationoflSIROLIMUS—avoidconcomitantuse;miconazoleincreasesplasmaconcentrationoflSIROLIMUSlSympathomimetics,Beta2:ketoconazoleincreasesplasmaconcentrationofOLODATEROL;ketoconazoleinhibitsmetabolismoflSALMETEROL(increasedplasmaconcentration)lTacrolimus:ketoconazoleincreasesplasmaconcentrationoflTACROLIMUS(considerreducingdoseoftacrolimus);miconazoleoralgelpossiblyincreasesplasmaconcentrationoflTACROLIMUSlTadalafil:ketoconazoleincreasesplasmaconcentrationoflTADALAFIL—avoidconcomitantuseoftadalafilforpulmonaryhypertensionAntifungals,Imidazole(continued)lTheophylline:ketoconazolepossiblyincreasesplasmaconcentrationoflTHEOPHYLLINElTicagrelor:ketoconazoleincreasesplasmaconcentrationoflTICAGRELOR—manufacturerofticagreloradvisesavoidconcomitantuse TRIANGLE Tolvaptan:ketoconazoleincreasesplasmaconcentrationofTOLVAPTAN—manufacturerofketoconazoleadvisesavoidconcomitantuse TRIANGLE Ulcer-healingDrugs:absorptionofketoconazolereducedbyHISTAMINEH2-ANTAGONISTS,PROTONPUMPINHIBITORSandSUCRALFATE TRIANGLE Ulipristal:ketoconazoleincreasesplasmaconcentrationoflow-doseULIPRISTAL—manufactureroflow-doseulipristaladvisesavoidconcomitantuselVardenafil:ketoconazoleincreasesplasmaconcentrationoflVARDENAFIL—avoidconcomitantuse TRIANGLE Vitamins:miconazolepossiblyreduceseffectsofALFACALCIDOL,CALCITRIOL,COLECALCIFEROL,DIHYDROTACHYSTEROL,ERGOCALCIFEROL,PARICALCITOLandVITAMIND;ketoconazolepossiblyincreasesplasmaconcentrationofPARICALCITOLAntifungals,PolyeneseeAmphotericinAntifungals,TriazoleNOTEIngeneral,fluconazoleinteractionsrelatetomultiple-dosetreatmentlAliskiren:itraconazoleincreasesplasmaconcentrationoflALISKIREN—avoidconcomitantuselAminophylline:fluconazolepossiblyincreasesplasmaconcentrationoflAMINOPHYLLINElAnalgesics:fluconazoleincreasesplasmaconcentrationofCELECOXIB(halvedoseofcelecoxib);voriconazoleincreasesplasmaconcentrationofDICLOFENAC,IBUPROFENandlOXYCODONE;fluconazoleincreasesplasmaconcentrationofFLURBIPROFEN,IBUPROFENandMETHADONE;fluconazoleincreasesplasmaconcentrationofPARECOXIB(reducedoseofparecoxib);voriconazoleincreasesplasmaconcentrationoflALFENTANILandlMETHADONE(considerreducingdoseofalfentanilandmethadone);fluconazoleinhibitsmetabolismofALFENTANIL(riskofprolongedordelayedrespiratorydepression);itraconazolepossiblyinhibitsmetabolismofALFENTANIL;triazolespossiblyincreaseplasmaconcentrationoflFENTANYL;itraconazolepossiblyincreasesplasmaconcentrationoflMETHADONE(increasedriskofventriculararrhythmias);itraconazoleincreasesplasmaconcentrationofOXYCODONE TRIANGLE Antacids:absorptionofitraconazolereducedbyANTACIDSlAnti-arrhythmics:manufacturerofitraconazoleadvisesavoidconcomitantusewithlDISOPYRAMIDE;avoidanceofitraconazole,posaconazoleandvoriconazoleadvisedbymanufactureroflDRONEDARONElAntibacterials:plasmaconcentrationofitraconazoleincreasedbyCLARITHROMYCIN;manufactureroffluconazoleadvisesavoidconcomitantusewithERYTHROMYCIN;triazolespossiblyincreaseplasmaconcentrationoflRIFABUTIN(increasedriskofuveitis—reducerifabutindose);posaconazoleincreasesplasmaconcentrationoflRIFABUTIN(alsoplasmaconcentrationofposaconazolereduced);voriconazoleincreasesplasmaconcentrationoflRIFABUTIN,alsorifabutinreducesplasmaconcentrationofvoriconazole(increasedoseofvoriconazoleandalsomonitorforrifabutintoxicity);fluconazoleincreasesplasmaconcentrationoflRIFABUTIN(increasedriskofuveitis—reducerifabutindose);plasmaconcentrationofitraconazolereducedbylRIFABUTINandlRIFAMPICIN—manufacturerofitraconazoleadvisesavoidconcomitantuse;plasmaconcentrationofposaconazolereducedbylRIFAMPICIN;plasmaconcentrationofvoriconazolereducedbylRIFAMPICIN—avoidconcomitantuse;metabolismoffluconazoleacceleratedbylRIFAMPICIN(reducedplasmaconcentration);fluconazolepossiblyincreasesplasmaconcentrationofBEDAQUILINE—avoidconcomitantuseiffluconazolegivenformorethan14dayslAnticoagulants:avoidanceofitraconazole,posaconazoleandvoriconazoleadvisedbymanufacturerofAPIXABAN;fluconazole,itraconazoleandvoriconazoleenhance1152Appendix1InteractionsBNF70Interactions|Appendix1"
"Antifungals,TriazolelAnticoagulants(continued)anticoagulanteffectoflCOUMARINS;avoidanceofitraconazoleadvisedbymanufacturerofDABIGATRANandRIVAROXABAN;avoidanceofposaconazoleandvoriconazoleadvisedbymanufacturerofRIVAROXABANlAntidepressants:avoidanceoftriazolesadvisedbymanufactureroflREBOXETINE;fluconazolepossiblyincreasesplasmaconcentrationofAMITRIPTYLINEandNORTRIPTYLINE;plasmaconcentrationofvoriconazolereducedbylSTJOHN’SWORT—avoidconcomitantuselAntidiabetics:posaconazolepossiblyenhanceshypoglycaemiceffectofGLIPIZIDE;fluconazolepossiblyenhanceshypoglycaemiceffectofNATEGLINIDE;itraconazolepossiblyenhanceshypoglycaemiceffectofREPAGLINIDE;fluconazoleincreasesplasmaconcentrationoflSULFONYLUREAS;voriconazolepossiblyincreasesplasmaconcentrationofSULFONYLUREASlAntiepileptics:fluconazolepossiblyincreasesplasmaconcentrationofCARBAMAZEPINE;plasmaconcentrationofvoriconazolepossiblyreducedbylCARBAMAZEPINE,lPHENOBARBITALandlPRIMIDONE—avoidconcomitantuse;plasmaconcentrationofitraconazoleandposaconazolepossiblyreducedbylCARBAMAZEPINE;voriconazoleincreasesplasmaconcentrationoflFOSPHENYTOINandlPHENYTOIN,alsofosphenytoinandphenytoinreducesplasmaconcentrationofvoriconazole(increasedoseofvoriconazoleandalsomonitorforfosphenytoinandphenytointoxicity);plasmaconcentrationofposaconazolereducedbylFOSPHENYTOINandlPHENYTOIN;plasmaconcentrationofitraconazolereducedbylFOSPHENYTOINandlPHENYTOIN—avoidconcomitantuse;fluconazoleincreasesplasmaconcentrationoflFOSPHENYTOINandlPHENYTOIN(considerreducingdoseoffosphenytoinandphenytoin);plasmaconcentrationofitraconazoleandposaconazolepossiblyreducedbylPHENOBARBITAL;plasmaconcentrationofitraconazoleandposaconazolepossiblyreducedbylPRIMIDONE TRIANGLE Antifungals:triazolespossiblyantagoniseeffectsofAMPHOTERICIN;monitoringforincreasedvoriconazolesideeffectsadvisedbymanufacturerofFLUCONAZOLEifvoriconazolegivenafterfluconazole;plasmaconcentrationofitraconazoleincreasedbyMICAFUNGIN(considerreducingdoseofitraconazole);plasmaconcentrationoffluconazoleincreasedbyTERBINAFINElAntihistamines:itraconazoleinhibitsmetabolismoflMIZOLASTINE—avoidconcomitantuselAntimalarials:avoidanceoftriazolesadvisedbymanufactureroflARTEMETHERWITHLUMEFANTRINE;avoidanceoftriazolesadvisedbymanufactureroflARTENIMOLWITHPIPERAQUINE(possibleriskofventriculararrhythmias)lAntimuscarinics:avoidanceofitraconazoleadvisedbymanufacturerofDARIFENACINandTOLTERODINE;manufactureroffesoterodineadvisesdosereductionwhenitraconazolegivenwithFESOTERODINE—consultfesoterodineproductliterature;itraconazolepossiblyincreasesplasmaconcentrationoflSOLIFENACIN—seeunderSolifenacin,p670lAntipsychotics:itraconazolepossiblyincreasesplasmaconcentrationofHALOPERIDOL;itraconazolepossiblyincreasesplasmaconcentrationoflARIPIPRAZOLE(reducedoseofaripiprazole—consultaripiprazoleproductliterature);itraconazole,posaconazoleandvoriconazolepossiblyincreaseplasmaconcentrationoflLURASIDONE—avoidconcomitantuse;fluconazolepossiblyincreasestheplasmaconcentrationoflLURASIDONE(seeunderLurasidone,p315);increasedriskofventriculararrhythmiaswhentriazolesgivenwithlPIMOZIDE—avoidconcomitantuse;triazolespossiblyincreaseplasmaconcentrationoflQUETIAPINE—manufacturerofquetiapineadvisesavoidconcomitantuse;itraconazolepossiblyincreasesside-effectsofRISPERIDONElAntivirals:plasmaconcentrationofvoriconazoleincreasedordecreasedbylATAZANAVIRandplasmaconcentrationofatazanaviralsoreduced;posaconazoleincreasesplasmaAntifungals,TriazolelAntivirals(continued)concentrationoflATAZANAVIR;itraconazole,posaconazoleandvoriconazolepossiblyincreasetheplasmaconcentrationoflDACLATASVIR—reducedoseofdaclatasvir(seeunderDaclatasvir,p544);plasmaconcentrationofvoriconazolereducedbylEFAVIRENZ,alsoplasmaconcentrationofefavirenzincreased(increasevoriconazoledoseandreduceefavirenzdose);plasmaconcentrationofitraconazoleandposaconazolereducedbylEFAVIRENZ;plasmaconcentrationofbothdrugsmayincreasewhenitraconazolegivenwithFOSAMPRENAVIR;plasmaconcentrationofposaconazolepossiblyreducedbyFOSAMPRENAVIR;itraconazoleincreasesplasmaconcentrationoflINDINAVIR(considerreducingdoseofindinavir);fluconazoleincreasesplasmaconcentrationoflNEVIRAPINE,RITONAVIRandTIPRANAVIR;plasmaconcentrationofitraconazolepossiblyreducedbyNEVIRAPINE—considerincreasingdoseofitraconazole;plasmaconcentrationofvoriconazolereducedbylRITONAVIR—avoidconcomitantuse;combinationofitraconazolewithlRITONAVIRmayincreaseplasmaconcentrationofeitherdrug(orboth);triazolespossiblyincreaseplasmaconcentrationofSAQUINAVIR;fluconazole,itraconazole,posaconazoleandvoriconazolepossiblyincreaseplasmaconcentrationoflSIMEPREVIR—manufacturerofsimepreviradvisesavoidconcomitantuse;plasmaconcentrationofvoriconazolepossiblyaffectedbylTELAPREVIR(possibleincreasedriskofventriculararrhythmias);plasmaconcentrationofposaconazolepossiblyincreasedbylTELAPREVIR(increasedriskofventriculararrhythmias);plasmaconcentrationofitraconazolepossiblyincreasedbyTELAPREVIR;fluconazoleincreasesplasmaconcentrationoflZIDOVUDINE(increasedriskoftoxicity)lAnxiolyticsandHypnotics:itraconazoleincreasesplasmaconcentrationofALPRAZOLAM;fluconazoleandvoriconazoleincreaseplasmaconcentrationoflDIAZEPAM(riskofprolongedsedation);fluconazole,itraconazole,posaconazoleandvoriconazoleincreaseplasmaconcentrationoflMIDAZOLAM(riskofprolongedsedation);itraconazoleincreasesplasmaconcentrationofBUSPIRONE(reducedoseofbuspirone)lAvanafil:itraconazoleandvoriconazolepossiblyincreaseplasmaconcentrationoflAVANAFIL—manufacturerofavanafiladvisesavoidconcomitantuse;fluconazolepossiblyincreasesplasmaconcentrationoflAVANAFIL—seeunderAvanafil,p698lBosentan:fluconazolepossiblyincreasesplasmaconcentrationoflBOSENTAN—avoidconcomitantuse;itraconazolepossiblyincreasesplasmaconcentrationofBOSENTANlCalcium-channelBlockers:negativeinotropiceffectpossiblyincreasedwhenitraconazolegivenwithCALCIUM-CHANNELBLOCKERS;itraconazoleinhibitsmetabolismoflFELODIPINE(increasedplasmaconcentration);avoidanceofitraconazoleadvisedbymanufacturerofLERCANIDIPINE;itraconazolepossiblyinhibitsmetabolismofDIHYDROPYRIDINES(increasedplasmaconcentration)lCardiacGlycosides:itraconazoleincreasesplasmaconcentrationoflDIGOXINlCiclosporin:fluconazole,itraconazole,posaconazoleandvoriconazoleinhibitmetabolismoflCICLOSPORIN(increasedplasmaconcentration)lCilostazol:itraconazolepossiblyincreasesplasmaconcentrationoflCILOSTAZOL(seeunderCilostazol,p206)lClopidogrel:fluconazole,itraconazoleandvoriconazolepossiblyreduceantiplateleteffectoflCLOPIDOGREL TRIANGLE Cobicistat:plasmaconcentrationofitraconazolepossiblyincreasedbyCOBICISTAT—manufacturerofcobicistatadvisesreducedoseofitraconazolelColchicine:itraconazolepossiblyincreasesriskoflCOLCHICINEtoxicity—suspendorreducedoseofcolchicine(avoidconcomitantuseinhepaticorrenalimpairment)lCorticosteroids:itraconazolepossiblyinhibitsmetabolismofCORTICOSTEROIDSandMETHYLPREDNISOLONE;itraconazoleincreasestheplasmaconcentrationofinhaledandoral(andBNF70Appendix1Interactions1153Interactions|Appendix1"
"Antifungals,TriazolelCorticosteroids(continued)possiblyalsointranasalandrectal)lBUDESONIDE;itraconazoleincreasesplasmaconcentrationofinhaledFLUTICASONElCytotoxics:itraconazoleinhibitsmetabolismofBUSULFAN(increasedriskoftoxicity);fluconazoleanditraconazolepossiblyincreaseside-effectsofCYCLOPHOSPHAMIDE;itraconazolepossiblyincreasestheplasmaconcentrationofAFATINIB—manufacturerofafatinibadvisesseparatingadministrationofitraconazoleby6to12hours;itraconazolepossiblyincreasesplasmaconcentrationofAXITINIB(reducedoseofaxitinib—consultaxitinibproductliterature);fluconazole,itraconazole,posaconazoleandvoriconazolepossiblyincreasetheplasmaconcentrationoflBOSUTINIB—manufacturerofbosutinibadvisesavoidorconsiderreducingdoseofbosutinib;itraconazolepossiblyincreasesplasmaconcentrationofCABOZANTINIB;itraconazoleandvoriconazolepossiblyincreaseplasmaconcentrationoflCRIZOTINIB—manufacturerofcrizotinibadvisesavoidconcomitantuse;avoidanceofitraconazoleadvisedbymanufacturerofDASATINIBandlTEMSIROLIMUS(plasmaconcentrationofdasatinibandtemsirolimuspossiblyincreased);itraconazole,posaconazoleandvoriconazolepossiblyincreaseplasmaconcentrationoflEVEROLIMUS—manufacturerofeverolimusadvisesavoidconcomitantuse;itraconazoleincreasesplasmaconcentrationofGEFITINIB;fluconazole,itraconazoleandvoriconazolepossiblyincreasetheplasmaconcentrationoflIBRUTINIB—reducedoseofibrutinib(seeunderIbrutinib,p809);avoidanceofitraconazole,posaconazoleandvoriconazoleadvisedbymanufactureroflLAPATINIB;avoidanceofitraconazoleandvoriconazoleadvisedbymanufactureroflNILOTINIB;itraconazoleandvoriconazolepossiblyincreaseplasmaconcentrationoflPAZOPANIB(reducedoseofpazopanib);itraconazoleandvoriconazolepossiblyincreaseplasmaconcentrationofPONATINIB—considerreducinginitialdoseofponatinib(seeunderPonatinib,p814);manufacturerofruxolitinibadvisesdosereductionwhenfluconazole,itraconazole,posaconazoleandvoriconazolegivenwithlRUXOLITINIB—consultruxolitinibproductliterature;itraconazoleandvoriconazolepossiblyincreasetheplasmaconcentrationoflCABAZITAXEL—manufacturerofcabazitaxeladvisesavoidorconsiderreducingdoseofcabazitaxel;itraconazoleandvoriconazolepossiblyincreaseplasmaconcentrationoflDOCETAXEL—manufacturerofdocetaxeladvisesavoidconcomitantuseorconsiderreducingdocetaxeldose;increasedriskoftoxicitywhenitraconazolegivenwithlIRINOTECAN—avoidconcomitantuse;itraconazolepossiblyincreasesriskoflVINBLASTINE,lVINDESINE,lVINFLUNINEandlVINORELBINEtoxicity;posaconazolepossiblyinhibitsmetabolismoflVINBLASTINEandlVINCRISTINE(increasedriskofneurotoxicity);itraconazoleincreasesriskoflVINCRISTINEtoxicitylDapoxetine:manufacturerofdapoxetineadvisesdosereductionwhenfluconazolegivenwithDAPOXETINE(seeunderDapoxetine,p703);avoidanceofitraconazoleadvisedbymanufactureroflDAPOXETINE(increasedriskoftoxicity)lDiuretics:fluconazoleincreasesplasmaconcentrationofEPLERENONE(reducedoseofeplerenone);itraconazoleincreasesplasmaconcentrationoflEPLERENONE—avoidconcomitantuse;plasmaconcentrationoffluconazoleincreasedbyHYDROCHLOROTHIAZIDElDomperidone:possibleincreasedriskofventriculararrhythmiaswhenitraconazoleorvoriconazolegivenwithlDOMPERIDONE—avoidconcomitantuselErgotAlkaloids:increasedriskofergotismwhenvoriconazolegivenwithlERGOMETRINE—avoidconcomitantuse;manufacturerofitraconazoleadvisesavoidconcomitantusewithlERGOMETRINE(increasedriskofergotism);increasedriskofergotismwhentriazolesgivenwithlERGOTAMINE—avoidconcomitantusel5HT1-receptorAgonists:itraconazoleincreasesplasmaconcentrationoflELETRIPTAN(riskoftoxicity)—avoidconcomitantuseAntifungals,Triazole(continued)lIvabradine:fluconazoleincreasesplasmaconcentrationofIVABRADINE—reduceinitialdoseofivabradine;itraconazolepossiblyincreasesplasmaconcentrationoflIVABRADINE—avoidconcomitantuselIvacaftor:itraconazole,posaconazoleandvoriconazolepossiblyincreaseplasmaconcentrationoflIVACAFTOR(seeunderIvacaftor,p257);fluconazoleincreasesplasmaconcentrationoflIVACAFTOR(seeunderIvacaftor,p257)lLenalidomide:itraconazolepossiblyincreasesplasmaconcentrationoflLENALIDOMIDE(increasedriskoftoxicity) TRIANGLE LeukotrieneReceptorAntagonists:fluconazoleincreasesplasmaconcentrationofZAFIRLUKASTlLipid-regulatingDrugs:increasedriskofmyopathywhenitraconazole,posaconazoleorvoriconazolegivenwithlATORVASTATIN;possibleincreasedriskofmyopathywhenfluconazolegivenwithlATORVASTATINorlSIMVASTATIN;fluconazoleincreasesplasmaconcentrationofFLUVASTATIN—possibleincreasedriskofmyopathy;itraconazoleincreasesplasmaconcentrationoflROSUVASTATIN—adjustdoseofrosuvastatin(consultproductliterature);increasedriskofmyopathywhenitraconazoleorposaconazolegivenwithlSIMVASTATIN(avoidconcomitantuse);increasedriskofmyopathywhenvoriconazolegivenwithlSIMVASTATIN;avoidanceoftriazolesadvisedbymanufactureroflLOMITAPIDE(plasmaconcentrationoflomitapidepossiblyincreased) TRIANGLE Mirabegron:whengivenwithitraconazoleavoidorreducedoseofMIRABEGRONinhepaticorrenalimpairment—seeMirabegron,p671 TRIANGLE Oestrogens:plasmaconcentrationofvoriconazoleincreasedbyOESTROGENS TRIANGLE Progestogens:plasmaconcentrationofvoriconazolepossiblyincreasedbyPROGESTOGENSlRanolazine:itraconazole,posaconazoleandvoriconazolepossiblyincreaseplasmaconcentrationoflRANOLAZINE—manufacturerofranolazineadvisesavoidconcomitantuselRetinoids:fluconazoleandvoriconazolepossiblyincreaseriskoflTRETINOINtoxicity TRIANGLE Riociguat:avoidanceofitraconazoleandvoriconazoleadvisedbymanufacturerofRIOCIGUAT TRIANGLE Sildenafil:itraconazoleincreasesplasmaconcentrationofSILDENAFIL—reduceinitialdoseofsildenafillSirolimus:fluconazoleandposaconazolepossiblyincreaseplasmaconcentrationofSIROLIMUS;itraconazoleandvoriconazoleincreaseplasmaconcentrationoflSIROLIMUS—avoidconcomitantuselTacrolimus:fluconazole,itraconazole,posaconazoleandvoriconazoleincreaseplasmaconcentrationoflTACROLIMUS(considerreducingdoseoftacrolimus) TRIANGLE Tadalafil:itraconazolepossiblyincreasesplasmaconcentrationofTADALAFILlTheophylline:fluconazolepossiblyincreasesplasmaconcentrationoflTHEOPHYLLINElUlcer-healingDrugs:plasmaconcentrationofposaconazolereducedbylCIMETIDINEandlESOMEPRAZOLE—manufacturerofposaconazolesuspensionadvisesavoidconcomitantuse;plasmaconcentrationofposaconazolepossiblyreducedbylFAMOTIDINE,lLANSOPRAZOLE,lNIZATIDINE,lOMEPRAZOLE,lPANTOPRAZOLE,lRABEPRAZOLEandlRANITIDINE—manufacturerofposaconazolesuspensionadvisesavoidconcomitantuse;voriconazolepossiblyincreasesplasmaconcentrationofESOMEPRAZOLE;voriconazoleincreasesplasmaconcentrationofOMEPRAZOLE(considerreducingdoseofomeprazole);absorptionofitraconazolereducedbyHISTAMINEH2-ANTAGONISTSandPROTONPUMPINHIBITORS TRIANGLE Ulipristal:avoidanceofitraconazoleadvisedbymanufacturerofULIPRISTALlVardenafil:itraconazolepossiblyincreasesplasmaconcentrationoflVARDENAFIL—avoidconcomitantuseAntihistaminesNOTESedativeinteractionsapplytoalesserextenttothenon-sedatingantihistaminesInteractionsdonotgenerallyapplytoantihistaminesusedfortopicalaction(includinginhalation)1154Appendix1InteractionsBNF70Interactions|Appendix1"
"Antihistamines(continued) TRIANGLE Alcohol:increasedsedativeeffectwhenantihistaminesgivenwithALCOHOL(possiblylesseffectwithnon-sedatingantihistamines)lAnalgesics:sedativeeffectspossiblyincreasedwhensedatingantihistaminesgivenwithlOPIOIDANALGESICS TRIANGLE Antacids:absorptionoffexofenadinereducedbyANTACIDSlAnti-arrhythmics:increasedriskofventriculararrhythmiaswhenmizolastinegivenwithlAMIODARONE,lDISOPYRAMIDEorlFLECAINIDE—avoidconcomitantuse;manufacturerofmizolastineadvisesavoidconcomitantusewithPROPAFENONE(possibleriskofventriculararrhythmias)lAntibacterials:manufacturerofloratadineadvisesplasmaconcentrationpossiblyincreasedbyERYTHROMYCIN;metabolismofmizolastineinhibitedbylERYTHROMYCIN—avoidconcomitantuse;increasedriskofventriculararrhythmiaswhenmizolastinegivenwithlMOXIFLOXACIN—avoidconcomitantuse;effectsoffexofenadinepossiblyreducedbyRIFAMPICIN;metabolismofmizolastinepossiblyinhibitedbylMACROLIDES(avoidconcomitantuse)lAntidepressants:avoidanceofmizolastineadvisedbymanufactureroflCITALOPRAMandlESCITALOPRAM(riskofventriculararrhythmias);increasedantimuscarinicandsedativeeffectswhenantihistaminesgivenwithMAOISorTRICYCLICS;manufacturerofpromethazineadvisesavoidfor2weeksafterstoppingMAOIS;manufacturerofhydroxyzineadvisesavoidconcomitantusewithMAOIS;cyproheptadinepossiblyantagonisesantidepressanteffectofSSRIS;possibleincreasedantimuscarinicandsedativeeffectswhenantihistaminesgivenwithTRICYCLIC-RELATEDANTIDEPRESSANTS TRIANGLE Antidiabetics:thrombocytecountdepressedwhenketotifengivenwithMETFORMIN(manufacturerofketotifenadvisesavoidconcomitantuse)lAntifungals:metabolismofmizolastineinhibitedbylITRACONAZOLE—avoidconcomitantuse;metabolismofmizolastinepossiblyinhibitedbylIMIDAZOLES(avoidconcomitantuse)lAntimalarials:avoidanceofmizolastineadvisedbymanufactureroflARTENIMOLWITHPIPERAQUINE(possibleriskofventriculararrhythmias) TRIANGLE Antimuscarinics:increasedriskofantimuscarinicside-effectswhenantihistaminesgivenwithANTIMUSCARINICSlAntivirals:plasmaconcentrationofchlorphenaminepossiblyincreasedbyLOPINAVIR;plasmaconcentrationofnon-sedatingantihistaminespossiblyincreasedbyRITONAVIR;increasedriskofventriculararrhythmiaswhenmizolastinegivenwithlSAQUINAVIR—avoidconcomitantuse TRIANGLE AnxiolyticsandHypnotics:increasedsedativeeffectwhenantihistaminesgivenwithANXIOLYTICSANDHYPNOTICSlBeta-blockers:increasedriskofventriculararrhythmiaswhenmizolastinegivenwithlSOTALOL—avoidconcomitantuse TRIANGLE Betahistine:antihistaminestheoreticallyantagoniseeffectofBETAHISTINElCytotoxics:possibleincreasedriskofventriculararrhythmiaswhenmizolastinegivenwithlVANDETANIB—avoidconcomitantuse TRIANGLE GrapefruitJuice:plasmaconcentrationofbilastinereducedbyGRAPEFRUITJUICE TRIANGLE Histamine:antihistaminestheoreticallyantagoniseeffectsofHISTAMINE—manufacturerofhistamineadvisesavoidconcomitantuse TRIANGLE Ulcer-healingDrugs:manufacturerofloratadineadvisesplasmaconcentrationpossiblyincreasedbyCIMETIDINE;plasmaconcentrationofhydroxyzineincreasedbyCIMETIDINE TRIANGLE Ulipristal:manufacturerofulipristaladvisesgivefexofenadineatleast15hoursbeforeorafterULIPRISTALAntihistamines,Non-sedatingseeAntihistaminesAntihistamines,SedatingseeAntihistaminesAntimalarialsseeArtemetherwithLumefantrine,ArtenimolwithPiperaquine,Chloroquine,Hydroxychloroquine,Mefloquine,Primaquine,Proguanil,Pyrimethamine,andQuinineAntimetabolitesseeCapecitabine,Cladribine,Cytarabine,Decitabine,Fludarabine,Fluorouracil,Gemcitabine,Antimetabolites(continued)Mercaptopurine,Methotrexate,Pemetrexed,Raltitrexed,Tegafur,andTioguanineAntimuscarinicsNOTEManydrugshaveantimuscariniceffects;concomitantuseoftwoormoresuchdrugscanincreaseside-effectssuchasdrymouth,urineretention,andconstipation;concomitantusecanalsoleadtoconfusionintheelderlyInteractionsdonotgenerallyapplytoantimuscarinicsusedbyinhalation TRIANGLE Alcohol:increasedsedativeeffectwhenhyoscinegivenwithALCOHOL TRIANGLE Analgesics:possibleincreasedriskofantimuscarinicside-effectswhenantimuscarinicsgivenwithCODEINE;increasedriskofantimuscarinicside-effectswhenantimuscarinicsgivenwithNEFOPAMlAnti-arrhythmics:increasedriskofventriculararrhythmiaswhentolterodinegivenwithlAMIODARONE,lDISOPYRAMIDEorlFLECAINIDE;increasedriskofantimuscarinicside-effectswhenantimuscarinicsgivenwithDISOPYRAMIDE TRIANGLE Antibacterials:manufactureroffesoterodineadvisesdosereductionwhenfesoterodinegivenwithCLARITHROMYCINandTELITHROMYCIN—consultfesoterodineproductliterature;manufactureroftolterodineadvisesavoidconcomitantusewithCLARITHROMYCINandERYTHROMYCIN;plasmaconcentrationofdarifenacinpossiblyincreasedbyERYTHROMYCIN;plasmaconcentrationofactivemetaboliteoffesoterodinereducedbyRIFAMPICIN TRIANGLE Antidepressants:plasmaconcentrationofdarifenacinandprocyclidineincreasedbyPAROXETINE;increasedriskofantimuscarinicside-effectswhenantimuscarinicsgivenwithMAOISorTRICYCLICS;possibleincreasedantimuscarinicside-effectswhenantimuscarinicsgivenwithTRICYCLIC-RELATEDANTIDEPRESSANTSlAntifungals:antimuscarinicsreduceabsorptionofKETOCONAZOLE;manufactureroffesoterodineadvisesdosereductionwhenfesoterodinegivenwithITRACONAZOLEandKETOCONAZOLE—consultfesoterodineproductliterature;plasmaconcentrationofdarifenacinincreasedbyKETOCONAZOLE—avoidconcomitantuse;plasmaconcentrationofsolifenacinincreasedbylKETOCONAZOLE—seeunderSolifenacin,p670;plasmaconcentrationofoxybutyninincreasedbyKETOCONAZOLE;manufactureroftolterodineadvisesavoidconcomitantusewithITRACONAZOLEandlKETOCONAZOLE;manufacturerofdarifenacinadvisesavoidconcomitantusewithITRACONAZOLE;plasmaconcentrationofsolifenacinpossiblyincreasedbylITRACONAZOLE—seeunderSolifenacin,p670 TRIANGLE Antihistamines:increasedriskofantimuscarinicside-effectswhenantimuscarinicsgivenwithANTIHISTAMINES TRIANGLE Antipsychotics:antimuscarinicspossiblyreduceeffectsofHALOPERIDOL;increasedriskofantimuscarinicside-effectswhenantimuscarinicsgivenwithCLOZAPINE;antimuscarinicsreduceplasmaconcentrationofPHENOTHIAZINES,butriskofantimuscarinicside-effectsincreasedlAntivirals:manufactureroffesoterodineadvisesdosereductionwhenfesoterodinegivenwithATAZANAVIR,INDINAVIR,RITONAVIRandSAQUINAVIR—consultfesoterodineproductliterature;manufacturerofdarifenacinadvisesavoidconcomitantusewithATAZANAVIR,FOSAMPRENAVIR,INDINAVIR,LOPINAVIR,RITONAVIR,SAQUINAVIRandTIPRANAVIR;manufactureroftolterodineadvisesavoidconcomitantusewithFOSAMPRENAVIR,INDINAVIR,LOPINAVIR,RITONAVIRandSAQUINAVIR;plasmaconcentrationofsolifenacinpossiblyincreasedbylRITONAVIR—seeunderSolifenacin,p670lBeta-blockers:increasedriskofventriculararrhythmiaswhentolterodinegivenwithlSOTALOL TRIANGLE Calcium-channelBlockers:plasmaconcentrationofsolifenacinincreasedbyVERAPAMIL;manufacturerofdarifenacinadvisesavoidconcomitantusewithVERAPAMIL TRIANGLE CardiacGlycosides:darifenacinpossiblyincreasesplasmaconcentrationofDIGOXIN TRIANGLE Ciclosporin:manufacturerofdarifenacinadvisesavoidconcomitantusewithCICLOSPORIN TRIANGLE Domperidone:antimuscarinicsantagoniseeffectsofDOMPERIDONEongastro-intestinalactivityBNF70Appendix1Interactions1155Interactions|Appendix1"
"Antimuscarinics(continued) TRIANGLE Dopaminergics:antimuscarinicspossiblyreduceabsorptionofCO-BENELDOPA,CO-CARELDOPAandLEVODOPA TRIANGLE HormoneAntagonists:possibleincreasedriskofbradycardiawhenipratropiumoroxybutyningivenwithPASIREOTIDE TRIANGLE Memantine:effectsofantimuscarinicspossiblyenhancedbyMEMANTINE TRIANGLE Metoclopramide:antimuscarinicsantagoniseeffectsofMETOCLOPRAMIDEongastro-intestinalactivity TRIANGLE Nitrates:antimuscarinicspossiblyreduceeffectsofsublingualtabletsofNITRATES(failuretodissolveundertongueowingtodrymouth) TRIANGLE Parasympathomimetics:antimuscarinicsantagoniseeffectsofPARASYMPATHOMIMETICSAntipsychoticsNOTEIncreasedriskoftoxicitywithmyelosuppressivedrugsNOTEAvoidconcomitantuseofclozapinewithdrugsthathaveasubstantialpotentialforcausingagranulocytosis TRIANGLE ACEInhibitors:enhancedhypotensiveeffectwhenantipsychoticsgivenwithACEINHIBITORS TRIANGLE AdrenergicNeuroneBlockers:enhancedhypotensiveeffectwhenphenothiazinesgivenwithADRENERGICNEURONEBLOCKERS;higherdosesofchlorpromazineantagonisehypotensiveeffectofADRENERGICNEURONEBLOCKERS;haloperidolantagoniseshypotensiveeffectofADRENERGICNEURONEBLOCKERS TRIANGLE Adsorbents:absorptionofphenothiazinespossiblyreducedbyKAOLIN TRIANGLE Alcohol:increasedsedativeeffectwhenantipsychoticsgivenwithALCOHOL TRIANGLE Alpha-blockers:enhancedhypotensiveeffectwhenantipsychoticsgivenwithALPHA-BLOCKERSlAnaesthetics,General:droperidolenhanceseffectsofTHIOPENTAL;enhancedhypotensiveeffectwhenantipsychoticsgivenwithlGENERALANAESTHETICSlAnalgesics:possibleseveredrowsinesswhenhaloperidolgivenwithACEMETACINorINDOMETACIN;increasedriskofventriculararrhythmiaswhenantipsychoticsthatprolongtheQTintervalgivenwithlMETHADONE;increasedriskofventriculararrhythmiaswhenamisulpridegivenwithlMETHADONE—avoidconcomitantuse;increasedriskofconvulsionswhenantipsychoticsgivenwithTRAMADOL;enhancedhypotensiveandsedativeeffectswhenantipsychoticsgivenwithOPIOIDANALGESICS TRIANGLE Angiotensin-IIReceptorAntagonists:enhancedhypotensiveeffectwhenantipsychoticsgivenwithANGIOTENSIN-IIRECEPTORANTAGONISTS TRIANGLE Antacids:absorptionofphenothiazinesandsulpiridereducedbyANTACIDSlAnti-arrhythmics:increasedriskofventriculararrhythmiaswhenantipsychoticsthatprolongtheQTintervalgivenwithlANTI-ARRHYTHMICSthatprolongtheQTinterval;increasedriskofventriculararrhythmiaswhenamisulpride,droperidol,haloperidol,phenothiazines,pimozideorzuclopenthixolgivenwithlAMIODARONE—avoidconcomitantuse;increasedriskofventriculararrhythmiaswhenbenperidolgivenwithlAMIODARONE—manufacturerofbenperidoladvisesavoidconcomitantuse;increasedriskofventriculararrhythmiaswhensulpiridegivenwithlAMIODARONEorlDISOPYRAMIDE;increasedriskofventriculararrhythmiaswhenamisulpride,droperidol,pimozideorzuclopenthixolgivenwithlDISOPYRAMIDE—avoidconcomitantuse;possibleincreasedriskofventriculararrhythmiaswhenhaloperidolgivenwithlDISOPYRAMIDE—avoidconcomitantuse;increasedriskofventriculararrhythmiaswhenphenothiazinesgivenwithlDISOPYRAMIDE;avoidanceofphenothiazinesadvisedbymanufactureroflDRONEDARONE(riskofventriculararrhythmias);increasedriskofarrhythmiaswhenclozapinegivenwithlFLECAINIDElAntibacterials:plasmaconcentrationoflurasidonepossiblyincreasedbylCLARITHROMYCINandlTELITHROMYCIN—avoidconcomitantuse;increasedriskofventriculararrhythmiaswhenpimozidegivenwithlCLARITHROMYCIN,lMOXIFLOXACINorlTELITHROMYCIN—avoidconcomitantuse;plasmaconcentrationofquetiapinepossiblyincreasedbylCLARITHROMYCIN—manufacturerofquetiapineadvisesavoidAntipsychoticslAntibacterials(continued)concomitantuse;plasmaconcentrationoflurasidonepossiblyincreasedbylERYTHROMYCIN(seeunderLurasidone,p315);increasedriskofventriculararrhythmiaswhenamisulpridegivenwithlERYTHROMYCIN—avoidconcomitantuse;plasmaconcentrationofclozapinepossiblyincreasedbylERYTHROMYCIN(possibleincreasedriskofconvulsions);possibleincreasedriskofventriculararrhythmiaswhenpimozidegivenwithlERYTHROMYCIN—avoidconcomitantuse;plasmaconcentrationofquetiapineincreasedbylERYTHROMYCIN—manufacturerofquetiapineadvisesavoidconcomitantuse;increasedriskofventriculararrhythmiaswhensulpiridegivenwithparenterallERYTHROMYCIN;increasedriskofventriculararrhythmiaswhenzuclopenthixolgivenwithparenterallERYTHROMYCIN—avoidconcomitantuse;plasmaconcentrationofclozapineincreasedbyCIPROFLOXACIN;plasmaconcentrationofolanzapinepossiblyincreasedbyCIPROFLOXACIN;increasedriskofventriculararrhythmiaswhendroperidol,haloperidol,phenothiazinesorzuclopenthixolgivenwithlMOXIFLOXACIN—avoidconcomitantuse;increasedriskofventriculararrhythmiaswhenbenperidolgivenwithlMOXIFLOXACIN—manufacturerofbenperidoladvisesavoidconcomitantuse;plasmaconcentrationofaripiprazolepossiblyreducedbylRIFABUTINandlRIFAMPICIN(avoidconcomitantuseorconsiderincreasingthedoseofaripiprazole—consultaripiprazoleproductliterature);plasmaconcentrationoflurasidonereducedbylRIFAMPICIN—avoidconcomitantuse;plasmaconcentrationofclozapinepossiblyreducedbyRIFAMPICIN;metabolismofhaloperidolacceleratedbylRIFAMPICIN(reducedplasmaconcentration);avoidconcomitantuseofclozapinewithlCHLORAMPHENICOLorlSULFONAMIDES(increasedriskofagranulocytosis);increasedriskofventriculararrhythmiaswhendroperidol,haloperidolorpimozidegivenwithlDELAMANID;increasedriskofventriculararrhythmiaswhenphenothiazinesthatprolongtheQTintervalgivenwithlDELAMANID;manufacturerofdroperidoladvisesavoidconcomitantusewithlMACROLIDES(riskofventriculararrhythmias);possibleincreasedriskofventriculararrhythmiaswhenchlorpromazinegivenwithlTELITHROMYCIN;plasmaconcentrationofquetiapinepossiblyincreasedbyTELITHROMYCINlAntidepressants:plasmaconcentrationofclozapinepossiblyincreasedbyCITALOPRAM(increasedriskoftoxicity);avoidanceofhaloperidol,phenothiazinesandpimozideadvisedbymanufactureroflCITALOPRAM(riskofventriculararrhythmias);avoidanceofhaloperidol,phenothiazinesandpimozideadvisedbymanufactureroflESCITALOPRAM(riskofventriculararrhythmias);plasmaconcentrationofaripiprazolepossiblyincreasedbylFLUOXETINEandlPAROXETINE(reducedoseofaripiprazole—consultaripiprazoleproductliterature);plasmaconcentrationofclozapine,haloperidolandrisperidoneincreasedbylFLUOXETINE;manufacturerofdroperidoladvisesavoidconcomitantusewithlFLUOXETINE,lFLUVOXAMINE,lSERTRALINEandlTRICYCLICS(riskofventriculararrhythmias);plasmaconcentrationofasenapineandhaloperidolpossiblyincreasedbyFLUVOXAMINE;plasmaconcentrationofclozapineandolanzapineincreasedbylFLUVOXAMINE;asenapinepossiblyincreasesplasmaconcentrationofPAROXETINE;plasmaconcentrationofclozapineincreasedbylPAROXETINEandlSERTRALINE;plasmaconcentrationofrisperidonepossiblyincreasedbyPAROXETINE(increasedriskoftoxicity);metabolismofperphenazineinhibitedbyPAROXETINE(reducedoseofperphenazine);plasmaconcentrationofhaloperidolincreasedbyVENLAFAXINE;clozapinepossiblyincreasesCNSeffectsoflMAOIS;plasmaconcentrationofpimozidepossiblyincreasedbylSSRIS(increasedriskofventriculararrhythmias—avoidconcomitantuse);plasmaconcentrationoflurasidonepossiblyreducedbylSTJOHN’SWORT—avoidconcomitantuse;plasmaconcentrationofaripiprazolepossiblyreducedbylSTJOHN’SWORT(avoidconcomitantuseorconsiderincreasingthedoseofaripiprazole—consult1156Appendix1InteractionsBNF70Interactions|Appendix1"
"AntipsychoticslAntidepressants(continued)aripiprazoleproductliterature);manufactureroffluphenazine,haloperidol,sulpirideandzuclopenthixoladvisesavoidconcomitantusewithlTRICYCLICS(riskofventriculararrhythmias);increasedriskofantimuscarinicside-effectswhenphenothiazinesgivenwithTRICYCLICS;possibleincreasedriskofventriculararrhythmiaswhenrisperidonegivenwithlTRICYCLICS;possibleincreasedantimuscarinicside-effectswhenclozapinegivenwithTRICYCLICS TRIANGLE Antidiabetics:phenothiazinespossiblyantagonisehypoglycaemiceffectofSULFONYLUREASlAntiepileptics:antipsychoticsantagoniseanticonvulsanteffectoflANTIEPILEPTICS(convulsivethresholdlowered);metabolismofhaloperidol,olanzapine,quetiapineandrisperidoneacceleratedbyCARBAMAZEPINE(reducedplasmaconcentration);metabolismofclozapineacceleratedbylCARBAMAZEPINE(reducedplasmaconcentration),alsoavoidconcomitantuseofdrugswithsubstantialpotentialforcausingagranulocytosis;plasmaconcentrationofaripiprazolereducedbylCARBAMAZEPINE(avoidconcomitantuseorconsiderincreasingthedoseofaripiprazole—consultaripiprazoleproductliterature);plasmaconcentrationofpaliperidonereducedbyCARBAMAZEPINE;plasmaconcentrationoflurasidonepossiblyreducedbylCARBAMAZEPINE,lFOSPHENYTOIN,lPHENOBARBITAL,lPHENYTOINandlPRIMIDONE—avoidconcomitantuse;chlorpromazinepossiblyincreasesordecreasesplasmaconcentrationofFOSPHENYTOINandPHENYTOIN;metabolismofclozapineandquetiapineacceleratedbyFOSPHENYTOIN(reducedplasmaconcentration);plasmaconcentrationofaripiprazolepossiblyreducedbylFOSPHENYTOIN,lPHENOBARBITAL,lPHENYTOINandlPRIMIDONE(avoidconcomitantuseorconsiderincreasingthedoseofaripiprazole—consultaripiprazoleproductliterature);plasmaconcentrationofhaloperidolreducedbyFOSPHENYTOINandPHENYTOIN;metabolismofhaloperidolacceleratedbyPHENOBARBITALandPRIMIDONE(reducedplasmaconcentration);plasmaconcentrationofbothdrugsreducedwhenchlorpromazinegivenwithPHENOBARBITALandPRIMIDONE;plasmaconcentrationofclozapinepossiblyreducedbyPHENOBARBITALandPRIMIDONE;metabolismofclozapineandquetiapineacceleratedbyPHENYTOIN(reducedplasmaconcentration);increasedriskofside-effectsincludingneutropeniawhenolanzapinegivenwithlSODIUMVALPROATEandlVALPROICACID;plasmaconcentrationofclozapinepossiblyincreasedordecreasedbySODIUMVALPROATEandVALPROICACIDlAntifungals:plasmaconcentrationoflurasidoneincreasedbylKETOCONAZOLE—avoidconcomitantuse;metabolismofaripiprazoleinhibitedbylKETOCONAZOLE(reducedoseofaripiprazole);plasmaconcentrationoflurasidonepossiblyincreasedbylFLUCONAZOLE(seeunderLurasidone,p315);plasmaconcentrationoflurasidonepossiblyincreasedbylITRACONAZOLE,lPOSACONAZOLEandlVORICONAZOLE—avoidconcomitantuse;plasmaconcentrationofaripiprazolepossiblyincreasedbylITRACONAZOLE(reducedoseofaripiprazole—consultaripiprazoleproductliterature);side-effectsofrisperidonepossiblyincreasedbyITRACONAZOLE;plasmaconcentrationofhaloperidolpossiblyincreasedbyITRACONAZOLE;increasedriskofventriculararrhythmiaswhenpimozidegivenwithlIMIDAZOLESorlTRIAZOLES—avoidconcomitantuse;plasmaconcentrationofquetiapinepossiblyincreasedbylIMIDAZOLESandlTRIAZOLES—manufacturerofquetiapineadvisesavoidconcomitantuselAntimalarials:avoidanceofantipsychoticsadvisedbymanufactureroflARTEMETHERWITHLUMEFANTRINE;avoidanceofdroperidol,haloperidol,phenothiazinesandpimozideadvisedbymanufactureroflARTENIMOLWITHPIPERAQUINE(possibleriskofventriculararrhythmias);increasedriskofventriculararrhythmiaswhendroperidolgivenwithlCHLOROQUINE,lHYDROXYCHLOROQUINEorlQUININE—avoidconcomitantuse;possibleincreasedriskofventriculararrhythmiaswhenhaloperidolgivenwithlMEFLOQUINEorAntipsychoticslAntimalarials(continued)lQUININE—avoidconcomitantuse;manufacturerofrisperidoneadvisespossibleriskofventriculararrhythmiaswhenrisperidonegivenwithlMEFLOQUINE;increasedriskofventriculararrhythmiaswhenpimozidegivenwithlMEFLOQUINEorlQUININE—avoidconcomitantuse;manufacturerofamisulprideadvisesavoidconcomitantusewithMEFLOQUINE;possibleincreasedriskofventriculararrhythmiaswhenrisperidonegivenwithlQUININE TRIANGLE Antimuscarinics:increasedriskofantimuscarinicside-effectswhenclozapinegivenwithANTIMUSCARINICS;plasmaconcentrationofphenothiazinesreducedbyANTIMUSCARINICS,butriskofantimuscarinicside-effectsincreased;effectsofhaloperidolpossiblyreducedbyANTIMUSCARINICSlAntipsychotics:increasedriskofventriculararrhythmiaswhenamisulpride,pimozideorsulpiridegivenwithlDROPERIDOL—avoidconcomitantuse;increasedriskofventriculararrhythmiaswhenphenothiazinesthatprolongtheQTintervalgivenwithlDROPERIDOL—avoidconcomitantuse;avoidconcomitantuseofclozapinewithdepotformulationoflFLUPENTIXOL,lFLUPHENAZINE,lHALOPERIDOL,lPIPOTIAZINE,lRISPERIDONEorlZUCLOPENTHIXOLascannotbewithdrawnquicklyifneutropeniaoccurs;increasedriskofventriculararrhythmiaswhensulpiridegivenwithlHALOPERIDOL;chlorpromazinepossiblyincreasesplasmaconcentrationofHALOPERIDOL;increasedriskofventriculararrhythmiaswhendroperidolgivenwithlHALOPERIDOL—avoidconcomitantuse;increasedriskofventriculararrhythmiaswhenpimozidegivenwithlPHENOTHIAZINES—avoidconcomitantuse;lurasidonepossiblyincreasesplasmaconcentrationofPIMOZIDE(increasedriskoftoxicity);possibleincreasedriskofventriculararrhythmiaswhenantipsychoticsthatprolongtheQTintervalgivenwithlRISPERIDONE;increasedriskofventriculararrhythmiaswhenpimozidegivenwithlSULPIRIDElAntivirals:plasmaconcentrationofaripiprazolepossiblyincreasedbylATAZANAVIR,lDARUNAVIR,lFOSAMPRENAVIR,lINDINAVIR,lLOPINAVIR,lRITONAVIR,lSAQUINAVIRandlTIPRANAVIR(reducedoseofaripiprazole—consultaripiprazoleproductliterature);plasmaconcentrationofquetiapinepossiblyincreasedbylATAZANAVIR,lBOCEPREVIR,lDARUNAVIR,lFOSAMPRENAVIR,lINDINAVIR,lLOPINAVIR,lRITONAVIR,lSAQUINAVIR,lTELAPREVIRandlTIPRANAVIR—manufacturerofquetiapineadvisesavoidconcomitantuse;plasmaconcentrationofpimozidepossiblyincreasedbylATAZANAVIR—avoidconcomitantuse;avoidanceofpimozideadvisedbymanufactureroflBOCEPREVIRandlTELAPREVIR;plasmaconcentrationoflurasidonepossiblyincreasedbylBOCEPREVIR,lINDINAVIR,lRITONAVIR,lSAQUINAVIRandlTELAPREVIR—avoidconcomitantuse;plasmaconcentrationofaripiprazolepossiblyreducedbylEFAVIRENZandlNEVIRAPINE(avoidconcomitantuseorconsiderincreasingthedoseofaripiprazole—consultaripiprazoleproductliterature);plasmaconcentrationofpimozidepossiblyincreasedbylEFAVIRENZ,lINDINAVIRandlSAQUINAVIR(increasedriskofventriculararrhythmias—avoidconcomitantuse);plasmaconcentrationofpimozideincreasedbylFOSAMPRENAVIRandlRITONAVIR(increasedriskofventriculararrhythmias—avoidconcomitantuse);plasmaconcentrationofantipsychoticspossiblyincreasedbylRITONAVIR;plasmaconcentrationofolanzapinereducedbyRITONAVIR—considerincreasingdoseofolanzapine;avoidanceofclozapineadvisedbymanufactureroflRITONAVIR(increasedriskoftoxicity);increasedriskofventriculararrhythmiaswhenclozapine,haloperidolorphenothiazinesgivenwithlSAQUINAVIR—avoidconcomitantuselAnxiolyticsandHypnotics:increasedsedativeeffectwhenantipsychoticsgivenwithANXIOLYTICSANDHYPNOTICS;plasmaconcentrationofhaloperidolpossiblyincreasedbyALPRAZOLAM;lurasidoneincreasesplasmaconcentrationofMIDAZOLAM;seriousadverseeventsreportedwithconcomitantuseofclozapineandBNF70Appendix1Interactions1157Interactions|Appendix1"
"AntipsychoticslAnxiolyticsandHypnotics(continued)lBENZODIAZEPINES(causalitynotestablished);increasedriskofhypotension,bradycardiaandrespiratorydepressionwhenintramuscularolanzapinegivenwithparenterallBENZODIAZEPINES;plasmaconcentrationofhaloperidolincreasedbyBUSPIRONElAprepitant:avoidanceofpimozideadvisedbymanufactureroflAPREPITANTlAtomoxetine:increasedriskofventriculararrhythmiaswhenantipsychoticsthatprolongtheQTintervalgivenwithlATOMOXETINElBeta-blockers:enhancedhypotensiveeffectwhenphenothiazinesgivenwithBETA-BLOCKERS;plasmaconcentrationofbothdrugsmayincreasewhenchlorpromazinegivenwithlPROPRANOLOL;increasedriskofventriculararrhythmiaswhendroperidolorzuclopenthixolgivenwithlSOTALOL—avoidconcomitantuse;increasedriskofventriculararrhythmiaswhenamisulpride,phenothiazines,pimozideorsulpiridegivenwithlSOTALOL;possibleincreasedriskofventriculararrhythmiaswhenrisperidonegivenwithlSOTALOL;possibleincreasedriskofventriculararrhythmiaswhenhaloperidolgivenwithlSOTALOL—avoidconcomitantuselCalcium-channelBlockers:enhancedhypotensiveeffectwhenantipsychoticsgivenwithCALCIUM-CHANNELBLOCKERS;plasmaconcentrationoflurasidoneincreasedbylDILTIAZEM(seeunderLurasidone,p315);plasmaconcentrationoflurasidonepossiblyincreasedbylVERAPAMIL(seeunderLurasidone,p315) TRIANGLE Clonidine:enhancedhypotensiveeffectwhenphenothiazinesgivenwithCLONIDINElCobicistat:plasmaconcentrationoflurasidonepossiblyincreasedbylCOBICISTAT—avoidconcomitantuse;plasmaconcentrationofpimozidepossiblyincreasedbylCOBICISTAT—manufacturerofcobicistatadvisesavoidconcomitantuselCytotoxics:avoidconcomitantuseofclozapinewithlCYTOTOXICS(increasedriskofagranulocytosis);possibleincreasedriskofventriculararrhythmiaswhenhaloperidolgivenwithlBOSUTINIB;cautionwithpimozideadvisedbymanufactureroflCRIZOTINIB;avoidanceofpimozideandquetiapineadvisedbymanufacturerofIDELALISIB;avoidanceofpimozideadvisedbymanufactureroflLAPATINIB;possibleincreasedriskofventriculararrhythmiaswhenamisulpride,chlorpromazine,haloperidol,pimozide,sulpirideorzuclopenthixolgivenwithlVANDETANIB—avoidconcomitantuse;increasedriskofventriculararrhythmiaswhenantipsychoticsthatprolongtheQTintervalgivenwithlARSENICTRIOXIDE;increasedriskofventriculararrhythmiaswhenhaloperidolgivenwithlARSENICTRIOXIDE TRIANGLE Deferasirox:avoidanceofclozapineadvisedbymanufacturerofDEFERASIROX TRIANGLE Desferrioxamine:manufactureroflevomepromazineadvisesavoidconcomitantusewithDESFERRIOXAMINE;avoidanceofprochlorperazineadvisedbymanufacturerofDESFERRIOXAMINE TRIANGLE Diazoxide:enhancedhypotensiveeffectwhenphenothiazinesgivenwithDIAZOXIDElDiuretics:riskofventriculararrhythmiaswithamisulprideincreasedbyhypokalaemiacausedbylDIURETICS;riskofventriculararrhythmiaswithpimozideincreasedbyhypokalaemiacausedbylDIURETICS(avoidconcomitantuse);enhancedhypotensiveeffectwhenphenothiazinesgivenwithDIURETICS TRIANGLE Dopaminergics:increasedriskofextrapyramidalside-effectswhenantipsychoticsgivenwithAMANTADINE;antipsychoticsantagoniseeffectsofAPOMORPHINE,CO-BENELDOPA,CO-CARELDOPA,LEVODOPAandPERGOLIDE;antipsychoticsantagonisehypoprolactinaemicandantiparkinsonianeffectsofBROMOCRIPTINEandCABERGOLINE;manufacturerofamisulprideadvisesavoidconcomitantuseofCO-BENELDOPA,CO-CARELDOPAandLEVODOPA(antagonismofeffect);avoidanceofantipsychoticsadvisedbymanufacturerofPRAMIPEXOLE,ROPINIROLEandROTIGOTINE(antagonismofeffect)Antipsychotics(continued) TRIANGLE ErgotAlkaloids:lurasidonepossiblyincreasesplasmaconcentrationofERGOTALKALOIDS(increasedriskoftoxicity)lFosaprepitant:avoidanceofpimozideadvisedbymanufactureroflFOSAPREPITANTlGrapefruitJuice:manufactureroflurasidoneandpimozideadvisesavoidconcomitantusewithGRAPEFRUITJUICE;plasmaconcentrationofquetiapinepossiblyincreasedbylGRAPEFRUITJUICE—manufacturerofquetiapineadvisesavoidconcomitantuse TRIANGLE Histamine:antipsychoticstheoreticallyantagoniseeffectsofHISTAMINE—manufacturerofhistamineadvisesavoidconcomitantuselHormoneAntagonists:manufacturerofdroperidoladvisesavoidconcomitantusewithlTAMOXIFEN(riskofventriculararrhythmias)lIvabradine:increasedriskofventriculararrhythmiaswhenpimozidegivenwithlIVABRADINElLithium:increasedriskofextrapyramidalside-effectsandpossiblyneurotoxicitywhenclozapine,flupentixol,haloperidol,phenothiazines,risperidoneorzuclopenthixolgivenwithlLITHIUM;possibleriskoftoxicitywhenolanzapinegivenwithLITHIUM;extrapyramidalside-effectsofquetiapinepossiblyincreasedbyLITHIUM;increasedriskofextrapyramidalside-effectswhensulpiridegivenwithLITHIUM TRIANGLE Memantine:effectsofantipsychoticspossiblyreducedbyMEMANTINE TRIANGLE Methyldopa:enhancedhypotensiveeffectwhenantipsychoticsgivenwithMETHYLDOPA(alsoincreasedriskofextrapyramidaleffects) TRIANGLE Metoclopramide:increasedriskofextrapyramidalside-effectswhenantipsychoticsgivenwithMETOCLOPRAMIDE TRIANGLE Moxonidine:enhancedhypotensiveeffectwhenphenothiazinesgivenwithMOXONIDINE TRIANGLE MuscleRelaxants:promazinepossiblyenhanceseffectsofSUXAMETHONIUM TRIANGLE Nitrates:enhancedhypotensiveeffectwhenphenothiazinesgivenwithNITRATESlPenicillamine:avoidconcomitantuseofclozapinewithlPENICILLAMINE(increasedriskofagranulocytosis)lPentamidineIsetionate:increasedriskofventriculararrhythmiaswhenamisulprideordroperidolgivenwithlPENTAMIDINEISETIONATE—avoidconcomitantuse;increasedriskofventriculararrhythmiaswhenphenothiazinesgivenwithlPENTAMIDINEISETIONATE TRIANGLE SodiumBenzoate:haloperidolpossiblyreduceseffectsofSODIUMBENZOATE TRIANGLE SodiumOxybate:antipsychoticspossiblyenhanceeffectsofSODIUMOXYBATE TRIANGLE SodiumPhenylbutyrate:haloperidolpossiblyreduceseffectsofSODIUMPHENYLBUTYRATE TRIANGLE Sympathomimetics:antipsychoticsantagonisehypertensiveeffectofSYMPATHOMIMETICS;antipsychoticeffectsofchlorpromazinepossiblyantagonisedbyDEXAMFETAMINE;chlorpromazinepossiblyreduceseffectsofLISDEXAMFETAMINE;side-effectsofrisperidonepossiblyincreasedbyMETHYLPHENIDATElTacrolimus:manufacturerofdroperidoladvisesavoidconcomitantusewithlTACROLIMUS(riskofventriculararrhythmias) TRIANGLE Tetrabenazine:increasedriskofextrapyramidalside-effectswhenantipsychoticsgivenwithTETRABENAZINE TRIANGLE Ulcer-healingDrugs:effectsofantipsychotics,chlorpromazineandclozapinepossiblyenhancedbyCIMETIDINE;plasmaconcentrationofclozapinepossiblyreducedbyOMEPRAZOLE;absorptionofsulpiridereducedbySUCRALFATE TRIANGLE VasodilatorAntihypertensives:enhancedhypotensiveeffectwhenphenothiazinesgivenwithHYDRALAZINE,MINOXIDILorSODIUMNITROPRUSSIDEAntiviralsseeindividualdrugsAnxiolyticsandHypnotics TRIANGLE ACEInhibitors:enhancedhypotensiveeffectwhenanxiolyticsandhypnoticsgivenwithACEINHIBITORS1158Appendix1InteractionsBNF70Interactions|Appendix1"
"AnxiolyticsandHypnotics(continued) TRIANGLE AdrenergicNeuroneBlockers:enhancedhypotensiveeffectwhenanxiolyticsandhypnoticsgivenwithADRENERGICNEURONEBLOCKERS TRIANGLE Alcohol:increasedsedativeeffectwhenanxiolyticsandhypnoticsgivenwithALCOHOL TRIANGLE Alpha-blockers:enhancedhypotensiveandsedativeeffectswhenanxiolyticsandhypnoticsgivenwithALPHA-BLOCKERS TRIANGLE Aminophylline:effectsofbenzodiazepinespossiblyreducedbyAMINOPHYLLINE TRIANGLE Anaesthetics,General:increasedsedativeeffectwhenanxiolyticsandhypnoticsgivenwithGENERALANAESTHETICS TRIANGLE Analgesics:metabolismofmidazolampossiblyinhibitedbyFENTANYL;increasedsedativeeffectwhenanxiolyticsandhypnoticsgivenwithOPIOIDANALGESICS TRIANGLE Angiotensin-IIReceptorAntagonists:enhancedhypotensiveeffectwhenanxiolyticsandhypnoticsgivenwithANGIOTENSIN-IIRECEPTORANTAGONISTSlAntibacterials:metabolismofmidazolaminhibitedbylCLARITHROMYCIN,lERYTHROMYCINandlTELITHROMYCIN(increasedplasmaconcentrationwithincreasedsedation);plasmaconcentrationofbuspironeincreasedbyERYTHROMYCIN(reducedoseofbuspirone);metabolismofzopicloneinhibitedbyERYTHROMYCIN;manufacturerofzolpidemadvisesavoidconcomitantusewithCIPROFLOXACIN;metabolismofbenzodiazepinespossiblyacceleratedbyRIFAMPICIN(reducedplasmaconcentration);metabolismofdiazepamandzaleplonacceleratedbyRIFAMPICIN(reducedplasmaconcentration);metabolismofbuspironepossiblyacceleratedbyRIFAMPICIN;metabolismofzolpidemacceleratedbyRIFAMPICIN(reducedplasmaconcentrationandreducedeffect);plasmaconcentrationofzopiclonesignificantlyreducedbyRIFAMPICIN;metabolismofdiazepaminhibitedbyISONIAZID TRIANGLE Anticoagulants:chloralmaytransientlyenhanceanticoagulanteffectofCOUMARINSlAntidepressants:plasmaconcentrationofalprazolamincreasedbyFLUOXETINE;plasmaconcentrationofmelatoninincreasedbylFLUVOXAMINE—avoidconcomitantuse;plasmaconcentrationofsomebenzodiazepinesincreasedbyFLUVOXAMINE;sedativeeffectspossiblyincreasedwhenzolpidemgivenwithSERTRALINE;manufacturerofbuspironeadvisesavoidconcomitantusewithMAOIS;avoidanceofbuspironefor14daysafterstoppinglTRANYLCYPROMINEadvisedbymanufactureroftranylcypromine;plasmaconcentrationoforalmidazolampossiblyreducedbySTJOHN’SWORT;increasedsedativeeffectwhenanxiolyticsandhypnoticsgivenwithMIRTAZAPINE,TRICYCLIC-RELATEDANTIDEPRESSANTSorTRICYCLICS TRIANGLE Antiepileptics:plasmaconcentrationofmidazolamreducedbyCARBAMAZEPINEandPERAMPANEL;plasmaconcentrationofclonazepamoftenreducedbyCARBAMAZEPINE,FOSPHENYTOIN,PHENOBARBITAL,PHENYTOINandPRIMIDONE;benzodiazepinespossiblyincreaseordecreaseplasmaconcentrationofFOSPHENYTOINandPHENYTOIN;diazepamincreasesordecreasesplasmaconcentrationofFOSPHENYTOINandPHENYTOIN;increasedsedativeeffectwhenanxiolyticsandhypnoticsgivenwithPHENOBARBITALorPRIMIDONE;clobazampossiblyincreasesplasmaconcentrationofSODIUMVALPROATEandVALPROICACID;plasmaconcentrationofdiazepamandlorazepampossiblyincreasedbySODIUMVALPROATE;increasedriskofside-effectswhenclonazepamgivenwithSODIUMVALPROATEorVALPROICACID;plasmaconcentrationofclobazamincreasedbySTIRIPENTOL;plasmaconcentrationofdiazepamandlorazepampossiblyincreasedbyVALPROICACIDlAntifungals:plasmaconcentrationofalprazolamincreasedbylKETOCONAZOLE—manufacturerofketoconazoleadvisesavoidconcomitantuse;plasmaconcentrationofmidazolamincreasedbylKETOCONAZOLE(riskofprolongedsedation—avoidconcomitantuseoforalmidazolam);plasmaconcentrationofzolpidemincreasedbyKETOCONAZOLE;plasmaconcentrationofdiazepamandmidazolamincreasedbylFLUCONAZOLE(riskofprolongedsedation);plasmaconcentrationofalprazolamincreasedbyITRACONAZOLE;plasmaconcentrationofmidazolamincreasedbylITRACONAZOLE,lPOSACONAZOLEandlVORICONAZOLE(riskofAnxiolyticsandHypnoticslAntifungals(continued)prolongedsedation);plasmaconcentrationofbuspironeincreasedbyITRACONAZOLE(reducedoseofbuspirone);plasmaconcentrationofdiazepamincreasedbylVORICONAZOLE(riskofprolongedsedation) TRIANGLE Antihistamines:increasedsedativeeffectwhenanxiolyticsandhypnoticsgivenwithANTIHISTAMINESlAntipsychotics:increasedsedativeeffectwhenanxiolyticsandhypnoticsgivenwithANTIPSYCHOTICS;alprazolampossiblyincreasesplasmaconcentrationofHALOPERIDOL;buspironeincreasesplasmaconcentrationofHALOPERIDOL;seriousadverseeventsreportedwithconcomitantuseofbenzodiazepinesandlCLOZAPINE(causalitynotestablished);plasmaconcentrationofmidazolamincreasedbyLURASIDONE;increasedriskofhypotension,bradycardiaandrespiratorydepressionwhenparenteralbenzodiazepinesgivenwithintramuscularlOLANZAPINElAntivirals:plasmaconcentrationofmidazolampossiblyincreasedbylATAZANAVIR—avoidconcomitantuseoforalmidazolam;plasmaconcentrationoforalmidazolamincreasedbylBOCEPREVIR—manufacturerofbocepreviradvisesavoidconcomitantuse;increasedriskofprolongedsedationwhenmidazolamgivenwithlEFAVIRENZ—avoidconcomitantuse;plasmaconcentrationofmidazolampossiblyincreasedbylFOSAMPRENAVIR,lINDINAVIR,lRITONAVIRandlTELAPREVIR(riskofprolongedsedation—avoidconcomitantuseoforalmidazolam);increasedriskofprolongedsedationwhenalprazolamgivenwithlINDINAVIR—avoidconcomitantuse;plasmaconcentrationofanxiolyticsandhypnoticspossiblyincreasedbylRITONAVIR;plasmaconcentrationofalprazolam,diazepam,flurazepamandzolpidempossiblyincreasedbylRITONAVIR(riskofextremesedationandrespiratorydepression—avoidconcomitantuse);plasmaconcentrationofbuspironeincreasedbyRITONAVIR(increasedriskoftoxicity);plasmaconcentrationofmidazolamincreasedbylSAQUINAVIR(riskofprolongedsedation—avoidconcomitantuseoforalmidazolam);plasmaconcentrationoforalmidazolamincreasedbySIMEPREVIR TRIANGLE Aprepitant:plasmaconcentrationofmidazolamincreasedbyAPREPITANT(riskofprolongedsedation) TRIANGLE Beta-blockers:enhancedhypotensiveeffectwhenanxiolyticsandhypnoticsgivenwithBETA-BLOCKERS TRIANGLE Calcium-channelBlockers:enhancedhypotensiveeffectwhenanxiolyticsandhypnoticsgivenwithCALCIUM-CHANNELBLOCKERS;midazolamincreasesabsorptionofLERCANIDIPINE;metabolismofmidazolaminhibitedbyDILTIAZEMandVERAPAMIL(increasedplasmaconcentrationwithincreasedsedation);plasmaconcentrationofbuspironeincreasedbyDILTIAZEMandVERAPAMIL(reducedoseofbuspirone) TRIANGLE CardiacGlycosides:alprazolamincreasesplasmaconcentrationofDIGOXIN(increasedriskoftoxicity) TRIANGLE Clonidine:enhancedhypotensiveeffectwhenanxiolyticsandhypnoticsgivenwithCLONIDINElCobicistat:avoidanceoforalmidazolamadvisedbymanufactureroflCOBICISTATlCytotoxics:plasmaconcentrationofmidazolamincreasedbylCRIZOTINIBandNILOTINIB;avoidanceoforalmidazolamadvisedbymanufacturerofIDELALISIB TRIANGLE Deferasirox:plasmaconcentrationofmidazolampossiblyreducedbyDEFERASIROX TRIANGLE Diazoxide:enhancedhypotensiveeffectwhenanxiolyticsandhypnoticsgivenwithDIAZOXIDE TRIANGLE Disulfiram:metabolismofbenzodiazepinesinhibitedbyDISULFIRAM(increasedsedativeeffects);increasedriskoftemazepamtoxicitywhengivenwithDISULFIRAM TRIANGLE Diuretics:enhancedhypotensiveeffectwhenanxiolyticsandhypnoticsgivenwithDIURETICS;administrationofchloralwithparenteralFUROSEMIDEmaydisplacethyroidhormonefrombindingsites TRIANGLE Dopaminergics:benzodiazepinespossiblyantagoniseeffectsofCO-BENELDOPA,CO-CARELDOPAandLEVODOPA TRIANGLE Fosaprepitant:plasmaconcentrationofmidazolamincreasedbyFOSAPREPITANT(riskofprolongedsedation)BNF70Appendix1Interactions1159Interactions|Appendix1"
"AnxiolyticsandHypnotics(continued) TRIANGLE GrapefruitJuice:plasmaconcentrationoforalmidazolampossiblyincreasedbyGRAPEFRUITJUICE;plasmaconcentrationofbuspironeincreasedbyGRAPEFRUITJUICE TRIANGLE Ivacaftor:plasmaconcentrationofmidazolamincreasedbyIVACAFTOR TRIANGLE Lipid-regulatingDrugs:plasmaconcentrationofmidazolampossiblyincreasedbyATORVASTATIN;separatingadministrationfromalprazolamby12hoursadvisedbymanufacturerofLOMITAPIDE TRIANGLE Lithium:increasedriskofneurotoxicitywhenclonazepamgivenwithLITHIUM TRIANGLE Lofexidine:increasedsedativeeffectwhenanxiolyticsandhypnoticsgivenwithLOFEXIDINE TRIANGLE Methyldopa:enhancedhypotensiveeffectwhenanxiolyticsandhypnoticsgivenwithMETHYLDOPAlMethylthioninium:possibleriskofCNStoxicitywhenbuspironegivenwithlMETHYLTHIONINIUM—avoidconcomitantuse(ifavoidancenotpossible,uselowestpossibledoseofmethylthioniniumandobservepatientforupto4hoursafteradministration) TRIANGLE Moxonidine:enhancedhypotensiveeffectwhenanxiolyticsandhypnoticsgivenwithMOXONIDINE;sedativeeffectspossiblyincreasedwhenbenzodiazepinesgivenwithMOXONIDINE TRIANGLE MuscleRelaxants:increasedsedativeeffectwhenanxiolyticsandhypnoticsgivenwithBACLOFENorTIZANIDINE TRIANGLE Nitrates:enhancedhypotensiveeffectwhenanxiolyticsandhypnoticsgivenwithNITRATES TRIANGLE Oestrogens:plasmaconcentrationofmelatoninincreasedbyOESTROGENS;plasmaconcentrationofchlordiazepoxide,diazepamandnitrazepampossiblyincreasedbyOESTROGENS;plasmaconcentrationoflorazepam,oxazepamandtemazepampossiblyreducedbyOESTROGENS TRIANGLE Progestogens:plasmaconcentrationofchlordiazepoxide,diazepamandnitrazepampossiblyincreasedbyPROGESTOGENS;plasmaconcentrationoflorazepam,oxazepamandtemazepampossiblyreducedbyPROGESTOGENSlSodiumOxybate:benzodiazepinesenhanceeffectsoflSODIUMOXYBATE(avoidconcomitantuse) TRIANGLE Theophylline:effectsofbenzodiazepinespossiblyreducedbyTHEOPHYLLINE TRIANGLE Ulcer-healingDrugs:plasmaconcentrationofmelatoninincreasedbyCIMETIDINE;metabolismofbenzodiazepines,clomethiazoleandzaleploninhibitedbyCIMETIDINE(increasedplasmaconcentration);metabolismofdiazepampossiblyinhibitedbyESOMEPRAZOLEandOMEPRAZOLE(increasedplasmaconcentration) TRIANGLE VasodilatorAntihypertensives:enhancedhypotensiveeffectwhenanxiolyticsandhypnoticsgivenwithHYDRALAZINE,MINOXIDILorSODIUMNITROPRUSSIDEApixabanlAnalgesics:increasedriskofhaemorrhagewhenanticoagulantsgivenwithintravenouslDICLOFENAC(avoidconcomitantuse,includinglow-doseheparins);increasedriskofhaemorrhagewhenanticoagulantsgivenwithlKETOROLAC(avoidconcomitantuse,includinglow-doseheparins)lAntibacterials:manufacturerofapixabanadvisesavoidconcomitantusewithCLARITHROMYCINandTELITHROMYCIN;plasmaconcentrationofapixabanpossiblyreducedbylRIFAMPICIN—manufacturerofapixabanadvisesavoidconcomitantusewhengivenfortreatmentofdeep-veinthrombosisorpulmonaryembolismlAnticoagulants:increasedriskofhaemorrhagewhenapixabangivenwithotherlANTICOAGULANTS(avoidconcomitantuseexceptwhenswitchingwithotheranticoagulantsorusingheparintomaintaincatheterpatency);increasedriskofhaemorrhagewhenotheranticoagulantsgivenwithlDABIGATRANandlRIVAROXABAN(avoidconcomitantuseexceptwhenswitchingwithotheranticoagulantsorusingheparintomaintaincatheterpatency)lAntidepressants:plasmaconcentrationofapixabanpossiblyreducedbylSTJOHN’SWORT—manufacturerofapixabanadvisesavoidconcomitantusewhengivenfortreatmentofdeep-veinthrombosisorpulmonaryembolismApixaban(continued)lAntiepileptics:plasmaconcentrationofapixabanpossiblyreducedbylCARBAMAZEPINE—manufacturerofapixabanadvisesavoidconcomitantusewhengivenfortreatmentofdeep-veinthrombosisorpulmonaryembolism;plasmaconcentrationofapixabanpossiblyreducedbylFOSPHENYTOIN,lPHENOBARBITAL,lPHENYTOINandlPRIMIDONElAntifungals:plasmaconcentrationofapixabanincreasedbylKETOCONAZOLE—manufacturerofapixabanadvisesavoidconcomitantuse;manufacturerofapixabanadvisesavoidconcomitantusewithITRACONAZOLE,POSACONAZOLEandVORICONAZOLE TRIANGLE Antivirals:manufacturerofapixabanadvisesavoidconcomitantusewithATAZANAVIR,BOCEPREVIR,DARUNAVIR,FOSAMPRENAVIR,INDINAVIR,LOPINAVIR,RITONAVIR,SAQUINAVIR,TELAPREVIRandTIPRANAVIR TRIANGLE Cobicistat:manufacturerofapixabanadvisesavoidconcomitantusewithCOBICISTAT TRIANGLE Sulfinpyrazone:increasedriskofbleedingwhenapixabangivenwithSULFINPYRAZONEApomorphine TRIANGLE Antipsychotics:effectsofapomorphineantagonisedbyANTIPSYCHOTICS TRIANGLE Dopaminergics:effectsofapomorphinepossiblyenhancedbyENTACAPONEl5HT3-receptorAntagonists:possibleincreasedhypotensiveeffectwhenapomorphinegivenwithlONDANSETRON—avoidconcomitantuse TRIANGLE Memantine:effectsofdopaminergicspossiblyenhancedbyMEMANTINE TRIANGLE Methyldopa:antiparkinsonianeffectofdopaminergicsantagonisedbyMETHYLDOPAApraclonidine TRIANGLE Antidepressants:manufacturerofapraclonidineadvisesavoidconcomitantusewithMAOIS,TRICYCLIC-RELATEDANTIDEPRESSANTSandTRICYCLICS TRIANGLE Sympathomimetics:manufacturerofapraclonidineadvisesavoidconcomitantusewithSYMPATHOMIMETICSAprepitant TRIANGLE Antibacterials:plasmaconcentrationofaprepitantpossiblyincreasedbyCLARITHROMYCINandTELITHROMYCIN;plasmaconcentrationofaprepitantreducedbyRIFAMPICIN TRIANGLE Anticoagulants:aprepitantpossiblyreducesanticoagulanteffectofWARFARINlAntidepressants:manufacturerofaprepitantadvisesavoidconcomitantusewithlSTJOHN’SWORT TRIANGLE Antidiabetics:aprepitantreducesplasmaconcentrationofTOLBUTAMIDE TRIANGLE Antiepileptics:plasmaconcentrationofaprepitantpossiblyreducedbyCARBAMAZEPINE,FOSPHENYTOIN,PHENOBARBITAL,PHENYTOINandPRIMIDONE TRIANGLE Antifungals:plasmaconcentrationofaprepitantincreasedbyKETOCONAZOLElAntipsychotics:manufacturerofaprepitantadvisesavoidconcomitantusewithlPIMOZIDE TRIANGLE Antivirals:plasmaconcentrationofaprepitantpossiblyincreasedbyRITONAVIR TRIANGLE AnxiolyticsandHypnotics:aprepitantincreasesplasmaconcentrationofMIDAZOLAM(riskofprolongedsedation)lAvanafil:aprepitantpossiblyincreasesplasmaconcentrationoflAVANAFIL—seeunderAvanafil,p698 TRIANGLE Calcium-channelBlockers:plasmaconcentrationofbothdrugsmayincreasewhenaprepitantgivenwithDILTIAZEM TRIANGLE Corticosteroids:aprepitantinhibitsmetabolismofDEXAMETHASONEandMETHYLPREDNISOLONE(reducedoseofdexamethasoneandmethylprednisolone)lCytotoxics:aprepitantpossiblyincreasestheplasmaconcentrationoflBOSUTINIB—manufacturerofbosutinibadvisesavoidorconsiderreducingdoseofbosutinib;aprepitantpossiblyincreasestheplasmaconcentrationoflIBRUTINIB—reducedoseofibrutinib(seeunderIbrutinib,p809) TRIANGLE Dapoxetine:manufacturerofdapoxetineadvisesdosereductionwhenaprepitantgivenwithDAPOXETINE(seeunderDapoxetine,p703)1160Appendix1InteractionsBNF70Interactions|Appendix1"
"Aprepitant(continued)lOestrogens:aprepitantpossiblycausescontraceptivefailureofhormonalcontraceptivescontaininglOESTROGENS(alternativecontraceptionrecommended)lProgestogens:aprepitantpossiblycausescontraceptivefailureofhormonalcontraceptivescontaininglPROGESTOGENS(alternativecontraceptionrecommended)ArgatrobanlAnalgesics:increasedriskofhaemorrhagewhenanticoagulantsgivenwithintravenouslDICLOFENAC(avoidconcomitantuse,includinglow-doseheparins);increasedriskofhaemorrhagewhenanticoagulantsgivenwithlKETOROLAC(avoidconcomitantuse,includinglow-doseheparins)lAnticoagulants:increasedriskofhaemorrhagewhenotheranticoagulantsgivenwithlAPIXABAN,lDABIGATRANandlRIVAROXABAN(avoidconcomitantuseexceptwhenswitchingwithotheranticoagulantsorusingheparintomaintaincatheterpatency)AripiprazoleseeAntipsychoticsArsenicTrioxidelAnti-arrhythmics:increasedriskofventriculararrhythmiaswhenarsenictrioxidegivenwithlAMIODARONEorlDISOPYRAMIDElAntibacterials:increasedriskofventriculararrhythmiaswhenarsenictrioxidegivenwithlDELAMANID,lERYTHROMYCIN,lLEVOFLOXACINorlMOXIFLOXACINlAntidepressants:increasedriskofventriculararrhythmiaswhenarsenictrioxidegivenwithlAMITRIPTYLINEorlCLOMIPRAMINElAntifungals:increasedriskofventriculararrhythmiaswhenarsenictrioxidegivenwithlAMPHOTERICINlAntimalarials:avoidanceofarsenictrioxideadvisedbymanufactureroflARTENIMOLWITHPIPERAQUINE(possibleriskofventriculararrhythmias)lAntipsychotics:increasedriskofventriculararrhythmiaswhenarsenictrioxidegivenwithlANTIPSYCHOTICSthatprolongtheQTinterval;increasedriskofventriculararrhythmiaswhenarsenictrioxidegivenwithlHALOPERIDOL;avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lBeta-blockers:increasedriskofventriculararrhythmiaswhenarsenictrioxidegivenwithlSOTALOLlCytotoxics:possibleincreasedriskofventriculararrhythmiaswhenarsenictrioxidegivenwithlVANDETANIB—avoidconcomitantuselDiuretics:riskofventriculararrhythmiaswitharsenictrioxideincreasedbyhypokalaemiacausedbylACETAZOLAMIDE,lLOOPDIURETICSorlTHIAZIDESANDRELATEDDIURETICSlLithium:increasedriskofventriculararrhythmiaswhenarsenictrioxidegivenwithlLITHIUMArtemetherwithLumefantrinelAnti-arrhythmics:manufacturerofartemetherwithlumefantrineadvisesavoidconcomitantusewithlAMIODARONE,lDISOPYRAMIDEandlFLECAINIDE(riskofventriculararrhythmias)lAntibacterials:manufacturerofartemetherwithlumefantrineadvisesavoidconcomitantusewithlMACROLIDESandlQUINOLONESlAntidepressants:possibleincreasedriskofventriculararrhythmiaswhenartemetherwithlumefantrinegivenwithlCITALOPRAMorlESCITALOPRAM—avoidconcomitantuse;manufacturerofartemetherwithlumefantrineadvisesavoidconcomitantusewithlANTIDEPRESSANTSlAntifungals:manufacturerofartemetherwithlumefantrineadvisesavoidconcomitantusewithlIMIDAZOLESandlTRIAZOLESlAntimalarials:manufacturerofartemetherwithlumefantrineadvisesavoidconcomitantusewithlANTIMALARIALS;increasedriskofventriculararrhythmiaswhenartemetherwithlumefantrinegivenwithlQUININElAntipsychotics:manufacturerofartemetherwithlumefantrineadvisesavoidconcomitantusewithlANTIPSYCHOTICSlAntivirals:manufacturerofartemetherwithlumefantrineadvisescautionwithATAZANAVIR,FOSAMPRENAVIR,INDINAVIR,ArtemetherwithLumefantrinelAntivirals(continued)LOPINAVIR,RITONAVIR,SAQUINAVIRandTIPRANAVIR;avoidanceofartemetherwithlumefantrineadvisedbymanufactureroflBOCEPREVIR;plasmaconcentrationoflumefantrineincreasedwhenartemetherwithlumefantrinegivenwithDARUNAVIR;plasmaconcentrationofartemetherwithlumefantrinereducedbylEFAVIRENZandETRAVIRINElBeta-blockers:manufacturerofartemetherwithlumefantrineadvisesavoidconcomitantusewithlMETOPROLOLandlSOTALOLlCytotoxics:possibleincreasedriskofventriculararrhythmiaswhenartemetherwithlumefantrinegivenwithlVANDETANIB—avoidconcomitantuse TRIANGLE GrapefruitJuice:plasmaconcentrationofartemetherwithlumefantrinepossiblyincreasedbyGRAPEFRUITJUICE TRIANGLE Histamine:avoidanceofantimalarialsadvisedbymanufacturerofHISTAMINElUlcer-healingDrugs:manufacturerofartemetherwithlumefantrineadvisesavoidconcomitantusewithlCIMETIDINE TRIANGLE Vaccines:antimalarialsinactivateORALTYPHOIDVACCINE—seeunderTyphoidVaccineinBNFArtenimolwithPiperaquineNOTEPiperaquinehasalonghalf-life;thereisapotentialfordruginteractionstooccurforupto3monthsaftertreatmenthasbeenstoppedlAnalgesics:manufacturerofartenimolwithpiperaquineadvisesavoidconcomitantusewithlMETHADONE(possibleriskofventriculararrhythmias)lAnti-arrhythmics:manufacturerofartenimolwithpiperaquineadvisesavoidconcomitantusewithlAMIODARONEandlDISOPYRAMIDE(possibleriskofventriculararrhythmias)lAntibacterials:manufacturerofartenimolwithpiperaquineadvisesavoidconcomitantusewithlMACROLIDESandlMOXIFLOXACIN(possibleriskofventriculararrhythmias);manufacturerofartenimolwithpiperaquineadvisesavoidconcomitantusewithRIFAMPICINlAntidepressants:possibleincreasedriskofventriculararrhythmiaswhenartenimolwithpiperaquinegivenwithlCITALOPRAMorlESCITALOPRAM—avoidconcomitantuse;manufacturerofartenimolwithpiperaquineadvisesavoidconcomitantusewithlANTIDEPRESSANTS TRIANGLE Antiepileptics:manufacturerofartenimolwithpiperaquineadvisesavoidconcomitantusewithCARBAMAZEPINE,FOSPHENYTOIN,PHENOBARBITAL,PHENYTOINandPRIMIDONElAntifungals:manufacturerofartenimolwithpiperaquineadvisesavoidconcomitantusewithlIMIDAZOLESandlTRIAZOLES(possibleriskofventriculararrhythmias)lAntihistamines:manufacturerofartenimolwithpiperaquineadvisesavoidconcomitantusewithlMIZOLASTINE(possibleriskofventriculararrhythmias)lAntimalarials:avoidanceofantimalarialsadvisedbymanufactureroflARTEMETHERWITHLUMEFANTRINElAntipsychotics:manufacturerofartenimolwithpiperaquineadvisesavoidconcomitantusewithlDROPERIDOL,lHALOPERIDOL,lPHENOTHIAZINESandlPIMOZIDE(possibleriskofventriculararrhythmias)lAntivirals:manufacturerofartenimolwithpiperaquineadvisesavoidconcomitantusewithlSAQUINAVIR(possibleriskofventriculararrhythmias)lBeta-blockers:manufacturerofartenimolwithpiperaquineadvisesavoidconcomitantusewithlSOTALOL(possibleriskofventriculararrhythmias)lCytotoxics:manufacturerofartenimolwithpiperaquineadvisesavoidconcomitantusewithlARSENICTRIOXIDE(possibleriskofventriculararrhythmias);manufacturerofartenimolwithpiperaquineadvisesavoidconcomitantusewithlVINBLASTINE,lVINCRISTINE,lVINFLUNINEandlVINORELBINElDomperidone:manufacturerofartenimolwithpiperaquineadvisesavoidconcomitantusewithlDOMPERIDONE(possibleriskofventriculararrhythmias) TRIANGLE GrapefruitJuice:manufacturerofartenimolwithpiperaquineadvisesavoidconcomitantusewithGRAPEFRUITJUICEBNF70Appendix1Interactions1161Interactions|Appendix1"
"ArtenimolwithPiperaquine(continued) TRIANGLE Histamine:avoidanceofantimalarialsadvisedbymanufacturerofHISTAMINElPentamidineIsetionate:manufacturerofartenimolwithpiperaquineadvisesavoidconcomitantusewithlPENTAMIDINEISETIONATE(possibleriskofventriculararrhythmias) TRIANGLE Vaccines:antimalarialsinactivateORALTYPHOIDVACCINE—seeunderTyphoidVaccineinBNFAscorbicacidseeVitaminsAsenapineseeAntipsychoticsAspirin TRIANGLE Adsorbents:absorptionofaspirinpossiblyreducedbyKAOLIN TRIANGLE Anaesthetics,General:aspirinpossiblyenhanceseffectsofTHIOPENTALlAnalgesics:avoidconcomitantuseofaspirinwithlNSAIDS(increasedside-effects);antiplateleteffectofaspirinpossiblyreducedbyIBUPROFEN TRIANGLE Antacids:excretionofaspirinincreasedbyalkalineurineduetosomeANTACIDSlAnticoagulants:increasedriskofbleedingwhenaspiringivenwithlCOUMARINSorlPHENINDIONE(duetoantiplateleteffect);aspirinenhancesanticoagulanteffectoflHEPARINSlAntidepressants:increasedriskofbleedingwhenaspiringivenwithlSSRISorlVENLAFAXINE TRIANGLE Antiepileptics:aspirinenhanceseffectsofFOSPHENYTOIN,PHENYTOIN,SODIUMVALPROATEandVALPROICACID TRIANGLE Clopidogrel:increasedriskofbleedingwhenaspiringivenwithCLOPIDOGREL TRIANGLE Corticosteroids:increasedriskofgastro-intestinalbleedingandulcerationwhenaspiringivenwithCORTICOSTEROIDS,alsocorticosteroidsreduceplasmaconcentrationofsalicylatelCytotoxics:aspirinreducesexcretionoflMETHOTREXATE(increasedriskoftoxicity);aspirinpossiblyreducesrenalexcretionofPEMETREXED—consultproductliteraturelDiuretics:increasedriskoftoxicitywhenhigh-doseaspiringivenwithlACETAZOLAMIDE;aspirinantagonisesdiureticeffectofSPIRONOLACTONE;possibleincreasedriskoftoxicitywhenhigh-doseaspiringivenwithLOOPDIURETICS(alsopossiblereducedeffectofloopdiuretics) TRIANGLE Iloprost:increasedriskofbleedingwhenaspiringivenwithILOPROST TRIANGLE LeukotrieneReceptorAntagonists:aspirinincreasesplasmaconcentrationofZAFIRLUKAST TRIANGLE Metoclopramide:rateofabsorptionofaspirinincreasedbyMETOCLOPRAMIDE(enhancedeffect) TRIANGLE Sulfinpyrazone:aspirinantagoniseseffectsofSULFINPYRAZONEAtazanavir TRIANGLE Antacids:absorptionofatazanavirreducedbyANTACIDS(giveatleast2hoursbeforeor1hourafterantacids)lAnti-arrhythmics:atazanavirpossiblyincreasesplasmaconcentrationoflAMIODARONEandlLIDOCAINElAntibacterials:plasmaconcentrationofbothdrugsincreasedwhenatazanavirgivenwithCLARITHROMYCIN;atazanavirincreasesplasmaconcentrationoflRIFABUTIN(reducedoseofrifabutin);plasmaconcentrationofatazanavirreducedbylRIFAMPICIN—avoidconcomitantuse;avoidanceofconcomitantatazanavirinsevererenalandhepaticimpairmentadvisedbymanufactureroflTELITHROMYCIN TRIANGLE Anticoagulants:atazanavirmayenhanceorreduceanticoagulanteffectofWARFARIN;avoidanceofatazanaviradvisedbymanufacturerofAPIXABANandRIVAROXABANlAntidepressants:plasmaconcentrationofatazanavirreducedbylSTJOHN’SWORT—avoidconcomitantuselAntifungals:plasmaconcentrationofatazanavirincreasedbylPOSACONAZOLE;atazanavirincreasesordecreasestheplasmaconcentrationoflVORICONAZOLEandplasmaconcentrationofatazanaviralsoreducedlAntimalarials:cautionwithatazanaviradvisedbymanufacturerofARTEMETHERWITHLUMEFANTRINE;atazanavirpossiblyincreasesplasmaconcentrationoflQUININE(increasedriskoftoxicity) TRIANGLE Antimuscarinics:avoidanceofatazanaviradvisedbymanufacturerofDARIFENACIN;manufactureroffesoterodineadvisesdosereductionwhenatazanavirgivenwithFESOTERODINE—consultfesoterodineproductliteratureAtazanavir(continued)lAntipsychotics:atazanavirpossiblyincreasesplasmaconcentrationoflARIPIPRAZOLE(reducedoseofaripiprazole—consultaripiprazoleproductliterature);atazanavirpossiblyincreasesplasmaconcentrationoflPIMOZIDE—avoidconcomitantuse;atazanavirpossiblyincreasesplasmaconcentrationoflQUETIAPINE—manufacturerofquetiapineadvisesavoidconcomitantuselAntivirals:plasmaconcentrationofatazanavirreducedbylBOCEPREVIR;atazanavirincreasestheplasmaconcentrationoflDACLATASVIR—reducedoseofdaclatasvir(seeunderDaclatasvir,p544);absorptionofatazanavirreducedbyDIDANOSINEtablets(giveatleast2hoursbeforeor1hourafterdidanosinetablets);manufacturerofatazanaviradvisesavoidconcomitantusewithlEFAVIRENZ(plasmaconcentrationofatazanavirreduced);atazanavirboostedwithritonavirincreasesplasmaconcentrationoflELVITEGRAVIR(reducedoseofelvitegravir);avoidconcomitantuseofatazanavirwithlINDINAVIR;atazanavirincreasesplasmaconcentrationoflMARAVIROC(considerreducingdoseofmaraviroc);plasmaconcentrationofatazanavirpossiblyreducedbylNEVIRAPINE—avoidconcomitantuse;increasedriskofventriculararrhythmiaswhenatazanavirgivenwithlSAQUINAVIR—avoidconcomitantuse;atazanavirpossiblyreducesplasmaconcentrationofTELAPREVIR,alsoplasmaconcentrationofatazanavirpossiblyincreased;plasmaconcentrationofatazanavirreducedbyTENOFOVIR,alsoplasmaconcentrationoftenofovirpossiblyincreased;atazanavirincreasesplasmaconcentrationofTIPRANAVIR(alsoplasmaconcentrationofatazanavirreduced)lAnxiolyticsandHypnotics:atazanavirpossiblyincreasesplasmaconcentrationoflMIDAZOLAM—avoidconcomitantuseoforalmidazolamlAvanafil:atazanavirpossiblyincreasesplasmaconcentrationoflAVANAFIL—manufacturerofavanafiladvisesavoidconcomitantuselCalcium-channelBlockers:atazanavirincreasesplasmaconcentrationoflDILTIAZEM(reducedoseofdiltiazem);atazanavirpossiblyincreasesplasmaconcentrationofVERAPAMILlCiclosporin:atazanavirpossiblyincreasesplasmaconcentrationoflCICLOSPORINlColchicine:atazanavirpossiblyincreasesriskoflCOLCHICINEtoxicity—suspendorreducedoseofcolchicine(avoidconcomitantuseinhepaticorrenalimpairment)lCytotoxics:atazanavirpossiblyincreasesplasmaconcentrationofAXITINIB(reducedoseofaxitinib—consultaxitinibproductliterature);atazanavirpossiblyincreasestheplasmaconcentrationoflBOSUTINIB—manufacturerofbosutinibadvisesavoidorconsiderreducingdoseofbosutinib;atazanavirpossiblyincreasesplasmaconcentrationoflCRIZOTINIBandlEVEROLIMUS—manufacturerofcrizotinibandeverolimusadvisesavoidconcomitantuse;atazanavirpossiblyincreasestheplasmaconcentrationoflIBRUTINIB—reducedoseofibrutinib(seeunderIbrutinib,p809);atazanavirpossiblyincreasesplasmaconcentrationoflPAZOPANIB(reducedoseofpazopanib);avoidanceofatazanaviradvisedbymanufactureroflCABAZITAXEL;atazanavirpossiblyinhibitsmetabolismoflIRINOTECAN(increasedriskoftoxicity)lDapoxetine:avoidanceofatazanaviradvisedbymanufactureroflDAPOXETINE(increasedriskoftoxicity)lErgotAlkaloids:atazanavirpossiblyincreasesplasmaconcentrationoflERGOTALKALOIDS—avoidconcomitantuselLipid-regulatingDrugs:possibleincreasedriskofmyopathywhenatazanavirgivenwithlATORVASTATINorPRAVASTATIN;atazanavirincreasesplasmaconcentrationoflROSUVASTATIN—adjustdoseofrosuvastatin(consultproductliterature);increasedriskofmyopathywhenatazanavirgivenwithlSIMVASTATIN(avoidconcomitantuse) TRIANGLE Oestrogens:atazanavirincreasesplasmaconcentrationofETHINYLESTRADIOLlOrlistat:absorptionofatazanavirpossiblyreducedbylORLISTAT TRIANGLE Progestogens:atazanavirincreasesplasmaconcentrationofNORETHISTERONE1162Appendix1InteractionsBNF70Interactions|Appendix1"
"Atazanavir(continued)lRanolazine:atazanavirpossiblyincreasesplasmaconcentrationoflRANOLAZINE—manufacturerofranolazineadvisesavoidconcomitantuselSildenafil:atazanavirpossiblyincreasesside-effectsoflSILDENAFILlSirolimus:atazanavirpossiblyincreasesplasmaconcentrationoflSIROLIMUSlTacrolimus:atazanavirpossiblyincreasesplasmaconcentrationoflTACROLIMUSlTicagrelor:atazanavirpossiblyincreasesplasmaconcentrationoflTICAGRELOR—manufacturerofticagreloradvisesavoidconcomitantuselUlcer-healingDrugs:manufacturerofatazanaviradvisesadjustdosesofbothdrugswhenatazanavirgivenwithCIMETIDINEandNIZATIDINE—consultatazanavirproductliterature;plasmaconcentrationofatazanavirreducedbylFAMOTIDINEandlRANITIDINE(adjustdosesofbothdrugs—consultatazanavirproductliterature);plasmaconcentrationofatazanavirreducedbylPROTONPUMPINHIBITORS—avoidoradjustdoseofbothdrugs(consultproductliterature)AtenololseeBeta-blockersAtomoxetinelAnalgesics:increasedriskofventriculararrhythmiaswhenatomoxetinegivenwithlMETHADONE;possibleincreasedriskofconvulsionswhenatomoxetinegivenwithTRAMADOLlAnti-arrhythmics:increasedriskofventriculararrhythmiaswhenatomoxetinegivenwithlAMIODARONEorlDISOPYRAMIDElAntibacterials:increasedriskofventriculararrhythmiaswhenatomoxetinegivenwithparenterallERYTHROMYCIN;increasedriskofventriculararrhythmiaswhenatomoxetinegivenwithlMOXIFLOXACINlAntidepressants:metabolismofatomoxetinepossiblyinhibitedbyFLUOXETINEandPAROXETINE;possibleincreasedriskofconvulsionswhenatomoxetinegivenwithANTIDEPRESSANTS;atomoxetineshouldnotbestarteduntil2weeksafterstoppinglMAOIS,alsoMAOIsshouldnotbestarteduntilatleast2weeksafterstoppingatomoxetine;increasedriskofventriculararrhythmiaswhenatomoxetinegivenwithlTRICYCLICSlAntimalarials:increasedriskofventriculararrhythmiaswhenatomoxetinegivenwithlMEFLOQUINElAntipsychotics:increasedriskofventriculararrhythmiaswhenatomoxetinegivenwithlANTIPSYCHOTICSthatprolongtheQTintervallBeta-blockers:increasedriskofventriculararrhythmiaswhenatomoxetinegivenwithlSOTALOL TRIANGLE Bupropion:possibleincreasedriskofconvulsionswhenatomoxetinegivenwithBUPROPIONlDiuretics:riskofventriculararrhythmiaswithatomoxetineincreasedbyhypokalaemiacausedbylDIURETICS TRIANGLE Sympathomimetics,Beta2:Increasedriskofcardiovascularside-effectswhenatomoxetinegivenwithparenteralSALBUTAMOLAtorvastatinseeStatinsAtovaquonelAntibacterials:manufacturerofatovaquoneadvisesavoidconcomitantusewithRIFABUTIN(plasmaconcentrationofbothdrugsreduced);plasmaconcentrationofatovaquonereducedbylRIFAMPICIN(andconcentrationofrifampicinincreased)—avoidconcomitantuse;plasmaconcentrationofatovaquonereducedbyTETRACYCLINElAntivirals:plasmaconcentrationofatovaquonereducedbylEFAVIRENZ—avoidconcomitantuse;atovaquonepossiblyreducesplasmaconcentrationofINDINAVIR;plasmaconcentrationofatovaquonepossiblyreducedbyRITONAVIR—manufacturerofatovaquoneadvisesavoidconcomitantuse;atovaquoneincreasesplasmaconcentrationofZIDOVUDINE(increasedriskoftoxicity) TRIANGLE Cytotoxics:atovaquonepossiblyincreasesplasmaconcentrationofETOPOSIDE TRIANGLE Histamine:avoidanceofatovaquoneadvisedbymanufacturerofHISTAMINE TRIANGLE Metoclopramide:plasmaconcentrationofatovaquonereducedbyMETOCLOPRAMIDE—avoidconcomitantuseAtracuriumseeMuscleRelaxantsAtropineseeAntimuscarinicsAvanafil TRIANGLE ACEInhibitors:avanafilpossiblyenhanceshypotensiveeffectofENALAPRIL TRIANGLE Alcohol:possibleenhancedhypotensiveeffectwhenavanafilgivenwithALCOHOLlAlpha-blockers:enhancedhypotensiveeffectwhenavanafilgivenwithlALPHA-BLOCKERS—whenpatientisstableonthealphablockerinitiateavanafilatthelowestpossibledoselAntibacterials:plasmaconcentrationofavanafilpossiblyincreasedbylCLARITHROMYCINandlTELITHROMYCIN—manufacturerofavanafiladvisesavoidconcomitantuse;plasmaconcentrationofavanafilincreasedbylERYTHROMYCIN—seeunderAvanafil,p698;plasmaconcentrationofavanafilpossiblyreducedbyRIFAMPICIN—manufacturerofavanafiladvisesavoidconcomitantuse TRIANGLE Antiepileptics:plasmaconcentrationofavanafilpossiblyreducedbyCARBAMAZEPINE,PHENOBARBITALandPRIMIDONE—manufacturerofavanafiladvisesavoidconcomitantuselAntifungals:plasmaconcentrationofavanafilincreasedbylKETOCONAZOLE—avoidconcomitantuse;plasmaconcentrationofavanafilpossiblyincreasedbylFLUCONAZOLE—seeunderAvanafil,p698;plasmaconcentrationofavanafilpossiblyincreasedbylITRACONAZOLEandlVORICONAZOLE—manufacturerofavanafiladvisesavoidconcomitantuselAntivirals:plasmaconcentrationofavanafilpossiblyincreasedbylATAZANAVIR,lINDINAVIRandlSAQUINAVIR—manufacturerofavanafiladvisesavoidconcomitantuse;plasmaconcentrationofavanafilpossiblyreducedbyEFAVIRENZ—manufacturerofavanafiladvisesavoidconcomitantuse;plasmaconcentrationofavanafilpossiblyincreasedbylFOSAMPRENAVIR—seeunderAvanafil,p698;plasmaconcentrationofavanafilsignificantlyincreasedbylRITONAVIR—avoidconcomitantuselAprepitant:plasmaconcentrationofavanafilpossiblyincreasedbylAPREPITANT—seeunderAvanafil,p698 TRIANGLE Bosentan:plasmaconcentrationofavanafilpossiblyreducedbyBOSENTAN—manufacturerofavanafiladvisesavoidconcomitantuselCalcium-channelBlockers:plasmaconcentrationofavanafilpossiblyincreasedbylDILTIAZEMandlVERAPAMIL—seeunderAvanafil,p698 TRIANGLE Fosaprepitant:plasmaconcentrationofavanafilpossiblyincreasedbyFOSAPREPITANT TRIANGLE GrapefruitJuice:plasmaconcentrationofavanafilpossiblyincreasedbyGRAPEFRUITJUICE—manufacturerofavanafiladvisesavoidgrapefruitjuicefor24hoursbeforeavanafillNicorandil:avanafilsignificantlyenhanceshypotensiveeffectoflNICORANDIL(avoidconcomitantuse)lNitrates:avanafilsignificantlyenhanceshypotensiveeffectoflNITRATES(avoidconcomitantuse)lRiociguat:possibleenhancedhypotensiveeffectwhenavanafilgivenwithlRIOCIGUAT—avoidconcomitantuseAxitinib TRIANGLE Antibacterials:plasmaconcentrationofaxitinibpossiblyincreasedbyCLARITHROMYCIN,ERYTHROMYCINandTELITHROMYCIN(reducedoseofaxitinib—consultaxitinibproductliterature);plasmaconcentrationofaxitinibpossiblydecreasedbyRIFABUTIN(increasedoseofaxitinib—consultaxitinibproductliterature);plasmaconcentrationofaxitinibdecreasedbyRIFAMPICIN(increasedoseofaxitinib—consultaxitinibproductliterature) TRIANGLE Antidepressants:plasmaconcentrationofaxitinibpossiblyreducedbySTJOHN’SWORT—considerincreasingdoseofaxitinib TRIANGLE Antiepileptics:plasmaconcentrationofaxitinibpossiblydecreasedbyCARBAMAZEPINE,FOSPHENYTOIN,PHENOBARBITAL,PHENYTOINandPRIMIDONE(increasedoseofaxitinib—consultaxitinibproductliterature) TRIANGLE Antifungals:plasmaconcentrationofaxitinibincreasedbyKETOCONAZOLE(reducedoseofaxitinib—consultaxitinibproductliterature);plasmaconcentrationofaxitinibpossiblyBNF70Appendix1Interactions1163Interactions|Appendix1"
"AxitinibAntifungals(continued)increasedbyITRACONAZOLE(reducedoseofaxitinib—consultaxitinibproductliterature)lAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis) TRIANGLE Antivirals:plasmaconcentrationofaxitinibpossiblyincreasedbyATAZANAVIR,INDINAVIR,RITONAVIRandSAQUINAVIR(reducedoseofaxitinib—consultaxitinibproductliterature) TRIANGLE Corticosteroids:plasmaconcentrationofaxitinibpossiblydecreasedbyDEXAMETHASONE(increasedoseofaxitinib—consultaxitinibproductliterature) TRIANGLE GrapefruitJuice:plasmaconcentrationofaxitinibpossiblyincreasedbyGRAPEFRUITJUICEAzathioprine TRIANGLE ACEInhibitors:increasedriskofanaemiaorleucopeniawhenazathioprinegivenwithCAPTOPRILespeciallyinrenalimpairment;increasedriskofanaemiawhenazathioprinegivenwithENALAPRILespeciallyinrenalimpairmentlAllopurinol:enhancedeffectsandincreasedtoxicityofazathioprinewhengivenwithlALLOPURINOL(reducedoseofazathioprinetoonequarterofusualdose)lAntibacterials:increasedriskofhaematologicaltoxicitywhenazathioprinegivenwithlSULFAMETHOXAZOLE(asco-trimoxazole);increasedriskofhaematologicaltoxicitywhenazathioprinegivenwithlTRIMETHOPRIM(alsowithco-trimoxazole)lAnticoagulants:azathioprinepossiblyreducesanticoagulanteffectoflCOUMARINSlAntivirals:myelosuppressiveeffectsofazathioprinepossiblyenhancedbylRIBAVIRINlFebuxostat:avoidanceofazathioprineadvisedbymanufactureroflFEBUXOSTATAzelastineseeAntihistaminesAzilsartanseeAngiotensin-IIReceptorAntagonistsAzithromycinseeMacrolidesAztreonamlAnticoagulants:aztreonampossiblyenhancesanticoagulanteffectoflCOUMARINS TRIANGLE Vaccines:antibacterialsinactivateORALTYPHOIDVACCINE—seeunderTyphoidVaccineinBNFBaclofenseeMuscleRelaxantsBambuterolseeSympathomimetics,Beta2BasiliximablAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lVaccines:riskofgeneralisedinfectionswhenmonoclonalantibodiesgivenwithlivelVACCINES—avoidconcomitantuseBCGVaccineseeVaccinesBeclometasoneseeCorticosteroidsBedaquilinelAntibacterials:plasmaconcentrationofbedaquilinepossiblyincreasedbyCIPROFLOXACIN,CLARITHROMYCINandERYTHROMYCIN—avoidconcomitantuseifciprofloxacin,clarithromycinanderythromycingivenformorethan14days;manufacturerofbedaquilineadvisesavoidconcomitantusewithMOXIFLOXACIN;plasmaconcentrationofbedaquilinepossiblyreducedbyRIFABUTIN—manufacturerofbedaquilineadvisesavoidconcomitantuse;plasmaconcentrationofbedaquilinereducedbylRIFAMPICIN—manufacturerofbedaquilineadvisesavoidconcomitantuse;possibleincreasedriskofventriculararrhythmiaswhenbedaquilinegivenwithlCLOFAZIMINE TRIANGLE Antidepressants:plasmaconcentrationofbedaquilinepossiblyreducedbySTJOHN’SWORT—manufacturerofbedaquilineadvisesavoidconcomitantuselAntiepileptics:plasmaconcentrationofbedaquilinepossiblyreducedbylCARBAMAZEPINE,lFOSPHENYTOINandlPHENYTOIN—manufacturerofbedaquilineadvisesavoidconcomitantuse TRIANGLE Antifungals:plasmaconcentrationofbedaquilineincreasedbyKETOCONAZOLE—avoidconcomitantuseifketoconazolegivenformorethan14days;plasmaconcentrationofbedaquilinepossiblyincreasedbyFLUCONAZOLE—avoidconcomitantuseiffluconazolegivenformorethan14daysBedaquiline(continued) TRIANGLE Antivirals:plasmaconcentrationofbedaquilinepossiblyreducedbyEFAVIRENZandETRAVIRINE—manufacturerofbedaquilineadvisesavoidconcomitantuse;plasmaconcentrationofbedaquilinepossiblyincreasedbyRITONAVIR—avoidconcomitantuseifritonavirgivenformorethan14days TRIANGLE Vaccines:antibacterialsinactivateORALTYPHOIDVACCINE—seeunderTyphoidVaccineinBNFBeeVenomExtractslACEInhibitors:possiblesevereanaphylactoidreactionwhenbeevenomextractsgivenwithlACEINHIBITORSBelimumablAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lVaccines:riskofgeneralisedinfectionswhenmonoclonalantibodiesgivenwithlivelVACCINES—avoidconcomitantuseBendamustinelAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)BendroflumethiazideseeDiureticsBenperidolseeAntipsychoticsBenzodiazepinesseeAnxiolyticsandHypnoticsBenzthiazideseeDiureticsBenzylpenicillinseePenicillinsBeta-blockersNOTESincesystemicabsorptionmayfollowtopicalapplicationofbeta-blockerstotheeyethepossibilityofinteractions,inparticular,withdrugssuchasverapamilshouldbeborneinmind TRIANGLE ACEInhibitors:enhancedhypotensiveeffectwhenbeta-blockersgivenwithACEINHIBITORS TRIANGLE AdrenergicNeuroneBlockers:enhancedhypotensiveeffectwhenbeta-blockersgivenwithADRENERGICNEURONEBLOCKERS TRIANGLE Alcohol:enhancedhypotensiveeffectwhenbeta-blockersgivenwithALCOHOL TRIANGLE Aldesleukin:enhancedhypotensiveeffectwhenbeta-blockersgivenwithALDESLEUKINlAlpha-blockers:enhancedhypotensiveeffectwhenbeta-blockersgivenwithlALPHA-BLOCKERS,alsoincreasedriskoffirst-dosehypotensionwithpost-synapticalpha-blockerssuchasprazosin TRIANGLE Anaesthetics,General:enhancedhypotensiveeffectwhenbeta-blockersgivenwithGENERALANAESTHETICSlAnaesthetics,Local:propranololincreasesriskoflBUPIVACAINEtoxicity TRIANGLE Analgesics:hypotensiveeffectofbeta-blockersantagonisedbyNSAIDS;plasmaconcentrationofesmololpossiblyincreasedbyMORPHINE TRIANGLE Angiotensin-IIReceptorAntagonists:enhancedhypotensiveeffectwhenbeta-blockersgivenwithANGIOTENSIN-IIRECEPTORANTAGONISTSlAnti-arrhythmics:increasedmyocardialdepressionwhenbeta-blockersgivenwithlANTI-ARRHYTHMICS;increasedriskofventriculararrhythmiaswhensotalolgivenwithlAMIODARONE,lDISOPYRAMIDEorlDRONEDARONE—avoidconcomitantuse;increasedriskofbradycardia,AVblockandmyocardialdepressionwhenbeta-blockersgivenwithlAMIODARONE;plasmaconcentrationofmetoprololandpropranololpossiblyincreasedbyDRONEDARONE;increasedriskofmyocardialdepressionandbradycardiawhenbeta-blockersgivenwithlFLECAINIDE;propranololincreasesriskoflLIDOCAINEtoxicity;nadololpossiblyincreasesriskofLIDOCAINEtoxicity;plasmaconcentrationofmetoprololandpropranololincreasedbyPROPAFENONElAntibacterials:increasedriskofventriculararrhythmiaswhensotalolgivenwithlMOXIFLOXACIN—avoidconcomitantuse;metabolismofbisoprololandpropranololacceleratedbyRIFAMPICIN(plasmaconcentrationsignificantlyreduced);plasmaconcentrationofcarvedilol,celiprololandmetoprololreducedbyRIFAMPICIN;plasmaconcentrationoforaltimololpossiblyreducedbyRIFAMPICIN;increasedriskofventriculararrhythmiaswhensotalolgivenwithlDELAMANIDlAntidepressants:plasmaconcentrationofmetoprololincreasedbyCITALOPRAMandESCITALOPRAM;increasedriskof1164Appendix1InteractionsBNF70Interactions|Appendix1"
"Beta-blockerslAntidepressants(continued)ventriculararrhythmiaswhensotalolgivenwithlCITALOPRAM—avoidconcomitantuse;avoidanceofsotaloladvisedbymanufactureroflESCITALOPRAM(riskofventriculararrhythmias);plasmaconcentrationofpropranololincreasedbyFLUVOXAMINE;plasmaconcentrationofmetoprololpossiblyincreasedbylPAROXETINE—increasedriskofAVblock(manufacturerofparoxetineadvisesavoidconcomitantuseincardiacinsufficiency);labetalolandpropranololincreaseplasmaconcentrationofIMIPRAMINE;enhancedhypotensiveeffectwhenbeta-blockersgivenwithMAOIS;increasedriskofventriculararrhythmiaswhensotalolgivenwithlTRICYCLICS TRIANGLE Antidiabetics:beta-blockersmaymaskwarningsignsofhypoglycaemia(suchastremor)withANTIDIABETICS;beta-blockersenhancehypoglycaemiceffectofINSULIN TRIANGLE Antiepileptics:plasmaconcentrationofpropranololpossiblyreducedbyPHENOBARBITALandPRIMIDONE TRIANGLE Antifungals:plasmaconcentrationofnadololpossiblyincreasedbyKETOCONAZOLElAntihistamines:increasedriskofventriculararrhythmiaswhensotalolgivenwithlMIZOLASTINE—avoidconcomitantuselAntimalarials:avoidanceofmetoprololandsotaloladvisedbymanufactureroflARTEMETHERWITHLUMEFANTRINE;avoidanceofsotaloladvisedbymanufactureroflARTENIMOLWITHPIPERAQUINE(possibleriskofventriculararrhythmias);increasedriskofbradycardiawhenbeta-blockersgivenwithMEFLOQUINElAntimuscarinics:increasedriskofventriculararrhythmiaswhensotalolgivenwithlTOLTERODINElAntipsychotics:increasedriskofventriculararrhythmiaswhensotalolgivenwithlDROPERIDOLorlZUCLOPENTHIXOL—avoidconcomitantuse;possibleincreasedriskofventriculararrhythmiaswhensotalolgivenwithlHALOPERIDOL—avoidconcomitantuse;plasmaconcentrationofbothdrugsmayincreasewhenpropranololgivenwithlCHLORPROMAZINE;increasedriskofventriculararrhythmiaswhensotalolgivenwithlAMISULPRIDE,lPHENOTHIAZINES,lPIMOZIDEorlSULPIRIDE;enhancedhypotensiveeffectwhenbeta-blockersgivenwithPHENOTHIAZINES;possibleincreasedriskofventriculararrhythmiaswhensotalolgivenwithlRISPERIDONElAntivirals:increasedriskofventriculararrhythmiaswhensotalolgivenwithlSAQUINAVIR—avoidconcomitantuse;avoidanceofsotaloladvisedbymanufactureroflTELAPREVIR(riskofventriculararrhythmias);avoidanceofmetoprololforheartfailureadvisedbymanufactureroflTIPRANAVIR TRIANGLE AnxiolyticsandHypnotics:enhancedhypotensiveeffectwhenbeta-blockersgivenwithANXIOLYTICSANDHYPNOTICSlAtomoxetine:increasedriskofventriculararrhythmiaswhensotalolgivenwithlATOMOXETINElCalcium-channelBlockers:enhancedhypotensiveeffectwhenbeta-blockersgivenwithCALCIUM-CHANNELBLOCKERS;possibleseverehypotensionandheartfailurewhenbeta-blockersgivenwithlNIFEDIPINE;increasedriskofAVblockandbradycardiawhenbeta-blockersgivenwithlDILTIAZEM;asystole,severehypotensionandheartfailurewhenbeta-blockersgivenwithlVERAPAMIL(seeunderVerapamil,p156) TRIANGLE CardiacGlycosides:increasedriskofAVblockandbradycardiawhenbeta-blockersgivenwithCARDIACGLYCOSIDESlCiclosporin:carvedilolincreasesplasmaconcentrationoflCICLOSPORINlClonidine:increasedriskofwithdrawalhypertensionwhenbeta-blockersgivenwithlCLONIDINE(withdrawbeta-blockersseveraldaysbeforeslowlywithdrawingclonidine) TRIANGLE Corticosteroids:hypotensiveeffectofbeta-blockersantagonisedbyCORTICOSTEROIDSlCytotoxics:possibleincreasedriskofventriculararrhythmiaswhensotalolgivenwithlBOSUTINIB;possibleincreasedriskofbradycardiawhenbeta-blockersgivenwithCRIZOTINIB;possibleincreasedriskofventriculararrhythmiaswhensotalolgivenwithlVANDETANIB—avoidconcomitantuse;increasedriskofventriculararrhythmiaswhensotalolgivenwithlARSENICTRIOXIDEBeta-blockers(continued) TRIANGLE Diazoxide:enhancedhypotensiveeffectwhenbeta-blockersgivenwithDIAZOXIDElDiuretics:enhancedhypotensiveeffectwhenbeta-blockersgivenwithDIURETICS;riskofventriculararrhythmiaswithsotalolincreasedbyhypokalaemiacausedbylLOOPDIURETICSorlTHIAZIDESANDRELATEDDIURETICS TRIANGLE Dopaminergics:enhancedhypotensiveeffectwhenbeta-blockersgivenwithCO-BENELDOPA,CO-CARELDOPAorLEVODOPA TRIANGLE ErgotAlkaloids:increasedperipheralvasoconstrictionwhenbeta-blockersgivenwithERGOTAMINElFingolimod:possibleincreasedriskofbradycardiawhenbeta-blockersgivenwithlFINGOLIMOD TRIANGLE HormoneAntagonists:possibleincreasedriskofbradycardiawhencarteolol,metoprolol,propranololorsotalolgivenwithPASIREOTIDE TRIANGLE 5HT1-receptorAgonists:propranololincreasesplasmaconcentrationofRIZATRIPTAN(manufacturerofrizatriptanadviseshalvedoseandavoidwithin2hoursofpropranolol)lIvabradine:increasedriskofventriculararrhythmiaswhensotalolgivenwithlIVABRADINE TRIANGLE Methyldopa:enhancedhypotensiveeffectwhenbeta-blockersgivenwithMETHYLDOPA TRIANGLE Mirabegron:plasmaconcentrationofmetoprololincreasedbyMIRABEGRONlMoxisylyte:possiblesevereposturalhypotensionwhenbeta-blockersgivenwithlMOXISYLYTE TRIANGLE Moxonidine:enhancedhypotensiveeffectwhenbeta-blockersgivenwithMOXONIDINE TRIANGLE MuscleRelaxants:propranololenhanceseffectsofMUSCLERELAXANTS;enhancedhypotensiveeffectwhenbeta-blockersgivenwithBACLOFEN;possibleenhancedhypotensiveeffectandbradycardiawhenbeta-blockersgivenwithTIZANIDINE TRIANGLE Nitrates:enhancedhypotensiveeffectwhenbeta-blockersgivenwithNITRATES TRIANGLE Oestrogens:hypotensiveeffectofbeta-blockersantagonisedbyOESTROGENS TRIANGLE Parasympathomimetics:propranololantagoniseseffectsofNEOSTIGMINEandPYRIDOSTIGMINE;increasedriskofarrhythmiaswhenbeta-blockersgivenwithPILOCARPINE TRIANGLE Prostaglandins:enhancedhypotensiveeffectwhenbeta-blockersgivenwithALPROSTADILlRanolazine:avoidanceofsotaloladvisedbymanufactureroflRANOLAZINElSympathomimetics:increasedriskofseverehypertensionandbradycardiawhennon-cardioselectivebeta-blockersgivenwithlADRENALINE(EPINEPHRINE),alsoreponsetoadrenaline(epinephrine)maybereduced;increasedriskofseverehypertensionandbradycardiawhennon-cardioselectivebeta-blockersgivenwithlDOBUTAMINE;possibleincreasedriskofseverehypertensionandbradycardiawhennon-cardioselectivebeta-blockersgivenwithlNORADRENALINE(NOREPINEPHRINE) TRIANGLE ThyroidHormones:metabolismofpropranololacceleratedbyLEVOTHYROXINE TRIANGLE Ulcer-healingDrugs:plasmaconcentrationoflabetalol,metoprololandpropranololincreasedbyCIMETIDINE;plasmaconcentrationoforaltimololpossiblyincreasedbyCIMETIDINE TRIANGLE VasodilatorAntihypertensives:enhancedhypotensiveeffectwhenbeta-blockersgivenwithHYDRALAZINE,MINOXIDILorSODIUMNITROPRUSSIDEBetahistine TRIANGLE Antihistamines:effectofbetahistinetheoreticallyantagonisedbyANTIHISTAMINESBetamethasoneseeCorticosteroidsBetaxololseeBeta-blockersBethanecholseeParasympathomimeticsBevacizumablAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lVaccines:riskofgeneralisedinfectionswhenmonoclonalantibodiesgivenwithlivelVACCINES—avoidconcomitantuseBexarotenelAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)BNF70Appendix1Interactions1165Interactions|Appendix1"
"Bexarotene(continued)lLipid-regulatingDrugs:plasmaconcentrationofbexaroteneincreasedbylGEMFIBROZIL—avoidconcomitantuseBezafibrateseeFibratesBicalutamide TRIANGLE Anticoagulants:bicalutamidepossiblyenhancesanticoagulanteffectofCOUMARINS TRIANGLE Lipid-regulatingDrugs:separatingadministrationfrombicalutamideby12hoursadvisedbymanufacturerofLOMITAPIDEBiguanidesseeAntidiabeticsBilastineseeAntihistaminesBileAcidSequestrantsseeColesevelam,Colestipol,andColestyramineBileAcids TRIANGLE Antacids:absorptionofbileacidspossiblyreducedbyANTACIDSlCiclosporin:ursodeoxycholicacidincreasesabsorptionoflCICLOSPORIN TRIANGLE Lipid-regulatingDrugs:absorptionofbileacidspossiblyreducedbyCOLESTIPOLandCOLESTYRAMINEBisoprololseeBeta-blockersBisphosphonates TRIANGLE Antacids:absorptionofbisphosphonatesreducedbyANTACIDS TRIANGLE Antibacterials:increasedriskofhypocalcaemiawhenbisphosphonatesgivenwithAMINOGLYCOSIDES TRIANGLE CalciumSalts:absorptionofbisphosphonatesreducedbyCALCIUMSALTSlCytotoxics:sodiumclodronateincreasesplasmaconcentrationoflESTRAMUSTINE TRIANGLE IronSalts:absorptionofbisphosphonatesreducedbyoralIRONSALTSBivalirudinlAnalgesics:increasedriskofhaemorrhagewhenanticoagulantsgivenwithintravenouslDICLOFENAC(avoidconcomitantuse,includinglow-doseheparins);increasedriskofhaemorrhagewhenanticoagulantsgivenwithlKETOROLAC(avoidconcomitantuse,includinglow-doseheparins)lAnticoagulants:increasedriskofhaemorrhagewhenotheranticoagulantsgivenwithlAPIXABAN,lDABIGATRANandlRIVAROXABAN(avoidconcomitantuseexceptwhenswitchingwithotheranticoagulantsorusingheparintomaintaincatheterpatency)BleomycinlAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis) TRIANGLE CardiacGlycosides:bleomycinpossiblyreducesabsorptionofDIGOXINtabletslCytotoxics:increasedriskofpulmonarytoxicitywhenbleomycingivenwithlBRENTUXIMABVEDOTIN—avoidconcomitantuse;increasedpulmonarytoxicitywhenbleomycingivenwithlCISPLATINBoceprevir TRIANGLE Alpha-blockers:boceprevirpossiblyincreasesplasmaconcentrationofDOXAZOSINandTAMSULOSIN—manufacturerofbocepreviradvisesavoidconcomitantuse TRIANGLE Analgesics:possibleincreasedriskofprolongedsedationandrespiratorydepressionwhenboceprevirgivenwithBUPRENORPHINE;boceprevirpossiblyaffectsplasmaconcentrationofMETHADONElAntibacterials:manufacturerofbocepreviradvisesavoidconcomitantusewithlRIFAMPICIN(plasmaconcentrationofboceprevirpossiblyreduced) TRIANGLE Anticoagulants:avoidanceofbocepreviradvisedbymanufacturerofAPIXABANlAntiepileptics:manufacturerofbocepreviradvisesavoidconcomitantusewithlCARBAMAZEPINE,lFOSPHENYTOIN,lPHENOBARBITAL,lPHENYTOINandlPRIMIDONE(plasmaconcentrationofboceprevirpossiblyreduced)lAntifungals:plasmaconcentrationofboceprevirincreasedbylKETOCONAZOLElAntimalarials:manufacturerofbocepreviradvisesavoidconcomitantusewithlARTEMETHERWITHLUMEFANTRINEBoceprevir(continued)lAntipsychotics:boceprevirpossiblyincreasesplasmaconcentrationoflLURASIDONE—avoidconcomitantuse;manufacturerofbocepreviradvisesavoidconcomitantusewithlPIMOZIDE;boceprevirpossiblyincreasesplasmaconcentrationoflQUETIAPINE—manufacturerofquetiapineadvisesavoidconcomitantuselAntivirals:boceprevirreducesplasmaconcentrationoflATAZANAVIR;boceprevirpossiblyincreasestheplasmaconcentrationoflDACLATASVIR—reducedoseofdaclatasvir(seeunderDaclatasvir,p544);avoidconcomitantuseofboceprevirwithlDARUNAVIR;effectsofbothdrugspossiblyreducedwhenboceprevirgivenwithETRAVIRINE;avoidanceofbocepreviradvisedbymanufactureroflFOSAMPRENAVIR,NEVIRAPINEandTIPRANAVIR;manufacturersadviseavoidconcomitantuseofboceprevirwithlLOPINAVIR;boceprevirincreasesplasmaconcentrationofMARAVIROC(considerreducingdoseofmaraviroc);plasmaconcentrationofbothdrugsreducedwhenboceprevirgivenwithlRITONAVIRlAnxiolyticsandHypnotics:boceprevirincreasesplasmaconcentrationoforallMIDAZOLAM—manufacturerofbocepreviradvisesavoidconcomitantuse TRIANGLE CardiacGlycosides:boceprevirpossiblyincreasesside-effectsofDIGOXINlCiclosporin:boceprevirincreasesplasmaconcentrationoflCICLOSPORINlCilostazol:boceprevirpossiblyincreasesplasmaconcentrationoflCILOSTAZOL(seeunderCilostazol,p206) TRIANGLE Cobicistat:avoidanceofbocepreviradvisedbymanufacturerofCOBICISTATlCytotoxics:boceprevirpossiblyincreasestheplasmaconcentrationoflBOSUTINIB—manufacturerofbosutinibadvisesavoidorconsiderreducingdoseofbosutinib;manufacturerofbocepreviradvisesavoidconcomitantusewithlDASATINIB,lERLOTINIB,lGEFITINIB,lIMATINIB,lLAPATINIB,lNILOTINIB,lPAZOPANIB,lSORAFENIBandlSUNITINIB;manufacturerofruxolitinibadvisesdosereductionwhenboceprevirgivenwithlRUXOLITINIB—consultruxolitinibproductliteraturelDomperidone:possibleincreasedriskofventriculararrhythmiaswhenboceprevirgivenwithlDOMPERIDONE—avoidconcomitantuselErgotAlkaloids:manufacturerofbocepreviradvisesavoidconcomitantusewithlERGOTALKALOIDSlLipid-regulatingDrugs:boceprevirincreasesplasmaconcentrationofATORVASTATIN(reducedoseofatorvastatin);boceprevirincreasesplasmaconcentrationofPRAVASTATIN;manufacturersadviseavoidconcomitantuseofboceprevirwithlSIMVASTATIN TRIANGLE Progestogens:boceprevirincreasesplasmaconcentrationofDROSPIRENONE(increasedriskoftoxicity)lSirolimus:boceprevirincreasesplasmaconcentrationoflSIROLIMUS(increasedriskoftoxicity—reducesirolimusdose)lTacrolimus:boceprevirincreasesplasmaconcentrationoflTACROLIMUS(reducedoseoftacrolimus)BortezomiblAntibacterials:plasmaconcentrationofbortezomibreducedbylRIFAMPICIN—manufacturerofbortezomibadvisesavoidconcomitantuse TRIANGLE Antidepressants:plasmaconcentrationofbortezomibpossiblyreducedbySTJOHN’SWORT—manufacturerofbortezomibadvisesavoidconcomitantuse TRIANGLE Antiepileptics:plasmaconcentrationofbortezomibpossiblyreducedbyCARBAMAZEPINE,FOSPHENYTOIN,PHENOBARBITAL,PHENYTOINandPRIMIDONE—manufacturerofbortezomibadvisesavoidconcomitantuse TRIANGLE Antifungals:plasmaconcentrationofbortezomibincreasedbyKETOCONAZOLElAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)BosentanlAntibacterials:plasmaconcentrationofbosentanreducedbylRIFAMPICIN—avoidconcomitantuse TRIANGLE Anticoagulants:manufacturerofbosentanrecommendsmonitoringanticoagulanteffectofCOUMARINS1166Appendix1InteractionsBNF70Interactions|Appendix1"
"Bosentan(continued)lAntidiabetics:increasedriskofhepatotoxicitywhenbosentangivenwithlGLIBENCLAMIDE—avoidconcomitantuselAntifungals:plasmaconcentrationofbosentanincreasedbyKETOCONAZOLE;plasmaconcentrationofbosentanpossiblyincreasedbylFLUCONAZOLE—avoidconcomitantuse;plasmaconcentrationofbosentanpossiblyincreasedbyITRACONAZOLElAntivirals:avoidanceofbosentanadvisedbymanufacturerofELVITEGRAVIRandTIPRANAVIR;bosentanpossiblyreducesplasmaconcentrationofINDINAVIR;plasmaconcentrationofbosentanincreasedbylLOPINAVIRandlRITONAVIR(considerreducingdoseofbosentan);bosentanpossiblyreducesplasmaconcentrationofTELAPREVIR,alsoplasmaconcentrationofbosentanpossiblyincreased TRIANGLE Avanafil:bosentanpossiblyreducesplasmaconcentrationofAVANAFIL—manufacturerofavanafiladvisesavoidconcomitantuselCiclosporin:plasmaconcentrationofbosentanincreasedbylCICLOSPORIN(alsoplasmaconcentrationofciclosporinreduced—avoidconcomitantuse) TRIANGLE Cobicistat:avoidanceofbosentanadvisedbymanufacturerofCOBICISTATlCytotoxics:bosentanpossiblyreducesplasmaconcentrationoflBOSUTINIB—manufacturerofbosutinibadvisesavoidconcomitantuse TRIANGLE Lipid-regulatingDrugs:bosentanreducesplasmaconcentrationofSIMVASTATINlOestrogens:bosentanpossiblycausescontraceptivefailureofhormonalcontraceptivescontaininglOESTROGENS(alternativecontraceptionrecommended)lProgestogens:bosentanpossiblycausescontraceptivefailureofhormonalcontraceptivescontaininglPROGESTOGENS(alternativecontraceptionrecommended) TRIANGLE Riociguat:bosentanreducesplasmaconcentrationofRIOCIGUAT TRIANGLE Sildenafil:bosentanreducesplasmaconcentrationofSILDENAFIL,alsoplasmaconcentrationofbosentanincreased TRIANGLE Tadalafil:bosentanreducesplasmaconcentrationofTADALAFILBosutiniblAnalgesics:possibleincreasedriskofventriculararrhythmiaswhenbosutinibgivenwithlMETHADONE TRIANGLE Antacids:manufacturerofbosutinibadvisesseparatingadministrationwithANTACIDSbyabout12hourslAnti-arrhythmics:possibleincreasedriskofventriculararrhythmiaswhenbosutinibgivenwithlAMIODARONEandlDISOPYRAMIDE;plasmaconcentrationofbosutinibpossiblyincreasedbylDRONEDARONE—manufacturerofbosutinibadvisesavoidorconsiderreducingdoseofbosutiniblAntibacterials:plasmaconcentrationofbosutinibpossiblyincreasedbylCIPROFLOXACIN,lCLARITHROMYCIN,lERYTHROMYCINandlTELITHROMYCIN—manufacturerofbosutinibadvisesavoidorconsiderreducingdoseofbosutinib;possibleincreasedriskofventriculararrhythmiaswhenbosutinibgivenwithlMOXIFLOXACIN;plasmaconcentrationofbosutinibpossiblyreducedbylRIFABUTIN—manufacturerofbosutinibadvisesavoidconcomitantuse;plasmaconcentrationofbosutinibreducedbylRIFAMPICIN—manufacturerofbosutinibadvisesavoidconcomitantuselAntidepressants:plasmaconcentrationofbosutinibpossiblyreducedbylSTJOHN’SWORT—manufacturerofbosutinibadvisesavoidconcomitantuselAntiepileptics:plasmaconcentrationofbosutinibpossiblyreducedbylCARBAMAZEPINE,lFOSPHENYTOIN,lPHENOBARBITAL,lPHENYTOINandlPRIMIDONE—manufacturerofbosutinibadvisesavoidconcomitantuselAntifungals:plasmaconcentrationofbosutinibincreasedbylKETOCONAZOLE—manufacturerofbosutinibadvisesavoidorconsiderreducingdoseofbosutinib;plasmaconcentrationofbosutinibpossiblyincreasedbylFLUCONAZOLE,lITRACONAZOLE,lPOSACONAZOLEandlVORICONAZOLE—manufacturerofbosutinibadvisesavoidorconsiderreducingdoseofbosutiniblAntimalarials:possibleincreasedriskofventriculararrhythmiaswhenbosutinibgivenwithlCHLOROQUINEandlHYDROXYCHLOROQUINEBosutinib(continued)lAntipsychotics:possibleincreasedriskofventriculararrhythmiaswhenbosutinibgivenwithlHALOPERIDOL;avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lAntivirals:plasmaconcentrationofbosutinibpossiblyincreasedbylATAZANAVIR,lBOCEPREVIR,lDARUNAVIR,lFOSAMPRENAVIR,lINDINAVIR,lRITONAVIR,lSAQUINAVIRandlTELAPREVIR—manufacturerofbosutinibadvisesavoidorconsiderreducingdoseofbosutinib;plasmaconcentrationofbosutinibpossiblyreducedbylEFAVIRENZandlETRAVIRINE—manufacturerofbosutinibadvisesavoidconcomitantuselAprepitant:plasmaconcentrationofbosutinibpossiblyincreasedbylAPREPITANT—manufacturerofbosutinibadvisesavoidorconsiderreducingdoseofbosutiniblBeta-blockers:possibleincreasedriskofventriculararrhythmiaswhenbosutinibgivenwithlSOTALOLlBosentan:plasmaconcentrationofbosutinibpossiblyreducedbylBOSENTAN—manufacturerofbosutinibadvisesavoidconcomitantuselCalcium-channelBlockers:plasmaconcentrationofbosutinibpossiblyincreasedbylDILTIAZEMandlVERAPAMIL—manufacturerofbosutinibadvisesavoidorconsiderreducingdoseofbosutiniblCytotoxics:plasmaconcentrationofbosutinibpossiblyincreasedbylIMATINIB—manufacturerofbosutinibadvisesavoidorconsiderreducingdoseofbosutiniblDomperidone:manufacturerofbosutinibadvisesavoidconcomitantusewithlDOMPERIDONE(riskofventriculararrhythmias)lFosaprepitant:plasmaconcentrationofbosutinibpossiblyincreasedbylFOSAPREPITANT—manufacturerofbosutinibadvisesavoidorconsiderreducingdoseofbosutiniblGrapefruitJuice:plasmaconcentrationofbosutinibpossiblyincreasedbylGRAPEFRUITJUICE—manufacturerofbosutinibadvisesavoidorconsiderreducingdoseofbosutiniblModafinil:plasmaconcentrationofbosutinibpossiblyreducedbylMODAFINIL—manufacturerofbosutinibadvisesavoidconcomitantuse TRIANGLE Ulcer-healingDrugs:plasmaconcentrationofbosutinibreducedbyLANSOPRAZOLEBrentuximabvedotin TRIANGLE Antibacterials:effectsofbrentuximabvedotinpossiblyreducedbyRIFAMPICINlAntifungals:possibleincreasedriskofneutropeniawhenbrentuximabvedotingivenwithlKETOCONAZOLElAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lCytotoxics:increasedriskofpulmonarytoxicitywhenbrentuximabvedotingivenwithlBLEOMYCIN—avoidconcomitantuselVaccines:riskofgeneralisedinfectionswhenmonoclonalantibodiesgivenwithlivelVACCINES—avoidconcomitantuseBrimonidine TRIANGLE Antidepressants:manufacturerofbrimonidineadvisesavoidconcomitantusewithMAOIS,TRICYCLIC-RELATEDANTIDEPRESSANTSandTRICYCLICSBrinzolamideseeDiureticsBromocriptine TRIANGLE Alcohol:toleranceofbromocriptinereducedbyALCOHOL TRIANGLE Antibacterials:plasmaconcentrationofbromocriptineincreasedbyERYTHROMYCIN(increasedriskoftoxicity);plasmaconcentrationofbromocriptinepossiblyincreasedbyMACROLIDES(increasedriskoftoxicity) TRIANGLE Antipsychotics:hypoprolactinaemicandantiparkinsonianeffectsofbromocriptineantagonisedbyANTIPSYCHOTICS TRIANGLE Domperidone:hypoprolactinaemiceffectofbromocriptinepossiblyantagonisedbyDOMPERIDONE TRIANGLE HormoneAntagonists:plasmaconcentrationofbromocriptineincreasedbyOCTREOTIDE TRIANGLE Memantine:effectsofdopaminergicspossiblyenhancedbyMEMANTINE TRIANGLE Methyldopa:antiparkinsonianeffectofdopaminergicsantagonisedbyMETHYLDOPA TRIANGLE Metoclopramide:hypoprolactinaemiceffectofbromocriptineantagonisedbyMETOCLOPRAMIDEBNF70Appendix1Interactions1167Interactions|Appendix1"
"Bromocriptine(continued)lSympathomimetics:riskoftoxicitywhenbromocriptinegivenwithlISOMETHEPTENEBuclizineseeAntihistaminesBudesonideseeCorticosteroidsBumetanideseeDiureticsBupivacaine TRIANGLE Anti-arrhythmics:increasedmyocardialdepressionwhenbupivacainegivenwithANTI-ARRHYTHMICSlBeta-blockers:increasedriskofbupivacainetoxicitywhengivenwithlPROPRANOLOLBuprenorphineseeOpioidAnalgesicsBupropionlAntidepressants:bupropionpossiblyincreasesplasmaconcentrationofCITALOPRAM;manufacturerofbupropionadvisesavoidfor2weeksafterstoppinglMAOIS;manufacturerofbupropionadvisesavoidconcomitantusewithlMOCLOBEMIDE;bupropionpossiblyincreasesplasmaconcentrationofTRICYCLICS(possibleincreasedriskofconvulsions) TRIANGLE Antiepileptics:plasmaconcentrationofbupropionreducedbyCARBAMAZEPINE,FOSPHENYTOINandPHENYTOIN;metabolismofbupropioninhibitedbySODIUMVALPROATEandVALPROICACID TRIANGLE Antivirals:metabolismofbupropionacceleratedbyEFAVIRENZ(reducedplasmaconcentration);plasmaconcentrationofbupropionreducedbyRITONAVIR TRIANGLE Atomoxetine:possibleincreasedriskofconvulsionswhenbupropiongivenwithATOMOXETINE TRIANGLE Dopaminergics:increasedriskofside-effectswhenbupropiongivenwithAMANTADINE,CO-BENELDOPA,CO-CARELDOPAorLEVODOPAlHormoneAntagonists:bupropionpossiblyinhibitsmetabolismoflTAMOXIFENtoactivemetabolite(avoidconcomitantuse)lMethylthioninium:possibleriskofCNStoxicitywhenbupropiongivenwithlMETHYLTHIONINIUM—avoidconcomitantuse(ifavoidancenotpossible,uselowestpossibledoseofmethylthioniniumandobservepatientforupto4hoursafteradministration)BuspironeseeAnxiolyticsandHypnoticsBusulfan TRIANGLE Analgesics:metabolismofintravenousbusulfanpossiblyinhibitedbyPARACETAMOL(manufacturerofintravenousbusulfanadvisescautionwithin72hoursofparacetamol)lAntibacterials:plasmaconcentrationofbusulfanincreasedbylMETRONIDAZOLE(increasedriskoftoxicity) TRIANGLE Antiepileptics:plasmaconcentrationofbusulfanpossiblyreducedbyFOSPHENYTOINandPHENYTOIN TRIANGLE Antifungals:metabolismofbusulfaninhibitedbyITRACONAZOLE(increasedriskoftoxicity)lAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis) TRIANGLE Cytotoxics:increasedriskofhepatotoxicitywhenbusulfangivenwithTIOGUANINEButyrophenonesseeAntipsychoticsCabazitaxellAntibacterials:plasmaconcentrationofcabazitaxelpossiblyincreasedbylCLARITHROMYCINandlTELITHROMYCIN—manufacturerofcabazitaxeladvisesavoidorconsiderreducingdoseofcabazitaxel;manufacturerofcabazitaxeladvisesavoidconcomitantusewithlRIFABUTIN;plasmaconcentrationofcabazitaxelreducedbylRIFAMPICIN—manufacturerofcabazitaxeladvisesavoidconcomitantuselAntidepressants:manufacturerofcabazitaxeladvisesavoidconcomitantusewithlSTJOHN’SWORTlAntiepileptics:manufacturerofcabazitaxeladvisesavoidconcomitantusewithlCARBAMAZEPINE,lFOSPHENYTOIN,lPHENOBARBITAL,lPHENYTOINandlPRIMIDONElAntifungals:manufacturerofcabazitaxeladvisesavoidconcomitantusewithlKETOCONAZOLE;plasmaconcentrationofcabazitaxelpossiblyincreasedbylITRACONAZOLEandlVORICONAZOLE—manufacturerofcabazitaxeladvisesavoidorconsiderreducingdoseofcabazitaxellAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)Cabazitaxel(continued)lAntivirals:manufacturerofcabazitaxeladvisesavoidconcomitantusewithlATAZANAVIR;plasmaconcentrationofcabazitaxelpossiblyincreasedbylINDINAVIR,lRITONAVIRandlSAQUINAVIR—manufacturerofcabazitaxeladvisesavoidorconsiderreducingdoseofcabazitaxelCabergoline TRIANGLE Antibacterials:plasmaconcentrationofcabergolineincreasedbyERYTHROMYCIN(increasedriskoftoxicity);plasmaconcentrationofcabergolinepossiblyincreasedbyMACROLIDES(increasedriskoftoxicity) TRIANGLE Antipsychotics:hypoprolactinaemicandantiparkinsonianeffectsofcabergolineantagonisedbyANTIPSYCHOTICS TRIANGLE Domperidone:hypoprolactinaemiceffectofcabergolinepossiblyantagonisedbyDOMPERIDONE TRIANGLE Memantine:effectsofdopaminergicspossiblyenhancedbyMEMANTINE TRIANGLE Methyldopa:antiparkinsonianeffectofdopaminergicsantagonisedbyMETHYLDOPA TRIANGLE Metoclopramide:hypoprolactinaemiceffectofcabergolineantagonisedbyMETOCLOPRAMIDECabozantiniblAntibacterials:plasmaconcentrationofcabozantinibpossiblyincreasedbyCLARITHROMYCINandERYTHROMYCIN;plasmaconcentrationofcabozantinibreducedbylRIFAMPICIN—avoidconcomitantuse TRIANGLE Antidepressants:plasmaconcentrationofcabozantinibpossiblyreducedbySTJOHN’SWORT—manufacturerofcabozantinibadvisesavoidconcomitantuselAntiepileptics:plasmaconcentrationofcabozantinibpossiblyreducedbylCARBAMAZEPINE,lFOSPHENYTOIN,lPHENOBARBITAL,lPHENYTOINandlPRIMIDONE—avoidconcomitantuse TRIANGLE Antifungals:plasmaconcentrationofcabozantinibincreasedbyKETOCONAZOLE;plasmaconcentrationofcabozantinibpossiblyincreasedbyITRACONAZOLElAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis) TRIANGLE Antivirals:plasmaconcentrationofcabozantinibpossiblyincreasedbyRITONAVIR TRIANGLE Corticosteroids:plasmaconcentrationofcabozantinibpossiblyreducedbyDEXAMETHASONE—manufacturerofcabozantinibadvisesavoidconcomitantuse TRIANGLE GrapefruitJuice:plasmaconcentrationofcabozantinibpossiblyincreasedbyGRAPEFRUITJUICECaffeinecitrate TRIANGLE Aminophylline:manufacturerofcaffeinecitrateadvisesavoidconcomitantusewithAMINOPHYLLINE TRIANGLE Anti-arrhythmics:caffeinecitrateantagonisesanti-arrhythmiceffectofADENOSINE—manufacturerofadenosineadvisesavoidcaffeinecitrateforatleast12hoursbeforeadenosine TRIANGLE Antiepileptics:plasmaconcentrationofcaffeinecitratereducedbyFOSPHENYTOINandPHENYTOIN;caffeinecitratepossiblyantagoniseseffectsofPHENOBARBITALandPRIMIDONE TRIANGLE Theophylline:manufacturerofcaffeinecitrateadvisesavoidconcomitantusewithTHEOPHYLLINE TRIANGLE Ulcer-healingDrugs:plasmaconcentrationofcaffeinecitrateincreasedbyCIMETIDINECalcitriolseeVitaminsCalciumSaltsNOTEseealsoAntacids TRIANGLE Antibacterials:calciumsaltsreduceabsorptionofCIPROFLOXACINandTETRACYCLINE TRIANGLE Antivirals:calciumsaltsreduceabsorptionofDOLUTEGRAVIR—manufacturerofdolutegraviradvisesgiveatleast2hoursbeforeor6hoursaftercalciumsalts;manufacturerofrilpivirineadvisesgivecalciumsalts2hoursbeforeor4hoursafterRILPIVIRINE TRIANGLE Bisphosphonates:calciumsaltsreduceabsorptionofBISPHOSPHONATES TRIANGLE CardiacGlycosides:largeintravenousdosesofcalciumsaltscanprecipitatearrhythmiaswhengivenwithCARDIACGLYCOSIDES TRIANGLE Corticosteroids:absorptionofcalciumsaltsreducedbyCORTICOSTEROIDS1168Appendix1InteractionsBNF70Interactions|Appendix1"
"CalciumSalts(continued) TRIANGLE Cytotoxics:calciumsaltsreduceabsorptionofESTRAMUSTINE(manufacturerofestramustineadvisesavoidconcomitantadministration) TRIANGLE Diuretics:increasedriskofhypercalcaemiawhencalciumsaltsgivenwithTHIAZIDESANDRELATEDDIURETICS TRIANGLE Eltrombopag:calciumsaltspossiblyreduceabsorptionofELTROMBOPAG(giveatleast4hoursapart) TRIANGLE Fluorides:calciumsaltsreduceabsorptionofFLUORIDES TRIANGLE IronSalts:calciumsaltsreduceabsorptionoforalIRONSALTS TRIANGLE ThyroidHormones:calciumsaltsreduceabsorptionofLEVOTHYROXINE TRIANGLE Zinc:calciumsaltsreduceabsorptionofZINCCalcium-channelBlockersNOTEDihydropyridinecalcium-channelblockersincludeamlodipine,felodipine,isradipine,lacidipine,lercanidipine,nicardipine,nifedipine,andnimodipine TRIANGLE ACEInhibitors:enhancedhypotensiveeffectwhencalcium-channelblockersgivenwithACEINHIBITORS TRIANGLE AdrenergicNeuroneBlockers:enhancedhypotensiveeffectwhencalcium-channelblockersgivenwithADRENERGICNEURONEBLOCKERS TRIANGLE Alcohol:enhancedhypotensiveeffectwhencalcium-channelblockersgivenwithALCOHOL;verapamilpossiblyincreasesplasmaconcentrationofALCOHOL TRIANGLE Aldesleukin:enhancedhypotensiveeffectwhencalcium-channelblockersgivenwithALDESLEUKIN TRIANGLE Aliskiren:verapamilincreasesplasmaconcentrationofALISKIRENlAlpha-blockers:verapamilincreasesplasmaconcentrationofTAMSULOSIN;enhancedhypotensiveeffectwhencalcium-channelblockersgivenwithlALPHA-BLOCKERS,alsoincreasedriskoffirst-dosehypotensionwithpost-synapticalpha-blockerssuchasprazosinlAminophylline:calcium-channelblockerspossiblyincreaseplasmaconcentrationoflAMINOPHYLLINE(enhancedeffect);diltiazemincreasesplasmaconcentrationofAMINOPHYLLINE;verapamilincreasesplasmaconcentrationoflAMINOPHYLLINE(enhancedeffect)lAnaesthetics,General:enhancedhypotensiveeffectwhencalcium-channelblockersgivenwithGENERALANAESTHETICSorISOFLURANE;hypotensiveeffectofverapamilenhancedbylGENERALANAESTHETICS(alsoAVdelay) TRIANGLE Analgesics:hypotensiveeffectofcalcium-channelblockersantagonisedbyNSAIDS;diltiazeminhibitsmetabolismofALFENTANIL(riskofprolongedordelayedrespiratorydepression) TRIANGLE Angiotensin-IIReceptorAntagonists:enhancedhypotensiveeffectwhencalcium-channelblockersgivenwithANGIOTENSIN-IIRECEPTORANTAGONISTSlAnti-arrhythmics:increasedriskofbradycardia,AVblockandmyocardialdepressionwhendiltiazemorverapamilgivenwithlAMIODARONE;increasedriskofmyocardialdepressionandasystolewhenverapamilgivenwithlDISOPYRAMIDEorlFLECAINIDE;increasedriskofbradycardiaandmyocardialdepressionwhendiltiazemandverapamilgivenwithlDRONEDARONE;nifedipineincreasesplasmaconcentrationoflDRONEDARONElAntibacterials:metabolismofcalcium-channelblockerspossiblyinhibitedbylCLARITHROMYCIN,lERYTHROMYCINandlTELITHROMYCIN(increasedriskofside-effects);manufactureroflercanidipineadvisesavoidconcomitantusewithERYTHROMYCIN;metabolismofdiltiazem,nifedipine,nimodipineandverapamilacceleratedbylRIFAMPICIN(plasmaconcentrationsignificantlyreduced);metabolismofisradipineandnicardipinepossiblyacceleratedbylRIFAMPICIN(possiblesignificantlyreducedplasmaconcentration);plasmaconcentrationoffelodipinepossiblyreducedbyRIFAMPICIN;avoidanceofverapamiladvisedbymanufacturerofFIDAXOMICINlAnticoagulants:verapamilpossiblyincreasesplasmaconcentrationoflDABIGATRAN(seeunderDabigatranEtexilate,p117)lAntidepressants:metabolismofnifedipinepossiblyinhibitedbyFLUOXETINE(increasedplasmaconcentration);diltiazemandverapamilincreaseplasmaconcentrationofIMIPRAMINE;Calcium-channelBlockerslAntidepressants(continued)enhancedhypotensiveeffectwhencalcium-channelblockersgivenwithMAOIS;plasmaconcentrationofnifedipinereducedbySTJOHN’SWORT;plasmaconcentrationofamlodipineandfelodipinepossiblyreducedbySTJOHN’SWORT;plasmaconcentrationofverapamilsignificantlyreducedbylSTJOHN’SWORT;diltiazemandverapamilpossiblyincreaseplasmaconcentrationofTRICYCLICS TRIANGLE Antidiabetics:glucosetoleranceoccasionallyimpairedwhennifedipinegivenwithINSULINlAntiepileptics:effectsofdihydropyridines,nicardipineandnifedipineprobablyreducedbyCARBAMAZEPINE;effectsoffelodipineandisradipinereducedbyCARBAMAZEPINE;diltiazemandverapamilenhanceeffectsoflCARBAMAZEPINE;manufacturerofnimodipineadvisesavoidconcomitantusewithCARBAMAZEPINE,FOSPHENYTOINandPHENYTOIN(plasmaconcentrationofnimodipinepossiblyreduced);effectsoffelodipineandverapamilreducedbyFOSPHENYTOIN;manufacturerofisradipineadvisesavoidconcomitantusewithFOSPHENYTOIN,PHENOBARBITAL,PHENYTOINandPRIMIDONE;diltiazemincreasesplasmaconcentrationoflFOSPHENYTOINandlPHENYTOINbutalsoeffectofdiltiazemreduced;effectsofcalcium-channelblockersprobablyreducedbylPHENOBARBITALandlPRIMIDONE;manufacturerofnimodipineadvisesavoidconcomitantusewithlPHENOBARBITALandlPRIMIDONE(plasmaconcentrationofnimodipinereduced);effectsoffelodipineandverapamilreducedbyPHENYTOINlAntifungals:metabolismofdihydropyridinespossiblyinhibitedbyITRACONAZOLEandKETOCONAZOLE(increasedplasmaconcentration);metabolismoffelodipineisinhibitedbylKETOCONAZOLE(increasedplasmaconcentration)—manufacturerofketoconazoleadvisesavoidconcomitantuse;manufactureroflercanidipineadvisesavoidconcomitantusewithITRACONAZOLEandKETOCONAZOLE;negativeinotropiceffectpossiblyincreasedwhencalcium-channelblockersgivenwithITRACONAZOLE;metabolismoffelodipineinhibitedbylITRACONAZOLE(increasedplasmaconcentration);plasmaconcentrationofnifedipineincreasedbyMICAFUNGIN TRIANGLE Antimalarials:possibleincreasedriskofbradycardiawhencalcium-channelblockersgivenwithMEFLOQUINE TRIANGLE Antimuscarinics:avoidanceofverapamiladvisedbymanufacturerofDARIFENACIN;verapamilincreasesplasmaconcentrationofSOLIFENACINlAntipsychotics:enhancedhypotensiveeffectwhencalcium-channelblockersgivenwithANTIPSYCHOTICS;diltiazemincreasestheplasmaconcentrationoflLURASIDONE(seeunderLurasidone,p315);verapamilpossiblyincreasestheplasmaconcentrationoflLURASIDONE(seeunderLurasidone,p315)lAntivirals:plasmaconcentrationofverapamilpossiblyincreasedbyATAZANAVIR;plasmaconcentrationofdiltiazemincreasedbylATAZANAVIR(reducedoseofdiltiazem);plasmaconcentrationofdiltiazemreducedbyEFAVIRENZ;manufactureroflercanidipineadvisesavoidconcomitantusewithRITONAVIR;plasmaconcentrationofcalcium-channelblockerspossiblyincreasedbylRITONAVIR;cautionwithdiltiazem,felodipine,nicardipine,nifedipineandverapamiladvisedbymanufacturerofTELAPREVIR;plasmaconcentrationofamlodipineincreasedbyTELAPREVIR(considerreducingdoseofamlodipine) TRIANGLE AnxiolyticsandHypnotics:enhancedhypotensiveeffectwhencalcium-channelblockersgivenwithANXIOLYTICSANDHYPNOTICS;diltiazemandverapamilinhibitmetabolismofMIDAZOLAM(increasedplasmaconcentrationwithincreasedsedation);absorptionoflercanidipineincreasedbyMIDAZOLAM;diltiazemandverapamilincreaseplasmaconcentrationofBUSPIRONE(reducedoseofbuspirone) TRIANGLE Aprepitant:plasmaconcentrationofbothdrugsmayincreasewhendiltiazemgivenwithAPREPITANTlAvanafil:diltiazemandverapamilpossiblyincreaseplasmaconcentrationoflAVANAFIL—seeunderAvanafil,p698lBeta-blockers:enhancedhypotensiveeffectwhencalcium-channelblockersgivenwithBETA-BLOCKERS;increasedriskofBNF70Appendix1Interactions1169Interactions|Appendix1"
"Calcium-channelBlockerslBeta-blockers(continued)AVblockandbradycardiawhendiltiazemgivenwithlBETA-BLOCKERS;asystole,severehypotensionandheartfailurewhenverapamilgivenwithlBETA-BLOCKERS(seeunderVerapamil,p156);possibleseverehypotensionandheartfailurewhennifedipinegivenwithlBETA-BLOCKERS TRIANGLE Calcium-channelBlockers:plasmaconcentrationofbothdrugsmayincreasewhendiltiazemgivenwithNIFEDIPINElCardiacGlycosides:diltiazem,lercanidipineandnicardipineincreaseplasmaconcentrationoflDIGOXIN;verapamilincreasesplasmaconcentrationoflDIGOXIN,alsoincreasedriskofAVblockandbradycardia;nifedipinepossiblyincreasesplasmaconcentrationoflDIGOXINlCiclosporin:diltiazem,nicardipineandverapamilincreaseplasmaconcentrationoflCICLOSPORIN;combinationoflercanidipinewithlCICLOSPORINmayincreaseplasmaconcentrationofeitherdrug(orboth)—avoidconcomitantuse;plasmaconcentrationofnifedipinepossiblyincreasedbyCICLOSPORIN(increasedriskoftoxicityincludinggingivalhyperplasia) TRIANGLE Cilostazol:diltiazemincreasesplasmaconcentrationofCILOSTAZOL(considerreducingdoseofcilostazol) TRIANGLE Clonidine:enhancedhypotensiveeffectwhencalcium-channelblockersgivenwithCLONIDINElColchicine:diltiazemandverapamilpossiblyincreaseriskoflCOLCHICINEtoxicity—suspendorreducedoseofcolchicine(avoidconcomitantuseinhepaticorrenalimpairment) TRIANGLE Corticosteroids:hypotensiveeffectofcalcium-channelblockersantagonisedbyCORTICOSTEROIDS;diltiazemincreasesplasmaconcentrationofMETHYLPREDNISOLONElCytotoxics:verapamilpossiblyincreasesplasmaconcentrationofDOXORUBICIN;verapamilpossiblyincreasestheplasmaconcentrationofAFATINIB—manufacturerofafatinibadvisesseparatingadministrationofverapamilby6to12hours;diltiazemandverapamilpossiblyincreasetheplasmaconcentrationoflBOSUTINIB—manufacturerofbosutinibadvisesavoidorconsiderreducingdoseofbosutinib;possibleincreasedriskofbradycardiawhendiltiazemorverapamilgivenwithCRIZOTINIB;plasmaconcentrationofbothdrugsmayincreasewhenverapamilgivenwithlEVEROLIMUS(considerreducingthedoseofeverolimus—consulteverolimusproductliterature);diltiazemandverapamilpossiblyincreasetheplasmaconcentrationoflIBRUTINIB—reducedoseofibrutinib(seeunderIbrutinib,p809);nifedipinepossiblyinhibitsmetabolismofVINCRISTINE TRIANGLE Dapoxetine:manufacturerofdapoxetineadvisesdosereductionwhendiltiazemandverapamilgivenwithDAPOXETINE(seeunderDapoxetine,p703) TRIANGLE Diazoxide:enhancedhypotensiveeffectwhencalcium-channelblockersgivenwithDIAZOXIDE TRIANGLE Diuretics:enhancedhypotensiveeffectwhencalcium-channelblockersgivenwithDIURETICS;diltiazemandverapamilincreaseplasmaconcentrationofEPLERENONE(reducedoseofeplerenone) TRIANGLE Dopaminergics:enhancedhypotensiveeffectwhencalcium-channelblockersgivenwithCO-BENELDOPA,CO-CARELDOPAorLEVODOPAlFingolimod:possibleincreasedriskofbradycardiawhendiltiazemorverapamilgivenwithlFINGOLIMOD TRIANGLE Fosaprepitant:plasmaconcentrationofbothdrugsmayincreasewhendiltiazemgivenwithFOSAPREPITANT TRIANGLE GrapefruitJuice:plasmaconcentrationoffelodipine,isradipine,lacidipine,lercanidipine,nicardipine,nifedipine,nimodipineandverapamilincreasedbyGRAPEFRUITJUICE;plasmaconcentrationofamlodipinepossiblyincreasedbyGRAPEFRUITJUICE TRIANGLE HormoneAntagonists:diltiazemandverapamilincreaseplasmaconcentrationofDUTASTERIDE;possibleincreasedriskofbradycardiawhendiltiazemorverapamilgivenwithPASIREOTIDElIvabradine:diltiazemandverapamilincreaseplasmaconcentrationoflIVABRADINE—avoidconcomitantuselLenalidomide:verapamilpossiblyincreasesplasmaconcentrationoflLENALIDOMIDE(increasedriskoftoxicity)Calcium-channelBlockers(continued)lLipid-regulatingDrugs:diltiazemincreasesplasmaconcentrationofATORVASTATIN—possibleincreasedriskofmyopathy;plasmaconcentrationofverapamilincreasedbylATORVASTATIN,alsopossibleincreasedriskofmyopathy(considerreducingdoseofatorvastatin);possibleincreasedriskofmyopathywhenamlodipineanddiltiazemgivenwithlSIMVASTATIN(seeunderSimvastatin,p181);increasedriskofmyopathywhenverapamilgivenwithlSIMVASTATIN(seeunderSimvastatin,p181);separatingadministrationfromamlodipineandlacidipineby12hoursadvisedbymanufacturerofLOMITAPIDE;avoidanceofdiltiazemandverapamiladvisedbymanufactureroflLOMITAPIDE(plasmaconcentrationoflomitapidepossiblyincreased) TRIANGLE Lithium:neurotoxicitymayoccurwhendiltiazemorverapamilgivenwithLITHIUMwithoutincreasedplasmaconcentrationoflithiumlMagnesium(parenteral):profoundhypotensionreportedwithconcomitantuseofnifedipineandlPARENTERALMAGNESIUMinpre-eclampsia TRIANGLE Methyldopa:enhancedhypotensiveeffectwhencalcium-channelblockersgivenwithMETHYLDOPA TRIANGLE Moxisylyte:enhancedhypotensiveeffectwhencalcium-channelblockersgivenwithMOXISYLYTE TRIANGLE Moxonidine:enhancedhypotensiveeffectwhencalcium-channelblockersgivenwithMOXONIDINE TRIANGLE MuscleRelaxants:verapamilenhanceseffectsofNON-DEPOLARISINGMUSCLERELAXANTSandSUXAMETHONIUM;enhancedhypotensiveeffectwhencalcium-channelblockersgivenwithBACLOFENorTIZANIDINE;manufacturerofverapamiladvisesavoidconcomitantuseofintravenousDANTROLENE;possibleincreasedriskofventriculararrhythmiaswhendiltiazemgivenwithintravenousDANTROLENE—manufacturerofdiltiazemadvisesavoidconcomitantuse;calcium-channelblockerspossiblyenhanceeffectsofNON-DEPOLARISINGMUSCLERELAXANTS TRIANGLE Nitrates:enhancedhypotensiveeffectwhencalcium-channelblockersgivenwithNITRATES TRIANGLE Oestrogens:hypotensiveeffectofcalcium-channelblockersantagonisedbyOESTROGENS TRIANGLE Prostaglandins:enhancedhypotensiveeffectwhencalcium-channelblockersgivenwithALPROSTADIL TRIANGLE Ranolazine:diltiazemandverapamilincreaseplasmaconcentrationofRANOLAZINE(considerreducingdoseofranolazine) TRIANGLE Sildenafil:enhancedhypotensiveeffectwhenamlodipinegivenwithSILDENAFILlSirolimus:diltiazemincreasesplasmaconcentrationoflSIROLIMUS;plasmaconcentrationofbothdrugsincreasedwhenverapamilgivenwithlSIROLIMUS;nicardipinepossiblyincreasesplasmaconcentrationofSIROLIMUS TRIANGLE Sulfinpyrazone:plasmaconcentrationofverapamilreducedbySULFINPYRAZONElTacrolimus:diltiazem,nicardipineandnifedipineincreaseplasmaconcentrationoflTACROLIMUS;felodipineandverapamilpossiblyincreaseplasmaconcentrationofTACROLIMUSlTheophylline:calcium-channelblockerspossiblyincreaseplasmaconcentrationoflTHEOPHYLLINE(enhancedeffect);diltiazemincreasesplasmaconcentrationofTHEOPHYLLINE;verapamilincreasesplasmaconcentrationoflTHEOPHYLLINE(enhancedeffect) TRIANGLE Ticagrelor:diltiazemincreasesplasmaconcentrationofTICAGRELOR TRIANGLE Ulcer-healingDrugs:metabolismofcalcium-channelblockerspossiblyinhibitedbyCIMETIDINE(increasedplasmaconcentration);plasmaconcentrationofisradipineincreasedbyCIMETIDINE(halvedoseofisradipine) TRIANGLE Ulipristal:avoidanceofverapamiladvisedbymanufactureroflow-doseULIPRISTAL TRIANGLE Vardenafil:enhancedhypotensiveeffectwhennifedipinegivenwithVARDENAFIL TRIANGLE VasodilatorAntihypertensives:enhancedhypotensiveeffectwhencalcium-channelblockersgivenwithHYDRALAZINE,MINOXIDILorSODIUMNITROPRUSSIDE1170Appendix1InteractionsBNF70Interactions|Appendix1"
"Calcium-channelBlockers(dihydropyridines)seeCalcium-channelBlockersCanagliflozinseeAntidiabeticsCanakinumablAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lVaccines:riskofgeneralisedinfectionswhenmonoclonalantibodiesgivenwithlivelVACCINES—avoidconcomitantuseCandesartanseeAngiotensin-IIReceptorAntagonistsCannabisExtractlAntibacterials:plasmaconcentrationofcannabisextractreducedbylRIFAMPICIN—manufacturerofcannabisextractadvisesavoidconcomitantuselAntidepressants:plasmaconcentrationofcannabisextractpossiblyreducedbylSTJOHN’SWORT—manufacturerofcannabisextractadvisesavoidconcomitantuse;possibleincreasedriskofhypertensionandtachycardiawhencannabisextractgivenwithTRICYCLICSlAntiepileptics:plasmaconcentrationofcannabisextractpossiblyreducedbylCARBAMAZEPINE,lFOSPHENYTOIN,lPHENOBARBITAL,lPHENYTOINandlPRIMIDONE—manufacturerofcannabisextractadvisesavoidconcomitantuse TRIANGLE Antifungals:plasmaconcentrationofcannabisextractincreasedbyKETOCONAZOLECapecitabinelAllopurinol:manufacturerofcapecitabineadvisesavoidconcomitantusewithlALLOPURINOL TRIANGLE Antibacterials:metabolismofcapecitabineinhibitedbyMETRONIDAZOLE(increasedtoxicity)lAnticoagulants:capecitabineenhancesanticoagulanteffectoflCOUMARINS TRIANGLE Antiepileptics:capecitabinepossiblyinhibitsmetabolismofFOSPHENYTOINandPHENYTOIN(increasedriskoftoxicity)lAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis) TRIANGLE Cytotoxics:capecitabinepossiblyincreasesplasmaconcentrationofERLOTINIB TRIANGLE Filgrastim:neutropeniapossiblyexacerbatedwhencapecitabinegivenwithFILGRASTIMlFolates:toxicityofcapecitabineincreasedbylFOLICACID—avoidconcomitantuse TRIANGLE Lipegfilgrastim:neutropeniapossiblyexacerbatedwhencapecitabinegivenwithLIPEGFILGRASTIM TRIANGLE Pegfilgrastim:neutropeniapossiblyexacerbatedwhencapecitabinegivenwithPEGFILGRASTIM TRIANGLE Ulcer-healingDrugs:metabolismofcapecitabineinhibitedbyCIMETIDINE(increasedplasmaconcentration)Capreomycin TRIANGLE Antibacterials:increasedriskofnephrotoxicitywhencapreomycingivenwithCOLISTIMETHATESODIUMorPOLYMYXINS;increasedriskofnephrotoxicityandototoxicitywhencapreomycingivenwithAMINOGLYCOSIDESorVANCOMYCIN TRIANGLE Cytotoxics:increasedriskofnephrotoxicityandototoxicitywhencapreomycingivenwithPLATINUMCOMPOUNDS TRIANGLE Vaccines:antibacterialsinactivateORALTYPHOIDVACCINE—seeunderTyphoidVaccineinBNFCaptoprilseeACEInhibitorsCarbamazepine TRIANGLE Alcohol:CNSside-effectsofcarbamazepinepossiblyincreasedbyALCOHOL TRIANGLE Aminophylline:carbamazepineacceleratesmetabolismofAMINOPHYLLINE(reducedeffect)lAnalgesics:effectsofcarbamazepineenhancedbylDEXTROPROPOXYPHENE;carbamazepinepossiblyacceleratesmetabolismofFENTANYL(reducedeffect);carbamazepinereducesplasmaconcentrationofMETHADONE;carbamazepinereduceseffectsofTRAMADOL;carbamazepinepossiblyacceleratesmetabolismofPARACETAMOL(alsoisolatedreportsofhepatotoxicity)lAnthelmintics:carbamazepinereducesplasmaconcentrationoflALBENDAZOLEandlPRAZIQUANTEL—considerincreasingalbendazoleandpraziquanteldosewhengivenforsystemicinfectionsCarbamazepine(continued)lAnti-arrhythmics:carbamazepinepossiblyreducesplasmaconcentrationoflDRONEDARONE—avoidconcomitantuselAntibacterials:plasmaconcentrationofcarbamazepineincreasedbylCLARITHROMYCIN(considerreducingdoseofcarbamazepine);plasmaconcentrationofcarbamazepineincreasedbylERYTHROMYCIN;plasmaconcentrationofcarbamazepinereducedbylRIFABUTIN;carbamazepineacceleratesmetabolismofDOXYCYCLINE(reducedeffect);carbamazepinepossiblyreducesplasmaconcentrationoflBEDAQUILINE—manufacturerofbedaquilineadvisesavoidconcomitantuse;avoidanceofcarbamazepineadvisedbymanufacturerofDELAMANID;plasmaconcentrationofcarbamazepineincreasedbylISONIAZID(alsopossiblyincreasedisoniazidhepatotoxicity);carbamazepinereducesplasmaconcentrationoflTELITHROMYCIN(avoidduringandfor2weeksaftercarbamazepine)lAnticoagulants:carbamazepinepossiblyreducesplasmaconcentrationoflAPIXABAN—manufacturerofapixabanadvisesavoidconcomitantusewhengivenfortreatmentofdeep-veinthrombosisorpulmonaryembolism;carbamazepineacceleratesmetabolismoflCOUMARINS(reducedanticoagulanteffect);carbamazepinepossiblyreducesplasmaconcentrationofDABIGATRAN—manufacturerofdabigatranadvisesavoidconcomitantuse;carbamazepinepossiblyreducesplasmaconcentrationoflRIVAROXABAN—manufacturerofrivaroxabanadvisesmonitorforsignsofthrombosislAntidepressants:carbamazepinepossiblyreducesplasmaconcentrationofREBOXETINE;plasmaconcentrationofcarbamazepineincreasedbylFLUOXETINEandlFLUVOXAMINE;carbamazepinereducesplasmaconcentrationoflMIANSERIN,MIRTAZAPINEandTRAZODONE;anticonvulsanteffectofantiepilepticspossiblyantagonisedbyMAOISandlTRICYCLIC-RELATEDANTIDEPRESSANTS(convulsivethresholdlowered);manufacturerofcarbamazepineadvisesavoidfor2weeksafterstoppinglMAOIS,alsoantagonismofanticonvulsanteffect;anticonvulsanteffectofantiepilepticsantagonisedbylSSRISandlTRICYCLICS(convulsivethresholdlowered);plasmaconcentrationofcarbamazepinepossiblyreducedbySTJOHN’SWORT;carbamazepineacceleratesmetabolismoflTRICYCLICS(reducedplasmaconcentrationandreducedeffect)lAntiepileptics:carbamazepinepossiblyreducesplasmaconcentrationofESLICARBAZEPINEbutriskofside-effectsincreased;carbamazepinepossiblyreducesplasmaconcentrationofETHOSUXIMIDEandRETIGABINE;plasmaconcentrationofbothdrugsoftenreducedwhencarbamazepinegivenwithFOSPHENYTOINorPHENYTOIN,alsoplasmaconcentrationoffosphenytoinorphenytoinmaybeincreased;carbamazepineoftenreducesplasmaconcentrationofLAMOTRIGINE,alsoplasmaconcentrationofanactivemetaboliteofcarbamazepinesometimesraised(butevidenceisconflicting);possibleincreasedriskofcarbamazepinetoxicitywhengivenwithLEVETIRACETAM;plasmaconcentrationofcarbamazepinesometimesreducedbyOXCARBAZEPINE(butconcentrationofanactivemetaboliteofcarbamazepinemaybeincreased),alsoplasmaconcentrationofanactivemetaboliteofoxcarbazepineoftenreduced;carbamazepinereducesplasmaconcentrationoflPERAMPANEL(seeunderPerampanel,p398);carbamazepinepossiblyincreasesplasmaconcentrationofPHENOBARBITALandPRIMIDONE;plasmaconcentrationofbothdrugspossiblyreducedwhencarbamazepinegivenwithRUFINAMIDE;carbamazepinereducesplasmaconcentrationofSODIUMVALPROATEandVALPROICACID,alsoplasmaconcentrationofactivemetaboliteofcarbamazepineincreased;plasmaconcentrationofcarbamazepineincreasedbylSTIRIPENTOL;carbamazepinereducesplasmaconcentrationofTIAGABINEandZONISAMIDE;carbamazepineoftenreducesplasmaconcentrationofTOPIRAMATElAntifungals:plasmaconcentrationofcarbamazepinepossiblyincreasedbyKETOCONAZOLE,alsoplasmaconcentrationofketoconazolepossiblyreduced;plasmaconcentrationofcarbamazepinepossiblyincreasedbyFLUCONAZOLEandBNF70Appendix1Interactions1171Interactions|Appendix1"
"CarbamazepinelAntifungals(continued)MICONAZOLE;carbamazepinepossiblyreducesplasmaconcentrationofITRACONAZOLEandlPOSACONAZOLE;carbamazepinepossiblyreducesplasmaconcentrationoflVORICONAZOLE—avoidconcomitantuse;carbamazepinepossiblyreducesplasmaconcentrationofCASPOFUNGIN—considerincreasingdoseofcaspofunginlAntimalarials:avoidanceofcarbamazepineadvisedbymanufacturerofARTENIMOLWITHPIPERAQUINE;anticonvulsanteffectofantiepilepticsantagonisedbylMEFLOQUINElAntipsychotics:anticonvulsanteffectofantiepilepticsantagonisedbylANTIPSYCHOTICS(convulsivethresholdlowered);carbamazepineacceleratesmetabolismofHALOPERIDOL,OLANZAPINE,QUETIAPINEandRISPERIDONE(reducedplasmaconcentration);carbamazepinereducesplasmaconcentrationoflARIPIPRAZOLE(avoidconcomitantuseorconsiderincreasingthedoseofaripiprazole—consultaripiprazoleproductliterature);carbamazepineacceleratesmetabolismoflCLOZAPINE(reducedplasmaconcentration),alsoavoidconcomitantuseofdrugswithsubstantialpotentialforcausingagranulocytosis;carbamazepinepossiblyreducesplasmaconcentrationoflLURASIDONE—avoidconcomitantuse;carbamazepinereducesplasmaconcentrationofPALIPERIDONElAntivirals:avoidanceofcarbamazepineadvisedbymanufactureroflBOCEPREVIRandlRILPIVIRINE(plasmaconcentrationofboceprevirandrilpivirinepossiblyreduced);carbamazepinepossiblyreducesplasmaconcentrationoflDACLATASVIRandlSIMEPREVIR—manufacturerofdaclatasvirandsimepreviradvisesavoidconcomitantuse;carbamazepinepossiblyreducesplasmaconcentrationofDARUNAVIR,FOSAMPRENAVIR,LOPINAVIR,SAQUINAVIRandTIPRANAVIR;avoidanceofcarbamazepineadvisedbymanufacturerofDOLUTEGRAVIR,lELVITEGRAVIR,ETRAVIRINE,SOFOSBUVIRandlTELAPREVIR;plasmaconcentrationofbothdrugsreducedwhencarbamazepinegivenwithEFAVIRENZ;carbamazepinepossiblyreducesplasmaconcentrationoflINDINAVIR,alsoplasmaconcentrationofcarbamazepinepossiblyincreased;carbamazepinereducesplasmaconcentrationofNEVIRAPINE;plasmaconcentrationofcarbamazepinepossiblyincreasedbylRITONAVIR TRIANGLE AnxiolyticsandHypnotics:carbamazepineoftenreducesplasmaconcentrationofCLONAZEPAM;carbamazepinereducesplasmaconcentrationofMIDAZOLAM TRIANGLE Aprepitant:carbamazepinepossiblyreducesplasmaconcentrationofAPREPITANT TRIANGLE Avanafil:carbamazepinepossiblyreducesplasmaconcentrationofAVANAFIL—manufacturerofavanafiladvisesavoidconcomitantuse TRIANGLE Bupropion:carbamazepinereducesplasmaconcentrationofBUPROPIONlCalcium-channelBlockers:carbamazepinereduceseffectsofFELODIPINEandISRADIPINE;carbamazepineprobablyreduceseffectsofDIHYDROPYRIDINES,NICARDIPINEandNIFEDIPINE;avoidanceofcarbamazepineadvisedbymanufacturerofNIMODIPINE(plasmaconcentrationofnimodipinepossiblyreduced);effectsofcarbamazepineenhancedbylDILTIAZEMandlVERAPAMILlCannabisExtract:carbamazepinepossiblyreducesplasmaconcentrationoflCANNABISEXTRACT—manufacturerofcannabisextractadvisesavoidconcomitantuselCiclosporin:carbamazepineacceleratesmetabolismoflCICLOSPORIN(reducedplasmaconcentration)lClopidogrel:carbamazepinepossiblyreducesantiplateleteffectoflCLOPIDOGRELlCobicistat:carbamazepinepossiblyreducesplasmaconcentrationoflCOBICISTAT—manufacturerofcobicistatadvisesavoidconcomitantuselCorticosteroids:carbamazepineacceleratesmetabolismoflCORTICOSTEROIDS(reducedeffect)lCytotoxics:carbamazepinepossiblydecreasesplasmaconcentrationofAXITINIB(increasedoseofaxitinib—consultaxitinibproductliterature);carbamazepinepossiblyreducesplasmaconcentrationofBORTEZOMIB,lBOSUTINIB,CRIZOTINIB,lIBRUTINIB,lIDELALISIBandPONATINIB—manufacturerofCarbamazepinelCytotoxics(continued)bortezomib,bosutinib,crizotinib,ibrutinib,idelalisibandponatinibadvisesavoidconcomitantuse;carbamazepinepossiblyreducesplasmaconcentrationoflCABOZANTINIB—avoidconcomitantuse;avoidanceofcarbamazepineadvisedbymanufactureroflCABAZITAXEL,DABRAFENIB,GEFITINIBandVEMURAFENIB;avoidanceofcarbamazepineadvisedbymanufacturerofDASATINIB,VANDETANIBandlVISMODEGIB(plasmaconcentrationofdasatinib,vandetanibandvismodegibpossiblyreduced);carbamazepinereducesplasmaconcentrationoflIMATINIBandlLAPATINIB—avoidconcomitantuse;carbamazepinepossiblyreducesplasmaconcentrationofERIBULIN;carbamazepinereducesplasmaconcentrationofIRINOTECANanditsactivemetabolite;manufacturerofprocarbazineadvisespossibleincreasedriskofhypersensitivityreactionswhencarbamazepinegivenwithPROCARBAZINElDiuretics:increasedriskofhyponatraemiawhencarbamazepinegivenwithDIURETICS;plasmaconcentrationofcarbamazepineincreasedbylACETAZOLAMIDE;carbamazepinereducesplasmaconcentrationoflEPLERENONE—avoidconcomitantuse TRIANGLE Fingolimod:carbamazepinereducesplasmaconcentrationofFINGOLIMOD TRIANGLE Fosaprepitant:carbamazepinepossiblyreducesplasmaconcentrationofFOSAPREPITANTlHormoneAntagonists:carbamazepinepossiblyreducesplasmaconcentrationoflABIRATERONE—manufacturerofabirateroneadvisesavoidconcomitantuse;metabolismofcarbamazepineinhibitedbylDANAZOL(increasedriskoftoxicity);carbamazepinepossiblyacceleratesmetabolismofTOREMIFENE(reducedplasmaconcentration) TRIANGLE 5HT3-receptorAntagonists:carbamazepineacceleratesmetabolismofONDANSETRON(reducedeffect)lIvacaftor:carbamazepinepossiblyreducesplasmaconcentrationoflIVACAFTOR—manufacturerofivacaftoradvisesavoidconcomitantuselLipid-regulatingDrugs:carbamazepinereducesplasmaconcentrationoflSIMVASTATIN—considerincreasingdoseofsimvastatin TRIANGLE Lithium:neurotoxicitymayoccurwhencarbamazepinegivenwithLITHIUMwithoutincreasedplasmaconcentrationoflithium TRIANGLE Macitentan:avoidanceofcarbamazepineadvisedbymanufacturerofMACITENTAN TRIANGLE MuscleRelaxants:carbamazepineantagonisesmusclerelaxanteffectofNON-DEPOLARISINGMUSCLERELAXANTS(acceleratedrecoveryfromneuromuscularblockade)lOestrogens:carbamazepineacceleratesmetabolismoflOESTROGENS(reducedcontraceptiveeffectwithcombinedoralcontraceptives,contraceptivepatches,andvaginalrings—seeContraceptiveInteractionsinBNF)lOrlistat:possibleincreasedriskofconvulsionswhenantiepilepticsgivenwithlORLISTATlProgestogens:carbamazepineacceleratesmetabolismoflPROGESTOGENS(reducedcontraceptiveeffectwithcombinedoralcontraceptives,progestogen-onlyoralcontraceptives,contraceptivepatches,vaginalrings,etonogestrel-releasingimplant,andemergencyhormonalcontraception—seeContraceptiveInteractionsinBNF) TRIANGLE Retinoids:plasmaconcentrationofcarbamazepinepossiblyreducedbyISOTRETINOIN TRIANGLE Roflumilast:carbamazepinepossiblyinhibitseffectsofROFLUMILAST(manufacturerofroflumilastadvisesavoidconcomitantuse) TRIANGLE Theophylline:carbamazepineacceleratesmetabolismofTHEOPHYLLINE(reducedeffect) TRIANGLE ThyroidHormones:carbamazepineacceleratesmetabolismofTHYROIDHORMONES(mayincreaserequirementsforthyroidhormonesinhypothyroidism) TRIANGLE Tibolone:carbamazepineacceleratesmetabolismofTIBOLONE(reducedplasmaconcentration) TRIANGLE Ticagrelor:carbamazepinepossiblyreducesplasmaconcentrationofTICAGRELOR1172Appendix1InteractionsBNF70Interactions|Appendix1"
"Carbamazepine(continued)lUlcer-healingDrugs:metabolismofcarbamazepineinhibitedbylCIMETIDINE(increasedplasmaconcentration)lUlipristal:avoidanceofcarbamazepineadvisedbymanufactureroflULIPRISTAL(contraceptiveeffectofulipristalpossiblyreduced) TRIANGLE Vitamins:carbamazepinepossiblyincreasesrequirementsforALFACALCIDOL,CALCITRIOL,COLECALCIFEROL,DIHYDROTACHYSTEROL,ERGOCALCIFEROL,PARICALCITOLorVITAMINDCarbapenemsseeErtapenem,ImipenemwithCilastatin,andMeropenemCarbonicAnhydraseInhibitorsseeDiureticsCarboplatinseePlatinumCompoundsCarboprostseeProstaglandinsCardiacGlycosides TRIANGLE ACEInhibitors:plasmaconcentrationofdigoxinpossiblyincreasedbyCAPTOPRIL TRIANGLE Alpha-blockers:plasmaconcentrationofdigoxinincreasedbyPRAZOSIN TRIANGLE Aminosalicylates:absorptionofdigoxinpossiblyreducedbySULFASALAZINE TRIANGLE Analgesics:plasmaconcentrationofcardiacglycosidespossiblyincreasedbyNSAIDS,alsopossibleexacerbationofheartfailureandreductionofrenalfunction TRIANGLE Antacids:absorptionofdigoxinpossiblyreducedbyANTACIDSlAnti-arrhythmics:plasmaconcentrationofdigoxinincreasedbylAMIODARONE,lDRONEDARONEandlPROPAFENONE(halvedoseofdigoxin) TRIANGLE Antibacterials:plasmaconcentrationofdigoxinpossiblyincreasedbyGENTAMICIN,TELITHROMYCINandTRIMETHOPRIM;absorptionofdigoxinreducedbyNEOMYCIN;plasmaconcentrationofdigoxinpossiblyreducedbyRIFAMPICIN;plasmaconcentrationofdigoxinincreasedbyMACROLIDES(increasedriskoftoxicity)lAntidepressants:plasmaconcentrationofdigoxinreducedbylSTJOHN’SWORT—avoidconcomitantuse TRIANGLE Antidiabetics:plasmaconcentrationofdigoxinpossiblyreducedbyACARBOSE;plasmaconcentrationofdigoxinincreasedbyCANAGLIFLOZINandSITAGLIPTIN TRIANGLE Antiepileptics:plasmaconcentrationofdigoxinpossiblyreducedbyFOSPHENYTOINandPHENYTOINlAntifungals:increasedcardiactoxicitywithcardiacglycosidesifhypokalaemiaoccurswithlAMPHOTERICIN;plasmaconcentrationofdigoxinincreasedbylITRACONAZOLElAntimalarials:plasmaconcentrationofdigoxinpossiblyincreasedbylCHLOROQUINEandlHYDROXYCHLOROQUINE;possibleincreasedriskofbradycardiawhendigoxingivenwithMEFLOQUINE;plasmaconcentrationofdigoxinincreasedbylQUININE TRIANGLE Antimuscarinics:plasmaconcentrationofdigoxinpossiblyincreasedbyDARIFENACINlAntivirals:side-effectsofdigoxinpossiblyincreasedbyBOCEPREVIR;plasmaconcentrationofdigoxinincreasedbylDACLATASVIR,ETRAVIRINE,SIMEPREVIRandTELAPREVIR;plasmaconcentrationofdigoxinpossiblyincreasedbyRITONAVIR TRIANGLE AnxiolyticsandHypnotics:plasmaconcentrationofdigoxinincreasedbyALPRAZOLAM(increasedriskoftoxicity) TRIANGLE Beta-blockers:increasedriskofAVblockandbradycardiawhencardiacglycosidesgivenwithBETA-BLOCKERS TRIANGLE CalciumSalts:arrhythmiascanbeprecipitatedwhencardiacglycosidesgivenwithlargeintravenousdosesofCALCIUMSALTSlCalcium-channelBlockers:plasmaconcentrationofdigoxinincreasedbylDILTIAZEM,lLERCANIDIPINEandlNICARDIPINE;plasmaconcentrationofdigoxinpossiblyincreasedbylNIFEDIPINE;plasmaconcentrationofdigoxinincreasedbylVERAPAMIL,alsoincreasedriskofAVblockandbradycardialCiclosporin:plasmaconcentrationofdigoxinincreasedbylCICLOSPORIN(increasedriskoftoxicity) TRIANGLE Cobicistat:plasmaconcentrationofdigoxinpossiblyincreasedbyCOBICISTAT—reduceinitialdoseofdigoxinlColchicine:possibleincreasedriskofmyopathywhendigoxingivenwithlCOLCHICINECardiacGlycosides(continued) TRIANGLE Corticosteroids:increasedriskofhypokalaemiawhencardiacglycosidesgivenwithCORTICOSTEROIDS TRIANGLE Cytotoxics:absorptionofdigoxintabletspossiblyreducedbyBLEOMYCIN,CARMUSTINE,CYCLOPHOSPHAMIDE,CYTARABINE,DOXORUBICIN,MELPHALAN,METHOTREXATE,PROCARBAZINEandVINCRISTINE;possibleincreasedriskofbradycardiawhendigoxingivenwithCRIZOTINIB;manufacturerofdigoxinadvisesgiveIBRUTINIBatleast6hoursbeforeorafteribrutinib;plasmaconcentrationofdigoxinincreasedbyVANDETANIB—possibleincreasedriskofbradycardialDiuretics:increasedcardiactoxicitywithcardiacglycosidesifhypokalaemiaoccurswithlACETAZOLAMIDE,lLOOPDIURETICSorlTHIAZIDESANDRELATEDDIURETICS;plasmaconcentrationofdigoxinpossiblyincreasedbyPOTASSIUMCANRENOATE;plasmaconcentrationofdigoxinincreasedbylSPIRONOLACTONE TRIANGLE Ivacaftor:plasmaconcentrationofdigoxinincreasedbyIVACAFTOR TRIANGLE Lenalidomide:plasmaconcentrationofdigoxinpossiblyincreasedbyLENALIDOMIDE TRIANGLE Lipid-regulatingDrugs:absorptionofcardiacglycosidespossiblyreducedbyCOLESTIPOLandCOLESTYRAMINE;plasmaconcentrationofdigoxinpossiblyincreasedbyATORVASTATIN TRIANGLE Mirabegron:plasmaconcentrationofdigoxinincreasedbyMIRABEGRON—reduceinitialdoseofdigoxin TRIANGLE MuscleRelaxants:riskofventriculararrhythmiaswhencardiacglycosidesgivenwithSUXAMETHONIUM;possibleincreasedriskofbradycardiawhencardiacglycosidesgivenwithTIZANIDINE TRIANGLE Penicillamine:plasmaconcentrationofdigoxinpossiblyreducedbyPENICILLAMINE TRIANGLE Ranolazine:plasmaconcentrationofdigoxinincreasedbyRANOLAZINE TRIANGLE Sympathomimetics,Beta2:plasmaconcentrationofdigoxinpossiblyreducedbySALBUTAMOLlTicagrelor:plasmaconcentrationofdigoxinincreasedbylTICAGRELOR TRIANGLE Tolvaptan:plasmaconcentrationofdigoxinincreasedbyTOLVAPTAN(increasedriskoftoxicity) TRIANGLE Ulcer-healingDrugs:plasmaconcentrationofdigoxinpossiblyslightlyincreasedbyPROTONPUMPINHIBITORS;absorptionofcardiacglycosidespossiblyreducedbySUCRALFATE TRIANGLE Ulipristal:manufacturerofulipristaladvisesgivedigoxinatleast15hoursbeforeorafterULIPRISTALCarmustinelAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis) TRIANGLE CardiacGlycosides:carmustinepossiblyreducesabsorptionofDIGOXINtablets TRIANGLE Ulcer-healingDrugs:myelosuppressiveeffectsofcarmustinepossiblyenhancedbyCIMETIDINECarteololseeBeta-blockersCarvedilolseeBeta-blockersCaspofungin TRIANGLE Antibacterials:plasmaconcentrationofcaspofungininitiallyincreasedandthenreducedbyRIFAMPICIN(considerincreasingdoseofcaspofungin) TRIANGLE Antiepileptics:plasmaconcentrationofcaspofunginpossiblyreducedbyCARBAMAZEPINE,FOSPHENYTOINandPHENYTOIN—considerincreasingdoseofcaspofungin TRIANGLE Antivirals:plasmaconcentrationofcaspofunginpossiblyreducedbyEFAVIRENZandNEVIRAPINE—considerincreasingdoseofcaspofunginlCiclosporin:plasmaconcentrationofcaspofunginincreasedbylCICLOSPORIN(manufacturerofcaspofunginrecommendsmonitoringliverenzymes) TRIANGLE Corticosteroids:plasmaconcentrationofcaspofunginpossiblyreducedbyDEXAMETHASONE—considerincreasingdoseofcaspofunginlTacrolimus:caspofunginreducesplasmaconcentrationoflTACROLIMUSCatumaxomablAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)BNF70Appendix1Interactions1173Interactions|Appendix1"
"Catumaxomab(continued)lVaccines:riskofgeneralisedinfectionswhenmonoclonalantibodiesgivenwithlivelVACCINES—avoidconcomitantuseCefaclorseeCephalosporinsCefadroxilseeCephalosporinsCefalexinseeCephalosporinsCefiximeseeCephalosporinsCefotaximeseeCephalosporinsCefradineseeCephalosporinsCeftarolineseeCephalosporinsCeftazidimeseeCephalosporinsCeftriaxoneseeCephalosporinsCefuroximeseeCephalosporinsCelecoxibseeNSAIDsCeliprololseeBeta-blockersCephalosporins TRIANGLE Antacids:absorptionofcefaclorreducedbyANTACIDS TRIANGLE Antibacterials:possibleincreasedriskofnephrotoxicitywhencephalosporinsgivenwithAMINOGLYCOSIDESlAnticoagulants:cephalosporinspossiblyenhanceanticoagulanteffectoflCOUMARINS TRIANGLE Teriflunomide:plasmaconcentrationofcefaclorincreasedbyTERIFLUNOMIDE TRIANGLE Vaccines:antibacterialsinactivateORALTYPHOIDVACCINE—seeunderTyphoidVaccineinBNFCertolizumabpegollAbatacept:avoidconcomitantuseofcertolizumabpegolwithlABATACEPTlAnakinra:avoidconcomitantuseofcertolizumabpegolwithlANAKINRAlAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lVaccines:riskofgeneralisedinfectionswhenmonoclonalantibodiesgivenwithlivelVACCINES—avoidconcomitantuseCetirizineseeAntihistaminesCetuximablAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lVaccines:riskofgeneralisedinfectionswhenmonoclonalantibodiesgivenwithlivelVACCINES—avoidconcomitantuseChenodeoxycholicAcidseeBileAcidsChloralseeAnxiolyticsandHypnoticsChloramphenicol TRIANGLE Antibacterials:metabolismofchloramphenicolacceleratedbyRIFAMPICIN(reducedplasmaconcentration)lAnticoagulants:chloramphenicolenhancesanticoagulanteffectoflCOUMARINSlAntidiabetics:chloramphenicolenhanceseffectsoflSULFONYLUREASlAntiepileptics:chloramphenicolincreasesplasmaconcentrationoflFOSPHENYTOINandlPHENYTOIN(increasedriskoftoxicity);metabolismofchloramphenicolpossiblyacceleratedbylPHENOBARBITALandlPRIMIDONE(reducedplasmaconcentration)lAntipsychotics:avoidconcomitantuseofchloramphenicolwithlCLOZAPINE(increasedriskofagranulocytosis)lCiclosporin:chloramphenicolpossiblyincreasesplasmaconcentrationoflCICLOSPORINlClopidogrel:chloramphenicolpossiblyreducesantiplateleteffectoflCLOPIDOGREL TRIANGLE Hydroxocobalamin:chloramphenicolreducesresponsetoHYDROXOCOBALAMINlTacrolimus:chloramphenicolpossiblyincreasesplasmaconcentrationoflTACROLIMUS TRIANGLE Vaccines:antibacterialsinactivateORALTYPHOIDVACCINE—seeunderTyphoidVaccineinBNFChlordiazepoxideseeAnxiolyticsandHypnoticsChloroprocainelAntibacterials:chloroprocainepossiblyinhibitseffectsoflSULFONAMIDES(manufacturerofchloroprocaineadvisesavoidconcomitantuse)Chloroquine TRIANGLE Adsorbents:absorptionofchloroquinereducedbyKAOLINChloroquine(continued) TRIANGLE AgalsidaseAlfaandBeta:chloroquinepossiblyinhibitseffectsofAGALSIDASEALFAANDBETA(manufacturersofagalsidasealfaandbetaadviseavoidconcomitantuse) TRIANGLE Antacids:absorptionofchloroquinereducedbyANTACIDSlAnthelmintics:chloroquinereducesplasmaconcentrationoflPRAZIQUANTEL—considerincreasingpraziquanteldosewhengivenforsystemicinfectionslAnti-arrhythmics:increasedriskofventriculararrhythmiaswhenchloroquinegivenwithlAMIODARONE—avoidconcomitantuselAntibacterials:increasedriskofventriculararrhythmiaswhenchloroquinegivenwithlMOXIFLOXACIN—avoidconcomitantuselAntidepressants:possibleincreasedriskofventriculararrhythmiaswhenchloroquinegivenwithlCITALOPRAMandlESCITALOPRAMlAntimalarials:avoidanceofantimalarialsadvisedbymanufactureroflARTEMETHERWITHLUMEFANTRINE;increasedriskofconvulsionswhenchloroquinegivenwithlMEFLOQUINElAntipsychotics:increasedriskofventriculararrhythmiaswhenchloroquinegivenwithlDROPERIDOL—avoidconcomitantuselCardiacGlycosides:chloroquinepossiblyincreasesplasmaconcentrationoflDIGOXINlCiclosporin:chloroquineincreasesplasmaconcentrationoflCICLOSPORIN(increasedriskoftoxicity)lCytotoxics:possibleincreasedriskofventriculararrhythmiaswhenchloroquinegivenwithlBOSUTINIB TRIANGLE Histamine:avoidanceofantimalarialsadvisedbymanufacturerofHISTAMINE TRIANGLE Lanthanum:absorptionofchloroquinepossiblyreducedbyLANTHANUM(giveatleast2hoursapart) TRIANGLE Laronidase:chloroquinepossiblyinhibitseffectsofLARONIDASE(manufactureroflaronidaseadvisesavoidconcomitantuse) TRIANGLE Parasympathomimetics:chloroquinehaspotentialtoincreasesymptomsofmyastheniagravisandthusdiminisheffectofNEOSTIGMINEandPYRIDOSTIGMINE TRIANGLE Ulcer-healingDrugs:metabolismofchloroquineinhibitedbyCIMETIDINE(increasedplasmaconcentration) TRIANGLE Vaccines:antimalarialsinactivateORALTYPHOIDVACCINE—seeunderTyphoidVaccineinBNFChlorothiazideseeDiureticsChlorphenamineseeAntihistaminesChlorpromazineseeAntipsychoticsChlortalidoneseeDiureticsCholeraVaccineseeVaccinesCiclesonideseeCorticosteroidsCiclosporinlACEInhibitors:increasedriskofhyperkalaemiawhenciclosporingivenwithlACEINHIBITORSlAliskiren:ciclosporinincreasesplasmaconcentrationoflALISKIREN—avoidconcomitantuse TRIANGLE Allopurinol:plasmaconcentrationofciclosporinpossiblyincreasedbyALLOPURINOL(riskofnephrotoxicity)lAmbrisentan:ciclosporinincreasesplasmaconcentrationoflAMBRISENTAN(seeunderAmbrisentan,p162)lAnalgesics:increasedriskofnephrotoxicitywhenciclosporingivenwithlNSAIDS;ciclosporinincreasesplasmaconcentrationoflDICLOFENAC(halvedoseofdiclofenac)lAngiotensin-IIReceptorAntagonists:increasedriskofhyperkalaemiawhenciclosporingivenwithlANGIOTENSIN-IIRECEPTORANTAGONISTS TRIANGLE Anti-arrhythmics:plasmaconcentrationofciclosporinpossiblyincreasedbyAMIODARONEandPROPAFENONElAntibacterials:metabolismofciclosporininhibitedbylCLARITHROMYCINandlERYTHROMYCIN(increasedplasmaconcentration);metabolismofciclosporinacceleratedbylRIFAMPICIN(reducedplasmaconcentration);plasmaconcentrationofciclosporinpossiblyreducedbylSULFADIAZINE;increasedriskofnephrotoxicitywhenciclosporingivenwithlAMINOGLYCOSIDES,lPOLYMYXINS,lQUINOLONES,lSULFONAMIDESorlVANCOMYCIN;plasmaconcentrationofciclosporinpossiblyincreasedby1174Appendix1InteractionsBNF70Interactions|Appendix1"
"CiclosporinlAntibacterials(continued)lCHLORAMPHENICOLandlTELITHROMYCIN;increasedriskofmyopathywhenciclosporingivenwithlDAPTOMYCIN(preferablyavoidconcomitantuse);avoidanceofciclosporinadvisedbymanufacturerofFIDAXOMICIN;metabolismofciclosporinpossiblyinhibitedbylMACROLIDES(increasedplasmaconcentration);increasedriskofnephrotoxicitywhenciclosporingivenwithlTRIMETHOPRIM,alsoplasmaconcentrationofciclosporinreducedbyintravenoustrimethoprimlAnticoagulants:ciclosporinpossiblyincreasesplasmaconcentrationoflDABIGATRAN—manufacturerofdabigatranadvisesavoidconcomitantuselAntidepressants:plasmaconcentrationofciclosporinreducedbylSTJOHN’SWORT—avoidconcomitantuse TRIANGLE Antidiabetics:ciclosporinpossiblyenhanceshypoglycaemiceffectofREPAGLINIDElAntiepileptics:metabolismofciclosporinacceleratedbylCARBAMAZEPINE,lFOSPHENYTOIN,lPHENOBARBITAL,lPHENYTOINandlPRIMIDONE(reducedplasmaconcentration);plasmaconcentrationofciclosporinpossiblyreducedbyOXCARBAZEPINElAntifungals:metabolismofciclosporininhibitedbylFLUCONAZOLE,lITRACONAZOLE,lKETOCONAZOLE,lPOSACONAZOLEandlVORICONAZOLE(increasedplasmaconcentration);metabolismofciclosporinpossiblyinhibitedbylMICONAZOLE(increasedplasmaconcentration);increasedriskofnephrotoxicitywhenciclosporingivenwithlAMPHOTERICIN;ciclosporinincreasesplasmaconcentrationoflCASPOFUNGIN(manufacturerofcaspofunginrecommendsmonitoringliverenzymes);plasmaconcentrationofciclosporinpossiblyreducedbyGRISEOFULVINandTERBINAFINE;plasmaconcentrationofciclosporinpossiblyincreasedbyMICAFUNGINlAntimalarials:plasmaconcentrationofciclosporinincreasedbylCHLOROQUINEandlHYDROXYCHLOROQUINE(increasedriskoftoxicity) TRIANGLE Antimuscarinics:avoidanceofciclosporinadvisedbymanufacturerofDARIFENACINlAntivirals:increasedriskofnephrotoxicitywhenciclosporingivenwithACICLOVIRorVALACICLOVIR;plasmaconcentrationofciclosporinpossiblyincreasedbylATAZANAVIRandlRITONAVIR;plasmaconcentrationofciclosporinincreasedbylBOCEPREVIR,lFOSAMPRENAVIRandlINDINAVIR;plasmaconcentrationofciclosporinpossiblyreducedbylEFAVIRENZ;plasmaconcentrationofbothdrugsincreasedwhenciclosporingivenwithlSAQUINAVIR;plasmaconcentrationofbothdrugsincreasedwhenciclosporingivenwithlTELAPREVIR(reducedoseofciclosporin)lBeta-blockers:plasmaconcentrationofciclosporinincreasedbylCARVEDILOLlBileAcids:absorptionofciclosporinincreasedbylURSODEOXYCHOLICACIDlBosentan:ciclosporinincreasesplasmaconcentrationoflBOSENTAN(alsoplasmaconcentrationofciclosporinreduced—avoidconcomitantuse)lCalcium-channelBlockers:combinationofciclosporinwithlLERCANIDIPINEmayincreaseplasmaconcentrationofeitherdrug(orboth)—avoidconcomitantuse;plasmaconcentrationofciclosporinincreasedbylDILTIAZEM,lNICARDIPINEandlVERAPAMIL;ciclosporinpossiblyincreasesplasmaconcentrationofNIFEDIPINE(increasedriskoftoxicityincludinggingivalhyperplasia)lCardiacGlycosides:ciclosporinincreasesplasmaconcentrationoflDIGOXIN(increasedriskoftoxicity)lColchicine:possibleincreasedriskofnephrotoxicityandmyotoxicitywhenciclosporingivenwithlCOLCHICINE—suspendorreducedoseofcolchicine(avoidconcomitantuseinhepaticorrenalimpairment) TRIANGLE Colestilan:manufacturerofcolestilanadvisesgiveciclosporinatleast1hourbeforeor3hoursafterCOLESTILANlCorticosteroids:plasmaconcentrationofciclosporinincreasedbyhigh-doselMETHYLPREDNISOLONE(riskofconvulsions);ciclosporinincreasesplasmaconcentrationofPREDNISOLONECiclosporin(continued)lCytotoxics:increasedriskofnephrotoxicitywhenciclosporingivenwithlMELPHALAN;increasedriskofneurotoxicitywhenciclosporingivenwithlDOXORUBICIN;ciclosporinincreasesplasmaconcentrationoflEPIRUBICINandlIDARUBICIN;ciclosporinreducesexcretionofMITOXANTRONE(increasedplasmaconcentration);riskoftoxicitywhenciclosporingivenwithlMETHOTREXATE;ciclosporinpossiblyincreasestheplasmaconcentrationofAFATINIB—manufacturerofafatinibadvisesseparatingadministrationofciclosporinby6to12hours;cautionwithciclosporinadvisedbymanufactureroflCRIZOTINIB;ciclosporinincreasesplasmaconcentrationoflEVEROLIMUS(considerreducingthedoseofeverolimus—consulteverolimusproductliterature);plasmaconcentrationofciclosporinpossiblyincreasedbyIMATINIB;invitrostudiessuggestapossibleinteractionbetweenciclosporinandDOCETAXEL(consultdocetaxelproductliterature);ciclosporinpossiblyincreasesplasmaconcentrationofETOPOSIDE(increasedriskoftoxicity) TRIANGLE Dexrazoxane:increasedriskofimmunosupressionwithciclosporinadvisedbymanufacturerofDEXRAZOXANElDiuretics:plasmaconcentrationofciclosporinpossiblyincreasedbylACETAZOLAMIDE;increasedriskofhyperkalaemiawhenciclosporingivenwithlPOTASSIUM-SPARINGDIURETICSANDALDOSTERONEANTAGONISTS;increasedriskofnephrotoxicityandpossiblyhypermagnesaemiawhenciclosporingivenwithTHIAZIDESANDRELATEDDIURETICSlGrapefruitJuice:plasmaconcentrationofciclosporinincreasedbylGRAPEFRUITJUICE(increasedriskoftoxicity)lHormoneAntagonists:metabolismofciclosporininhibitedbylDANAZOL(increasedplasmaconcentration);plasmaconcentrationofciclosporinreducedbyLANREOTIDEandlOCTREOTIDE;plasmaconcentrationofciclosporinpossiblyreducedbylPASIREOTIDElLenalidomide:ciclosporinpossiblyincreasesplasmaconcentrationoflLENALIDOMIDE(increasedriskoftoxicity)lLipid-regulatingDrugs:absorptionofciclosporinreducedbylCOLESEVELAM;increasedriskofrenalimpairmentwhenciclosporingivenwithBEZAFIBRATEorFENOFIBRATE;increasedriskofmyopathywhenciclosporingivenwithlATORVASTATIN(seeunderAtorvastatin,p179);increasedriskofmyopathywhenciclosporingivenwithlFLUVASTATINorlPRAVASTATIN;increasedriskofmyopathywhenciclosporingivenwithlROSUVASTATINorlSIMVASTATIN(avoidconcomitantuse);plasmaconcentrationofbothdrugsmayincreasewhenciclosporingivenwithlEZETIMIBE;separatingadministrationfromciclosporinby12hoursadvisedbymanufacturerofLOMITAPIDE TRIANGLE Mannitol:possibleincreasedriskofnephrotoxicitywhenciclosporingivenwithMANNITOLlMetoclopramide:plasmaconcentrationofciclosporinincreasedbylMETOCLOPRAMIDE TRIANGLE Mifamurtide:avoidanceofciclosporinadvisedbymanufacturerofMIFAMURTIDElModafinil:plasmaconcentrationofciclosporinreducedbylMODAFINIL TRIANGLE Oestrogens:plasmaconcentrationofciclosporinpossiblyincreasedbyOESTROGENSlOrlistat:absorptionofciclosporinpossiblyreducedbylORLISTATlPotassiumSalts:increasedriskofhyperkalaemiawhenciclosporingivenwithlPOTASSIUMSALTS TRIANGLE Progestogens:plasmaconcentrationofciclosporinpossiblyincreasedbyPROGESTOGENS TRIANGLE Ranolazine:plasmaconcentrationofbothdrugsmayincreasewhenciclosporingivenwithRANOLAZINE TRIANGLE Sevelamer:plasmaconcentrationofciclosporinpossiblyreducedbySEVELAMER TRIANGLE Sirolimus:ciclosporinincreasesplasmaconcentrationofSIROLIMUSlSulfinpyrazone:plasmaconcentrationofciclosporinreducedbylSULFINPYRAZONElTacrolimus:plasmaconcentrationofciclosporinincreasedbylTACROLIMUS(increasedriskofnephrotoxicity)—avoidconcomitantuseBNF70Appendix1Interactions1175Interactions|Appendix1"
"Ciclosporin(continued) TRIANGLE Ticagrelor:ciclosporinincreasesplasmaconcentrationofTICAGRELORlUlcer-healingDrugs:plasmaconcentrationofciclosporinpossiblyincreasedbylCIMETIDINE;plasmaconcentrationofciclosporinpossiblyaffectedbyOMEPRAZOLE TRIANGLE Vitamins:plasmaconcentrationofciclosporinpossiblyaffectedbyVITAMINECilostazollAnagrelide:avoidanceofcilostazoladvisedbymanufactureroflANAGRELIDElAntibacterials:plasmaconcentrationofcilostazolpossiblyincreasedbylCLARITHROMYCIN(seeunderCilostazol,p206);plasmaconcentrationofcilostazolincreasedbylERYTHROMYCIN(seeunderCilostazol,p206)lAntifungals:plasmaconcentrationofcilostazolincreasedbylKETOCONAZOLE(seeunderCilostazol,p206);plasmaconcentrationofcilostazolpossiblyincreasedbylITRACONAZOLE(seeunderCilostazol,p206)lAntivirals:plasmaconcentrationofcilostazolpossiblyincreasedbylBOCEPREVIR,lRITONAVIRandlTELAPREVIR(seeunderCilostazol,p206) TRIANGLE Calcium-channelBlockers:plasmaconcentrationofcilostazolincreasedbyDILTIAZEM(considerreducingdoseofcilostazol) TRIANGLE Lipid-regulatingDrugs:separatingadministrationfromcilostazolby12hoursadvisedbymanufacturerofLOMITAPIDElUlcer-healingDrugs:plasmaconcentrationofcilostazolincreasedbylOMEPRAZOLE(seeunderCilostazol,p206)CimetidineseeHistamineH2-antagonistsCinacalcet TRIANGLE Antifungals:metabolismofcinacalcetinhibitedbyKETOCONAZOLE(increasedplasmaconcentration)lHormoneAntagonists:cinacalcetpossiblyinhibitsmetabolismoflTAMOXIFENtoactivemetabolite(avoidconcomitantuse)CinnarizineseeAntihistaminesCiprofibrateseeFibratesCiprofloxacinseeQuinolonesCisatracuriumseeMuscleRelaxantsCisplatinseePlatinumCompoundsCitalopramseeAntidepressants,SSRICladribinelAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lAntivirals:avoidanceofcladribineadvisedbymanufactureroflLAMIVUDINEClarithromycinseeMacrolidesClemastineseeAntihistaminesClindamycinlMuscleRelaxants:clindamycinenhanceseffectsoflNON-DEPOLARISINGMUSCLERELAXANTSandlSUXAMETHONIUM TRIANGLE Parasympathomimetics:clindamycinantagoniseseffectsofNEOSTIGMINEandPYRIDOSTIGMINE TRIANGLE Vaccines:antibacterialsinactivateORALTYPHOIDVACCINE—seeunderTyphoidVaccineinBNFClobazamseeAnxiolyticsandHypnoticsClofaziminelAntibacterials:possibleincreasedriskofventriculararrhythmiaswhenclofaziminegivenwithlBEDAQUILINE TRIANGLE Vaccines:antibacterialsinactivateORALTYPHOIDVACCINE—seeunderTyphoidVaccineinBNFClomethiazoleseeAnxiolyticsandHypnoticsClomipramineseeAntidepressants,TricyclicClonazepamseeAnxiolyticsandHypnoticsClonidine TRIANGLE ACEInhibitors:enhancedhypotensiveeffectwhenclonidinegivenwithACEINHIBITORS;previoustreatmentwithclonidinepossiblydelaysantihypertensiveeffectofCAPTOPRIL TRIANGLE AdrenergicNeuroneBlockers:enhancedhypotensiveeffectwhenclonidinegivenwithADRENERGICNEURONEBLOCKERS TRIANGLE Alcohol:enhancedhypotensiveeffectwhenclonidinegivenwithALCOHOL TRIANGLE Aldesleukin:enhancedhypotensiveeffectwhenclonidinegivenwithALDESLEUKIN TRIANGLE Alpha-blockers:enhancedhypotensiveeffectwhenclonidinegivenwithALPHA-BLOCKERSClonidine(continued) TRIANGLE Anaesthetics,General:enhancedhypotensiveeffectwhenclonidinegivenwithGENERALANAESTHETICS TRIANGLE Analgesics:hypotensiveeffectofclonidineantagonisedbyNSAIDS TRIANGLE Angiotensin-IIReceptorAntagonists:enhancedhypotensiveeffectwhenclonidinegivenwithANGIOTENSIN-IIRECEPTORANTAGONISTSlAntidepressants:enhancedhypotensiveeffectwhenclonidinegivenwithMAOIS;hypotensiveeffectofclonidinepossiblyantagonisedbyMIRTAZAPINE;hypotensiveeffectofclonidineantagonisedbylTRICYCLICS,alsoincreasedriskofhypertensiononclonidinewithdrawal TRIANGLE Antipsychotics:enhancedhypotensiveeffectwhenclonidinegivenwithPHENOTHIAZINES TRIANGLE AnxiolyticsandHypnotics:enhancedhypotensiveeffectwhenclonidinegivenwithANXIOLYTICSANDHYPNOTICSlBeta-blockers:increasedriskofwithdrawalhypertensionwhenclonidinegivenwithlBETA-BLOCKERS(withdrawbeta-blockersseveraldaysbeforeslowlywithdrawingclonidine) TRIANGLE Calcium-channelBlockers:enhancedhypotensiveeffectwhenclonidinegivenwithCALCIUM-CHANNELBLOCKERS TRIANGLE Corticosteroids:hypotensiveeffectofclonidineantagonisedbyCORTICOSTEROIDS TRIANGLE Cytotoxics:possibleincreasedriskofbradycardiawhenclonidinegivenwithCRIZOTINIB TRIANGLE Diazoxide:enhancedhypotensiveeffectwhenclonidinegivenwithDIAZOXIDE TRIANGLE Diuretics:enhancedhypotensiveeffectwhenclonidinegivenwithDIURETICS TRIANGLE Dopaminergics:enhancedhypotensiveeffectwhenclonidinegivenwithCO-BENELDOPA,CO-CARELDOPAorLEVODOPA TRIANGLE Histamine:avoidanceofclonidineadvisedbymanufacturerofHISTAMINE TRIANGLE Methyldopa:enhancedhypotensiveeffectwhenclonidinegivenwithMETHYLDOPA TRIANGLE Moxisylyte:enhancedhypotensiveeffectwhenclonidinegivenwithMOXISYLYTE TRIANGLE Moxonidine:enhancedhypotensiveeffectwhenclonidinegivenwithMOXONIDINE TRIANGLE MuscleRelaxants:enhancedhypotensiveeffectwhenclonidinegivenwithBACLOFENorTIZANIDINE TRIANGLE Nitrates:enhancedhypotensiveeffectwhenclonidinegivenwithNITRATES TRIANGLE Oestrogens:hypotensiveeffectofclonidineantagonisedbyOESTROGENS TRIANGLE Prostaglandins:enhancedhypotensiveeffectwhenclonidinegivenwithALPROSTADILlSympathomimetics:possibleriskofhypertensionwhenclonidinegivenwithADRENALINE(EPINEPHRINE)orNORADRENALINE(NOREPINEPHRINE);seriousadverseeventsreportedwithconcomitantuseofclonidineandlMETHYLPHENIDATE(causalitynotestablished) TRIANGLE VasodilatorAntihypertensives:enhancedhypotensiveeffectwhenclonidinegivenwithHYDRALAZINE,MINOXIDILorSODIUMNITROPRUSSIDEClopamideseeDiureticsClopidogrel TRIANGLE Analgesics:increasedriskofbleedingwhenclopidogrelgivenwithNSAIDSorASPIRINlAntibacterials:antiplateleteffectofclopidogrelpossiblyreducedbylCHLORAMPHENICOL,lCIPROFLOXACINandlERYTHROMYCINlAnticoagulants:manufacturerofclopidogreladvisesavoidconcomitantusewithlWARFARIN;antiplateletactionofclopidogrelenhancesanticoagulanteffectoflCOUMARINSandlPHENINDIONE;increasedriskofbleedingwhenclopidogrelgivenwithHEPARINSlAntidepressants:antiplateleteffectofclopidogrelpossiblyreducedbylFLUOXETINE,lFLUVOXAMINEandlMOCLOBEMIDElAntiepileptics:antiplateleteffectofclopidogrelpossiblyreducedbylCARBAMAZEPINEandlOXCARBAZEPINElAntifungals:antiplateleteffectofclopidogrelpossiblyreducedbylFLUCONAZOLE,lITRACONAZOLE,lKETOCONAZOLEandlVORICONAZOLE1176Appendix1InteractionsBNF70Interactions|Appendix1"
"Clopidogrel(continued)lAntivirals:antiplateleteffectofclopidogrelpossiblyreducedbylETRAVIRINE TRIANGLE Dipyridamole:increasedriskofbleedingwhenclopidogrelgivenwithDIPYRIDAMOLE TRIANGLE Iloprost:increasedriskofbleedingwhenclopidogrelgivenwithILOPROSTlLipid-regulatingDrugs:clopidogrelincreasesplasmaconcentrationoflROSUVASTATIN—adjustdoseofrosuvastatin(consultproductliterature) TRIANGLE Prasugrel:possibleincreasedriskofbleedingwhenclopidogrelgivenwithPRASUGRELlUlcer-healingDrugs:antiplateleteffectofclopidogrelpossiblyreducedbylCIMETIDINE,LANSOPRAZOLE,PANTOPRAZOLEandRABEPRAZOLE;antiplateleteffectofclopidogrelreducedbylESOMEPRAZOLEandlOMEPRAZOLEClozapineseeAntipsychoticsCo-amoxiclavseePenicillinsCo-beneldopa TRIANGLE ACEInhibitors:enhancedhypotensiveeffectwhenco-beneldopagivenwithACEINHIBITORS TRIANGLE AdrenergicNeuroneBlockers:enhancedhypotensiveeffectwhenco-beneldopagivenwithADRENERGICNEURONEBLOCKERS TRIANGLE Alpha-blockers:enhancedhypotensiveeffectwhenco-beneldopagivenwithALPHA-BLOCKERSlAnaesthetics,General:increasedriskofarrhythmiaswhenco-beneldopagivenwithlVOLATILELIQUIDGENERALANAESTHETICS TRIANGLE Angiotensin-IIReceptorAntagonists:enhancedhypotensiveeffectwhenco-beneldopagivenwithANGIOTENSIN-IIRECEPTORANTAGONISTS TRIANGLE Antibacterials:effectsofco-beneldopapossiblyreducedbyISONIAZIDlAntidepressants:riskofhypertensivecrisiswhenco-beneldopagivenwithlMAOIS,avoidco-beneldopaforatleast2weeksafterstoppingMAOIs;increasedriskofside-effectswhenco-beneldopagivenwithMOCLOBEMIDE TRIANGLE Antiepileptics:effectsofco-beneldopapossiblyreducedbyFOSPHENYTOINandPHENYTOIN TRIANGLE Antimuscarinics:absorptionofco-beneldopapossiblyreducedbyANTIMUSCARINICS TRIANGLE Antipsychotics:effectsofco-beneldopaantagonisedbyANTIPSYCHOTICS;avoidanceofco-beneldopaadvisedbymanufacturerofAMISULPRIDE(antagonismofeffect) TRIANGLE AnxiolyticsandHypnotics:effectsofco-beneldopapossiblyantagonisedbyBENZODIAZEPINES TRIANGLE Beta-blockers:enhancedhypotensiveeffectwhenco-beneldopagivenwithBETA-BLOCKERS TRIANGLE Bupropion:increasedriskofside-effectswhenco-beneldopagivenwithBUPROPION TRIANGLE Calcium-channelBlockers:enhancedhypotensiveeffectwhenco-beneldopagivenwithCALCIUM-CHANNELBLOCKERS TRIANGLE Clonidine:enhancedhypotensiveeffectwhenco-beneldopagivenwithCLONIDINE TRIANGLE Diazoxide:enhancedhypotensiveeffectwhenco-beneldopagivenwithDIAZOXIDE TRIANGLE Diuretics:enhancedhypotensiveeffectwhenco-beneldopagivenwithDIURETICS TRIANGLE Dopaminergics:enhancedeffectsandincreasedtoxicityofco-beneldopawhengivenwithSELEGILINE(reducedoseofco-beneldopa) TRIANGLE IronSalts:absorptionofco-beneldopapossiblyreducedbyoralIRONSALTS TRIANGLE Memantine:effectsofdopaminergicspossiblyenhancedbyMEMANTINE TRIANGLE Methyldopa:enhancedhypotensiveeffectwhenco-beneldopagivenwithMETHYLDOPA;antiparkinsonianeffectofdopaminergicsantagonisedbyMETHYLDOPA TRIANGLE Moxonidine:enhancedhypotensiveeffectwhenco-beneldopagivenwithMOXONIDINE TRIANGLE MuscleRelaxants:possibleagitation,confusionandhallucinationswhenco-beneldopagivenwithBACLOFEN TRIANGLE Nitrates:enhancedhypotensiveeffectwhenco-beneldopagivenwithNITRATESCo-beneldopa(continued) TRIANGLE VasodilatorAntihypertensives:enhancedhypotensiveeffectwhenco-beneldopagivenwithHYDRALAZINE,MINOXIDILorSODIUMNITROPRUSSIDECobicistatlAlpha-blockers:cobicistatpossiblyincreasesplasmaconcentrationoflALFUZOSIN—manufacturerofcobicistatadvisesavoidconcomitantuselAnti-arrhythmics:cobicistatpossiblyincreasesplasmaconcentrationoflAMIODARONE—manufacturerofcobicistatadvisesavoidconcomitantuselAntibacterials:plasmaconcentrationofcobicistatreducedbylRIFABUTIN(adjustdose—consultproductliterature);plasmaconcentrationofcobicistatpossiblyreducedbylRIFAMPICIN—manufacturerofcobicistatadvisesavoidconcomitantuselAnticoagulants:avoidanceofcobicistatadvisedbymanufacturerofAPIXABAN;cobicistatpossiblyenhancesanticoagulanteffectoflRIVAROXABAN—avoidconcomitantuselAntidepressants:plasmaconcentrationofcobicistatpossiblyreducedbylSTJOHN’SWORT—manufacturerofcobicistatadvisesavoidconcomitantuselAntiepileptics:plasmaconcentrationofcobicistatpossiblyreducedbylCARBAMAZEPINE,lFOSPHENYTOIN,lPHENOBARBITAL,lPHENYTOINandlPRIMIDONE—manufacturerofcobicistatadvisesavoidconcomitantuse TRIANGLE Antifungals:cobicistatpossiblyincreasesplasmaconcentrationofITRACONAZOLEandKETOCONAZOLE—manufacturerofcobicistatadvisesreducedoseofitraconazoleandketoconazolelAntipsychotics:cobicistatpossiblyincreasesplasmaconcentrationoflLURASIDONE—avoidconcomitantuse;cobicistatpossiblyincreasesplasmaconcentrationoflPIMOZIDE—manufacturerofcobicistatadvisesavoidconcomitantuselAntivirals:manufacturerofcobicistatadvisesavoidconcomitantusewithBOCEPREVIR;cobicistatpossiblyincreasestheplasmaconcentrationoflDACLATASVIR—reducedoseofdaclatasvir(seeunderDaclatasvir,p544);cobicistatpossiblyincreasesplasmaconcentrationoflMARAVIROC(reducedoseofmaraviroc);avoidanceofcobicistatadvisedbymanufacturerofNEVIRAPINE;cobicistatpossiblyincreasesplasmaconcentrationoflSIMEPREVIR—manufacturerofsimepreviradvisesavoidconcomitantuse;plasmaconcentrationofbothdrugsreducedwhencobicistatgivenwithlTIPRANAVIR(avoidconcomitantuse)lAnxiolyticsandHypnotics:manufacturerofcobicistatadvisesavoidconcomitantusewithorallMIDAZOLAM TRIANGLE Bosentan:manufacturerofcobicistatadvisesavoidconcomitantusewithBOSENTAN TRIANGLE CardiacGlycosides:cobicistatpossiblyincreasesplasmaconcentrationofDIGOXIN—reduceinitialdoseofdigoxinlCytotoxics:cobicistatpossiblyincreasestheplasmaconcentrationoflIBRUTINIB—reducedoseofibrutinib(seeunderIbrutinib,p809)lDomperidone:possibleincreasedriskofventriculararrhythmiaswhencobicistatgivenwithlDOMPERIDONE—avoidconcomitantuselErgotAlkaloids:cobicistatpossiblyincreasesplasmaconcentrationoflERGOTALKALOIDS—manufacturerofcobicistatadvisesavoidconcomitantuselLipid-regulatingDrugs:cobicistatpossiblyincreasesplasmaconcentrationofATORVASTATIN—manufacturerofcobicistatadvisesreducedoseofatorvastatin;manufacturerofcobicistatadvisesavoidconcomitantusewithlSIMVASTATINlOestrogens:cobicistatacceleratesmetabolismoflOESTROGENS(reducedcontraceptiveeffectwithcombinedoralcontraceptives,contraceptivepatches,andvaginalrings—seeContraceptiveInteractionsinBNF) TRIANGLE Progestogens:cobicistatincreasesplasmaconcentrationofNORGESTIMATElSildenafil:cobicistatpossiblyincreasesplasmaconcentrationoflSILDENAFIL—manufacturerofcobicistatadvisesavoidconcomitantuseofsildenafilforpulmonaryarterialBNF70Appendix1Interactions1177Interactions|Appendix1"
"CobicistatlSildenafil(continued)hypertensionorreducedoseofsildenafilforerectiledysfunction—consultcobicistatproductliterature TRIANGLE Sympathomimetics,Beta2:manufacturerofcobicistatadvisesavoidconcomitantusewithSALMETEROLlTadalafil:cobicistatpossiblyincreasesplasmaconcentrationoflTADALAFIL—manufacturerofcobicistatadvisesreducedoseoftadalafil(consultcobicistatproductliterature)lVardenafil:cobicistatpossiblyincreasesplasmaconcentrationoflVARDENAFIL—manufacturerofcobicistatadvisesreducedoseofvardenafil(consultcobicistatproductliterature)Co-careldopa TRIANGLE ACEInhibitors:enhancedhypotensiveeffectwhenco-careldopagivenwithACEINHIBITORS TRIANGLE AdrenergicNeuroneBlockers:enhancedhypotensiveeffectwhenco-careldopagivenwithADRENERGICNEURONEBLOCKERS TRIANGLE Alpha-blockers:enhancedhypotensiveeffectwhenco-careldopagivenwithALPHA-BLOCKERSlAnaesthetics,General:increasedriskofarrhythmiaswhenco-careldopagivenwithlVOLATILELIQUIDGENERALANAESTHETICS TRIANGLE Angiotensin-IIReceptorAntagonists:enhancedhypotensiveeffectwhenco-careldopagivenwithANGIOTENSIN-IIRECEPTORANTAGONISTS TRIANGLE Antibacterials:effectsofco-careldopapossiblyreducedbyISONIAZIDlAntidepressants:riskofhypertensivecrisiswhenco-careldopagivenwithlMAOIS,avoidco-careldopaforatleast2weeksafterstoppingMAOIs;increasedriskofside-effectswhenco-careldopagivenwithMOCLOBEMIDE TRIANGLE Antiepileptics:effectsofco-careldopapossiblyreducedbyFOSPHENYTOINandPHENYTOIN TRIANGLE Antimuscarinics:absorptionofco-careldopapossiblyreducedbyANTIMUSCARINICS TRIANGLE Antipsychotics:effectsofco-careldopaantagonisedbyANTIPSYCHOTICS;avoidanceofco-careldopaadvisedbymanufacturerofAMISULPRIDE(antagonismofeffect) TRIANGLE AnxiolyticsandHypnotics:effectsofco-careldopapossiblyantagonisedbyBENZODIAZEPINES TRIANGLE Beta-blockers:enhancedhypotensiveeffectwhenco-careldopagivenwithBETA-BLOCKERS TRIANGLE Bupropion:increasedriskofside-effectswhenco-careldopagivenwithBUPROPION TRIANGLE Calcium-channelBlockers:enhancedhypotensiveeffectwhenco-careldopagivenwithCALCIUM-CHANNELBLOCKERS TRIANGLE Clonidine:enhancedhypotensiveeffectwhenco-careldopagivenwithCLONIDINE TRIANGLE Diazoxide:enhancedhypotensiveeffectwhenco-careldopagivenwithDIAZOXIDE TRIANGLE Diuretics:enhancedhypotensiveeffectwhenco-careldopagivenwithDIURETICS TRIANGLE Dopaminergics:enhancedeffectsandincreasedtoxicityofco-careldopawhengivenwithSELEGILINE(reducedoseofco-careldopa) TRIANGLE IronSalts:absorptionofco-careldopapossiblyreducedbyoralIRONSALTS TRIANGLE Memantine:effectsofdopaminergicspossiblyenhancedbyMEMANTINE TRIANGLE Methyldopa:enhancedhypotensiveeffectwhenco-careldopagivenwithMETHYLDOPA;antiparkinsonianeffectofdopaminergicsantagonisedbyMETHYLDOPA TRIANGLE Moxonidine:enhancedhypotensiveeffectwhenco-careldopagivenwithMOXONIDINE TRIANGLE MuscleRelaxants:possibleagitation,confusionandhallucinationswhenco-careldopagivenwithBACLOFEN TRIANGLE Nitrates:enhancedhypotensiveeffectwhenco-careldopagivenwithNITRATES TRIANGLE VasodilatorAntihypertensives:enhancedhypotensiveeffectwhenco-careldopagivenwithHYDRALAZINE,MINOXIDILorSODIUMNITROPRUSSIDECodeineseeOpioidAnalgesicsCo-fluampicilseePenicillinsColchicinelAnti-arrhythmics:possibleincreasedriskofcolchicinetoxicitywhengivenwithlAMIODARONEColchicine(continued)lAntibacterials:possibleincreasedriskofcolchicinetoxicitywhengivenwithlAZITHROMYCIN,lCLARITHROMYCIN,lERYTHROMYCINandlTELITHROMYCIN—suspendorreducedoseofcolchicine(avoidconcomitantuseinhepaticorrenalimpairment)lAntifungals:possibleincreasedriskofcolchicinetoxicitywhengivenwithlITRACONAZOLEandlKETOCONAZOLE—suspendorreducedoseofcolchicine(avoidconcomitantuseinhepaticorrenalimpairment)lAntivirals:possibleincreasedriskofcolchicinetoxicitywhengivenwithlATAZANAVIR,lINDINAVIR,lRITONAVIRandlTELAPREVIR—suspendorreducedoseofcolchicine(avoidconcomitantuseinhepaticorrenalimpairment)lCalcium-channelBlockers:possibleincreasedriskofcolchicinetoxicitywhengivenwithlDILTIAZEMandlVERAPAMIL—suspendorreducedoseofcolchicine(avoidconcomitantuseinhepaticorrenalimpairment)lCardiacGlycosides:possibleincreasedriskofmyopathywhencolchicinegivenwithlDIGOXINlCiclosporin:possibleincreasedriskofnephrotoxicityandmyotoxicitywhencolchicinegivenwithlCICLOSPORIN—suspendorreducedoseofcolchicine(avoidconcomitantuseinhepaticorrenalimpairment)lGrapefruitJuice:possibleincreasedriskofcolchicinetoxicitywhengivenwithlGRAPEFRUITJUICElLipid-regulatingDrugs:possibleincreasedriskofmyopathywhencolchicinegivenwithlFIBRATESorlSTATINSColecalciferolseeVitaminsColesevelamNOTEOtherdrugsshouldbetakenatleast4hoursbeforeoraftercolesevelamtoreducepossibleinterferencewithabsorption TRIANGLE Antidiabetics:colesevelamreducesabsorptionofGLIBENCLAMIDEandGLIPIZIDE;colesevelamreducesabsorptionofGLIMEPIRIDE—manufacturerofglimepirideadvisesgiveatleast4hoursbeforecolesevelam;manufacturerofcanagliflozinadvisesgivebileacidsequestrantsatleast1hourafteror4–6beforeCANAGLIFLOZIN TRIANGLE Antiepileptics:colesevelampossiblyreducesabsorptionofFOSPHENYTOINandPHENYTOINlCiclosporin:colesevelamreducesabsorptionoflCICLOSPORIN TRIANGLE Lipid-regulatingDrugs:bileacidsequestrantspossiblyreduceabsorptionofLOMITAPIDE(giveatleast4hoursapart) TRIANGLE Oestrogens:colesevelamreducesabsorptionofETHINYLESTRADIOL TRIANGLE ThyroidHormones:colesevelamreducesabsorptionofLEVOTHYROXINEColestilanNOTEOtherdrugsshouldbetakenatleast1hourbeforeor3hoursaftercolestilantoreducepossibleinterferencewithabsorption TRIANGLE Ciclosporin:manufacturerofcolestilanadvisesgiveCICLOSPORINatleast1hourbeforeor3hoursaftercolestilan TRIANGLE Mycophenolate:manufacturerofcolestilanadvisesgiveMYCOPHENOLATEatleast1hourbeforeor3hoursaftercolestilan TRIANGLE Tacrolimus:manufacturerofcolestilanadvisesgiveTACROLIMUSatleast1hourbeforeor3hoursaftercolestilan TRIANGLE ThyroidHormones:manufacturerofcolestilanadvisesgiveLEVOTHYROXINEatleast1hourbeforeor3hoursaftercolestilanColestipolNOTEOtherdrugsshouldbetakenatleast1hourbeforeor4–6hoursaftercolestipoltoreducepossibleinterferencewithabsorption TRIANGLE Antibacterials:colestipolpossiblyreducesabsorptionofTETRACYCLINE TRIANGLE Antidiabetics:manufacturerofcanagliflozinadvisesgivebileacidsequestrantsatleast1hourafteror4–6beforeCANAGLIFLOZIN TRIANGLE BileAcids:colestipolpossiblyreducesabsorptionofBILEACIDS TRIANGLE CardiacGlycosides:colestipolpossiblyreducesabsorptionofCARDIACGLYCOSIDES TRIANGLE Diuretics:colestipolreducesabsorptionofTHIAZIDESANDRELATEDDIURETICS(giveatleast2hoursapart)1178Appendix1InteractionsBNF70Interactions|Appendix1"
"Colestipol(continued) TRIANGLE Lipid-regulatingDrugs:bileacidsequestrantspossiblyreduceabsorptionofLOMITAPIDE(giveatleast4hoursapart) TRIANGLE ThyroidHormones:colestipolreducesabsorptionofTHYROIDHORMONESColestyramineNOTEOtherdrugsshouldbetakenatleast1hourbeforeor4–6hoursaftercolestyraminetoreducepossibleinterferencewithabsorption TRIANGLE Analgesics:colestyramineincreasestheexcretionofMELOXICAM;colestyraminereducesabsorptionofPARACETAMOL TRIANGLE Antibacterials:colestyraminepossiblyreducesabsorptionofTETRACYCLINE;colestyramineantagoniseseffectsoforalVANCOMYCINlAnticoagulants:colestyraminemayenhanceorreduceanticoagulanteffectoflCOUMARINSandlPHENINDIONE TRIANGLE Antidiabetics:colestyraminepossiblyenhanceshypoglycaemiceffectofACARBOSE;manufacturerofcanagliflozinadvisesgivebileacidsequestrantsatleast1hourafteror4–6beforeCANAGLIFLOZIN TRIANGLE Antiepileptics:colestyraminepossiblyreducesabsorptionofSODIUMVALPROATEandVALPROICACID TRIANGLE BileAcids:colestyraminepossiblyreducesabsorptionofBILEACIDS TRIANGLE CardiacGlycosides:colestyraminepossiblyreducesabsorptionofCARDIACGLYCOSIDES TRIANGLE Diuretics:colestyraminereducesabsorptionofTHIAZIDESANDRELATEDDIURETICS(giveatleast2hoursapart) TRIANGLE Leflunomide:colestyraminesignificantlydecreaseseffectofLEFLUNOMIDE(enhancedelimination)—avoidunlessdrugeliminationdesired TRIANGLE Lipid-regulatingDrugs:bileacidsequestrantspossiblyreduceabsorptionofLOMITAPIDE(giveatleast4hoursapart) TRIANGLE Mycophenolate:colestyraminereducesabsorptionofMYCOPHENOLATE TRIANGLE Raloxifene:colestyraminereducesabsorptionofRALOXIFENE(manufacturerofraloxifeneadvisesavoidconcomitantadministration) TRIANGLE Teriflunomide:colestyraminesignificantlydecreaseseffectofTERIFLUNOMIDE(enhancedelimination)—avoidunlessdrugeliminationdesired TRIANGLE ThyroidHormones:colestyraminereducesabsorptionofTHYROIDHORMONES TRIANGLE Vitamins:colestyraminepossiblyreducesabsorptionofCALCITRIOL(giveatleast1hourbeforeor4to6hoursaftercolestyramine)ColistimethateSodiumseePolymyxinsContraceptives,oralseeOestrogensandProgestogensCorticosteroidsNOTEInteractionsdonotgenerallyapplytocorticosteroidsusedfortopicalaction(includinginhalation)unlessspecified TRIANGLE ACEInhibitors:corticosteroidsantagonisehypotensiveeffectofACEINHIBITORS TRIANGLE AdrenergicNeuroneBlockers:corticosteroidsantagonisehypotensiveeffectofADRENERGICNEURONEBLOCKERSlAldesleukin:avoidanceofcorticosteroidsadvisedbymanufactureroflALDESLEUKIN TRIANGLE Alpha-blockers:corticosteroidsantagonisehypotensiveeffectofALPHA-BLOCKERS TRIANGLE Aminophylline:increasedriskofhypokalaemiawhencorticosteroidsgivenwithAMINOPHYLLINE TRIANGLE Analgesics:increasedriskofgastro-intestinalbleedingandulcerationwhencorticosteroidsgivenwithNSAIDS;increasedriskofgastro-intestinalbleedingandulcerationwhencorticosteroidsgivenwithASPIRIN,alsocorticosteroidsreduceplasmaconcentrationofsalicylate TRIANGLE Angiotensin-IIReceptorAntagonists:corticosteroidsantagonisehypotensiveeffectofANGIOTENSIN-IIRECEPTORANTAGONISTS TRIANGLE Antacids:absorptionofdeflazacortreducedbyANTACIDS TRIANGLE Anthelmintics:dexamethasoneincreasesplasmaconcentrationofactivemetaboliteofALBENDAZOLE;continuoususeofdexamethasonepossiblyreducesplasmaconcentrationofPRAZIQUANTELlAntibacterials:plasmaconcentrationofmethylprednisolonepossiblyincreasedbyCLARITHROMYCIN;metabolismofCorticosteroidslAntibacterials(continued)corticosteroidspossiblyinhibitedbyERYTHROMYCIN;metabolismofmethylprednisoloneinhibitedbyERYTHROMYCIN;corticosteroidspossiblyreduceplasmaconcentrationofISONIAZID;metabolismofcorticosteroidsacceleratedbylRIFAMYCINS(reducedeffect)lAnticoagulants:corticosteroidsmayenhanceorreduceanticoagulanteffectoflCOUMARINS(high-dosecorticosteroidsenhanceanticoagulanteffect);corticosteroidsmayenhanceorreduceanticoagulanteffectofPHENINDIONE TRIANGLE Antidiabetics:corticosteroidsantagonisehypoglycaemiceffectofANTIDIABETICSlAntiepileptics:metabolismofcorticosteroidsacceleratedbylCARBAMAZEPINE,lFOSPHENYTOIN,lPHENOBARBITAL,lPHENYTOINandlPRIMIDONE(reducedeffect)lAntifungals:metabolismofcorticosteroidspossiblyinhibitedbyITRACONAZOLEandKETOCONAZOLE;plasmaconcentrationofactivemetaboliteofciclesonideincreasedbylKETOCONAZOLE;plasmaconcentrationofinhaledmometasoneincreasedbyKETOCONAZOLE;plasmaconcentrationofinhaledandoral(andpossiblyalsointranasalandrectal)budesonideincreasedbylITRACONAZOLEandlKETOCONAZOLE;inhaledfluticasoneplasmaconcentrationispossiblyincreasedbyKETOCONAZOLE;metabolismofmethylprednisoloneinhibitedbyKETOCONAZOLE;increasedriskofhypokalaemiawhencorticosteroidsgivenwithlAMPHOTERICIN—avoidconcomitantuseunlesscorticosteroidsneededtocontrolreactions;plasmaconcentrationofinhaledfluticasoneincreasedbyITRACONAZOLE;metabolismofmethylprednisolonepossiblyinhibitedbyITRACONAZOLE;dexamethasonepossiblyreducesplasmaconcentrationofCASPOFUNGIN—considerincreasingdoseofcaspofunginlAntivirals:dexamethasonepossiblyreducesplasmaconcentrationofDACLATASVIRandSIMEPREVIR—manufacturerofdaclatasvirandsimepreviradvisesavoidconcomitantuse;dexamethasonepossiblyreducesplasmaconcentrationofINDINAVIR,LOPINAVIR,SAQUINAVIRandTELAPREVIR;avoidanceofdexamethasone(exceptwhengivenasasingledose)advisedbymanufactureroflRILPIVIRINE;plasmaconcentrationofinhaledandintranasalfluticasoneincreasedbylRITONAVIR—increasedriskofadrenalsuppression;plasmaconcentrationofbudesonide(includinginhaled,intranasal,andrectalbudesonide)possiblyincreasedbylRITONAVIR—increasedriskofadrenalsuppresion;plasmaconcentrationofcorticosteroidspossiblyincreasedbylRITONAVIR—increasedriskofadrenalsuppresision;plasmaconcentrationofinhaledandintranasalbudesonideandfluticasonepossiblyincreasedbyTELAPREVIR TRIANGLE Aprepitant:metabolismofdexamethasoneandmethylprednisoloneinhibitedbyAPREPITANT(reducedoseofdexamethasoneandmethylprednisolone) TRIANGLE Beta-blockers:corticosteroidsantagonisehypotensiveeffectofBETA-BLOCKERS TRIANGLE CalciumSalts:corticosteroidsreduceabsorptionofCALCIUMSALTS TRIANGLE Calcium-channelBlockers:corticosteroidsantagonisehypotensiveeffectofCALCIUM-CHANNELBLOCKERS;plasmaconcentrationofmethylprednisoloneincreasedbyDILTIAZEM TRIANGLE CardiacGlycosides:increasedriskofhypokalaemiawhencorticosteroidsgivenwithCARDIACGLYCOSIDESlCiclosporin:high-dosemethylprednisoloneincreasesplasmaconcentrationoflCICLOSPORIN(riskofconvulsions);plasmaconcentrationofprednisoloneincreasedbyCICLOSPORIN TRIANGLE Clonidine:corticosteroidsantagonisehypotensiveeffectofCLONIDINE TRIANGLE Cytotoxics:possibleincreasedriskofhepatoxicitywhendexamethasonegivenwithhigh-doseMETHOTREXATE;dexamethasonepossiblydecreasesplasmaconcentrationofAXITINIB(increasedoseofaxitinib—consultaxitinibproductliterature);dexamethasonepossiblyreducesplasmaconcentrationofCABOZANTINIB—manufacturerofcabozantinibadvisesavoidconcomitantuse TRIANGLE Diazoxide:corticosteroidsantagonisehypotensiveeffectofDIAZOXIDEBNF70Appendix1Interactions1179Interactions|Appendix1"
"Corticosteroids(continued) TRIANGLE Diuretics:corticosteroidsantagonisediureticeffectofDIURETICS;increasedriskofhypokalaemiawhencorticosteroidsgivenwithACETAZOLAMIDE,LOOPDIURETICSorTHIAZIDESANDRELATEDDIURETICS TRIANGLE Fosaprepitant:metabolismofdexamethasoneandmethylprednisoloneinhibitedbyFOSAPREPITANT(reducedoseofdexamethasoneandmethylprednisolone)lGrapefruitJuice:plasmaconcentrationoforalbudesonideincreasedbylGRAPEFRUITJUICE—avoidconcurrentuseorseparateadministrationbyasmuchaspossibleandconsiderreducingoralbudesonidedose TRIANGLE Histamine:avoidanceofcorticosteroidsadvisedbymanufacturerofHISTAMINE TRIANGLE Methyldopa:corticosteroidsantagonisehypotensiveeffectofMETHYLDOPA TRIANGLE Mifamurtide:avoidanceofcorticosteroidsadvisedbymanufacturerofMIFAMURTIDE TRIANGLE Mifepristone:effectofcorticosteroids(includinginhaledcorticosteroids)maybereducedfor3–4daysafterMIFEPRISTONE TRIANGLE Moxonidine:corticosteroidsantagonisehypotensiveeffectofMOXONIDINE TRIANGLE MuscleRelaxants:corticosteroidspossiblyantagoniseeffectsofPANCURONIUMandVECURONIUM TRIANGLE Nitrates:corticosteroidsantagonisehypotensiveeffectofNITRATES TRIANGLE Oestrogens:plasmaconcentrationofcorticosteroidsincreasedbyoralcontraceptivescontainingOESTROGENS TRIANGLE SodiumBenzoate:corticosteroidspossiblyreduceeffectsofSODIUMBENZOATE TRIANGLE SodiumPhenylbutyrate:corticosteroidspossiblyreduceeffectsofSODIUMPHENYLBUTYRATE TRIANGLE Somatropin:corticosteroidsmayinhibitgrowth-promotingeffectofSOMATROPIN TRIANGLE Sympathomimetics:metabolismofdexamethasoneacceleratedbyEPHEDRINE TRIANGLE Sympathomimetics,Beta2:increasedriskofhypokalaemiawhencorticosteroidsgivenwithhighdosesofBETA2SYMPATHOMIMETICS TRIANGLE Theophylline:increasedriskofhypokalaemiawhencorticosteroidsgivenwithTHEOPHYLLINElVaccines:highdosesofcorticosteroidsimpairimmuneresponsetolVACCINES—avoidconcomitantusewithlivevaccines TRIANGLE VasodilatorAntihypertensives:corticosteroidsantagonisehypotensiveeffectofHYDRALAZINE,MINOXIDILandSODIUMNITROPRUSSIDECo-trimoxazoleseeTrimethoprimandSulfamethoxazoleCoumarinsNOTEChangeinpatient’sclinicalcondition,particularlyassociatedwithliverdisease,intercurrentillness,ordrugadministration,necessitatesmorefrequenttestingMajorchangesindiet(especiallyinvolvingsaladsandvegetables)andinalcoholconsumptionmayalsoaffectanticoagulantcontrollAlcohol:anticoagulantcontrolwithcoumarinsmaybeaffectedbymajorchangesinconsumptionoflALCOHOL TRIANGLE Allopurinol:anticoagulanteffectofcoumarinspossiblyenhancedbyALLOPURINOLlAnabolicSteroids:anticoagulanteffectofcoumarinsenhancedbylANABOLICSTEROIDSlAnalgesics:anticoagulanteffectofcoumarinspossiblyenhancedbylNSAIDS;increasedriskofhaemorrhagewhenanticoagulantsgivenwithintravenouslDICLOFENAC(avoidconcomitantuse,includinglow-doseheparins);increasedriskofhaemorrhagewhenanticoagulantsgivenwithlKETOROLAC(avoidconcomitantuse,includinglow-doseheparins);anticoagulanteffectofcoumarinsenhancedbylTRAMADOL;increasedriskofbleedingwhencoumarinsgivenwithlASPIRIN(duetoantiplateleteffect);anticoagulanteffectofcoumarinspossiblyenhancedbyprolongedregularuseofPARACETAMOLlAnthelmintics:anticoagulanteffectofcoumarinspossiblyenhancedbyIVERMECTIN;anticoagulanteffectofwarfarinpossiblyenhancedbylLEVAMISOLECoumarins(continued)lAnti-arrhythmics:metabolismofcoumarinsinhibitedbylAMIODARONE(enhancedanticoagulanteffect);anticoagulanteffectofwarfarinmaybeenhancedorreducedbyDISOPYRAMIDE;anticoagulanteffectofcoumarinspossiblyenhancedbylDRONEDARONE;anticoagulanteffectofcoumarinsenhancedbylPROPAFENONElAntibacterials:experienceinanticoagulantclinicssuggeststhatINRpossiblyalteredwhencoumarinsaregivenwithlNEOMYCIN(givenforlocalactionongut);anticoagulanteffectofcoumarinspossiblyenhancedbylAZITHROMYCIN,lAZTREONAM,lCEPHALOSPORINS,CIPROFLOXACIN,LEVOFLOXACIN,lTETRACYCLINES,TIGECYCLINEandTRIMETHOPRIM;anticoagulanteffectofcoumarinsenhancedbylCHLORAMPHENICOL,lCLARITHROMYCIN,lERYTHROMYCIN,lMETRONIDAZOLE,lNALIDIXICACID,lNORFLOXACIN,lOFLOXACINandlSULFONAMIDES;plasmaconcentrationofwarfarinpossiblyincreasedbyORITAVANCIN;aninteractionbetweencoumarinsandbroad-spectrumPENICILLINShasnotbeendemonstratedinstudies,butcommonexperienceinanticoagulantclinicsisthatINRcanbealtered;metabolismofcoumarinsacceleratedbylRIFAMYCINS(reducedanticoagulanteffect)lAnticoagulants:increasedriskofhaemorrhagewhenotheranticoagulantsgivenwithlAPIXABAN,lDABIGATRANandlRIVAROXABAN(avoidconcomitantuseexceptwhenswitchingwithotheranticoagulantsorusingheparintomaintaincatheterpatency)lAntidepressants:anticoagulanteffectofwarfarinpossiblyenhancedbylVENLAFAXINE;anticoagulanteffectofwarfarinmaybeenhancedorreducedbyTRAZODONE;anticoagulanteffectofcoumarinspossiblyenhancedbylSSRIS;anticoagulanteffectofcoumarinsreducedbylSTJOHN’SWORT(avoidconcomitantuse);anticoagulanteffectofwarfarinenhancedbyMIRTAZAPINE;anticoagulanteffectofcoumarinsmaybeenhancedorreducedbylTRICYCLICSlAntidiabetics:anticoagulanteffectofwarfarinpossiblyenhancedbyEXENATIDE;coumarinspossiblyenhancehypoglycaemiceffectoflSULFONYLUREAS,alsopossiblechangestoanticoagulanteffectlAntiepileptics:metabolismofcoumarinsacceleratedbylCARBAMAZEPINE,lPHENOBARBITALandlPRIMIDONE(reducedanticoagulanteffect);plasmaconcentrationofwarfarinreducedbyESLICARBAZEPINE;metabolismofcoumarinsacceleratedbylFOSPHENYTOINandlPHENYTOIN(possibilityofreducedanticoagulanteffect,butenhancementalsoreported);anticoagulanteffectofcoumarinspossiblyenhancedbySODIUMVALPROATEandVALPROICACIDlAntifungals:anticoagulanteffectofcoumarinsenhancedbylFLUCONAZOLE,lITRACONAZOLE,lKETOCONAZOLEandlVORICONAZOLE;anticoagulanteffectofcoumarinsenhancedbylMICONAZOLE(miconazoleoralgelandpossiblyvaginalandtopicalformulationsabsorbed);anticoagulanteffectofcoumarinsreducedbylGRISEOFULVIN TRIANGLE Antimalarials:isolatedreportsthatanticoagulanteffectofwarfarinmaybeenhancedbyPROGUANIL;plasmaconcentrationofbothdrugsincreasedwhenwarfaringivenwithQUININElAntivirals:anticoagulanteffectofwarfarinmaybeenhancedorreducedbyATAZANAVIR,lNEVIRAPINEandlRITONAVIR;plasmaconcentrationofcoumarinspossiblyaffectedbylEFAVIRENZ;anticoagulanteffectofcoumarinsmaybeenhancedorreducedbyFOSAMPRENAVIR;anticoagulanteffectofcoumarinspossiblyenhancedbylRITONAVIR;anticoagulanteffectofwarfarinpossiblyenhancedbySAQUINAVIR;plasmaconcentrationofwarfarinpossiblyaffectedbylTELAPREVIR TRIANGLE AnxiolyticsandHypnotics:anticoagulanteffectofcoumarinsmaytransientlybeenhancedbyCHLORAL TRIANGLE Aprepitant:anticoagulanteffectofwarfarinpossiblyreducedbyAPREPITANTlAzathioprine:anticoagulanteffectofcoumarinspossiblyreducedbylAZATHIOPRINE TRIANGLE Bosentan:monitoringanticoagulanteffectofcoumarinsrecommendedbymanufacturerofBOSENTAN1180Appendix1InteractionsBNF70Interactions|Appendix1"
"Coumarins(continued)lClopidogrel:anticoagulanteffectofcoumarinsenhancedduetoantiplateletactionoflCLOPIDOGREL;avoidanceofwarfarinadvisedbymanufactureroflCLOPIDOGRELlCorticosteroids:anticoagulanteffectofcoumarinsmaybeenhancedorreducedbylCORTICOSTEROIDS(high-dosecorticosteroidsenhanceanticoagulanteffect)lCranberryJuice:anticoagulanteffectofcoumarinspossiblyenhancedbylCRANBERRYJUICE—avoidconcomitantuselCytotoxics:anticoagulanteffectofcoumarinspossiblyenhancedbylETOPOSIDE,lIFOSFAMIDEandlSORAFENIB;anticoagulanteffectofcoumarinsenhancedbylCAPECITABINE,lFLUOROURACILandlTEGAFUR;anticoagulanteffectofwarfarinpossiblyenhancedbylGEFITINIB,GEMCITABINEandlVEMURAFENIB;anticoagulanteffectofcoumarinspossiblyreducedbylMERCAPTOPURINEandlMITOTANE;plasmaconcentrationofwarfarinreducedbyDABRAFENIB;increasedriskofbleedingwhencoumarinsgivenwithlERLOTINIB;avoidanceofcoumarinsadvisedbymanufacturerofIBRUTINIB;replacementofwarfarinwithaheparinadvisedbymanufacturerofIMATINIB(possibilityofenhancedwarfarineffect);increasedriskofbleedingwhenwarfaringivenwithlREGORAFENIBlDipyridamole:anticoagulanteffectofcoumarinsenhancedduetoantiplateletactionoflDIPYRIDAMOLElDisulfiram:anticoagulanteffectofcoumarinsenhancedbylDISULFIRAMlDopaminergics:anticoagulanteffectofwarfarinenhancedbylENTACAPONElEnteralFoods:anticoagulanteffectofcoumarinsantagonisedbyvitaminK(presentinsomelENTERALFEEDS) TRIANGLE Fosaprepitant:anticoagulanteffectofwarfarinpossiblyreducedbyFOSAPREPITANTlGlucosamine:anticoagulanteffectofwarfarinenhancedbylGLUCOSAMINE(avoidconcomitantuse)lHormoneAntagonists:anticoagulanteffectofcoumarinspossiblyenhancedbyBICALUTAMIDEandlTOREMIFENE;metabolismofcoumarinsinhibitedbylDANAZOL(enhancedanticoagulanteffect);plasmaconcentrationofcoumarinspossiblyreducedbylENZALUTAMIDE;anticoagulanteffectofcoumarinsenhancedbylFLUTAMIDEandlTAMOXIFEN TRIANGLE Iloprost:anticoagulanteffectofcoumarinspossiblyenhancedbyILOPROST TRIANGLE Lactulose:anticoagulanteffectofcoumarinspossiblyenhancedbyLACTULOSE TRIANGLE Leflunomide:anticoagulanteffectofwarfarinpossiblyenhancedbyLEFLUNOMIDE TRIANGLE LeukotrieneReceptorAntagonists:anticoagulanteffectofwarfarinenhancedbyZAFIRLUKAST TRIANGLE Levocarnitine:anticoagulanteffectofcoumarinspossiblyenhancedbyLEVOCARNITINElLipid-regulatingDrugs:anticoagulanteffectofcoumarinsmaybeenhancedorreducedbylCOLESTYRAMINE;anticoagulanteffectofwarfarinmaybetransientlyreducedbyATORVASTATIN;anticoagulanteffectofcoumarinsenhancedbylFIBRATESandlFLUVASTATIN;anticoagulanteffectofcoumarinspossiblyenhancedbyEZETIMIBEandlROSUVASTATIN;anticoagulanteffectofcoumarinscanbeenhancedbySIMVASTATIN;anticoagulanteffectofwarfarinpossiblyenhancedbyLOMITAPIDE TRIANGLE Memantine:anticoagulanteffectofwarfarinpossiblyenhancedbyMEMANTINE TRIANGLE Oestrogens:anticoagulanteffectofcoumarinsmaybeenhancedorreducedbyOESTROGENS TRIANGLE Orlistat:monitoringanticoagulanteffectofcoumarinsrecommendedbymanufacturerofORLISTAT TRIANGLE Prasugrel:possibleincreasedriskofbleedingwhencoumarinsgivenwithPRASUGREL TRIANGLE Progestogens:anticoagulanteffectofcoumarinsmaybeenhancedorreducedbyPROGESTOGENS TRIANGLE Raloxifene:anticoagulanteffectofcoumarinsantagonisedbyRALOXIFENElRetinoids:anticoagulanteffectofcoumarinspossiblyreducedbylACITRETINlSulfinpyrazone:anticoagulanteffectofcoumarinsenhancedbylSULFINPYRAZONECoumarins(continued)lSympathomimetics:anticoagulanteffectofcoumarinspossiblyenhancedbylMETHYLPHENIDATElTestolactone:anticoagulanteffectofcoumarinsenhancedbylTESTOLACTONElTestosterone:anticoagulanteffectofcoumarinsenhancedbylTESTOSTERONElThyroidHormones:anticoagulanteffectofcoumarinsenhancedbylTHYROIDHORMONES TRIANGLE Ubidecarenone:anticoagulanteffectofwarfarinmaybeenhancedorreducedbyUBIDECARENONElUlcer-healingDrugs:metabolismofcoumarinsinhibitedbylCIMETIDINE(enhancedanticoagulanteffect);anticoagulanteffectofcoumarinspossiblyenhancedbylESOMEPRAZOLEandlOMEPRAZOLE;anticoagulanteffectofcoumarinsmightbeenhancedbyPANTOPRAZOLE;absorptionofcoumarinspossiblyreducedbylSUCRALFATE(reducedanticoagulanteffect) TRIANGLE Vaccines:anticoagulanteffectofwarfarinpossiblyenhancedbyINFLUENZAVACCINElVitamins:anticoagulanteffectofcoumarinspossiblyenhancedbylVITAMINE;anticoagulanteffectofcoumarinsantagonisedbylVITAMINKCranberryJuicelAnticoagulants:cranberryjuicepossiblyenhancesanticoagulanteffectoflCOUMARINS—avoidconcomitantuseCrizotiniblAnalgesics:manufacturerofcrizotinibadvisescautionwithlALFENTANILandlFENTANYLlAntibacterials:plasmaconcentrationofcrizotinibpossiblyincreasedbylCLARITHROMYCINandlTELITHROMYCIN—manufacturerofcrizotinibadvisesavoidconcomitantuse;plasmaconcentrationofcrizotinibpossiblyreducedbyRIFABUTIN—manufacturerofcrizotinibadvisesavoidconcomitantuse;plasmaconcentrationofcrizotinibreducedbylRIFAMPICIN—manufacturerofcrizotinibadvisesavoidconcomitantuse TRIANGLE Antidepressants:plasmaconcentrationofcrizotinibpossiblyreducedbySTJOHN’SWORT—manufacturerofcrizotinibadvisesavoidconcomitantuse TRIANGLE Antiepileptics:plasmaconcentrationofcrizotinibpossiblyreducedbyCARBAMAZEPINE,FOSPHENYTOIN,PHENOBARBITAL,PHENYTOINandPRIMIDONE—manufacturerofcrizotinibadvisesavoidconcomitantuselAntifungals:plasmaconcentrationofcrizotinibincreasedbylKETOCONAZOLE—avoidconcomitantuse;plasmaconcentrationofcrizotinibpossiblyincreasedbylITRACONAZOLEandlVORICONAZOLE—manufacturerofcrizotinibadvisesavoidconcomitantuse TRIANGLE Antimalarials:possibleincreasedriskofbradycardiawhencrizotinibgivenwithMEFLOQUINElAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis);manufacturerofcrizotinibadvisescautionwithlPIMOZIDElAntivirals:plasmaconcentrationofcrizotinibpossiblyincreasedbylATAZANAVIR,lINDINAVIR,lRITONAVIRandlSAQUINAVIR—manufacturerofcrizotinibadvisesavoidconcomitantuselAnxiolyticsandHypnotics:crizotinibincreasesplasmaconcentrationoflMIDAZOLAM TRIANGLE Beta-blockers:possibleincreasedriskofbradycardiawhencrizotinibgivenwithBETA-BLOCKERS TRIANGLE Calcium-channelBlockers:possibleincreasedriskofbradycardiawhencrizotinibgivenwithDILTIAZEMorVERAPAMIL TRIANGLE CardiacGlycosides:possibleincreasedriskofbradycardiawhencrizotinibgivenwithDIGOXINlCiclosporin:manufacturerofcrizotinibadvisescautionwithlCICLOSPORIN TRIANGLE Clonidine:possibleincreasedriskofbradycardiawhencrizotinibgivenwithCLONIDINElCytotoxics:crizotinibpossiblyincreasestheplasmaconcentrationoflIBRUTINIB—reducedoseofibrutinib(seeunderIbrutinib,p809)lErgotAlkaloids:manufacturerofcrizotinibadvisescautionwithlERGOTALKALOIDSBNF70Appendix1Interactions1181Interactions|Appendix1"
"Crizotinib(continued)lGrapefruitJuice:plasmaconcentrationofcrizotinibpossiblyincreasedbylGRAPEFRUITJUICE—manufacturerofcrizotinibadvisesavoidconcomitantuselOestrogens:manufacturerofcrizotinibadvisescontraceptiveeffectoflOESTROGENSpossiblyreduced TRIANGLE Parasympathomimetics:possibleincreasedriskofbradycardiawhencrizotinibgivenwithPILOCARPINElProgestogens:manufacturerofcrizotinibadvisescontraceptiveeffectoflPROGESTOGENSpossiblyreducedlSirolimus:manufacturerofcrizotinibadvisescautionwithlSIROLIMUSlTacrolimus:manufacturerofcrizotinibadvisescautionwithlTACROLIMUSCyclizineseeAntihistaminesCyclopenthiazideseeDiureticsCyclopentolateseeAntimuscarinicsCyclophosphamide TRIANGLE Antifungals:side-effectsofcyclophosphamidepossiblyincreasedbyFLUCONAZOLEandITRACONAZOLElAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis) TRIANGLE CardiacGlycosides:cyclophosphamidepossiblyreducesabsorptionofDIGOXINtabletslCytotoxics:increasedtoxicitywhenhigh-dosecyclophosphamidegivenwithlPENTOSTATIN—avoidconcomitantuse TRIANGLE MuscleRelaxants:cyclophosphamideenhanceseffectsofSUXAMETHONIUMCycloserinelAlcohol:increasedriskofconvulsionswhencycloserinegivenwithlALCOHOL TRIANGLE Antibacterials:increasedriskofCNStoxicitywhencycloserinegivenwithISONIAZID TRIANGLE Vaccines:antibacterialsinactivateORALTYPHOIDVACCINE—seeunderTyphoidVaccineinBNFCyproheptadineseeAntihistaminesCytarabine TRIANGLE Antifungals:cytarabinepossiblyreducesplasmaconcentrationofFLUCYTOSINElAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis) TRIANGLE CardiacGlycosides:cytarabinepossiblyreducesabsorptionofDIGOXINtablets TRIANGLE Cytotoxics:intracellularconcentrationofcytarabineincreasedbyFLUDARABINECytotoxicsseeindividualdrugsDabigatranlAnalgesics:possibleincreasedriskofbleedingwhendabigatrangivenwithlNSAIDS;increasedriskofhaemorrhagewhenanticoagulantsgivenwithintravenouslDICLOFENAC(avoidconcomitantuse,includinglow-doseheparins);increasedriskofhaemorrhagewhenanticoagulantsgivenwithlKETOROLAC(avoidconcomitantuse,includinglow-doseheparins)lAnti-arrhythmics:plasmaconcentrationofdabigatranincreasedbylAMIODARONE(seeunderDabigatranEtexilate,p117);plasmaconcentrationofdabigatranincreasedbylDRONEDARONE—avoidconcomitantuselAntibacterials:possibleincreasedriskofbleedingwhendabigatrangivenwithCLARITHROMYCIN;plasmaconcentrationofdabigatranreducedbylRIFAMPICIN—manufacturerofdabigatranadvisesavoidconcomitantuselAnticoagulants:increasedriskofhaemorrhagewhendabigatrangivenwithotherlANTICOAGULANTS(avoidconcomitantuseexceptwhenswitchingwithotheranticoagulantsorusingheparintomaintaincatheterpatency);increasedriskofhaemorrhagewhenotheranticoagulantsgivenwithlAPIXABANandlRIVAROXABAN(avoidconcomitantuseexceptwhenswitchingwithotheranticoagulantsorusingheparintomaintaincatheterpatency)lAntidepressants:possibleincreasedriskofbleedingwhendabigatrangivenwithlSSRI-RELATEDANTIDEPRESSANTSorlSSRIS;plasmaconcentrationofdabigatranpossiblyreducedDabigatranlAntidepressants(continued)bySTJOHN’SWORT—manufacturerofdabigatranadvisesavoidconcomitantuse TRIANGLE Antiepileptics:plasmaconcentrationofdabigatranpossiblyreducedbyCARBAMAZEPINE,FOSPHENYTOINandPHENYTOIN—manufacturerofdabigatranadvisesavoidconcomitantuselAntifungals:plasmaconcentrationofdabigatranincreasedbylKETOCONAZOLE—avoidconcomitantuse;manufacturerofdabigatranadvisesavoidconcomitantusewithITRACONAZOLE TRIANGLE Antivirals:plasmaconcentrationofdabigatranpossiblyincreasedbyRILPIVIRINEandTELAPREVIRlCalcium-channelBlockers:plasmaconcentrationofdabigatranpossiblyincreasedbylVERAPAMIL(seeunderDabigatranEtexilate,p117)lCiclosporin:plasmaconcentrationofdabigatranpossiblyincreasedbylCICLOSPORIN—manufacturerofdabigatranadvisesavoidconcomitantuselSulfinpyrazone:possibleincreasedriskofbleedingwhendabigatrangivenwithlSULFINPYRAZONElTacrolimus:plasmaconcentrationofdabigatranpossiblyincreasedbylTACROLIMUS—manufacturerofdabigatranadvisesavoidconcomitantuselTicagrelor:plasmaconcentrationofdabigatranincreasedbylTICAGRELOR TRIANGLE Ulipristal:manufacturerofulipristaladvisesgivedabigatranatleast15hoursbeforeorafterULIPRISTALDabrafenib TRIANGLE Antibacterials:manufacturerofdabrafenibadvisesavoidconcomitantusewithRIFAMPICIN TRIANGLE Anticoagulants:dabrafenibreducesplasmaconcentrationofWARFARIN TRIANGLE Antidepressants:manufacturerofdabrafenibadvisesavoidconcomitantusewithSTJOHN’SWORT TRIANGLE Antiepileptics:manufacturerofdabrafenibadvisesavoidconcomitantusewithCARBAMAZEPINE,FOSPHENYTOIN,PHENOBARBITAL,PHENYTOINandPRIMIDONE TRIANGLE Antifungals:plasmaconcentrationofdabrafenibincreasedbyKETOCONAZOLElAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis) TRIANGLE Lipid-regulatingDrugs:plasmaconcentrationofdabrafenibincreasedbyGEMFIBROZILlOestrogens:manufacturerofdabrafenibadvisescontraceptiveeffectofhormonalcontraceptivescontaininglOESTROGENSpossiblyreduced(alternativecontraceptiverecommended)lProgestogens:manufacturerofdabrafenibadvisescontraceptiveeffectofhormonalcontraceptivescontaininglPROGESTOGENSpossiblyreduced(alternativecontraceptiverecommended) TRIANGLE Ulcer-healingDrugs:manufacturerofdabrafenibadvisesavoidconcomitantusewithPROTONPUMPINHIBITORS(plasmaconcentrationofdabrafenibpossiblyreduced)DacarbazinelAldesleukin:avoidanceofdacarbazineadvisedbymanufactureroflALDESLEUKINlAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)DaclatasvirlAnti-arrhythmics:possibleincreasedriskofbradycardiawhendaclatasvir(withsofosbuvir)givenwithlAMIODARONE—seeunderAmiodarone,p88lAntibacterials:plasmaconcentrationofdaclatasvirpossiblyincreasedbylCLARITHROMYCINandlTELITHROMYCIN—reducedoseofdaclatasvir(seeunderDaclatasvir,p544);plasmaconcentrationofdaclatasvirpossiblyreducedbylRIFABUTIN—manufacturerofdaclatasviradvisesavoidconcomitantuse;plasmaconcentrationofdaclatasvirreducedbylRIFAMPICIN—avoidconcomitantuse TRIANGLE Antidepressants:plasmaconcentrationofdaclatasvirpossiblyreducedbySTJOHN’SWORT—manufacturerofdaclatasviradvisesavoidconcomitantuselAntiepileptics:plasmaconcentrationofdaclatasvirpossiblyreducedbylCARBAMAZEPINE,lFOSPHENYTOIN,lOXCARBAZEPINE,lPHENOBARBITAL,lPHENYTOINand1182Appendix1InteractionsBNF70Interactions|Appendix1"
"DaclatasvirlAntiepileptics(continued)lPRIMIDONE—manufacturerofdaclatasviradvisesavoidconcomitantuselAntifungals:plasmaconcentrationofdaclatasvirincreasedbylKETOCONAZOLE—reducedoseofdaclatasvir(seeunderDaclatasvir,p544);plasmaconcentrationofdaclatasvirpossiblyincreasedbylITRACONAZOLE,lPOSACONAZOLEandlVORICONAZOLE—reducedoseofdaclatasvir(seeunderDaclatasvir,p544)lAntivirals:plasmaconcentrationofdaclatasvirincreasedbylATAZANAVIRandlTELAPREVIR—reducedoseofdaclatasvir(seeunderDaclatasvir,p544);plasmaconcentrationofdaclatasvirpossiblyincreasedbylBOCEPREVIR—reducedoseofdaclatasvir(seeunderDaclatasvir,p544);manufacturerofdaclatasviradvisesavoidconcomitantusewithDARUNAVIRandLOPINAVIR(plasmaconcentrationofdaclatasvirpossiblyincreased);plasmaconcentrationofdaclatasvirreducedbylEFAVIRENZ—increasedoseofdaclatasvir(seeunderDaclatasvir,p544);manufacturerofdaclatasviradvisesavoidconcomitantusewithETRAVIRINEandNEVIRAPINE(plasmaconcentrationofdaclatasvirpossiblyreduced)lCardiacGlycosides:daclatasvirincreasesplasmaconcentrationoflDIGOXINlCobicistat:plasmaconcentrationofdaclatasvirpossiblyincreasedbylCOBICISTAT—reducedoseofdaclatasvir(seeunderDaclatasvir,p544) TRIANGLE Corticosteroids:plasmaconcentrationofdaclatasvirpossiblyreducedbyDEXAMETHASONE—manufacturerofdaclatasviradvisesavoidconcomitantuse TRIANGLE Lipid-regulatingDrugs:daclatasvirincreasesplasmaconcentrationofROSUVASTATINDactinomycinlAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis) TRIANGLE Vitamins:dactinomycinpossiblyreduceseffectsofALFACALCIDOL,CALCITRIOL,COLECALCIFEROL,DIHYDROTACHYSTEROL,ERGOCALCIFEROL,PARICALCITOLandVITAMINDDairyProducts TRIANGLE Antibacterials:dairyproductsreduceabsorptionofCIPROFLOXACINandNORFLOXACIN;dairyproductsreduceabsorptionofTETRACYCLINES(exceptdoxycyclineandminocycline) TRIANGLE Cytotoxics:dairyproductspossiblyreduceplasmaconcentrationofMERCAPTOPURINE—manufacturerofmercaptopurineadvisesgiveatleast1hourbeforeor2hoursafterdairyproducts TRIANGLE Eltrombopag:dairyproductspossiblyreduceabsorptionofELTROMBOPAG(giveatleast4hoursapart)DalteparinseeHeparinsDanaparoidlAnalgesics:increasedriskofhaemorrhagewhenanticoagulantsgivenwithintravenouslDICLOFENAC(avoidconcomitantuse,includinglow-doseheparins);increasedriskofhaemorrhagewhenanticoagulantsgivenwithlKETOROLAC(avoidconcomitantuse,includinglow-doseheparins)lAnticoagulants:increasedriskofhaemorrhagewhenotheranticoagulantsgivenwithlAPIXABAN,lDABIGATRANandlRIVAROXABAN(avoidconcomitantuseexceptwhenswitchingwithotheranticoagulantsorusingheparintomaintaincatheterpatency)DanazollAnticoagulants:danazolinhibitsmetabolismoflCOUMARINS(enhancedanticoagulanteffect)lAntiepileptics:danazolinhibitsmetabolismoflCARBAMAZEPINE(increasedriskoftoxicity)lCiclosporin:danazolinhibitsmetabolismoflCICLOSPORIN(increasedplasmaconcentration)lLipid-regulatingDrugs:possibleincreasedriskofmyopathywhendanazolgivenwithlSIMVASTATIN—avoidconcomitantuse TRIANGLE Tacrolimus:danazolpossiblyincreasesplasmaconcentrationofTACROLIMUSDantroleneseeMuscleRelaxantsDapagliflozinseeAntidiabeticsDapoxetinelAlcohol:increasedsedativeeffectwhendapoxetinegivenwithlALCOHOLlAnalgesics:possibleincreasedriskofserotonergiceffectswhendapoxetinegivenwithlTRAMADOL(manufacturerofdapoxetineadvisestramadolshouldnotbestarteduntil1weekafterstoppingdapoxetine,avoiddapoxetinefor2weeksafterstoppingtramadol)lAntibacterials:manufacturerofdapoxetineadvisesdosereductionwhendapoxetinegivenwithCLARITHROMYCINandERYTHROMYCIN(seeunderDapoxetine,p703);manufacturerofdapoxetineadvisesavoidconcomitantusewithlTELITHROMYCIN(increasedriskoftoxicity)lAntidepressants:possibleincreasedriskofserotonergiceffectswhendapoxetinegivenwithlSSRIS,lSTJOHN’SWORT,lDULOXETINE,lTRICYCLICSandlVENLAFAXINE(manufacturerofdapoxetineadvisesSSRIs,StJohn’swort,duloxetine,tricyclicsandvenlafaxineshouldnotbestarteduntil1weekafterstoppingdapoxetine,avoiddapoxetinefor2weeksafterstoppingSSRIs,StJohn’swort,duloxetine,tricyclicsandvenlafaxine);increasedriskofserotonergiceffectswhendapoxetinegivenwithlMAOIS(MAOIsshouldnotbestarteduntil1weekafterstoppingdapoxetine,avoiddapoxetinefor2weeksafterstoppingMAOIs)lAntifungals:plasmaconcentrationofdapoxetineincreasedbylKETOCONAZOLE—manufacturerofdapoxetineadvisesavoidconcomitantuse;manufacturerofdapoxetineadvisesdosereductionwhendapoxetinegivenwithFLUCONAZOLE(seeunderDapoxetine,p703);manufacturerofdapoxetineadvisesavoidconcomitantusewithlITRACONAZOLE(increasedriskoftoxicity)lAntivirals:manufacturerofdapoxetineadvisesavoidconcomitantusewithlATAZANAVIR,lRITONAVIRandlSAQUINAVIR(increasedriskoftoxicity);manufacturerofdapoxetineadvisesdosereductionwhendapoxetinegivenwithFOSAMPRENAVIR(seeunderDapoxetine,p703) TRIANGLE Aprepitant:manufacturerofdapoxetineadvisesdosereductionwhendapoxetinegivenwithAPREPITANT(seeunderDapoxetine,p703) TRIANGLE Calcium-channelBlockers:manufacturerofdapoxetineadvisesdosereductionwhendapoxetinegivenwithDILTIAZEMandVERAPAMIL(seeunderDapoxetine,p703)l5HT1-receptorAgonists:possibleincreasedriskofserotonergiceffectswhendapoxetinegivenwithl5HT1AGONISTS(manufacturerofdapoxetineadvises5HT1agonistsshouldnotbestarteduntil1weekafterstoppingdapoxetine,avoiddapoxetinefor2weeksafterstopping5HT1agonists)lLithium:possibleincreasedriskofserotonergiceffectswhendapoxetinegivenwithlLITHIUM(manufacturerofdapoxetineadviseslithiumshouldnotbestarteduntil1weekafterstoppingdapoxetine,avoiddapoxetinefor2weeksafterstoppinglithium) TRIANGLE Sildenafil:manufacturerofdapoxetineadvisesavoidconcomitantusewithSILDENAFIL TRIANGLE Tadalafil:manufacturerofdapoxetineadvisesavoidconcomitantusewithTADALAFIL TRIANGLE Vardenafil:manufacturerofdapoxetineadvisesavoidconcomitantusewithVARDENAFILDapsone TRIANGLE Antibacterials:plasmaconcentrationofdapsonereducedbyRIFAMYCINS;plasmaconcentrationofbothdrugsmayincreasewhendapsonegivenwithTRIMETHOPRIMlAntivirals:increasedriskofventriculararrhythmiaswhendapsonegivenwithlSAQUINAVIR—avoidconcomitantuse TRIANGLE Vaccines:antibacterialsinactivateORALTYPHOIDVACCINE—seeunderTyphoidVaccineinBNFDaptomycinlCiclosporin:increasedriskofmyopathywhendaptomycingivenwithlCICLOSPORIN(preferablyavoidconcomitantuse)lLipid-regulatingDrugs:increasedriskofmyopathywhendaptomycingivenwithlFIBRATESorlSTATINS(preferablyavoidconcomitantuse)BNF70Appendix1Interactions1183Interactions|Appendix1"
"Daptomycin(continued) TRIANGLE Vaccines:antibacterialsinactivateORALTYPHOIDVACCINE—seeunderTyphoidVaccineinBNFDarifenacinseeAntimuscarinicsDarunavir TRIANGLE Anti-arrhythmics:darunavirpossiblyincreasesplasmaconcentrationofLIDOCAINE—avoidconcomitantuselAntibacterials:darunavirincreasesplasmaconcentrationoflRIFABUTIN(reducedoseofrifabutin);plasmaconcentrationofdarunavirsignificantlyreducedbylRIFAMPICIN—avoidconcomitantuse TRIANGLE Anticoagulants:avoidanceofdarunaviradvisedbymanufacturerofAPIXABANandRIVAROXABANlAntidepressants:darunavirpossiblyreducesplasmaconcentrationofPAROXETINEandSERTRALINE;plasmaconcentrationofdarunavirreducedbylSTJOHN’SWORT—avoidconcomitantuse TRIANGLE Antiepileptics:plasmaconcentrationofdarunavirpossiblyreducedbyCARBAMAZEPINE,FOSPHENYTOIN,PHENOBARBITAL,PHENYTOINandPRIMIDONE TRIANGLE Antifungals:plasmaconcentrationofbothdrugsincreasedwhendarunavirgivenwithKETOCONAZOLElAntimalarials:plasmaconcentrationoflumefantrineincreasedwhendarunavirgivenwithARTEMETHERWITHLUMEFANTRINE;darunavirpossiblyincreasesplasmaconcentrationoflQUININE(increasedriskoftoxicity)lAntipsychotics:darunavirpossiblyincreasesplasmaconcentrationoflARIPIPRAZOLE(reducedoseofaripiprazole—consultaripiprazoleproductliterature);darunavirpossiblyincreasesplasmaconcentrationoflQUETIAPINE—manufacturerofquetiapineadvisesavoidconcomitantuselAntivirals:avoidconcomitantuseofdarunavirwithlBOCEPREVIRorlTELAPREVIR;avoidanceofdarunaviradvisedbymanufacturerofDACLATASVIR(plasmaconcentrationofdaclatasvirpossiblyincreased);manufacturerofdarunaviradvisestakeDIDANOSINE1hourbeforeor2hoursafterdarunavir;plasmaconcentrationofdarunavirreducedbylEFAVIRENZ(adjustdose—consultproductliterature);plasmaconcentrationofbothdrugsincreasedwhendarunavirgivenwithINDINAVIR;plasmaconcentrationofdarunavirreducedbylLOPINAVIR,alsoplasmaconcentrationoflopinavirincreased(avoidconcomitantuse);darunavirincreasesplasmaconcentrationoflMARAVIROC(considerreducingdoseofmaraviroc);increasedriskofrashwhendarunavirgivenwithRALTEGRAVIR;plasmaconcentrationofdarunavirreducedbySAQUINAVIR;plasmaconcentrationofbothdrugsincreasedwhendarunavirgivenwithlSIMEPREVIR—manufacturerofsimepreviradvisesavoidconcomitantuselCytotoxics:darunavirpossiblyincreasestheplasmaconcentrationoflBOSUTINIB—manufacturerofbosutinibadvisesavoidorconsiderreducingdoseofbosutinib;darunavirpossiblyincreasesplasmaconcentrationoflEVEROLIMUS—manufacturerofeverolimusadvisesavoidconcomitantuse;darunavirpossiblyincreasestheplasmaconcentrationoflIBRUTINIB—reducedoseofibrutinib(seeunderIbrutinib,p809)lErgotAlkaloids:increasedriskofergotismwhendarunavirgivenwithlERGOTALKALOIDS—manufacturerofdarunaviradvisesavoidconcomitantuselLipid-regulatingDrugs:possibleincreasedriskofmyopathywhendarunavirgivenwithATORVASTATIN;darunavirpossiblyincreasesplasmaconcentrationofPRAVASTATIN;darunavirincreasesplasmaconcentrationoflROSUVASTATIN—adjustdoseofrosuvastatin(consultproductliterature);avoidanceofdarunaviradvisedbymanufactureroflLOMITAPIDE(plasmaconcentrationoflomitapidepossiblyincreased)lOrlistat:absorptionofdarunavirpossiblyreducedbylORLISTATlRanolazine:darunavirpossiblyincreasesplasmaconcentrationoflRANOLAZINE—manufacturerofranolazineadvisesavoidconcomitantuseDasatiniblAntibacterials:manufacturerofdasatinibadvisesavoidconcomitantusewithCLARITHROMYCIN,ERYTHROMYCINandDasatiniblAntibacterials(continued)TELITHROMYCIN(plasmaconcentrationofdasatinibpossiblyincreased);metabolismofdasatinibacceleratedbylRIFAMPICIN(reducedplasmaconcentration—avoidconcomitantuse) TRIANGLE Antiepileptics:manufacturerofdasatinibadvisesavoidconcomitantusewithCARBAMAZEPINE,FOSPHENYTOIN,PHENOBARBITAL,PHENYTOINandPRIMIDONE(plasmaconcentrationofdasatinibpossiblyreduced) TRIANGLE Antifungals:plasmaconcentrationofdasatinibpossiblyincreasedbyKETOCONAZOLE;manufacturerofdasatinibadvisesavoidconcomitantusewithITRACONAZOLE(plasmaconcentrationofdasatinibpossiblyincreased)lAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lAntivirals:avoidanceofdasatinibadvisedbymanufactureroflBOCEPREVIR;manufacturerofdasatinibadvisesavoidconcomitantusewithRITONAVIR(plasmaconcentrationofdasatinibpossiblyincreased) TRIANGLE GrapefruitJuice:manufacturerofdasatinibadvisesavoidconcomitantusewithGRAPEFRUITJUICE(plasmaconcentrationofdasatinibpossiblyincreased) TRIANGLE Lipid-regulatingDrugs:dasatinibpossiblyincreasesplasmaconcentrationofSIMVASTATIN TRIANGLE Ulcer-healingDrugs:plasmaconcentrationofdasatinibpossiblyreducedbyFAMOTIDINEDecitabinelAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)DeferasiroxlAminophylline:deferasiroxincreasesplasmaconcentrationoflAMINOPHYLLINE(considerreducingdoseofaminophylline) TRIANGLE Antacids:absorptionofdeferasiroxpossiblyreducedbyANTACIDScontainingaluminium(manufacturerofdeferasiroxadvisesavoidconcomitantuse) TRIANGLE Antibacterials:plasmaconcentrationofdeferasiroxreducedbyRIFAMPICIN TRIANGLE Antidiabetics:deferasiroxincreasesplasmaconcentrationofREPAGLINIDE TRIANGLE Antipsychotics:manufacturerofdeferasiroxadvisesavoidconcomitantusewithCLOZAPINE TRIANGLE AnxiolyticsandHypnotics:deferasiroxpossiblyreducesplasmaconcentrationofMIDAZOLAM TRIANGLE MuscleRelaxants:manufacturerofdeferasiroxadvisesavoidconcomitantusewithTIZANIDINElTheophylline:deferasiroxincreasesplasmaconcentrationoflTHEOPHYLLINE(considerreducingdoseoftheophylline)Deferiprone TRIANGLE Antacids:absorptionofdeferipronepossiblyreducedbyANTACIDScontainingaluminium(manufacturerofdeferiproneadvisesavoidconcomitantuse)DeflazacortseeCorticosteroidsDelamanidlAnalgesics:increasedriskofventriculararrhythmiaswhendelamanidgivenwithlMETHADONElAnti-arrhythmics:increasedriskofventriculararrhythmiaswhendelamanidgivenwithlAMIODARONEorlDISOPYRAMIDElAntibacterials:possibleincreasedriskofventriculararrhythmiaswhendelamanidgivenwithlCLARITHROMYCINandlERYTHROMYCIN;increasedriskofventriculararrhythmiaswhendelamanidgivenwithlMOXIFLOXACIN;plasmaconcentrationofdelamanidreducedbylRIFAMPICIN;delamanidincreasesplasmaconcentrationofETHAMBUTOLlAntidepressants:possibleincreasedriskofventriculararrhythmiaswhendelamanidgivenwithlTRICYCLICSthatprolongtheQTinterval TRIANGLE Antiepileptics:manufacturerofdelamanidadvisesavoidconcomitantusewithCARBAMAZEPINElAntipsychotics:increasedriskofventriculararrhythmiaswhendelamanidgivenwithlDROPERIDOL,lHALOPERIDOLorlPIMOZIDE;increasedriskofventriculararrhythmiaswhendelamanidgivenwithlPHENOTHIAZINESthatprolongtheQTinterval1184Appendix1InteractionsBNF70Interactions|Appendix1"
"Delamanid(continued)lAntivirals:plasmaconcentrationofdelamanidincreasedbyLOPINAVIRandRITONAVIR;increasedriskofventriculararrhythmiaswhendelamanidgivenwithlSAQUINAVIRlBeta-blockers:increasedriskofventriculararrhythmiaswhendelamanidgivenwithlSOTALOLlCytotoxics:increasedriskofventriculararrhythmiaswhendelamanidgivenwithlARSENICTRIOXIDEorlVINFLUNINE;possibleincreasedriskofventriculararrhythmiaswhendelamanidgivenwithlVINBLASTINE,lVINCRISTINE,lVINDESINEandlVINORELBINElDomperidone:possibleincreasedriskofventriculararrhythmiaswhendelamanidgivenwithlDOMPERIDONElPentamidineIsetionate:increasedriskofventriculararrhythmiaswhendelamanidgivenwithlPENTAMIDINEISETIONATE TRIANGLE Vaccines:antibacterialsinactivateORALTYPHOIDVACCINE—seeunderTyphoidVaccineinBNFDemeclocyclineseeTetracyclinesDesferrioxamine TRIANGLE Antipsychotics:avoidanceofdesferrioxamineadvisedbymanufacturerofLEVOMEPROMAZINE;manufacturerofdesferrioxamineadvisesavoidconcomitantusewithPROCHLORPERAZINEDesfluraneseeAnaesthetics,GeneralDesloratadineseeAntihistaminesDesmopressin TRIANGLE Analgesics:effectsofdesmopressinenhancedbyINDOMETACIN TRIANGLE Loperamide:plasmaconcentrationoforaldesmopressinincreasedbyLOPERAMIDEDesogestrelseeProgestogensDexamethasoneseeCorticosteroidsDexamfetamineseeSympathomimeticsDexibuprofenseeNSAIDsDexketoprofenseeNSAIDsDexrazoxanelAntiepileptics:dexrazoxanepossiblyreducesabsorptionoflFOSPHENYTOINandlPHENYTOIN TRIANGLE Ciclosporin:manufacturerofdexrazoxaneadvisesincreasedriskofimmunosuppressionwithCICLOSPORIN TRIANGLE Tacrolimus:manufacturerofdexrazoxaneadvisesincreasedriskofimmunosuppressionwithTACROLIMUSlVaccines:riskofgeneralisedinfectionswhendexrazoxanegivenwithlivelVACCINES—avoidconcomitantuseDextromethorphanseeOpioidAnalgesicsDextropropoxypheneseeOpioidAnalgesicsDiamorphineseeOpioidAnalgesicsDiazepamseeAnxiolyticsandHypnoticsDiazoxide TRIANGLE ACEInhibitors:enhancedhypotensiveeffectwhendiazoxidegivenwithACEINHIBITORS TRIANGLE AdrenergicNeuroneBlockers:enhancedhypotensiveeffectwhendiazoxidegivenwithADRENERGICNEURONEBLOCKERS TRIANGLE Alcohol:enhancedhypotensiveeffectwhendiazoxidegivenwithALCOHOL TRIANGLE Aldesleukin:enhancedhypotensiveeffectwhendiazoxidegivenwithALDESLEUKIN TRIANGLE Alpha-blockers:enhancedhypotensiveeffectwhendiazoxidegivenwithALPHA-BLOCKERS TRIANGLE Anaesthetics,General:enhancedhypotensiveeffectwhendiazoxidegivenwithGENERALANAESTHETICS TRIANGLE Analgesics:hypotensiveeffectofdiazoxideantagonisedbyNSAIDS TRIANGLE Angiotensin-IIReceptorAntagonists:enhancedhypotensiveeffectwhendiazoxidegivenwithANGIOTENSIN-IIRECEPTORANTAGONISTS TRIANGLE Antidepressants:enhancedhypotensiveeffectwhendiazoxidegivenwithMAOISorTRICYCLIC-RELATEDANTIDEPRESSANTS TRIANGLE Antidiabetics:diazoxideantagoniseshypoglycaemiceffectofANTIDIABETICS TRIANGLE Antiepileptics:diazoxidereducesplasmaconcentrationofFOSPHENYTOINandPHENYTOIN,alsoeffectofdiazoxidemaybereduced TRIANGLE Antipsychotics:enhancedhypotensiveeffectwhendiazoxidegivenwithPHENOTHIAZINESDiazoxide(continued) TRIANGLE AnxiolyticsandHypnotics:enhancedhypotensiveeffectwhendiazoxidegivenwithANXIOLYTICSANDHYPNOTICS TRIANGLE Beta-blockers:enhancedhypotensiveeffectwhendiazoxidegivenwithBETA-BLOCKERS TRIANGLE Calcium-channelBlockers:enhancedhypotensiveeffectwhendiazoxidegivenwithCALCIUM-CHANNELBLOCKERS TRIANGLE Clonidine:enhancedhypotensiveeffectwhendiazoxidegivenwithCLONIDINE TRIANGLE Corticosteroids:hypotensiveeffectofdiazoxideantagonisedbyCORTICOSTEROIDS TRIANGLE Diuretics:enhancedhypotensiveandhyperglycaemiceffectswhendiazoxidegivenwithDIURETICS TRIANGLE Dopaminergics:enhancedhypotensiveeffectwhendiazoxidegivenwithCO-BENELDOPA,CO-CARELDOPAorLEVODOPA TRIANGLE Methyldopa:enhancedhypotensiveeffectwhendiazoxidegivenwithMETHYLDOPA TRIANGLE Moxisylyte:enhancedhypotensiveeffectwhendiazoxidegivenwithMOXISYLYTE TRIANGLE Moxonidine:enhancedhypotensiveeffectwhendiazoxidegivenwithMOXONIDINE TRIANGLE MuscleRelaxants:enhancedhypotensiveeffectwhendiazoxidegivenwithBACLOFENorTIZANIDINE TRIANGLE Nitrates:enhancedhypotensiveeffectwhendiazoxidegivenwithNITRATES TRIANGLE Prostaglandins:enhancedhypotensiveeffectwhendiazoxidegivenwithALPROSTADIL TRIANGLE VasodilatorAntihypertensives:enhancedhypotensiveeffectwhendiazoxidegivenwithHYDRALAZINE,MINOXIDILorSODIUMNITROPRUSSIDEDiclofenacseeNSAIDsDicycloverineseeAntimuscarinicsDidanosineNOTEAntacidsintabletformulationmightaffectabsorptionofotherdrugs—giveatleast2hoursapartlAllopurinol:plasmaconcentrationofdidanosineincreasedbylALLOPURINOL(riskoftoxicity)—avoidconcomitantuse TRIANGLE Analgesics:plasmaconcentrationofdidanosinepossiblyreducedbyMETHADONE TRIANGLE Antibacterials:manufacturerofnorfloxacinadvisesgivedidanosineatleast2hoursbeforeorafterNORFLOXACINlAntivirals:didanosinetabletsreduceabsorptionofATAZANAVIR(giveatleast2hoursbeforeor1hourafterdidanosinetablets);manufacturerofdarunaviradvisestakedidanosine1hourbeforeor2hoursafterDARUNAVIR;plasmaconcentrationofdidanosinepossiblyincreasedbyGANCICLOVIRandVALGANCICLOVIR;didanosinetabletsreduceabsorptionofINDINAVIR(giveatleast1hourapart);increasedriskofside-effectswhendidanosinegivenwithlRIBAVIRIN—avoidconcomitantuse;manufacturerofrilpivirineadvisesgivedidanosine2hoursbeforeor4hoursafterRILPIVIRINE;manufacturerofritonaviradvisesdidanosineandRITONAVIRshouldbetaken25hoursapart;increasedriskofside-effectswhendidanosinegivenwithlSTAVUDINE;plasmaconcentrationofdidanosineincreasedbylTENOFOVIR(increasedriskoftoxicity)—avoidconcomitantuse;plasmaconcentrationofdidanosinereducedbyTIPRANAVIR—manufactureroftipranaviradvisestipranaviranddidanosinecapsulesshouldbetakenatleast2hoursapartlCytotoxics:increasedriskoftoxicitywhendidanosinegivenwithlHYDROXYCARBAMIDE—avoidconcomitantuselOrlistat:absorptionofdidanosinepossiblyreducedbylORLISTATDienogestseeProgestogensDiethylcarbamazine TRIANGLE Antacids:excretionofdiethylcarbamazineincreasedbySODIUMBICARBONATEDigoxinseeCardiacGlycosidesDihydrocodeineseeOpioidAnalgesicsDihydrotachysterolseeVitaminsDiltiazemseeCalcium-channelBlockersDimethylsulfoxidelAnalgesics:avoidconcomitantuseofdimethylsulfoxidewithlSULINDACDinoprostoneseeProstaglandinsBNF70Appendix1Interactions1185Interactions|Appendix1"
"DiphenoxylateseeOpioidAnalgesicsDiphtheriaVaccinesseeVaccinesDipipanoneseeOpioidAnalgesicsDipyridamole TRIANGLE Antacids:absorptionofdipyridamolepossiblyreducedbyANTACIDSlAnti-arrhythmics:dipyridamoleenhancesandextendseffectoflADENOSINE(importantriskoftoxicity)—reducedoseofadenosine,seep87lAnticoagulants:antiplateletactionofdipyridamoleenhancesanticoagulanteffectoflCOUMARINSandlPHENINDIONE;dipyridamoleenhancesanticoagulanteffectofHEPARINS TRIANGLE Clopidogrel:increasedriskofbleedingwhendipyridamolegivenwithCLOPIDOGREL TRIANGLE Cytotoxics:dipyridamolepossiblyreduceseffectsofFLUDARABINEDisopyramide TRIANGLE Anaesthetics,Local:increasedmyocardialdepressionwhenanti-arrhythmicsgivenwithBUPIVACAINE,LEVOBUPIVACAINE,PRILOCAINEorROPIVACAINElAnti-arrhythmics:increasedmyocardialdepressionwhenanti-arrhythmicsgivenwithotherlANTI-ARRHYTHMICS;increasedriskofventriculararrhythmiaswhendisopyramidegivenwithlAMIODARONEorlDRONEDARONE—avoidconcomitantuselAntibacterials:plasmaconcentrationofdisopyramidepossiblyincreasedbylAZITHROMYCIN(increasedriskoftoxicity);plasmaconcentrationofdisopyramidepossiblyincreasedbylCLARITHROMYCIN(increasedriskofventriculararrhythmias);plasmaconcentrationofdisopyramideincreasedbylERYTHROMYCIN(increasedriskoftoxicity);increasedriskofventriculararrhythmiaswhendisopyramidegivenwithlMOXIFLOXACIN—avoidconcomitantuse;increasedriskofventriculararrhythmiaswhendisopyramidegivenwithlDELAMANID;metabolismofdisopyramideacceleratedbylRIFAMYCINS(reducedplasmaconcentration);possibleincreasedriskofventriculararrhythmiaswhendisopyramidegivenwithlTELITHROMYCIN TRIANGLE Anticoagulants:disopyramidemayenhanceorreduceanticoagulanteffectofWARFARINlAntidepressants:avoidanceofdisopyramideadvisedbymanufactureroflCITALOPRAMandlESCITALOPRAM(riskofventriculararrhythmias);increasedriskofventriculararrhythmiaswhendisopyramidegivenwithlTRICYCLICS TRIANGLE Antidiabetics:disopyramidepossiblyenhanceshypoglycaemiceffectofGLICLAZIDE,INSULINandMETFORMIN TRIANGLE Antiepileptics:plasmaconcentrationofdisopyramidereducedbyFOSPHENYTOINandPHENYTOIN;metabolismofdisopyramideacceleratedbyPHENOBARBITALandPRIMIDONE(reducedplasmaconcentration)lAntifungals:increasedriskofventriculararrhythmiaswhendisopyramidegivenwithlKETOCONAZOLE—avoidconcomitantuse;avoidanceofdisopyramideadvisedbymanufactureroflITRACONAZOLElAntihistamines:increasedriskofventriculararrhythmiaswhendisopyramidegivenwithlMIZOLASTINE—avoidconcomitantuselAntimalarials:avoidanceofdisopyramideadvisedbymanufactureroflARTEMETHERWITHLUMEFANTRINE(riskofventriculararrhythmias);avoidanceofdisopyramideadvisedbymanufactureroflARTENIMOLWITHPIPERAQUINE(possibleriskofventriculararrhythmias)lAntimuscarinics:increasedriskofantimuscarinicside-effectswhendisopyramidegivenwithANTIMUSCARINICS;increasedriskofventriculararrhythmiaswhendisopyramidegivenwithlTOLTERODINElAntipsychotics:increasedriskofventriculararrhythmiaswhenanti-arrhythmicsthatprolongtheQTintervalgivenwithlANTIPSYCHOTICSthatprolongtheQTinterval;increasedriskofventriculararrhythmiaswhendisopyramidegivenwithlAMISULPRIDE,lDROPERIDOL,lPIMOZIDEorlZUCLOPENTHIXOL—avoidconcomitantuse;possibleincreasedriskofventriculararrhythmiaswhendisopyramidegivenwithlHALOPERIDOL—avoidconcomitantuse;increasedriskofventriculararrhythmiaswhendisopyramidegivenwithlPHENOTHIAZINESorlSULPIRIDEDisopyramide(continued)lAntivirals:plasmaconcentrationofdisopyramidepossiblyincreasedbylRITONAVIR(increasedriskoftoxicity);increasedriskofventriculararrhythmiaswhendisopyramidegivenwithlSAQUINAVIR—avoidconcomitantuse;avoidanceofdisopyramideadvisedbymanufactureroflTELAPREVIR(riskofventriculararrhythmias)lAtomoxetine:increasedriskofventriculararrhythmiaswhendisopyramidegivenwithlATOMOXETINElBeta-blockers:increasedmyocardialdepressionwhenanti-arrhythmicsgivenwithlBETA-BLOCKERS;increasedriskofventriculararrhythmiaswhendisopyramidegivenwithlSOTALOL—avoidconcomitantuselCalcium-channelBlockers:increasedriskofmyocardialdepressionandasystolewhendisopyramidegivenwithlVERAPAMILlCytotoxics:possibleincreasedriskofventriculararrhythmiaswhendisopyramidegivenwithlBOSUTINIB;possibleincreasedriskofventriculararrhythmiaswhendisopyramidegivenwithlVANDETANIB—avoidconcomitantuse;increasedriskofventriculararrhythmiaswhendisopyramidegivenwithlARSENICTRIOXIDElDiuretics:increasedcardiactoxicitywithdisopyramideifhypokalaemiaoccurswithlACETAZOLAMIDE,lLOOPDIURETICSorlTHIAZIDESANDRELATEDDIURETICSlFingolimod:possibleincreasedriskofbradycardiawhendisopyramidegivenwithlFINGOLIMODlIvabradine:increasedriskofventriculararrhythmiaswhendisopyramidegivenwithlIVABRADINE TRIANGLE Nitrates:disopyramidereduceseffectsofsublingualtabletsofNITRATES(failuretodissolveundertongueowingtodrymouth)lPentamidineIsetionate:possibleincreasedriskofventriculararrhythmiaswhendisopyramidegivenwithlPENTAMIDINEISETIONATElRanolazine:avoidanceofdisopyramideadvisedbymanufactureroflRANOLAZINE TRIANGLE Sildenafil:manufacturerofdisopyramideadvisesavoidconcomitantusewithSILDENAFIL(riskofventriculararrhythmias) TRIANGLE Tadalafil:manufacturerofdisopyramideadvisesavoidconcomitantusewithTADALAFIL(riskofventriculararrhythmias) TRIANGLE Vardenafil:manufacturerofdisopyramideadvisesavoidconcomitantusewithVARDENAFIL(riskofventriculararrhythmias)Disulfiram TRIANGLE Alcohol:disulfiramreactionwhendisulfiramgivenwithALCOHOL TRIANGLE Aminophylline:disulfiraminhibitsmetabolismofAMINOPHYLLINE(increasedriskoftoxicity) TRIANGLE Antibacterials:psychoticreactionreportedwhendisulfiramgivenwithMETRONIDAZOLE;CNSeffectsofdisulfirampossiblyincreasedbyISONIAZIDlAnticoagulants:disulfiramenhancesanticoagulanteffectoflCOUMARINS TRIANGLE Antidepressants:increaseddisulfiramreactionwithalcoholreportedwithconcomitantAMITRIPTYLINE;disulfiraminhibitsmetabolismofTRICYCLICS(increasedplasmaconcentration)lAntiepileptics:disulfiraminhibitsmetabolismoflFOSPHENYTOINandlPHENYTOIN(increasedriskoftoxicity) TRIANGLE AnxiolyticsandHypnotics:disulfiramincreasesriskofTEMAZEPAMtoxicity;disulfiraminhibitsmetabolismofBENZODIAZEPINES(increasedsedativeeffects)lParaldehyde:riskoftoxicitywhendisulfiramgivenwithlPARALDEHYDE TRIANGLE Theophylline:disulfiraminhibitsmetabolismofTHEOPHYLLINE(increasedriskoftoxicity)DiureticsNOTESincesystemicabsorptionmayfollowtopicalapplicationofbrinzolamidetotheeye,thepossibilityofinteractionsshouldbeborneinmindNOTESincesystemicabsorptionmayfollowtopicalapplicationofdorzolamidetotheeye,thepossibilityofinteractionsshouldbeborneinmind1186Appendix1InteractionsBNF70Interactions|Appendix1"
"Diuretics(continued)lACEInhibitors:enhancedhypotensiveeffectwhendiureticsgivenwithlACEINHIBITORS;increasedriskofseverehyperkalaemiawhenpotassium-sparingdiureticsandaldosteroneantagonistsgivenwithlACEINHIBITORS TRIANGLE AdrenergicNeuroneBlockers:enhancedhypotensiveeffectwhendiureticsgivenwithADRENERGICNEURONEBLOCKERS TRIANGLE Alcohol:enhancedhypotensiveeffectwhendiureticsgivenwithALCOHOL TRIANGLE Aldesleukin:enhancedhypotensiveeffectwhendiureticsgivenwithALDESLEUKIN TRIANGLE Aliskiren:plasmaconcentrationoffurosemidereducedbyALISKIREN;increasedriskofhyperkalaemiawhenpotassium-sparingdiureticsandaldosteroneantagonistsgivenwithALISKIREN TRIANGLE Allopurinol:increasedriskofhypersensitivitywhenthiazidesandrelateddiureticsgivenwithALLOPURINOLespeciallyinrenalimpairmentlAlpha-blockers:enhancedhypotensiveeffectwhendiureticsgivenwithlALPHA-BLOCKERS,alsoincreasedriskoffirst-dosehypotensionwithpost-synapticalpha-blockerssuchasprazosin TRIANGLE Aminophylline:increasedriskofhypokalaemiawhenacetazolamide,loopdiureticsorthiazidesandrelateddiureticsgivenwithAMINOPHYLLINE TRIANGLE Anaesthetics,General:enhancedhypotensiveeffectwhendiureticsgivenwithGENERALANAESTHETICSlAnalgesics:diureticsincreaseriskofnephrotoxicityofNSAIDS,alsoantagonismofdiureticeffect;diureticeffectofpotassiumcanrenoatepossiblyantagonisedbyNSAIDS;possibleincreasedriskofhyperkalaemiawhenpotassium-sparingdiureticsandaldosteroneantagonistsgivenwithNSAIDS;furosemidepossiblyincreasestheexcretionofACEMETACIN;effectsofdiureticsantagonisedbyINDOMETACINandKETOROLAC;increasedriskofhyperkalaemiawhenpotassium-sparingdiureticsandaldosteroneantagonistsgivenwithINDOMETACIN;occasionalreportsofreducedrenalfunctionwhentriamterenegivenwithlINDOMETACIN—avoidconcomitantuse;increasedriskoftoxicitywhenacetazolamidegivenwithhigh-doselASPIRIN;diureticeffectofspironolactoneantagonisedbyASPIRIN;possibleincreasedriskoftoxicitywhenloopdiureticsgivenwithhigh-doseASPIRIN(alsopossiblereducedeffectofloopdiuretics)lAngiotensin-IIReceptorAntagonists:enhancedhypotensiveeffectwhendiureticsgivenwithlANGIOTENSIN-IIRECEPTORANTAGONISTS;increasedriskofhyperkalaemiawhenpotassium-sparingdiureticsandaldosteroneantagonistsgivenwithlANGIOTENSIN-IIRECEPTORANTAGONISTSlAnti-arrhythmics:hypokalaemiacausedbyacetazolamide,loopdiureticsorthiazidesandrelateddiureticsincreasescardiactoxicitywithAMIODARONE;plasmaconcentrationofeplerenoneincreasedbyAMIODARONE(reducedoseofeplerenone);hypokalaemiacausedbyacetazolamide,loopdiureticsorthiazidesandrelateddiureticsincreasescardiactoxicitywithlDISOPYRAMIDE;hypokalaemiacausedbyacetazolamide,loopdiureticsorthiazidesandrelateddiureticsincreasescardiactoxicitywithlFLECAINIDE;hypokalaemiacausedbyacetazolamide,loopdiureticsorthiazidesandrelateddiureticsantagonisesactionoflLIDOCAINElAntibacterials:plasmaconcentrationofeplerenoneincreasedbylCLARITHROMYCINandlTELITHROMYCIN—avoidconcomitantuse;plasmaconcentrationofeplerenoneincreasedbyERYTHROMYCIN(reducedoseofeplerenone);plasmaconcentrationofeplerenonereducedbylRIFAMPICIN—avoidconcomitantuse;avoidanceofdiureticsadvisedbymanufacturerofLYMECYCLINE;increasedriskofotoxicitywhenloopdiureticsgivenwithlAMINOGLYCOSIDES,lPOLYMYXINSorlVANCOMYCIN;acetazolamideantagoniseseffectsoflMETHENAMINE;possibleincreasedriskofhyperkalaemiawhenspironolactonegivenwithTRIMETHOPRIM;increasedriskofhyperkalaemiawheneplerenonegivenwithTRIMETHOPRIMlAntidepressants:possibleincreasedriskofhypokalaemiawhenloopdiureticsorthiazidesandrelateddiureticsgivenwithREBOXETINE;enhancedhypotensiveeffectwhendiureticsDiureticslAntidepressants(continued)givenwithMAOIS;plasmaconcentrationofeplerenonereducedbylSTJOHN’SWORT—avoidconcomitantuse;increasedriskofposturalhypotensionwhendiureticsgivenwithTRICYCLICS TRIANGLE Antidiabetics:loopdiureticsandthiazidesandrelateddiureticsantagonisehypoglycaemiceffectofANTIDIABETICS;diureticeffectofdiureticspossiblyenhancedbyCANAGLIFLOZIN;avoidanceofloopdiureticsadvisedbymanufacturerofCANAGLIFLOZIN;diureticeffectofloopdiureticsandthiazidesandrelateddiureticspossiblyenhancedbyDAPAGLIFLOZINlAntiepileptics:plasmaconcentrationofeplerenonereducedbylCARBAMAZEPINE,lFOSPHENYTOIN,lPHENOBARBITAL,lPHENYTOINandlPRIMIDONE—avoidconcomitantuse;increasedriskofhyponatraemiawhendiureticsgivenwithCARBAMAZEPINE;acetazolamideincreasesplasmaconcentrationoflCARBAMAZEPINE;effectsoffurosemideantagonisedbyFOSPHENYTOINandPHENYTOIN;acetazolamidepossiblyincreasesplasmaconcentrationoflFOSPHENYTOINandlPHENYTOIN;increasedriskofosteomalaciawhencarbonicanhydraseinhibitorsgivenwithFOSPHENYTOIN,PHENOBARBITAL,PHENYTOINorPRIMIDONE;hydrochlorothiazidepossiblyincreasesplasmaconcentrationofTOPIRAMATE;avoidanceofcarbonicanhydraseinhibitorsinchildrenadvisedbymanufacturerofZONISAMIDElAntifungals:plasmaconcentrationofeplerenoneincreasedbylITRACONAZOLEandlKETOCONAZOLE—avoidconcomitantuse;increasedriskofhypokalaemiawhenloopdiureticsorthiazidesandrelateddiureticsgivenwithAMPHOTERICIN;hydrochlorothiazideincreasesplasmaconcentrationofFLUCONAZOLE;plasmaconcentrationofeplerenoneincreasedbyFLUCONAZOLE(reducedoseofeplerenone)lAntipsychotics:hypokalaemiacausedbydiureticsincreasesriskofventriculararrhythmiaswithlAMISULPRIDE;enhancedhypotensiveeffectwhendiureticsgivenwithPHENOTHIAZINES;hypokalaemiacausedbydiureticsincreasesriskofventriculararrhythmiaswithlPIMOZIDE(avoidconcomitantuse)lAntivirals:plasmaconcentrationofeplerenoneincreasedbylRITONAVIR—avoidconcomitantuse;plasmaconcentrationofeplerenoneincreasedbySAQUINAVIR(reducedoseofeplerenone) TRIANGLE AnxiolyticsandHypnotics:enhancedhypotensiveeffectwhendiureticsgivenwithANXIOLYTICSANDHYPNOTICS;administrationofparenteralfurosemidewithCHLORALmaydisplacethyroidhormonefrombindingsiteslAtomoxetine:hypokalaemiacausedbydiureticsincreasesriskofventriculararrhythmiaswithlATOMOXETINElBeta-blockers:enhancedhypotensiveeffectwhendiureticsgivenwithBETA-BLOCKERS;hypokalaemiacausedbyloopdiureticsorthiazidesandrelateddiureticsincreasesriskofventriculararrhythmiaswithlSOTALOL TRIANGLE CalciumSalts:increasedriskofhypercalcaemiawhenthiazidesandrelateddiureticsgivenwithCALCIUMSALTS TRIANGLE Calcium-channelBlockers:enhancedhypotensiveeffectwhendiureticsgivenwithCALCIUM-CHANNELBLOCKERS;plasmaconcentrationofeplerenoneincreasedbyDILTIAZEMandVERAPAMIL(reducedoseofeplerenone)lCardiacGlycosides:hypokalaemiacausedbyacetazolamide,loopdiureticsorthiazidesandrelateddiureticsincreasescardiactoxicitywithlCARDIACGLYCOSIDES;spironolactoneincreasesplasmaconcentrationoflDIGOXIN;potassiumcanrenoatepossiblyincreasesplasmaconcentrationofDIGOXINlCiclosporin:increasedriskofnephrotoxicityandpossiblyhypermagnesaemiawhenthiazidesandrelateddiureticsgivenwithCICLOSPORIN;increasedriskofhyperkalaemiawhenpotassium-sparingdiureticsandaldosteroneantagonistsgivenwithlCICLOSPORIN;acetazolamidepossiblyincreasesplasmaconcentrationoflCICLOSPORIN TRIANGLE Clonidine:enhancedhypotensiveeffectwhendiureticsgivenwithCLONIDINE TRIANGLE Corticosteroids:diureticeffectofdiureticsantagonisedbyCORTICOSTEROIDS;increasedriskofhypokalaemiawhenBNF70Appendix1Interactions1187Interactions|Appendix1"
"DiureticsCorticosteroids(continued)acetazolamide,loopdiureticsorthiazidesandrelateddiureticsgivenwithCORTICOSTEROIDSlCytotoxics:alkalineurineduetoacetazolamideincreasesexceretionofMETHOTREXATE;hypokalaemiacausedbyacetazolamide,loopdiureticsorthiazidesandrelateddiureticsincreasesriskofventriculararrhythmiaswithlARSENICTRIOXIDE;avoidanceofspironolactoneadvisedbymanufacturerofMITOTANE(antagonismofeffect);increasedriskofnephrotoxicityandototoxicitywhendiureticsgivenwithPLATINUMCOMPOUNDS TRIANGLE Diazoxide:enhancedhypotensiveandhyperglycaemiceffectswhendiureticsgivenwithDIAZOXIDE TRIANGLE Diuretics:increasedriskofhypokalaemiawhenloopdiureticsorthiazidesandrelateddiureticsgivenwithACETAZOLAMIDE;profounddiuresispossiblewhenmetolazonegivenwithFUROSEMIDE;increasedriskofhypokalaemiawhenthiazidesandrelateddiureticsgivenwithLOOPDIURETICS TRIANGLE Dopaminergics:enhancedhypotensiveeffectwhendiureticsgivenwithCO-BENELDOPA,CO-CARELDOPAorLEVODOPA TRIANGLE HormoneAntagonists:increasedriskofhypercalcaemiawhenthiazidesandrelateddiureticsgivenwithTOREMIFENE TRIANGLE Lipid-regulatingDrugs:absorptionofthiazidesandrelateddiureticsreducedbyCOLESTIPOLandCOLESTYRAMINE(giveatleast2hoursapart)lLithium:loopdiureticsandthiazidesandrelateddiureticsreduceexcretionoflLITHIUM(increasedplasmaconcentrationandriskoftoxicity)—loopdiureticssaferthanthiazides;potassium-sparingdiureticsandaldosteroneantagonistsreduceexcretionoflLITHIUM(increasedplasmaconcentrationandriskoftoxicity);acetazolamideincreasestheexcretionoflLITHIUM TRIANGLE Methyldopa:enhancedhypotensiveeffectwhendiureticsgivenwithMETHYLDOPA TRIANGLE Moxisylyte:enhancedhypotensiveeffectwhendiureticsgivenwithMOXISYLYTE TRIANGLE Moxonidine:enhancedhypotensiveeffectwhendiureticsgivenwithMOXONIDINE TRIANGLE MuscleRelaxants:enhancedhypotensiveeffectwhendiureticsgivenwithBACLOFENorTIZANIDINE TRIANGLE Nitrates:enhancedhypotensiveeffectwhendiureticsgivenwithNITRATES TRIANGLE Oestrogens:diureticeffectofdiureticsantagonisedbyOESTROGENSlPotassiumSalts:increasedriskofhyperkalaemiawhenpotassium-sparingdiureticsandaldosteroneantagonistsgivenwithlPOTASSIUMSALTS TRIANGLE Progestogens:riskofhyperkalaemiawhenpotassium-sparingdiureticsandaldosteroneantagonistsgivenwithDROSPIRENONE(monitorserumpotassiumduringfirstcycle) TRIANGLE Prostaglandins:enhancedhypotensiveeffectwhendiureticsgivenwithALPROSTADIL TRIANGLE Sympathomimetics,Beta2:increasedriskofhypokalaemiawhenacetazolamide,loopdiureticsorthiazidesandrelateddiureticsgivenwithhighdosesofBETA2SYMPATHOMIMETICSlTacrolimus:increasedriskofhyperkalaemiawhenpotassium-sparingdiureticsandaldosteroneantagonistsgivenwithlTACROLIMUS TRIANGLE Theophylline:increasedriskofhypokalaemiawhenacetazolamide,loopdiureticsorthiazidesandrelateddiureticsgivenwithTHEOPHYLLINE TRIANGLE VasodilatorAntihypertensives:enhancedhypotensiveeffectwhendiureticsgivenwithHYDRALAZINE,MINOXIDILorSODIUMNITROPRUSSIDE TRIANGLE Vitamins:increasedriskofhypercalcaemiawhenthiazidesandrelateddiureticsgivenwithALFACALCIDOL,CALCITRIOL,COLECALCIFEROL,DIHYDROTACHYSTEROL,ERGOCALCIFEROL,PARICALCITOLorVITAMINDDiuretics,LoopseeDiureticsDiuretics,Potassium-sparingandAldosteroneAntagonistsseeDiureticsDiuretics,ThiazideandrelatedseeDiureticsDobutamineseeSympathomimeticsDocetaxellAntibacterials:plasmaconcentrationofdocetaxelpossiblyincreasedbylCLARITHROMYCINandlTELITHROMYCIN—manufacturerofdocetaxeladvisesavoidconcomitantuseorconsiderreducingdocetaxeldoselAntifungals:invitrostudiessuggestapossibleinteractionbetweendocetaxelandKETOCONAZOLE(consultdocetaxelproductliterature);plasmaconcentrationofdocetaxelpossiblyincreasedbylITRACONAZOLEandlVORICONAZOLE—manufacturerofdocetaxeladvisesavoidconcomitantuseorconsiderreducingdocetaxeldoselAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lAntivirals:plasmaconcentrationofdocetaxelpossiblyincreasedbylINDINAVIR,lRITONAVIRandlSAQUINAVIR—manufacturerofdocetaxeladvisesavoidconcomitantuseorconsiderreducingdocetaxeldose TRIANGLE Ciclosporin:invitrostudiessuggestapossibleinteractionbetweendocetaxelandCICLOSPORIN(consultdocetaxelproductliterature) TRIANGLE Cytotoxics:possibleincreasedriskofneutropeniawhendocetaxelgivenwithLAPATINIB;plasmaconcentrationofdocetaxelincreasedbySORAFENIBDolutegravir TRIANGLE Antacids:absorptionofdolutegravirreducedbyALUMINIUMHYDROXIDEandORALMAGNESIUMSALTS—manufacturerofdolutegraviradvisesgiveatleast2hoursbeforeor6hoursafteraluminiumhydroxideandoralmagnesiumsaltslAntibacterials:plasmaconcentrationofdolutegravirreducedbylRIFAMPICIN(seeunderDolutegravir,p557) TRIANGLE Antidepressants:manufacturerofdolutegraviradvisesavoidconcomitantusewithSTJOHN’SWORT TRIANGLE Antiepileptics:manufacturerofdolutegraviradvisesavoidconcomitantusewithCARBAMAZEPINE,FOSPHENYTOIN,OXCARBAZEPINE,PHENOBARBITAL,PHENYTOINandPRIMIDONElAntivirals:plasmaconcentrationofdolutegravirreducedbylEFAVIRENZ,lETRAVIRINEandlTIPRANAVIR(seeunderDolutegravir,p557);plasmaconcentrationofdolutegravirreducedbylFOSAMPRENAVIR;plasmaconcentrationofdolutegravirpossiblyreducedbylNEVIRAPINE(seeunderDolutegravir,p557) TRIANGLE CalciumSalts:absorptionofdolutegravirreducedbyCALCIUMSALTS—manufacturerofdolutegraviradvisesgiveatleast2hoursbeforeor6hoursaftercalciumsalts TRIANGLE IronSalts:absorptionofdolutegravirreducedbyoralIRONSALTS—manufacturerofdolutegraviradvisesgiveatleast2hoursbeforeor6hoursafteroralironsaltsDomperidone TRIANGLE Analgesics:effectsofdomperidoneongastro-intestinalactivityantagonisedbyOPIOIDANALGESICSlAntibacterials:possibleincreasedriskofventriculararrhythmiaswhendomperidonegivenwithlCLARITHROMYCINorlTELITHROMYCIN—avoidconcomitantuse;plasmaconcentrationofdomperidoneincreasedbylERYTHROMYCIN(increasedriskofventriculararrhythmias—avoidconcomitantuse);possibleincreasedriskofventriculararrhythmiaswhendomperidonegivenwithlDELAMANIDlAntifungals:avoidanceofdomperidoneadvisedbymanufactureroflKETOCONAZOLE(riskofventriculararrhythmias);possibleincreasedriskofventriculararrhythmiaswhendomperidonegivenwithlITRACONAZOLEorlVORICONAZOLE—avoidconcomitantuselAntimalarials:avoidanceofdomperidoneadvisedbymanufactureroflARTENIMOLWITHPIPERAQUINE(possibleriskofventriculararrhythmias) TRIANGLE Antimuscarinics:effectsofdomperidoneongastro-intestinalactivityantagonisedbyANTIMUSCARINICSlAntivirals:possibleincreasedriskofventriculararrhythmiaswhendomperidonegivenwithlBOCEPREVIR,lRITONAVIR,lSAQUINAVIRorlTELAPREVIR—avoidconcomitantuselCobicistat:possibleincreasedriskofventriculararrhythmiaswhendomperidonegivenwithlCOBICISTAT—avoidconcomitantuselCytotoxics:avoidanceofdomperidoneadvisedbymanufactureroflBOSUTINIB(riskofventriculararrhythmias)1188Appendix1InteractionsBNF70Interactions|Appendix1"
"Domperidone(continued) TRIANGLE Dopaminergics:domperidonepossiblyantagoniseshypoprolactinaemiceffectsofBROMOCRIPTINEandCABERGOLINEDonepezilseeParasympathomimeticsDopamineseeSympathomimeticsDopaminergicsseeAmantadine,Apomorphine,Bromocriptine,Cabergoline,Entacapone,Levodopa,Pergolide,Pramipexole,Quinagolide,Rasagiline,Ropinirole,Rotigotine,Selegiline,andTolcaponeDopexamineseeSympathomimeticsDorzolamideseeDiureticsDosulepinseeAntidepressants,TricyclicDoxapram TRIANGLE Aminophylline:increasedCNSstimulationwhendoxapramgivenwithAMINOPHYLLINElAnaesthetics,General:increasedriskofarrhythmiaswhendoxapramgivenwithlVOLATILELIQUIDGENERALANAESTHETICS(avoiddoxapramforatleast10minutesaftervolatileliquidgeneralanaesthetics) TRIANGLE Antidepressants:effectsofdoxapramenhancedbyMAOIS TRIANGLE Sympathomimetics:increasedriskofhypertensionwhendoxapramgivenwithSYMPATHOMIMETICS TRIANGLE Theophylline:increasedCNSstimulationwhendoxapramgivenwithTHEOPHYLLINEDoxazosinseeAlpha-blockersDoxepinseeAntidepressants,TricyclicDoxorubicinlAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis) TRIANGLE Antivirals:doxorubicinpossiblyinhibitseffectsofSTAVUDINE TRIANGLE Calcium-channelBlockers:plasmaconcentrationofdoxorubicinpossiblyincreasedbyVERAPAMIL TRIANGLE CardiacGlycosides:doxorubicinpossiblyreducesabsorptionofDIGOXINtabletslCiclosporin:increasedriskofneurotoxicitywhendoxorubicingivenwithlCICLOSPORIN TRIANGLE Cytotoxics:plasmaconcentrationofdoxorubicinincreasedbySORAFENIB TRIANGLE Ulcer-healingDrugs:plasmaconcentrationofdoxorubicinreducedbyCIMETIDINElVaccines:riskofgeneralisedinfectionswhendoxorubicingivenwithlivelVACCINES—avoidconcomitantuseDoxycyclineseeTetracyclinesDronedarone TRIANGLE Anaesthetics,Local:increasedmyocardialdepressionwhenanti-arrhythmicsgivenwithBUPIVACAINE,LEVOBUPIVACAINE,PRILOCAINEorROPIVACAINElAnti-arrhythmics:increasedmyocardialdepressionwhenanti-arrhythmicsgivenwithotherlANTI-ARRHYTHMICS;increasedriskofventriculararrhythmiaswhendronedaronegivenwithlAMIODARONEorlDISOPYRAMIDE—avoidconcomitantuselAntibacterials:manufacturerofdronedaroneadvisesavoidconcomitantusewithlCLARITHROMYCIN(riskofventriculararrhythmias);plasmaconcentrationofdronedaroneincreasedbylERYTHROMYCIN(increasedriskofventriculararrhythmias—avoidconcomitantuse);plasmaconcentrationofdronedaronereducedbylRIFAMPICIN—avoidconcomitantuse;avoidanceofdronedaroneadvisedbymanufacturerofFIDAXOMICIN;increasedriskofventriculararrhythmiaswhendronedaronegivenwithlTELITHROMYCIN—avoidconcomitantuselAnticoagulants:dronedaronepossiblyenhancesanticoagulanteffectoflCOUMARINSandlPHENINDIONE;dronedaroneincreasesplasmaconcentrationoflDABIGATRAN—avoidconcomitantuse;avoidanceofdronedaroneadvisedbymanufacturerofRIVAROXABANlAntidepressants:avoidanceofdronedaroneadvisedbymanufactureroflCITALOPRAMandlESCITALOPRAM(riskofventriculararrhythmias);plasmaconcentrationofdronedaronepossiblyreducedbylSTJOHN’SWORT—avoidconcomitantuse;manufacturerofdronedaroneadvisesavoidconcomitantusewithlTRICYCLICS(riskofventriculararrhythmias)Dronedarone(continued)lAntiepileptics:plasmaconcentrationofdronedaronepossiblyreducedbylCARBAMAZEPINE,lFOSPHENYTOIN,lPHENOBARBITAL,lPHENYTOINandlPRIMIDONE—avoidconcomitantuselAntifungals:plasmaconcentrationofdronedaroneincreasedbylKETOCONAZOLE—avoidconcomitantuse;manufacturerofdronedaroneadvisesavoidconcomitantusewithlITRACONAZOLE,lPOSACONAZOLEandlVORICONAZOLElAntipsychotics:increasedriskofventriculararrhythmiaswhenanti-arrhythmicsthatprolongtheQTintervalgivenwithlANTIPSYCHOTICSthatprolongtheQTinterval;manufacturerofdronedaroneadvisesavoidconcomitantusewithlPHENOTHIAZINES(riskofventriculararrhythmias)lAntivirals:manufacturerofdronedaroneadvisesavoidconcomitantusewithlRITONAVIR;increasedriskofventriculararrhythmiaswhendronedaronegivenwithlSAQUINAVIR—avoidconcomitantuselBeta-blockers:increasedmyocardialdepressionwhenanti-arrhythmicsgivenwithlBETA-BLOCKERS;dronedaronepossiblyincreasesplasmaconcentrationofMETOPROLOLandPROPRANOLOL;increasedriskofventriculararrhythmiaswhendronedaronegivenwithlSOTALOL—avoidconcomitantuselCalcium-channelBlockers:plasmaconcentrationofdronedaroneincreasedbylNIFEDIPINE;increasedriskofbradycardiaandmyocardialdepressionwhendronedaronegivenwithlDILTIAZEMandlVERAPAMILlCardiacGlycosides:dronedaroneincreasesplasmaconcentrationoflDIGOXIN(halvedoseofdigoxin)lCytotoxics:dronedaronepossiblyincreasestheplasmaconcentrationoflBOSUTINIB—manufacturerofbosutinibadvisesavoidorconsiderreducingdoseofbosutinib;dronedaronepossiblyincreasestheplasmaconcentrationoflIBRUTINIB—reducedoseofibrutinib(seeunderIbrutinib,p809)lFingolimod:possibleincreasedriskofbradycardiawhendronedaronegivenwithlFINGOLIMODlGrapefruitJuice:plasmaconcentrationofdronedaroneincreasedbylGRAPEFRUITJUICE—avoidconcomitantuselLipid-regulatingDrugs:dronedaronepossiblyincreasesplasmaconcentrationofATORVASTATIN;dronedaroneincreasesplasmaconcentrationoflROSUVASTATIN—adjustdoseofrosuvastatin(consultproductliterature);increasedriskofmyopathywhendronedaronegivenwithlSIMVASTATIN;avoidanceofdronedaroneadvisedbymanufactureroflLOMITAPIDE(plasmaconcentrationoflomitapidepossiblyincreased) TRIANGLE Sirolimus:manufacturerofdronedaroneadvisescautionwithSIROLIMUS TRIANGLE Tacrolimus:manufacturerofdronedaroneadvisescautionwithTACROLIMUSDroperidolseeAntipsychoticsDrospirenoneseeProgestogensDuloxetine TRIANGLE Analgesics:possibleincreasedserotonergiceffectswhenSSRI-relatedantidepressantsgivenwithFENTANYL;possibleincreasedserotonergiceffectswhenduloxetinegivenwithPETHIDINEorTRAMADOLlAntibacterials:metabolismofduloxetineinhibitedbylCIPROFLOXACIN—avoidconcomitantuselAnticoagulants:possibleincreasedriskofbleedingwhenSSRI-relatedantidepressantsgivenwithlDABIGATRANlAntidepressants:metabolismofduloxetineinhibitedbylFLUVOXAMINE—avoidconcomitantuse;possibleincreasedserotonergiceffectswhenduloxetinegivenwithSSRIS,STJOHN’SWORT,AMITRIPTYLINE,CLOMIPRAMINE,lMOCLOBEMIDEorVENLAFAXINE;duloxetineshouldnotbestarteduntil2weeksafterstoppinglMAOIS,alsoMAOIsshouldnotbestarteduntilatleast5daysafterstoppingduloxetine;afterstoppingSSRI-relatedantidepressantsdonotstartlMOCLOBEMIDEforatleast1weeklAntimalarials:avoidanceofantidepressantsadvisedbymanufactureroflARTEMETHERWITHLUMEFANTRINEandlARTENIMOLWITHPIPERAQUINEBNF70Appendix1Interactions1189Interactions|Appendix1"
"Duloxetine(continued) TRIANGLE Atomoxetine:possibleincreasedriskofconvulsionswhenantidepressantsgivenwithATOMOXETINElDapoxetine:possibleincreasedriskofserotonergiceffectswhenduloxetinegivenwithlDAPOXETINE(manufacturerofdapoxetineadvisesduloxetineshouldnotbestarteduntil1weekafterstoppingdapoxetine,avoiddapoxetinefor2weeksafterstoppingduloxetine) TRIANGLE 5HT1-receptorAgonists:possibleincreasedserotonergiceffectswhenduloxetinegivenwith5HT1AGONISTS TRIANGLE 5HT3-receptorAntagonists:possibleincreasedserotonergiceffectswhenSSRI-relatedantidepressantsgivenwith5HT3ANTAGONISTSlMethylthioninium:riskofCNStoxicitywhenSSRI-relatedantidepressantsgivenwithlMETHYLTHIONINIUM—avoidconcomitantuse(ifavoidancenotpossible,uselowestpossibledoseofmethylthioniniumandobservepatientforupto4hoursafteradministration)Dutasteride TRIANGLE Calcium-channelBlockers:plasmaconcentrationofdutasterideincreasedbyDILTIAZEMandVERAPAMILDydrogesteroneseeProgestogensEfavirenz TRIANGLE Analgesics:efavirenzreducesplasmaconcentrationofMETHADONE TRIANGLE Antibacterials:efavirenzreducesplasmaconcentrationofCLARITHROMYCIN,alsoplasmaconcentrationofactivemetaboliteofclarithromycinincreased;efavirenzreducesplasmaconcentrationofRIFABUTIN—increasedoseofrifabutin;plasmaconcentrationofefavirenzreducedbyRIFAMPICIN—increasedoseofefavirenz;efavirenzpossiblyreducesplasmaconcentrationofBEDAQUILINE—manufacturerofbedaquilineadvisesavoidconcomitantuselAnticoagulants:efavirenzpossiblyaffectsplasmaconcentrationoflCOUMARINSlAntidepressants:plasmaconcentrationofefavirenzreducedbylSTJOHN’SWORT—avoidconcomitantuse TRIANGLE Antiepileptics:plasmaconcentrationofbothdrugsreducedwhenefavirenzgivenwithCARBAMAZEPINElAntifungals:efavirenzreducesplasmaconcentrationofITRACONAZOLE,lKETOCONAZOLEandlPOSACONAZOLE;efavirenzreducesplasmaconcentrationoflVORICONAZOLE,alsoplasmaconcentrationofefavirenzincreased(increasevoriconazoledoseandreduceefavirenzdose);efavirenzpossiblyreducesplasmaconcentrationofCASPOFUNGIN—considerincreasingdoseofcaspofunginlAntimalarials:efavirenzreducesplasmaconcentrationoflARTEMETHERWITHLUMEFANTRINE;efavirenzpossiblyaffectsplasmaconcentrationofPROGUANILlAntipsychotics:efavirenzpossiblyreducesplasmaconcentrationoflARIPIPRAZOLE(avoidconcomitantuseorconsiderincreasingthedoseofaripiprazole—consultaripiprazoleproductliterature);efavirenzpossiblyincreasesplasmaconcentrationoflPIMOZIDE(increasedriskofventriculararrhythmias—avoidconcomitantuse)lAntivirals:avoidanceofefavirenzadvisedbymanufactureroflATAZANAVIR(plasmaconcentrationofatazanavirreduced);efavirenzreducestheplasmaconcentrationoflDACLATASVIR—increasedoseofdaclatasvir(seeunderDaclatasvir,p544);efavirenzreducesplasmaconcentrationoflDARUNAVIR(adjustdose—consultproductliterature);efavirenzreducestheplasmaconcentrationoflDOLUTEGRAVIR(seeunderDolutegravir,p557);avoidanceofefavirenzadvisedbymanufacturerofELVITEGRAVIR;efavirenzpossiblyreducesplasmaconcentrationoflETRAVIRINE—avoidconcomitantuse;efavirenzreducesplasmaconcentrationofINDINAVIRandSIMEPREVIR;efavirenzreducesplasmaconcentrationoflLOPINAVIR—considerincreasingdoseoflopinavir;efavirenzpossiblyreducesplasmaconcentrationoflMARAVIROC—considerincreasingdoseofmaraviroc;plasmaconcentrationofefavirenzreducedbylNEVIRAPINE—avoidconcomitantuse;toxicityofefavirenzincreasedbylRITONAVIR,monitorliverfunctiontests—manufacturerofAtripla®advisesavoidconcomitantusewithhigh-doseritonavir;efavirenzsignificantlyreducesEfavirenzlAntivirals(continued)plasmaconcentrationofSAQUINAVIR;efavirenzreducesplasmaconcentrationoflTELAPREVIR—increasedoseoftelaprevirlAnxiolyticsandHypnotics:increasedriskofprolongedsedationwhenefavirenzgivenwithlMIDAZOLAM—avoidconcomitantuselAtovaquone:efavirenzreducesplasmaconcentrationoflATOVAQUONE—avoidconcomitantuse TRIANGLE Avanafil:efavirenzpossiblyreducesplasmaconcentrationofAVANAFIL—manufacturerofavanafiladvisesavoidconcomitantuse TRIANGLE Bupropion:efavirenzacceleratesmetabolismofBUPROPION(reducedplasmaconcentration) TRIANGLE Calcium-channelBlockers:efavirenzreducesplasmaconcentrationofDILTIAZEMlCiclosporin:efavirenzpossiblyreducesplasmaconcentrationoflCICLOSPORINlCytotoxics:efavirenzpossiblyreducesplasmaconcentrationoflBOSUTINIB—manufacturerofbosutinibadvisesavoidconcomitantuselErgotAlkaloids:increasedriskofergotismwhenefavirenzgivenwithlERGOTALKALOIDS—avoidconcomitantuse TRIANGLE GrapefruitJuice:plasmaconcentrationofefavirenzpossiblyincreasedbyGRAPEFRUITJUICE TRIANGLE Lipid-regulatingDrugs:efavirenzreducesplasmaconcentrationofATORVASTATIN,PRAVASTATINandSIMVASTATINlOrlistat:absorptionofefavirenzpossiblyreducedbylORLISTATlProgestogens:efavirenzpossiblyreducescontraceptiveeffectoflPROGESTOGENSlTacrolimus:efavirenzpossiblyaffectsplasmaconcentrationoflTACROLIMUSEletriptansee5HT1-receptorAgonists(underHT)Eltrombopag TRIANGLE Antacids:absorptionofeltrombopagreducedbyANTACIDS(giveatleast4hoursapart) TRIANGLE Antivirals:plasmaconcentrationofeltrombopagpossiblyreducedbyLOPINAVIR TRIANGLE CalciumSalts:absorptionofeltrombopagpossiblyreducedbyCALCIUMSALTS(giveatleast4hoursapart) TRIANGLE DairyProducts:absorptionofeltrombopagpossiblyreducedbyDAIRYPRODUCTS(giveatleast4hoursapart) TRIANGLE IronSalts:absorptionofeltrombopagpossiblyreducedbyoralIRONSALTS(giveatleast4hoursapart)lLipid-regulatingDrugs:eltrombopagincreasesplasmaconcentrationoflROSUVASTATIN—adjustdoseofrosuvastatin(consultproductliterature) TRIANGLE Selenium:absorptionofeltrombopagpossiblyreducedbySELENIUM(giveatleast4hoursapart) TRIANGLE Zinc:absorptionofeltrombopagpossiblyreducedbyZINC(giveatleast4hoursapart)Elvitegravir TRIANGLE Antacids:absorptionofelvitegravirreducedbyALUMINIUMHYDROXIDEandORALMAGNESIUMSALTS(giveatleast4hoursapart)lAntibacterials:plasmaconcentrationofelvitegravirreducedbylRIFABUTINalsoplasmaconcentrationofactivemetaboliteofrifabutinincreased—reducedoseofrifabutin;manufacturerofelvitegraviradvisesavoidconcomitantusewithlRIFAMPICINlAntidepressants:manufacturerofelvitegraviradvisesavoidconcomitantusewithlSTJOHN’SWORTlAntiepileptics:manufacturerofelvitegraviradvisesavoidconcomitantusewithlCARBAMAZEPINE,lFOSPHENYTOIN,lPHENOBARBITAL,lPHENYTOINandlPRIMIDONElAntivirals:plasmaconcentrationofelvitegravirincreasedbylATAZANAVIRandlLOPINAVIRboostedwithritonavir(reducedoseofelvitegravir);manufacturerofelvitegraviradvisesavoidconcomitantusewithEFAVIRENZandNEVIRAPINE TRIANGLE Bosentan:manufacturerofelvitegraviradvisesavoidconcomitantusewithBOSENTANlOrlistat:absorptionofelvitegravirpossiblyreducedbylORLISTAT1190Appendix1InteractionsBNF70Interactions|Appendix1"
"Elvitegravir(continued) TRIANGLE Progestogens:elvitegravirincreasesplasmaconcentrationofNORGESTIMATEEmpagliflozinseeAntidiabeticsEmtricitabine TRIANGLE Antivirals:manufacturerofemtricitabineadvisesavoidconcomitantusewithLAMIVUDINElOrlistat:absorptionofemtricitabinepossiblyreducedbylORLISTATEnalaprilseeACEInhibitorsEnfuvirtidelOrlistat:absorptionofenfuvirtidepossiblyreducedbylORLISTATEnoxaparinseeHeparinsEnoximoneseePhosphodiesteraseInhibitorsEntacaponelAnticoagulants:entacaponeenhancesanticoagulanteffectoflWARFARINlAntidepressants:manufacturerofentacaponeadvisescautionwithMOCLOBEMIDE,TRICYCLICSandVENLAFAXINE;avoidconcomitantuseofentacaponewithnon-selectivelMAOIS TRIANGLE Dopaminergics:entacaponepossiblyenhanceseffectsofAPOMORPHINE;entacaponepossiblyreducesplasmaconcentrationofRASAGILINE;manufacturerofentacaponeadvisesmaxdoseof10mgSELEGILINEifusedconcomitantly TRIANGLE IronSalts:absorptionofentacaponereducedbyoralIRONSALTS TRIANGLE Memantine:effectsofdopaminergicspossiblyenhancedbyMEMANTINE TRIANGLE Methyldopa:entacaponepossiblyenhanceseffectsofMETHYLDOPA;antiparkinsonianeffectofdopaminergicsantagonisedbyMETHYLDOPA TRIANGLE Sympathomimetics:entacaponepossiblyenhanceseffectsofADRENALINE(EPINEPHRINE),DOBUTAMINE,DOPAMINEandNORADRENALINE(NOREPINEPHRINE)EnteralFoodslAnticoagulants:thepresenceofvitaminKinsomeenteralfeedscanantagonisetheanticoagulanteffectoflCOUMARINSandlPHENINDIONE TRIANGLE Antiepileptics:enteralfeedspossiblyreduceabsorptionofFOSPHENYTOINandPHENYTOINEnzalutamide TRIANGLE Antibacterials:manufacturerofenzalutamideadvisesavoidconcomitantusewithRIFAMPICINlAnticoagulants:enzalutamidepossiblyreducesplasmaconcentrationoflCOUMARINSlLipid-regulatingDrugs:plasmaconcentrationofenzalutamideincreasedbylGEMFIBROZIL—manufacturerofenzalutamideadvisesavoidconcomitantuseorhalvedoseofenzalutamideEphedrineseeSympathomimeticsEpinephrineNOTEEpinephrineinteractionsasforadrenaline,seeundersympathomimeticsEpirubicinlAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lCiclosporin:plasmaconcentrationofepirubicinincreasedbylCICLOSPORINlUlcer-healingDrugs:plasmaconcentrationofepirubicinincreasedbylCIMETIDINEEplerenoneseeDiureticsEprosartanseeAngiotensin-IIReceptorAntagonistsEptifibatide TRIANGLE Iloprost:increasedriskofbleedingwheneptifibatidegivenwithILOPROSTErgocalciferolseeVitaminsErgometrineseeErgotAlkaloidsErgotAlkaloidslAntibacterials:increasedriskofergotismwhenergometrinegivenwithlCLARITHROMYCINorlERYTHROMYCIN—avoidconcomitantuse;increasedriskofergotismwhenergotaminegivenwithlMACROLIDESorlTELITHROMYCIN—avoidconcomitantuse;increasedriskofergotismwhenergotaminegivenwithTETRACYCLINESErgotAlkaloids(continued) TRIANGLE Antidepressants:possibleriskofhypertensionwhenergotaminegivenwithREBOXETINElAntifungals:avoidanceofergotalkaloidsadvisedbymanufactureroflKETOCONAZOLE;avoidanceofergometrineadvisedbymanufactureroflITRACONAZOLE(increasedriskofergotism);increasedriskofergotismwhenergometrinegivenwithlVORICONAZOLE—avoidconcomitantuse;increasedriskofergotismwhenergotaminegivenwithlIMIDAZOLESorlTRIAZOLES—avoidconcomitantuse TRIANGLE Antipsychotics:plasmaconcentrationofergotalkaloidspossiblyincreasedbyLURASIDONE(increasedriskoftoxicity)lAntivirals:plasmaconcentrationofergotalkaloidspossiblyincreasedbylATAZANAVIR—avoidconcomitantuse;avoidanceofergotalkaloidsadvisedbymanufactureroflBOCEPREVIRandlTELAPREVIR;increasedriskofergotismwhenergotalkaloidsgivenwithlDARUNAVIR—manufacturerofdarunaviradvisesavoidconcomitantuse;increasedriskofergotismwhenergotalkaloidsgivenwithlEFAVIRENZ—avoidconcomitantuse;increasedriskofergotismwhenergotaminegivenwithlFOSAMPRENAVIR,lINDINAVIR,lRITONAVIRorlSAQUINAVIR—avoidconcomitantuse;increasedriskofergotismwhenergometrinegivenwithlINDINAVIRorlRITONAVIR—avoidconcomitantuse TRIANGLE Beta-blockers:increasedperipheralvasoconstrictionwhenergotaminegivenwithBETA-BLOCKERSlCobicistat:plasmaconcentrationofergotalkaloidspossiblyincreasedbylCOBICISTAT—manufacturerofcobicistatadvisesavoidconcomitantuselCytotoxics:cautionwithergotalkaloidsadvisedbymanufactureroflCRIZOTINIB;avoidanceofergotamineadvisedbymanufacturerofIDELALISIBl5HT1-receptorAgonists:increasedriskofvasospasmwhenergotaminegivenwithlALMOTRIPTAN,lRIZATRIPTAN,lSUMATRIPTANorlZOLMITRIPTAN(avoidergotaminefor6hoursafteralmotriptan,rizatriptan,sumatriptanorzolmitriptan,avoidalmotriptan,rizatriptan,sumatriptanorzolmitriptanfor24hoursafterergotamine);increasedriskofvasospasmwhenergotaminegivenwithlELETRIPTAN,lFROVATRIPTANorlNARATRIPTAN(avoidergotaminefor24hoursaftereletriptan,frovatriptanornaratriptan,avoideletriptan,frovatriptanornaratriptanfor24hoursafterergotamine) TRIANGLE Sympathomimetics:increasedriskofergotismwhenergotaminegivenwithSYMPATHOMIMETICSlTicagrelor:plasmaconcentrationofergotalkaloidspossiblyincreasedbylTICAGRELORlUlcer-healingDrugs:increasedriskofergotismwhenergotaminegivenwithlCIMETIDINE—avoidconcomitantuseErgotamineseeErgotAlkaloidsEribulin TRIANGLE Antibacterials:plasmaconcentrationoferibulinpossiblyreducedbyRIFAMPICIN TRIANGLE Antidepressants:plasmaconcentrationoferibulinpossiblyreducedbySTJOHN’SWORT TRIANGLE Antiepileptics:plasmaconcentrationoferibulinpossiblyreducedbyCARBAMAZEPINE,FOSPHENYTOINandPHENYTOINlAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)ErlotiniblAnalgesics:increasedriskofbleedingwhenerlotinibgivenwithlNSAIDSlAntacids:plasmaconcentrationoferlotinibpossiblyreducedbylANTACIDS—giveantacidsatleast4hoursbeforeor2hoursaftererlotinib TRIANGLE Antibacterials:plasmaconcentrationoferlotinibincreasedbyCIPROFLOXACIN;metabolismoferlotinibacceleratedbyRIFAMPICIN(reducedplasmaconcentration)lAnticoagulants:increasedriskofbleedingwhenerlotinibgivenwithlCOUMARINS TRIANGLE Antifungals:metabolismoferlotinibinhibitedbyKETOCONAZOLE(increasedplasmaconcentration)lAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lAntivirals:avoidanceoferlotinibadvisedbymanufactureroflBOCEPREVIRBNF70Appendix1Interactions1191Interactions|Appendix1"
"Erlotinib(continued) TRIANGLE Cytotoxics:plasmaconcentrationoferlotinibpossiblyincreasedbyCAPECITABINElUlcer-healingDrugs:manufactureroferlotinibadvisesavoidconcomitantusewithlCIMETIDINE,lESOMEPRAZOLE,lFAMOTIDINE,lLANSOPRAZOLE,lNIZATIDINE,lPANTOPRAZOLEandlRABEPRAZOLE;plasmaconcentrationoferlotinibreducedbylRANITIDINE—manufactureroferlotinibadvisesgiveatleast2hoursbeforeor10hoursafterranitidine;plasmaconcentrationoferlotinibreducedbylOMEPRAZOLE—manufactureroferlotinibadvisesavoidconcomitantuseErtapenemlAntiepileptics:carbapenemsreduceplasmaconcentrationoflSODIUMVALPROATEandlVALPROICACID—avoidconcomitantuse TRIANGLE Vaccines:antibacterialsinactivateORALTYPHOIDVACCINE—seeunderTyphoidVaccineinBNFErythromycinseeMacrolidesEscitalopramseeAntidepressants,SSRIEslicarbazepine TRIANGLE Anticoagulants:eslicarbazepinereducesplasmaconcentrationofWARFARINlAntidepressants:anticonvulsanteffectofantiepilepticspossiblyantagonisedbyMAOISandlTRICYCLIC-RELATEDANTIDEPRESSANTS(convulsivethresholdlowered);anticonvulsanteffectofantiepilepticsantagonisedbylSSRISandlTRICYCLICS(convulsivethresholdlowered) TRIANGLE Antiepileptics:plasmaconcentrationofeslicarbazepinepossiblyreducedbyCARBAMAZEPINEbutriskofside-effectsincreased;plasmaconcentrationofeslicarbazepinereducedbyFOSPHENYTOINandPHENYTOIN,alsoplasmaconcentrationoffosphenytoinandphenytoinincreased;manufacturerofeslicarbazepineadvisesavoidconcomitantusewithOXCARBAZEPINElAntimalarials:anticonvulsanteffectofantiepilepticsantagonisedbylMEFLOQUINElAntipsychotics:anticonvulsanteffectofantiepilepticsantagonisedbylANTIPSYCHOTICS(convulsivethresholdlowered) TRIANGLE Lipid-regulatingDrugs:eslicarbazepinereducesplasmaconcentrationofROSUVASTATIN;eslicarbazepinereducesplasmaconcentrationofSIMVASTATIN—considerincreasingdoseofsimvastatinlOestrogens:eslicarbazepineacceleratesmetabolismoflOESTROGENS(reducedcontraceptiveeffectwithcombinedoralcontraceptives,contraceptivepatches,andvaginalrings—seeContraceptiveInteractionsinBNF)lOrlistat:possibleincreasedriskofconvulsionswhenantiepilepticsgivenwithlORLISTATlProgestogens:eslicarbazepineacceleratesmetabolismoflPROGESTOGENS(reducedcontraceptiveeffectwithcombinedoralcontraceptives,progestogen-onlyoralcontraceptives,contraceptivepatches,vaginalrings,etonogestrel-releasingimplant,andemergencyhormonalcontraception—seeContraceptiveInteractionsinBNF)EsmololseeBeta-blockersEsomeprazoleseeProtonPumpInhibitorsEstradiolseeOestrogensEstramustine TRIANGLE Antacids:absorptionofestramustinepossiblyreducedbyALUMINIUMHYDROXIDEandORALMAGNESIUMSALTS—manufacturerofestramustineadvisesavoidconcomitantadministrationlAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lBisphosphonates:plasmaconcentrationofestramustineincreasedbylSODIUMCLODRONATE TRIANGLE CalciumSalts:absorptionofestramustinereducedbyCALCIUMSALTS(manufacturerofestramustineadvisesavoidconcomitantadministration)EstriolseeOestrogensEstroneseeOestrogensEtanerceptlAbatacept:avoidconcomitantuseofetanerceptwithlABATACEPTEtanercept(continued)lAnakinra:avoidconcomitantuseofetanerceptwithlANAKINRAlVaccines:riskofgeneralisedinfectionswhenetanerceptgivenwithlivelVACCINES—avoidconcomitantuseEthambutol TRIANGLE Antibacterials:plasmaconcentrationofethambutolincreasedbyDELAMANID TRIANGLE Vaccines:antibacterialsinactivateORALTYPHOIDVACCINE—seeunderTyphoidVaccineinBNFEthinylestradiolseeOestrogensEthosuximidelAntibacterials:metabolismofethosuximideinhibitedbylISONIAZID(increasedplasmaconcentrationandriskoftoxicity)lAntidepressants:anticonvulsanteffectofantiepilepticspossiblyantagonisedbyMAOISandlTRICYCLIC-RELATEDANTIDEPRESSANTS(convulsivethresholdlowered);anticonvulsanteffectofantiepilepticsantagonisedbylSSRISandlTRICYCLICS(convulsivethresholdlowered)lAntiepileptics:plasmaconcentrationofethosuximidepossiblyreducedbyCARBAMAZEPINE,PHENOBARBITALandPRIMIDONE;plasmaconcentrationofethosuximidepossiblyreducedbylFOSPHENYTOINandlPHENYTOIN,alsoplasmaconcentrationoffosphenytoinandphenytoinpossiblyincreased;plasmaconcentrationofethosuximidepossiblyincreasedbySODIUMVALPROATEandVALPROICACIDlAntimalarials:anticonvulsanteffectofantiepilepticsantagonisedbylMEFLOQUINElAntipsychotics:anticonvulsanteffectofantiepilepticsantagonisedbylANTIPSYCHOTICS(convulsivethresholdlowered)lOrlistat:possibleincreasedriskofconvulsionswhenantiepilepticsgivenwithlORLISTATEtodolacseeNSAIDsEtomidateseeAnaesthetics,GeneralEtonogestrelseeProgestogensEtoposidelAnticoagulants:etoposidepossiblyenhancesanticoagulanteffectoflCOUMARINS TRIANGLE Antiepileptics:plasmaconcentrationofetoposidepossiblyreducedbyFOSPHENYTOIN,PHENOBARBITAL,PHENYTOINandPRIMIDONE TRIANGLE Antifungals:plasmaconcentrationofetoposideincreasedbyKETOCONAZOLElAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis) TRIANGLE Atovaquone:plasmaconcentrationofetoposidepossiblyincreasedbyATOVAQUONE TRIANGLE Ciclosporin:plasmaconcentrationofetoposidepossiblyincreasedbyCICLOSPORIN(increasedriskoftoxicity)EtoricoxibseeNSAIDsEtravirinelAntibacterials:etravirinereducesplasmaconcentrationoflCLARITHROMYCIN(butconcentrationofanactivemetaboliteincreased),alsoplasmaconcentrationofetravirineincreased;plasmaconcentrationofbothdrugsreducedwhenetravirinegivenwithlRIFABUTIN;manufacturerofetravirineadvisesavoidconcomitantusewithRIFAMPICIN;etravirinepossiblyreducesplasmaconcentrationofBEDAQUILINE—manufacturerofbedaquilineadvisesavoidconcomitantuse TRIANGLE Antidepressants:manufacturerofetravirineadvisesavoidconcomitantusewithSTJOHN’SWORT TRIANGLE Antiepileptics:manufacturerofetravirineadvisesavoidconcomitantusewithCARBAMAZEPINE,FOSPHENYTOIN,PHENOBARBITAL,PHENYTOINandPRIMIDONE TRIANGLE Antimalarials:etravirinereducesplasmaconcentrationofARTEMETHERWITHLUMEFANTRINElAntivirals:effectsofbothdrugspossiblyreducedwhenetravirinegivenwithBOCEPREVIR;avoidanceofetravirineadvisedbymanufacturerofDACLATASVIR(plasmaconcentrationofdaclatasvirpossiblyreduced);etravirinereducestheplasmaconcentrationoflDOLUTEGRAVIR(seeunderDolutegravir,p557);plasmaconcentrationofetravirinepossiblyreducedbylEFAVIRENZandlNEVIRAPINE—1192Appendix1InteractionsBNF70Interactions|Appendix1"
"EtravirinelAntivirals(continued)avoidconcomitantuse;etravirineincreasesplasmaconcentrationoflFOSAMPRENAVIR(considerreducingdoseoffosamprenavir);etravirinepossiblyreducesplasmaconcentrationoflINDINAVIR—avoidconcomitantuse;etravirinepossiblyreducesplasmaconcentrationofMARAVIROC;avoidanceofetravirineadvisedbymanufacturerofSIMEPREVIR;plasmaconcentrationofetravirinereducedbylTIPRANAVIR,alsoplasmaconcentrationoftipranavirincreased(avoidconcomitantuse) TRIANGLE CardiacGlycosides:etravirineincreasesplasmaconcentrationofDIGOXINlClopidogrel:etravirinepossiblyreducesantiplateleteffectoflCLOPIDOGRELlCytotoxics:etravirinepossiblyreducesplasmaconcentrationoflBOSUTINIB—manufacturerofbosutinibadvisesavoidconcomitantuse TRIANGLE Lipid-regulatingDrugs:etravirinepossiblyreducesplasmaconcentrationofATORVASTATINlOrlistat:absorptionofetravirinepossiblyreducedbylORLISTAT TRIANGLE Sildenafil:etravirinereducesplasmaconcentrationofSILDENAFILEverolimuslACEInhibitors:increasedriskofangioedemawheneverolimusgivenwithlACEINHIBITORSlAntibacterials:plasmaconcentrationofeverolimuspossiblyincreasedbylCLARITHROMYCINandlTELITHROMYCIN—manufacturerofeverolimusadvisesavoidconcomitantuse;plasmaconcentrationofeverolimusincreasedbylERYTHROMYCIN(considerreducingthedoseofeverolimus—consulteverolimusproductliterature);plasmaconcentrationofeverolimusreducedbylRIFAMPICIN(avoidconcomitantuseorconsiderincreasingthedoseofeverolimus—consulteverolimusproductliterature) TRIANGLE Antidepressants:plasmaconcentrationofeverolimuspossiblyreducedbySTJOHN’SWORT—manufacturerofeverolimusadvisesavoidconcomitantuselAntifungals:plasmaconcentrationofeverolimusincreasedbylKETOCONAZOLE—manufacturerofketoconazoleadvisesavoidconcomitantuse;plasmaconcentrationofeverolimuspossiblyincreasedbylITRACONAZOLE,lPOSACONAZOLEandlVORICONAZOLE—manufacturerofeverolimusadvisesavoidconcomitantuselAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lAntivirals:plasmaconcentrationofeverolimuspossiblyincreasedbylATAZANAVIR,lDARUNAVIR,lINDINAVIR,lRITONAVIRandlSAQUINAVIR—manufacturerofeverolimusadvisesavoidconcomitantuselCalcium-channelBlockers:plasmaconcentrationofbothdrugsmayincreasewheneverolimusgivenwithlVERAPAMIL(considerreducingthedoseofeverolimus—consulteverolimusproductliterature)lCiclosporin:plasmaconcentrationofeverolimusincreasedbylCICLOSPORIN(considerreducingthedoseofeverolimus—consulteverolimusproductliterature)lCytotoxics:plasmaconcentrationofeverolimusincreasedbylIMATINIB(considerreducingthedoseofeverolimus—consulteverolimusproductliterature) TRIANGLE GrapefruitJuice:manufacturerofeverolimusadvisesavoidconcomitantusewithGRAPEFRUITJUICEExemestane TRIANGLE Antibacterials:plasmaconcentrationofexemestanepossiblyreducedbyRIFAMPICINExenatideseeAntidiabeticsEzetimibe TRIANGLE Anticoagulants:ezetimibepossiblyenhancesanticoagulanteffectofCOUMARINSlCiclosporin:plasmaconcentrationofbothdrugsmayincreasewhenezetimibegivenwithlCICLOSPORINlLipid-regulatingDrugs:ezetimibeincreasesplasmaconcentrationoflROSUVASTATIN—adjustdoseofrosuvastatin(consultproductliterature);increasedriskofcholelithiasisEzetimibelLipid-regulatingDrugs(continued)andgallbladderdiseasewhenezetimibegivenwithFIBRATES—discontinueifsuspectedFamotidineseeHistamineH2-antagonistsFampridinelUlcer-healingDrugs:manufactureroffampridineadvisesavoidconcomitantusewithlCIMETIDINEFebuxostatlAzathioprine:manufactureroffebuxostatadvisesavoidconcomitantusewithlAZATHIOPRINElCytotoxics:manufactureroffebuxostatadvisesavoidconcomitantusewithlMERCAPTOPURINEFelodipineseeCalcium-channelBlockersFenofibrateseeFibratesFenoprofenseeNSAIDsFentanylseeOpioidAnalgesicsFerrousFumarateseeIronsaltsFerrousGluconateseeIronsaltsFerrousSulfateseeIronsaltsFesoterodineseeAntimuscarinicsFexofenadineseeAntihistaminesFibrateslAntibacterials:increasedriskofmyopathywhenfibratesgivenwithlDAPTOMYCIN(preferablyavoidconcomitantuse)lAnticoagulants:fibratesenhanceanticoagulanteffectoflCOUMARINSandlPHENINDIONElAntidiabetics:fibratesmayimproveglucosetoleranceandhaveanadditiveeffectwithINSULINorSULFONYLUREAS;gemfibrozilpossiblyenhanceshypoglycaemiceffectofNATEGLINIDE;increasedriskofseverehypoglycaemiawhengemfibrozilgivenwithlREPAGLINIDE—avoidconcomitantuse TRIANGLE Ciclosporin:increasedriskofrenalimpairmentwhenbezafibrateorfenofibrategivenwithCICLOSPORINlColchicine:possibleincreasedriskofmyopathywhenfibratesgivenwithlCOLCHICINElCytotoxics:gemfibrozilincreasesplasmaconcentrationofDABRAFENIB;gemfibrozilincreasesplasmaconcentrationoflBEXAROTENE—avoidconcomitantuselHormoneAntagonists:gemfibrozilincreasesplasmaconcentrationoflENZALUTAMIDE—manufacturerofenzalutamideadvisesavoidconcomitantuseorhalvedoseofenzalutamide TRIANGLE LeukotrieneReceptorAntagonists:gemfibrozilincreasesplasmaconcentrationofMONTELUKASTlLipid-regulatingDrugs:increasedriskofmyopathywhengemfibrozilgivenwithlATORVASTATIN,lFLUVASTATINorlPRAVASTATIN(preferablyavoidconcomitantuse);increasedriskofmyopathywhenfibratesgivenwithlROSUVASTATIN(seeunderRosuvastatin,p180);possibleincreasedriskofmyopathywhenbezafibrategivenwithlSIMVASTATIN(seeunderSimvastatin,p181);possibleincreasedriskofmyopathywhenciprofibrategivenwithlSIMVASTATIN(seeunderSimvastatin,p181);increasedriskofmyopathywhengemfibrozilgivenwithlSIMVASTATIN(avoidconcomitantuse);increasedriskofcholelithiasisandgallbladderdiseasewhenfibratesgivenwithEZETIMIBE—discontinueifsuspected;increasedriskofmyopathywhenfibratesgivenwithlSTATINS;reducemaximumdoseoffenofibratewhengivenwithSTATINS—seeunderFenofibrate,p175Fidaxomicin TRIANGLE Anti-arrhythmics:manufactureroffidaxomicinadvisesavoidconcomitantusewithAMIODARONEandDRONEDARONE TRIANGLE Antibacterials:manufactureroffidaxomicinadvisesavoidconcomitantusewithCLARITHROMYCINandERYTHROMYCIN TRIANGLE Antifungals:manufactureroffidaxomicinadvisesavoidconcomitantusewithKETOCONAZOLE TRIANGLE Calcium-channelBlockers:manufactureroffidaxomicinadvisesavoidconcomitantusewithVERAPAMIL TRIANGLE Ciclosporin:manufactureroffidaxomicinadvisesavoidconcomitantusewithCICLOSPORIN TRIANGLE Vaccines:antibacterialsinactivateORALTYPHOIDVACCINE—seeunderTyphoidVaccineinBNFBNF70Appendix1Interactions1193Interactions|Appendix1"
"Filgrastim TRIANGLE Cytotoxics:neutropeniapossiblyexacerbatedwhenfilgrastimgivenwithCAPECITABINE,FLUOROURACILorTEGAFURFingolimodlAnti-arrhythmics:possibleincreasedriskofbradycardiawhenfingolimodgivenwithlAMIODARONE,lDISOPYRAMIDEorlDRONEDARONE TRIANGLE Antidepressants:plasmaconcentrationoffingolimodpossiblyreducedbySTJOHN’SWORT—manufactureroffingolimodadvisesavoidconcomitantuse TRIANGLE Antiepileptics:plasmaconcentrationoffingolimodreducedbyCARBAMAZEPINElAntifungals:plasmaconcentrationoffingolimodincreasedbylKETOCONAZOLElBeta-blockers:possibleincreasedriskofbradycardiawhenfingolimodgivenwithlBETA-BLOCKERSlCalcium-channelBlockers:possibleincreasedriskofbradycardiawhenfingolimodgivenwithlDILTIAZEMorlVERAPAMILFlavoxateseeAntimuscarinicsFlecainide TRIANGLE Anaesthetics,Local:increasedmyocardialdepressionwhenanti-arrhythmicsgivenwithBUPIVACAINE,LEVOBUPIVACAINE,PRILOCAINEorROPIVACAINElAnti-arrhythmics:increasedmyocardialdepressionwhenanti-arrhythmicsgivenwithotherlANTI-ARRHYTHMICS;plasmaconcentrationofflecainideincreasedbylAMIODARONE(halvedoseofflecainide)lAntidepressants:plasmaconcentrationofflecainideincreasedbyFLUOXETINE;increasedriskofventriculararrhythmiaswhenflecainidegivenwithlTRICYCLICSlAntihistamines:increasedriskofventriculararrhythmiaswhenflecainidegivenwithlMIZOLASTINE—avoidconcomitantuselAntimalarials:avoidanceofflecainideadvisedbymanufactureroflARTEMETHERWITHLUMEFANTRINE(riskofventriculararrhythmias);plasmaconcentrationofflecainideincreasedbylQUININElAntimuscarinics:increasedriskofventriculararrhythmiaswhenflecainidegivenwithlTOLTERODINElAntipsychotics:increasedriskofventriculararrhythmiaswhenanti-arrhythmicsthatprolongtheQTintervalgivenwithlANTIPSYCHOTICSthatprolongtheQTinterval;increasedriskofarrhythmiaswhenflecainidegivenwithlCLOZAPINElAntivirals:plasmaconcentrationofflecainidepossiblyincreasedbylFOSAMPRENAVIR,lINDINAVIR,lLOPINAVIRandlRITONAVIR(increasedriskofventriculararrhythmias—avoidconcomitantuse);increasedriskofventriculararrhythmiaswhenflecainidegivenwithlSAQUINAVIR—avoidconcomitantuse;cautionwithflecainideadvisedbymanufactureroflTELAPREVIR(riskofventriculararrhythmias)lBeta-blockers:increasedriskofmyocardialdepressionandbradycardiawhenflecainidegivenwithlBETA-BLOCKERS;increasedmyocardialdepressionwhenanti-arrhythmicsgivenwithlBETA-BLOCKERSlCalcium-channelBlockers:increasedriskofmyocardialdepressionandasystolewhenflecainidegivenwithlVERAPAMILlDiuretics:increasedcardiactoxicitywithflecainideifhypokalaemiaoccurswithlACETAZOLAMIDE,lLOOPDIURETICSorlTHIAZIDESANDRELATEDDIURETICS TRIANGLE Ulcer-healingDrugs:metabolismofflecainideinhibitedbyCIMETIDINE(increasedplasmaconcentration)FlucloxacillinseePenicillinsFluconazoleseeAntifungals,TriazoleFlucytosine TRIANGLE Antifungals:renalexcretionofflucytosinedecreasedandcellularuptakeincreasedbyAMPHOTERICIN(toxicitypossiblyincreased) TRIANGLE Cytotoxics:plasmaconcentrationofflucytosinepossiblyreducedbyCYTARABINEFludarabinelAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lCytotoxics:fludarabineincreasesintracellularconcentrationofCYTARABINE;increasedpulmonarytoxicitywhenFludarabinelCytotoxics(continued)fludarabinegivenwithlPENTOSTATIN(unacceptablyhighincidenceoffatalities) TRIANGLE Dipyridamole:effectsoffludarabinepossiblyreducedbyDIPYRIDAMOLEFludrocortisoneseeCorticosteroidsFluorides TRIANGLE CalciumSalts:absorptionoffluoridesreducedbyCALCIUMSALTSFluorouracil TRIANGLE Antibacterials:metabolismoffluorouracilinhibitedbyMETRONIDAZOLE(increasedtoxicity)lAnticoagulants:fluorouracilenhancesanticoagulanteffectoflCOUMARINS TRIANGLE Antiepileptics:fluorouracilpossiblyinhibitsmetabolismofFOSPHENYTOINandPHENYTOIN(increasedriskoftoxicity)lAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis) TRIANGLE Filgrastim:neutropeniapossiblyexacerbatedwhenfluorouracilgivenwithFILGRASTIMlFolates:toxicityoffluorouracilincreasedbylFOLICACID—avoidconcomitantuse TRIANGLE Lipegfilgrastim:neutropeniapossiblyexacerbatedwhenfluorouracilgivenwithLIPEGFILGRASTIM TRIANGLE Pegfilgrastim:neutropeniapossiblyexacerbatedwhenfluorouracilgivenwithPEGFILGRASTIMlTemoporfin:increasedskinphotosensitivitywhentopicalfluorouracilusedwithlTEMOPORFIN TRIANGLE Ulcer-healingDrugs:metabolismoffluorouracilinhibitedbyCIMETIDINE(increasedplasmaconcentration)FluoxetineseeAntidepressants,SSRIFlupentixolseeAntipsychoticsFluphenazineseeAntipsychoticsFlurazepamseeAnxiolyticsandHypnoticsFlurbiprofenseeNSAIDsFlutamidelAnticoagulants:flutamideenhancesanticoagulanteffectoflCOUMARINSFluticasoneseeCorticosteroidsFluvastatinseeStatinsFluvoxamineseeAntidepressants,SSRIFolates TRIANGLE Aminosalicylates:absorptionoffolicacidpossiblyreducedbySULFASALAZINE TRIANGLE Antacids:absorptionoffolicacidpossiblyreducedbyANTACIDS(manufactureroffolicacidadvisesgiveatleast2hoursapart) TRIANGLE Antiepileptics:folatespossiblyreduceplasmaconcentrationofFOSPHENYTOIN,PHENOBARBITAL,PHENYTOINandPRIMIDONElCytotoxics:folicacidincreasestoxicityoflCAPECITABINE,lFLUOROURACILandlTEGAFUR—avoidconcomitantuse;avoidanceoffolatesadvisedbymanufactureroflRALTITREXEDFolicAcidseeFolatesFolinicAcidseeFolatesFondaparinuxlAnalgesics:increasedriskofhaemorrhagewhenanticoagulantsgivenwithintravenouslDICLOFENAC(avoidconcomitantuse,includinglow-doseheparins);increasedriskofhaemorrhagewhenanticoagulantsgivenwithlKETOROLAC(avoidconcomitantuse,includinglow-doseheparins)lAnticoagulants:increasedriskofhaemorrhagewhenotheranticoagulantsgivenwithlAPIXABAN,lDABIGATRANandlRIVAROXABAN(avoidconcomitantuseexceptwhenswitchingwithotheranticoagulantsorusingheparintomaintaincatheterpatency)FormoterolseeSympathomimetics,Beta2FosamprenavirNOTEFosamprenavirisaprodrugofamprenavir TRIANGLE Analgesics:fosamprenavirreducesplasmaconcentrationofMETHADONElAnti-arrhythmics:fosamprenavirpossiblyincreasesplasmaconcentrationoflAMIODARONE,lFLECAINIDEandlPROPAFENONE(increasedriskofventriculararrhythmias—1194Appendix1InteractionsBNF70Interactions|Appendix1"
"FosamprenavirlAnti-arrhythmics(continued)avoidconcomitantuse);fosamprenavirpossiblyincreasesplasmaconcentrationoflLIDOCAINE—avoidconcomitantuselAntibacterials:fosamprenavirincreasesplasmaconcentrationoflRIFABUTIN(reducedoseofrifabutin);plasmaconcentrationoffosamprenavirsignificantlyreducedbylRIFAMPICIN—avoidconcomitantuse;avoidanceofconcomitantfosamprenavirinsevererenalandhepaticimpairmentadvisedbymanufactureroflTELITHROMYCIN TRIANGLE Anticoagulants:avoidanceoffosamprenaviradvisedbymanufacturerofAPIXABANandRIVAROXABAN;fosamprenavirmayenhanceorreduceanticoagulanteffectofCOUMARINSlAntidepressants:plasmaconcentrationoffosamprenavirreducedbylSTJOHN’SWORT—avoidconcomitantuse TRIANGLE Antiepileptics:plasmaconcentrationoffosamprenavirpossiblyreducedbyCARBAMAZEPINE,PHENOBARBITALandPRIMIDONE TRIANGLE Antifungals:fosamprenavirincreasesplasmaconcentrationofKETOCONAZOLE(alsoplasmaconcentrationoffosamprenavirpossiblyincreased);plasmaconcentrationofbothdrugsmayincreasewhenfosamprenavirgivenwithITRACONAZOLE;fosamprenavirpossiblyreducesplasmaconcentrationofPOSACONAZOLElAntimalarials:cautionwithfosamprenaviradvisedbymanufacturerofARTEMETHERWITHLUMEFANTRINE;fosamprenavirpossiblyincreasesplasmaconcentrationoflQUININE(increasedriskoftoxicity) TRIANGLE Antimuscarinics:avoidanceoffosamprenaviradvisedbymanufacturerofDARIFENACINandTOLTERODINElAntipsychotics:fosamprenavirpossiblyincreasesplasmaconcentrationoflARIPIPRAZOLE(reducedoseofaripiprazole—consultaripiprazoleproductliterature);fosamprenavirincreasesplasmaconcentrationoflPIMOZIDE(increasedriskofventriculararrhythmias—avoidconcomitantuse);fosamprenavirpossiblyincreasesplasmaconcentrationoflQUETIAPINE—manufacturerofquetiapineadvisesavoidconcomitantuselAntivirals:manufactureroffosamprenaviradvisesavoidconcomitantusewithlBOCEPREVIRandlRALTEGRAVIR;fosamprenavirreducesplasmaconcentrationoflDOLUTEGRAVIR;plasmaconcentrationoffosamprenavirincreasedbylETRAVIRINE(considerreducingdoseoffosamprenavir);plasmaconcentrationoffosamprenavirreducedbyLOPINAVIR,effectonlopinavirplasmaconcentrationnotpredictable—avoidconcomitantuse;plasmaconcentrationoffosamprenavirreducedbylMARAVIROC—avoidconcomitantuse;plasmaconcentrationoffosamprenavirpossiblyreducedbyNEVIRAPINE—avoidunboostedfosamprenavir;manufacturersadviseavoidconcomitantuseoffosamprenavirwithlTELAPREVIR;plasmaconcentrationoffosamprenavirreducedbylTIPRANAVIRlAnxiolyticsandHypnotics:fosamprenavirpossiblyincreasesplasmaconcentrationoflMIDAZOLAM(riskofprolongedsedation—avoidconcomitantuseoforalmidazolam)lAvanafil:fosamprenavirpossiblyincreasesplasmaconcentrationoflAVANAFIL—seeunderAvanafil,p698lCiclosporin:fosamprenavirincreasesplasmaconcentrationoflCICLOSPORINlCytotoxics:fosamprenavirpossiblyincreasestheplasmaconcentrationoflBOSUTINIB—manufacturerofbosutinibadvisesavoidorconsiderreducingdoseofbosutinib;fosamprenavirpossiblyincreasestheplasmaconcentrationoflIBRUTINIB—reducedoseofibrutinib(seeunderIbrutinib,p809) TRIANGLE Dapoxetine:manufacturerofdapoxetineadvisesdosereductionwhenfosamprenavirgivenwithDAPOXETINE(seeunderDapoxetine,p703)lErgotAlkaloids:increasedriskofergotismwhenfosamprenavirgivenwithlERGOTAMINE—avoidconcomitantuselLipid-regulatingDrugs:possibleincreasedriskofmyopathywhenfosamprenavirgivenwithATORVASTATIN;possibleincreasedriskofmyopathywhenfosamprenavirgivenwithlROSUVASTATIN—manufacturerofrosuvastatinadvisesavoidconcomitantuse;possibleincreasedriskofmyopathywhenfosamprenavirgivenwithlSIMVASTATIN—avoidconcomitantFosamprenavirlLipid-regulatingDrugs(continued)use;avoidanceoffosamprenaviradvisedbymanufactureroflLOMITAPIDE(plasmaconcentrationoflomitapidepossiblyincreased)lOrlistat:absorptionoffosamprenavirpossiblyreducedbylORLISTATlRanolazine:fosamprenavirpossiblyincreasesplasmaconcentrationoflRANOLAZINE—manufacturerofranolazineadvisesavoidconcomitantuse TRIANGLE Sildenafil:fosamprenavirpossiblyincreasesplasmaconcentrationofSILDENAFILlTacrolimus:fosamprenavirincreasesplasmaconcentrationoflTACROLIMUS TRIANGLE Tadalafil:fosamprenavirpossiblyincreasesplasmaconcentrationofTADALAFIL TRIANGLE Vardenafil:fosamprenavirpossiblyincreasesplasmaconcentrationofVARDENAFILFosaprepitant TRIANGLE Antibacterials:plasmaconcentrationoffosaprepitantpossiblyincreasedbyCLARITHROMYCINandTELITHROMYCIN;plasmaconcentrationoffosaprepitantreducedbyRIFAMPICIN TRIANGLE Anticoagulants:fosaprepitantpossiblyreducesanticoagulanteffectofWARFARINlAntidepressants:manufactureroffosaprepitantadvisesavoidconcomitantusewithlSTJOHN’SWORT TRIANGLE Antidiabetics:fosaprepitantreducesplasmaconcentrationofTOLBUTAMIDE TRIANGLE Antiepileptics:plasmaconcentrationoffosaprepitantpossiblyreducedbyCARBAMAZEPINE,FOSPHENYTOIN,PHENOBARBITAL,PHENYTOINandPRIMIDONE TRIANGLE Antifungals:plasmaconcentrationoffosaprepitantincreasedbyKETOCONAZOLElAntipsychotics:manufactureroffosaprepitantadvisesavoidconcomitantusewithlPIMOZIDE TRIANGLE Antivirals:plasmaconcentrationoffosaprepitantpossiblyincreasedbyRITONAVIR TRIANGLE AnxiolyticsandHypnotics:fosaprepitantincreasesplasmaconcentrationofMIDAZOLAM(riskofprolongedsedation) TRIANGLE Avanafil:fosaprepitantpossiblyincreasesplasmaconcentrationofAVANAFIL TRIANGLE Calcium-channelBlockers:plasmaconcentrationofbothdrugsmayincreasewhenfosaprepitantgivenwithDILTIAZEM TRIANGLE Corticosteroids:fosaprepitantinhibitsmetabolismofDEXAMETHASONEandMETHYLPREDNISOLONE(reducedoseofdexamethasoneandmethylprednisolone)lCytotoxics:fosaprepitantpossiblyincreasestheplasmaconcentrationoflBOSUTINIB—manufacturerofbosutinibadvisesavoidorconsiderreducingdoseofbosutinib;fosaprepitantpossiblyincreasesplasmaconcentrationofIBRUTINIB TRIANGLE Lipid-regulatingDrugs:separatingadministrationfromfosaprepitantby12hoursadvisedbymanufacturerofLOMITAPIDElOestrogens:fosaprepitantpossiblycausescontraceptivefailureofhormonalcontraceptivescontaininglOESTROGENS(alternativecontraceptionrecommended)lProgestogens:fosaprepitantpossiblycausescontraceptivefailureofhormonalcontraceptivescontaininglPROGESTOGENS(alternativecontraceptionrecommended)FoscarnetlPentamidineIsetionate:increasedriskofhypocalcaemiawhenfoscarnetgivenwithparenterallPENTAMIDINEISETIONATEFosfomycin TRIANGLE Metoclopramide:plasmaconcentrationoffosfomycinreducedbyMETOCLOPRAMIDE TRIANGLE Vaccines:antibacterialsinactivateORALTYPHOIDVACCINE—seeunderTyphoidVaccineinBNFFosinoprilseeACEInhibitorsFosphenytoin TRIANGLE Alcohol:plasmaconcentrationoffosphenytoinpossiblyreducedbychronicheavyconsumptionofALCOHOLlAminophylline:plasmaconcentrationofbothdrugsreducedwhenfosphenytoingivenwithlAMINOPHYLLINElAnalgesics:excretionoffosphenytoinpossiblyreducedbyACEMETACIN(increasedriskoftoxicity);fosphenytoinpossiblyBNF70Appendix1Interactions1195Interactions|Appendix1"
"FosphenytoinlAnalgesics(continued)acceleratesmetabolismofFENTANYL(reducedeffect);fosphenytoinacceleratesmetabolismofMETHADONE(reducedeffectandriskofwithdrawaleffects);fosphenytoinpossiblyincreasesriskoflPETHIDINEtoxicity;effectsoffosphenytoinenhancedbyASPIRIN;fosphenytoinpossiblyacceleratesmetabolismofPARACETAMOL(alsoisolatedreportsofhepatotoxicity) TRIANGLE Antacids:absorptionoffosphenytoinreducedbyANTACIDSlAnthelmintics:fosphenytoinreducesplasmaconcentrationoflALBENDAZOLEandlPRAZIQUANTEL—considerincreasingalbendazoleandpraziquanteldosewhengivenforsystemicinfections;plasmaconcentrationoffosphenytoinpossiblyincreasedbyLEVAMISOLElAnti-arrhythmics:metabolismoffosphenytoininhibitedbylAMIODARONE(increasedplasmaconcentration);fosphenytoinreducesplasmaconcentrationofDISOPYRAMIDE;fosphenytoinpossiblyreducesplasmaconcentrationoflDRONEDARONE—avoidconcomitantuselAntibacterials:metabolismoffosphenytoininhibitedbyCLARITHROMYCIN(increasedplasmaconcentration);metabolismoffosphenytoinpossiblyinhibitedbyMETRONIDAZOLE(increasedplasmaconcentration);plasmaconcentrationoffosphenytoinincreasedordecreasedbyCIPROFLOXACIN;fosphenytoinacceleratesmetabolismofDOXYCYCLINE(reducedplasmaconcentration);fosphenytoinpossiblyreducesplasmaconcentrationoflBEDAQUILINE—manufacturerofbedaquilineadvisesavoidconcomitantuse;plasmaconcentrationoffosphenytoinincreasedbylCHLORAMPHENICOL(increasedriskoftoxicity);metabolismoffosphenytoinpossiblyinhibitedbyISONIAZID(increasedriskoftoxicity);metabolismoffosphenytoinacceleratedbylRIFAMYCINS(reducedplasmaconcentration);plasmaconcentrationoffosphenytoinpossiblyincreasedbySULFONAMIDES;fosphenytoinreducesplasmaconcentrationoflTELITHROMYCIN(avoidduringandfor2weeksafterfosphenytoin);plasmaconcentrationoffosphenytoinincreasedbylTRIMETHOPRIM(alsoincreasedantifolateeffect)lAnticoagulants:fosphenytoinpossiblyreducesplasmaconcentrationoflAPIXABAN;fosphenytoinacceleratesmetabolismoflCOUMARINS(possibilityofreducedanticoagulanteffect,butenhancementalsoreported);fosphenytoinpossiblyreducesplasmaconcentrationofDABIGATRAN—manufacturerofdabigatranadvisesavoidconcomitantuse;fosphenytoinpossiblyreducesplasmaconcentrationoflRIVAROXABAN—manufacturerofrivaroxabanadvisesmonitorforsignsofthrombosislAntidepressants:plasmaconcentrationoffosphenytoinincreasedbylFLUOXETINEandlFLUVOXAMINE;fosphenytoinreducesplasmaconcentrationoflMIANSERIN,MIRTAZAPINEandPAROXETINE;plasmaconcentrationoffosphenytoinpossiblyincreasedbySERTRALINE,alsoplasmaconcentrationofsertralinepossiblyreduced;anticonvulsanteffectofantiepilepticspossiblyantagonisedbyMAOISandlTRICYCLIC-RELATEDANTIDEPRESSANTS(convulsivethresholdlowered);anticonvulsanteffectofantiepilepticsantagonisedbylSSRISandlTRICYCLICS(convulsivethresholdlowered);plasmaconcentrationoffosphenytoinpossiblyreducedbylSTJOHN’SWORT—avoidconcomitantuse;fosphenytoinpossiblyreducesplasmaconcentrationoflTRICYCLICS TRIANGLE Antidiabetics:plasmaconcentrationoffosphenytointransientlyincreasedbyTOLBUTAMIDE(possibilityoftoxicity)lAntiepileptics:plasmaconcentrationofbothdrugsoftenreducedwhenfosphenytoingivenwithCARBAMAZEPINE,alsoplasmaconcentrationoffosphenytoinmaybeincreased;fosphenytoinreducesplasmaconcentrationofESLICARBAZEPINE,alsoplasmaconcentrationoffosphenytoinincreased;plasmaconcentrationoffosphenytoinpossiblyincreasedbylETHOSUXIMIDE,alsoplasmaconcentrationofethosuximidepossiblyreduced;fosphenytoinreducesplasmaconcentrationofLAMOTRIGINE,TIAGABINEandZONISAMIDE;plasmaconcentrationoffosphenytoinincreasedbyOXCARBAZEPINE,alsoplasmaconcentrationofanactivemetaboliteofoxcarbazepinereduced;fosphenytoinreducesFosphenytoinlAntiepileptics(continued)plasmaconcentrationoflPERAMPANEL(seeunderPerampanel,p398);fosphenytoinoftenincreasesplasmaconcentrationofPHENOBARBITALandPRIMIDONE,plasmaconcentrationoffosphenytoinoftenreducedbutmaybeincreased;fosphenytoinpossiblyreducesplasmaconcentrationofRETIGABINE;fosphenytoinpossiblyreducesplasmaconcentrationofRUFINAMIDE,alsoplasmaconcentrationoffosphenytoinpossiblyincreased;plasmaconcentrationoffosphenytoinincreasedorpossiblyreducedwhengivenwithSODIUMVALPROATEandVALPROICACID,alsoplasmaconcentrationofsodiumvalproateandvalproicacidreduced;plasmaconcentrationoffosphenytoinincreasedbylSTIRIPENTOL;plasmaconcentrationoffosphenytoinincreasedbylTOPIRAMATE(alsoplasmaconcentrationoftopiramatereduced);plasmaconcentrationoffosphenytoinreducedbyVIGABATRINlAntifungals:fosphenytoinreducesplasmaconcentrationoflKETOCONAZOLEandlPOSACONAZOLE;anticonvulsanteffectoffosphenytoinenhancedbylMICONAZOLE(plasmaconcentrationoffosphenytoinincreased);plasmaconcentrationoffosphenytoinincreasedbylFLUCONAZOLE(considerreducingdoseoffosphenytoin);fosphenytoinreducesplasmaconcentrationoflITRACONAZOLE—avoidconcomitantuse;plasmaconcentrationoffosphenytoinincreasedbylVORICONAZOLE,alsofosphenytoinreducesplasmaconcentrationofvoriconazole(increasedoseofvoriconazoleandalsomonitorforfosphenytointoxicity);fosphenytoinpossiblyreducesplasmaconcentrationofCASPOFUNGIN—considerincreasingdoseofcaspofunginlAntimalarials:avoidanceoffosphenytoinadvisedbymanufacturerofARTENIMOLWITHPIPERAQUINE;anticonvulsanteffectofantiepilepticsantagonisedbylMEFLOQUINE;anticonvulsanteffectoffosphenytoinantagonisedbylPYRIMETHAMINE,alsoincreasedantifolateeffectlAntipsychotics:anticonvulsanteffectofantiepilepticsantagonisedbylANTIPSYCHOTICS(convulsivethresholdlowered);fosphenytoinreducesplasmaconcentrationofHALOPERIDOL;plasmaconcentrationoffosphenytoinpossiblyincreasedordecreasedbyCHLORPROMAZINE;fosphenytoinpossiblyreducesplasmaconcentrationoflARIPIPRAZOLE(avoidconcomitantuseorconsiderincreasingthedoseofaripiprazole—consultaripiprazoleproductliterature);fosphenytoinacceleratesmetabolismofCLOZAPINEandQUETIAPINE(reducedplasmaconcentration);fosphenytoinpossiblyreducesplasmaconcentrationoflLURASIDONE—avoidconcomitantuselAntivirals:fosphenytoinpossiblyreducesplasmaconcentrationofABACAVIR,DARUNAVIR,LOPINAVIRandSAQUINAVIR;avoidanceoffosphenytoinadvisedbymanufactureroflBOCEPREVIRandlRILPIVIRINE(plasmaconcentrationofboceprevirandrilpivirinepossiblyreduced);fosphenytoinpossiblyreducesplasmaconcentrationoflDACLATASVIRandlSIMEPREVIR—manufacturerofdaclatasvirandsimepreviradvisesavoidconcomitantuse;avoidanceoffosphenytoinadvisedbymanufacturerofDOLUTEGRAVIR,lELVITEGRAVIR,ETRAVIRINE,SOFOSBUVIRandlTELAPREVIR;fosphenytoinpossiblyreducesplasmaconcentrationoflINDINAVIR,alsoplasmaconcentrationoffosphenytoinpossiblyincreased;fosphenytoinpossiblyreducesplasmaconcentrationofRITONAVIR,alsoplasmaconcentrationoffosphenytoinpossiblyaffected;plasmaconcentrationoffosphenytoinincreasedordecreasedbyZIDOVUDINE TRIANGLE AnxiolyticsandHypnotics:fosphenytoinoftenreducesplasmaconcentrationofCLONAZEPAM;plasmaconcentrationoffosphenytoinincreasedordecreasedbyDIAZEPAM;plasmaconcentrationoffosphenytoinpossiblyincreasedordecreasedbyBENZODIAZEPINES TRIANGLE Aprepitant:fosphenytoinpossiblyreducesplasmaconcentrationofAPREPITANT TRIANGLE Bupropion:fosphenytoinreducesplasmaconcentrationofBUPROPION TRIANGLE Caffeinecitrate:fosphenytoinreducesplasmaconcentrationofCAFFEINECITRATE1196Appendix1InteractionsBNF70Interactions|Appendix1"
"Fosphenytoin(continued)lCalcium-channelBlockers:fosphenytoinreduceseffectsofFELODIPINEandVERAPAMIL;avoidanceoffosphenytoinadvisedbymanufacturerofISRADIPINE;avoidanceoffosphenytoinadvisedbymanufacturerofNIMODIPINE(plasmaconcentrationofnimodipinepossiblyreduced);plasmaconcentrationoffosphenytoinincreasedbylDILTIAZEMbutalsoeffectofdiltiazemreducedlCannabisExtract:fosphenytoinpossiblyreducesplasmaconcentrationoflCANNABISEXTRACT—manufacturerofcannabisextractadvisesavoidconcomitantuse TRIANGLE CardiacGlycosides:fosphenytoinpossiblyreducesplasmaconcentrationofDIGOXINlCiclosporin:fosphenytoinacceleratesmetabolismoflCICLOSPORIN(reducedplasmaconcentration)lCobicistat:fosphenytoinpossiblyreducesplasmaconcentrationoflCOBICISTAT—manufacturerofcobicistatadvisesavoidconcomitantuselCorticosteroids:fosphenytoinacceleratesmetabolismoflCORTICOSTEROIDS(reducedeffect)lCytotoxics:fosphenytoinpossiblyreducesplasmaconcentrationofBUSULFAN,ERIBULINandETOPOSIDE;metabolismoffosphenytoinpossiblyinhibitedbyCAPECITABINE,FLUOROURACILandTEGAFUR(increasedriskoftoxicity);fosphenytoinincreasesantifolateeffectofMETHOTREXATE;plasmaconcentrationoffosphenytoinpossiblyreducedbyCISPLATIN;fosphenytoinpossiblydecreasesplasmaconcentrationofAXITINIB(increasedoseofaxitinib—consultaxitinibproductliterature);fosphenytoinpossiblyreducesplasmaconcentrationofBORTEZOMIB,lBOSUTINIB,CRIZOTINIB,lIBRUTINIB,lIDELALISIBandPONATINIB—manufacturerofbortezomib,bosutinib,crizotinib,ibrutinib,idelalisibandponatinibadvisesavoidconcomitantuse;fosphenytoinpossiblyreducesplasmaconcentrationoflCABOZANTINIB—avoidconcomitantuse;avoidanceoffosphenytoinadvisedbymanufactureroflCABAZITAXEL,DABRAFENIB,GEFITINIB,lLAPATINIBandVEMURAFENIB;avoidanceoffosphenytoinadvisedbymanufacturerofDASATINIBandlVISMODEGIB(plasmaconcentrationofdasatinibandvismodegibpossiblyreduced);fosphenytoinreducesplasmaconcentrationoflIMATINIB—avoidconcomitantuse;fosphenytoinreducesplasmaconcentrationofIRINOTECANanditsactivemetabolite;manufacturerofprocarbazineadvisespossibleincreasedriskofhypersensitivityreactionswhenfosphenytoingivenwithPROCARBAZINElDexrazoxane:absorptionoffosphenytoinpossiblyreducedbylDEXRAZOXANE TRIANGLE Diazoxide:plasmaconcentrationoffosphenytoinreducedbyDIAZOXIDE,alsoeffectofdiazoxidemaybereducedlDisulfiram:metabolismoffosphenytoininhibitedbylDISULFIRAM(increasedriskoftoxicity)lDiuretics:plasmaconcentrationoffosphenytoinpossiblyincreasedbylACETAZOLAMIDE;fosphenytoinantagoniseseffectsofFUROSEMIDE;fosphenytoinreducesplasmaconcentrationoflEPLERENONE—avoidconcomitantuse;increasedriskofosteomalaciawhenfosphenytoingivenwithCARBONICANHYDRASEINHIBITORS TRIANGLE Dopaminergics:fosphenytoinpossiblyreduceseffectsofCO-BENELDOPA,CO-CARELDOPAandLEVODOPA TRIANGLE EnteralFoods:absorptionoffosphenytoinpossiblyreducedbyENTERALFEEDS TRIANGLE Folates:plasmaconcentrationoffosphenytoinpossiblyreducedbyFOLATES TRIANGLE Fosaprepitant:fosphenytoinpossiblyreducesplasmaconcentrationofFOSAPREPITANTlHormoneAntagonists:fosphenytoinpossiblyreducesplasmaconcentrationoflABIRATERONE—manufacturerofabirateroneadvisesavoidconcomitantuse;fosphenytoinpossiblyacceleratesmetabolismofTOREMIFENE TRIANGLE 5HT3-receptorAntagonists:fosphenytoinacceleratesmetabolismofONDANSETRON(reducedeffect)lIvacaftor:fosphenytoinpossiblyreducesplasmaconcentrationoflIVACAFTOR—manufacturerofivacaftoradvisesavoidconcomitantuseFosphenytoin(continued) TRIANGLE Leflunomide:plasmaconcentrationoffosphenytoinpossiblyincreasedbyLEFLUNOMIDE TRIANGLE Lipid-regulatingDrugs:absorptionoffosphenytoinpossiblyreducedbyCOLESEVELAM;combinationoffosphenytoinwithFLUVASTATINmayincreaseplasmaconcentrationofeitherdrug(orboth) TRIANGLE Lithium:neurotoxicitymayoccurwhenfosphenytoingivenwithLITHIUMwithoutincreasedplasmaconcentrationoflithium TRIANGLE Macitentan:avoidanceoffosphenytoinadvisedbymanufacturerofMACITENTAN TRIANGLE Modafinil:plasmaconcentrationoffosphenytoinpossiblyincreasedbyMODAFINILlMuscleRelaxants:long-termuseoffosphenytoinreduceseffectsoflNON-DEPOLARISINGMUSCLERELAXANTS(butacuteuseoffosphenytoinmightincreaseeffectsofnon-depolarisingmusclerelaxants)lOestrogens:fosphenytoinacceleratesmetabolismoflOESTROGENS(reducedcontraceptiveeffectwithcombinedoralcontraceptives,contraceptivepatches,andvaginalrings—seeContraceptiveInteractionsinBNF)lOrlistat:possibleincreasedriskofconvulsionswhenantiepilepticsgivenwithlORLISTATlProgestogens:fosphenytoinacceleratesmetabolismoflPROGESTOGENS(reducedcontraceptiveeffectwithcombinedoralcontraceptives,progestogen-onlyoralcontraceptives,contraceptivepatches,vaginalrings,etonogestrel-releasingimplant,andemergencyhormonalcontraception—seeContraceptiveInteractionsinBNF) TRIANGLE Roflumilast:fosphenytoinpossiblyinhibitseffectsofROFLUMILAST(manufacturerofroflumilastadvisesavoidconcomitantuse)lSulfinpyrazone:plasmaconcentrationoffosphenytoinincreasedbylSULFINPYRAZONE TRIANGLE Sympathomimetics:plasmaconcentrationoffosphenytoinincreasedbyMETHYLPHENIDATE TRIANGLE Tacrolimus:fosphenytoinreducesplasmaconcentrationofTACROLIMUS,alsoplasmaconcentrationoffosphenytoinpossiblyincreasedlTheophylline:plasmaconcentrationofbothdrugsreducedwhenfosphenytoingivenwithlTHEOPHYLLINE TRIANGLE ThyroidHormones:fosphenytoinacceleratesmetabolismofTHYROIDHORMONES(mayincreaserequirementsinhypothyroidism),alsoplasmaconcentrationoffosphenytoinpossiblyincreased TRIANGLE Tibolone:fosphenytoinacceleratesmetabolismofTIBOLONE TRIANGLE Ticagrelor:fosphenytoinpossiblyreducesplasmaconcentrationofTICAGRELORlUlcer-healingDrugs:metabolismoffosphenytoininhibitedbylCIMETIDINE(increasedplasmaconcentration);effectsoffosphenytoinenhancedbylESOMEPRAZOLE;effectsoffosphenytoinpossiblyenhancedbyOMEPRAZOLE;absorptionoffosphenytoinreducedbylSUCRALFATElUlipristal:avoidanceoffosphenytoinadvisedbymanufactureroflULIPRISTAL(contraceptiveeffectofulipristalpossiblyreduced) TRIANGLE Vaccines:effectsoffosphenytoinenhancedbyINFLUENZAVACCINE TRIANGLE Vitamins:fosphenytoinpossiblyincreasesrequirementsforALFACALCIDOL,CALCITRIOL,COLECALCIFEROL,DIHYDROTACHYSTEROL,ERGOCALCIFEROL,PARICALCITOLorVITAMINDFrovatriptansee5HT1-receptorAgonists(underHT)FurosemideseeDiureticsFusidicAcidlAntivirals:plasmaconcentrationofbothdrugsincreasedwhenfusidicacidgivenwithlRITONAVIR—avoidconcomitantuse;plasmaconcentrationofbothdrugsmayincreasewhenfusidicacidgivenwithSAQUINAVIRlLipid-regulatingDrugs:riskofmyopathyandrhabdomyolysiswhenfusidicacidgivenwithlSTATINS—avoidconcomitantuseandfor7daysafterlastfusidicaciddose TRIANGLE Sugammadex:fusidicacidpossiblyreducesresponsetoSUGAMMADEXBNF70Appendix1Interactions1197Interactions|Appendix1"
"FusidicAcid(continued) TRIANGLE Vaccines:antibacterialsinactivateORALTYPHOIDVACCINE—seeunderTyphoidVaccineinBNFGabapentin TRIANGLE Analgesics:bioavailabilityofgabapentinincreasedbyMORPHINE TRIANGLE Antacids:absorptionofgabapentinreducedbyANTACIDSlAntidepressants:anticonvulsanteffectofantiepilepticspossiblyantagonisedbyMAOISandlTRICYCLIC-RELATEDANTIDEPRESSANTS(convulsivethresholdlowered);anticonvulsanteffectofantiepilepticsantagonisedbylSSRISandlTRICYCLICS(convulsivethresholdlowered)lAntimalarials:anticonvulsanteffectofantiepilepticsantagonisedbylMEFLOQUINElAntipsychotics:anticonvulsanteffectofantiepilepticsantagonisedbylANTIPSYCHOTICS(convulsivethresholdlowered)lOrlistat:possibleincreasedriskofconvulsionswhenantiepilepticsgivenwithlORLISTATGalantamineseeParasympathomimeticsGanciclovirNOTEIncreasedriskofmyelosuppressionwithothermyelosuppressivedrugs—consultproductliteraturelAntibacterials:increasedriskofconvulsionswhenganciclovirgivenwithlIMIPENEMWITHCILASTATINlAntivirals:ganciclovirpossiblyincreasesplasmaconcentrationofDIDANOSINE;profoundmyelosuppressionwhenganciclovirgivenwithlZIDOVUDINE(ifpossibleavoidconcomitantadministration,particularlyduringinitialganciclovirtherapy) TRIANGLE Mycophenolate:plasmaconcentrationofganciclovirpossiblyincreasedbyMYCOPHENOLATE,alsoplasmaconcentrationofinactivemetaboliteofmycophenolatepossiblyincreased TRIANGLE Tacrolimus:possibleincreasedriskofnephrotoxicitywhenganciclovirgivenwithTACROLIMUSGefitiniblAntibacterials:plasmaconcentrationofgefitinibreducedbylRIFAMPICIN—avoidconcomitantuselAnticoagulants:gefitinibpossiblyenhancesanticoagulanteffectoflWARFARIN TRIANGLE Antidepressants:manufacturerofgefitinibadvisesavoidconcomitantusewithSTJOHN’SWORT TRIANGLE Antiepileptics:manufacturerofgefitinibadvisesavoidconcomitantusewithCARBAMAZEPINE,FOSPHENYTOIN,PHENOBARBITAL,PHENYTOINandPRIMIDONE TRIANGLE Antifungals:plasmaconcentrationofgefitinibincreasedbyITRACONAZOLElAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lAntivirals:avoidanceofgefitinibadvisedbymanufactureroflBOCEPREVIRlUlcer-healingDrugs:plasmaconcentrationofgefitinibreducedbylRANITIDINEGemcitabine TRIANGLE Anticoagulants:gemcitabinepossiblyenhancesanticoagulanteffectofWARFARINlAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)GemeprostseeProstaglandinsGemfibrozilseeFibratesGentamicinseeAminoglycosidesGestodeneseeProgestogensGlibenclamideseeAntidiabeticsGliclazideseeAntidiabeticsGlimepirideseeAntidiabeticsGlipizideseeAntidiabeticsGlucosaminelAnticoagulants:glucosamineenhancesanticoagulanteffectoflWARFARIN(avoidconcomitantuse)GlycerylTrinitrateseeNitratesGlycopyrroniumseeAntimuscarinicsGolimumablAbatacept:avoidconcomitantuseofgolimumabwithlABATACEPTGolimumab(continued)lAnakinra:avoidconcomitantuseofgolimumabwithlANAKINRAlAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lVaccines:riskofgeneralisedinfectionswhenmonoclonalantibodiesgivenwithlivelVACCINES—avoidconcomitantuseGranisetronsee5HT3-receptorAntagonists(underHT)GrapefruitJuicelAliskiren:grapefruitjuicereducesplasmaconcentrationoflALISKIREN—avoidconcomitantuse TRIANGLE Anthelmintics:grapefruitjuiceincreasesplasmaconcentrationofactivemetaboliteofALBENDAZOLE;grapefruitjuiceincreasesplasmaconcentrationofPRAZIQUANTELlAnti-arrhythmics:grapefruitjuiceincreasesplasmaconcentrationofAMIODARONE;grapefruitjuiceincreasesplasmaconcentrationoflDRONEDARONE—avoidconcomitantuse TRIANGLE Antidepressants:grapefruitjuicepossiblyincreasesplasmaconcentrationofSERTRALINE TRIANGLE Antihistamines:grapefruitjuicereducesplasmaconcentrationofBILASTINE TRIANGLE Antimalarials:grapefruitjuicepossiblyincreasesplasmaconcentrationofARTEMETHERWITHLUMEFANTRINE;avoidanceofgrapefruitjuiceadvisedbymanufacturerofARTENIMOLWITHPIPERAQUINElAntipsychotics:avoidanceofgrapefruitjuiceadvisedbymanufacturerofLURASIDONEandPIMOZIDE;grapefruitjuicepossiblyincreasesplasmaconcentrationoflQUETIAPINE—manufacturerofquetiapineadvisesavoidconcomitantuse TRIANGLE Antivirals:grapefruitjuicepossiblyincreasesplasmaconcentrationofEFAVIRENZ TRIANGLE AnxiolyticsandHypnotics:grapefruitjuicepossiblyincreasesplasmaconcentrationoforalMIDAZOLAM;grapefruitjuiceincreasesplasmaconcentrationofBUSPIRONE TRIANGLE Avanafil:grapefruitjuicepossiblyincreasesplasmaconcentrationofAVANAFIL—manufacturerofavanafiladvisesavoidgrapefruitjuicefor24hoursbeforeavanafil TRIANGLE Calcium-channelBlockers:grapefruitjuicepossiblyincreasesplasmaconcentrationofAMLODIPINE;grapefruitjuiceincreasesplasmaconcentrationofFELODIPINE,ISRADIPINE,LACIDIPINE,LERCANIDIPINE,NICARDIPINE,NIFEDIPINE,NIMODIPINEandVERAPAMILlCiclosporin:grapefruitjuiceincreasesplasmaconcentrationoflCICLOSPORIN(increasedriskoftoxicity)lColchicine:grapefruitjuicepossiblyincreasesriskoflCOLCHICINEtoxicitylCorticosteroids:grapefruitjuiceincreasesplasmaconcentrationoforallBUDESONIDE—avoidconcurrentuseorseparateadministrationbyasmuchaspossibleandconsiderreducingoralbudesonidedoselCytotoxics:grapefruitjuicepossiblyincreasesplasmaconcentrationofAXITINIB,CABOZANTINIBandPONATINIB;grapefruitjuicepossiblyincreasestheplasmaconcentrationoflBOSUTINIB—manufacturerofbosutinibadvisesavoidorconsiderreducingdoseofbosutinib;grapefruitjuicepossiblyincreasesplasmaconcentrationoflCRIZOTINIBandVINFLUNINE—manufacturerofcrizotinibandvinflunineadvisesavoidconcomitantuse;avoidanceofgrapefruitjuiceadvisedbymanufacturerofDASATINIB(plasmaconcentrationofdasatinibpossiblyincreased);avoidanceofgrapefruitjuiceadvisedbymanufacturerofEVEROLIMUS,IBRUTINIB,lLAPATINIB,lNILOTINIBandlPAZOPANIB TRIANGLE Ivabradine:grapefruitjuiceincreasesplasmaconcentrationofIVABRADINE TRIANGLE Ivacaftor:grapefruitjuicepossiblyincreasesplasmaconcentrationofIVACAFTOR—manufacturerofivacaftoradvisesavoidconcomitantuselLipid-regulatingDrugs:grapefruitjuicepossiblyincreasesplasmaconcentrationofATORVASTATIN;grapefruitjuiceincreasesplasmaconcentrationoflSIMVASTATIN—avoidconcomitantuse;avoidanceofgrapefruitjuiceadvisedbymanufacturerofLOMITAPIDE TRIANGLE Pirfenidone:avoidanceofgrapefruitjuiceadvisedbymanufacturerofPIRFENIDONE1198Appendix1InteractionsBNF70Interactions|Appendix1"
"GrapefruitJuice(continued)lRanolazine:grapefruitjuicepossiblyincreasesplasmaconcentrationoflRANOLAZINE—manufacturerofranolazineadvisesavoidconcomitantuse TRIANGLE Sildenafil:grapefruitjuicepossiblyincreasesplasmaconcentrationofSILDENAFILlSirolimus:grapefruitjuiceincreasesplasmaconcentrationoflSIROLIMUS—avoidconcomitantuselTacrolimus:grapefruitjuiceincreasesplasmaconcentrationoflTACROLIMUS TRIANGLE Tadalafil:grapefruitjuicepossiblyincreasesplasmaconcentrationofTADALAFILlTolvaptan:grapefruitjuiceincreasesplasmaconcentrationoflTOLVAPTAN—avoidconcomitantuse TRIANGLE Ulipristal:avoidanceofgrapefruitjuiceadvisedbymanufactureroflow-doseULIPRISTALlVardenafil:grapefruitjuicepossiblyincreasesplasmaconcentrationoflVARDENAFIL—avoidconcomitantuseGriseofulvin TRIANGLE Alcohol:griseofulvinpossiblyenhanceseffectsofALCOHOLlAnticoagulants:griseofulvinreducesanticoagulanteffectoflCOUMARINS TRIANGLE Antiepileptics:absorptionofgriseofulvinreducedbyPHENOBARBITALandPRIMIDONE(reducedeffect) TRIANGLE Ciclosporin:griseofulvinpossiblyreducesplasmaconcentrationofCICLOSPORIN TRIANGLE Oestrogens:anecdotalreportsofcontraceptivefailureandmenstrualirregularitieswhengriseofulvingivenwithOESTROGENS TRIANGLE Progestogens:anecdotalreportsofcontraceptivefailureandmenstrualirregularitieswhengriseofulvingivenwithPROGESTOGENSGuanethidineseeAdrenergicNeuroneBlockersHaemophilusVaccineseeVaccinesHaloperidolseeAntipsychoticsHeparinseeHeparinsHeparins TRIANGLE ACEInhibitors:increasedriskofhyperkalaemiawhenheparinsgivenwithACEINHIBITORS TRIANGLE Aliskiren:increasedriskofhyperkalaemiawhenheparinsgivenwithALISKIRENlAnalgesics:possibleincreasedriskofbleedingwhenheparinsgivenwithNSAIDS;increasedriskofhaemorrhagewhenanticoagulantsgivenwithintravenouslDICLOFENAC(avoidconcomitantuse,includinglow-doseheparins);increasedriskofhaemorrhagewhenanticoagulantsgivenwithlKETOROLAC(avoidconcomitantuse,includinglow-doseheparins);anticoagulanteffectofheparinsenhancedbylASPIRIN TRIANGLE Angiotensin-IIReceptorAntagonists:increasedriskofhyperkalaemiawhenheparinsgivenwithANGIOTENSIN-IIRECEPTORANTAGONISTSlAnticoagulants:increasedriskofhaemorrhagewhenotheranticoagulantsgivenwithlAPIXABAN,lDABIGATRANandlRIVAROXABAN(avoidconcomitantuseexceptwhenswitchingwithotheranticoagulantsorusingheparintomaintaincatheterpatency) TRIANGLE Clopidogrel:increasedriskofbleedingwhenheparinsgivenwithCLOPIDOGREL TRIANGLE Dipyridamole:anticoagulanteffectofheparinsenhancedbyDIPYRIDAMOLE TRIANGLE Iloprost:anticoagulanteffectofheparinspossiblyenhancedbyILOPROSTlNitrates:anticoagulanteffectofheparinsreducedbyinfusionoflGLYCERYLTRINITRATEHepatitisVaccinesseeVaccinesHistamine TRIANGLE Antidepressants:manufacturerofhistamineadvisesavoidconcomitantusewithMAOIS;effectsofhistaminetheoreticallyantagonisedbyTRICYCLICS—manufacturerofhistamineadvisesavoidconcomitantuse TRIANGLE Antihistamines:effectsofhistaminetheoreticallyantagonisedbyANTIHISTAMINES—manufacturerofhistamineadvisesavoidconcomitantuseHistamine(continued) TRIANGLE Antimalarials:manufacturerofhistamineadvisesavoidconcomitantusewithANTIMALARIALS TRIANGLE Antipsychotics:effectsofhistaminetheoreticallyantagonisedbyANTIPSYCHOTICS—manufacturerofhistamineadvisesavoidconcomitantuse TRIANGLE Atovaquone:manufacturerofhistamineadvisesavoidconcomitantusewithATOVAQUONE TRIANGLE Clonidine:manufacturerofhistamineadvisesavoidconcomitantusewithCLONIDINE TRIANGLE Corticosteroids:manufacturerofhistamineadvisesavoidconcomitantusewithCORTICOSTEROIDS TRIANGLE Ulcer-healingDrugs:effectsofhistaminetheoreticallyantagonisedbyHISTAMINEH2-ANTAGONISTS—manufacturerofhistamineadvisesavoidconcomitantuseHistamineH2-antagonistslAlpha-blockers:cimetidineandranitidineantagoniseeffectsoflTOLAZOLINElAminophylline:cimetidineinhibitsmetabolismoflAMINOPHYLLINE(increasedplasmaconcentration) TRIANGLE Analgesics:cimetidineinhibitsmetabolismofOPIOIDANALGESICS(increasedplasmaconcentration) TRIANGLE Anthelmintics:cimetidinepossiblyenhanceseffectsofALBENDAZOLE;cimetidinepossiblyinhibitsmetabolismofMEBENDAZOLE(increasedplasmaconcentration);cimetidineincreasesplasmaconcentrationofPRAZIQUANTELlAnti-arrhythmics:cimetidineincreasesplasmaconcentrationofAMIODARONEandlPROPAFENONE;cimetidineinhibitsmetabolismofFLECAINIDE(increasedplasmaconcentration);cimetidineincreasesplasmaconcentrationoflLIDOCAINE(increasedriskoftoxicity) TRIANGLE Antibacterials:cimetidineincreasesplasmaconcentrationofERYTHROMYCIN(increasedriskoftoxicity,includingdeafness);cimetidineinhibitsmetabolismofMETRONIDAZOLE(increasedplasmaconcentration);metabolismofcimetidineacceleratedbyRIFAMPICIN(reducedplasmaconcentration)lAnticoagulants:cimetidineinhibitsmetabolismoflCOUMARINS(enhancedanticoagulanteffect) TRIANGLE Antidepressants:cimetidineincreasesplasmaconcentrationofCITALOPRAM,ESCITALOPRAM,MIRTAZAPINEandSERTRALINE;cimetidineinhibitsmetabolismofAMITRIPTYLINE,DOXEPIN,IMIPRAMINEandNORTRIPTYLINE(increasedplasmaconcentration);cimetidineincreasesplasmaconcentrationofMOCLOBEMIDE(halvedoseofmoclobemide);cimetidinepossiblyincreasesplasmaconcentrationofTRICYCLICS TRIANGLE Antidiabetics:cimetidinereducesexcretionofMETFORMIN(increasedplasmaconcentration);cimetidineenhanceshypoglycaemiceffectofSULFONYLUREASlAntiepileptics:cimetidineinhibitsmetabolismoflCARBAMAZEPINE,lFOSPHENYTOIN,lPHENYTOIN,lSODIUMVALPROATEandlVALPROICACID(increasedplasmaconcentration)lAntifungals:histamineH2-antagonistsreduceabsorptionofITRACONAZOLEandKETOCONAZOLE;cimetidinereducesplasmaconcentrationoflPOSACONAZOLE—manufacturerofposaconazolesuspensionadvisesavoidconcomitantuse;famotidine,nizatidineandranitidinepossiblyreduceplasmaconcentrationoflPOSACONAZOLE—manufacturerofposaconazolesuspensionadvisesavoidconcomitantuse;cimetidineincreasesplasmaconcentrationofTERBINAFINE TRIANGLE Antihistamines:manufacturerofloratadineadvisescimetidinepossiblyincreasesplasmaconcentrationofLORATADINE;cimetidineincreasesplasmaconcentrationofHYDROXYZINElAntimalarials:avoidanceofcimetidineadvisedbymanufactureroflARTEMETHERWITHLUMEFANTRINE;cimetidineinhibitsmetabolismofCHLOROQUINE,HYDROXYCHLOROQUINEandQUININE(increasedplasmaconcentration) TRIANGLE Antipsychotics:cimetidinepossiblyenhanceseffectsofANTIPSYCHOTICS,CHLORPROMAZINEandCLOZAPINElAntivirals:manufacturerofatazanaviradvisesadjustdosesofbothdrugswhencimetidineandnizatidinegivenwithATAZANAVIR—consultatazanavirproductliterature;famotidineandranitidinereducetheplasmaconcentrationoflATAZANAVIR(adjustdosesofbothdrugs—consultatazanavirproductliterature);famotidineincreasesplasmaBNF70Appendix1Interactions1199Interactions|Appendix1"
"HistamineH2-antagonistslAntivirals(continued)concentrationofRALTEGRAVIR;avoidanceofhistamineH2-antagonistsfor12hoursbeforeor4hoursafterRILPIVIRINEadvisedbymanufacturerofrilpivirine—consultproductliterature;cimetidinepossiblyincreasesplasmaconcentrationofSAQUINAVIR TRIANGLE AnxiolyticsandHypnotics:cimetidineinhibitsmetabolismofBENZODIAZEPINES,CLOMETHIAZOLEandZALEPLON(increasedplasmaconcentration);cimetidineincreasesplasmaconcentrationofMELATONIN TRIANGLE Beta-blockers:cimetidineincreasesplasmaconcentrationofLABETALOL,METOPROLOLandPROPRANOLOL;cimetidinepossiblyincreasesplasmaconcentrationoforalTIMOLOL TRIANGLE Caffeinecitrate:cimetidineincreasesplasmaconcentrationofCAFFEINECITRATE TRIANGLE Calcium-channelBlockers:cimetidinepossiblyinhibitsmetabolismofCALCIUM-CHANNELBLOCKERS(increasedplasmaconcentration);cimetidineincreasesplasmaconcentrationofISRADIPINE(halvedoseofisradipine)lCiclosporin:cimetidinepossiblyincreasesplasmaconcentrationoflCICLOSPORINlClopidogrel:cimetidinepossiblyreducesantiplateleteffectoflCLOPIDOGRELlCytotoxics:cimetidinepossiblyenhancesmyelosuppressiveeffectsofCARMUSTINEandLOMUSTINE;cimetidinereducesplasmaconcentrationofDOXORUBICIN;cimetidineincreasesplasmaconcentrationoflEPIRUBICIN;cimetidineinhibitsmetabolismofCAPECITABINE,FLUOROURACILandTEGAFUR(increasedplasmaconcentration);famotidinepossiblyreducesplasmaconcentrationofDASATINIB;avoidanceofcimetidine,famotidineandnizatidineadvisedbymanufactureroflERLOTINIB;ranitidinereducesplasmaconcentrationoflERLOTINIB—manufactureroferlotinibadvisesgiveatleast2hoursbeforeor10hoursafterranitidine;ranitidinereducesplasmaconcentrationoflGEFITINIB;histamineH2-antagonistspossiblyreduceabsorptionofLAPATINIB;histamineH2-antagonistspossiblyreduceabsorptionofPAZOPANIB—manufacturerofpazopanibadvisesgiveatleast2hoursbeforeor10hoursafterhistamineH2-antagonists TRIANGLE Dopaminergics:cimetidinereducesexcretionofPRAMIPEXOLE(increasedplasmaconcentration)lErgotAlkaloids:increasedriskofergotismwhencimetidinegivenwithlERGOTAMINE—avoidconcomitantuselFampridine:avoidanceofcimetidineadvisedbymanufactureroflFAMPRIDINE TRIANGLE Histamine:histamineH2-antagoniststheoreticallyantagoniseeffectsofHISTAMINE—manufacturerofhistamineadvisesavoidconcomitantuse TRIANGLE HormoneAntagonists:absorptionofcimetidinepossiblydelayedbyOCTREOTIDE TRIANGLE 5HT1-receptorAgonists:cimetidineinhibitsmetabolismofZOLMITRIPTAN(reducedoseofzolmitriptan) TRIANGLE Lipid-regulatingDrugs:separatingadministrationfromcimetidineandranitidineby12hoursadvisedbymanufacturerofLOMITAPIDE TRIANGLE Roflumilast:cimetidineinhibitsthemetabolismofROFLUMILAST TRIANGLE Sildenafil:cimetidineincreasesplasmaconcentrationofSILDENAFIL—considerreducingdoseofsildenafilforerectiledysfunction TRIANGLE Sympathomimetics:cimetidinepossiblyinhibitsmetabolismofDOBUTAMINElTheophylline:cimetidineinhibitsmetabolismoflTHEOPHYLLINE(increasedplasmaconcentration) TRIANGLE ThyroidHormones:cimetidinereducesabsorptionofLEVOTHYROXINEHomatropineseeAntimuscarinicsHormoneAntagonistsseeAbiraterone,Bicalutamide,Danazol,Dutasteride,Enzalutamide,Exemestane,Flutamide,Lanreotide,Octreotide,Pasireotide,Tamoxifen,andToremifene5HT1-receptorAgonistslAntibacterials:plasmaconcentrationofeletriptanincreasedbylCLARITHROMYCINandlERYTHROMYCIN(riskoftoxicity)—5HT1-receptorAgonistslAntibacterials(continued)avoidconcomitantuse;metabolismofzolmitriptanpossiblyinhibitedbyQUINOLONES(reducedoseofzolmitriptan)lAntidepressants:increasedriskofCNStoxicitywhen5HT1agonistsgivenwithlCITALOPRAM(manufacturerofcitalopramadvisesavoidconcomitantuse);increasedriskofCNStoxicitywhensumatriptangivenwithlCITALOPRAM,lESCITALOPRAM,lFLUOXETINE,lFLUVOXAMINEorlPAROXETINE;metabolismoffrovatriptaninhibitedbyFLUVOXAMINE;metabolismofzolmitriptanpossiblyinhibitedbyFLUVOXAMINE(reducedoseofzolmitriptan);CNStoxicityreportedwhensumatriptangivenwithSERTRALINE;possibleincreasedserotonergiceffectswhen5HT1agonistsgivenwithDULOXETINEorVENLAFAXINE;riskofCNStoxicitywhenrizatriptanorsumatriptangivenwithlMAOIS(avoidrizatriptanorsumatriptanfor2weeksafterMAOIs);riskofCNStoxicitywhenzolmitriptangivenwithlMAOISorlMOCLOBEMIDE(reducedoseofzolmitriptan);riskofCNStoxicitywhenrizatriptanorsumatriptangivenwithlMOCLOBEMIDE(avoidrizatriptanorsumatriptanfor2weeksaftermoclobemide);possibleincreasedserotonergiceffectswhennaratriptangivenwithSSRIS;increasedserotonergiceffectswhen5HT1agonistsgivenwithlSTJOHN’SWORT—avoidconcomitantuselAntifungals:plasmaconcentrationofeletriptanincreasedbylITRACONAZOLEandlKETOCONAZOLE(riskoftoxicity)—avoidconcomitantuse;plasmaconcentrationofalmotriptanincreasedbyKETOCONAZOLE(increasedriskoftoxicity)lAntivirals:plasmaconcentrationofeletriptanincreasedbylINDINAVIRandlRITONAVIR(riskoftoxicity)—avoidconcomitantuse TRIANGLE Beta-blockers:plasmaconcentrationofrizatriptanincreasedbyPROPRANOLOL(manufacturerofrizatriptanadviseshalvedoseandavoidwithin2hoursofpropranolol)lDapoxetine:possibleincreasedriskofserotonergiceffectswhen5HT1agonistsgivenwithlDAPOXETINE(manufacturerofdapoxetineadvises5HT1agonistsshouldnotbestarteduntil1weekafterstoppingdapoxetine,avoiddapoxetinefor2weeksafterstopping5HT1agonists) TRIANGLE Dopaminergics:avoidanceof5HT1agonistsadvisedbymanufacturerofSELEGILINElErgotAlkaloids:increasedriskofvasospasmwheneletriptan,frovatriptanornaratriptangivenwithlERGOTAMINE(avoidergotaminefor24hoursaftereletriptan,frovatriptanornaratriptan,avoideletriptan,frovatriptanornaratriptanfor24hoursafterergotamine);increasedriskofvasospasmwhenalmotriptan,rizatriptan,sumatriptanorzolmitriptangivenwithlERGOTAMINE(avoidergotaminefor6hoursafteralmotriptan,rizatriptan,sumatriptanorzolmitriptan,avoidalmotriptan,rizatriptan,sumatriptanorzolmitriptanfor24hoursafterergotamine) TRIANGLE Lithium:possibleriskoftoxicitywhensumatriptangivenwithLITHIUM TRIANGLE Ulcer-healingDrugs:metabolismofzolmitriptaninhibitedbyCIMETIDINE(reducedoseofzolmitriptan)5HT3-receptorAntagonists TRIANGLE Analgesics:ondansetronpossiblyantagoniseseffectsofTRAMADOL TRIANGLE Antibacterials:metabolismofondansetronacceleratedbyRIFAMPICIN(reducedeffect) TRIANGLE Antidepressants:possibleincreasedserotonergiceffectswhen5HT3antagonistsgivenwithSSRI-RELATEDANTIDEPRESSANTSorSSRIS TRIANGLE Antiepileptics:metabolismofondansetronacceleratedbyCARBAMAZEPINE,FOSPHENYTOINandPHENYTOIN(reducedeffect)lCytotoxics:increasedriskofventriculararrhythmiaswhenondansetrongivenwithlVANDETANIB—avoidconcomitantuselDopaminergics:possibleincreasedhypotensiveeffectwhenondansetrongivenwithlAPOMORPHINE—avoidconcomitantuseHumanpapillomavirusVaccineseeVaccinesHydralazineseeVasodilatorAntihypertensives1200Appendix1InteractionsBNF70Interactions|Appendix1"
"HydrochlorothiazideseeDiureticsHydrocortisoneseeCorticosteroidsHydroflumethiazideseeDiureticsHydromorphoneseeOpioidAnalgesicsHydrotalciteseeAntacidsHydroxocobalamin TRIANGLE Antibacterials:responsetohydroxocobalaminreducedbyCHLORAMPHENICOLHydroxycarbamidelAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lAntivirals:increasedriskoftoxicitywhenhydroxycarbamidegivenwithlDIDANOSINEandlSTAVUDINE—avoidconcomitantuseHydroxychloroquine TRIANGLE Adsorbents:absorptionofhydroxychloroquinereducedbyKAOLIN TRIANGLE AgalsidaseAlfaandBeta:hydroxychloroquinepossiblyinhibitseffectsofAGALSIDASEALFAANDBETA(manufacturersofagalsidasealfaandbetaadviseavoidconcomitantuse) TRIANGLE Antacids:absorptionofhydroxychloroquinereducedbyANTACIDSlAnti-arrhythmics:increasedriskofventriculararrhythmiaswhenhydroxychloroquinegivenwithlAMIODARONE—avoidconcomitantuselAntibacterials:increasedriskofventriculararrhythmiaswhenhydroxychloroquinegivenwithlMOXIFLOXACIN—avoidconcomitantuselAntimalarials:avoidanceofantimalarialsadvisedbymanufactureroflARTEMETHERWITHLUMEFANTRINE;increasedriskofconvulsionswhenhydroxychloroquinegivenwithlMEFLOQUINElAntipsychotics:increasedriskofventriculararrhythmiaswhenhydroxychloroquinegivenwithlDROPERIDOL—avoidconcomitantuselCardiacGlycosides:hydroxychloroquinepossiblyincreasesplasmaconcentrationoflDIGOXINlCiclosporin:hydroxychloroquineincreasesplasmaconcentrationoflCICLOSPORIN(increasedriskoftoxicity)lCytotoxics:possibleincreasedriskofventriculararrhythmiaswhenhydroxychloroquinegivenwithlBOSUTINIB TRIANGLE Histamine:avoidanceofantimalarialsadvisedbymanufacturerofHISTAMINE TRIANGLE Lanthanum:absorptionofhydroxychloroquinepossiblyreducedbyLANTHANUM(giveatleast2hoursapart) TRIANGLE Laronidase:hydroxychloroquinepossiblyinhibitseffectsofLARONIDASE(manufactureroflaronidaseadvisesavoidconcomitantuse) TRIANGLE Parasympathomimetics:hydroxychloroquinehaspotentialtoincreasesymptomsofmyastheniagravisandthusdiminisheffectofNEOSTIGMINEandPYRIDOSTIGMINE TRIANGLE Ulcer-healingDrugs:metabolismofhydroxychloroquineinhibitedbyCIMETIDINE(increasedplasmaconcentration) TRIANGLE Vaccines:antimalarialsinactivateORALTYPHOIDVACCINE—seeunderTyphoidVaccineinBNFHydroxyzineseeAntihistaminesHyoscineseeAntimuscarinicsIbandronicAcidseeBisphosphonatesIbrutiniblAnti-arrhythmics:plasmaconcentrationofibrutinibpossiblyincreasedbylAMIODARONEandlDRONEDARONE—reducedoseofibrutinib(seeunderIbrutinib,p809)lAntibacterials:plasmaconcentrationofibrutinibpossiblyincreasedbylCIPROFLOXACIN,lCLARITHROMYCIN,lERYTHROMYCINandlTELITHROMYCIN—reducedoseofibrutinib(seeunderIbrutinib,p809);plasmaconcentrationofibrutinibreducedbylRIFAMPICIN—avoidconcomitantuse TRIANGLE Anticoagulants:manufacturerofibrutinibadvisesavoidconcomitantusewithCOUMARINSandPHENINDIONElAntidepressants:plasmaconcentrationofibrutinibpossiblyreducedbylSTJOHN’SWORT—manufacturerofibrutinibadvisesavoidconcomitantuselAntiepileptics:plasmaconcentrationofibrutinibpossiblyreducedbylCARBAMAZEPINE,lFOSPHENYTOINandIbrutiniblAntiepileptics(continued)lPHENYTOIN—manufacturerofibrutinibadvisesavoidconcomitantuselAntifungals:plasmaconcentrationofibrutinibincreasedbylKETOCONAZOLE—reducedoseofibrutinib(seeunderIbrutinib,p809);plasmaconcentrationofibrutinibpossiblyincreasedbylFLUCONAZOLE,lITRACONAZOLEandlVORICONAZOLE—reducedoseofibrutinib(seeunderIbrutinib,p809)lAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lAntivirals:plasmaconcentrationofibrutinibpossiblyincreasedbylATAZANAVIR,lDARUNAVIR,lFOSAMPRENAVIR,lINDINAVIR,lRITONAVIRandlSAQUINAVIR—reducedoseofibrutinib(seeunderIbrutinib,p809)lAprepitant:plasmaconcentrationofibrutinibpossiblyincreasedbylAPREPITANT—reducedoseofibrutinib(seeunderIbrutinib,p809)lCalcium-channelBlockers:plasmaconcentrationofibrutinibpossiblyincreasedbylDILTIAZEMandlVERAPAMIL—reducedoseofibrutinib(seeunderIbrutinib,p809) TRIANGLE CardiacGlycosides:manufacturerofibrutinibadvisesgiveDIGOXINatleast6hoursbeforeorafteribrutiniblCobicistat:plasmaconcentrationofibrutinibpossiblyincreasedbylCOBICISTAT—reducedoseofibrutinib(seeunderIbrutinib,p809)lCytotoxics:plasmaconcentrationofibrutinibpossiblyincreasedbylCRIZOTINIBandlIMATINIB—reducedoseofibrutinib(seeunderIbrutinib,p809) TRIANGLE Fosaprepitant:plasmaconcentrationofibrutinibpossiblyincreasedbyFOSAPREPITANT TRIANGLE GrapefruitJuice:manufacturerofibrutinibadvisesavoidconcomitantusewithGRAPEFRUITJUICE TRIANGLE Vitamins:manufacturerofibrutinibadvisesavoidconcomitantusewithVITAMINEIbuprofenseeNSAIDsIdarubicinlAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lCiclosporin:plasmaconcentrationofidarubicinincreasedbylCICLOSPORINIdelalisib TRIANGLE Alpha-blockers:manufacturerofidelalisibadvisesavoidconcomitantusewithALFUZOSIN TRIANGLE Anti-arrhythmics:manufacturerofidelalisibadvisesavoidconcomitantusewithAMIODARONElAntibacterials:plasmaconcentrationofidelalisibreducedbylRIFAMPICIN—avoidconcomitantuselAntidepressants:plasmaconcentrationofidelalisibpossiblyreducedbylSTJOHN’SWORT—manufacturerofidelalisibadvisesavoidconcomitantuselAntiepileptics:plasmaconcentrationofidelalisibpossiblyreducedbylCARBAMAZEPINE,lFOSPHENYTOINandlPHENYTOIN—manufacturerofidelalisibadvisesavoidconcomitantuse TRIANGLE Antifungals:plasmaconcentrationofidelalisibincreasedbyKETOCONAZOLElAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis);manufacturerofidelalisibadvisesavoidconcomitantusewithPIMOZIDEandQUETIAPINE TRIANGLE AnxiolyticsandHypnotics:manufacturerofidelalisibadvisesavoidconcomitantuseoforalMIDAZOLAM TRIANGLE ErgotAlkaloids:manufacturerofidelalisibadvisesavoidconcomitantusewithERGOTAMINE TRIANGLE Lipid-regulatingDrugs:manufacturerofidelalisibadvisesavoidconcomitantusewithSIMVASTATIN TRIANGLE Sildenafil:manufacturerofidelalisibadvisesavoidconcomitantuseofSILDENAFILforpulmonaryarterialhypertension TRIANGLE Sympathomimetics,Beta2:manufacturerofidelalisibadvisesavoidconcomitantusewithSALMETEROLIfosfamidelAnticoagulants:ifosfamidepossiblyenhancesanticoagulanteffectoflCOUMARINSBNF70Appendix1Interactions1201Interactions|Appendix1"
"Ifosfamide(continued) TRIANGLE Antifungals:metabolismofifosfamideinhibitedbyKETOCONAZOLElAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis) TRIANGLE Cytotoxics:increasedriskofotoxicitywhenifosfamidegivenwithCISPLATINIloprost TRIANGLE Analgesics:increasedriskofbleedingwheniloprostgivenwithNSAIDSorASPIRIN TRIANGLE Anticoagulants:iloprostpossiblyenhancesanticoagulanteffectofCOUMARINSandHEPARINS;increasedriskofbleedingwheniloprostgivenwithPHENINDIONE TRIANGLE Clopidogrel:increasedriskofbleedingwheniloprostgivenwithCLOPIDOGREL TRIANGLE Eptifibatide:increasedriskofbleedingwheniloprostgivenwithEPTIFIBATIDE TRIANGLE Tirofiban:increasedriskofbleedingwheniloprostgivenwithTIROFIBANImatinib TRIANGLE Analgesics:manufacturerofimatinibadvisescautionwithPARACETAMOLlAntibacterials:plasmaconcentrationofimatinibreducedbylRIFAMPICIN—avoidconcomitantuse TRIANGLE Anticoagulants:manufacturerofimatinibadvisesreplacementofWARFARINwithaheparin(possibilityofenhancedwarfarineffect)lAntidepressants:plasmaconcentrationofimatinibreducedbylSTJOHN’SWORT—avoidconcomitantuselAntiepileptics:plasmaconcentrationofimatinibreducedbylCARBAMAZEPINE,lFOSPHENYTOIN,lOXCARBAZEPINEandlPHENYTOIN—avoidconcomitantuse TRIANGLE Antifungals:plasmaconcentrationofimatinibincreasedbyKETOCONAZOLElAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lAntivirals:avoidanceofimatinibadvisedbymanufactureroflBOCEPREVIR TRIANGLE Ciclosporin:imatinibpossiblyincreasesplasmaconcentrationofCICLOSPORINlCytotoxics:imatinibpossiblyincreasestheplasmaconcentrationoflBOSUTINIB—manufacturerofbosutinibadvisesavoidorconsiderreducingdoseofbosutinib;imatinibincreasesplasmaconcentrationoflEVEROLIMUS(considerreducingthedoseofeverolimus—consulteverolimusproductliterature);imatinibpossiblyincreasestheplasmaconcentrationoflIBRUTINIB—reducedoseofibrutinib(seeunderIbrutinib,p809) TRIANGLE Lipid-regulatingDrugs:imatinibincreasesplasmaconcentrationofSIMVASTATIN TRIANGLE Tacrolimus:imatinibincreasesplasmaconcentrationofTACROLIMUS TRIANGLE ThyroidHormones:imatinibpossiblyreducesplasmaconcentrationofLEVOTHYROXINEImidaprilseeACEInhibitorsImipenemwithCilastatinlAntiepileptics:carbapenemsreduceplasmaconcentrationoflSODIUMVALPROATEandlVALPROICACID—avoidconcomitantuselAntivirals:increasedriskofconvulsionswhenimipenemwithcilastatingivenwithlGANCICLOVIRorlVALGANCICLOVIR TRIANGLE Vaccines:antibacterialsinactivateORALTYPHOIDVACCINE—seeunderTyphoidVaccineinBNFImipramineseeAntidepressants,TricyclicImmunoglobulinslVaccines:anti-dimmunoglobulinsandnormalimmunoglobulinmightimpairimmuneresponsetolBCGVACCINE—giveBCGvaccineatleast3weeksbeforeor3monthsafteranti-dimmunoglobulinsandnormalimmunoglobulin;anti-dimmunoglobulinsandnormalimmunoglobulinmightimpairimmuneresponsetolMMRVACCINE—giveMMRvaccineatleast3weeksbeforeor3monthsafteranti-dimmunoglobulinsandnormalimmunoglobulin;anti-dimmunoglobulinsandnormalimmunoglobulinmightimpairimmuneresponsetoliveImmunoglobulinslVaccines(continued)lINFLUENZAVACCINE—giveliveinfluenzavaccineatleast3weeksbeforeor3monthsafteranti-dimmunoglobulinsandnormalimmunoglobulin;anti-dimmunoglobulinsandnormalimmunoglobulinmightimpairimmuneresponsetolORALTYPHOIDVACCINE—giveoraltyphoidvaccineatleast3weeksbeforeor3monthsafteranti-dimmunoglobulinsandnormalimmunoglobulin;anti-dimmunoglobulinsandnormalimmunoglobulinmightimpairimmuneresponsetoorallPOLIOMYELITISVACCINE—giveoralpoliomyelitisvaccineatleast3weeksbeforeor3monthsafteranti-dimmunoglobulinsandnormalimmunoglobulin;anti-dimmunoglobulinsandnormalimmunoglobulinmightimpairimmuneresponsetolROTAVIRUSVACCINE—giverotavirusvaccineatleast3weeksbeforeor3monthsafteranti-dimmunoglobulinsandnormalimmunoglobulin;anti-dimmunoglobulinsandnormalimmunoglobulinmightimpairimmuneresponsetolSMALLPOXVACCINE—givesmallpoxvaccineatleast3weeksbeforeor3monthsafteranti-dimmunoglobulinsandnormalimmunoglobulin;anti-dimmunoglobulinsandnormalimmunoglobulinmightimpairimmuneresponsetolVARICELLA-ZOSTERVACCINE—givevaricella-zostervaccineatleast3weeksbeforeor3monthsafteranti-dimmunoglobulinsandnormalimmunoglobulin;anti-dimmunoglobulinsandnormalimmunoglobulinmightimpairimmuneresponsetolYELLOWFEVERVACCINE—giveyellowfevervaccineatleast3weeksbeforeor3monthsafteranti-dimmunoglobulinsandnormalimmunoglobulinIndacaterolseeSympathomimetics,Beta2IndapamideseeDiureticsIndinavir TRIANGLE Aldesleukin:plasmaconcentrationofindinavirpossiblyincreasedbyALDESLEUKINlAnti-arrhythmics:indinavirpossiblyincreasesplasmaconcentrationoflAMIODARONE—avoidconcomitantuse;indinavirpossiblyincreasesplasmaconcentrationoflFLECAINIDE(increasedriskofventriculararrhythmias—avoidconcomitantuse)lAntibacterials:indinavirincreasesplasmaconcentrationoflRIFABUTIN,alsoplasmaconcentrationofindinavirdecreased(reducedoseofrifabutinandincreasedoseofindinavir);metabolismofindinaviracceleratedbylRIFAMPICIN(reducedplasmaconcentration—avoidconcomitantuse);avoidanceofconcomitantindinavirinsevererenalandhepaticimpairmentadvisedbymanufactureroflTELITHROMYCIN TRIANGLE Anticoagulants:avoidanceofindinaviradvisedbymanufacturerofAPIXABANandRIVAROXABANlAntidepressants:plasmaconcentrationofindinavirreducedbylSTJOHN’SWORT—avoidconcomitantuselAntiepileptics:plasmaconcentrationofindinavirpossiblyreducedbylCARBAMAZEPINE,lFOSPHENYTOINandlPHENYTOIN,alsoplasmaconcentrationofcarbamazepine,fosphenytoinandphenytoinpossiblyincreased;plasmaconcentrationofindinavirpossiblyreducedbylPHENOBARBITALandlPRIMIDONElAntifungals:plasmaconcentrationofindinavirincreasedbylITRACONAZOLEandlKETOCONAZOLE(considerreducingdoseofindinavir)lAntimalarials:cautionwithindinaviradvisedbymanufacturerofARTEMETHERWITHLUMEFANTRINE;indinavirpossiblyincreasesplasmaconcentrationoflQUININE(increasedriskoftoxicity) TRIANGLE Antimuscarinics:avoidanceofindinaviradvisedbymanufacturerofDARIFENACINandTOLTERODINE;manufactureroffesoterodineadvisesdosereductionwhenindinavirgivenwithFESOTERODINE—consultfesoterodineproductliteraturelAntipsychotics:indinavirpossiblyincreasesplasmaconcentrationoflARIPIPRAZOLE(reducedoseofaripiprazole—consultaripiprazoleproductliterature);indinavirpossiblyincreasesplasmaconcentrationoflLURASIDONE—avoidconcomitantuse;indinavirpossiblyincreasesplasmaconcentrationoflPIMOZIDE(increasedriskofventriculararrhythmias—avoidconcomitantuse);indinavirpossiblyincreasesplasmaconcentrationof1202Appendix1InteractionsBNF70Interactions|Appendix1"
"IndinavirlAntipsychotics(continued)lQUETIAPINE—manufacturerofquetiapineadvisesavoidconcomitantuselAntivirals:avoidconcomitantuseofindinavirwithlATAZANAVIR;plasmaconcentrationofbothdrugsincreasedwhenindinavirgivenwithDARUNAVIR;absorptionofindinavirreducedbyDIDANOSINEtablets(giveatleast1hourapart);plasmaconcentrationofindinavirreducedbyEFAVIRENZandNEVIRAPINE;plasmaconcentrationofindinavirpossiblyreducedbylETRAVIRINE—avoidconcomitantuse;indinavirincreasesplasmaconcentrationoflMARAVIROC(considerreducingdoseofmaraviroc);plasmaconcentrationofindinavirincreasedbyRITONAVIR;indinavirincreasesplasmaconcentrationofSAQUINAVIRlAnxiolyticsandHypnotics:increasedriskofprolongedsedationwhenindinavirgivenwithlALPRAZOLAM—avoidconcomitantuse;indinavirpossiblyincreasesplasmaconcentrationoflMIDAZOLAM(riskofprolongedsedation—avoidconcomitantuseoforalmidazolam) TRIANGLE Atovaquone:plasmaconcentrationofindinavirpossiblyreducedbyATOVAQUONElAvanafil:indinavirpossiblyincreasesplasmaconcentrationoflAVANAFIL—manufacturerofavanafiladvisesavoidconcomitantuse TRIANGLE Bosentan:plasmaconcentrationofindinavirpossiblyreducedbyBOSENTANlCiclosporin:indinavirincreasesplasmaconcentrationoflCICLOSPORINlColchicine:indinavirpossiblyincreasesriskoflCOLCHICINEtoxicity—suspendorreducedoseofcolchicine(avoidconcomitantuseinhepaticorrenalimpairment) TRIANGLE Corticosteroids:plasmaconcentrationofindinavirpossiblyreducedbyDEXAMETHASONElCytotoxics:indinavirpossiblyincreasesplasmaconcentrationofAXITINIB(reducedoseofaxitinib—consultaxitinibproductliterature);indinavirpossiblyincreasestheplasmaconcentrationoflBOSUTINIBandlCABAZITAXEL—manufacturerofbosutinibandcabazitaxeladvisesavoidorconsiderreducingdoseofbosutinibandcabazitaxel;indinavirpossiblyincreasesplasmaconcentrationoflCRIZOTINIBandlEVEROLIMUS—manufacturerofcrizotinibandeverolimusadvisesavoidconcomitantuse;indinavirpossiblyincreasestheplasmaconcentrationoflIBRUTINIB—reducedoseofibrutinib(seeunderIbrutinib,p809);indinavirpossiblyincreasesplasmaconcentrationoflPAZOPANIB(reducedoseofpazopanib);indinavirpossiblyincreasesplasmaconcentrationofPONATINIB—considerreducinginitialdoseofponatinib(seeunderPonatinib,p814);manufacturerofruxolitinibadvisesdosereductionwhenindinavirgivenwithlRUXOLITINIB—consultruxolitinibproductliterature;indinavirpossiblyincreasesplasmaconcentrationoflDOCETAXEL—manufacturerofdocetaxeladvisesavoidconcomitantuseorconsiderreducingdocetaxeldoselErgotAlkaloids:increasedriskofergotismwhenindinavirgivenwithlERGOMETRINEorlERGOTAMINE—avoidconcomitantusel5HT1-receptorAgonists:indinavirincreasesplasmaconcentrationoflELETRIPTAN(riskoftoxicity)—avoidconcomitantuselLipid-regulatingDrugs:possibleincreasedriskofmyopathywhenindinavirgivenwithATORVASTATIN;possibleincreasedriskofmyopathywhenindinavirgivenwithlROSUVASTATIN—manufacturerofrosuvastatinadvisesavoidconcomitantuse;increasedriskofmyopathywhenindinavirgivenwithlSIMVASTATIN(avoidconcomitantuse);avoidanceofindinaviradvisedbymanufactureroflLOMITAPIDE(plasmaconcentrationoflomitapidepossiblyincreased)lOrlistat:absorptionofindinavirpossiblyreducedbylORLISTATlRanolazine:indinavirpossiblyincreasesplasmaconcentrationoflRANOLAZINE—manufacturerofranolazineadvisesavoidconcomitantuselSildenafil:indinavirincreasesplasmaconcentrationoflSILDENAFIL—reduceinitialdoseofsildenafilIndinavir(continued) TRIANGLE Tadalafil:indinavirpossiblyincreasesplasmaconcentrationofTADALAFILlVardenafil:indinavirincreasesplasmaconcentrationoflVARDENAFIL—avoidconcomitantuseIndometacinseeNSAIDsIndoraminseeAlpha-blockersInfliximablAbatacept:avoidconcomitantuseofinfliximabwithlABATACEPTlAnakinra:avoidconcomitantuseofinfliximabwithlANAKINRAlAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lVaccines:riskofgeneralisedinfectionswhenmonoclonalantibodiesgivenwithlivelVACCINES—avoidconcomitantuseInfluenzaVaccineseeVaccinesInsulinseeAntidiabeticsInterferonAlfaseeInterferonsInterferonGammaseeInterferonsInterferonslAminophylline:interferonalfaandpeginterferonalfainhibitmetabolismoflAMINOPHYLLINE(considerreducingdoseofaminophylline)lAntivirals:cautionwithpeginterferonalfaadvisedbymanufacturerofADEFOVIR;increasedriskofperipheralneuropathywheninterferonalfaandpeginterferonalfagivenwithlTELBIVUDINElTheophylline:interferonalfaandpeginterferonalfainhibitmetabolismoflTHEOPHYLLINE(considerreducingdoseoftheophylline) TRIANGLE Vaccines:manufacturerofinterferongammaadvisesavoidconcomitantusewithVACCINESIpilimumablAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis) TRIANGLE Cytotoxics:manufacturerofipilimumabadvisesavoidconcomitantusewithVEMURAFENIBlVaccines:riskofgeneralisedinfectionswhenmonoclonalantibodiesgivenwithlivelVACCINES—avoidconcomitantuseIpratropiumseeAntimuscarinicsIrbesartanseeAngiotensin-IIReceptorAntagonistsIrinotecanlAntidepressants:metabolismofirinotecanacceleratedbylSTJOHN’SWORT(reducedplasmaconcentration—avoidconcomitantuse) TRIANGLE Antiepileptics:plasmaconcentrationofirinotecananditsactivemetabolitereducedbyCARBAMAZEPINE,FOSPHENYTOIN,PHENOBARBITAL,PHENYTOINandPRIMIDONElAntifungals:plasmaconcentrationofirinotecanreducedbylKETOCONAZOLE(butconcentrationofactivemetaboliteofirinotecanincreased)—avoidconcomitantuse;increasedriskoftoxicitywhenirinotecangivenwithlITRACONAZOLE—avoidconcomitantuselAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lAntivirals:metabolismofirinotecanpossiblyinhibitedbylATAZANAVIR(increasedriskoftoxicity)lCytotoxics:plasmaconcentrationofactivemetaboliteofirinotecanincreasedbylLAPATINIB—considerreducingdoseofirinotecan;plasmaconcentrationofirinotecanincreasedbyREGORAFENIB;plasmaconcentrationofirinotecanpossiblyincreasedbySORAFENIBIronSalts TRIANGLE Antacids:absorptionoforalironsaltsreducedbyORALMAGNESIUMSALTS(asmagnesiumtrisilicate) TRIANGLE Antibacterials:oralironsaltsreduceabsorptionofCIPROFLOXACIN,LEVOFLOXACIN,MOXIFLOXACINandOFLOXACIN;oralironsaltsreduceabsorptionofNORFLOXACIN(giveatleast2hoursapart);oralironsaltsreduceabsorptionofTETRACYCLINES,alsoabsorptionoforalironsaltsreducedbytetracyclines TRIANGLE Antivirals:oralironsaltsreduceabsoptionofDOLUTEGRAVIR—manufacturerofdolutegraviradvisesgiveatleast2hoursbeforeor6hoursafteroralironsaltsBNF70Appendix1Interactions1203Interactions|Appendix1"
"IronSalts(continued) TRIANGLE Bisphosphonates:oralironsaltsreduceabsorptionofBISPHOSPHONATES TRIANGLE CalciumSalts:absorptionoforalironsaltsreducedbyCALCIUMSALTS TRIANGLE Dopaminergics:oralironsaltspossiblyreduceabsorptionofCO-BENELDOPA,CO-CARELDOPAandLEVODOPA;oralironsaltsreduceabsorptionofENTACAPONE TRIANGLE Eltrombopag:oralironsaltspossiblyreduceabsorptionofELTROMBOPAG(giveatleast4hoursapart) TRIANGLE Methyldopa:oralironsaltsantagonisehypotensiveeffectofMETHYLDOPA TRIANGLE Mycophenolate:oralironsaltsreduceabsorptionofMYCOPHENOLATE TRIANGLE Penicillamine:oralironsaltsreduceabsorptionofPENICILLAMINE TRIANGLE ThyroidHormones:oralironsaltsreduceabsorptionofLEVOTHYROXINE(giveatleast2hoursapart) TRIANGLE Trientine:absorptionoforalironsaltsreducedbyTRIENTINE TRIANGLE Zinc:oralironsaltsreduceabsorptionofZINC,alsoabsorptionoforalironsaltsreducedbyzincIsocarboxazidseeMAOIsIsofluraneseeAnaesthetics,GeneralIsomethepteneseeSympathomimeticsIsoniazid TRIANGLE Aminophylline:isoniazidpossiblyincreasesplasmaconcentrationofAMINOPHYLLINE TRIANGLE Anaesthetics,General:increasedriskofhepatotoxicitywhenisoniazidgivenwithISOFLURANE TRIANGLE Analgesics:avoidanceofisoniazidadvisedbymanufacturerofPETHIDINE TRIANGLE Antacids:absorptionofisoniazidreducedbyANTACIDSlAntibacterials:increasedriskofhepatotoxicitywhenisoniazidgivenwithlRIFAMPICIN;increasedriskofCNStoxicitywhenisoniazidgivenwithCYCLOSERINElAntiepileptics:isoniazidincreasesplasmaconcentrationoflCARBAMAZEPINE(alsopossiblyincreasedisoniazidhepatotoxicity);isoniazidinhibitsmetabolismoflETHOSUXIMIDE(increasedplasmaconcentrationandriskoftoxicity);isoniazidpossiblyinhibitsmetabolismofFOSPHENYTOINandPHENYTOIN(increasedriskoftoxicity) TRIANGLE Antifungals:isoniazidpossiblyreducesplasmaconcentrationofKETOCONAZOLE TRIANGLE AnxiolyticsandHypnotics:isoniazidinhibitsthemetabolismofDIAZEPAM TRIANGLE Corticosteroids:plasmaconcentrationofisoniazidpossiblyreducedbyCORTICOSTEROIDS TRIANGLE Disulfiram:isoniazidpossiblyincreasesCNSeffectsofDISULFIRAM TRIANGLE Dopaminergics:isoniazidpossiblyreduceseffectsofCO-BENELDOPA,CO-CARELDOPAandLEVODOPA TRIANGLE Lipid-regulatingDrugs:separatingadministrationfromisoniazidby12hoursadvisedbymanufacturerofLOMITAPIDE TRIANGLE Theophylline:isoniazidpossiblyincreasesplasmaconcentrationofTHEOPHYLLINE TRIANGLE Vaccines:antibacterialsinactivateORALTYPHOIDVACCINE—seeunderTyphoidVaccineinBNFIsosorbideDinitrateseeNitratesIsosorbideMononitrateseeNitratesIsotretinoinseeRetinoidsIsradipineseeCalcium-channelBlockersItraconazoleseeAntifungals,TriazoleIvabradinelAnti-arrhythmics:increasedriskofventriculararrhythmiaswhenivabradinegivenwithlAMIODARONEorlDISOPYRAMIDElAntibacterials:plasmaconcentrationofivabradinepossiblyincreasedbylCLARITHROMYCINandlTELITHROMYCIN—avoidconcomitantuse;increasedriskofventriculararrhythmiaswhenivabradinegivenwithlERYTHROMYCIN—avoidconcomitantuse TRIANGLE Antidepressants:plasmaconcentrationofivabradinereducedbySTJOHN’SWORT—avoidconcomitantuselAntifungals:plasmaconcentrationofivabradineincreasedbylKETOCONAZOLE—avoidconcomitantuse;plasmaconcentrationofivabradineincreasedbyFLUCONAZOLE—IvabradinelAntifungals(continued)reduceinitialdoseofivabradine;plasmaconcentrationofivabradinepossiblyincreasedbylITRACONAZOLE—avoidconcomitantuselAntimalarials:increasedriskofventriculararrhythmiaswhenivabradinegivenwithlMEFLOQUINElAntipsychotics:increasedriskofventriculararrhythmiaswhenivabradinegivenwithlPIMOZIDElAntivirals:plasmaconcentrationofivabradinepossiblyincreasedbylRITONAVIR—avoidconcomitantuselBeta-blockers:increasedriskofventriculararrhythmiaswhenivabradinegivenwithlSOTALOLlCalcium-channelBlockers:plasmaconcentrationofivabradineincreasedbylDILTIAZEMandlVERAPAMIL—avoidconcomitantuse TRIANGLE GrapefruitJuice:plasmaconcentrationofivabradineincreasedbyGRAPEFRUITJUICElPentamidineIsetionate:increasedriskofventriculararrhythmiaswhenivabradinegivenwithlPENTAMIDINEISETIONATEIvacaftorlAntibacterials:plasmaconcentrationofivacaftorpossiblyincreasedbylCLARITHROMYCIN,lERYTHROMYCINandlTELITHROMYCIN(seeunderIvacaftor,p257);plasmaconcentrationofivacaftorpossiblyreducedbylRIFABUTIN—manufacturerofivacaftoradvisesavoidconcomitantuse;plasmaconcentrationofivacaftorreducedbylRIFAMPICIN—manufacturerofivacaftoradvisesavoidconcomitantuselAntidepressants:plasmaconcentrationofivacaftorpossiblyreducedbylSTJOHN’SWORT—manufacturerofivacaftoradvisesavoidconcomitantuselAntiepileptics:plasmaconcentrationofivacaftorpossiblyreducedbylCARBAMAZEPINE,lFOSPHENYTOIN,lPHENOBARBITAL,lPHENYTOINandlPRIMIDONE—manufacturerofivacaftoradvisesavoidconcomitantuselAntifungals:plasmaconcentrationofivacaftorincreasedbylFLUCONAZOLEandlKETOCONAZOLE(seeunderIvacaftor,p257);plasmaconcentrationofivacaftorpossiblyincreasedbylITRACONAZOLE,lPOSACONAZOLEandlVORICONAZOLE(seeunderIvacaftor,p257) TRIANGLE AnxiolyticsandHypnotics:ivacaftorincreasesplasmaconcentrationofMIDAZOLAM TRIANGLE CardiacGlycosides:ivacaftorincreasesplasmaconcentrationofDIGOXIN TRIANGLE GrapefruitJuice:plasmaconcentrationofivacaftorpossiblyincreasedbyGRAPEFRUITJUICE—manufacturerofivacaftoradvisesavoidconcomitantuse TRIANGLE Lipid-regulatingDrugs:separatingadministrationfromivacaftorby12hoursadvisedbymanufacturerofLOMITAPIDEIvermectin TRIANGLE Anthelmintics:plasmaconcentrationofivermectinpossiblyincreasedbyLEVAMISOLE TRIANGLE Anticoagulants:ivermectinpossiblyenhancesanticoagulanteffectofCOUMARINSJapaneseEncephalitisVaccineseeVaccinesKaolin TRIANGLE Analgesics:kaolinpossiblyreducesabsorptionofASPIRIN TRIANGLE Antibacterials:kaolinpossiblyreducesabsorptionofTETRACYCLINES TRIANGLE Antimalarials:kaolinreducesabsorptionofCHLOROQUINEandHYDROXYCHLOROQUINE TRIANGLE Antipsychotics:kaolinpossiblyreducesabsorptionofPHENOTHIAZINESKetamineseeAnaesthetics,GeneralKetoconazoleseeAntifungals,ImidazoleKetoprofenseeNSAIDsKetorolacseeNSAIDsKetotifenseeAntihistaminesLabetalolseeBeta-blockersLacidipineseeCalcium-channelBlockersLacosamidelAntidepressants:anticonvulsanteffectofantiepilepticspossiblyantagonisedbyMAOISandlTRICYCLIC-RELATEDANTIDEPRESSANTS(convulsivethresholdlowered);1204Appendix1InteractionsBNF70Interactions|Appendix1"
"LacosamidelAntidepressants(continued)anticonvulsanteffectofantiepilepticsantagonisedbylSSRISandlTRICYCLICS(convulsivethresholdlowered)lAntimalarials:anticonvulsanteffectofantiepilepticsantagonisedbylMEFLOQUINElAntipsychotics:anticonvulsanteffectofantiepilepticsantagonisedbylANTIPSYCHOTICS(convulsivethresholdlowered)lOrlistat:possibleincreasedriskofconvulsionswhenantiepilepticsgivenwithlORLISTATLactulose TRIANGLE Anticoagulants:lactulosepossiblyenhancesanticoagulanteffectofCOUMARINSLamivudine TRIANGLE Antibacterials:plasmaconcentrationoflamivudineincreasedbyTRIMETHOPRIM(asco-trimoxazole)—avoidconcomitantuseofhigh-doseco-trimoxazole TRIANGLE Antivirals:avoidanceoflamivudineadvisedbymanufacturerofEMTRICITABINElCytotoxics:manufactureroflamivudineadvisesavoidconcomitantusewithlCLADRIBINElOrlistat:absorptionoflamivudinepossiblyreducedbylORLISTATLamotriginelAntibacterials:plasmaconcentrationoflamotriginereducedbylRIFAMPICINlAntidepressants:anticonvulsanteffectofantiepilepticspossiblyantagonisedbyMAOISandlTRICYCLIC-RELATEDANTIDEPRESSANTS(convulsivethresholdlowered);anticonvulsanteffectofantiepilepticsantagonisedbylSSRISandlTRICYCLICS(convulsivethresholdlowered)lAntiepileptics:plasmaconcentrationoflamotrigineoftenreducedbyCARBAMAZEPINE,alsoplasmaconcentrationofanactivemetaboliteofcarbamazepinesometimesraised(butevidenceisconflicting);plasmaconcentrationoflamotriginereducedbyFOSPHENYTOIN,PHENOBARBITAL,PHENYTOINandPRIMIDONE;plasmaconcentrationoflamotrigineincreasedbylSODIUMVALPROATEandlVALPROICACID(increasedriskoftoxicity—reducelamotriginedose)lAntimalarials:anticonvulsanteffectofantiepilepticsantagonisedbylMEFLOQUINElAntipsychotics:anticonvulsanteffectofantiepilepticsantagonisedbylANTIPSYCHOTICS(convulsivethresholdlowered) TRIANGLE Antivirals:plasmaconcentrationoflamotriginepossiblyreducedbyRITONAVIRlOestrogens:plasmaconcentrationoflamotriginereducedbylOESTROGENS—considerincreasingdoseoflamotriginelOrlistat:possibleincreasedriskofconvulsionswhenantiepilepticsgivenwithlORLISTAT TRIANGLE Progestogens:plasmaconcentrationoflamotriginepossiblyincreasedbyDESOGESTRELLanreotide TRIANGLE Antidiabetics:lanreotidepossiblyreducesrequirementsforANTIDIABETICS TRIANGLE Ciclosporin:lanreotidereducesplasmaconcentrationofCICLOSPORINLansoprazoleseeProtonPumpInhibitorsLanthanum TRIANGLE Antibacterials:lanthanumpossiblyreducesabsorptionofQUINOLONES(giveatleast2hoursbeforeor4hoursafterlanthanum) TRIANGLE Antifungals:lanthanumpossiblyreducesabsorptionofKETOCONAZOLE(giveatleast2hoursapart) TRIANGLE Antimalarials:lanthanumpossiblyreducesabsorptionofCHLOROQUINEandHYDROXYCHLOROQUINE(giveatleast2hoursapart) TRIANGLE ThyroidHormones:lanthanumreducesabsorptionofLEVOTHYROXINE(giveatleast2hoursapart)LapatiniblAntibacterials:manufactureroflapatinibadvisesavoidconcomitantusewithlRIFABUTIN,lRIFAMPICINandlTELITHROMYCINLapatinib(continued)lAntidepressants:manufactureroflapatinibadvisesavoidconcomitantusewithlSTJOHN’SWORTlAntidiabetics:manufactureroflapatinibadvisesavoidconcomitantusewithlREPAGLINIDElAntiepileptics:plasmaconcentrationoflapatinibreducedbylCARBAMAZEPINE—avoidconcomitantuse;manufactureroflapatinibadvisesavoidconcomitantusewithlFOSPHENYTOINandlPHENYTOINlAntifungals:plasmaconcentrationoflapatinibincreasedbylKETOCONAZOLE—avoidconcomitantuse;manufactureroflapatinibadvisesavoidconcomitantusewithlITRACONAZOLE,lPOSACONAZOLEandlVORICONAZOLElAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis);manufactureroflapatinibadvisesavoidconcomitantusewithlPIMOZIDElAntivirals:avoidanceoflapatinibadvisedbymanufactureroflBOCEPREVIR;manufactureroflapatinibadvisesavoidconcomitantusewithlRITONAVIRandlSAQUINAVIRlCytotoxics:lapatinibincreasesplasmaconcentrationofPAZOPANIB;possibleincreasedriskofneutropeniawhenlapatinibgivenwithDOCETAXEL;increasedriskofneutropeniawhenlapatinibgivenwithlPACLITAXEL;lapatinibincreasesplasmaconcentrationofactivemetaboliteoflIRINOTECAN—considerreducingdoseofirinotecanlGrapefruitJuice:manufactureroflapatinibadvisesavoidconcomitantusewithlGRAPEFRUITJUICE TRIANGLE Lipid-regulatingDrugs:separatingadministrationfromlapatinibby12hoursadvisedbymanufacturerofLOMITAPIDE TRIANGLE Ulcer-healingDrugs:absorptionoflapatinibpossiblyreducedbyHISTAMINEH2-ANTAGONISTSandPROTONPUMPINHIBITORSLaronidase TRIANGLE Antimalarials:effectsoflaronidasepossiblyinhibitedbyCHLOROQUINEandHYDROXYCHLOROQUINE(manufactureroflaronidaseadvisesavoidconcomitantuse)LeflunomideNOTEIncreasedriskoftoxicitywithotherhaematotoxicandhepatotoxicdrugs TRIANGLE Antibacterials:plasmaconcentrationofactivemetaboliteofleflunomidepossiblyincreasedbyRIFAMPICIN TRIANGLE Anticoagulants:leflunomidepossiblyenhancesanticoagulanteffectofWARFARIN TRIANGLE Antidiabetics:leflunomidepossiblyenhanceshypoglycaemiceffectofTOLBUTAMIDE TRIANGLE Antiepileptics:leflunomidepossiblyincreasesplasmaconcentrationofFOSPHENYTOINandPHENYTOINlCytotoxics:riskoftoxicitywhenleflunomidegivenwithlMETHOTREXATE TRIANGLE Lipid-regulatingDrugs:theeffectofleflunomideissignificantlydecreasedbyCOLESTYRAMINE(enhancedelimination)—avoidunlessdrugeliminationdesiredlVaccines:riskofgeneralisedinfectionswhenleflunomidegivenwithlivelVACCINES—avoidconcomitantuseLenalidomidelAntibacterials:plasmaconcentrationoflenalidomidepossiblyincreasedbylCLARITHROMYCIN(increasedriskoftoxicity)lAntifungals:plasmaconcentrationoflenalidomidepossiblyincreasedbylITRACONAZOLEandlKETOCONAZOLE(increasedriskoftoxicity)lCalcium-channelBlockers:plasmaconcentrationoflenalidomidepossiblyincreasedbylVERAPAMIL(increasedriskoftoxicity) TRIANGLE CardiacGlycosides:lenalidomidepossiblyincreasesplasmaconcentrationofDIGOXINlCiclosporin:plasmaconcentrationoflenalidomidepossiblyincreasedbylCICLOSPORIN(increasedriskoftoxicity)LercanidipineseeCalcium-channelBlockersLeukotrieneReceptorAntagonists TRIANGLE Aminophylline:zafirlukastpossiblyincreasesplasmaconcentrationofAMINOPHYLLINE,alsoplasmaconcentrationofzafirlukastreduced TRIANGLE Analgesics:plasmaconcentrationofzafirlukastincreasedbyASPIRIN TRIANGLE Antibacterials:plasmaconcentrationofzafirlukastreducedbyERYTHROMYCINBNF70Appendix1Interactions1205Interactions|Appendix1"
"LeukotrieneReceptorAntagonists(continued) TRIANGLE Anticoagulants:zafirlukastenhancesanticoagulanteffectofWARFARIN TRIANGLE Antiepileptics:plasmaconcentrationofmontelukastreducedbyPHENOBARBITALandPRIMIDONE TRIANGLE Antifungals:plasmaconcentrationofzafirlukastincreasedbyFLUCONAZOLE TRIANGLE Lipid-regulatingDrugs:plasmaconcentrationofmontelukastincreasedbyGEMFIBROZIL TRIANGLE Theophylline:zafirlukastpossiblyincreasesplasmaconcentrationofTHEOPHYLLINE,alsoplasmaconcentrationofzafirlukastreducedLevamisole TRIANGLE Alcohol:possibilityofdisulfiram-likereactionwhenlevamisolegivenwithALCOHOL TRIANGLE Anthelmintics:plasmaconcentrationofbothdrugspossiblyreducedwhenlevamisolegivenwithALBENDAZOLE;levamisolepossiblyincreasesplasmaconcentrationofIVERMECTINlAnticoagulants:levamisolepossiblyenhancesanticoagulanteffectoflWARFARIN TRIANGLE Antiepileptics:levamisolepossiblyincreasesplasmaconcentrationofFOSPHENYTOINandPHENYTOINLevetiracetamlAntidepressants:anticonvulsanteffectofantiepilepticspossiblyantagonisedbyMAOISandlTRICYCLIC-RELATEDANTIDEPRESSANTS(convulsivethresholdlowered);anticonvulsanteffectofantiepilepticsantagonisedbylSSRISandlTRICYCLICS(convulsivethresholdlowered) TRIANGLE Antiepileptics:levetiracetampossiblyincreasesriskofCARBAMAZEPINEtoxicitylAntimalarials:anticonvulsanteffectofantiepilepticsantagonisedbylMEFLOQUINElAntipsychotics:anticonvulsanteffectofantiepilepticsantagonisedbylANTIPSYCHOTICS(convulsivethresholdlowered)lOrlistat:possibleincreasedriskofconvulsionswhenantiepilepticsgivenwithlORLISTATLevobunololseeBeta-blockersLevobupivacaine TRIANGLE Anti-arrhythmics:increasedmyocardialdepressionwhenlevobupivacainegivenwithANTI-ARRHYTHMICSLevocarnitine TRIANGLE Anticoagulants:levocarnitinepossiblyenhancesanticoagulanteffectofCOUMARINSLevocetirizineseeAntihistaminesLevodopa TRIANGLE ACEInhibitors:enhancedhypotensiveeffectwhenlevodopagivenwithACEINHIBITORS TRIANGLE AdrenergicNeuroneBlockers:enhancedhypotensiveeffectwhenlevodopagivenwithADRENERGICNEURONEBLOCKERS TRIANGLE Alpha-blockers:enhancedhypotensiveeffectwhenlevodopagivenwithALPHA-BLOCKERSlAnaesthetics,General:increasedriskofarrhythmiaswhenlevodopagivenwithlVOLATILELIQUIDGENERALANAESTHETICS TRIANGLE Angiotensin-IIReceptorAntagonists:enhancedhypotensiveeffectwhenlevodopagivenwithANGIOTENSIN-IIRECEPTORANTAGONISTS TRIANGLE Antibacterials:effectsoflevodopapossiblyreducedbyISONIAZIDlAntidepressants:riskofhypertensivecrisiswhenlevodopagivenwithlMAOIS,avoidlevodopaforatleast2weeksafterstoppingMAOIs;increasedriskofside-effectswhenlevodopagivenwithMOCLOBEMIDE TRIANGLE Antiepileptics:effectsoflevodopapossiblyreducedbyFOSPHENYTOINandPHENYTOIN TRIANGLE Antimuscarinics:absorptionoflevodopapossiblyreducedbyANTIMUSCARINICS TRIANGLE Antipsychotics:effectsoflevodopaantagonisedbyANTIPSYCHOTICS;avoidanceoflevodopaadvisedbymanufacturerofAMISULPRIDE(antagonismofeffect) TRIANGLE AnxiolyticsandHypnotics:effectsoflevodopapossiblyantagonisedbyBENZODIAZEPINES TRIANGLE Beta-blockers:enhancedhypotensiveeffectwhenlevodopagivenwithBETA-BLOCKERSLevodopa(continued) TRIANGLE Bupropion:increasedriskofside-effectswhenlevodopagivenwithBUPROPION TRIANGLE Calcium-channelBlockers:enhancedhypotensiveeffectwhenlevodopagivenwithCALCIUM-CHANNELBLOCKERS TRIANGLE Clonidine:enhancedhypotensiveeffectwhenlevodopagivenwithCLONIDINE TRIANGLE Diazoxide:enhancedhypotensiveeffectwhenlevodopagivenwithDIAZOXIDE TRIANGLE Diuretics:enhancedhypotensiveeffectwhenlevodopagivenwithDIURETICS TRIANGLE Dopaminergics:enhancedeffectsandincreasedtoxicityoflevodopawhengivenwithSELEGILINE(reducedoseoflevodopa) TRIANGLE IronSalts:absorptionoflevodopapossiblyreducedbyoralIRONSALTS TRIANGLE Memantine:effectsofdopaminergicspossiblyenhancedbyMEMANTINE TRIANGLE Methyldopa:enhancedhypotensiveeffectwhenlevodopagivenwithMETHYLDOPA;antiparkinsonianeffectofdopaminergicsantagonisedbyMETHYLDOPA TRIANGLE Moxonidine:enhancedhypotensiveeffectwhenlevodopagivenwithMOXONIDINE TRIANGLE MuscleRelaxants:possibleagitation,confusionandhallucinationswhenlevodopagivenwithBACLOFEN TRIANGLE Nitrates:enhancedhypotensiveeffectwhenlevodopagivenwithNITRATES TRIANGLE VasodilatorAntihypertensives:enhancedhypotensiveeffectwhenlevodopagivenwithHYDRALAZINE,MINOXIDILorSODIUMNITROPRUSSIDE TRIANGLE Vitamins:effectsoflevodopareducedbyPYRIDOXINEwhengivenwithoutdopa-decarboxylaseinhibitorLevofloxacinseeQuinolonesLevofolinicAcidseeFolatesLevomepromazineseeAntipsychoticsLevonorgestrelseeProgestogensLevothyroxineseeThyroidHormonesLidocaineNOTEInteractionslesslikelywhenlidocaineusedtopically TRIANGLE Anaesthetics,Local:increasedmyocardialdepressionwhenanti-arrhythmicsgivenwithBUPIVACAINE,LEVOBUPIVACAINE,PRILOCAINEorROPIVACAINElAnti-arrhythmics:increasedmyocardialdepressionwhenanti-arrhythmicsgivenwithotherlANTI-ARRHYTHMICSlAntipsychotics:increasedriskofventriculararrhythmiaswhenanti-arrhythmicsthatprolongtheQTintervalgivenwithlANTIPSYCHOTICSthatprolongtheQTintervallAntivirals:plasmaconcentrationoflidocainepossiblyincreasedbylATAZANAVIRandLOPINAVIR;plasmaconcentrationoflidocainepossiblyincreasedbyDARUNAVIRandlFOSAMPRENAVIR—avoidconcomitantuse;increasedriskofventriculararrhythmiaswhenlidocainegivenwithlSAQUINAVIR—avoidconcomitantuse;cautionwithintravenouslidocaineadvisedbymanufacturerofTELAPREVIRlBeta-blockers:increasedmyocardialdepressionwhenanti-arrhythmicsgivenwithlBETA-BLOCKERS;possibleincreasedriskoflidocainetoxicitywhengivenwithNADOLOL;increasedriskoflidocainetoxicitywhengivenwithlPROPRANOLOLlDiuretics:actionoflidocaineantagonisedbyhypokalaemiacausedbylACETAZOLAMIDE,lLOOPDIURETICSorlTHIAZIDESANDRELATEDDIURETICS TRIANGLE MuscleRelaxants:neuromuscularblockadeenhancedandprolongedwhenlidocainegivenwithSUXAMETHONIUMlUlcer-healingDrugs:plasmaconcentrationoflidocaineincreasedbylCIMETIDINE(increasedriskoftoxicity)LinagliptinseeAntidiabeticsLinezolidNOTELinezolidisareversible,non-selectiveMAOinhibitor—seeinteractionsofMAOIs TRIANGLE Antibacterials:plasmaconcentrationoflinezolidreducedbyRIFAMPICIN(possibletherapeuticfailureoflinezolid) TRIANGLE Vaccines:antibacterialsinactivateORALTYPHOIDVACCINE—seeunderTyphoidVaccineinBNFLiothyronineseeThyroidHormones1206Appendix1InteractionsBNF70Interactions|Appendix1"
"Lipegfilgrastim TRIANGLE Cytotoxics:neutropeniapossiblyexacerbatedwhenlipegfilgrastimgivenwithCAPECITABINE,FLUOROURACILorTEGAFURLipid-regulatingDrugsseeColesevelam,Colestipol,Colestyramine,Ezetimibe,Fibrates,Lomitapide,NicotinicAcid,andStatinsLiraglutideseeAntidiabeticsLisdexamfetamineseeSympathomimeticsLisinoprilseeACEInhibitorsLithiumlACEInhibitors:excretionoflithiumreducedbylACEINHIBITORS(increasedplasmaconcentration) TRIANGLE Aminophylline:excretionoflithiumincreasedbyAMINOPHYLLINE(reducedplasmaconcentration)lAnalgesics:excretionoflithiumreducedbylNSAIDS(increasedriskoftoxicity);excretionoflithiumreducedbylKETOROLAC(increasedriskoftoxicity)—avoidconcomitantuselAngiotensin-IIReceptorAntagonists:excretionoflithiumreducedbylANGIOTENSIN-IIRECEPTORANTAGONISTS(increasedplasmaconcentration) TRIANGLE Antacids:excretionoflithiumincreasedbySODIUMBICARBONATE(reducedplasmaconcentration)lAnti-arrhythmics:avoidanceoflithiumadvisedbymanufactureroflAMIODARONE(riskofventriculararrhythmias) TRIANGLE Antibacterials:increasedriskoflithiumtoxicitywhengivenwithMETRONIDAZOLElAntidepressants:possibleincreasedserotonergiceffectswhenlithiumgivenwithVENLAFAXINE;increasedriskofCNSeffectswhenlithiumgivenwithlSSRIS(lithiumtoxicityreported);riskoftoxicitywhenlithiumgivenwithTRICYCLICS TRIANGLE Antiepileptics:neurotoxicitymayoccurwhenlithiumgivenwithCARBAMAZEPINE,FOSPHENYTOINorPHENYTOINwithoutincreasedplasmaconcentrationoflithium;plasmaconcentrationoflithiumpossiblyaffectedbyTOPIRAMATElAntipsychotics:increasedriskofextrapyramidalside-effectsandpossiblyneurotoxicitywhenlithiumgivenwithCLOZAPINE,FLUPENTIXOL,HALOPERIDOL,PHENOTHIAZINES,lRISPERIDONEorZUCLOPENTHIXOL;possibleriskoftoxicitywhenlithiumgivenwithOLANZAPINE;lithiumpossiblyincreasesextrapyramidalside-effectsofQUETIAPINE;increasedriskofextrapyramidalside-effectswhenlithiumgivenwithSULPIRIDE TRIANGLE AnxiolyticsandHypnotics:increasedriskofneurotoxicitywhenlithiumgivenwithCLONAZEPAM TRIANGLE Calcium-channelBlockers:neurotoxicitymayoccurwhenlithiumgivenwithDILTIAZEMorVERAPAMILwithoutincreasedplasmaconcentrationoflithiumlCytotoxics:increasedriskofventriculararrhythmiaswhenlithiumgivenwithlARSENICTRIOXIDElDapoxetine:possibleincreasedriskofserotonergiceffectswhenlithiumgivenwithlDAPOXETINE(manufacturerofdapoxetineadviseslithiumshouldnotbestarteduntil1weekafterstoppingdapoxetine,avoiddapoxetinefor2weeksafterstoppinglithium)lDiuretics:excretionoflithiumincreasedbylACETAZOLAMIDE;excretionoflithiumreducedbylLOOPDIURETICSandlTHIAZIDESANDRELATEDDIURETICS(increasedplasmaconcentrationandriskoftoxicity)—loopdiureticssaferthanthiazides;excretionoflithiumreducedbylPOTASSIUM-SPARINGDIURETICSANDALDOSTERONEANTAGONISTS(increasedplasmaconcentrationandriskoftoxicity) TRIANGLE 5HT1-receptorAgonists:possibleriskoftoxicitywhenlithiumgivenwithSUMATRIPTANlMethyldopa:neurotoxicitymayoccurwhenlithiumgivenwithlMETHYLDOPAwithoutincreasedplasmaconcentrationoflithium TRIANGLE MuscleRelaxants:lithiumenhanceseffectsofMUSCLERELAXANTS;hyperkinesiscausedbylithiumpossiblyaggravatedbyBACLOFEN TRIANGLE Parasympathomimetics:lithiumantagoniseseffectsofNEOSTIGMINELithium(continued) TRIANGLE Theophylline:excretionoflithiumincreasedbyTHEOPHYLLINE(reducedplasmaconcentration)LixisenatideseeAntidiabeticsLofepramineseeAntidepressants,TricyclicLofexidine TRIANGLE Alcohol:increasedsedativeeffectwhenlofexidinegivenwithALCOHOL TRIANGLE AnxiolyticsandHypnotics:increasedsedativeeffectwhenlofexidinegivenwithANXIOLYTICSANDHYPNOTICSLomitapide TRIANGLE Alcohol:manufactureroflomitapideadvisesavoidconcomitantusewithALCOHOLlAnti-arrhythmics:manufactureroflomitapideadvisesseparatingadministrationfromAMIODARONEby12hours;manufactureroflomitapideadvisesavoidconcomitantusewithlDRONEDARONE(plasmaconcentrationoflomitapidepossiblyincreased)lAntibacterials:manufactureroflomitapideadvisesseparatingadministrationfromAZITHROMYCINandISONIAZIDby12hours;manufactureroflomitapideadvisesavoidconcomitantusewithlCLARITHROMYCIN,lERYTHROMYCINandlTELITHROMYCIN(plasmaconcentrationoflomitapidepossiblyincreased) TRIANGLE Anticoagulants:lomitapidepossiblyenhancesanticoagulanteffectofWARFARIN TRIANGLE Antidepressants:manufactureroflomitapideadvisesseparatingadministrationfromFLUOXETINEandFLUVOXAMINEby12hours TRIANGLE Antidiabetics:manufactureroflomitapideadvisesseparatingadministrationfromLINAGLIPTINby12hourslAntifungals:plasmaconcentrationoflomitapideincreasedbylKETOCONAZOLE—avoidconcomitantuse;manufactureroflomitapideadvisesavoidconcomitantusewithlTRIAZOLES(plasmaconcentrationoflomitapidepossiblyincreased)lAntivirals:manufactureroflomitapideadvisesavoidconcomitantusewithlDARUNAVIR,lFOSAMPRENAVIR,lINDINAVIR,lLOPINAVIR,lRITONAVIR,lSAQUINAVIR,lTELAPREVIRandlTIPRANAVIR(plasmaconcentrationoflomitapidepossiblyincreased) TRIANGLE AnxiolyticsandHypnotics:manufactureroflomitapideadvisesseparatingadministrationfromALPRAZOLAMby12hourslCalcium-channelBlockers:manufactureroflomitapideadvisesseparatingadministrationfromAMLODIPINEandLACIDIPINEby12hours;manufactureroflomitapideadvisesavoidconcomitantusewithlDILTIAZEMandlVERAPAMIL(plasmaconcentrationoflomitapidepossiblyincreased) TRIANGLE Ciclosporin:manufactureroflomitapideadvisesseparatingadministrationfromCICLOSPORINby12hours TRIANGLE Cilostazol:manufactureroflomitapideadvisesseparatingadministrationfromCILOSTAZOLby12hours TRIANGLE Cytotoxics:manufactureroflomitapideadvisesseparatingadministrationfromLAPATINIB,NILOTINIBandPAZOPANIBby12hours TRIANGLE Fosaprepitant:manufactureroflomitapideadvisesseparatingadministrationfromFOSAPREPITANTby12hours TRIANGLE GrapefruitJuice:manufactureroflomitapideadvisesavoidconcomitantusewithGRAPEFRUITJUICE TRIANGLE HormoneAntagonists:manufactureroflomitapideadvisesseparatingadministrationfromBICALUTAMIDEby12hours TRIANGLE Ivacaftor:manufactureroflomitapideadvisesseparatingadministrationfromIVACAFTORby12hourslLipid-regulatingDrugs:lomitapideincreasesplasmaconcentrationofATORVASTATIN—manufactureroflomitapideadvisesreducedoseofatorvastatinbyhalforseparateadministrationby12hours;lomitapideincreasesplasmaconcentrationoflSIMVASTATIN(seeunderSimvastatin,p181);absorptionoflomitapidepossiblyreducedbyBILEACIDSEQUESTRANTS(giveatleast4hoursapart) TRIANGLE Oestrogens:manufactureroflomitapideadvisesseparatingadministrationfromOESTROGENSby12hours TRIANGLE Ranolazine:manufactureroflomitapideadvisesseparatingadministrationfromRANOLAZINEby12hours TRIANGLE Tacrolimus:manufactureroflomitapideadvisesseparatingadministrationfromTACROLIMUSby12hours TRIANGLE Ticagrelor:manufactureroflomitapideadvisesseparatingadministrationfromTICAGRELORby12hoursBNF70Appendix1Interactions1207Interactions|Appendix1"
"Lomitapide(continued) TRIANGLE Tolvaptan:manufactureroflomitapideadvisesseparatingadministrationfromTOLVAPTANby12hours TRIANGLE Ulcer-healingDrugs:manufactureroflomitapideadvisesseparatingadministrationfromCIMETIDINEandRANITIDINEby12hoursLomustinelAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis) TRIANGLE Ulcer-healingDrugs:myelosuppressiveeffectsoflomustinepossiblyenhancedbyCIMETIDINELoperamide TRIANGLE Desmopressin:loperamideincreasesplasmaconcentrationoforalDESMOPRESSINLopinavirNOTEIncombinationwithritonavirasKaletra®(ritonavirispresenttoinhibitlopinavirmetabolismandincreaseplasma-lopinavirconcentration)—seealsoRitonavirlAnti-arrhythmics:lopinavirpossiblyincreasesplasmaconcentrationoflFLECAINIDE(increasedriskofventriculararrhythmias—avoidconcomitantuse);lopinavirpossiblyincreasesplasmaconcentrationofLIDOCAINElAntibacterials:plasmaconcentrationoflopinavirreducedbylRIFAMPICIN—avoidconcomitantuse;lopinavirincreasesplasmaconcentrationofDELAMANID;avoidanceofconcomitantlopinavirinsevererenalandhepaticimpairmentadvisedbymanufactureroflTELITHROMYCIN TRIANGLE Anticoagulants:avoidanceoflopinaviradvisedbymanufacturerofAPIXABAN;manufacturersadviseavoidconcomitantuseoflopinavirwithRIVAROXABANlAntidepressants:plasmaconcentrationoflopinavirreducedbylSTJOHN’SWORT—avoidconcomitantuselAntiepileptics:plasmaconcentrationoflopinavirpossiblyreducedbyCARBAMAZEPINE,FOSPHENYTOIN,lPHENOBARBITAL,PHENYTOINandlPRIMIDONE TRIANGLE Antihistamines:lopinavirpossiblyincreasesplasmaconcentrationofCHLORPHENAMINE TRIANGLE Antimalarials:cautionwithlopinaviradvisedbymanufacturerofARTEMETHERWITHLUMEFANTRINE TRIANGLE Antimuscarinics:avoidanceoflopinaviradvisedbymanufacturerofDARIFENACINandTOLTERODINElAntipsychotics:lopinavirpossiblyincreasesplasmaconcentrationoflARIPIPRAZOLE(reducedoseofaripiprazole—consultaripiprazoleproductliterature);lopinavirpossiblyincreasesplasmaconcentrationoflQUETIAPINE—manufacturerofquetiapineadvisesavoidconcomitantuselAntivirals:manufacturersadviseavoidconcomitantuseoflopinavirwithlBOCEPREVIRandlTELAPREVIR;avoidanceoflopinaviradvisedbymanufacturerofDACLATASVIR(plasmaconcentrationofdaclatasvirpossiblyincreased);lopinavirreducesplasmaconcentrationoflDARUNAVIR,alsoplasmaconcentrationoflopinavirincreased(avoidconcomitantuse);plasmaconcentrationoflopinavirreducedbylEFAVIRENZ—considerincreasingdoseoflopinavir;lopinavirboostedwithritonavirincreasesplasmaconcentrationoflELVITEGRAVIR(reducedoseofelvitegravir);lopinavirreducesplasmaconcentrationofFOSAMPRENAVIR,effectonlopinavirplasmaconcentrationnotpredictable—avoidconcomitantuse;lopinavirincreasesplasmaconcentrationoflMARAVIROC(considerreducingdoseofmaraviroc);plasmaconcentrationoflopinavirpossiblyreducedbylNEVIRAPINE—considerincreasingdoseoflopinavir;increasedriskofventriculararrhythmiaswhenlopinavirgivenwithlSAQUINAVIR—avoidconcomitantuse;lopinavirincreasesplasmaconcentrationofTENOFOVIR;plasmaconcentrationoflopinavirreducedbylTIPRANAVIRlBosentan:lopinavirincreasesplasmaconcentrationoflBOSENTAN(considerreducingdoseofbosentan) TRIANGLE Corticosteroids:plasmaconcentrationoflopinavirpossiblyreducedbyDEXAMETHASONElCytotoxics:manufacturerofruxolitinibadvisesdosereductionwhenlopinavirgivenwithlRUXOLITINIB—consultruxolitinibproductliterature TRIANGLE Eltrombopag:lopinavirpossiblyreducesplasmaconcentrationofELTROMBOPAGLopinavir(continued)lLipid-regulatingDrugs:possibleincreasedriskofmyopathywhenlopinavirgivenwithATORVASTATIN;lopinavirincreasesplasmaconcentrationoflROSUVASTATIN—adjustdoseofrosuvastatin(consultproductliterature);possibleincreasedriskofmyopathywhenlopinavirgivenwithlSIMVASTATIN—avoidconcomitantuse;avoidanceoflopinaviradvisedbymanufactureroflLOMITAPIDE(plasmaconcentrationoflomitapidepossiblyincreased)lOrlistat:absorptionoflopinavirpossiblyreducedbylORLISTATlRanolazine:lopinavirpossiblyincreasesplasmaconcentrationoflRANOLAZINE—manufacturerofranolazineadvisesavoidconcomitantuse TRIANGLE Sirolimus:lopinavirpossiblyincreasesplasmaconcentrationofSIROLIMUS TRIANGLE Sympathomimetics,Beta2:manufactureroflopinaviradvisesavoidconcomitantusewithSALMETEROLLoprazolamseeAnxiolyticsandHypnoticsLoratadineseeAntihistaminesLorazepamseeAnxiolyticsandHypnoticsLormetazepamseeAnxiolyticsandHypnoticsLosartanseeAngiotensin-IIReceptorAntagonistsLurasidoneseeAntipsychoticsLymecyclineseeTetracyclinesMacitentanlAntibacterials:plasmaconcentrationofmacitentanreducedbylRIFAMPICIN—avoidconcomitantuse TRIANGLE Antidepressants:manufacturerofmacitentanadvisesavoidconcomitantusewithSTJOHN’SWORT TRIANGLE Antiepileptics:manufacturerofmacitentanadvisesavoidconcomitantusewithCARBAMAZEPINE,FOSPHENYTOINandPHENYTOIN TRIANGLE Antifungals:plasmaconcentrationofmacitentanincreasedbyKETOCONAZOLEMacrogolsNOTESomemanufacturerssuggesttakingotheroralmedication1hourbeforeor1houraftermacrogolstoreducepossibleinterferencewithabsorptionMacrolidesNOTESeealsoTelithromycinNOTEInteractionsdonotapplytosmallamountsoferythromycinusedtopicallylAminophylline:clarithromycinpossiblyincreasesplasmaconcentrationofAMINOPHYLLINE;erythromycinincreasesplasmaconcentrationoflAMINOPHYLLINE(alsoaminophyllinemayreduceabsorptionoforalerythromycin) TRIANGLE Analgesics:erythromycinincreasesplasmaconcentrationofALFENTANIL;clarithromycinpossiblyincreasesplasmaconcentrationofFENTANYL TRIANGLE Antacids:absorptionofazithromycinreducedbyANTACIDSlAnti-arrhythmics:increasedriskofventriculararrhythmiaswhenparenteralerythromycingivenwithlAMIODARONE—avoidconcomitantuse;azithromycinpossiblyincreasesplasmaconcentrationoflDISOPYRAMIDE(increasedriskoftoxicity);erythromycinincreasesplasmaconcentrationoflDISOPYRAMIDE(increasedriskoftoxicity);clarithromycinpossiblyincreasesplasmaconcentrationoflDISOPYRAMIDE(increasedriskofventriculararrhythmias);avoidanceofclarithromycinadvisedbymanufactureroflDRONEDARONE(riskofventriculararrhythmias);erythromycinincreasesplasmaconcentrationoflDRONEDARONE(increasedriskofventriculararrhythmias—avoidconcomitantuse)lAntibacterials:increasedriskofventriculararrhythmiaswhenparenteralerythromycingivenwithlMOXIFLOXACIN—avoidconcomitantuse;increasedriskofside-effectsincludingneutropeniawhenazithromycingivenwithlRIFABUTIN;clarithromycinincreasesplasmaconcentrationoflRIFABUTIN(increasedriskoftoxicity—reducerifabutindose);erythromycinpossiblyincreasesplasmaconcentrationoflRIFABUTIN(increasedriskoftoxicity—reducerifabutindose);clarithromycinanderythromycinpossiblyincreaseplasmaconcentrationofBEDAQUILINE—avoidconcomitantuseifclarithromycinanderythromycingivenformorethan14days;possibleincreasedriskofventriculararrhythmias1208Appendix1InteractionsBNF70Interactions|Appendix1"
"MacrolideslAntibacterials(continued)whenclarithromycinanderythromycingivenwithlDELAMANID;avoidanceofclarithromycinanderythromycinadvisedbymanufacturerofFIDAXOMICIN;plasmaconcentrationofclarithromycinreducedbyRIFAMYCINSlAnticoagulants:avoidanceofclarithromycinadvisedbymanufacturerofAPIXABAN;clarithromycinanderythromycinenhanceanticoagulanteffectoflCOUMARINS;azithromycinpossiblyenhancesanticoagulanteffectoflCOUMARINS;possibleincreasedriskofbleedingwhenclarithromycingivenwithDABIGATRANlAntidepressants:avoidanceofmacrolidesadvisedbymanufactureroflREBOXETINE;avoidanceofintravenouserythromycinadvisedbymanufactureroflCITALOPRAMandlESCITALOPRAM(riskofventriculararrhythmias);clarithromycinpossiblyincreasesplasmaconcentrationofTRAZODONE TRIANGLE Antidiabetics:clarithromycinenhanceseffectsofREPAGLINIDElAntiepileptics:clarithromycinincreasesplasmaconcentrationoflCARBAMAZEPINE(considerreducingdoseofcarbamazepine);erythromycinincreasesplasmaconcentrationoflCARBAMAZEPINE;clarithromycininhibitsmetabolismofFOSPHENYTOINandPHENYTOIN(increasedplasmaconcentration);erythromycinpossiblyinhibitsmetabolismofSODIUMVALPROATEandVALPROICACID(increasedplasmaconcentration)lAntifungals:avoidanceofconcomitantclarithromycininsevererenalimapirmentadvisedbymanufactureroflKETOCONAZOLE;avoidanceoferythromycinadvisedbymanufacturerofFLUCONAZOLE;clarithromycinincreasesplasmaconcentrationofITRACONAZOLElAntihistamines:manufacturerofloratadineadviseserythromycinpossiblyincreasesplasmaconcentrationofLORATADINE;macrolidespossiblyinhibitmetabolismoflMIZOLASTINE(avoidconcomitantuse);erythromycininhibitsmetabolismoflMIZOLASTINE—avoidconcomitantuselAntimalarials:avoidanceofmacrolidesadvisedbymanufactureroflARTEMETHERWITHLUMEFANTRINE;avoidanceofmacrolidesadvisedbymanufactureroflARTENIMOLWITHPIPERAQUINE(possibleriskofventriculararrhythmias) TRIANGLE Antimuscarinics:erythromycinpossiblyincreasesplasmaconcentrationofDARIFENACIN;manufactureroffesoterodineadvisesdosereductionwhenclarithromycingivenwithFESOTERODINE—consultfesoterodineproductliterature;avoidanceofclarithromycinanderythromycinadvisedbymanufacturerofTOLTERODINElAntipsychotics:avoidanceofmacrolidesadvisedbymanufactureroflDROPERIDOL(riskofventriculararrhythmias);increasedriskofventriculararrhythmiaswhenparenteralerythromycingivenwithlZUCLOPENTHIXOL—avoidconcomitantuse;increasedriskofventriculararrhythmiaswhenerythromycingivenwithlAMISULPRIDE—avoidconcomitantuse;erythromycinpossiblyincreasesplasmaconcentrationoflCLOZAPINE(possibleincreasedriskofconvulsions);clarithromycinpossiblyincreasesplasmaconcentrationoflLURASIDONE—avoidconcomitantuse;erythromycinpossiblyincreasestheplasmaconcentrationoflLURASIDONE(seeunderLurasidone,p315);increasedriskofventriculararrhythmiaswhenclarithromycingivenwithlPIMOZIDE—avoidconcomitantuse;possibleincreasedriskofventriculararrhythmiaswhenerythromycingivenwithlPIMOZIDE—avoidconcomitantuse;clarithromycinpossiblyincreasesplasmaconcentrationoflQUETIAPINE—manufacturerofquetiapineadvisesavoidconcomitantuse;erythromycinincreasesplasmaconcentrationoflQUETIAPINE—manufacturerofquetiapineadvisesavoidconcomitantuse;increasedriskofventriculararrhythmiaswhenparenteralerythromycingivenwithlSULPIRIDElAntivirals:plasmaconcentrationofbothdrugsincreasedwhenclarithromycingivenwithATAZANAVIR;clarithromycinpossiblyincreasestheplasmaconcentrationoflDACLATASVIR—reducedoseofdaclatasvir(seeunderDaclatasvir,p544);plasmaconcentrationofclarithromycinreducedbyEFAVIRENZ,alsoplasmaconcentrationofactiveMacrolideslAntivirals(continued)metaboliteofclarithromycinincreased;plasmaconcentrationofclarithromycinreducedbylETRAVIRINEandNEVIRAPINE(butconcentrationofanactivemetaboliteincreased),alsoplasmaconcentrationofetravirineandnevirapineincreased;clarithromycinpossiblyincreasesplasmaconcentrationoflMARAVIROC(considerreducingdoseofmaraviroc);avoidanceofclarithromycinanderythromycinadvisedbymanufactureroflRILPIVIRINE(plasmaconcentrationofrilpivirinepossiblyincreased);plasmaconcentrationofazithromycinanderythromycinpossiblyincreasedbyRITONAVIR;plasmaconcentrationofclarithromycinincreasedbylRITONAVIR(reducedoseofclarithromycininrenalimpairment);increasedriskofventriculararrhythmiaswhenerythromycingivenwithlSAQUINAVIR—avoidconcomitantuse;plasmaconcentrationofbothdrugspossiblyincreasedwhenclarithromycingivenwithlSAQUINAVIRandlTELAPREVIR(increasedriskofventriculararrhythmias);plasmaconcentrationofbothdrugsincreasedwhenerythromycingivenwithlSIMEPREVIR—manufacturerofsimepreviradvisesavoidconcomitantuse;clarithromycinpossiblyincreasesplasmaconcentrationoflSIMEPREVIR—manufacturerofsimepreviradvisesavoidconcomitantuse;plasmaconcentrationofbothdrugspossiblyincreasedwhenerythromycingivenwithlTELAPREVIR(increasedriskofventriculararrhythmias);plasmaconcentrationofclarithromycinincreasedbylTIPRANAVIR(reducedoseofclarithromycininrenalimpairment),alsoclarithromycinincreasesplasmaconcentrationoftipranavir;clarithromycintabletsreduceabsorptionofZIDOVUDINE(giveatleast2hoursapart)lAnxiolyticsandHypnotics:clarithromycinanderythromycininhibitmetabolismoflMIDAZOLAM(increasedplasmaconcentrationwithincreasedsedation);erythromycinincreasesplasmaconcentrationofBUSPIRONE(reducedoseofbuspirone);erythromycininhibitsthemetabolismofZOPICLONE TRIANGLE Aprepitant:clarithromycinpossiblyincreasesplasmaconcentrationofAPREPITANTlAtomoxetine:increasedriskofventriculararrhythmiaswhenparenteralerythromycingivenwithlATOMOXETINElAvanafil:clarithromycinpossiblyincreasesplasmaconcentrationoflAVANAFIL—manufacturerofavanafiladvisesavoidconcomitantuse;erythromycinincreasesplasmaconcentrationoflAVANAFIL—seeunderAvanafil,p698lCalcium-channelBlockers:clarithromycinanderythromycinpossiblyinhibitmetabolismoflCALCIUM-CHANNELBLOCKERS(increasedriskofside-effects);avoidanceoferythromycinadvisedbymanufacturerofLERCANIDIPINE TRIANGLE CardiacGlycosides:macrolidesincreaseplasmaconcentrationofDIGOXIN(increasedriskoftoxicity)lCiclosporin:macrolidespossiblyinhibitmetabolismoflCICLOSPORIN(increasedplasmaconcentration);clarithromycinanderythromycininhibitmetabolismoflCICLOSPORIN(increasedplasmaconcentration)lCilostazol:clarithromycinpossiblyincreasesplasmaconcentrationoflCILOSTAZOL(seeunderCilostazol,p206);erythromycinincreasesplasmaconcentrationoflCILOSTAZOL(seeunderCilostazol,p206)lClopidogrel:erythromycinpossiblyreducesantiplateleteffectoflCLOPIDOGRELlColchicine:azithromycin,clarithromycinanderythromycinpossiblyincreaseriskoflCOLCHICINEtoxicity—suspendorreducedoseofcolchicine(avoidconcomitantuseinhepaticorrenalimpairment) TRIANGLE Corticosteroids:erythromycinpossiblyinhibitsmetabolismofCORTICOSTEROIDS;erythromycininhibitsthemetabolismofMETHYLPREDNISOLONE;clarithromycinpossiblyincreasesplasmaconcentrationofMETHYLPREDNISOLONElCytotoxics:erythromycinpossiblyincreasestheplasmaconcentrationofAFATINIB—manufacturerofafatinibadvisesseparatingadministrationoferythromycinby6to12hours;clarithromycinanderythromycinpossiblyincreaseplasmaconcentrationofAXITINIB(reducedoseofaxitinib—consultBNF70Appendix1Interactions1209Interactions|Appendix1"
"MacrolideslCytotoxics(continued)axitinibproductliterature);clarithromycinanderythromycinpossiblyincreasetheplasmaconcentrationoflBOSUTINIB—manufacturerofbosutinibadvisesavoidorconsiderreducingdoseofbosutinib;clarithromycinanderythromycinpossiblyincreaseplasmaconcentrationofCABOZANTINIB;clarithromycinpossiblyincreasesplasmaconcentrationoflCRIZOTINIBandlEVEROLIMUS—manufacturerofcrizotinibandeverolimusadvisesavoidconcomitantuse;avoidanceofclarithromycinanderythromycinadvisedbymanufacturerofDASATINIB(plasmaconcentrationofdasatinibpossiblyincreased);erythromycinincreasesplasmaconcentrationoflEVEROLIMUS(considerreducingthedoseofeverolimus—consulteverolimusproductliterature);clarithromycinanderythromycinpossiblyincreasetheplasmaconcentrationoflIBRUTINIB—reducedoseofibrutinib(seeunderIbrutinib,p809);avoidanceofclarithromycinadvisedbymanufactureroflNILOTINIB;clarithromycinpossiblyincreasesplasmaconcentrationoflPAZOPANIB(reducedoseofpazopanib);clarithromycinpossiblyincreasesplasmaconcentrationofPONATINIB—considerreducinginitialdoseofponatinib(seeunderPonatinib,p814);manufacturerofruxolitinibadvisesdosereductionwhenclarithromycingivenwithlRUXOLITINIB—consultruxolitinibproductliterature;possibleincreasedriskofventriculararrhythmiaswhenparenteralerythromycingivenwithlVANDETANIB—avoidconcomitantuse;clarithromycinpossiblyincreasestheplasmaconcentrationoflCABAZITAXEL—manufacturerofcabazitaxeladvisesavoidorconsiderreducingdoseofcabazitaxel;clarithromycinpossiblyincreasesplasmaconcentrationoflDOCETAXEL—manufacturerofdocetaxeladvisesavoidconcomitantuseorconsiderreducingdocetaxeldose;increasedriskofventriculararrhythmiaswhenerythromycingivenwithlARSENICTRIOXIDE;erythromycinincreasestoxicityoflVINBLASTINE—avoidconcomitantuse;possibleincreasedriskofneutropeniawhenclarithromycingivenwithlVINORELBINE TRIANGLE Dapoxetine:manufacturerofdapoxetineadvisesdosereductionwhenclarithromycinanderythromycingivenwithDAPOXETINE(seeunderDapoxetine,p703)lDiuretics:clarithromycinincreasesplasmaconcentrationoflEPLERENONE—avoidconcomitantuse;erythromycinincreasesplasmaconcentrationofEPLERENONE(reducedoseofeplerenone)lDomperidone:possibleincreasedriskofventriculararrhythmiaswhenclarithromycingivenwithlDOMPERIDONE—avoidconcomitantuse;erythromycinincreasesplasmaconcentrationoflDOMPERIDONE(increasedriskofventriculararrhythmias—avoidconcomitantuse) TRIANGLE Dopaminergics:erythromycinincreasesplasmaconcentrationofBROMOCRIPTINEandCABERGOLINE(increasedriskoftoxicity);macrolidespossiblyincreaseplasmaconcentrationofBROMOCRIPTINEandCABERGOLINE(increasedriskoftoxicity)lErgotAlkaloids:increasedriskofergotismwhenclarithromycinorerythromycingivenwithlERGOMETRINE—avoidconcomitantuse;increasedriskofergotismwhenmacrolidesgivenwithlERGOTAMINE—avoidconcomitantuse TRIANGLE Fosaprepitant:clarithromycinpossiblyincreasesplasmaconcentrationofFOSAPREPITANTl5HT1-receptorAgonists:clarithromycinanderythromycinincreaseplasmaconcentrationoflELETRIPTAN(riskoftoxicity)—avoidconcomitantuselIvabradine:clarithromycinpossiblyincreasesplasmaconcentrationoflIVABRADINE—avoidconcomitantuse;increasedriskofventriculararrhythmiaswhenerythromycingivenwithlIVABRADINE—avoidconcomitantuselIvacaftor:clarithromycinanderythromycinpossiblyincreaseplasmaconcentrationoflIVACAFTOR(seeunderIvacaftor,p257)lLenalidomide:clarithromycinpossiblyincreasesplasmaconcentrationoflLENALIDOMIDE(increasedriskoftoxicity) TRIANGLE LeukotrieneReceptorAntagonists:erythromycinreducesplasmaconcentrationofZAFIRLUKASTlLipid-regulatingDrugs:clarithromycinincreasesplasmaconcentrationoflATORVASTATINandPRAVASTATIN;possibleMacrolideslLipid-regulatingDrugs(continued)increasedriskofmyopathywhenerythromycingivenwithATORVASTATIN;erythromycinincreasesplasmaconcentrationofPRAVASTATIN;erythromycinreducesplasmaconcentrationofROSUVASTATIN;increasedriskofmyopathywhenclarithromycinorerythromycingivenwithlSIMVASTATIN(avoidconcomitantuse);separatingadministrationfromazithromycinby12hoursadvisedbymanufacturerofLOMITAPIDE;avoidanceofclarithromycinanderythromycinadvisedbymanufactureroflLOMITAPIDE(plasmaconcentrationoflomitapidepossiblyincreased) TRIANGLE Mirabegron:whengivenwithclarithromycinavoidorreducedoseofMIRABEGRONinhepaticorrenalimpairment—seeMirabegron,p671 TRIANGLE Oestrogens:erythromycinincreasesplasmaconcentrationofESTRADIOL TRIANGLE Parasympathomimetics:erythromycinincreasesplasmaconcentrationofGALANTAMINElPentamidineIsetionate:increasedriskofventriculararrhythmiaswhenparenteralerythromycingivenwithlPENTAMIDINEISETIONATE TRIANGLE Progestogens:erythromycinincreasesplasmaconcentrationofDIENOGESTlRanolazine:clarithromycinpossiblyincreasesplasmaconcentrationoflRANOLAZINE—manufacturerofranolazineadvisesavoidconcomitantuselSildenafil:clarithromycinincreasestheplasmaconcentrationoflSILDENAFIL—considerreducinginitialdoseofsildenafilforerectiledysfunctionorreducesildenafildosefrequencytooncedailyforpulmonaryhypertension;erythromycinincreasesplasmaconcentrationofSILDENAFIL—reduceinitialdoseofsildenafilforerectiledysfunctionorreducesildenafildosefrequencytotwicedailyforpulmonaryhypertensionlSirolimus:clarithromycinincreasesplasmaconcentrationoflSIROLIMUS—avoidconcomitantuse;plasmaconcentrationofbothdrugsincreasedwhenerythromycingivenwithlSIROLIMUSlTacrolimus:clarithromycinanderythromycinincreaseplasmaconcentrationoflTACROLIMUS TRIANGLE Tadalafil:clarithromycinanderythromycinpossiblyincreaseplasmaconcentrationofTADALAFILlTheophylline:clarithromycinpossiblyincreasesplasmaconcentrationofTHEOPHYLLINE;erythromycinincreasesplasmaconcentrationoflTHEOPHYLLINE(alsotheophyllinemayreduceabsorptionoforalerythromycin)lTicagrelor:clarithromycinpossiblyincreasesplasmaconcentrationoflTICAGRELOR—manufacturerofticagreloradvisesavoidconcomitantuse;erythromycinpossiblyincreasesplasmaconcentrationofTICAGRELOR TRIANGLE Ulcer-healingDrugs:plasmaconcentrationoferythromycinincreasedbyCIMETIDINE(increasedriskoftoxicity,includingdeafness);plasmaconcentrationofbothdrugsincreasedwhenclarithromycingivenwithOMEPRAZOLE TRIANGLE Ulipristal:avoidanceofclarithromycinadvisedbymanufactureroflow-doseULIPRISTAL;erythromycinincreasesplasmaconcentrationoflow-doseULIPRISTAL—manufactureroflow-doseulipristaladvisesavoidconcomitantuse TRIANGLE Vaccines:antibacterialsinactivateORALTYPHOIDVACCINE—seeunderTyphoidVaccineinBNF TRIANGLE Vardenafil:clarithromycinpossiblyincreasesplasmaconcentrationofVARDENAFIL(considerreducinginitialdoseofvardenafil);erythromycinincreasesplasmaconcentrationofVARDENAFIL(reducedoseofvardenafil)Magnesium(parenteral)lCalcium-channelBlockers:profoundhypotensionreportedwithconcomitantuseofparenteralmagnesiumandlNIFEDIPINEinpre-eclampsia TRIANGLE MuscleRelaxants:parenteralmagnesiumenhanceseffectsofNON-DEPOLARISINGMUSCLERELAXANTSandSUXAMETHONIUMMagnesiumSalts(oral)seeAntacidsMannitol TRIANGLE Antibacterials:avoidanceofmannitoladvisedbymanufacturerofTOBRAMYCIN1210Appendix1InteractionsBNF70Interactions|Appendix1"
"Mannitol(continued) TRIANGLE Ciclosporin:possibleincreasedriskofnephrotoxicitywhenmannitolgivenwithCICLOSPORINMAOIsNOTEForinteractionsofreversibleMAO-Ainhibitors(RIMAs)seeMoclobemide,andforinteractionsofMAO-BinhibitorsseeRasagilineandSelegiline;theantibacterialLinezolidisareversible,non-selectiveMAOinhibitor TRIANGLE ACEInhibitors:MAOIspossiblyenhancehypotensiveeffectofACEINHIBITORS TRIANGLE AdrenergicNeuroneBlockers:enhancedhypotensiveeffectwhenMAOIsgivenwithADRENERGICNEURONEBLOCKERSlAlcohol:MAOIsinteractwithtyraminefoundinsomebeveragescontaininglALCOHOLandsomedealcoholisedbeverages(hypertensivecrisis)—ifnotyramine,enhancedhypotensiveeffect TRIANGLE Alpha2-adrenoceptorStimulants:avoidanceofMAOIsadvisedbymanufacturerofAPRACLONIDINEandBRIMONIDINElAlpha-blockers:avoidanceofMAOIsadvisedbymanufactureroflINDORAMIN;enhancedhypotensiveeffectwhenMAOIsgivenwithALPHA-BLOCKERSlAnalgesics:possibleincreasedserotonergiceffectswhenMAOIsgivenwithFENTANYL;CNSexcitationordepression(hypertensionorhypotension)whenMAOIsgivenwithlPETHIDINE—avoidconcomitantuseandfor2weeksafterstoppingMAOIs;possibleincreasedserotonergiceffectsandincreasedriskofconvulsionswhenMAOIsgivenwithlTRAMADOL—somemanufacturersadviseavoidconcomitantuseandfor2weeksafterstoppingMAOIs;avoidanceofMAOIsadvisedbymanufactureroflNEFOPAM;possibleCNSexcitationordepression(hypertensionorhypotension)whenMAOIsgivenwithlOPIOIDANALGESICS—somemanufacturersadviseavoidconcomitantuseandfor2weeksafterstoppingMAOIs TRIANGLE Angiotensin-IIReceptorAntagonists:MAOIspossiblyenhancehypotensiveeffectofANGIOTENSIN-IIRECEPTORANTAGONISTSlAntidepressants:increasedriskofhypertensionandCNSexcitationwhenMAOIsgivenwithlREBOXETINE(MAOIsshouldnotbestarteduntil1weekafterstoppingreboxetine,avoidreboxetinefor2weeksafterstoppingMAOIs);afterstoppingMAOIsdonotstartlCITALOPRAM,lESCITALOPRAM,lFLUVOXAMINE,lPAROXETINEorlSERTRALINEfor2weeks,alsoMAOIsshouldnotbestarteduntilatleast1weekafterstoppingcitalopram,escitalopram,fluvoxamine,paroxetineorsertraline;afterstoppingMAOIsdonotstartlFLUOXETINEfor2weeks,alsoMAOIsshouldnotbestarteduntilatleast5weeksafterstoppingfluoxetine;afterstoppingMAOIsdonotstartlDULOXETINEfor2weeks,alsoMAOIsshouldnotbestarteduntilatleast5daysafterstoppingduloxetine;enhancedCNSeffectsandtoxicitywhenMAOIsgivenwithlVENLAFAXINE(venlafaxineshouldnotbestarteduntil2weeksafterstoppingMAOIs,avoidMAOIsfor1weekafterstoppingvenlafaxine);increasedriskofhypertensionandCNSexcitationwhenMAOIsgivenwithotherlMAOIS(avoidforatleast2weeksafterstoppingpreviousMAOIsandthenstartatareduceddose);afterstoppingMAOIsdonotstartlMOCLOBEMIDEforatleast1week;MAOIsincreaseCNSeffectsoflSSRIS(riskofserioustoxicity);afterstoppingMAOIsdonotstartlMIRTAZAPINEfor2weeks,alsoMAOIsshouldnotbestarteduntilatleast2weeksafterstoppingmirtazapine;afterstoppingMAOIsdonotstartlTRICYCLIC-RELATEDANTIDEPRESSANTSfor2weeks,alsoMAOIsshouldnotbestarteduntilatleast1–2weeksafterstoppingtricyclic-relatedantidepressants;increasedriskofhypertensionandCNSexcitationwhenMAOIsgivenwithlTRICYCLICS,tricyclicsshouldnotbestarteduntil2weeksafterstoppingMAOIs(3weeksifstartingclomipramineorimipramine),alsoMAOIsshouldnotbestartedforatleast1–2weeksafterstoppingtricyclics(3weeksinthecaseofclomipramineorimipramine) TRIANGLE Antidiabetics:MAOIspossiblyenhancehypoglycaemiceffectofANTIDIABETICS;MAOIsenhancehypoglycaemiceffectofINSULIN,METFORMINandSULFONYLUREASlAntiepileptics:MAOIspossiblyantagoniseanticonvulsanteffectofANTIEPILEPTICS(convulsivethresholdlowered);MAOIslAntiepileptics(continued)avoidancefor2weeksafterstoppingMAOIsadvisedbymanufactureroflCARBAMAZEPINE,alsoantagonismofanticonvulsanteffect TRIANGLE Antihistamines:avoidanceofMAOIsadvisedbymanufacturerofHYDROXYZINE;avoidanceofpromethazinefor2weeksafterstoppingMAOIsadvisedbymanufacturerofPROMETHAZINE;increasedantimuscarinicandsedativeeffectswhenMAOIsgivenwithANTIHISTAMINESlAntimalarials:avoidanceofantidepressantsadvisedbymanufactureroflARTEMETHERWITHLUMEFANTRINEandlARTENIMOLWITHPIPERAQUINE TRIANGLE Antimuscarinics:increasedriskofantimuscarinicside-effectswhenMAOIsgivenwithANTIMUSCARINICSlAntipsychotics:CNSeffectsofMAOIspossiblyincreasedbylCLOZAPINElAnxiolyticsandHypnotics:avoidanceofMAOIsadvisedbymanufacturerofBUSPIRONE;manufactureroftranylcypromineadvisesavoidlBUSPIRONEfor14daysafterstoppingtranylcyprominelAtomoxetine:afterstoppingMAOIsdonotstartlATOMOXETINEfor2weeks,alsoMAOIsshouldnotbestarteduntilatleast2weeksafterstoppingatomoxetine;possibleincreasedriskofconvulsionswhenantidepressantsgivenwithATOMOXETINE TRIANGLE Beta-blockers:enhancedhypotensiveeffectwhenMAOIsgivenwithBETA-BLOCKERSlBupropion:avoidanceofbupropionfor2weeksafterstoppingMAOIsadvisedbymanufactureroflBUPROPION TRIANGLE Calcium-channelBlockers:enhancedhypotensiveeffectwhenMAOIsgivenwithCALCIUM-CHANNELBLOCKERS TRIANGLE Clonidine:enhancedhypotensiveeffectwhenMAOIsgivenwithCLONIDINElDapoxetine:increasedriskofserotonergiceffectswhenMAOIsgivenwithlDAPOXETINE(MAOIsshouldnotbestarteduntil1weekafterstoppingdapoxetine,avoiddapoxetinefor2weeksafterstoppingMAOIs) TRIANGLE Diazoxide:enhancedhypotensiveeffectwhenMAOIsgivenwithDIAZOXIDE TRIANGLE Diuretics:enhancedhypotensiveeffectwhenMAOIsgivenwithDIURETICSlDopaminergics:riskofhypertensivecrisiswhenMAOIsgivenwithlCO-BENELDOPA,lCO-CARELDOPAorlLEVODOPA,avoidco-beneldopa,co-careldopaorlevodopaforatleast2weeksafterstoppingMAOIs;avoidconcomitantuseofnon-selectiveMAOIswithlENTACAPONE;riskofhypertensivecrisiswhenMAOIsgivenwithlRASAGILINE,avoidMAOIsforatleast2weeksafterstoppingrasagiline;enhancedhypotensiveeffectwhenMAOIsgivenwithlSELEGILINE—manufacturerofselegilineadvisesavoidconcomitantuse;avoidconcomitantuseofMAOIswithTOLCAPONE TRIANGLE Doxapram:MAOIsenhanceeffectsofDOXAPRAM TRIANGLE Histamine:avoidanceofMAOIsadvisedbymanufacturerofHISTAMINEl5HT1-receptorAgonists:riskofCNStoxicitywhenMAOIsgivenwithlRIZATRIPTANorlSUMATRIPTAN(avoidrizatriptanorsumatriptanfor2weeksafterMAOIs);riskofCNStoxicitywhenMAOIsgivenwithlZOLMITRIPTAN(reducedoseofzolmitriptan)lMethyldopa:avoidanceofMAOIsadvisedbymanufactureroflMETHYLDOPA TRIANGLE Moxonidine:enhancedhypotensiveeffectwhenMAOIsgivenwithMOXONIDINE TRIANGLE MuscleRelaxants:phenelzineenhanceseffectsofSUXAMETHONIUM TRIANGLE Nicorandil:enhancedhypotensiveeffectwhenMAOIsgivenwithNICORANDIL TRIANGLE Nitrates:enhancedhypotensiveeffectwhenMAOIsgivenwithNITRATES TRIANGLE Pholcodine:avoidanceofpholcodinefor2weeksafterstoppingMAOIsadvisedbymanufacturerofPHOLCODINElSympathomimetics:riskofhypertensivecrisiswhenMAOIsgivenwithlADRENALINE(EPINEPHRINE),lDOBUTAMINE,lDOPAMINE,lNORADRENALINE(NOREPINEPHRINE)orlXYLOMETAZOLINE;riskofhypertensivecrisiswhenMAOIsgivenwithlDEXAMFETAMINE,lEPHEDRINE,lISOMETHEPTENE,BNF70Appendix1Interactions1211Interactions|Appendix1"
"MAOIslSympathomimetics(continued)lLISDEXAMFETAMINE,lMETARAMINOL,lMETHYLPHENIDATE,lPHENYLEPHRINEorlPSEUDOEPHEDRINE,avoiddexamfetamine,ephedrine,isometheptene,lisdexamfetamine,metaraminol,methylphenidate,phenylephrineorpseudoephedrineforatleast2weeksafterstoppingMAOIs;riskofhypertensivecrisiswhenMAOIsgivenwithlOXYMETAZOLINE,somemanufacturersadviseavoidoxymetazolineforatleast2weeksafterstoppingMAOIslTetrabenazine:riskofCNStoxicitywhenMAOIsgivenwithlTETRABENAZINE(avoidtetrabenazinefor2weeksafterMAOIs) TRIANGLE VasodilatorAntihypertensives:enhancedhypotensiveeffectwhenMAOIsgivenwithHYDRALAZINE,MINOXIDILorSODIUMNITROPRUSSIDEMAOIs,reversibleseeMoclobemideMaraviroclAntibacterials:plasmaconcentrationofmaravirocpossiblyincreasedbylCLARITHROMYCINandlTELITHROMYCIN(considerreducingdoseofmaraviroc);plasmaconcentrationofmaravirocreducedbylRIFAMPICIN—considerincreasingdoseofmaraviroclAntidepressants:plasmaconcentrationofmaravirocpossiblyreducedbylSTJOHN’SWORT—avoidconcomitantuselAntifungals:plasmaconcentrationofmaravirocincreasedbylKETOCONAZOLE(considerreducingdoseofmaraviroc)lAntivirals:plasmaconcentrationofmaravirocincreasedbylATAZANAVIR,BOCEPREVIR,lDARUNAVIR,lINDINAVIR,lLOPINAVIR,lSAQUINAVIRandTELAPREVIR(considerreducingdoseofmaraviroc);plasmaconcentrationofmaravirocpossiblyreducedbylEFAVIRENZ—considerincreasingdoseofmaraviroc;plasmaconcentrationofmaravirocpossiblyreducedbyETRAVIRINE;maravirocreducesplasmaconcentrationoflFOSAMPRENAVIR—avoidconcomitantuse;plasmaconcentrationofmaravirocincreasedbyRITONAVIRlCobicistat:plasmaconcentrationofmaravirocpossiblyincreasedbylCOBICISTAT(reducedoseofmaraviroc)lOrlistat:absorptionofmaravirocpossiblyreducedbylORLISTATMebendazole TRIANGLE Ulcer-healingDrugs:metabolismofmebendazolepossiblyinhibitedbyCIMETIDINE(increasedplasmaconcentration)MedroxyprogesteroneseeProgestogensMefenamicAcidseeNSAIDsMefloquinelAnti-arrhythmics:increasedriskofventriculararrhythmiaswhenmefloquinegivenwithlAMIODARONE—avoidconcomitantuselAntibacterials:increasedriskofventriculararrhythmiaswhenmefloquinegivenwithlMOXIFLOXACIN—avoidconcomitantuse;plasmaconcentrationofmefloquinereducedbylRIFAMPICIN—avoidconcomitantuselAntiepileptics:mefloquineantagonisesanticonvulsanteffectoflANTIEPILEPTICS TRIANGLE Antifungals:plasmaconcentrationofmefloquineincreasedbyKETOCONAZOLElAntimalarials:avoidanceofantimalarialsadvisedbymanufactureroflARTEMETHERWITHLUMEFANTRINE;increasedriskofconvulsionswhenmefloquinegivenwithlCHLOROQUINEorlHYDROXYCHLOROQUINE;increasedriskofconvulsionswhenmefloquinegivenwithlQUININE(butshouldnotpreventtheuseofintravenousquinineinseverecases)lAntipsychotics:possibleincreasedriskofventriculararrhythmiaswhenmefloquinegivenwithlHALOPERIDOL—avoidconcomitantuse;avoidanceofmefloquineadvisedbymanufacturerofAMISULPRIDE;increasedriskofventriculararrhythmiaswhenmefloquinegivenwithlPIMOZIDE—avoidconcomitantuse;manufacturerofrisperidoneadvisespossibleriskofventriculararrhythmiaswhenmefloquinegivenwithlRISPERIDONE TRIANGLE Antivirals:mefloquinepossiblyreducesplasmaconcentrationofRITONAVIRMefloquine(continued)lAtomoxetine:increasedriskofventriculararrhythmiaswhenmefloquinegivenwithlATOMOXETINE TRIANGLE Beta-blockers:increasedriskofbradycardiawhenmefloquinegivenwithBETA-BLOCKERS TRIANGLE Calcium-channelBlockers:possibleincreasedriskofbradycardiawhenmefloquinegivenwithCALCIUM-CHANNELBLOCKERS TRIANGLE CardiacGlycosides:possibleincreasedriskofbradycardiawhenmefloquinegivenwithDIGOXIN TRIANGLE Cytotoxics:possibleincreasedriskofbradycardiawhenmefloquinegivenwithCRIZOTINIB TRIANGLE Histamine:avoidanceofantimalarialsadvisedbymanufacturerofHISTAMINElIvabradine:increasedriskofventriculararrhythmiaswhenmefloquinegivenwithlIVABRADINE TRIANGLE Vaccines:antimalarialsinactivateORALTYPHOIDVACCINE—seeunderTyphoidVaccineinBNFMegestrolseeProgestogensMelatoninseeAnxiolyticsandHypnoticsMeloxicamseeNSAIDsMelphalan TRIANGLE Antibacterials:increasedriskofmelphalantoxicitywhengivenwithNALIDIXICACIDlAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis) TRIANGLE CardiacGlycosides:melphalanpossiblyreducesabsorptionofDIGOXINtabletslCiclosporin:increasedriskofnephrotoxicitywhenmelphalangivenwithlCICLOSPORINMemantinelAnaesthetics,General:increasedriskofCNStoxicitywhenmemantinegivenwithlKETAMINE(manufacturerofmemantineadvisesavoidconcomitantuse)lAnalgesics:increasedriskofCNStoxicitywhenmemantinegivenwithlDEXTROMETHORPHAN(manufacturerofmemantineadvisesavoidconcomitantuse) TRIANGLE Anticoagulants:memantinepossiblyenhancesanticoagulanteffectofWARFARIN TRIANGLE Antimuscarinics:memantinepossiblyenhanceseffectsofANTIMUSCARINICS TRIANGLE Antipsychotics:memantinepossiblyreduceseffectsofANTIPSYCHOTICSlDopaminergics:memantinepossiblyenhanceseffectsofDOPAMINERGICSandSELEGILINE;increasedriskofCNStoxicitywhenmemantinegivenwithlAMANTADINE(manufacturerofmemantineadvisesavoidconcomitantuse) TRIANGLE MuscleRelaxants:memantinepossiblymodifieseffectsofBACLOFENandDANTROLENEMeningococcalVaccinesseeVaccinesMepacrine TRIANGLE Antimalarials:mepacrineincreasesplasmaconcentrationofPRIMAQUINE(increasedriskoftoxicity)MeprobamateseeAnxiolyticsandHypnoticsMeptazinolseeOpioidAnalgesicsMercaptopurinelAllopurinol:enhancedeffectsandincreasedtoxicityofmercaptopurinewhengivenwithlALLOPURINOL(reducedoseofmercaptopurinetoonequarterofusualdose)lAntibacterials:increasedriskofhaematologicaltoxicitywhenmercaptopurinegivenwithlSULFAMETHOXAZOLE(asco-trimoxazole);increasedriskofhaematologicaltoxicitywhenmercaptopurinegivenwithlTRIMETHOPRIM(alsowithco-trimoxazole)lAnticoagulants:mercaptopurinepossiblyreducesanticoagulanteffectoflCOUMARINSlAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis) TRIANGLE DairyProducts:plasmaconcentrationofmercaptopurinepossiblyreducedbyDAIRYPRODUCTS—manufacturerofmercaptopurineadvisesgiveatleast1hourbeforeor2hoursafterdairyproductslFebuxostat:avoidanceofmercaptopurineadvisedbymanufactureroflFEBUXOSTAT1212Appendix1InteractionsBNF70Interactions|Appendix1"
"MeropenemlAntiepileptics:carbapenemsreduceplasmaconcentrationoflSODIUMVALPROATEandlVALPROICACID—avoidconcomitantuse TRIANGLE Vaccines:antibacterialsinactivateORALTYPHOIDVACCINE—seeunderTyphoidVaccineinBNFMestranolseeOestrogensMetaraminolseeSympathomimeticsMetforminseeAntidiabeticsMethadoneseeOpioidAnalgesicsMethenamine TRIANGLE Antacids:avoidconcomitantuseofmethenaminewithANTACIDSlAntibacterials:increasedriskofcrystalluriawhenmethenaminegivenwithlSULFONAMIDESlDiuretics:effectsofmethenamineantagonisedbylACETAZOLAMIDE TRIANGLE PotassiumSalts:avoidconcomitantuseofmethenaminewithPOTASSIUMCITRATE TRIANGLE SodiumCitrate:avoidconcomitantuseofmethenaminewithSODIUMCITRATE TRIANGLE Vaccines:antibacterialsinactivateORALTYPHOIDVACCINE—seeunderTyphoidVaccineinBNFMethocarbamolseeMuscleRelaxantsMethotrexate TRIANGLE Aminophylline:methotrexatepossiblyincreasesplasmaconcentrationofAMINOPHYLLINElAnaesthetics,General:antifolateeffectofmethotrexateincreasedbylNITROUSOXIDE—avoidconcomitantuselAnalgesics:excretionofmethotrexateprobablyreducedbylNSAIDS(increasedriskoftoxicity);excretionofmethotrexatereducedbylASPIRIN,lDICLOFENAC,lIBUPROFEN,lINDOMETACIN,lKETOPROFEN,lMELOXICAMandlNAPROXEN(increasedriskoftoxicity)lAntibacterials:absorptionofmethotrexatepossiblyreducedbyNEOMYCIN;excretionofmethotrexatepossiblyreducedbyCIPROFLOXACIN(increasedriskoftoxicity);increasedriskofhaematologicaltoxicitywhenmethotrexategivenwithlSULFAMETHOXAZOLE(asco-trimoxazole);increasedriskofmethotrexatetoxicitywhengivenwithDOXYCYCLINE,SULFONAMIDESorTETRACYCLINE;excretionofmethotrexatereducedbyPENICILLINS(increasedriskoftoxicity);increasedriskofhaematologicaltoxicitywhenmethotrexategivenwithlTRIMETHOPRIM(alsowithco-trimoxazole) TRIANGLE Antiepileptics:antifolateeffectofmethotrexateincreasedbyFOSPHENYTOINandPHENYTOINlAntimalarials:antifolateeffectofmethotrexateincreasedbylPYRIMETHAMINElAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis) TRIANGLE CardiacGlycosides:methotrexatepossiblyreducesabsorptionofDIGOXINtabletslCiclosporin:riskoftoxicitywhenmethotrexategivenwithlCICLOSPORIN TRIANGLE Corticosteroids:possibleincreasedriskofhepatoxicitywhenhigh-dosemethotrexategivenwithDEXAMETHASONElCytotoxics:increasedpulmonarytoxicitywhenmethotrexategivenwithlCISPLATIN TRIANGLE Diuretics:excretionofmethotrexateincreasedbyalkalineurineduetoACETAZOLAMIDElLeflunomide:riskoftoxicitywhenmethotrexategivenwithlLEFLUNOMIDElRetinoids:plasmaconcentrationofmethotrexateincreasedbylACITRETIN(alsoincreasedriskofhepatotoxicity)—avoidconcomitantuse TRIANGLE Theophylline:methotrexatepossiblyincreasesplasmaconcentrationofTHEOPHYLLINE TRIANGLE Ulcer-healingDrugs:excretionofmethotrexatepossiblyreducedbyPROTONPUMPINHIBITORS(increasedriskoftoxicity)Methyldopa TRIANGLE ACEInhibitors:enhancedhypotensiveeffectwhenmethyldopagivenwithACEINHIBITORS TRIANGLE AdrenergicNeuroneBlockers:enhancedhypotensiveeffectwhenmethyldopagivenwithADRENERGICNEURONEBLOCKERSMethyldopa(continued) TRIANGLE Alcohol:enhancedhypotensiveeffectwhenmethyldopagivenwithALCOHOL TRIANGLE Aldesleukin:enhancedhypotensiveeffectwhenmethyldopagivenwithALDESLEUKIN TRIANGLE Alpha-blockers:enhancedhypotensiveeffectwhenmethyldopagivenwithALPHA-BLOCKERS TRIANGLE Anaesthetics,General:enhancedhypotensiveeffectwhenmethyldopagivenwithGENERALANAESTHETICS TRIANGLE Analgesics:hypotensiveeffectofmethyldopaantagonisedbyNSAIDS TRIANGLE Angiotensin-IIReceptorAntagonists:enhancedhypotensiveeffectwhenmethyldopagivenwithANGIOTENSIN-IIRECEPTORANTAGONISTSlAntidepressants:manufacturerofmethyldopaadvisesavoidconcomitantusewithlMAOIS TRIANGLE Antipsychotics:enhancedhypotensiveeffectwhenmethyldopagivenwithANTIPSYCHOTICS(alsoincreasedriskofextrapyramidaleffects) TRIANGLE AnxiolyticsandHypnotics:enhancedhypotensiveeffectwhenmethyldopagivenwithANXIOLYTICSANDHYPNOTICS TRIANGLE Beta-blockers:enhancedhypotensiveeffectwhenmethyldopagivenwithBETA-BLOCKERS TRIANGLE Calcium-channelBlockers:enhancedhypotensiveeffectwhenmethyldopagivenwithCALCIUM-CHANNELBLOCKERS TRIANGLE Clonidine:enhancedhypotensiveeffectwhenmethyldopagivenwithCLONIDINE TRIANGLE Corticosteroids:hypotensiveeffectofmethyldopaantagonisedbyCORTICOSTEROIDS TRIANGLE Diazoxide:enhancedhypotensiveeffectwhenmethyldopagivenwithDIAZOXIDE TRIANGLE Diuretics:enhancedhypotensiveeffectwhenmethyldopagivenwithDIURETICS TRIANGLE Dopaminergics:methyldopaantagonisesantiparkinsonianeffectofDOPAMINERGICS;increasedriskofextrapyramidalside-effectswhenmethyldopagivenwithAMANTADINE;enhancedhypotensiveeffectwhenmethyldopagivenwithCO-BENELDOPA,CO-CARELDOPAorLEVODOPA;effectsofmethyldopapossiblyenhancedbyENTACAPONE TRIANGLE IronSalts:hypotensiveeffectofmethyldopaantagonisedbyoralIRONSALTSlLithium:neurotoxicitymayoccurwhenmethyldopagivenwithlLITHIUMwithoutincreasedplasmaconcentrationoflithium TRIANGLE Moxisylyte:enhancedhypotensiveeffectwhenmethyldopagivenwithMOXISYLYTE TRIANGLE Moxonidine:enhancedhypotensiveeffectwhenmethyldopagivenwithMOXONIDINE TRIANGLE MuscleRelaxants:enhancedhypotensiveeffectwhenmethyldopagivenwithBACLOFENorTIZANIDINE TRIANGLE Nitrates:enhancedhypotensiveeffectwhenmethyldopagivenwithNITRATES TRIANGLE Oestrogens:hypotensiveeffectofmethyldopaantagonisedbyOESTROGENS TRIANGLE Prostaglandins:enhancedhypotensiveeffectwhenmethyldopagivenwithALPROSTADILlSympathomimetics,Beta2:acutehypotensionreportedwhenmethyldopagivenwithinfusionoflSALBUTAMOL TRIANGLE VasodilatorAntihypertensives:enhancedhypotensiveeffectwhenmethyldopagivenwithHYDRALAZINE,MINOXIDILorSODIUMNITROPRUSSIDEMethylphenidateseeSympathomimeticsMethylprednisoloneseeCorticosteroidsMethylthioniniumlAntidepressants:riskofCNStoxicitywhenmethylthioniniumgivenwithlSSRI-RELATEDANTIDEPRESSANTS,lSSRISandlCLOMIPRAMINE—avoidconcomitantuse(ifavoidancenotpossible,uselowestpossibledoseofmethylthioniniumandobservepatientforupto4hoursafteradministration);possibleriskofCNStoxicitywhenmethylthioniniumgivenwithlMIRTAZAPINE—avoidconcomitantuse(ifavoidancenotpossible,uselowestpossibledoseofmethylthioniniumandobservepatientforupto4hoursafteradministration)lAnxiolyticsandHypnotics:possibleriskofCNStoxicitywhenmethylthioniniumgivenwithlBUSPIRONE—avoidconcomitantuse(ifavoidancenotpossible,uselowestBNF70Appendix1Interactions1213Interactions|Appendix1"
"MethylthioniniumlAnxiolyticsandHypnotics(continued)possibledoseofmethylthioniniumandobservepatientforupto4hoursafteradministration)lBupropion:possibleriskofCNStoxicitywhenmethylthioniniumgivenwithlBUPROPION—avoidconcomitantuse(ifavoidancenotpossible,uselowestpossibledoseofmethylthioniniumandobservepatientforupto4hoursafteradministration)Metoclopramide TRIANGLE Alcohol:metoclopramidepossiblyincreasesabsorptionofALCOHOL TRIANGLE Anaesthetics,General:metoclopramideenhanceseffectsofTHIOPENTAL TRIANGLE Analgesics:metoclopramideincreasesrateofabsorptionofASPIRIN(enhancedeffect);effectsofmetoclopramideongastro-intestinalactivityantagonisedbyOPIOIDANALGESICS;metoclopramideincreasesrateofabsorptionofPARACETAMOL TRIANGLE Antibacterials:metoclopramidereducesplasmaconcentrationofFOSFOMYCIN TRIANGLE Antidepressants:CNStoxicityreportedwhenmetoclopramidegivenwithSSRIS TRIANGLE Antimuscarinics:effectsofmetoclopramideongastro-intestinalactivityantagonisedbyANTIMUSCARINICS TRIANGLE Antipsychotics:increasedriskofextrapyramidalside-effectswhenmetoclopramidegivenwithANTIPSYCHOTICS TRIANGLE Atovaquone:metoclopramidereducesplasmaconcentrationofATOVAQUONE—avoidconcomitantuselCiclosporin:metoclopramideincreasesplasmaconcentrationoflCICLOSPORIN TRIANGLE Dopaminergics:metoclopramideantagoniseshypoprolactinaemiceffectsofBROMOCRIPTINEandCABERGOLINE;metoclopramideantagonisesantiparkinsonianeffectofPERGOLIDE;avoidanceofmetoclopramideadvisedbymanufacturerofROPINIROLEandROTIGOTINE(antagonismofeffect) TRIANGLE MuscleRelaxants:metoclopramideenhanceseffectsofSUXAMETHONIUM TRIANGLE Tetrabenazine:increasedriskofextrapyramidalside-effectswhenmetoclopramidegivenwithTETRABENAZINEMetolazoneseeDiureticsMetoprololseeBeta-blockersMetronidazoleNOTEInteractionsdonotapplytotopicalmetronidazolepreparations TRIANGLE Alcohol:disulfiram-likereactionwhenmetronidazolegivenwithALCOHOLlAnticoagulants:metronidazoleenhancesanticoagulanteffectoflCOUMARINS TRIANGLE Antiepileptics:metronidazolepossiblyinhibitsmetabolismofFOSPHENYTOINandPHENYTOIN(increasedplasmaconcentration);metabolismofmetronidazoleacceleratedbyPHENOBARBITALandPRIMIDONE(reducedeffect)lCytotoxics:metronidazoleincreasesplasmaconcentrationoflBUSULFAN(increasedriskoftoxicity);metronidazoleinhibitsmetabolismofCAPECITABINE,FLUOROURACILandTEGAFUR(increasedtoxicity) TRIANGLE Disulfiram:psychoticreactionreportedwhenmetronidazolegivenwithDISULFIRAM TRIANGLE Lithium:metronidazoleincreasesriskofLITHIUMtoxicity TRIANGLE Mycophenolate:metronidazolepossiblyreducesbioavailabilityofMYCOPHENOLATE TRIANGLE Ulcer-healingDrugs:metabolismofmetronidazoleinhibitedbyCIMETIDINE(increasedplasmaconcentration) TRIANGLE Vaccines:antibacterialsinactivateORALTYPHOIDVACCINE—seeunderTyphoidVaccineinBNFMianserinseeAntidepressants,Tricyclic(related)Micafungin TRIANGLE Antifungals:micafunginpossiblyincreasesplasmaconcentrationofAMPHOTERICIN;micafunginincreasesplasmaconcentrationofITRACONAZOLE(considerreducingdoseofitraconazole) TRIANGLE Calcium-channelBlockers:micafunginincreasesplasmaconcentrationofNIFEDIPINEMicafungin(continued) TRIANGLE Ciclosporin:micafunginpossiblyincreasesplasmaconcentrationofCICLOSPORIN TRIANGLE Sirolimus:micafunginincreasesplasmaconcentrationofSIROLIMUSMiconazoleseeAntifungals,ImidazoleMidazolamseeAnxiolyticsandHypnoticsMifamurtide TRIANGLE Analgesics:manufacturerofmifamurtideadvisesavoidconcomitantusewithhighdosesofNSAIDS TRIANGLE Ciclosporin:manufacturerofmifamurtideadvisesavoidconcomitantusewithCICLOSPORIN TRIANGLE Corticosteroids:manufacturerofmifamurtideadvisesavoidconcomitantusewithCORTICOSTEROIDS TRIANGLE Tacrolimus:manufacturerofmifamurtideadvisesavoidconcomitantusewithTACROLIMUSMifepristone TRIANGLE Corticosteroids:mifepristonemayreduceeffectofCORTICOSTEROIDS(includinginhaledcorticosteroids)for3–4daysMilrinoneseePhosphodiesteraseInhibitorsMinocyclineseeTetracyclinesMinoxidilseeVasodilatorAntihypertensivesMirabegron TRIANGLE Antibacterials:avoidorreducedoseofmirabegroninhepaticorrenalimpairmentwhengivenwithCLARITHROMYCIN—seeMirabegron,p671 TRIANGLE Antifungals:avoidorreducedoseofmirabegroninhepaticorrenalimpairmentwhengivenwithITRACONAZOLEandKETOCONAZOLE—seeMirabegron,p671 TRIANGLE Antivirals:avoidorreducedoseofmirabegroninhepaticorrenalimpairmentwhengivenwithRITONAVIR—seeMirabegron,p671 TRIANGLE Beta-blockers:mirabegronincreasesplasmaconcentrationofMETOPROLOL TRIANGLE CardiacGlycosides:mirabegronincreasesplasmaconcentrationofDIGOXIN—reduceinitialdoseofdigoxinMirtazapinelAlcohol:increasedsedativeeffectwhenmirtazapinegivenwithlALCOHOL TRIANGLE Analgesics:possibleincreasedserotonergiceffectswhenmirtazapinegivenwithTRAMADOL TRIANGLE Anticoagulants:mirtazapineenhancesanticoagulanteffectofWARFARINlAntidepressants:possibleincreasedserotonergiceffectswhenmirtazapinegivenwithFLUOXETINE,FLUVOXAMINEorVENLAFAXINE;mirtazapineshouldnotbestarteduntil2weeksafterstoppinglMAOIS,alsoMAOIsshouldnotbestarteduntilatleast2weeksafterstoppingmirtazapine;afterstoppingmirtazapinedonotstartlMOCLOBEMIDEforatleast1week TRIANGLE Antiepileptics:plasmaconcentrationofmirtazapinereducedbyCARBAMAZEPINE,FOSPHENYTOINandPHENYTOIN TRIANGLE Antifungals:plasmaconcentrationofmirtazapineincreasedbyKETOCONAZOLElAntimalarials:avoidanceofantidepressantsadvisedbymanufactureroflARTEMETHERWITHLUMEFANTRINEandlARTENIMOLWITHPIPERAQUINE TRIANGLE AnxiolyticsandHypnotics:increasedsedativeeffectwhenmirtazapinegivenwithANXIOLYTICSANDHYPNOTICS TRIANGLE Atomoxetine:possibleincreasedriskofconvulsionswhenantidepressantsgivenwithATOMOXETINE TRIANGLE Clonidine:mirtazapinepossiblyantagoniseshypotensiveeffectofCLONIDINElMethylthioninium:possibleriskofCNStoxicitywhenmirtazapinegivenwithlMETHYLTHIONINIUM—avoidconcomitantuse(ifavoidancenotpossible,uselowestpossibledoseofmethylthioniniumandobservepatientforupto4hoursafteradministration) TRIANGLE Ulcer-healingDrugs:plasmaconcentrationofmirtazapineincreasedbyCIMETIDINEMitomycinlAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)1214Appendix1InteractionsBNF70Interactions|Appendix1"
"MitotanelAnticoagulants:mitotanepossiblyreducesanticoagulanteffectoflCOUMARINSlAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis) TRIANGLE Diuretics:manufacturerofmitotaneadvisesavoidconcomitantuseofSPIRONOLACTONE(antagonismofeffect)MitoxantronelAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis) TRIANGLE Ciclosporin:excretionofmitoxantronereducedbyCICLOSPORIN(increasedplasmaconcentration)MivacuriumseeMuscleRelaxantsMizolastineseeAntihistaminesMMRVaccineseeVaccinesMoclobemidelAnalgesics:possibleCNSexcitationordepression(hypertensionorhypotension)whenmoclobemidegivenwithlDEXTROMETHORPHANorlPETHIDINE—avoidconcomitantuse;possibleCNSexcitationordepression(hypertensionorhypotension)whenmoclobemidegivenwithlOPIOIDANALGESICS—manufacturerofmoclobemideadvisesconsiderreducingdoseofopioidanalgesicslAntidepressants:moclobemideshouldnotbestartedforatleast1weekafterstoppinglMAOIS,lSSRI-RELATEDANTIDEPRESSANTS,lCITALOPRAM,lFLUVOXAMINE,lMIRTAZAPINE,lPAROXETINE,lSERTRALINE,lTRICYCLIC-RELATEDANTIDEPRESSANTSorlTRICYCLICS;increasedriskofCNStoxicitywhenmoclobemidegivenwithlESCITALOPRAM,preferablyavoidconcomitantuse;moclobemideshouldnotbestarteduntil5weeksafterstoppinglFLUOXETINE;possibleincreasedserotonergiceffectswhenmoclobemidegivenwithlDULOXETINElAntimalarials:avoidanceofantidepressantsadvisedbymanufactureroflARTEMETHERWITHLUMEFANTRINEandlARTENIMOLWITHPIPERAQUINE TRIANGLE Atomoxetine:possibleincreasedriskofconvulsionswhenantidepressantsgivenwithATOMOXETINElBupropion:avoidanceofmoclobemideadvisedbymanufactureroflBUPROPIONlClopidogrel:moclobemidepossiblyreducesantiplateleteffectoflCLOPIDOGRELlDopaminergics:increasedriskofside-effectswhenmoclobemidegivenwithCO-BENELDOPA,CO-CARELDOPAorLEVODOPA;cautionwithmoclobemideadvisedbymanufacturerofENTACAPONE;avoidconcomitantuseofmoclobemidewithlSELEGILINEl5HT1-receptorAgonists:riskofCNStoxicitywhenmoclobemidegivenwithlRIZATRIPTANorlSUMATRIPTAN(avoidrizatriptanorsumatriptanfor2weeksaftermoclobemide);riskofCNStoxicitywhenmoclobemidegivenwithlZOLMITRIPTAN(reducedoseofzolmitriptan)lSympathomimetics:riskofhypertensivecrisiswhenmoclobemidegivenwithlSYMPATHOMIMETICS TRIANGLE Ulcer-healingDrugs:plasmaconcentrationofmoclobemideincreasedbyCIMETIDINE(halvedoseofmoclobemide)Modafinil TRIANGLE Antiepileptics:modafinilpossiblyincreasesplasmaconcentrationofFOSPHENYTOINandPHENYTOINlCiclosporin:modafinilreducesplasmaconcentrationoflCICLOSPORINlCytotoxics:modafinilpossiblyreducesplasmaconcentrationoflBOSUTINIB—manufacturerofbosutinibadvisesavoidconcomitantuselOestrogens:modafinilacceleratesmetabolismoflOESTROGENS(reducedcontraceptiveeffectwithcombinedoralcontraceptives,contraceptivepatches,andvaginalrings—seeContraceptiveInteractionsinBNF)MoexiprilseeACEInhibitorsMometasoneseeCorticosteroidsMonobactamsseeAztreonamMonoclonalantibodiesseeindividualdrugsMontelukastseeLeukotrieneReceptorAntagonistsMorphineseeOpioidAnalgesicsMoxifloxacinseeQuinolonesMoxisylyte TRIANGLE ACEInhibitors:enhancedhypotensiveeffectwhenmoxisylytegivenwithACEINHIBITORS TRIANGLE AdrenergicNeuroneBlockers:enhancedhypotensiveeffectwhenmoxisylytegivenwithADRENERGICNEURONEBLOCKERSlAlpha-blockers:possiblesevereposturalhypotensionwhenmoxisylytegivenwithlALPHA-BLOCKERS TRIANGLE Angiotensin-IIReceptorAntagonists:enhancedhypotensiveeffectwhenmoxisylytegivenwithANGIOTENSIN-IIRECEPTORANTAGONISTSlBeta-blockers:possiblesevereposturalhypotensionwhenmoxisylytegivenwithlBETA-BLOCKERS TRIANGLE Calcium-channelBlockers:enhancedhypotensiveeffectwhenmoxisylytegivenwithCALCIUM-CHANNELBLOCKERS TRIANGLE Clonidine:enhancedhypotensiveeffectwhenmoxisylytegivenwithCLONIDINE TRIANGLE Diazoxide:enhancedhypotensiveeffectwhenmoxisylytegivenwithDIAZOXIDE TRIANGLE Diuretics:enhancedhypotensiveeffectwhenmoxisylytegivenwithDIURETICS TRIANGLE Methyldopa:enhancedhypotensiveeffectwhenmoxisylytegivenwithMETHYLDOPA TRIANGLE Moxonidine:enhancedhypotensiveeffectwhenmoxisylytegivenwithMOXONIDINE TRIANGLE Nitrates:enhancedhypotensiveeffectwhenmoxisylytegivenwithNITRATES TRIANGLE VasodilatorAntihypertensives:enhancedhypotensiveeffectwhenmoxisylytegivenwithHYDRALAZINE,MINOXIDILorSODIUMNITROPRUSSIDEMoxonidine TRIANGLE ACEInhibitors:enhancedhypotensiveeffectwhenmoxonidinegivenwithACEINHIBITORS TRIANGLE AdrenergicNeuroneBlockers:enhancedhypotensiveeffectwhenmoxonidinegivenwithADRENERGICNEURONEBLOCKERS TRIANGLE Alcohol:enhancedhypotensiveeffectwhenmoxonidinegivenwithALCOHOL TRIANGLE Aldesleukin:enhancedhypotensiveeffectwhenmoxonidinegivenwithALDESLEUKIN TRIANGLE Alpha-blockers:enhancedhypotensiveeffectwhenmoxonidinegivenwithALPHA-BLOCKERS TRIANGLE Anaesthetics,General:enhancedhypotensiveeffectwhenmoxonidinegivenwithGENERALANAESTHETICS TRIANGLE Analgesics:hypotensiveeffectofmoxonidineantagonisedbyNSAIDS TRIANGLE Angiotensin-IIReceptorAntagonists:enhancedhypotensiveeffectwhenmoxonidinegivenwithANGIOTENSIN-IIRECEPTORANTAGONISTS TRIANGLE Antidepressants:enhancedhypotensiveeffectwhenmoxonidinegivenwithMAOIS;hypotensiveeffectofmoxonidinepossiblyantagonisedbyTRICYCLICS(manufacturerofmoxonidineadvisesavoidconcomitantuse) TRIANGLE Antipsychotics:enhancedhypotensiveeffectwhenmoxonidinegivenwithPHENOTHIAZINES TRIANGLE AnxiolyticsandHypnotics:enhancedhypotensiveeffectwhenmoxonidinegivenwithANXIOLYTICSANDHYPNOTICS;sedativeeffectspossiblyincreasedwhenmoxonidinegivenwithBENZODIAZEPINES TRIANGLE Beta-blockers:enhancedhypotensiveeffectwhenmoxonidinegivenwithBETA-BLOCKERS TRIANGLE Calcium-channelBlockers:enhancedhypotensiveeffectwhenmoxonidinegivenwithCALCIUM-CHANNELBLOCKERS TRIANGLE Clonidine:enhancedhypotensiveeffectwhenmoxonidinegivenwithCLONIDINE TRIANGLE Corticosteroids:hypotensiveeffectofmoxonidineantagonisedbyCORTICOSTEROIDS TRIANGLE Diazoxide:enhancedhypotensiveeffectwhenmoxonidinegivenwithDIAZOXIDE TRIANGLE Diuretics:enhancedhypotensiveeffectwhenmoxonidinegivenwithDIURETICS TRIANGLE Dopaminergics:enhancedhypotensiveeffectwhenmoxonidinegivenwithCO-BENELDOPA,CO-CARELDOPAorLEVODOPA TRIANGLE Methyldopa:enhancedhypotensiveeffectwhenmoxonidinegivenwithMETHYLDOPA TRIANGLE Moxisylyte:enhancedhypotensiveeffectwhenmoxonidinegivenwithMOXISYLYTEBNF70Appendix1Interactions1215Interactions|Appendix1"
"Moxonidine(continued) TRIANGLE MuscleRelaxants:enhancedhypotensiveeffectwhenmoxonidinegivenwithBACLOFENorTIZANIDINE TRIANGLE Nitrates:enhancedhypotensiveeffectwhenmoxonidinegivenwithNITRATES TRIANGLE Oestrogens:hypotensiveeffectofmoxonidineantagonisedbyOESTROGENS TRIANGLE Prostaglandins:enhancedhypotensiveeffectwhenmoxonidinegivenwithALPROSTADIL TRIANGLE VasodilatorAntihypertensives:enhancedhypotensiveeffectwhenmoxonidinegivenwithHYDRALAZINE,MINOXIDILorSODIUMNITROPRUSSIDEMuscleRelaxants TRIANGLE ACEInhibitors:enhancedhypotensiveeffectwhenbaclofenortizanidinegivenwithACEINHIBITORS TRIANGLE AdrenergicNeuroneBlockers:enhancedhypotensiveeffectwhenbaclofenortizanidinegivenwithADRENERGICNEURONEBLOCKERS TRIANGLE Alcohol:increasedsedativeeffectwhenbaclofen,methocarbamolortizanidinegivenwithALCOHOL TRIANGLE Alpha-blockers:enhancedhypotensiveeffectwhenbaclofenortizanidinegivenwithALPHA-BLOCKERSlAnaesthetics,General:effectsofatracuriumenhancedbyKETAMINE;increasedriskofmyocardialdepressionandbradycardiawhensuxamethoniumgivenwithlPROPOFOL;effectsofnon-depolarisingmusclerelaxantsandsuxamethoniumenhancedbyVOLATILELIQUIDGENERALANAESTHETICS TRIANGLE Analgesics:excretionofbaclofenpossiblyreducedbyNSAIDS(increasedriskoftoxicity);excretionofbaclofenreducedbyIBUPROFEN(increasedriskoftoxicity);increasedsedativeeffectwhenbaclofengivenwithFENTANYLorMORPHINE TRIANGLE Angiotensin-IIReceptorAntagonists:enhancedhypotensiveeffectwhenbaclofenortizanidinegivenwithANGIOTENSIN-IIRECEPTORANTAGONISTS TRIANGLE Anti-arrhythmics:neuromuscularblockadeenhancedandprolongedwhensuxamethoniumgivenwithLIDOCAINElAntibacterials:effectsofnon-depolarisingmusclerelaxantsandsuxamethoniumenhancedbyPIPERACILLIN;plasmaconcentrationoftizanidineincreasedbylCIPROFLOXACIN(increasedriskoftoxicity)—avoidconcomitantuse;plasmaconcentrationoftizanidinepossiblyincreasedbyNORFLOXACIN(increasedriskoftoxicity);plasmaconcentrationoftizanidinepossiblyreducedbyRIFAMPICIN;effectsofnon-depolarisingmusclerelaxantsandsuxamethoniumenhancedbylAMINOGLYCOSIDES;effectsofnon-depolarisingmusclerelaxantsandsuxamethoniumenhancedbylCLINDAMYCIN;effectsofnon-depolarisingmusclerelaxantsandsuxamethoniumenhancedbylPOLYMYXINS;effectsofsuxamethoniumenhancedbylVANCOMYCINlAntidepressants:plasmaconcentrationoftizanidineincreasedbylFLUVOXAMINE(increasedriskoftoxicity)—avoidconcomitantuse;effectsofsuxamethoniumenhancedbyPHENELZINE;musclerelaxanteffectofbaclofenenhancedbyTRICYCLICSlAntiepileptics:musclerelaxanteffectofnon-depolarisingmusclerelaxantsantagonisedbyCARBAMAZEPINE(acceleratedrecoveryfromneuromuscularblockade);effectsofnon-depolarisingmusclerelaxantsreducedbylong-termuseoflFOSPHENYTOINandlPHENYTOIN(buteffectsofnon-depolarisingmusclerelaxantsmightbeincreasedbyacuteuseoffosphenytoinandphenytoin) TRIANGLE Antimalarials:effectsofsuxamethoniumpossiblyenhancedbyQUININE TRIANGLE Antipsychotics:effectsofsuxamethoniumpossiblyenhancedbyPROMAZINE TRIANGLE AnxiolyticsandHypnotics:increasedsedativeeffectwhenbaclofenortizanidinegivenwithANXIOLYTICSANDHYPNOTICS TRIANGLE Beta-blockers:enhancedhypotensiveeffectwhenbaclofengivenwithBETA-BLOCKERS;possibleenhancedhypotensiveeffectandbradycardiawhentizanidinegivenwithBETA-BLOCKERS;effectsofmusclerelaxantsenhancedbyPROPRANOLOL TRIANGLE Calcium-channelBlockers:enhancedhypotensiveeffectwhenbaclofenortizanidinegivenwithCALCIUM-CHANNELBLOCKERS;MuscleRelaxantsCalcium-channelBlockers(continued)effectsofnon-depolarisingmusclerelaxantspossiblyenhancedbyCALCIUM-CHANNELBLOCKERS;possibleincreasedriskofventriculararrhythmiaswhenintravenousdantrolenegivenwithDILTIAZEM—manufacturerofdiltiazemadvisesavoidconcomitantuse;effectsofnon-depolarisingmusclerelaxantsandsuxamethoniumenhancedbyVERAPAMIL;avoidanceofintravenousdantroleneadvisedbymanufacturerofVERAPAMIL TRIANGLE CardiacGlycosides:possibleincreasedriskofbradycardiawhentizanidinegivenwithCARDIACGLYCOSIDES;riskofventriculararrhythmiaswhensuxamethoniumgivenwithCARDIACGLYCOSIDES TRIANGLE Clonidine:enhancedhypotensiveeffectwhenbaclofenortizanidinegivenwithCLONIDINE TRIANGLE Corticosteroids:effectsofpancuroniumandvecuroniumpossiblyantagonisedbyCORTICOSTEROIDS TRIANGLE Cytotoxics:effectsofsuxamethoniumenhancedbyCYCLOPHOSPHAMIDEandTHIOTEPA TRIANGLE Deferasirox:avoidanceoftizanidineadvisedbymanufacturerofDEFERASIROX TRIANGLE Diazoxide:enhancedhypotensiveeffectwhenbaclofenortizanidinegivenwithDIAZOXIDE TRIANGLE Diuretics:enhancedhypotensiveeffectwhenbaclofenortizanidinegivenwithDIURETICS TRIANGLE Dopaminergics:possibleagitation,confusionandhallucinationswhenbaclofengivenwithCO-BENELDOPA,CO-CARELDOPAorLEVODOPA TRIANGLE Lithium:effectsofmusclerelaxantsenhancedbyLITHIUM;baclofenpossiblyaggravateshyperkinesiscausedbyLITHIUM TRIANGLE Magnesium(parenteral):effectsofnon-depolarisingmusclerelaxantsandsuxamethoniumenhancedbyPARENTERALMAGNESIUM TRIANGLE Memantine:effectsofbaclofenanddantrolenepossiblymodifiedbyMEMANTINE TRIANGLE Methyldopa:enhancedhypotensiveeffectwhenbaclofenortizanidinegivenwithMETHYLDOPA TRIANGLE Metoclopramide:effectsofsuxamethoniumenhancedbyMETOCLOPRAMIDE TRIANGLE Moxonidine:enhancedhypotensiveeffectwhenbaclofenortizanidinegivenwithMOXONIDINE TRIANGLE Nitrates:enhancedhypotensiveeffectwhenbaclofenortizanidinegivenwithNITRATES TRIANGLE Oestrogens:plasmaconcentrationoftizanidinepossiblyincreasedbyOESTROGENS(increasedriskoftoxicity) TRIANGLE Parasympathomimetics:effectsofnon-depolarisingmusclerelaxantspossiblyantagonisedbyDONEPEZIL;effectsofsuxamethoniumpossiblyenhancedbyDONEPEZIL;effectsofsuxamethoniumenhancedbyGALANTAMINE,NEOSTIGMINE,PYRIDOSTIGMINEandRIVASTIGMINE;effectsofnon-depolarisingmusclerelaxantsantagonisedbyNEOSTIGMINE,PYRIDOSTIGMINEandRIVASTIGMINE TRIANGLE Progestogens:plasmaconcentrationoftizanidinepossiblyincreasedbyPROGESTOGENS(increasedriskoftoxicity) TRIANGLE Sympathomimetics,Beta2:effectsofsuxamethoniumenhancedbyBAMBUTEROL TRIANGLE VasodilatorAntihypertensives:enhancedhypotensiveeffectwhenbaclofenortizanidinegivenwithHYDRALAZINE;enhancedhypotensiveeffectwhenbaclofenortizanidinegivenwithMINOXIDIL;enhancedhypotensiveeffectwhenbaclofenortizanidinegivenwithSODIUMNITROPRUSSIDEMuscleRelaxants,depolarisingseeMuscleRelaxantsMuscleRelaxants,non-depolarisingseeMuscleRelaxantsMycophenolate TRIANGLE Antacids:absorptionofmycophenolatereducedbyANTACIDSlAntibacterials:bioavailabilityofmycophenolatepossiblyreducedbyMETRONIDAZOLEandNORFLOXACIN;plasmaconcentrationofmycophenolatepossiblyreducedbyCO-AMOXICLAV;plasmaconcentrationofactivemetaboliteofmycophenolatereducedbylRIFAMPICIN TRIANGLE Antivirals:mycophenolateincreasesplasmaconcentrationofACICLOVIRandVALACICLOVIR,alsoplasmaconcentrationofinactivemetaboliteofmycophenolateincreased;mycophenolatepossiblyincreasesplasmaconcentrationof1216Appendix1InteractionsBNF70Interactions|Appendix1"
"MycophenolateAntivirals(continued)GANCICLOVIRandVALGANCICLOVIR,alsoplasmaconcentrationofinactivemetaboliteofmycophenolatepossiblyincreased TRIANGLE Colestilan:manufacturerofcolestilanadvisesgivemycophenolateatleast1hourbeforeor3hoursafterCOLESTILAN TRIANGLE IronSalts:absorptionofmycophenolatereducedbyoralIRONSALTS TRIANGLE Lipid-regulatingDrugs:absorptionofmycophenolatereducedbyCOLESTYRAMINE TRIANGLE Sevelamer:plasmaconcentrationofmycophenolatepossiblyreducedbySEVELAMERNabumetoneseeNSAIDsNadololseeBeta-blockersNalidixicAcidseeQuinolonesNalmefenelAnalgesics:manufacturerofnalmefeneadvisesavoidconcomitantusewithlOPIOIDANALGESICSNandroloneseeAnabolicSteroidsNaproxenseeNSAIDsNaratriptansee5HT1-receptorAgonists(underHT)NatalizumublAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lVaccines:riskofgeneralisedinfectionswhenmonoclonalantibodiesgivenwithlivelVACCINES—avoidconcomitantuseNateglinideseeAntidiabeticsNebivololseeBeta-blockersNefopamlAntidepressants:manufacturerofnefopamadvisesavoidconcomitantusewithlMAOIS;side-effectspossiblyincreasedwhennefopamgivenwithTRICYCLICS TRIANGLE Antimuscarinics:increasedriskofantimuscarinicside-effectswhennefopamgivenwithANTIMUSCARINICSNeomycinseeAminoglycosidesNeostigmineseeParasympathomimeticsNevirapine TRIANGLE Analgesics:nevirapinepossiblyreducesplasmaconcentrationofMETHADONElAntibacterials:nevirapinereducesplasmaconcentrationofCLARITHROMYCIN(butconcentrationofanactivemetaboliteincreased),alsoplasmaconcentrationofnevirapineincreased;nevirapinepossiblyincreasesplasmaconcentrationofRIFABUTIN;plasmaconcentrationofnevirapinereducedbylRIFAMPICIN—avoidconcomitantuselAnticoagulants:nevirapinemayenhanceorreduceanticoagulanteffectoflWARFARINlAntidepressants:plasmaconcentrationofnevirapinereducedbylSTJOHN’SWORT—avoidconcomitantuse TRIANGLE Antiepileptics:plasmaconcentrationofnevirapinereducedbyCARBAMAZEPINElAntifungals:nevirapinereducesplasmaconcentrationoflKETOCONAZOLE—avoidconcomitantuse;plasmaconcentrationofnevirapineincreasedbylFLUCONAZOLE;nevirapinepossiblyreducesplasmaconcentrationofCASPOFUNGINandITRACONAZOLE—considerincreasingdoseofcaspofunginanditraconazolelAntipsychotics:nevirapinepossiblyreducesplasmaconcentrationoflARIPIPRAZOLE(avoidconcomitantuseorconsiderincreasingthedoseofaripiprazole—consultaripiprazoleproductliterature)lAntivirals:nevirapinepossiblyreducesplasmaconcentrationoflATAZANAVIRandlETRAVIRINE—avoidconcomitantuse;manufacturerofnevirapineadvisesavoidconcomitantusewithBOCEPREVIRandRILPIVIRINE;avoidanceofnevirapineadvisedbymanufacturerofDACLATASVIR(plasmaconcentrationofdaclatasvirpossiblyreduced);nevirapinepossiblyreducestheplasmaconcentrationoflDOLUTEGRAVIR(seeunderDolutegravir,p557);nevirapinereducesplasmaconcentrationoflEFAVIRENZ—avoidconcomitantuse;avoidanceofnevirapineadvisedbymanufacturerofELVITEGRAVIR;nevirapinepossiblyreducesplasmaconcentrationofFOSAMPRENAVIR—avoidunboostedfosamprenavir;nevirapinereducesplasmaconcentrationofNevirapinelAntivirals(continued)INDINAVIR;nevirapinepossiblyreducesplasmaconcentrationoflLOPINAVIRandTELAPREVIR—considerincreasingdoseoflopinavirandtelaprevir;nevirapinepossiblyreducesplasmaconcentrationoflSIMEPREVIR—manufacturerofsimepreviradvisesavoidconcomitantuse;increasedriskofgranulocytopeniawhennevirapinegivenwithlZIDOVUDINE TRIANGLE Cobicistat:manufacturerofnevirapineadvisesavoidconcomitantusewithCOBICISTATlOestrogens:nevirapineacceleratesmetabolismoflOESTROGENS(reducedcontraceptiveeffectwithcombinedoralcontraceptives,contraceptivepatches,andvaginalrings—seeContraceptiveInteractionsinBNF)lOrlistat:absorptionofnevirapinepossiblyreducedbylORLISTATlProgestogens:nevirapineacceleratesmetabolismoflPROGESTOGENS(reducedcontraceptiveeffectwithcombinedoralcontraceptives,progestogen-onlyoralcontraceptives,contraceptivepatches,vaginalrings,etonogestrel-releasingimplant,andemergencyhormonalcontraception—seeContraceptiveInteractionsinBNF)NicardipineseeCalcium-channelBlockersNicorandil TRIANGLE Alcohol:hypotensiveeffectofnicorandilpossiblyenhancedbyALCOHOL TRIANGLE Antidepressants:enhancedhypotensiveeffectwhennicorandilgivenwithMAOIS;hypotensiveeffectofnicorandilpossiblyenhancedbyTRICYCLICSlAvanafil:hypotensiveeffectofnicorandilsignificantlyenhancedbylAVANAFIL(avoidconcomitantuse)lSildenafil:hypotensiveeffectofnicorandilsignificantlyenhancedbylSILDENAFIL(avoidconcomitantuse)lTadalafil:hypotensiveeffectofnicorandilsignificantlyenhancedbylTADALAFIL(avoidconcomitantuse)lVardenafil:possibleincreasedhypotensiveeffectwhennicorandilgivenwithlVARDENAFIL—avoidconcomitantuse TRIANGLE VasodilatorAntihypertensives:possibleenhancedhypotensiveeffectwhennicorandilgivenwithHYDRALAZINE,MINOXIDILorSODIUMNITROPRUSSIDENicotine TRIANGLE Anti-arrhythmics:nicotinepossiblyenhanceseffectsofADENOSINENicotinicAcidlLipid-regulatingDrugs:increasedriskofmyopathywhennicotinicacidgivenwithlSTATINS(appliestolipidregulatingdosesofnicotinicacid)NifedipineseeCalcium-channelBlockersNilotiniblAntibacterials:manufacturerofnilotinibadvisesavoidconcomitantusewithlCLARITHROMYCINandlTELITHROMYCIN;plasmaconcentrationofnilotinibreducedbylRIFAMPICIN—avoidconcomitantuselAntifungals:plasmaconcentrationofnilotinibincreasedbylKETOCONAZOLE—avoidconcomitantuse;manufacturerofnilotinibadvisesavoidconcomitantusewithlITRACONAZOLEandlVORICONAZOLElAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lAntivirals:avoidanceofnilotinibadvisedbymanufactureroflBOCEPREVIR;plasmaconcentrationofnilotinibpossiblyincreasedbyRITONAVIR—manufacturerofnilotinibadvisesavoidconcomitantuse TRIANGLE AnxiolyticsandHypnotics:nilotinibincreasesplasmaconcentrationofMIDAZOLAMlGrapefruitJuice:manufacturerofnilotinibadvisesavoidconcomitantusewithlGRAPEFRUITJUICE TRIANGLE Lipid-regulatingDrugs:separatingadministrationfromnilotinibby12hoursadvisedbymanufacturerofLOMITAPIDENimodipineseeCalcium-channelBlockersNintedaniblAntibacterials:plasmaconcentrationofnintedanibreducedbylRIFAMPICIN—avoidconcomitantuselAntifungals:plasmaconcentrationofnintedanibincreasedbylKETOCONAZOLEBNF70Appendix1Interactions1217Interactions|Appendix1"
"Nitrates TRIANGLE ACEInhibitors:enhancedhypotensiveeffectwhennitratesgivenwithACEINHIBITORS TRIANGLE AdrenergicNeuroneBlockers:enhancedhypotensiveeffectwhennitratesgivenwithADRENERGICNEURONEBLOCKERS TRIANGLE Alcohol:enhancedhypotensiveeffectwhennitratesgivenwithALCOHOL TRIANGLE Aldesleukin:enhancedhypotensiveeffectwhennitratesgivenwithALDESLEUKIN TRIANGLE Alpha-blockers:enhancedhypotensiveeffectwhennitratesgivenwithALPHA-BLOCKERS TRIANGLE Anaesthetics,General:enhancedhypotensiveeffectwhennitratesgivenwithGENERALANAESTHETICS TRIANGLE Analgesics:hypotensiveeffectofnitratesantagonisedbyNSAIDS TRIANGLE Angiotensin-IIReceptorAntagonists:enhancedhypotensiveeffectwhennitratesgivenwithANGIOTENSIN-IIRECEPTORANTAGONISTS TRIANGLE Anti-arrhythmics:effectsofsublingualtabletsofnitratesreducedbyDISOPYRAMIDE(failuretodissolveundertongueowingtodrymouth)lAnticoagulants:infusionofglyceryltrinitratereducesanticoagulanteffectoflHEPARINS TRIANGLE Antidepressants:enhancedhypotensiveeffectwhennitratesgivenwithMAOIS;effectsofsublingualtabletsofnitratespossiblyreducedbyTRICYCLIC-RELATEDANTIDEPRESSANTS(failuretodissolveundertongueowingtodrymouth);effectsofsublingualtabletsofnitratesreducedbyTRICYCLICS(failuretodissolveundertongueowingtodrymouth) TRIANGLE Antimuscarinics:effectsofsublingualtabletsofnitratespossiblyreducedbyANTIMUSCARINICS(failuretodissolveundertongueowingtodrymouth) TRIANGLE Antipsychotics:enhancedhypotensiveeffectwhennitratesgivenwithPHENOTHIAZINES TRIANGLE AnxiolyticsandHypnotics:enhancedhypotensiveeffectwhennitratesgivenwithANXIOLYTICSANDHYPNOTICSlAvanafil:hypotensiveeffectofnitratessignificantlyenhancedbylAVANAFIL(avoidconcomitantuse) TRIANGLE Beta-blockers:enhancedhypotensiveeffectwhennitratesgivenwithBETA-BLOCKERS TRIANGLE Calcium-channelBlockers:enhancedhypotensiveeffectwhennitratesgivenwithCALCIUM-CHANNELBLOCKERS TRIANGLE Clonidine:enhancedhypotensiveeffectwhennitratesgivenwithCLONIDINE TRIANGLE Corticosteroids:hypotensiveeffectofnitratesantagonisedbyCORTICOSTEROIDS TRIANGLE Diazoxide:enhancedhypotensiveeffectwhennitratesgivenwithDIAZOXIDE TRIANGLE Diuretics:enhancedhypotensiveeffectwhennitratesgivenwithDIURETICS TRIANGLE Dopaminergics:enhancedhypotensiveeffectwhennitratesgivenwithCO-BENELDOPA,CO-CARELDOPAorLEVODOPA TRIANGLE Methyldopa:enhancedhypotensiveeffectwhennitratesgivenwithMETHYLDOPA TRIANGLE Moxisylyte:enhancedhypotensiveeffectwhennitratesgivenwithMOXISYLYTE TRIANGLE Moxonidine:enhancedhypotensiveeffectwhennitratesgivenwithMOXONIDINE TRIANGLE MuscleRelaxants:enhancedhypotensiveeffectwhennitratesgivenwithBACLOFENorTIZANIDINE TRIANGLE Oestrogens:hypotensiveeffectofnitratesantagonisedbyOESTROGENS TRIANGLE Prostaglandins:enhancedhypotensiveeffectwhennitratesgivenwithALPROSTADILlRiociguat:possibleenhancedhypotensiveeffectwhennitratesgivenwithlRIOCIGUAT—avoidconcomitantuselSildenafil:hypotensiveeffectofnitratessignificantlyenhancedbylSILDENAFIL(avoidconcomitantuse)lTadalafil:hypotensiveeffectofnitratessignificantlyenhancedbylTADALAFIL(avoidconcomitantuse)lVardenafil:possibleincreasedhypotensiveeffectwhennitratesgivenwithlVARDENAFIL—avoidconcomitantuse TRIANGLE VasodilatorAntihypertensives:enhancedhypotensiveeffectwhennitratesgivenwithHYDRALAZINE,MINOXIDILorSODIUMNITROPRUSSIDENitrazepamseeAnxiolyticsandHypnoticsNitrofurantoin TRIANGLE Antacids:absorptionofnitrofurantoinreducedbyORALMAGNESIUMSALTS(asmagnesiumtrisilicate) TRIANGLE Antibacterials:nitrofurantoinpossiblyantagoniseseffectsofNALIDIXICACID TRIANGLE Sulfinpyrazone:excretionofnitrofurantoinreducedbySULFINPYRAZONE(increasedriskoftoxicity) TRIANGLE Vaccines:antibacterialsinactivateORALTYPHOIDVACCINE—seeunderTyphoidVaccineinBNFNitroimidazolesseeMetronidazoleandTinidazoleNitrousOxideseeAnaesthetics,GeneralNizatidineseeHistamineH2-antagonistsNomegestrolseeProgestogensNoradrenaline(norepinephrine)seeSympathomimeticsNorelgestrominseeProgestogensNorepinephrineNOTENorepinephrineinteractionsasfornoradrenaline,seeundersympathomimeticsNorethisteroneseeProgestogensNorfloxacinseeQuinolonesNorgestimateseeProgestogensNorgestrelseeProgestogensNormalImmunoglobulinseeImmunoglobulinsNortriptylineseeAntidepressants,TricyclicNSAIDsNOTESeealsoAspirinInteractionsdonotgenerallyapplytotopicalNSAIDs TRIANGLE ACEInhibitors:increasedriskofrenalimpairmentwhenNSAIDsgivenwithACEINHIBITORS,alsohypotensiveeffectantagonised TRIANGLE AdrenergicNeuroneBlockers:NSAIDsantagonisehypotensiveeffectofADRENERGICNEURONEBLOCKERS TRIANGLE Aliskiren:NSAIDspossiblyantagonisehypotensiveeffectofALISKIREN TRIANGLE Alpha-blockers:NSAIDsantagonisehypotensiveeffectofALPHA-BLOCKERSlAnalgesics:avoidconcomitantuseofNSAIDswithlNSAIDSorlASPIRIN(increasedside-effects);avoidconcomitantuseofNSAIDswithlKETOROLAC(increasedside-effectsandhaemorrhage);ibuprofenpossiblyreducesantiplateleteffectofASPIRIN TRIANGLE Angiotensin-IIReceptorAntagonists:increasedriskofrenalimpairmentwhenNSAIDsgivenwithANGIOTENSIN-IIRECEPTORANTAGONISTS,alsohypotensiveeffectantagonised TRIANGLE Antacids:absorptionofacemetacinpossiblyreducedbyANTACIDSlAntibacterials:indometacinpossiblyincreasesplasmaconcentrationofAMIKACINandGENTAMICINinneonates;plasmaconcentrationofcelecoxib,diclofenacandetoricoxibreducedbyRIFAMPICIN;possibleincreasedriskofconvulsionswhenNSAIDsgivenwithlQUINOLONESlAnticoagulants:increasedriskofhaemorrhagewhenintravenousdiclofenacgivenwithlANTICOAGULANTS(avoidconcomitantuse,includinglow-doseheparins);increasedriskofhaemorrhagewhenketorolacgivenwithlANTICOAGULANTS(avoidconcomitantuse,includinglow-doseheparins);NSAIDspossiblyenhanceanticoagulanteffectoflCOUMARINSandlPHENINDIONE;possibleincreasedriskofbleedingwhenNSAIDsgivenwithlDABIGATRANorHEPARINSlAntidepressants:increasedriskofbleedingwhenNSAIDsgivenwithlSSRISorlVENLAFAXINElAntidiabetics:NSAIDspossiblyenhanceeffectsoflSULFONYLUREAS TRIANGLE Antiepileptics:acemetacinpossiblyreducesexcretionofFOSPHENYTOINandPHENYTOIN(increasedriskoftoxicity) TRIANGLE Antifungals:plasmaconcentrationofparecoxibincreasedbyFLUCONAZOLE(reducedoseofparecoxib);plasmaconcentrationofcelecoxibincreasedbyFLUCONAZOLE(halvedoseofcelecoxib);plasmaconcentrationofflurbiprofenandibuprofenincreasedbyFLUCONAZOLE;plasmaconcentrationofdiclofenacandibuprofenincreasedbyVORICONAZOLE TRIANGLE Antipsychotics:possibleseveredrowsinesswhenacemetacinorindometacingivenwithHALOPERIDOL1218Appendix1InteractionsBNF70Interactions|Appendix1"
"NSAIDs(continued)lAntivirals:plasmaconcentrationofpiroxicamincreasedbylRITONAVIR(riskoftoxicity)—avoidconcomitantuse;plasmaconcentrationofNSAIDspossiblyincreasedbyRITONAVIR;increasedriskofhaematologicaltoxicitywhenNSAIDsgivenwithZIDOVUDINE TRIANGLE Beta-blockers:NSAIDsantagonisehypotensiveeffectofBETA-BLOCKERS TRIANGLE Calcium-channelBlockers:NSAIDsantagonisehypotensiveeffectofCALCIUM-CHANNELBLOCKERS TRIANGLE CardiacGlycosides:NSAIDspossiblyincreaseplasmaconcentrationofCARDIACGLYCOSIDES,alsopossibleexacerbationofheartfailureandreductionofrenalfunctionlCiclosporin:increasedriskofnephrotoxicitywhenNSAIDsgivenwithlCICLOSPORIN;plasmaconcentrationofdiclofenacincreasedbylCICLOSPORIN(halvedoseofdiclofenac) TRIANGLE Clonidine:NSAIDsantagonisehypotensiveeffectofCLONIDINE TRIANGLE Clopidogrel:increasedriskofbleedingwhenNSAIDsgivenwithCLOPIDOGREL TRIANGLE Corticosteroids:increasedriskofgastro-intestinalbleedingandulcerationwhenNSAIDsgivenwithCORTICOSTEROIDSlCytotoxics:NSAIDsprobablyreduceexcretionoflMETHOTREXATE(increasedriskoftoxicity);diclofenac,ibuprofen,indometacin,ketoprofen,meloxicamandnaproxenreduceexcretionoflMETHOTREXATE(increasedriskoftoxicity);NSAIDspossiblyreducerenalexcretionofPEMETREXED—consultproductliterature;increasedriskofbleedingwhenNSAIDsgivenwithlERLOTINIB;avoidanceofmefenamicacidadvisedbymanufacturerofREGORAFENIB TRIANGLE Desmopressin:indometacinenhanceseffectsofDESMOPRESSIN TRIANGLE Diazoxide:NSAIDsantagonisehypotensiveeffectofDIAZOXIDElDimethylsulfoxide:avoidconcomitantuseofsulindacwithlDIMETHYLSULFOXIDElDiuretics:riskofnephrotoxicityofNSAIDsincreasedbyDIURETICS,alsoantagonismofdiureticeffect;indometacinandketorolacantagoniseeffectsofDIURETICS;excretionofacemetacinpossiblyincreasedbyFUROSEMIDE;NSAIDspossiblyantagonisediureticeffectofPOTASSIUMCANRENOATE;occasionalreportsofreducedrenalfunctionwhenindometacingivenwithlTRIAMTERENE—avoidconcomitantuse;possibleincreasedriskofhyperkalaemiawhenNSAIDsgivenwithPOTASSIUM-SPARINGDIURETICSANDALDOSTERONEANTAGONISTS;increasedriskofhyperkalaemiawhenindometacingivenwithPOTASSIUM-SPARINGDIURETICSANDALDOSTERONEANTAGONISTS TRIANGLE Iloprost:increasedriskofbleedingwhenNSAIDsgivenwithILOPROST TRIANGLE Lipid-regulatingDrugs:excretionofmeloxicamincreasedbyCOLESTYRAMINElLithium:NSAIDsreduceexcretionoflLITHIUM(increasedriskoftoxicity);ketorolacreducesexcretionoflLITHIUM(increasedriskoftoxicity)—avoidconcomitantuse TRIANGLE Methyldopa:NSAIDsantagonisehypotensiveeffectofMETHYLDOPA TRIANGLE Mifamurtide:avoidanceofhighdosesofNSAIDsadvisedbymanufacturerofMIFAMURTIDE TRIANGLE Moxonidine:NSAIDsantagonisehypotensiveeffectofMOXONIDINE TRIANGLE MuscleRelaxants:ibuprofenreducesexcretionofBACLOFEN(increasedriskoftoxicity);NSAIDspossiblyreduceexcretionofBACLOFEN(increasedriskoftoxicity) TRIANGLE Nitrates:NSAIDsantagonisehypotensiveeffectofNITRATES TRIANGLE Oestrogens:etoricoxibincreasesplasmaconcentrationofETHINYLESTRADIOL TRIANGLE Penicillamine:possibleincreasedriskofnephrotoxicitywhenNSAIDsgivenwithPENICILLAMINElPentoxifylline:possibleincreasedriskofbleedingwhenNSAIDsgivenwithPENTOXIFYLLINE;increasedriskofbleedingwhenketorolacgivenwithlPENTOXIFYLLINE(avoidconcomitantuse) TRIANGLE Prasugrel:possibleincreasedriskofbleedingwhenNSAIDsgivenwithPRASUGRELlTacrolimus:possibleincreasedriskofnephrotoxicitywhenNSAIDsgivenwithTACROLIMUS;increasedriskofnephrotoxicitywhenibuprofengivenwithlTACROLIMUSNSAIDs(continued) TRIANGLE VasodilatorAntihypertensives:NSAIDsantagonisehypotensiveeffectofHYDRALAZINE,MINOXIDILandSODIUMNITROPRUSSIDEObinutuzumablAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lVaccines:riskofgeneralisedinfectionswhenmonoclonalantibodiesgivenwithlivelVACCINES—avoidconcomitantuseOctreotide TRIANGLE Antidiabetics:octreotidepossiblyreducesrequirementsforANTIDIABETICSlCiclosporin:octreotidereducesplasmaconcentrationoflCICLOSPORIN TRIANGLE Dopaminergics:octreotideincreasesplasmaconcentrationofBROMOCRIPTINE TRIANGLE Ulcer-healingDrugs:octreotidepossiblydelaysabsorptionofCIMETIDINEOestrogens TRIANGLE ACEInhibitors:oestrogensantagonisehypotensiveeffectofACEINHIBITORS TRIANGLE AdrenergicNeuroneBlockers:oestrogensantagonisehypotensiveeffectofADRENERGICNEURONEBLOCKERS TRIANGLE Alpha-blockers:oestrogensantagonisehypotensiveeffectofALPHA-BLOCKERS TRIANGLE Aminophylline:oestrogensincreaseplasmaconcentrationofAMINOPHYLLINE(considerreducingdoseofaminophylline) TRIANGLE Analgesics:plasmaconcentrationofethinylestradiolincreasedbyETORICOXIB TRIANGLE Angiotensin-IIReceptorAntagonists:oestrogensantagonisehypotensiveeffectofANGIOTENSIN-IIRECEPTORANTAGONISTSlAntibacterials:plasmaconcentrationofestradiolincreasedbyERYTHROMYCIN;metabolismofoestrogensacceleratedbylRIFAMYCINS(reducedcontraceptiveeffectwithcombinedoralcontraceptives,contraceptivepatches,andvaginalrings—seeContraceptiveInteractionsinBNF)lAnticoagulants:oestrogensmayenhanceorreduceanticoagulanteffectofCOUMARINS;oestrogensantagoniseanticoagulanteffectoflPHENINDIONElAntidepressants:contraceptiveeffectofoestrogensreducedbylSTJOHN’SWORT(avoidconcomitantuse);oestrogensantagoniseantidepressanteffectofTRICYCLICS(butside-effectsoftricyclicspossiblyincreasedduetoincreasedplasmaconcentration) TRIANGLE Antidiabetics:oestrogensantagonisehypoglycaemiceffectofANTIDIABETICSlAntiepileptics:metabolismofoestrogensacceleratedbylCARBAMAZEPINE,lESLICARBAZEPINE,lFOSPHENYTOIN,lOXCARBAZEPINE,lPHENOBARBITAL,lPHENYTOIN,lPRIMIDONE,lRUFINAMIDEandlTOPIRAMATE(reducedcontraceptiveeffectwithcombinedoralcontraceptives,contraceptivepatches,andvaginalrings—seeContraceptiveInteractionsinBNF);oestrogensreduceplasmaconcentrationoflLAMOTRIGINE—considerincreasingdoseoflamotrigine;ethinylestradiolpossiblyreducesplasmaconcentrationofSODIUMVALPROATEandVALPROICACID TRIANGLE Antifungals:oestrogensincreaseplasmaconcentrationofVORICONAZOLE;anecdotalreportsofcontraceptivefailureandmenstrualirregularitieswhenoestrogensgivenwithGRISEOFULVIN;anecdotalreportsofcontraceptivefailurewhenoestrogensgivenwithIMIDAZOLES;occasionalreportsofbreakthroughbleedingwhenoestrogens(usedforcontraception)givenwithTERBINAFINElAntivirals:plasmaconcentrationofethinylestradiolincreasedbyATAZANAVIR;metabolismofoestrogensacceleratedbylNEVIRAPINEandlRITONAVIR(reducedcontraceptiveeffectwithcombinedoralcontraceptives,contraceptivepatches,andvaginalrings—seeContraceptiveInteractionsinBNF);plasmaconcentrationofethinylestradiolpossiblyreducedbylTELAPREVIR—manufactureroftelapreviradvisesadditionalcontraceptiveprecautions TRIANGLE AnxiolyticsandHypnotics:oestrogenspossiblyincreaseplasmaconcentrationofCHLORDIAZEPOXIDE,DIAZEPAMandNITRAZEPAM;oestrogenspossiblyreduceplasmaconcentrationofLORAZEPAM,OXAZEPAMandTEMAZEPAM;oestrogensincreaseplasmaconcentrationofMELATONINBNF70Appendix1Interactions1219Interactions|Appendix1"
"Oestrogens(continued)lAprepitant:possiblecontraceptivefailureofhormonalcontraceptivescontainingoestrogenswhengivenwithlAPREPITANT(alternativecontraceptionrecommended) TRIANGLE Beta-blockers:oestrogensantagonisehypotensiveeffectofBETA-BLOCKERSlBosentan:possiblecontraceptivefailureofhormonalcontraceptivescontainingoestrogenswhengivenwithlBOSENTAN(alternativecontraceptionrecommended) TRIANGLE Calcium-channelBlockers:oestrogensantagonisehypotensiveeffectofCALCIUM-CHANNELBLOCKERS TRIANGLE Ciclosporin:oestrogenspossiblyincreaseplasmaconcentrationofCICLOSPORIN TRIANGLE Clonidine:oestrogensantagonisehypotensiveeffectofCLONIDINElCobicistat:metabolismofoestrogensacceleratedbylCOBICISTAT(reducedcontraceptiveeffectwithcombinedoralcontraceptives,contraceptivepatches,andvaginalrings—seeContraceptiveInteractionsinBNF) TRIANGLE Corticosteroids:oralcontraceptivescontainingoestrogensincreaseplasmaconcentrationofCORTICOSTEROIDSlCytotoxics:possiblereductionincontraceptiveeffectofoestrogensadvisedbymanufactureroflCRIZOTINIBandlVEMURAFENIB;possiblereducedcontraceptiveeffectofhormonalcontraceptivescontainingoestrogensadvisedbymanufactureroflDABRAFENIB(alternativecontraceptionrecommended) TRIANGLE Diuretics:oestrogensantagonisediureticeffectofDIURETICSlDopaminergics:oestrogensincreaseplasmaconcentrationofROPINIROLE;oestrogensincreaseplasmaconcentrationoflSELEGILINE—manufacturerofselegilineadvisesavoidconcomitantuselFosaprepitant:possiblecontraceptivefailureofhormonalcontraceptivescontainingoestrogenswhengivenwithlFOSAPREPITANT(alternativecontraceptionrecommended) TRIANGLE Lipid-regulatingDrugs:absorptionofethinylestradiolreducedbyCOLESEVELAM;plasmaconcentrationofethinylestradiolincreasedbyATORVASTATINandROSUVASTATIN;separatingadministrationfromoestrogensby12hoursadvisedbymanufacturerofLOMITAPIDE TRIANGLE Methyldopa:oestrogensantagonisehypotensiveeffectofMETHYLDOPAlModafinil:metabolismofoestrogensacceleratedbylMODAFINIL(reducedcontraceptiveeffectwithcombinedoralcontraceptives,contraceptivepatches,andvaginalrings—seeContraceptiveInteractionsinBNF) TRIANGLE Moxonidine:oestrogensantagonisehypotensiveeffectofMOXONIDINE TRIANGLE MuscleRelaxants:oestrogenspossiblyincreaseplasmaconcentrationofTIZANIDINE(increasedriskoftoxicity) TRIANGLE Nitrates:oestrogensantagonisehypotensiveeffectofNITRATES TRIANGLE Somatropin:oestrogens(whenusedasoralreplacementtherapy)mayincreasedoserequirementsofSOMATROPIN TRIANGLE Tacrolimus:ethinylestradiolpossiblyincreasesplasmaconcentrationofTACROLIMUS TRIANGLE Teriflunomide:plasmaconcentrationofethinylestradiolincreasedbyTERIFLUNOMIDE TRIANGLE Theophylline:oestrogensincreaseplasmaconcentrationofTHEOPHYLLINE(considerreducingdoseoftheophylline) TRIANGLE ThyroidHormones:oestrogensmayincreaserequirementsforTHYROIDHORMONESinhypothyroidism TRIANGLE VasodilatorAntihypertensives:oestrogensantagonisehypotensiveeffectofHYDRALAZINE,MINOXIDILandSODIUMNITROPRUSSIDEOestrogens,conjugatedseeOestrogensOfatumumablAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lVaccines:riskofgeneralisedinfectionswhenmonoclonalantibodiesgivenwithlivelVACCINES—avoidconcomitantuseOfloxacinseeQuinolonesOlanzapineseeAntipsychoticsOlmesartanseeAngiotensin-IIReceptorAntagonistsOlodaterolseeSympathomimetics,Beta2OmeprazoleseeProtonPumpInhibitorsOndansetronsee5HT3-receptorAntagonists(underHT)OpioidAnalgesics TRIANGLE Alcohol:enhancedhypotensiveandsedativeeffectswhenopioidanalgesicsgivenwithALCOHOL TRIANGLE Anaesthetics,General:fentanylinhibitsmetabolismofETOMIDATE(considerreducingdoseofetomidate);opioidanalgesicspossiblyenhanceeffectsofINTRAVENOUSGENERALANAESTHETICSandVOLATILELIQUIDGENERALANAESTHETICS TRIANGLE Analgesics:avoidanceofbuprenorphineadvisedbymanufacturerofFENTANYL;manufactureroffentanyladvisesavoidconcomitantusewithPENTAZOCINElAntibacterials:plasmaconcentrationoffentanylpossiblyincreasedbyCLARITHROMYCIN;plasmaconcentrationofalfentanilincreasedbyERYTHROMYCIN;metabolismofalfentanil,codeine,fentanyl,methadoneandmorphineacceleratedbyRIFAMPICIN(reducedeffect);metabolismofoxycodonepossiblyacceleratedbyRIFAMPICIN;increasedriskofventriculararrhythmiaswhenmethadonegivenwithlDELAMANID;manufacturerofpethidineadvisesavoidconcomitantusewithISONIAZID;metabolismofoxycodoneinhibitedbyTELITHROMYCIN;possibleincreasedriskofventriculararrhythmiaswhenmethadonegivenwithlTELITHROMYCINlAnticoagulants:tramadolenhancesanticoagulanteffectoflCOUMARINSlAntidepressants:plasmaconcentrationofmethadonepossiblyincreasedbyFLUOXETINE,FLUVOXAMINE,PAROXETINEandSERTRALINE;possibleincreasedserotonergiceffectswhenpethidineortramadolgivenwithDULOXETINE;possibleincreasedserotonergiceffectswhentramadolgivenwithMIRTAZAPINEorVENLAFAXINE;possibleCNSexcitationordepression(hypertensionorhypotension)whenopioidanalgesicsgivenwithlMAOIS—somemanufacturersadviseavoidconcomitantuseandfor2weeksafterstoppingMAOIs;possibleincreasedserotonergiceffectsandincreasedriskofconvulsionswhentramadolgivenwithlMAOIS—somemanufacturersadviseavoidconcomitantuseandfor2weeksafterstoppingMAOIs;CNSexcitationordepression(hypertensionorhypotension)whenpethidinegivenwithlMAOIS—avoidconcomitantuseandfor2weeksafterstoppingMAOIs;possibleincreasedserotonergiceffectswhenfentanylgivenwithMAOIS,SSRI-RELATEDANTIDEPRESSANTSorSSRIS;possibleCNSexcitationordepression(hypertensionorhypotension)whenopioidanalgesicsgivenwithlMOCLOBEMIDE—manufacturerofmoclobemideadvisesconsiderreducingdoseofopioidanalgesics;possibleCNSexcitationordepression(hypertensionorhypotension)whendextromethorphanorpethidinegivenwithlMOCLOBEMIDE—avoidconcomitantuse;increasedriskofCNStoxicitywhentramadolgivenwithlSSRISorlTRICYCLICS;plasmaconcentrationofmethadonepossiblyreducedbySTJOHN’SWORT;sedativeeffectspossiblyincreasedwhenopioidanalgesicsgivenwithTRICYCLICSlAntiepileptics:effectsoftramadolreducedbyCARBAMAZEPINE;plasmaconcentrationofmethadonereducedbyCARBAMAZEPINE,PHENOBARBITALandPRIMIDONE;metabolismoffentanylpossiblyacceleratedbyCARBAMAZEPINE,FOSPHENYTOINandPHENYTOIN(reducedeffect);dextropropoxypheneenhanceseffectsoflCARBAMAZEPINE;metabolismofmethadoneacceleratedbyFOSPHENYTOINandPHENYTOIN(reducedeffectandriskofwithdrawaleffects);possibleincreasedriskofpethidinetoxicitywhengivenwithlFOSPHENYTOINandlPHENYTOIN;morphineincreasesbioavailabilityofGABAPENTINlAntifungals:metabolismofbuprenorphineinhibitedbylKETOCONAZOLE(reducedoseofbuprenorphine);possibleincreasedriskofventriculararrhythmiaswhenmethadonegivenwithlKETOCONAZOLE—manufacturerofketoconazoleadvisesavoidconcomitantuse;plasmaconcentrationofoxycodoneincreasedbyITRACONAZOLE,KETOCONAZOLEandlVORICONAZOLE;metabolismofalfentanilinhibitedbyFLUCONAZOLE(riskofprolongedordelayedrespiratorydepression);plasmaconcentrationofmethadoneincreasedbyFLUCONAZOLE;metabolismofalfentanilpossiblyinhibitedbyITRACONAZOLE;plasmaconcentrationofmethadone1220Appendix1InteractionsBNF70Interactions|Appendix1"
"OpioidAnalgesicslAntifungals(continued)possiblyincreasedbylITRACONAZOLE(increasedriskofventriculararrhythmias);plasmaconcentrationofalfentanilandmethadoneincreasedbylVORICONAZOLE(considerreducingdoseofalfentanilandmethadone);plasmaconcentrationoffentanylpossiblyincreasedbylTRIAZOLESlAntihistamines:sedativeeffectspossiblyincreasedwhenopioidanalgesicsgivenwithlSEDATINGANTIHISTAMINESlAntimalarials:avoidanceofmethadoneadvisedbymanufactureroflARTENIMOLWITHPIPERAQUINE(possibleriskofventriculararrhythmias) TRIANGLE Antimuscarinics:possibleincreasedriskofantimuscarinicside-effectswhencodeinegivenwithANTIMUSCARINICSlAntipsychotics:enhancedhypotensiveandsedativeeffectswhenopioidanalgesicsgivenwithANTIPSYCHOTICS;increasedriskofventriculararrhythmiaswhenmethadonegivenwithlANTIPSYCHOTICSthatprolongtheQTinterval;increasedriskofconvulsionswhentramadolgivenwithANTIPSYCHOTICS;increasedriskofventriculararrhythmiaswhenmethadonegivenwithlAMISULPRIDE—avoidconcomitantuselAntivirals:plasmaconcentrationofmethadonepossiblyreducedbyABACAVIR,NEVIRAPINEandRILPIVIRINE;plasmaconcentrationofmethadonepossiblyaffectedbyBOCEPREVIR;possibleincreasedriskofprolongedsedationandrespiratorydepressionwhenbuprenorphinegivenwithBOCEPREVIR;methadonepossiblyreducesplasmaconcentrationofDIDANOSINE;plasmaconcentrationofmethadonereducedbyEFAVIRENZ,FOSAMPRENAVIRandRITONAVIR;plasmaconcentrationofbuprenorphinepossiblyincreasedbyRITONAVIR;plasmaconcentrationofalfentanilandfentanylincreasedbylRITONAVIR;plasmaconcentrationofpethidinereducedbylRITONAVIR,butplasmaconcentrationoftoxicpethidinemetaboliteincreased(avoidconcomitantuse);plasmaconcentrationofmorphinepossiblyreducedbyRITONAVIR;plasmaconcentrationofdextropropoxypheneincreasedbylRITONAVIR(riskoftoxicity)—avoidconcomitantuse;increasedriskofventriculararrhythmiaswhenalfentanil,fentanylormethadonegivenwithlSAQUINAVIR—avoidconcomitantuse;cautionwithmethadoneadvisedbymanufactureroflTELAPREVIR(riskofventriculararrhythmias);buprenorphinepossiblyreducesplasmaconcentrationofTIPRANAVIR;methadonepossiblyincreasesplasmaconcentrationofZIDOVUDINE TRIANGLE AnxiolyticsandHypnotics:increasedsedativeeffectwhenopioidanalgesicsgivenwithANXIOLYTICSANDHYPNOTICS;fentanylpossiblyinhibitsmetabolismofMIDAZOLAMlAtomoxetine:increasedriskofventriculararrhythmiaswhenmethadonegivenwithlATOMOXETINE;possibleincreasedriskofconvulsionswhentramadolgivenwithATOMOXETINE TRIANGLE Beta-blockers:morphinepossiblyincreasesplasmaconcentrationofESMOLOL TRIANGLE Calcium-channelBlockers:metabolismofalfentanilinhibitedbyDILTIAZEM(riskofprolongedordelayedrespiratorydepression)lCytotoxics:possibleincreasedriskofventriculararrhythmiaswhenmethadonegivenwithlBOSUTINIB;cautionwithalfentanilandfentanyladvisedbymanufactureroflCRIZOTINIB;possibleincreasedriskofventriculararrhythmiaswhenmethadonegivenwithlVANDETANIB—avoidconcomitantuselDapoxetine:possibleincreasedriskofserotonergiceffectswhentramadolgivenwithlDAPOXETINE(manufacturerofdapoxetineadvisestramadolshouldnotbestarteduntil1weekafterstoppingdapoxetine,avoiddapoxetinefor2weeksafterstoppingtramadol) TRIANGLE Domperidone:opioidanalgesicsantagoniseeffectsofDOMPERIDONEongastro-intestinalactivitylDopaminergics:avoidconcomitantuseofdextromethorphanwithlRASAGILINE;riskofCNStoxicitywhenpethidinegivenwithlRASAGILINE(avoidpethidinefor2weeksafterrasagiline);avoidanceofopioidanalgesicsadvisedbymanufacturerofSELEGILINE;hyperpyrexiaandCNStoxicityreportedwhenpethidinegivenwithlSELEGILINE(avoidconcomitantuse)OpioidAnalgesics(continued) TRIANGLE HormoneAntagonists:plasmaconcentrationofdextromethorphanincreasedbyABIRATERONE TRIANGLE 5HT3-receptorAntagonists:effectsoftramadolpossiblyantagonisedbyONDANSETRONlMemantine:increasedriskofCNStoxicitywhendextromethorphangivenwithlMEMANTINE(manufacturerofmemantineadvisesavoidconcomitantuse) TRIANGLE Metoclopramide:opioidanalgesicsantagoniseeffectsofMETOCLOPRAMIDEongastro-intestinalactivity TRIANGLE MuscleRelaxants:increasedsedativeeffectwhenfentanylormorphinegivenwithBACLOFENlNalmefene:avoidanceofopioidanalgesicsadvisedbymanufactureroflNALMEFENElSodiumOxybate:opioidanalgesicsenhanceeffectsoflSODIUMOXYBATE(avoidconcomitantuse) TRIANGLE Ulcer-healingDrugs:metabolismofopioidanalgesicsinhibitedbyCIMETIDINE(increasedplasmaconcentration)Oritavancin TRIANGLE Anticoagulants:oritavancinpossiblyincreasesplasmaconcentrationofWARFARIN TRIANGLE Vaccines:antibacterialsinactivateORALTYPHOIDVACCINE—seeunderTyphoidVaccineinBNFOrlistat TRIANGLE Anti-arrhythmics:orlistatpossiblyreducesplasmaconcentrationofAMIODARONE TRIANGLE Anticoagulants:manufactureroforlistatrecommendsmonitoringanticoagulanteffectofCOUMARINS TRIANGLE Antidiabetics:manufactureroforlistatadvisesavoidconcomitantusewithACARBOSElAntiepileptics:possibleincreasedriskofconvulsionswhenorlistatgivenwithlANTIEPILEPTICSlAntivirals:orlistatpossiblyreducesabsorptionoflABACAVIR,lATAZANAVIR,lDARUNAVIR,lDIDANOSINE,lEFAVIRENZ,lELVITEGRAVIR,lEMTRICITABINE,lENFUVIRTIDE,lETRAVIRINE,lFOSAMPRENAVIR,lINDINAVIR,lLAMIVUDINE,lLOPINAVIR,lMARAVIROC,lNEVIRAPINE,lRALTEGRAVIR,lRILPIVIRINE,lRITONAVIR,lSAQUINAVIR,lSTAVUDINE,lTENOFOVIR,lTIPRANAVIRandlZIDOVUDINElCiclosporin:orlistatpossiblyreducesabsorptionoflCICLOSPORIN TRIANGLE ThyroidHormones:possibleincreasedriskofhypothyroidismwhenorlistatgivenwithLEVOTHYROXINEOrphenadrineseeAntimuscarinicsOxaliplatinseePlatinumCompoundsOxandroloneseeAnabolicSteroidsOxazepamseeAnxiolyticsandHypnoticsOxcarbazepinelAntidepressants:anticonvulsanteffectofantiepilepticspossiblyantagonisedbyMAOISandlTRICYCLIC-RELATEDANTIDEPRESSANTS(convulsivethresholdlowered);anticonvulsanteffectofantiepilepticsantagonisedbylSSRISandlTRICYCLICS(convulsivethresholdlowered)lAntiepileptics:oxcarbazepinesometimesreducesplasmaconcentrationofCARBAMAZEPINE(butconcentrationofanactivemetaboliteofcarbamazepinemaybeincreased),alsoplasmaconcentrationofanactivemetaboliteofoxcarbazepineoftenreduced;avoidanceofoxcarbazepineadvisedbymanufacturerofESLICARBAZEPINE;oxcarbazepineincreasesplasmaconcentrationofFOSPHENYTOIN,PHENOBARBITAL,PHENYTOINandPRIMIDONE,alsoplasmaconcentrationofanactivemetaboliteofoxcarbazepinereduced;oxcarbazepinereducesplasmaconcentrationoflPERAMPANEL(seeunderPerampanel,p398);plasmaconcentrationofanactivemetaboliteofoxcarbazepinesometimesreducedbySODIUMVALPROATEandVALPROICACIDlAntimalarials:anticonvulsanteffectofantiepilepticsantagonisedbylMEFLOQUINElAntipsychotics:anticonvulsanteffectofantiepilepticsantagonisedbylANTIPSYCHOTICS(convulsivethresholdlowered)lAntivirals:oxcarbazepinepossiblyreducesplasmaconcentrationoflDACLATASVIRandlSIMEPREVIR—manufacturerofdaclatasvirandsimepreviradvisesavoidconcomitantuse;avoidanceofoxcarbazepineadvisedbyBNF70Appendix1Interactions1221Interactions|Appendix1"
"OxcarbazepinelAntivirals(continued)manufacturerofDOLUTEGRAVIRandSOFOSBUVIR;avoidanceofoxcarbazepineadvisedbymanufactureroflRILPIVIRINE(plasmaconcentrationofrilpivirinepossiblyreduced) TRIANGLE Ciclosporin:oxcarbazepinepossiblyreducesplasmaconcentrationofCICLOSPORINlClopidogrel:oxcarbazepinepossiblyreducesantiplateleteffectoflCLOPIDOGRELlCytotoxics:oxcarbazepinereducesplasmaconcentrationoflIMATINIB—avoidconcomitantuselOestrogens:oxcarbazepineacceleratesmetabolismoflOESTROGENS(reducedcontraceptiveeffectwithcombinedoralcontraceptives,contraceptivepatches,andvaginalrings—seeContraceptiveInteractionsinBNF)lOrlistat:possibleincreasedriskofconvulsionswhenantiepilepticsgivenwithlORLISTATlProgestogens:oxcarbazepineacceleratesmetabolismoflPROGESTOGENS(reducedcontraceptiveeffectwithcombinedoralcontraceptives,progestogen-onlyoralcontraceptives,contraceptivepatches,vaginalrings,etonogestrel-releasingimplant,andemergencyhormonalcontraception—seeContraceptiveInteractionsinBNF)OxprenololseeBeta-blockersOxybutyninseeAntimuscarinicsOxycodoneseeOpioidAnalgesicsOxymetazolineseeSympathomimeticsOxytetracyclineseeTetracyclinesOxytocin TRIANGLE Anaesthetics,General:oxytociceffectpossiblyreduced,alsoenhancedhypotensiveeffectandriskofarrhythmiaswhenoxytocingivenwithVOLATILELIQUIDGENERALANAESTHETICS TRIANGLE Prostaglandins:uterotoniceffectofoxytocinpotentiatedbyPROSTAGLANDINS TRIANGLE Sympathomimetics:riskofhypertensionwhenoxytocingivenwithvasoconstrictorSYMPATHOMIMETICS(duetoenhancedvasopressoreffect)PaclitaxellAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis) TRIANGLE Antivirals:plasmaconcentrationofpaclitaxelincreasedbyRITONAVIRlCytotoxics:increasedriskofneutropeniawhenpaclitaxelgivenwithlLAPATINIBPaliperidoneseeAntipsychoticsPamidronateDisodiumseeBisphosphonatesPancreatin TRIANGLE Antidiabetics:pancreatinantagoniseshypoglycaemiceffectofACARBOSEPancuroniumseeMuscleRelaxantsPanitumumablAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lVaccines:riskofgeneralisedinfectionswhenmonoclonalantibodiesgivenwithlivelVACCINES—avoidconcomitantusePantoprazoleseeProtonPumpInhibitorsPapaveretumseeOpioidAnalgesicsParacetamol TRIANGLE Anticoagulants:prolongedregularuseofparacetamolpossiblyenhancesanticoagulanteffectofCOUMARINS TRIANGLE Antidiabetics:absorptionofparacetamolpossiblyreducedwhengiven1to4hoursafterLIXISENATIDE TRIANGLE Antiepileptics:metabolismofparacetamolpossiblyacceleratedbyCARBAMAZEPINE,FOSPHENYTOIN,PHENOBARBITAL,PHENYTOINandPRIMIDONE(alsoisolatedreportsofhepatotoxicity) TRIANGLE Antifungals:avoidanceofparacetamoladvisedbymanufacturerofKETOCONAZOLE TRIANGLE Cytotoxics:paracetamolpossiblyinhibitsmetabolismofintravenousBUSULFAN(manufacturerofintravenousbusulfanadvisescautionwithin72hoursofparacetamol);cautionwithparacetamoladvisedbymanufacturerofIMATINIB TRIANGLE Lipid-regulatingDrugs:absorptionofparacetamolreducedbyCOLESTYRAMINE TRIANGLE Metoclopramide:rateofabsorptionofparacetamolincreasedbyMETOCLOPRAMIDEParaldehydelAlcohol:increasedsedativeeffectwhenparaldehydegivenwithlALCOHOLlDisulfiram:riskoftoxicitywhenparaldehydegivenwithlDISULFIRAMParasympathomimetics TRIANGLE Anti-arrhythmics:effectsofneostigmineandpyridostigminepossiblyantagonisedbyPROPAFENONElAntibacterials:plasmaconcentrationofgalantamineincreasedbyERYTHROMYCIN;effectsofneostigmineandpyridostigmineantagonisedbylAMINOGLYCOSIDES;effectsofneostigmineandpyridostigmineantagonisedbyCLINDAMYCIN;effectsofneostigmineandpyridostigmineantagonisedbylPOLYMYXINS TRIANGLE Antidepressants:plasmaconcentrationofgalantamineincreasedbyPAROXETINE TRIANGLE Antifungals:plasmaconcentrationofgalantamineincreasedbyKETOCONAZOLE TRIANGLE Antimalarials:effectsofneostigmineandpyridostigminemaybediminishedbecauseofpotentialforCHLOROQUINEtoincreasesymptomsofmyastheniagravis;effectsofneostigmineandpyridostigminemaybediminishedbecauseofpotentialforHYDROXYCHLOROQUINEtoincreasesymptomsofmyastheniagravis TRIANGLE Antimuscarinics:effectsofparasympathomimeticsantagonisedbyANTIMUSCARINICS TRIANGLE Beta-blockers:increasedriskofarrhythmiaswhenpilocarpinegivenwithBETA-BLOCKERS;effectsofneostigmineandpyridostigmineantagonisedbyPROPRANOLOL TRIANGLE Cytotoxics:possibleincreasedriskofbradycardiawhenpilocarpinegivenwithCRIZOTINIB TRIANGLE Lithium:effectsofneostigmineantagonisedbyLITHIUM TRIANGLE MuscleRelaxants:donepezilpossiblyenhanceseffectsofSUXAMETHONIUM;galantamine,neostigmine,pyridostigmineandrivastigmineenhanceeffectsofSUXAMETHONIUM;neostigmine,pyridostigmineandrivastigmineantagoniseeffectsofNON-DEPOLARISINGMUSCLERELAXANTS;donepezilpossiblyantagoniseseffectsofNON-DEPOLARISINGMUSCLERELAXANTSParecoxibseeNSAIDsParicalcitolseeVitaminsParoxetineseeAntidepressants,SSRIPasireotide TRIANGLE Antidiabetics:pasireotidepossiblyreducesrequirementsforANTIDIABETICS TRIANGLE Antifungals:avoidanceofpasireotideadvisedbymanufacturerofKETOCONAZOLE TRIANGLE Antimuscarinics:possibleincreasedriskofbradycardiawhenpasireotidegivenwithIPRATROPIUMorOXYBUTYNIN TRIANGLE Beta-blockers:possibleincreasedriskofbradycardiawhenpasireotidegivenwithCARTEOLOL,METOPROLOL,PROPRANOLOLorSOTALOL TRIANGLE Calcium-channelBlockers:possibleincreasedriskofbradycardiawhenpasireotidegivenwithDILTIAZEMorVERAPAMILlCiclosporin:pasireotidepossiblyreducesplasmaconcentrationoflCICLOSPORINPazopaniblAntibacterials:plasmaconcentrationofpazopanibpossiblyincreasedbylCLARITHROMYCINandlTELITHROMYCIN(reducedoseofpazopanib);plasmaconcentrationofpazopanibpossiblyreducedbylRIFAMPICINlAntifungals:plasmaconcentrationofpazopanibincreasedbylKETOCONAZOLE(reducedoseofpazopanib);plasmaconcentrationofpazopanibpossiblyincreasedbylITRACONAZOLEandlVORICONAZOLE(reducedoseofpazopanib)lAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lAntivirals:plasmaconcentrationofpazopanibpossiblyincreasedbylATAZANAVIR,lINDINAVIRandlRITONAVIR(reducedoseofpazopanib);avoidanceofpazopanibadvisedbymanufactureroflBOCEPREVIR;increasedriskofventriculararrhythmiaswhenpazopanibgivenwithlSAQUINAVIR—avoidconcomitantuse1222Appendix1InteractionsBNF70Interactions|Appendix1"
"Pazopanib(continued) TRIANGLE Cytotoxics:plasmaconcentrationofpazopanibincreasedbyLAPATINIBlGrapefruitJuice:manufacturerofpazopanibadvisesavoidconcomitantusewithlGRAPEFRUITJUICE TRIANGLE Lipid-regulatingDrugs:separatingadministrationfrompazopanibby12hoursadvisedbymanufacturerofLOMITAPIDE TRIANGLE Ulcer-healingDrugs:absorptionofpazopanibpossiblyreducedbyHISTAMINEH2-ANTAGONISTS—manufacturerofpazopanibadvisesgiveatleast2hoursbeforeor10hoursafterhistamineH2-antagonists;absorptionofpazopanibpossiblyreducedbyPROTONPUMPINHIBITORS—manufacturerofpazopanibadvisesgiveatthesametimeasprotonpumpinhibitorsPegfilgrastim TRIANGLE Cytotoxics:neutropeniapossiblyexacerbatedwhenpegfilgrastimgivenwithCAPECITABINE,FLUOROURACILorTEGAFURPeginterferonAlfaseeInterferonsPemetrexed TRIANGLE Analgesics:renalexcretionofpemetrexedpossiblyreducedbyNSAIDSandASPIRIN—consultproductliteraturelAntimalarials:antifolateeffectofpemetrexedincreasedbylPYRIMETHAMINElAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)Penicillamine TRIANGLE Analgesics:possibleincreasedriskofnephrotoxicitywhenpenicillaminegivenwithNSAIDS TRIANGLE Antacids:absorptionofpenicillaminereducedbyANTACIDSlAntipsychotics:avoidconcomitantuseofpenicillaminewithlCLOZAPINE(increasedriskofagranulocytosis) TRIANGLE CardiacGlycosides:penicillaminepossiblyreducesplasmaconcentrationofDIGOXIN TRIANGLE IronSalts:absorptionofpenicillaminereducedbyoralIRONSALTS TRIANGLE SodiumAurothiomalate:manufacturerofpenicillamineadvisesavoidconcomitantusewithSODIUMAUROTHIOMALATE(increasedriskoftoxicity) TRIANGLE Zinc:penicillaminereducesabsorptionofZINC,alsoabsorptionofpenicillaminereducedbyzincPenicillins TRIANGLE Allopurinol:increasedriskofrashwhenamoxicillin,ampicillinorco-amoxiclavgivenwithALLOPURINOL TRIANGLE Antibacterials:absorptionofphenoxymethylpenicillinreducedbyNEOMYCIN;effectsofpenicillinspossiblyantagonisedbyTETRACYCLINES TRIANGLE Anticoagulants:aninteractionbetweenbroad-spectrumpenicillinsandCOUMARINSandPHENINDIONEhasnotbeendemonstratedinstudies,butcommonexperienceinanticoagulantclinicsisthatINRcanbealteredlAntiepileptics:manufacturerofpivmecillinamadvisesavoidconcomitantusewithlSODIUMVALPROATEandlVALPROICACID TRIANGLE Cytotoxics:penicillinsreduceexcretionofMETHOTREXATE(increasedriskoftoxicity) TRIANGLE MuscleRelaxants:piperacillinenhanceseffectsofNON-DEPOLARISINGMUSCLERELAXANTSandSUXAMETHONIUM TRIANGLE Mycophenolate:co-amoxiclavpossiblyreducesplasmaconcentrationofMYCOPHENOLATE TRIANGLE Sulfinpyrazone:excretionofpenicillinsreducedbySULFINPYRAZONE TRIANGLE Vaccines:antibacterialsinactivateORALTYPHOIDVACCINE—seeunderTyphoidVaccineinBNFPentamidineIsetionatelAnti-arrhythmics:increasedriskofventriculararrhythmiaswhenpentamidineisetionategivenwithlAMIODARONE—avoidconcomitantuse;possibleincreasedriskofventriculararrhythmiaswhenpentamidineisetionategivenwithlDISOPYRAMIDElAntibacterials:increasedriskofventriculararrhythmiaswhenpentamidineisetionategivenwithparenterallERYTHROMYCIN;increasedriskofventriculararrhythmiaswhenpentamidineisetionategivenwithlMOXIFLOXACIN—PentamidineIsetionatelAntibacterials(continued)avoidconcomitantuse;increasedriskofventriculararrhythmiaswhenpentamidineisetionategivenwithlDELAMANID;possibleincreasedriskofventriculararrhythmiaswhenparenteralpentamidineisetionategivenwithlTELITHROMYCINlAntidepressants:avoidanceofpentamidineisetionateadvisedbymanufactureroflCITALOPRAMandlESCITALOPRAM(riskofventriculararrhythmias);increasedriskofventriculararrhythmiaswhenpentamidineisetionategivenwithlTRICYCLICS TRIANGLE Antifungals:possibleincreasedriskofnephrotoxicitywhenpentamidineisetionategivenwithAMPHOTERICINlAntimalarials:avoidanceofpentamidineisetionateadvisedbymanufactureroflARTENIMOLWITHPIPERAQUINE(possibleriskofventriculararrhythmias)lAntipsychotics:increasedriskofventriculararrhythmiaswhenpentamidineisetionategivenwithlAMISULPRIDEorlDROPERIDOL—avoidconcomitantuse;increasedriskofventriculararrhythmiaswhenpentamidineisetionategivenwithlPHENOTHIAZINESlAntivirals:increasedriskofhypocalcaemiawhenparenteralpentamidineisetionategivenwithlFOSCARNET;increasedriskofventriculararrhythmiaswhenpentamidineisetionategivenwithlSAQUINAVIR—avoidconcomitantuselCytotoxics:possibleincreasedriskofventriculararrhythmiaswhenpentamidineisetionategivenwithlVANDETANIB—avoidconcomitantuselIvabradine:increasedriskofventriculararrhythmiaswhenpentamidineisetionategivenwithlIVABRADINEPentazocineseeOpioidAnalgesicsPentostatinlAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lCytotoxics:increasedtoxicitywhenpentostatingivenwithhigh-doselCYCLOPHOSPHAMIDE—avoidconcomitantuse;increasedpulmonarytoxicitywhenpentostatingivenwithlFLUDARABINE(unacceptablyhighincidenceoffatalities)Pentoxifylline TRIANGLE Aminophylline:pentoxifyllineincreasesplasmaconcentrationofAMINOPHYLLINElAnalgesics:possibleincreasedriskofbleedingwhenpentoxifyllinegivenwithNSAIDS;increasedriskofbleedingwhenpentoxifyllinegivenwithlKETOROLAC(avoidconcomitantuse) TRIANGLE Theophylline:pentoxifyllineincreasesplasmaconcentrationofTHEOPHYLLINEPerampanellAntidepressants:anticonvulsanteffectofantiepilepticspossiblyantagonisedbyMAOISandlTRICYCLIC-RELATEDANTIDEPRESSANTS(convulsivethresholdlowered);anticonvulsanteffectofantiepilepticsantagonisedbylSSRISandlTRICYCLICS(convulsivethresholdlowered)lAntiepileptics:plasmaconcentrationofperampanelreducedbylCARBAMAZEPINE,lFOSPHENYTOIN,lOXCARBAZEPINEandlPHENYTOIN(seeunderPerampanel,p398);plasmaconcentrationofperampanelreducedbyTOPIRAMATE TRIANGLE Antifungals:plasmaconcentrationofperampanelincreasedbyKETOCONAZOLElAntimalarials:anticonvulsanteffectofantiepilepticsantagonisedbylMEFLOQUINElAntipsychotics:anticonvulsanteffectofantiepilepticsantagonisedbylANTIPSYCHOTICS(convulsivethresholdlowered) TRIANGLE AnxiolyticsandHypnotics:perampanelreducesplasmaconcentrationofMIDAZOLAMlOrlistat:possibleincreasedriskofconvulsionswhenantiepilepticsgivenwithlORLISTATlProgestogens:perampanelacceleratesmetabolismoflPROGESTOGENS(reducedcontraceptiveeffectwithcombinedoralcontraceptives,progestogen-onlyoralcontraceptives,contraceptivepatches,vaginalrings,etonogestrel-releasingimplant,andemergencyhormonalcontraception—seeContraceptiveInteractionsinBNF)BNF70Appendix1Interactions1223Interactions|Appendix1"
"Pergolide TRIANGLE Antipsychotics:effectsofpergolideantagonisedbyANTIPSYCHOTICS TRIANGLE Memantine:effectsofdopaminergicspossiblyenhancedbyMEMANTINE TRIANGLE Methyldopa:antiparkinsonianeffectofdopaminergicsantagonisedbyMETHYLDOPA TRIANGLE Metoclopramide:antiparkinsonianeffectofpergolideantagonisedbyMETOCLOPRAMIDEPericyazineseeAntipsychoticsPerindoprilseeACEInhibitorsPerphenazineseeAntipsychoticsPertuzumablAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lVaccines:riskofgeneralisedinfectionswhenmonoclonalantibodiesgivenwithlivelVACCINES—avoidconcomitantusePethidineseeOpioidAnalgesicsPhenelzineseeMAOIsPhenindioneNOTEChangeinpatient’sclinicalconditionparticularlyassociatedwithliverdisease,intercurrentillness,ordrugadministration,necessitatesmorefrequenttestingMajorchangesindiet(especiallyinvolvingsaladsandvegetables)andinalcoholconsumptionmayalsoaffectanticoagulantcontrollAlcohol:anticoagulantcontrolwithphenindionemaybeaffectedbymajorchangesinconsumptionoflALCOHOLlAnabolicSteroids:anticoagulanteffectofphenindioneenhancedbylANABOLICSTEROIDSlAnalgesics:anticoagulanteffectofphenindionepossiblyenhancedbylNSAIDS;increasedriskofhaemorrhagewhenanticoagulantsgivenwithintravenouslDICLOFENAC(avoidconcomitantuse,includinglow-doseheparins);increasedriskofhaemorrhagewhenanticoagulantsgivenwithlKETOROLAC(avoidconcomitantuse,includinglow-doseheparins);increasedriskofbleedingwhenphenindionegivenwithlASPIRIN(duetoantiplateleteffect)lAnti-arrhythmics:metabolismofphenindioneinhibitedbylAMIODARONE(enhancedanticoagulanteffect);anticoagulanteffectofphenindionepossiblyenhancedbylDRONEDARONElAntibacterials:experienceinanticoagulantclinicssuggeststhatINRpossiblyalteredwhenphenindioneisgivenwithlNEOMYCIN(givenforlocalactionongut);anticoagulanteffectofphenindionepossiblyenhancedbyLEVOFLOXACINandlTETRACYCLINES;aninteractionbetweenphenindioneandbroad-spectrumPENICILLINShasnotbeendemonstratedinstudies,butcommonexperienceinanticoagulantclinicsisthatINRcanbealtered;metabolismofphenindionepossiblyinhibitedbySULFONAMIDESlAnticoagulants:increasedriskofhaemorrhagewhenotheranticoagulantsgivenwithlAPIXABAN,lDABIGATRANandlRIVAROXABAN(avoidconcomitantuseexceptwhenswitchingwithotheranticoagulantsorusingheparintomaintaincatheterpatency)lAntivirals:anticoagulanteffectofphenindionepossiblyenhancedbylRITONAVIRlClopidogrel:anticoagulanteffectofphenindioneenhancedduetoantiplateletactionoflCLOPIDOGREL TRIANGLE Corticosteroids:anticoagulanteffectofphenindionemaybeenhancedorreducedbyCORTICOSTEROIDS TRIANGLE Cytotoxics:avoidanceofphenindioneadvisedbymanufacturerofIBRUTINIBlDipyridamole:anticoagulanteffectofphenindioneenhancedduetoantiplateletactionoflDIPYRIDAMOLElEnteralFoods:anticoagulanteffectofphenindioneantagonisedbyvitaminK(presentinsomelENTERALFEEDS) TRIANGLE Iloprost:increasedriskofbleedingwhenphenindionegivenwithILOPROSTlLipid-regulatingDrugs:anticoagulanteffectofphenindionemaybeenhancedorreducedbylCOLESTYRAMINE;anticoagulanteffectofphenindionepossiblyenhancedbylROSUVASTATIN;anticoagulanteffectofphenindioneenhancedbylFIBRATESPhenindione(continued)lOestrogens:anticoagulanteffectofphenindioneantagonisedbylOESTROGENS TRIANGLE Prasugrel:possibleincreasedriskofbleedingwhenphenindionegivenwithPRASUGRELlProgestogens:anticoagulanteffectofphenindioneantagonisedbylPROGESTOGENSlTestolactone:anticoagulanteffectofphenindioneenhancedbylTESTOLACTONElTestosterone:anticoagulanteffectofphenindioneenhancedbylTESTOSTERONElThyroidHormones:anticoagulanteffectofphenindioneenhancedbylTHYROIDHORMONESlVitamins:anticoagulanteffectofphenindioneantagonisedbylVITAMINKPhenobarbital TRIANGLE Alcohol:increasedsedativeeffectwhenphenobarbitalgivenwithALCOHOLlAminophylline:phenobarbitalacceleratesmetabolismoflAMINOPHYLLINE(reducedeffect) TRIANGLE Analgesics:phenobarbitalreducesplasmaconcentrationofMETHADONE;phenobarbitalpossiblyacceleratesmetabolismofPARACETAMOL(alsoisolatedreportsofhepatotoxicity)lAnthelmintics:phenobarbitalreducesplasmaconcentrationoflALBENDAZOLEandlPRAZIQUANTEL—considerincreasingalbendazoleandpraziquanteldosewhengivenforsystemicinfectionslAnti-arrhythmics:phenobarbitalacceleratesmetabolismofDISOPYRAMIDE(reducedplasmaconcentration);phenobarbitalpossiblyreducesplasmaconcentrationoflDRONEDARONE—avoidconcomitantuse;phenobarbitalpossiblyacceleratesmetabolismofPROPAFENONElAntibacterials:phenobarbitalacceleratesmetabolismofMETRONIDAZOLE(reducedeffect);phenobarbitalpossiblyreducesplasmaconcentrationofRIFAMPICIN;phenobarbitalacceleratesmetabolismofDOXYCYCLINE(reducedplasmaconcentration);phenobarbitalpossiblyacceleratesmetabolismoflCHLORAMPHENICOL(reducedplasmaconcentration);phenobarbitalreducesplasmaconcentrationoflTELITHROMYCIN(avoidduringandfor2weeksafterphenobarbital)lAnticoagulants:phenobarbitalpossiblyreducesplasmaconcentrationoflAPIXABAN;phenobarbitalacceleratesmetabolismoflCOUMARINS(reducedanticoagulanteffect);phenobarbitalpossiblyreducesplasmaconcentrationoflRIVAROXABAN—manufacturerofrivaroxabanadvisesmonitorforsignsofthrombosislAntidepressants:phenobarbitalpossiblyreducesplasmaconcentrationofREBOXETINE;phenobarbitalreducesplasmaconcentrationofPAROXETINE;phenobarbitalacceleratesmetabolismoflMIANSERIN(reducedplasmaconcentration);anticonvulsanteffectofantiepilepticspossiblyantagonisedbyMAOISandlTRICYCLIC-RELATEDANTIDEPRESSANTS(convulsivethresholdlowered);anticonvulsanteffectofantiepilepticsantagonisedbylSSRISandlTRICYCLICS(convulsivethresholdlowered);plasmaconcentrationofphenobarbitalpossiblyreducedbylSTJOHN’SWORT—avoidconcomitantuse;phenobarbitalpossiblyacceleratesmetabolismoflTRICYCLICS(reducedplasmaconcentration)lAntiepileptics:plasmaconcentrationofphenobarbitalpossiblyincreasedbyCARBAMAZEPINE;phenobarbitalpossiblyreducesplasmaconcentrationofETHOSUXIMIDE,RUFINAMIDEandTOPIRAMATE;plasmaconcentrationofphenobarbitaloftenincreasedbyFOSPHENYTOINandPHENYTOIN,plasmaconcentrationoffosphenytoinandphenytoinoftenreducedbutmaybeincreased;phenobarbitalreducesplasmaconcentrationofLAMOTRIGINE,TIAGABINEandZONISAMIDE;plasmaconcentrationofphenobarbitalincreasedbyOXCARBAZEPINE,alsoplasmaconcentrationofanactivemetaboliteofoxcarbazepinereduced;plasmaconcentrationofphenobarbitalincreasedbySODIUMVALPROATEandVALPROICACID(alsoplasmaconcentrationofsodiumvalproateandvalproicacidreduced);plasmaconcentrationofphenobarbitalincreasedbylSTIRIPENTOLlAntifungals:phenobarbitalpossiblyreducesplasmaconcentrationofITRACONAZOLEandlPOSACONAZOLE;1224Appendix1InteractionsBNF70Interactions|Appendix1"
"PhenobarbitallAntifungals(continued)phenobarbitalpossiblyreducesplasmaconcentrationoflVORICONAZOLE—avoidconcomitantuse;phenobarbitalreducesabsorptionofGRISEOFULVIN(reducedeffect)lAntimalarials:avoidanceofphenobarbitaladvisedbymanufacturerofARTENIMOLWITHPIPERAQUINE;anticonvulsanteffectofantiepilepticsantagonisedbylMEFLOQUINElAntipsychotics:anticonvulsanteffectofantiepilepticsantagonisedbylANTIPSYCHOTICS(convulsivethresholdlowered);phenobarbitalacceleratesmetabolismofHALOPERIDOL(reducedplasmaconcentration);plasmaconcentrationofbothdrugsreducedwhenphenobarbitalgivenwithCHLORPROMAZINE;phenobarbitalpossiblyreducesplasmaconcentrationoflARIPIPRAZOLE(avoidconcomitantuseorconsiderincreasingthedoseofaripiprazole—consultaripiprazoleproductliterature);phenobarbitalpossiblyreducesplasmaconcentrationofCLOZAPINE;phenobarbitalpossiblyreducesplasmaconcentrationoflLURASIDONE—avoidconcomitantuselAntivirals:phenobarbitalpossiblyreducesplasmaconcentrationofABACAVIR,DARUNAVIR,FOSAMPRENAVIR,lINDINAVIR,lLOPINAVIRandlSAQUINAVIR;avoidanceofphenobarbitaladvisedbymanufactureroflBOCEPREVIRandlRILPIVIRINE(plasmaconcentrationofboceprevirandrilpivirinepossiblyreduced);phenobarbitalpossiblyreducesplasmaconcentrationoflDACLATASVIRandlSIMEPREVIR—manufacturerofdaclatasvirandsimepreviradvisesavoidconcomitantuse;avoidanceofphenobarbitaladvisedbymanufacturerofDOLUTEGRAVIR,lELVITEGRAVIR,ETRAVIRINE,SOFOSBUVIRandlTELAPREVIR TRIANGLE AnxiolyticsandHypnotics:increasedsedativeeffectwhenphenobarbitalgivenwithANXIOLYTICSANDHYPNOTICS;phenobarbitaloftenreducesplasmaconcentrationofCLONAZEPAM TRIANGLE Aprepitant:phenobarbitalpossiblyreducesplasmaconcentrationofAPREPITANT TRIANGLE Avanafil:phenobarbitalpossiblyreducesplasmaconcentrationofAVANAFIL—manufacturerofavanafiladvisesavoidconcomitantuse TRIANGLE Beta-blockers:phenobarbitalpossiblyreducesplasmaconcentrationofPROPRANOLOL TRIANGLE Caffeinecitrate:effectsofphenobarbitalpossiblyantagonisedbyCAFFEINECITRATElCalcium-channelBlockers:phenobarbitalprobablyreduceseffectsoflCALCIUM-CHANNELBLOCKERS;avoidanceofphenobarbitaladvisedbymanufacturerofISRADIPINE;avoidanceofphenobarbitaladvisedbymanufactureroflNIMODIPINE(plasmaconcentrationofnimodipinereduced)lCannabisExtract:phenobarbitalpossiblyreducesplasmaconcentrationoflCANNABISEXTRACT—manufacturerofcannabisextractadvisesavoidconcomitantuselCiclosporin:phenobarbitalacceleratesmetabolismoflCICLOSPORIN(reducedplasmaconcentration)lCobicistat:phenobarbitalpossiblyreducesplasmaconcentrationoflCOBICISTAT—manufacturerofcobicistatadvisesavoidconcomitantuselCorticosteroids:phenobarbitalacceleratesmetabolismoflCORTICOSTEROIDS(reducedeffect)lCytotoxics:phenobarbitalpossiblydecreasesplasmaconcentrationofAXITINIB(increasedoseofaxitinib—consultaxitinibproductliterature);phenobarbitalpossiblyreducesplasmaconcentrationofBORTEZOMIB,lBOSUTINIB,CRIZOTINIBandPONATINIB—manufacturerofbortezomib,bosutinib,crizotinibandponatinibadvisesavoidconcomitantuse;phenobarbitalpossiblyreducesplasmaconcentrationoflCABOZANTINIB—avoidconcomitantuse;avoidanceofphenobarbitaladvisedbymanufactureroflCABAZITAXEL,DABRAFENIBandGEFITINIB;avoidanceofphenobarbitaladvisedbymanufacturerofDASATINIBandVANDETANIB(plasmaconcentrationofdasatinibandvandetanibpossiblyreduced);phenobarbitalpossiblyreducesplasmaconcentrationofETOPOSIDE;phenobarbitalreducesplasmaconcentrationofIRINOTECANanditsactivemetabolite;manufacturerofprocarbazineadvisespossibleincreasedriskPhenobarbitallCytotoxics(continued)ofhypersensitivityreactionswhenphenobarbitalgivenwithPROCARBAZINElDiuretics:phenobarbitalreducesplasmaconcentrationoflEPLERENONE—avoidconcomitantuse;increasedriskofosteomalaciawhenphenobarbitalgivenwithCARBONICANHYDRASEINHIBITORS TRIANGLE Folates:plasmaconcentrationofphenobarbitalpossiblyreducedbyFOLATES TRIANGLE Fosaprepitant:phenobarbitalpossiblyreducesplasmaconcentrationofFOSAPREPITANTlHormoneAntagonists:phenobarbitalpossiblyreducesplasmaconcentrationoflABIRATERONE—manufacturerofabirateroneadvisesavoidconcomitantuse;phenobarbitalacceleratesmetabolismofTOREMIFENE(reducedplasmaconcentration)lIvacaftor:phenobarbitalpossiblyreducesplasmaconcentrationoflIVACAFTOR—manufacturerofivacaftoradvisesavoidconcomitantuse TRIANGLE LeukotrieneReceptorAntagonists:phenobarbitalreducesplasmaconcentrationofMONTELUKASTlOestrogens:phenobarbitalacceleratesmetabolismoflOESTROGENS(reducedcontraceptiveeffectwithcombinedoralcontraceptives,contraceptivepatches,andvaginalrings—seeContraceptiveInteractionsinBNF)lOrlistat:possibleincreasedriskofconvulsionswhenantiepilepticsgivenwithlORLISTATlProgestogens:phenobarbitalacceleratesmetabolismoflPROGESTOGENS(reducedcontraceptiveeffectwithcombinedoralcontraceptives,progestogen-onlyoralcontraceptives,contraceptivepatches,vaginalrings,etonogestrel-releasingimplant,andemergencyhormonalcontraception—seeContraceptiveInteractionsinBNF) TRIANGLE Roflumilast:phenobarbitalpossiblyinhibitseffectsofROFLUMILAST(manufacturerofroflumilastadvisesavoidconcomitantuse) TRIANGLE SodiumOxybate:avoidanceofphenobarbitaladvisedbymanufacturerofSODIUMOXYBATE TRIANGLE Sympathomimetics:plasmaconcentrationofphenobarbitalpossiblyincreasedbyMETHYLPHENIDATElTacrolimus:phenobarbitalreducesplasmaconcentrationoflTACROLIMUSlTheophylline:phenobarbitalacceleratesmetabolismoflTHEOPHYLLINE(reducedeffect) TRIANGLE ThyroidHormones:phenobarbitalacceleratesmetabolismofTHYROIDHORMONES(mayincreaserequirementsforthyroidhormonesinhypothyroidism) TRIANGLE Ticagrelor:phenobarbitalpossiblyreducesplasmaconcentrationofTICAGRELORlUlipristal:avoidanceofphenobarbitaladvisedbymanufactureroflULIPRISTAL(contraceptiveeffectofulipristalpossiblyreduced) TRIANGLE Vitamins:phenobarbitalpossiblyincreasesrequirementsforALFACALCIDOL,CALCITRIOL,COLECALCIFEROL,DIHYDROTACHYSTEROL,ERGOCALCIFEROL,PARICALCITOLorVITAMINDPhenothiazinesseeAntipsychoticsPhenoxybenzamineseeAlpha-blockersPhenoxymethylpenicillinseePenicillinsPhentolamineseeAlpha-blockersPhenylephrineseeSympathomimeticsPhenytoin TRIANGLE Alcohol:plasmaconcentrationofphenytoinpossiblyreducedbychronicheavyconsumptionofALCOHOLlAminophylline:plasmaconcentrationofbothdrugsreducedwhenphenytoingivenwithlAMINOPHYLLINElAnalgesics:excretionofphenytoinpossiblyreducedbyACEMETACIN(increasedriskoftoxicity);phenytoinpossiblyacceleratesmetabolismofFENTANYL(reducedeffect);phenytoinacceleratesmetabolismofMETHADONE(reducedeffectandriskofwithdrawaleffects);phenytoinpossiblyincreasesriskoflPETHIDINEtoxicity;effectsofphenytoinenhancedbyASPIRIN;phenytoinpossiblyacceleratesBNF70Appendix1Interactions1225Interactions|Appendix1"
"PhenytoinlAnalgesics(continued)metabolismofPARACETAMOL(alsoisolatedreportsofhepatotoxicity) TRIANGLE Antacids:absorptionofphenytoinreducedbyANTACIDSlAnthelmintics:phenytoinreducesplasmaconcentrationoflALBENDAZOLEandlPRAZIQUANTEL—considerincreasingalbendazoleandpraziquanteldosewhengivenforsystemicinfections;plasmaconcentrationofphenytoinpossiblyincreasedbyLEVAMISOLElAnti-arrhythmics:metabolismofphenytoininhibitedbylAMIODARONE(increasedplasmaconcentration);phenytoinreducesplasmaconcentrationofDISOPYRAMIDE;phenytoinpossiblyreducesplasmaconcentrationoflDRONEDARONE—avoidconcomitantuselAntibacterials:metabolismofphenytoininhibitedbyCLARITHROMYCIN(increasedplasmaconcentration);metabolismofphenytoinpossiblyinhibitedbyMETRONIDAZOLE(increasedplasmaconcentration);plasmaconcentrationofphenytoinincreasedordecreasedbyCIPROFLOXACIN;phenytoinacceleratesmetabolismofDOXYCYCLINE(reducedplasmaconcentration);phenytoinpossiblyreducesplasmaconcentrationoflBEDAQUILINE—manufacturerofbedaquilineadvisesavoidconcomitantuse;plasmaconcentrationofphenytoinincreasedbylCHLORAMPHENICOL(increasedriskoftoxicity);metabolismofphenytoinpossiblyinhibitedbyISONIAZID(increasedriskoftoxicity);metabolismofphenytoinacceleratedbylRIFAMYCINS(reducedplasmaconcentration);plasmaconcentrationofphenytoinpossiblyincreasedbySULFONAMIDES;phenytoinreducesplasmaconcentrationoflTELITHROMYCIN(avoidduringandfor2weeksafterphenytoin);plasmaconcentrationofphenytoinincreasedbylTRIMETHOPRIM(alsoincreasedantifolateeffect)lAnticoagulants:phenytoinpossiblyreducesplasmaconcentrationoflAPIXABAN;phenytoinacceleratesmetabolismoflCOUMARINS(possibilityofreducedanticoagulanteffect,butenhancementalsoreported);phenytoinpossiblyreducesplasmaconcentrationofDABIGATRAN—manufacturerofdabigatranadvisesavoidconcomitantuse;phenytoinpossiblyreducesplasmaconcentrationoflRIVAROXABAN—manufacturerofrivaroxabanadvisesmonitorforsignsofthrombosislAntidepressants:plasmaconcentrationofphenytoinincreasedbylFLUOXETINEandlFLUVOXAMINE;phenytoinreducesplasmaconcentrationoflMIANSERIN,MIRTAZAPINEandPAROXETINE;plasmaconcentrationofphenytoinpossiblyincreasedbySERTRALINE,alsoplasmaconcentrationofsertralinepossiblyreduced;anticonvulsanteffectofantiepilepticspossiblyantagonisedbyMAOISandlTRICYCLIC-RELATEDANTIDEPRESSANTS(convulsivethresholdlowered);anticonvulsanteffectofantiepilepticsantagonisedbylSSRISandlTRICYCLICS(convulsivethresholdlowered);plasmaconcentrationofphenytoinpossiblyreducedbylSTJOHN’SWORT—avoidconcomitantuse;phenytoinpossiblyreducesplasmaconcentrationoflTRICYCLICS TRIANGLE Antidiabetics:plasmaconcentrationofphenytointransientlyincreasedbyTOLBUTAMIDE(possibilityoftoxicity)lAntiepileptics:plasmaconcentrationofbothdrugsoftenreducedwhenphenytoingivenwithCARBAMAZEPINE,alsoplasmaconcentrationofphenytoinmaybeincreased;phenytoinreducesplasmaconcentrationofESLICARBAZEPINE,alsoplasmaconcentrationofphenytoinincreased;plasmaconcentrationofphenytoinpossiblyincreasedbylETHOSUXIMIDE,alsoplasmaconcentrationofethosuximidepossiblyreduced;phenytoinreducesplasmaconcentrationofLAMOTRIGINE,TIAGABINEandZONISAMIDE;plasmaconcentrationofphenytoinincreasedbyOXCARBAZEPINE,alsoplasmaconcentrationofanactivemetaboliteofoxcarbazepinereduced;phenytoinreducesplasmaconcentrationoflPERAMPANEL(seeunderPerampanel,p398);phenytoinoftenincreasesplasmaconcentrationofPHENOBARBITALandPRIMIDONE,plasmaconcentrationofphenytoinoftenreducedbutmaybeincreased;phenytoinpossiblyreducesplasmaconcentrationofRETIGABINE;PhenytoinlAntiepileptics(continued)phenytoinpossiblyreducesplasmaconcentrationofRUFINAMIDE,alsoplasmaconcentrationofphenytoinpossiblyincreased;plasmaconcentrationofphenytoinincreasedorpossiblyreducedwhengivenwithSODIUMVALPROATEandVALPROICACID,alsoplasmaconcentrationofsodiumvalproateandvalproicacidreduced;plasmaconcentrationofphenytoinincreasedbylSTIRIPENTOL;plasmaconcentrationofphenytoinincreasedbylTOPIRAMATE(alsoplasmaconcentrationoftopiramatereduced);plasmaconcentrationofphenytoinreducedbyVIGABATRINlAntifungals:phenytoinreducesplasmaconcentrationoflKETOCONAZOLEandlPOSACONAZOLE;anticonvulsanteffectofphenytoinenhancedbylMICONAZOLE(plasmaconcentrationofphenytoinincreased);plasmaconcentrationofphenytoinincreasedbylFLUCONAZOLE(considerreducingdoseofphenytoin);phenytoinreducesplasmaconcentrationoflITRACONAZOLE—avoidconcomitantuse;plasmaconcentrationofphenytoinincreasedbylVORICONAZOLE,alsophenytoinreducesplasmaconcentrationofvoriconazole(increasedoseofvoriconazoleandalsomonitorforphenytointoxicity);phenytoinpossiblyreducesplasmaconcentrationofCASPOFUNGIN—considerincreasingdoseofcaspofunginlAntimalarials:avoidanceofphenytoinadvisedbymanufacturerofARTENIMOLWITHPIPERAQUINE;anticonvulsanteffectofantiepilepticsantagonisedbylMEFLOQUINE;anticonvulsanteffectofphenytoinantagonisedbylPYRIMETHAMINE,alsoincreasedantifolateeffectlAntipsychotics:anticonvulsanteffectofantiepilepticsantagonisedbylANTIPSYCHOTICS(convulsivethresholdlowered);phenytoinreducesplasmaconcentrationofHALOPERIDOL;plasmaconcentrationofphenytoinpossiblyincreasedordecreasedbyCHLORPROMAZINE;phenytoinpossiblyreducesplasmaconcentrationoflARIPIPRAZOLE(avoidconcomitantuseorconsiderincreasingthedoseofaripiprazole—consultaripiprazoleproductliterature);phenytoinacceleratesmetabolismofCLOZAPINEandQUETIAPINE(reducedplasmaconcentration);phenytoinpossiblyreducesplasmaconcentrationoflLURASIDONE—avoidconcomitantuselAntivirals:phenytoinpossiblyreducesplasmaconcentrationofABACAVIR,DARUNAVIR,LOPINAVIRandSAQUINAVIR;avoidanceofphenytoinadvisedbymanufactureroflBOCEPREVIRandlRILPIVIRINE(plasmaconcentrationofboceprevirandrilpivirinepossiblyreduced);phenytoinpossiblyreducesplasmaconcentrationoflDACLATASVIRandlSIMEPREVIR—manufacturerofdaclatasvirandsimepreviradvisesavoidconcomitantuse;avoidanceofphenytoinadvisedbymanufacturerofDOLUTEGRAVIR,lELVITEGRAVIR,ETRAVIRINE,SOFOSBUVIRandlTELAPREVIR;phenytoinpossiblyreducesplasmaconcentrationoflINDINAVIR,alsoplasmaconcentrationofphenytoinpossiblyincreased;phenytoinpossiblyreducesplasmaconcentrationofRITONAVIR,alsoplasmaconcentrationofphenytoinpossiblyaffected;plasmaconcentrationofphenytoinincreasedordecreasedbyZIDOVUDINE TRIANGLE AnxiolyticsandHypnotics:phenytoinoftenreducesplasmaconcentrationofCLONAZEPAM;plasmaconcentrationofphenytoinincreasedordecreasedbyDIAZEPAM;plasmaconcentrationofphenytoinpossiblyincreasedordecreasedbyBENZODIAZEPINES TRIANGLE Aprepitant:phenytoinpossiblyreducesplasmaconcentrationofAPREPITANT TRIANGLE Bupropion:phenytoinreducesplasmaconcentrationofBUPROPION TRIANGLE Caffeinecitrate:phenytoinreducesplasmaconcentrationofCAFFEINECITRATElCalcium-channelBlockers:phenytoinreduceseffectsofFELODIPINEandVERAPAMIL;avoidanceofphenytoinadvisedbymanufacturerofISRADIPINE;avoidanceofphenytoinadvisedbymanufacturerofNIMODIPINE(plasmaconcentrationofnimodipinepossiblyreduced);plasma1226Appendix1InteractionsBNF70Interactions|Appendix1"
"PhenytoinlCalcium-channelBlockers(continued)concentrationofphenytoinincreasedbylDILTIAZEMbutalsoeffectofdiltiazemreducedlCannabisExtract:phenytoinpossiblyreducesplasmaconcentrationoflCANNABISEXTRACT—manufacturerofcannabisextractadvisesavoidconcomitantuse TRIANGLE CardiacGlycosides:phenytoinpossiblyreducesplasmaconcentrationofDIGOXINlCiclosporin:phenytoinacceleratesmetabolismoflCICLOSPORIN(reducedplasmaconcentration)lCobicistat:phenytoinpossiblyreducesplasmaconcentrationoflCOBICISTAT—manufacturerofcobicistatadvisesavoidconcomitantuselCorticosteroids:phenytoinacceleratesmetabolismoflCORTICOSTEROIDS(reducedeffect)lCytotoxics:phenytoinpossiblyreducesplasmaconcentrationofBUSULFAN,ERIBULINandETOPOSIDE;metabolismofphenytoinpossiblyinhibitedbyCAPECITABINE,FLUOROURACILandTEGAFUR(increasedriskoftoxicity);phenytoinincreasesantifolateeffectofMETHOTREXATE;plasmaconcentrationofphenytoinpossiblyreducedbyCISPLATIN;phenytoinpossiblydecreasesplasmaconcentrationofAXITINIB(increasedoseofaxitinib—consultaxitinibproductliterature);phenytoinpossiblyreducesplasmaconcentrationofBORTEZOMIB,lBOSUTINIB,CRIZOTINIB,lIBRUTINIB,lIDELALISIBandPONATINIB—manufacturerofbortezomib,bosutinib,crizotinib,ibrutinib,idelalisibandponatinibadvisesavoidconcomitantuse;phenytoinpossiblyreducesplasmaconcentrationoflCABOZANTINIB—avoidconcomitantuse;avoidanceofphenytoinadvisedbymanufactureroflCABAZITAXEL,DABRAFENIB,GEFITINIB,lLAPATINIBandVEMURAFENIB;avoidanceofphenytoinadvisedbymanufacturerofDASATINIBandlVISMODEGIB(plasmaconcentrationofdasatinibandvismodegibpossiblyreduced);phenytoinreducesplasmaconcentrationoflIMATINIB—avoidconcomitantuse;phenytoinreducesplasmaconcentrationofIRINOTECANanditsactivemetabolite;manufacturerofprocarbazineadvisespossibleincreasedriskofhypersensitivityreactionswhenphenytoingivenwithPROCARBAZINElDexrazoxane:absorptionofphenytoinpossiblyreducedbylDEXRAZOXANE TRIANGLE Diazoxide:plasmaconcentrationofphenytoinreducedbyDIAZOXIDE,alsoeffectofdiazoxidemaybereducedlDisulfiram:metabolismofphenytoininhibitedbylDISULFIRAM(increasedriskoftoxicity)lDiuretics:plasmaconcentrationofphenytoinpossiblyincreasedbylACETAZOLAMIDE;phenytoinantagoniseseffectsofFUROSEMIDE;phenytoinreducesplasmaconcentrationoflEPLERENONE—avoidconcomitantuse;increasedriskofosteomalaciawhenphenytoingivenwithCARBONICANHYDRASEINHIBITORS TRIANGLE Dopaminergics:phenytoinpossiblyreduceseffectsofCO-BENELDOPA,CO-CARELDOPAandLEVODOPA TRIANGLE EnteralFoods:absorptionofphenytoinpossiblyreducedbyENTERALFEEDS TRIANGLE Folates:plasmaconcentrationofphenytoinpossiblyreducedbyFOLATES TRIANGLE Fosaprepitant:phenytoinpossiblyreducesplasmaconcentrationofFOSAPREPITANTlHormoneAntagonists:phenytoinpossiblyreducesplasmaconcentrationoflABIRATERONE—manufacturerofabirateroneadvisesavoidconcomitantuse;phenytoinpossiblyacceleratesmetabolismofTOREMIFENE TRIANGLE 5HT3-receptorAntagonists:phenytoinacceleratesmetabolismofONDANSETRON(reducedeffect)lIvacaftor:phenytoinpossiblyreducesplasmaconcentrationoflIVACAFTOR—manufacturerofivacaftoradvisesavoidconcomitantuse TRIANGLE Leflunomide:plasmaconcentrationofphenytoinpossiblyincreasedbyLEFLUNOMIDE TRIANGLE Lipid-regulatingDrugs:absorptionofphenytoinpossiblyreducedbyCOLESEVELAM;combinationofphenytoinwithFLUVASTATINmayincreaseplasmaconcentrationofeitherdrug(orboth)Phenytoin(continued) TRIANGLE Lithium:neurotoxicitymayoccurwhenphenytoingivenwithLITHIUMwithoutincreasedplasmaconcentrationoflithium TRIANGLE Macitentan:avoidanceofphenytoinadvisedbymanufacturerofMACITENTAN TRIANGLE Modafinil:plasmaconcentrationofphenytoinpossiblyincreasedbyMODAFINILlMuscleRelaxants:long-termuseofphenytoinreduceseffectsoflNON-DEPOLARISINGMUSCLERELAXANTS(butacuteuseofphenytoinmightincreaseeffectsofnon-depolarisingmusclerelaxants)lOestrogens:phenytoinacceleratesmetabolismoflOESTROGENS(reducedcontraceptiveeffectwithcombinedoralcontraceptives,contraceptivepatches,andvaginalrings—seeContraceptiveInteractionsinBNF)lOrlistat:possibleincreasedriskofconvulsionswhenantiepilepticsgivenwithlORLISTATlProgestogens:phenytoinacceleratesmetabolismoflPROGESTOGENS(reducedcontraceptiveeffectwithcombinedoralcontraceptives,progestogen-onlyoralcontraceptives,contraceptivepatches,vaginalrings,etonogestrel-releasingimplant,andemergencyhormonalcontraception—seeContraceptiveInteractionsinBNF) TRIANGLE Roflumilast:phenytoinpossiblyinhibitseffectsofROFLUMILAST(manufacturerofroflumilastadvisesavoidconcomitantuse)lSulfinpyrazone:plasmaconcentrationofphenytoinincreasedbylSULFINPYRAZONE TRIANGLE Sympathomimetics:plasmaconcentrationofphenytoinincreasedbyMETHYLPHENIDATE TRIANGLE Tacrolimus:phenytoinreducesplasmaconcentrationofTACROLIMUS,alsoplasmaconcentrationofphenytoinpossiblyincreasedlTheophylline:plasmaconcentrationofbothdrugsreducedwhenphenytoingivenwithlTHEOPHYLLINE TRIANGLE ThyroidHormones:phenytoinacceleratesmetabolismofTHYROIDHORMONES(mayincreaserequirementsinhypothyroidism),alsoplasmaconcentrationofphenytoinpossiblyincreased TRIANGLE Tibolone:phenytoinacceleratesmetabolismofTIBOLONE TRIANGLE Ticagrelor:phenytoinpossiblyreducesplasmaconcentrationofTICAGRELORlUlcer-healingDrugs:metabolismofphenytoininhibitedbylCIMETIDINE(increasedplasmaconcentration);effectsofphenytoinenhancedbylESOMEPRAZOLE;effectsofphenytoinpossiblyenhancedbyOMEPRAZOLE;absorptionofphenytoinreducedbylSUCRALFATElUlipristal:avoidanceofphenytoinadvisedbymanufactureroflULIPRISTAL(contraceptiveeffectofulipristalpossiblyreduced) TRIANGLE Vaccines:effectsofphenytoinenhancedbyINFLUENZAVACCINE TRIANGLE Vitamins:phenytoinpossiblyincreasesrequirementsforALFACALCIDOL,CALCITRIOL,COLECALCIFEROL,DIHYDROTACHYSTEROL,ERGOCALCIFEROL,PARICALCITOLorVITAMINDPholcodine TRIANGLE Antidepressants:manufacturerofpholcodineadvisesavoidfor2weeksafterstoppingMAOISPhosphodiesteraseType-3InhibitorslAnagrelide:avoidanceofenoximoneandmilrinoneadvisedbymanufactureroflANAGRELIDEPilocarpineseeParasympathomimeticsPimozideseeAntipsychoticsPindololseeBeta-blockersPioglitazoneseeAntidiabeticsPiperacillinseePenicillinsPiperaquineseeArtenimolwithPiperaquinePipotiazineseeAntipsychoticsPirfenidonelAntibacterials:plasmaconcentrationofpirfenidoneincreasedbylCIPROFLOXACIN—seeunderPirfenidone,p260lAntidepressants:plasmaconcentrationofpirfenidoneincreasedbylFLUVOXAMINE—manufacturerofpirfenidoneadvisesavoidconcomitantuse TRIANGLE GrapefruitJuice:manufacturerofpirfenidoneadvisesavoidconcomitantusewithGRAPEFRUITJUICEBNF70Appendix1Interactions1227Interactions|Appendix1"
"PiroxicamseeNSAIDsPivmecillinamseePenicillinsPixantronelAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lVaccines:riskofgeneralisedinfectionswhenpixantronegivenwithlivelVACCINES—avoidconcomitantusePizotifen TRIANGLE AdrenergicNeuroneBlockers:pizotifenantagoniseshypotensiveeffectofADRENERGICNEURONEBLOCKERSPlatinumCompoundslAldesleukin:avoidanceofcisplatinadvisedbymanufactureroflALDESLEUKINlAntibacterials:increasedriskofnephrotoxicityandpossiblyofototoxicitywhenplatinumcompoundsgivenwithlAMINOGLYCOSIDESorlPOLYMYXINS;increasedriskofnephrotoxicityandototoxicitywhenplatinumcompoundsgivenwithCAPREOMYCIN;increasedriskofnephrotoxicityandpossiblyofototoxicitywhencisplatingivenwithVANCOMYCIN TRIANGLE Antiepileptics:cisplatinpossiblyreducesplasmaconcentrationofFOSPHENYTOINandPHENYTOINlAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lCytotoxics:increasedriskofotoxicitywhencisplatingivenwithIFOSFAMIDE;increasedpulmonarytoxicitywhencisplatingivenwithlBLEOMYCINandlMETHOTREXATE TRIANGLE Diuretics:increasedriskofnephrotoxicityandototoxicitywhenplatinumcompoundsgivenwithDIURETICSPneumococcalVaccineseeVaccinesPoliomyelitisVaccineseeVaccinesPolymyxins TRIANGLE Antibacterials:increasedriskofnephrotoxicitywhencolistimethatesodiumorpolymyxinsgivenwithAMINOGLYCOSIDES;increasedriskofnephrotoxicitywhencolistimethatesodiumorpolymyxinsgivenwithCAPREOMYCIN;increasedriskofnephrotoxicitywhenpolymyxinsgivenwithVANCOMYCIN;increasedriskofnephrotoxicityandototoxicitywhencolistimethatesodiumgivenwithVANCOMYCIN TRIANGLE Antifungals:increasedriskofnephrotoxicitywhenpolymyxinsgivenwithAMPHOTERICINlCiclosporin:increasedriskofnephrotoxicitywhenpolymyxinsgivenwithlCICLOSPORINlCytotoxics:increasedriskofnephrotoxicityandpossiblyofototoxicitywhenpolymyxinsgivenwithlPLATINUMCOMPOUNDSlDiuretics:increasedriskofotoxicitywhenpolymyxinsgivenwithlLOOPDIURETICSlMuscleRelaxants:polymyxinsenhanceeffectsoflNON-DEPOLARISINGMUSCLERELAXANTSandlSUXAMETHONIUMlParasympathomimetics:polymyxinsantagoniseeffectsoflNEOSTIGMINEandlPYRIDOSTIGMINE TRIANGLE Vaccines:antibacterialsinactivateORALTYPHOIDVACCINE—seeunderTyphoidVaccineinBNFPolysaccharide-ironComplexseeIronsaltsPolystyreneSulfonateResins TRIANGLE Antacids:riskofintestinalobstructionwhenpolystyrenesulfonateresinsgivenwithALUMINIUMHYDROXIDE;riskofmetabolicalkalosiswhenpolystyrenesulfonateresinsgivenwithORALMAGNESIUMSALTS TRIANGLE ThyroidHormones:polystyrenesulfonateresinsreduceabsorptionofLEVOTHYROXINEPomalidomidelAntidepressants:plasmaconcentrationofpomalidomideincreasedbylFLUVOXAMINEPonatiniblAntibacterials:plasmaconcentrationofponatinibpossiblyincreasedbyCLARITHROMYCINandTELITHROMYCIN—considerreducinginitialdoseofponatinib(seeunderPonatinib,p814);plasmaconcentrationofponatinibpossiblyreducedbyRIFABUTIN—manufacturerofponatinibadvisesavoidconcomitantuse;plasmaconcentrationofponatinibreducedbylRIFAMPICIN—manufacturerofponatinibadvisesavoidconcomitantusePonatinib(continued) TRIANGLE Antidepressants:plasmaconcentrationofponatinibpossiblyreducedbySTJOHN’SWORT—manufacturerofponatinibadvisesavoidconcomitantuse TRIANGLE Antiepileptics:plasmaconcentrationofponatinibpossiblyreducedbyCARBAMAZEPINE,FOSPHENYTOIN,PHENOBARBITAL,PHENYTOINandPRIMIDONE—manufacturerofponatinibadvisesavoidconcomitantuse TRIANGLE Antifungals:plasmaconcentrationofponatinibincreasedbyKETOCONAZOLE;plasmaconcentrationofponatinibpossiblyincreasedbyITRACONAZOLEandVORICONAZOLE—considerreducinginitialdoseofponatinib(seeunderPonatinib,p814)lAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis) TRIANGLE Antivirals:plasmaconcentrationofponatinibpossiblyincreasedbyINDINAVIR,RITONAVIRandSAQUINAVIR—considerreducinginitialdoseofponatinib(seeunderPonatinib,p814) TRIANGLE GrapefruitJuice:plasmaconcentrationofponatinibpossiblyincreasedbyGRAPEFRUITJUICEPosaconazoleseeAntifungals,TriazolePotassiumCanrenoateseeDiureticsPotassiumAminobenzoate TRIANGLE Antibacterials:potassiumaminobenzoateinhibitseffectsofSULFONAMIDESPotassiumBicarbonateseePotassiumSaltsPotassiumChlorideseePotassiumSaltsPotassiumCitrateseePotassiumSaltsPotassiumSaltsNOTEIncludessaltsubstituteslACEInhibitors:increasedriskofseverehyperkalaemiawhenpotassiumsaltsgivenwithlACEINHIBITORS TRIANGLE Aliskiren:increasedriskofhyperkalaemiawhenpotassiumsaltsgivenwithALISKIRENlAngiotensin-IIReceptorAntagonists:increasedriskofhyperkalaemiawhenpotassiumsaltsgivenwithlANGIOTENSIN-IIRECEPTORANTAGONISTS TRIANGLE Antibacterials:avoidconcomitantuseofpotassiumcitratewithMETHENAMINElCiclosporin:increasedriskofhyperkalaemiawhenpotassiumsaltsgivenwithlCICLOSPORINlDiuretics:increasedriskofhyperkalaemiawhenpotassiumsaltsgivenwithlPOTASSIUM-SPARINGDIURETICSANDALDOSTERONEANTAGONISTSlTacrolimus:increasedriskofhyperkalaemiawhenpotassiumsaltsgivenwithlTACROLIMUS TRIANGLE Ulcer-healingDrugs:avoidanceofpotassiumcitrateadvisedbymanufacturerofSUCRALFATEPramipexole TRIANGLE Antipsychotics:manufacturerofpramipexoleadvisesavoidconcomitantuseofANTIPSYCHOTICS(antagonismofeffect) TRIANGLE Memantine:effectsofdopaminergicspossiblyenhancedbyMEMANTINE TRIANGLE Methyldopa:antiparkinsonianeffectofdopaminergicsantagonisedbyMETHYLDOPA TRIANGLE Ulcer-healingDrugs:excretionofpramipexolereducedbyCIMETIDINE(increasedplasmaconcentration)Prasugrel TRIANGLE Analgesics:possibleincreasedriskofbleedingwhenprasugrelgivenwithNSAIDS TRIANGLE Anticoagulants:possibleincreasedriskofbleedingwhenprasugrelgivenwithCOUMARINSorPHENINDIONE TRIANGLE Clopidogrel:possibleincreasedriskofbleedingwhenprasugrelgivenwithCLOPIDOGRELPravastatinseeStatinsPraziquantellAntibacterials:plasmaconcentrationofpraziquantelreducedbylRIFAMPICIN—avoidconcomitantuselAntiepileptics:plasmaconcentrationofpraziquantelreducedbylCARBAMAZEPINE,lFOSPHENYTOIN,lPHENOBARBITAL,lPHENYTOINandlPRIMIDONE—considerincreasingpraziquanteldosewhengivenforsystemicinfections TRIANGLE Antifungals:plasmaconcentrationofpraziquantelincreasedbyKETOCONAZOLE1228Appendix1InteractionsBNF70Interactions|Appendix1"
"Praziquantel(continued)lAntimalarials:plasmaconcentrationofpraziquantelreducedbylCHLOROQUINE—considerincreasingpraziquanteldosewhengivenforsystemicinfections TRIANGLE Corticosteroids:plasmaconcentrationofpraziquantelpossiblyreducedbycontinuoususeofDEXAMETHASONE TRIANGLE GrapefruitJuice:plasmaconcentrationofpraziquantelincreasedbyGRAPEFRUITJUICE TRIANGLE Ulcer-healingDrugs:plasmaconcentrationofpraziquantelincreasedbyCIMETIDINEPrazosinseeAlpha-blockersPrednisoloneseeCorticosteroidsPrednisoneseeCorticosteroidsPregabalinlAntidepressants:anticonvulsanteffectofantiepilepticspossiblyantagonisedbyMAOISandlTRICYCLIC-RELATEDANTIDEPRESSANTS(convulsivethresholdlowered);anticonvulsanteffectofantiepilepticsantagonisedbylSSRISandlTRICYCLICS(convulsivethresholdlowered)lAntimalarials:anticonvulsanteffectofantiepilepticsantagonisedbylMEFLOQUINElAntipsychotics:anticonvulsanteffectofantiepilepticsantagonisedbylANTIPSYCHOTICS(convulsivethresholdlowered)lOrlistat:possibleincreasedriskofconvulsionswhenantiepilepticsgivenwithlORLISTATPrilocaine TRIANGLE Anti-arrhythmics:increasedmyocardialdepressionwhenprilocainegivenwithANTI-ARRHYTHMICS TRIANGLE Antibacterials:increasedriskofmethaemoglobinaemiawhenprilocainegivenwithSULFONAMIDESPrimaquinelAntimalarials:avoidanceofantimalarialsadvisedbymanufactureroflARTEMETHERWITHLUMEFANTRINE TRIANGLE Histamine:avoidanceofantimalarialsadvisedbymanufacturerofHISTAMINE TRIANGLE Mepacrine:plasmaconcentrationofprimaquineincreasedbyMEPACRINE(increasedriskoftoxicity) TRIANGLE Vaccines:antimalarialsinactivateORALTYPHOIDVACCINE—seeunderTyphoidVaccineinBNFPrimidone TRIANGLE Alcohol:increasedsedativeeffectwhenprimidonegivenwithALCOHOLlAminophylline:primidoneacceleratesmetabolismoflAMINOPHYLLINE(reducedeffect) TRIANGLE Analgesics:primidonereducesplasmaconcentrationofMETHADONE;primidonepossiblyacceleratesmetabolismofPARACETAMOL(alsoisolatedreportsofhepatotoxicity)lAnthelmintics:primidonereducesplasmaconcentrationoflALBENDAZOLEandlPRAZIQUANTEL—considerincreasingalbendazoleandpraziquanteldosewhengivenforsystemicinfectionslAnti-arrhythmics:primidoneacceleratesmetabolismofDISOPYRAMIDE(reducedplasmaconcentration);primidonepossiblyreducesplasmaconcentrationoflDRONEDARONE—avoidconcomitantuse;primidonepossiblyacceleratesmetabolismofPROPAFENONElAntibacterials:primidoneacceleratesmetabolismofMETRONIDAZOLE(reducedeffect);primidonepossiblyreducesplasmaconcentrationofRIFAMPICIN;primidoneacceleratesmetabolismofDOXYCYCLINE(reducedplasmaconcentration);primidonepossiblyacceleratesmetabolismoflCHLORAMPHENICOL(reducedplasmaconcentration);primidonereducesplasmaconcentrationoflTELITHROMYCIN(avoidduringandfor2weeksafterprimidone)lAnticoagulants:primidonepossiblyreducesplasmaconcentrationoflAPIXABAN;primidoneacceleratesmetabolismoflCOUMARINS(reducedanticoagulanteffect);primidonepossiblyreducesplasmaconcentrationoflRIVAROXABAN—manufacturerofrivaroxabanadvisesmonitorforsignsofthrombosislAntidepressants:primidonepossiblyreducesplasmaconcentrationofREBOXETINE;primidonereducesplasmaconcentrationofPAROXETINE;primidoneacceleratesmetabolismoflMIANSERIN(reducedplasmaconcentration);PrimidonelAntidepressants(continued)anticonvulsanteffectofantiepilepticspossiblyantagonisedbyMAOISandlTRICYCLIC-RELATEDANTIDEPRESSANTS(convulsivethresholdlowered);anticonvulsanteffectofantiepilepticsantagonisedbylSSRISandlTRICYCLICS(convulsivethresholdlowered);plasmaconcentrationofprimidonepossiblyreducedbylSTJOHN’SWORT—avoidconcomitantuse;primidonepossiblyacceleratesmetabolismoflTRICYCLICS(reducedplasmaconcentration)lAntiepileptics:plasmaconcentrationofprimidonepossiblyincreasedbyCARBAMAZEPINE;primidonepossiblyreducesplasmaconcentrationofETHOSUXIMIDE,RUFINAMIDEandTOPIRAMATE;plasmaconcentrationofprimidoneoftenincreasedbyFOSPHENYTOINandPHENYTOIN,plasmaconcentrationoffosphenytoinandphenytoinoftenreducedbutmaybeincreased;primidonereducesplasmaconcentrationofLAMOTRIGINE,TIAGABINEandZONISAMIDE;plasmaconcentrationofprimidoneincreasedbyOXCARBAZEPINE,alsoplasmaconcentrationofanactivemetaboliteofoxcarbazepinereduced;plasmaconcentrationofprimidoneincreasedbySODIUMVALPROATEandVALPROICACID(alsoplasmaconcentrationofsodiumvalproateandvalproicacidreduced);plasmaconcentrationofprimidoneincreasedbylSTIRIPENTOLlAntifungals:primidonepossiblyreducesplasmaconcentrationofITRACONAZOLEandlPOSACONAZOLE;primidonepossiblyreducesplasmaconcentrationoflVORICONAZOLE—avoidconcomitantuse;primidonereducesabsorptionofGRISEOFULVIN(reducedeffect)lAntimalarials:avoidanceofprimidoneadvisedbymanufacturerofARTENIMOLWITHPIPERAQUINE;anticonvulsanteffectofantiepilepticsantagonisedbylMEFLOQUINElAntipsychotics:anticonvulsanteffectofantiepilepticsantagonisedbylANTIPSYCHOTICS(convulsivethresholdlowered);primidoneacceleratesmetabolismofHALOPERIDOL(reducedplasmaconcentration);plasmaconcentrationofbothdrugsreducedwhenprimidonegivenwithCHLORPROMAZINE;primidonepossiblyreducesplasmaconcentrationoflARIPIPRAZOLE(avoidconcomitantuseorconsiderincreasingthedoseofaripiprazole—consultaripiprazoleproductliterature);primidonepossiblyreducesplasmaconcentrationofCLOZAPINE;primidonepossiblyreducesplasmaconcentrationoflLURASIDONE—avoidconcomitantuselAntivirals:primidonepossiblyreducesplasmaconcentrationofABACAVIR,DARUNAVIR,FOSAMPRENAVIR,lINDINAVIR,lLOPINAVIRandlSAQUINAVIR;avoidanceofprimidoneadvisedbymanufactureroflBOCEPREVIRandlRILPIVIRINE(plasmaconcentrationofboceprevirandrilpivirinepossiblyreduced);primidonepossiblyreducesplasmaconcentrationoflDACLATASVIRandlSIMEPREVIR—manufacturerofdaclatasvirandsimepreviradvisesavoidconcomitantuse;avoidanceofprimidoneadvisedbymanufacturerofDOLUTEGRAVIR,lELVITEGRAVIR,ETRAVIRINE,SOFOSBUVIRandlTELAPREVIR TRIANGLE AnxiolyticsandHypnotics:increasedsedativeeffectwhenprimidonegivenwithANXIOLYTICSANDHYPNOTICS;primidoneoftenreducesplasmaconcentrationofCLONAZEPAM TRIANGLE Aprepitant:primidonepossiblyreducesplasmaconcentrationofAPREPITANT TRIANGLE Avanafil:primidonepossiblyreducesplasmaconcentrationofAVANAFIL—manufacturerofavanafiladvisesavoidconcomitantuse TRIANGLE Beta-blockers:primidonepossiblyreducesplasmaconcentrationofPROPRANOLOL TRIANGLE Caffeinecitrate:effectsofprimidonepossiblyantagonisedbyCAFFEINECITRATElCalcium-channelBlockers:primidoneprobablyreduceseffectsoflCALCIUM-CHANNELBLOCKERS;avoidanceofprimidoneadvisedbymanufacturerofISRADIPINE;avoidanceofprimidoneadvisedbymanufactureroflNIMODIPINE(plasmaconcentrationofnimodipinereduced)lCannabisExtract:primidonepossiblyreducesplasmaconcentrationoflCANNABISEXTRACT—manufacturerofcannabisextractadvisesavoidconcomitantuseBNF70Appendix1Interactions1229Interactions|Appendix1"
"Primidone(continued)lCiclosporin:primidoneacceleratesmetabolismoflCICLOSPORIN(reducedplasmaconcentration)lCobicistat:primidonepossiblyreducesplasmaconcentrationoflCOBICISTAT—manufacturerofcobicistatadvisesavoidconcomitantuselCorticosteroids:primidoneacceleratesmetabolismoflCORTICOSTEROIDS(reducedeffect)lCytotoxics:primidonepossiblydecreasesplasmaconcentrationofAXITINIB(increasedoseofaxitinib—consultaxitinibproductliterature);primidonepossiblyreducesplasmaconcentrationofBORTEZOMIB,lBOSUTINIB,CRIZOTINIBandPONATINIB—manufacturerofbortezomib,bosutinib,crizotinibandponatinibadvisesavoidconcomitantuse;primidonepossiblyreducesplasmaconcentrationoflCABOZANTINIB—avoidconcomitantuse;avoidanceofprimidoneadvisedbymanufactureroflCABAZITAXEL,DABRAFENIBandGEFITINIB;avoidanceofprimidoneadvisedbymanufacturerofDASATINIBandVANDETANIB(plasmaconcentrationofdasatinibandvandetanibpossiblyreduced);primidonepossiblyreducesplasmaconcentrationofETOPOSIDE;primidonereducesplasmaconcentrationofIRINOTECANanditsactivemetabolite;manufacturerofprocarbazineadvisespossibleincreasedriskofhypersensitivityreactionswhenprimidonegivenwithPROCARBAZINElDiuretics:primidonereducesplasmaconcentrationoflEPLERENONE—avoidconcomitantuse;increasedriskofosteomalaciawhenprimidonegivenwithCARBONICANHYDRASEINHIBITORS TRIANGLE Folates:plasmaconcentrationofprimidonepossiblyreducedbyFOLATES TRIANGLE Fosaprepitant:primidonepossiblyreducesplasmaconcentrationofFOSAPREPITANTlHormoneAntagonists:primidonepossiblyreducesplasmaconcentrationoflABIRATERONE—manufacturerofabirateroneadvisesavoidconcomitantuse;primidoneacceleratesmetabolismofTOREMIFENE(reducedplasmaconcentration)lIvacaftor:primidonepossiblyreducesplasmaconcentrationoflIVACAFTOR—manufacturerofivacaftoradvisesavoidconcomitantuse TRIANGLE LeukotrieneReceptorAntagonists:primidonereducesplasmaconcentrationofMONTELUKASTlOestrogens:primidoneacceleratesmetabolismoflOESTROGENS(reducedcontraceptiveeffectwithcombinedoralcontraceptives,contraceptivepatches,andvaginalrings—seeContraceptiveInteractionsinBNF)lOrlistat:possibleincreasedriskofconvulsionswhenantiepilepticsgivenwithlORLISTATlProgestogens:primidoneacceleratesmetabolismoflPROGESTOGENS(reducedcontraceptiveeffectwithcombinedoralcontraceptives,progestogen-onlyoralcontraceptives,contraceptivepatches,vaginalrings,etonogestrel-releasingimplant,andemergencyhormonalcontraception—seeContraceptiveInteractionsinBNF) TRIANGLE Roflumilast:primidonepossiblyinhibitseffectsofROFLUMILAST(manufacturerofroflumilastadvisesavoidconcomitantuse) TRIANGLE SodiumOxybate:avoidanceofprimidoneadvisedbymanufacturerofSODIUMOXYBATE TRIANGLE Sympathomimetics:plasmaconcentrationofprimidonepossiblyincreasedbyMETHYLPHENIDATElTacrolimus:primidonereducesplasmaconcentrationoflTACROLIMUSlTheophylline:primidoneacceleratesmetabolismoflTHEOPHYLLINE(reducedeffect) TRIANGLE ThyroidHormones:primidoneacceleratesmetabolismofTHYROIDHORMONES(mayincreaserequirementsforthyroidhormonesinhypothyroidism) TRIANGLE Ticagrelor:primidonepossiblyreducesplasmaconcentrationofTICAGRELORlUlipristal:avoidanceofprimidoneadvisedbymanufactureroflULIPRISTAL(contraceptiveeffectofulipristalpossiblyreduced)Primidone(continued) TRIANGLE Vitamins:primidonepossiblyincreasesrequirementsforALFACALCIDOL,CALCITRIOL,COLECALCIFEROL,DIHYDROTACHYSTEROL,ERGOCALCIFEROL,PARICALCITOLorVITAMINDProcarbazine TRIANGLE Alcohol:disulfiram-likereactionwhenprocarbazinegivenwithALCOHOL TRIANGLE Antiepileptics:manufacturerofprocarbazineadvisespossibleincreasedriskofhypersensitivityreactionswhengivenwithCARBAMAZEPINE,FOSPHENYTOIN,PHENOBARBITAL,PHENYTOINandPRIMIDONElAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis) TRIANGLE CardiacGlycosides:procarbazinepossiblyreducesabsorptionofDIGOXINtabletsProchlorperazineseeAntipsychoticsProcyclidineseeAntimuscarinicsProgesteroneseeProgestogensProgestogenslAntibacterials:plasmaconcentrationofdienogestincreasedbyERYTHROMYCIN;metabolismofprogestogensacceleratedbylRIFAMYCINS(reducedcontraceptiveeffectwithcombinedoralcontraceptives,progestogen-onlyoralcontraceptives,contraceptivepatches,vaginalrings,etonogestrel-releasingimplant,andemergencyhormonalcontraception—seeContraceptiveInteractionsinBNF)lAnticoagulants:progestogensmayenhanceorreduceanticoagulanteffectofCOUMARINS;progestogensantagoniseanticoagulanteffectoflPHENINDIONElAntidepressants:contraceptiveeffectofprogestogensreducedbylSTJOHN’SWORT(avoidconcomitantuse) TRIANGLE Antidiabetics:progestogensantagonisehypoglycaemiceffectofANTIDIABETICSlAntiepileptics:metabolismofprogestogensacceleratedbylCARBAMAZEPINE,lESLICARBAZEPINE,lFOSPHENYTOIN,lOXCARBAZEPINE,lPERAMPANEL,lPHENOBARBITAL,lPHENYTOIN,lPRIMIDONE,lRUFINAMIDEandlTOPIRAMATE(reducedcontraceptiveeffectwithcombinedoralcontraceptives,progestogen-onlyoralcontraceptives,contraceptivepatches,vaginalrings,etonogestrel-releasingimplant,andemergencyhormonalcontraception—seeContraceptiveInteractionsinBNF);desogestrelpossiblyincreasesplasmaconcentrationofLAMOTRIGINE TRIANGLE Antifungals:progestogenspossiblyincreaseplasmaconcentrationofVORICONAZOLE;anecdotalreportsofcontraceptivefailureandmenstrualirregularitieswhenprogestogensgivenwithGRISEOFULVIN;occasionalreportsofbreakthroughbleedingwhenprogestogens(usedforcontraception)givenwithTERBINAFINElAntivirals:plasmaconcentrationofnorethisteroneincreasedbyATAZANAVIR;plasmaconcentrationofdrospirenoneincreasedbyBOCEPREVIR(increasedriskoftoxicity);contraceptiveeffectofprogestogenspossiblyreducedbylEFAVIRENZ;plasmaconcentrationofnorgestimateincreasedbyELVITEGRAVIR;metabolismofprogestogensacceleratedbylNEVIRAPINE(reducedcontraceptiveeffectwithcombinedoralcontraceptives,progestogen-onlyoralcontraceptives,contraceptivepatches,vaginalrings,etonogestrel-releasingimplant,andemergencyhormonalcontraception—seeContraceptiveInteractionsinBNF) TRIANGLE AnxiolyticsandHypnotics:progestogenspossiblyincreaseplasmaconcentrationofCHLORDIAZEPOXIDE,DIAZEPAMandNITRAZEPAM;progestogenspossiblyreduceplasmaconcentrationofLORAZEPAM,OXAZEPAMandTEMAZEPAMlAprepitant:possiblecontraceptivefailureofhormonalcontraceptivescontainingprogestogenswhengivenwithlAPREPITANT(alternativecontraceptionrecommended)lBosentan:possiblecontraceptivefailureofhormonalcontraceptivescontainingprogestogenswhengivenwithlBOSENTAN(alternativecontraceptionrecommended) TRIANGLE Ciclosporin:progestogenspossiblyincreaseplasmaconcentrationofCICLOSPORIN TRIANGLE Cobicistat:plasmaconcentrationofnorgestimateincreasedbyCOBICISTAT1230Appendix1InteractionsBNF70Interactions|Appendix1"
"Progestogens(continued)lCytotoxics:possiblereductionincontraceptiveeffectofprogestogensadvisedbymanufactureroflCRIZOTINIBandlVEMURAFENIB;possiblereducedcontraceptiveeffectofhormonalcontraceptivescontainingprogestogensadvisedbymanufactureroflDABRAFENIB(alternativecontraceptionrecommended) TRIANGLE Diuretics:riskofhyperkalaemiawhendrospirenonegivenwithPOTASSIUM-SPARINGDIURETICSANDALDOSTERONEANTAGONISTS(monitorserumpotassiumduringfirstcycle)lDopaminergics:progestogensincreaseplasmaconcentrationoflSELEGILINE—manufacturerofselegilineadvisesavoidconcomitantuselFosaprepitant:possiblecontraceptivefailureofhormonalcontraceptivescontainingprogestogenswhengivenwithlFOSAPREPITANT(alternativecontraceptionrecommended) TRIANGLE Lipid-regulatingDrugs:plasmaconcentrationofnorethisteroneincreasedbyATORVASTATIN;plasmaconcentrationofactivemetaboliteofnorgestimateincreasedbyROSUVASTATIN;plasmaconcentrationofnorgestrelincreasedbyROSUVASTATIN TRIANGLE MuscleRelaxants:progestogenspossiblyincreaseplasmaconcentrationofTIZANIDINE(increasedriskoftoxicity) TRIANGLE Sugammadex:plasmaconcentrationofprogestogenspossiblyreducedbySUGAMMADEX—manufacturerofsugammadexadvisesadditionalcontraceptiveprecautions TRIANGLE Teriflunomide:plasmaconcentrationoflevonorgestrelincreasedbyTERIFLUNOMIDElUlipristal:contraceptiveeffectofprogestogenspossiblyreducedbylULIPRISTALProguanil TRIANGLE Antacids:absorptionofproguanilreducedbyORALMAGNESIUMSALTS(asmagnesiumtrisilicate) TRIANGLE Anticoagulants:isolatedreportsthatproguanilmayenhanceanticoagulanteffectofWARFARINlAntimalarials:avoidanceofantimalarialsadvisedbymanufactureroflARTEMETHERWITHLUMEFANTRINE;increasedantifolateeffectwhenproguanilgivenwithPYRIMETHAMINE TRIANGLE Antivirals:plasmaconcentrationofproguanilpossiblyaffectedbyEFAVIRENZ TRIANGLE Histamine:avoidanceofantimalarialsadvisedbymanufacturerofHISTAMINE TRIANGLE Vaccines:antimalarialsinactivateORALTYPHOIDVACCINE—seeunderTyphoidVaccineinBNFPromazineseeAntipsychoticsPromethazineseeAntihistaminesPropafenone TRIANGLE Aminophylline:propafenoneincreasesplasmaconcentrationofAMINOPHYLLINE TRIANGLE Anaesthetics,Local:increasedmyocardialdepressionwhenanti-arrhythmicsgivenwithBUPIVACAINE,LEVOBUPIVACAINE,PRILOCAINEorROPIVACAINElAnti-arrhythmics:increasedmyocardialdepressionwhenanti-arrhythmicsgivenwithotherlANTI-ARRHYTHMICSlAntibacterials:metabolismofpropafenoneacceleratedbylRIFAMPICIN(reducedeffect)lAnticoagulants:propafenoneenhancesanticoagulanteffectoflCOUMARINSlAntidepressants:metabolismofpropafenonepossiblyinhibitedbyFLUOXETINEandPAROXETINE;increasedriskofarrhythmiaswhenpropafenonegivenwithlTRICYCLICS TRIANGLE Antiepileptics:metabolismofpropafenonepossiblyacceleratedbyPHENOBARBITALandPRIMIDONE TRIANGLE Antihistamines:avoidanceofpropafenoneadvisedbymanufacturerofMIZOLASTINE(possibleriskofventriculararrhythmias)lAntipsychotics:increasedriskofventriculararrhythmiaswhenanti-arrhythmicsthatprolongtheQTintervalgivenwithlANTIPSYCHOTICSthatprolongtheQTintervallAntivirals:plasmaconcentrationofpropafenonepossiblyincreasedbylFOSAMPRENAVIR(increasedriskofventriculararrhythmias—avoidconcomitantuse);plasmaconcentrationofpropafenoneincreasedbylRITONAVIR(increasedriskofventriculararrhythmias—avoidconcomitantuse);increasedriskofventriculararrhythmiaswhenpropafenonegivenwithlSAQUINAVIR—avoidconcomitantuse;cautionwithPropafenonelAntivirals(continued)propafenoneadvisedbymanufactureroflTELAPREVIR(riskofventriculararrhythmias)lBeta-blockers:increasedmyocardialdepressionwhenanti-arrhythmicsgivenwithlBETA-BLOCKERS;propafenoneincreasesplasmaconcentrationofMETOPROLOLandPROPRANOLOLlCardiacGlycosides:propafenoneincreasesplasmaconcentrationoflDIGOXIN(halvedoseofdigoxin) TRIANGLE Ciclosporin:propafenonepossiblyincreasesplasmaconcentrationofCICLOSPORIN TRIANGLE Parasympathomimetics:propafenonepossiblyantagoniseseffectsofNEOSTIGMINEandPYRIDOSTIGMINE TRIANGLE Theophylline:propafenoneincreasesplasmaconcentrationofTHEOPHYLLINElUlcer-healingDrugs:plasmaconcentrationofpropafenoneincreasedbylCIMETIDINEPropanthelineseeAntimuscarinicsPropiverineseeAntimuscarinicsPropofolseeAnaesthetics,GeneralPropranololseeBeta-blockersProstaglandins TRIANGLE ACEInhibitors:enhancedhypotensiveeffectwhenalprostadilgivenwithACEINHIBITORS TRIANGLE AdrenergicNeuroneBlockers:enhancedhypotensiveeffectwhenalprostadilgivenwithADRENERGICNEURONEBLOCKERS TRIANGLE Alpha-blockers:enhancedhypotensiveeffectwhenalprostadilgivenwithALPHA-BLOCKERS TRIANGLE Angiotensin-IIReceptorAntagonists:enhancedhypotensiveeffectwhenalprostadilgivenwithANGIOTENSIN-IIRECEPTORANTAGONISTS TRIANGLE Beta-blockers:enhancedhypotensiveeffectwhenalprostadilgivenwithBETA-BLOCKERS TRIANGLE Calcium-channelBlockers:enhancedhypotensiveeffectwhenalprostadilgivenwithCALCIUM-CHANNELBLOCKERS TRIANGLE Clonidine:enhancedhypotensiveeffectwhenalprostadilgivenwithCLONIDINE TRIANGLE Diazoxide:enhancedhypotensiveeffectwhenalprostadilgivenwithDIAZOXIDE TRIANGLE Diuretics:enhancedhypotensiveeffectwhenalprostadilgivenwithDIURETICS TRIANGLE Methyldopa:enhancedhypotensiveeffectwhenalprostadilgivenwithMETHYLDOPA TRIANGLE Moxonidine:enhancedhypotensiveeffectwhenalprostadilgivenwithMOXONIDINE TRIANGLE Nitrates:enhancedhypotensiveeffectwhenalprostadilgivenwithNITRATES TRIANGLE Oxytocin:prostaglandinspotentiateuterotoniceffectofOXYTOCIN TRIANGLE VasodilatorAntihypertensives:enhancedhypotensiveeffectwhenalprostadilgivenwithHYDRALAZINE,MINOXIDILorSODIUMNITROPRUSSIDEProteinKinaseInhibitorsseeindividualdrugsProtonPumpInhibitors TRIANGLE Antacids:absorptionoflansoprazolepossiblyreducedbyANTACIDS TRIANGLE Antibacterials:plasmaconcentrationofbothdrugsincreasedwhenomeprazolegivenwithCLARITHROMYCINlAnticoagulants:pantoprazolemightenhancetheanticoagulanteffectofCOUMARINS;esomeprazoleandomeprazolepossiblyenhanceanticoagulanteffectoflCOUMARINS TRIANGLE Antidepressants:omeprazoleincreasesplasmaconcentrationofESCITALOPRAM;plasmaconcentrationoflansoprazolepossiblyincreasedbyFLUVOXAMINE;plasmaconcentrationofomeprazolepossiblyreducedbySTJOHN’SWORTlAntiepileptics:omeprazolepossiblyenhanceseffectsofFOSPHENYTOINandPHENYTOIN;esomeprazoleenhanceseffectsoflFOSPHENYTOINandlPHENYTOINlAntifungals:protonpumpinhibitorsreduceabsorptionofITRACONAZOLEandKETOCONAZOLE;esomeprazolereducesplasmaconcentrationoflPOSACONAZOLE—manufacturerofposaconazolesuspensionadvisesavoidconcomitantuse;lansoprazole,omeprazole,pantoprazoleandrabeprazoleBNF70Appendix1Interactions1231Interactions|Appendix1"
"ProtonPumpInhibitorslAntifungals(continued)possiblyreduceplasmaconcentrationoflPOSACONAZOLE—manufacturerofposaconazolesuspensionadvisesavoidconcomitantuse;plasmaconcentrationofesomeprazolepossiblyincreasedbyVORICONAZOLE;plasmaconcentrationofomeprazoleincreasedbyVORICONAZOLE(considerreducingdoseofomeprazole) TRIANGLE Antipsychotics:omeprazolepossiblyreducesplasmaconcentrationofCLOZAPINElAntivirals:protonpumpinhibitorsreduceplasmaconcentrationoflATAZANAVIR—avoidoradjustdoseofbothdrugs(consultproductliterature);omeprazoleincreasesplasmaconcentrationofRALTEGRAVIR;avoidanceofesomeprazole,lansoprazole,pantoprazoleandrabeprazoleadvisedbymanufacturerofRILPIVIRINE(plasmaconcentrationofrilpivirinepossiblyreduced);omeprazolereducesplasmaconcentrationoflRILPIVIRINE—avoidconcomitantuse;esomeprazole,lansoprazole,pantoprazoleandrabeprazolepossiblyincreaseplasmaconcentrationoflSAQUINAVIR—manufacturerofsaquinaviradvisesavoidconcomitantuse;omeprazoleincreasesplasmaconcentrationoflSAQUINAVIR—manufacturerofsaquinaviradvisesavoidconcomitantuse;plasmaconcentrationofesomeprazoleandomeprazolereducedbylTIPRANAVIR TRIANGLE AnxiolyticsandHypnotics:esomeprazoleandomeprazolepossiblyinhibitmetabolismofDIAZEPAM(increasedplasmaconcentration) TRIANGLE CardiacGlycosides:protonpumpinhibitorspossiblyslightlyincreaseplasmaconcentrationofDIGOXIN TRIANGLE Ciclosporin:omeprazolepossiblyaffectsplasmaconcentrationofCICLOSPORINlCilostazol:omeprazoleincreasesplasmaconcentrationoflCILOSTAZOL(seeunderCilostazol,p206)lClopidogrel:esomeprazoleandomeprazolereduceantiplateleteffectoflCLOPIDOGREL;lansoprazole,pantoprazoleandrabeprazolepossiblyreduceantiplateleteffectofCLOPIDOGRELlCytotoxics:protonpumpinhibitorspossiblyreduceexcretionofMETHOTREXATE(increasedriskoftoxicity);lansoprazolereducesplasmaconcentrationofBOSUTINIB;avoidanceofprotonpumpinhibitorsadvisedbymanufacturerofDABRAFENIB(plasmaconcentrationofdabrafenibpossiblyreduced);avoidanceofesomeprazole,lansoprazole,pantoprazoleandrabeprazoleadvisedbymanufactureroflERLOTINIB;omeprazolereducesplasmaconcentrationoflERLOTINIB—manufactureroferlotinibadvisesavoidconcomitantuse;protonpumpinhibitorspossiblyreduceabsorptionofLAPATINIB;protonpumpinhibitorspossiblyreduceabsorptionofPAZOPANIB—manufacturerofpazopanibadvisesgiveatthesametimeasprotonpumpinhibitors TRIANGLE Tacrolimus:omeprazolepossiblyincreasesplasmaconcentrationofTACROLIMUS TRIANGLE Ulcer-healingDrugs:absorptionoflansoprazolepossiblyreducedbySUCRALFATEPseudoephedrineseeSympathomimeticsPyrazinamide TRIANGLE Sulfinpyrazone:pyrazinamideantagoniseseffectsofSULFINPYRAZONE TRIANGLE Vaccines:antibacterialsinactivateORALTYPHOIDVACCINE—seeunderTyphoidVaccineinBNFPyridostigmineseeParasympathomimeticsPyridoxineseeVitaminsPyrimethaminelAntibacterials:increasedantifolateeffectwhenpyrimethaminegivenwithlSULFONAMIDESorlTRIMETHOPRIMlAntiepileptics:pyrimethamineantagonisesanticonvulsanteffectoflFOSPHENYTOINandlPHENYTOIN,alsoincreasedantifolateeffectlAntimalarials:avoidanceofantimalarialsadvisedbymanufactureroflARTEMETHERWITHLUMEFANTRINE;increasedantifolateeffectwhenpyrimethaminegivenwithPROGUANIL TRIANGLE Antivirals:increasedantifolateeffectwhenpyrimethaminegivenwithZIDOVUDINEPyrimethamine(continued)lCytotoxics:pyrimethamineincreasesantifolateeffectoflMETHOTREXATEandlPEMETREXED TRIANGLE Histamine:avoidanceofantimalarialsadvisedbymanufacturerofHISTAMINE TRIANGLE Vaccines:antimalarialsinactivateORALTYPHOIDVACCINE—seeunderTyphoidVaccineinBNFQuetiapineseeAntipsychoticsQuinagolide TRIANGLE Memantine:effectsofdopaminergicspossiblyenhancedbyMEMANTINE TRIANGLE Methyldopa:antiparkinsonianeffectofdopaminergicsantagonisedbyMETHYLDOPAQuinaprilseeACEInhibitorsQuininelAnti-arrhythmics:increasedriskofventriculararrhythmiaswhenquininegivenwithlAMIODARONE—avoidconcomitantuse;quinineincreasesplasmaconcentrationoflFLECAINIDElAntibacterials:increasedriskofventriculararrhythmiaswhenquininegivenwithlMOXIFLOXACIN—avoidconcomitantuse;plasmaconcentrationofquininereducedbylRIFAMPICIN TRIANGLE Anticoagulants:plasmaconcentrationofbothdrugsincreasedwhenquininegivenwithWARFARINlAntidepressants:possibleincreasedriskofventriculararrhythmiaswhenquininegivenwithlCITALOPRAMorlESCITALOPRAM—avoidconcomitantuselAntimalarials:avoidanceofantimalarialsadvisedbymanufactureroflARTEMETHERWITHLUMEFANTRINE;increasedriskofventriculararrhythmiaswhenquininegivenwithlARTEMETHERWITHLUMEFANTRINE;increasedriskofconvulsionswhenquininegivenwithlMEFLOQUINE(butshouldnotpreventtheuseofintravenousquinineinseverecases)lAntipsychotics:increasedriskofventriculararrhythmiaswhenquininegivenwithlDROPERIDOLorlPIMOZIDE—avoidconcomitantuse;possibleincreasedriskofventriculararrhythmiaswhenquininegivenwithlHALOPERIDOL—avoidconcomitantuse;possibleincreasedriskofventriculararrhythmiaswhenquininegivenwithlRISPERIDONElAntivirals:plasmaconcentrationofquininepossiblyincreasedbylATAZANAVIR,lDARUNAVIR,lFOSAMPRENAVIR,lINDINAVIRandlTIPRANAVIR(increasedriskoftoxicity);plasmaconcentrationofquinineincreasedbylRITONAVIR(increasedriskoftoxicity);increasedriskofventriculararrhythmiaswhenquininegivenwithlSAQUINAVIR—avoidconcomitantuselCardiacGlycosides:quinineincreasesplasmaconcentrationoflDIGOXIN TRIANGLE Dopaminergics:quininepossiblyincreasesplasmaconcentrationofAMANTADINE TRIANGLE Histamine:avoidanceofantimalarialsadvisedbymanufacturerofHISTAMINE TRIANGLE MuscleRelaxants:quininepossiblyenhanceseffectsofSUXAMETHONIUM TRIANGLE Ulcer-healingDrugs:metabolismofquinineinhibitedbyCIMETIDINE(increasedplasmaconcentration) TRIANGLE Vaccines:antimalarialsinactivateORALTYPHOIDVACCINE—seeunderTyphoidVaccineinBNFQuinoloneslAminophylline:possibleincreasedriskofconvulsionswhenquinolonesgivenwithlAMINOPHYLLINE;ciprofloxacinandnorfloxacinincreaseplasmaconcentrationoflAMINOPHYLLINElAnalgesics:possibleincreasedriskofconvulsionswhenquinolonesgivenwithlNSAIDS TRIANGLE Antacids:absorptionofciprofloxacin,levofloxacin,moxifloxacin,norfloxacinandofloxacinreducedbyANTACIDSlAnti-arrhythmics:increasedriskofventriculararrhythmiaswhenlevofloxacinormoxifloxacingivenwithlAMIODARONE—avoidconcomitantuse;increasedriskofventriculararrhythmiaswhenmoxifloxacingivenwithlDISOPYRAMIDE—avoidconcomitantuselAntibacterials:increasedriskofventriculararrhythmiaswhenmoxifloxacingivenwithparenterallERYTHROMYCIN—avoidconcomitantuse;ciprofloxacinpossiblyincreasesplasma1232Appendix1InteractionsBNF70Interactions|Appendix1"
"QuinoloneslAntibacterials(continued)concentrationofBEDAQUILINE—avoidconcomitantuseifciprofloxacingivenformorethan14days;avoidanceofmoxifloxacinadvisedbymanufacturerofBEDAQUILINE;increasedriskofventriculararrhythmiaswhenmoxifloxacingivenwithlDELAMANID;effectsofnalidixicacidpossiblyantagonisedbyNITROFURANTOIN;possibleincreasedriskofventriculararrhythmiaswhenmoxifloxacingivenwithlTELITHROMYCINlAnticoagulants:nalidixicacid,norfloxacinandofloxacinenhanceanticoagulanteffectoflCOUMARINS;ciprofloxacinandlevofloxacinpossiblyenhanceanticoagulanteffectofCOUMARINS;levofloxacinpossiblyenhancesanticoagulanteffectofPHENINDIONElAntidepressants:avoidanceofmoxifloxacinadvisedbymanufactureroflCITALOPRAMandlESCITALOPRAM(riskofventriculararrhythmias);ciprofloxacininhibitsmetabolismoflDULOXETINE—avoidconcomitantuse;avoidanceofciprofloxacinadvisedbymanufactureroflAGOMELATINE;increasedriskofventriculararrhythmiaswhenmoxifloxacingivenwithlTRICYCLICS—avoidconcomitantuse TRIANGLE Antidiabetics:norfloxacinpossiblyenhanceseffectsofGLIBENCLAMIDE TRIANGLE Antiepileptics:ciprofloxacinincreasesordecreasesplasmaconcentrationofFOSPHENYTOINandPHENYTOINlAntihistamines:increasedriskofventriculararrhythmiaswhenmoxifloxacingivenwithlMIZOLASTINE—avoidconcomitantuselAntimalarials:avoidanceofquinolonesadvisedbymanufactureroflARTEMETHERWITHLUMEFANTRINE;avoidanceofmoxifloxacinadvisedbymanufactureroflARTENIMOLWITHPIPERAQUINE(possibleriskofventriculararrhythmias);increasedriskofventriculararrhythmiaswhenmoxifloxacingivenwithlCHLOROQUINE,lHYDROXYCHLOROQUINE,lMEFLOQUINEorlQUININE—avoidconcomitantuselAntipsychotics:increasedriskofventriculararrhythmiaswhenmoxifloxacingivenwithlBENPERIDOL—manufacturerofbenperidoladvisesavoidconcomitantuse;increasedriskofventriculararrhythmiaswhenmoxifloxacingivenwithlDROPERIDOL,lHALOPERIDOL,lPHENOTHIAZINES,lPIMOZIDEorlZUCLOPENTHIXOL—avoidconcomitantuse;ciprofloxacinincreasesplasmaconcentrationofCLOZAPINE;ciprofloxacinpossiblyincreasesplasmaconcentrationofOLANZAPINElAntivirals:manufacturerofnorfloxacinadvisesgiveDIDANOSINEatleast2hoursbeforeorafternorfloxacin;increasedriskofventriculararrhythmiaswhenmoxifloxacingivenwithlSAQUINAVIR—avoidconcomitantuse TRIANGLE AnxiolyticsandHypnotics:avoidanceofciprofloxacinadvisedbymanufacturerofZOLPIDEMlAtomoxetine:increasedriskofventriculararrhythmiaswhenmoxifloxacingivenwithlATOMOXETINElBeta-blockers:increasedriskofventriculararrhythmiaswhenmoxifloxacingivenwithlSOTALOL—avoidconcomitantuse TRIANGLE CalciumSalts:absorptionofciprofloxacinreducedbyCALCIUMSALTSlCiclosporin:increasedriskofnephrotoxicitywhenquinolonesgivenwithlCICLOSPORINlClopidogrel:ciprofloxacinpossiblyreducesantiplateleteffectoflCLOPIDOGRELlCytotoxics:nalidixicacidincreasesriskofMELPHALANtoxicity;ciprofloxacinpossiblyreducesexcretionofMETHOTREXATE(increasedriskoftoxicity);possibleincreasedriskofventriculararrhythmiaswhenmoxifloxacingivenwithlBOSUTINIB;ciprofloxacinpossiblyincreasestheplasmaconcentrationoflBOSUTINIB—manufacturerofbosutinibadvisesavoidorconsiderreducingdoseofbosutinib;ciprofloxacinincreasesplasmaconcentrationofERLOTINIB;ciprofloxacinpossiblyincreasestheplasmaconcentrationoflIBRUTINIB—reducedoseofibrutinib(seeunderIbrutinib,p809);possibleincreasedriskofventriculararrhythmiaswhenmoxifloxacingivenwithlVANDETANIB—avoidconcomitantuse;increasedriskofventriculararrhythmiaswhenlevofloxacinormoxifloxacingivenwithlARSENICTRIOXIDEQuinolones(continued) TRIANGLE DairyProducts:absorptionofciprofloxacinandnorfloxacinreducedbyDAIRYPRODUCTS TRIANGLE Dopaminergics:ciprofloxacinincreasesplasmaconcentrationofRASAGILINE;ciprofloxacininhibitsmetabolismofROPINIROLE(increasedplasmaconcentration) TRIANGLE 5HT1-receptorAgonists:quinolonespossiblyinhibitmetabolismofZOLMITRIPTAN(reducedoseofzolmitriptan) TRIANGLE IronSalts:absorptionofciprofloxacin,levofloxacin,moxifloxacinandofloxacinreducedbyoralIRONSALTS;absorptionofnorfloxacinreducedbyoralIRONSALTS(giveatleast2hoursapart) TRIANGLE Lanthanum:absorptionofquinolonespossiblyreducedbyLANTHANUM(giveatleast2hoursbeforeor4hoursafterlanthanum)lMuscleRelaxants:ciprofloxacinincreasesplasmaconcentrationoflTIZANIDINE(increasedriskoftoxicity)—avoidconcomitantuse;norfloxacinpossiblyincreasesplasmaconcentrationofTIZANIDINE(increasedriskoftoxicity) TRIANGLE Mycophenolate:norfloxacinpossiblyreducesbioavailabilityofMYCOPHENOLATElPentamidineIsetionate:increasedriskofventriculararrhythmiaswhenmoxifloxacingivenwithlPENTAMIDINEISETIONATE—avoidconcomitantuselPirfenidone:ciprofloxacinincreasesplasmaconcentrationoflPIRFENIDONE—seeunderPirfenidone,p260 TRIANGLE Sevelamer:bioavailabilityofciprofloxacinreducedbySEVELAMER TRIANGLE StrontiumRanelate:absorptionofquinolonesreducedbySTRONTIUMRANELATE(manufacturerofstrontiumranelateadvisesavoidconcomitantuse)lTheophylline:possibleincreasedriskofconvulsionswhenquinolonesgivenwithlTHEOPHYLLINE;ciprofloxacinandnorfloxacinincreaseplasmaconcentrationoflTHEOPHYLLINE TRIANGLE Ulcer-healingDrugs:absorptionofciprofloxacin,levofloxacin,moxifloxacinandofloxacinreducedbySUCRALFATE;absorptionofnorfloxacinreducedbySUCRALFATE(giveatleast2hoursapart) TRIANGLE Vaccines:antibacterialsinactivateORALTYPHOIDVACCINE—seeunderTyphoidVaccineinBNF TRIANGLE Zinc:absorptionofciprofloxacin,levofloxacin,moxifloxacinandofloxacinreducedbyZINC;absorptionofnorfloxacinreducedbyZINC(giveatleast2hoursapart)RabeprazoleseeProtonPumpInhibitorsRabiesVaccineseeVaccinesRaloxifene TRIANGLE Anticoagulants:raloxifeneantagonisesanticoagulanteffectofCOUMARINS TRIANGLE Lipid-regulatingDrugs:absorptionofraloxifenereducedbyCOLESTYRAMINE(manufacturerofraloxifeneadvisesavoidconcomitantadministration)Raltegravir TRIANGLE Antacids:plasmaconcentrationofraltegravirreducedbyALUMINIUMHYDROXIDEandORALMAGNESIUMSALTS—manufacturerofraltegraviradvisesavoidconcomitantuselAntibacterials:plasmaconcentrationofraltegravirreducedbylRIFAMPICIN—considerincreasingdoseofraltegravirlAntivirals:increasedriskofrashwhenraltegravirgivenwithDARUNAVIR;avoidanceofraltegraviradvisedbymanufactureroflFOSAMPRENAVIRlOrlistat:absorptionofraltegravirpossiblyreducedbylORLISTAT TRIANGLE Ulcer-healingDrugs:plasmaconcentrationofraltegravirincreasedbyFAMOTIDINEandOMEPRAZOLERaltitrexedlAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lFolates:manufacturerofraltitrexedadvisesavoidconcomitantusewithlFOLATESRamiprilseeACEInhibitorsRanitidineseeHistamineH2-antagonistsRanolazinelAnti-arrhythmics:manufacturerofranolazineadvisesavoidconcomitantusewithlDISOPYRAMIDEBNF70Appendix1Interactions1233Interactions|Appendix1"
"Ranolazine(continued)lAntibacterials:plasmaconcentrationofranolazinepossiblyincreasedbylCLARITHROMYCINandlTELITHROMYCIN—manufacturerofranolazineadvisesavoidconcomitantuse;plasmaconcentrationofranolazinereducedbylRIFAMPICIN—manufacturerofranolazineadvisesavoidconcomitantuse TRIANGLE Antidepressants:plasmaconcentrationofranolazineincreasedbyPAROXETINElAntifungals:plasmaconcentrationofranolazineincreasedbylKETOCONAZOLE—avoidconcomitantuse;plasmaconcentrationofranolazinepossiblyincreasedbylITRACONAZOLE,lPOSACONAZOLEandlVORICONAZOLE—manufacturerofranolazineadvisesavoidconcomitantuselAntivirals:plasmaconcentrationofranolazinepossiblyincreasedbylATAZANAVIR,lDARUNAVIR,lFOSAMPRENAVIR,lINDINAVIR,lLOPINAVIR,lRITONAVIR,lSAQUINAVIRandlTIPRANAVIR—manufacturerofranolazineadvisesavoidconcomitantuselBeta-blockers:manufacturerofranolazineadvisesavoidconcomitantusewithlSOTALOL TRIANGLE Calcium-channelBlockers:plasmaconcentrationofranolazineincreasedbyDILTIAZEMandVERAPAMIL(considerreducingdoseofranolazine) TRIANGLE CardiacGlycosides:ranolazineincreasesplasmaconcentrationofDIGOXIN TRIANGLE Ciclosporin:plasmaconcentrationofbothdrugsmayincreasewhenranolazinegivenwithCICLOSPORINlGrapefruitJuice:plasmaconcentrationofranolazinepossiblyincreasedbylGRAPEFRUITJUICE—manufacturerofranolazineadvisesavoidconcomitantuselLipid-regulatingDrugs:ranolazineincreasesplasmaconcentrationoflSIMVASTATIN(seeunderSimvastatin,p181);separatingadministrationfromranolazineby12hoursadvisedbymanufacturerofLOMITAPIDElTacrolimus:ranolazineincreasesplasmaconcentrationoflTACROLIMUSRasagilineNOTERasagilineisaMAO-BinhibitorlAnalgesics:avoidconcomitantuseofrasagilinewithlDEXTROMETHORPHAN;riskofCNStoxicitywhenrasagilinegivenwithlPETHIDINE(avoidpethidinefor2weeksafterrasagiline) TRIANGLE Antibacterials:plasmaconcentrationofrasagilineincreasedbyCIPROFLOXACINlAntidepressants:afterstoppingrasagilinedonotstartlFLUOXETINEfor2weeks,alsorasagilineshouldnotbestarteduntilatleast5weeksafterstoppingfluoxetine;afterstoppingrasagilinedonotstartlFLUVOXAMINEfor2weeks;riskofhypertensivecrisiswhenrasagilinegivenwithlMAOIS,avoidMAOIsforatleast2weeksafterstoppingrasagiline;increasedriskofCNStoxicitywhenrasagilinegivenwithlSSRISorlTRICYCLICS TRIANGLE Dopaminergics:plasmaconcentrationofrasagilinepossiblyreducedbyENTACAPONE TRIANGLE Memantine:effectsofdopaminergicspossiblyenhancedbyMEMANTINE TRIANGLE Methyldopa:antiparkinsonianeffectofdopaminergicsantagonisedbyMETHYLDOPAlSympathomimetics:avoidconcomitantuseofrasagilinewithlSYMPATHOMIMETICSReboxetinelAntibacterials:manufacturerofreboxetineadvisesavoidconcomitantusewithlMACROLIDESlAntidepressants:manufacturerofreboxetineadvisesavoidconcomitantusewithlFLUVOXAMINE;increasedriskofhypertensionandCNSexcitationwhenreboxetinegivenwithlMAOIS(MAOIsshouldnotbestarteduntil1weekafterstoppingreboxetine,avoidreboxetinefor2weeksafterstoppingMAOIs) TRIANGLE Antiepileptics:plasmaconcentrationofreboxetinepossiblyreducedbyCARBAMAZEPINE,PHENOBARBITALandPRIMIDONElAntifungals:manufacturerofreboxetineadvisesavoidconcomitantusewithlIMIDAZOLESandlTRIAZOLESReboxetine(continued)lAntimalarials:avoidanceofantidepressantsadvisedbymanufactureroflARTEMETHERWITHLUMEFANTRINEandlARTENIMOLWITHPIPERAQUINE TRIANGLE Atomoxetine:possibleincreasedriskofconvulsionswhenantidepressantsgivenwithATOMOXETINE TRIANGLE Diuretics:possibleincreasedriskofhypokalaemiawhenreboxetinegivenwithLOOPDIURETICSorTHIAZIDESANDRELATEDDIURETICS TRIANGLE ErgotAlkaloids:possibleriskofhypertensionwhenreboxetinegivenwithERGOTAMINERegorafenib TRIANGLE Analgesics:manufacturerofregorafenibadvisesavoidconcomitantusewithMEFENAMICACIDlAntibacterials:plasmaconcentrationofregorafenibreducedbylRIFAMPICIN—manufacturerofregorafenibadvisesavoidconcomitantuselAnticoagulants:increasedriskofbleedingwhenregorafenibgivenwithlWARFARINlAntifungals:plasmaconcentrationofregorafenibincreasedbylKETOCONAZOLE—avoidconcomitantuselAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis) TRIANGLE Cytotoxics:regorafenibincreasesplasmaconcentrationofIRINOTECANRemifentanilseeOpioidAnalgesicsRepaglinideseeAntidiabeticsRetigabine TRIANGLE Alcohol:increasedriskofblurredvisionwhenretigabinegivenwithALCOHOLlAntidepressants:anticonvulsanteffectofantiepilepticspossiblyantagonisedbyMAOISandlTRICYCLIC-RELATEDANTIDEPRESSANTS(convulsivethresholdlowered);anticonvulsanteffectofantiepilepticsantagonisedbylSSRISandlTRICYCLICS(convulsivethresholdlowered) TRIANGLE Antiepileptics:plasmaconcentrationofretigabinepossiblyreducedbyCARBAMAZEPINE,FOSPHENYTOINandPHENYTOINlAntimalarials:anticonvulsanteffectofantiepilepticsantagonisedbylMEFLOQUINElAntipsychotics:anticonvulsanteffectofantiepilepticsantagonisedbylANTIPSYCHOTICS(convulsivethresholdlowered)lOrlistat:possibleincreasedriskofconvulsionswhenantiepilepticsgivenwithlORLISTATRetinoidslAlcohol:etretinateformedfromacitretininpresenceoflALCOHOL(increasedriskofteratogenicityinwomenofchild-bearingpotential)lAntibacterials:possibleincreasedriskofbenignintracranialhypertensionwhenretinoidsgivenwithlTETRACYCLINES(avoidconcomitantuse)lAnticoagulants:acitretinpossiblyreducesanticoagulanteffectoflCOUMARINS TRIANGLE Antiepileptics:isotretinoinpossiblyreducesplasmaconcentrationofCARBAMAZEPINElAntifungals:plasmaconcentrationofalitretinoinincreasedbyKETOCONAZOLE;possibleincreasedriskoftretinointoxicitywhengivenwithlFLUCONAZOLE,lKETOCONAZOLEandlVORICONAZOLElCytotoxics:acitretinincreasesplasmaconcentrationoflMETHOTREXATE(alsoincreasedriskofhepatotoxicity)—avoidconcomitantuse TRIANGLE Lipid-regulatingDrugs:alitretinoinreducesplasmaconcentrationofSIMVASTATINlVitamins:riskofhypervitaminosisAwhenretinoidsgivenwithlVITAMINA—avoidconcomitantuseRibavirinlAntivirals:effectsofribavirinpossiblyreducedbylABACAVIR;increasedriskofside-effectswhenribaviringivenwithlDIDANOSINE—avoidconcomitantuse;increasedriskoftoxicitywhenribaviringivenwithlSTAVUDINE;increasedriskofanaemiawhenribaviringivenwithlZIDOVUDINE—avoidconcomitantuselAzathioprine:ribavirinpossiblyenhancesmyelosuppressiveeffectsoflAZATHIOPRINE1234Appendix1InteractionsBNF70Interactions|Appendix1"
"RifabutinseeRifamycinsRifampicinseeRifamycinsRifamycinsNOTEInteractionsdonotapplytorifaximin TRIANGLE ACEInhibitors:rifampicinreducesplasmaconcentrationofactivemetaboliteofIMIDAPRIL(reducedantihypertensiveeffect) TRIANGLE Aliskiren:rifampicinreducesplasmaconcentrationofALISKIREN TRIANGLE Ambrisentan:rifampicinpossiblyincreasesplasmaconcentrationofAMBRISENTAN TRIANGLE Aminophylline:rifampicinacceleratesmetabolismofAMINOPHYLLINE(reducedplasmaconcentration) TRIANGLE Analgesics:rifampicinreducesplasmaconcentrationofCELECOXIB,DICLOFENACandETORICOXIB;rifampicinacceleratesmetabolismofALFENTANIL,CODEINE,FENTANYL,METHADONEandMORPHINE(reducedeffect);rifampicinpossiblyacceleratesmetabolismofOXYCODONE TRIANGLE Angiotensin-IIReceptorAntagonists:rifampicinreducesplasmaconcentrationofLOSARTANanditsactivemetabolite TRIANGLE Antacids:absorptionofrifampicinreducedbyANTACIDSlAnthelmintics:rifampicinreducesplasmaconcentrationoflPRAZIQUANTEL—avoidconcomitantuselAnti-arrhythmics:rifamycinsacceleratemetabolismoflDISOPYRAMIDE(reducedplasmaconcentration);rifampicinreducesplasmaconcentrationoflDRONEDARONE—avoidconcomitantuse;rifampicinacceleratesmetabolismoflPROPAFENONE(reducedeffect)lAntibacterials:increasedriskofside-effectsincludingneutropeniawhenrifabutingivenwithlAZITHROMYCIN;rifamycinsreduceplasmaconcentrationofCLARITHROMYCINandDAPSONE;plasmaconcentrationofrifabutinincreasedbylCLARITHROMYCIN(increasedriskoftoxicity—reducerifabutindose);plasmaconcentrationofrifabutinpossiblyincreasedbylERYTHROMYCIN(increasedriskoftoxicity—reducerifabutindose);rifampicinpossiblyreducesplasmaconcentrationofTINIDAZOLEandTRIMETHOPRIM;rifampicinreducesplasmaconcentrationofDOXYCYCLINE—considerincreasingdoseofdoxycycline;rifabutinpossiblyreducesplasmaconcentrationofBEDAQUILINE—manufacturerofbedaquilineadvisesavoidconcomitantuse;rifampicinreducesplasmaconcentrationoflBEDAQUILINE—manufacturerofbedaquilineadvisesavoidconcomitantuse;rifampicinacceleratesmetabolismofCHLORAMPHENICOL(reducedplasmaconcentration);rifampicinreducesplasmaconcentrationoflDELAMANID;increasedriskofhepatotoxicitywhenrifampicingivenwithlISONIAZID;rifampicinreducesplasmaconcentrationofLINEZOLID(possibletherapeuticfailureoflinezolid);rifampicinreducesplasmaconcentrationoflTELITHROMYCIN(avoidduringandfor2weeksafterrifampicin)lAnticoagulants:rifampicinpossiblyreducesplasmaconcentrationoflAPIXABAN—manufacturerofapixabanadvisesavoidconcomitantusewhengivenfortreatmentofdeep-veinthrombosisorpulmonaryembolism;rifamycinsacceleratemetabolismoflCOUMARINS(reducedanticoagulanteffect);rifampicinreducesplasmaconcentrationoflDABIGATRAN—manufacturerofdabigatranadvisesavoidconcomitantuse;rifampicinreducesplasmaconcentrationoflRIVAROXABAN—manufacturerofrivaroxabanadvisesmonitorforsignsofthrombosislAntidiabetics:rifamycinsacceleratemetabolismoflTOLBUTAMIDE(reducedeffect);rifampicinreducesplasmaconcentrationoflCANAGLIFLOZINandNATEGLINIDE;rifampicinpossiblyreduceseffectsofLINAGLIPTIN;rifampicinpossiblyantagoniseshypoglycaemiceffectofREPAGLINIDE;rifamycinspossiblyacceleratemetabolismoflSULFONYLUREAS(reducedeffect)lAntiepileptics:rifabutinreducesplasmaconcentrationoflCARBAMAZEPINE;rifamycinsacceleratemetabolismoflFOSPHENYTOINandlPHENYTOIN(reducedplasmaconcentration);rifampicinreducesplasmaconcentrationoflLAMOTRIGINE;plasmaconcentrationofrifampicinpossiblyreducedbyPHENOBARBITALandPRIMIDONERifamycins(continued)lAntifungals:rifampicinacceleratesmetabolismoflKETOCONAZOLE(reducedplasmaconcentration),alsoplasmaconcentrationofrifampicinmaybereducedbyketoconazole;plasmaconcentrationofrifabutinincreasedbylFLUCONAZOLE(increasedriskofuveitis—reducerifabutindose);rifampicinacceleratesmetabolismoflFLUCONAZOLE(reducedplasmaconcentration);rifabutinandrifampicinreduceplasmaconcentrationoflITRACONAZOLE—manufacturerofitraconazoleadvisesavoidconcomitantuse;plasmaconcentrationofrifabutinincreasedbylPOSACONAZOLE(alsoplasmaconcentrationofposaconazolereduced);rifampicinreducesplasmaconcentrationoflPOSACONAZOLEandlTERBINAFINE;plasmaconcentrationofrifabutinincreasedbylVORICONAZOLE,alsorifabutinreducesplasmaconcentrationofvoriconazole(increasedoseofvoriconazoleandalsomonitorforrifabutintoxicity);rifampicinreducesplasmaconcentrationoflVORICONAZOLE—avoidconcomitantuse;rifampicininitiallyincreasesandthenreducesplasmaconcentrationofCASPOFUNGIN(considerincreasingdoseofcaspofungin);plasmaconcentrationofrifabutinpossiblyincreasedbylTRIAZOLES(increasedriskofuveitis—reducerifabutindose) TRIANGLE Antihistamines:rifampicinpossiblyreduceseffectsofFEXOFENADINElAntimalarials:avoidanceofrifampicinadvisedbymanufacturerofARTENIMOLWITHPIPERAQUINE;rifampicinreducesplasmaconcentrationoflMEFLOQUINE—avoidconcomitantuse;rifampicinreducesplasmaconcentrationoflQUININE TRIANGLE Antimuscarinics:rifampicinreducesplasmaconcentrationofactivemetaboliteofFESOTERODINElAntipsychotics:rifampicinacceleratesmetabolismoflHALOPERIDOL(reducedplasmaconcentration);rifabutinandrifampicinpossiblyreduceplasmaconcentrationoflARIPIPRAZOLE(avoidconcomitantuseorconsiderincreasingthedoseofaripiprazole—consultaripiprazoleproductliterature);rifampicinpossiblyreducesplasmaconcentrationofCLOZAPINE;rifampicinreducesplasmaconcentrationoflLURASIDONE—avoidconcomitantuselAntivirals:rifampicinpossiblyreducesplasmaconcentrationofABACAVIR;plasmaconcentrationofrifabutinincreasedbylATAZANAVIR,lDARUNAVIR,lFOSAMPRENAVIRandlTIPRANAVIR(reducedoseofrifabutin);rifampicinreducesplasmaconcentrationoflATAZANAVIR,lDACLATASVIR,lLOPINAVIR,lNEVIRAPINEandlRILPIVIRINE—avoidconcomitantuse;avoidanceofrifampicinadvisedbymanufactureroflBOCEPREVIR(plasmaconcentrationofboceprevirpossiblyreduced);rifabutinpossiblyreducesplasmaconcentrationoflDACLATASVIRandSIMEPREVIR—manufacturerofdaclatasvirandsimepreviradvisesavoidconcomitantuse;rifampicinsignificantlyreducesplasmaconcentrationoflDARUNAVIR,lFOSAMPRENAVIRandlTELAPREVIR—avoidconcomitantuse;rifampicinreducestheplasmaconcentrationoflDOLUTEGRAVIR(seeunderDolutegravir,p557);rifampicinreducesplasmaconcentrationofEFAVIRENZ—increasedoseofefavirenz;plasmaconcentrationofrifabutinreducedbyEFAVIRENZ—increasedoseofrifabutin;avoidanceofrifampicinadvisedbymanufactureroflELVITEGRAVIR,ETRAVIRINE,SOFOSBUVIRandZIDOVUDINE;rifabutinreducesplasmaconcentrationoflELVITEGRAVIRalsoplasmaconcentrationofactivemetaboliteofrifabutinincreased—reducedoseofrifabutin;plasmaconcentrationofbothdrugsreducedwhenrifabutingivenwithlETRAVIRINE;rifampicinacceleratesmetabolismoflINDINAVIR(reducedplasmaconcentration—avoidconcomitantuse);plasmaconcentrationofrifabutinincreasedbylINDINAVIR,alsoplasmaconcentrationofindinavirdecreased(reducedoseofrifabutinandincreasedoseofindinavir);rifampicinreducesplasmaconcentrationoflMARAVIROCandlRALTEGRAVIR—considerincreasingdoseofmaravirocandraltegravir;plasmaconcentrationofrifabutinpossiblyincreasedbyNEVIRAPINE;rifabutindecreasesplasmaconcentrationoflRILPIVIRINE(increasedoseofrilpivirine—consultrilpivirineproductliterature);BNF70Appendix1Interactions1235Interactions|Appendix1"
"RifamycinslAntivirals(continued)plasmaconcentrationofrifabutinincreasedbylRITONAVIR(increasedriskoftoxicity—reducerifabutindose);rifampicinreducesplasmaconcentrationofRITONAVIR;rifampicinsignificantlyreducesplasmaconcentrationoflSAQUINAVIR,alsoriskofhepatotoxicity—avoidconcomitantuse;plasmaconcentrationofrifabutinincreasedbylSAQUINAVIR(alsoplasmaconcentrationofsaquinavirreduced)—reducerifabutindose;rifampicinreducesplasmaconcentrationoflSIMEPREVIR—manufacturerofsimepreviradvisesavoidconcomitantuse;avoidanceofrifabutinadvisedbymanufacturerofSOFOSBUVIRandlTELAPREVIR;rifampicinpossiblyreducesplasmaconcentrationoflTIPRANAVIR—avoidconcomitantuse TRIANGLE AnxiolyticsandHypnotics:rifampicinacceleratesmetabolismofDIAZEPAMandZALEPLON(reducedplasmaconcentration);rifampicinpossiblyacceleratesmetabolismofBENZODIAZEPINES(reducedplasmaconcentration);rifampicinpossiblyacceleratesmetabolismofBUSPIRONE;rifampicinacceleratesmetabolismofZOLPIDEM(reducedplasmaconcentrationandreducedeffect);rifampicinsignificantlyreducesplasmaconcentrationofZOPICLONE TRIANGLE Aprepitant:rifampicinreducesplasmaconcentrationofAPREPITANTlAtovaquone:avoidanceofconcomitantrifabutinadvisedbymanufacturerofATOVAQUONE(plasmaconcentrationofbothdrugsreduced);rifampicinreducesplasmaconcentrationoflATOVAQUONE(andconcentrationofrifampicinincreased)—avoidconcomitantuse TRIANGLE Avanafil:rifampicinpossiblyreducesplasmaconcentrationofAVANAFIL—manufacturerofavanafiladvisesavoidconcomitantuse TRIANGLE Beta-blockers:rifampicinacceleratesmetabolismofBISOPROLOLandPROPRANOLOL(plasmaconcentrationsignificantlyreduced);rifampicinreducesplasmaconcentrationofCARVEDILOL,CELIPROLOLandMETOPROLOL;rifampicinpossiblyreducesplasmaconcentrationoforalTIMOLOLlBosentan:rifampicinreducesplasmaconcentrationoflBOSENTAN—avoidconcomitantuselCalcium-channelBlockers:rifampicinpossiblyreducesplasmaconcentrationofFELODIPINE;rifampicinpossiblyacceleratesmetabolismoflISRADIPINEandlNICARDIPINE(possiblesignificantlyreducedplasmaconcentration);rifampicinacceleratesmetabolismoflDILTIAZEM,lNIFEDIPINE,lNIMODIPINEandlVERAPAMIL(plasmaconcentrationsignificantlyreduced)lCannabisExtract:rifampicinreducesplasmaconcentrationoflCANNABISEXTRACT—manufacturerofcannabisextractadvisesavoidconcomitantuse TRIANGLE CardiacGlycosides:rifampicinpossiblyreducesplasmaconcentrationofDIGOXINlCiclosporin:rifampicinacceleratesmetabolismoflCICLOSPORIN(reducedplasmaconcentration)lCobicistat:rifabutinreducesplasmaconcentrationoflCOBICISTAT(adjustdose—consultproductliterature);rifampicinpossiblyreducesplasmaconcentrationoflCOBICISTAT—manufacturerofcobicistatadvisesavoidconcomitantuselCorticosteroids:rifamycinsacceleratemetabolismoflCORTICOSTEROIDS(reducedeffect)lCytotoxics:rifampicinpossiblyreduceseffectsofBRENTUXIMABVEDOTIN;rifampicinreducesplasmaconcentrationofAFATINIB,RUXOLITINIB,SORAFENIBandlTRABECTEDIN;rifabutinpossiblydecreasesplasmaconcentrationofAXITINIB(increasedoseofaxitinib—consultaxitinibproductliterature);rifampicindecreasesplasmaconcentrationofAXITINIB(increasedoseofaxitinib—consultaxitinibproductliterature);rifabutinpossiblyreducesplasmaconcentrationoflBOSUTINIB,CRIZOTINIBandPONATINIB—manufacturerofbosutinib,crizotinibandponatinibadvisesavoidconcomitantuse;rifampicinreducesplasmaconcentrationoflBORTEZOMIB,lBOSUTINIB,lCABAZITAXEL,lCRIZOTINIB,lPONATINIB,lREGORAFENIBandlVANDETANIB—manufacturerofbortezomib,bosutinib,cabazitaxel,crizotinib,ponatinib,RifamycinslCytotoxics(continued)regorafenibandvandetanibadvisesavoidconcomitantuse;rifampicinreducesplasmaconcentrationoflCABOZANTINIB,lGEFITINIB,lIBRUTINIB,lIDELALISIB,lIMATINIBandlNILOTINIB—avoidconcomitantuse;avoidanceofrifampicinadvisedbymanufacturerofDABRAFENIB,lLAPATINIBandVEMURAFENIB;rifampicinacceleratesmetabolismoflDASATINIB(reducedplasmaconcentration—avoidconcomitantuse);rifampicinacceleratesmetabolismofERLOTINIBandSUNITINIB(reducedplasmaconcentration);rifampicinreducesplasmaconcentrationoflEVEROLIMUS(avoidconcomitantuseorconsiderincreasingthedoseofeverolimus—consulteverolimusproductliterature);avoidanceofrifabutinadvisedbymanufactureroflCABAZITAXEL,lLAPATINIBandVEMURAFENIB;rifampicinpossiblyreducesplasmaconcentrationofERIBULINandlPAZOPANIB;rifampicinreducesplasmaconcentrationofactivemetaboliteoflTEMSIROLIMUS—avoidconcomitantuse;rifampicinpossiblyreducesplasmaconcentrationoflVINFLUNINE—manufacturerofvinflunineadvisesavoidconcomitantuse;avoidanceofrifampicinadvisedbymanufactureroflVISMODEGIB(plasmaconcentrationofvismodegibpossiblyreduced) TRIANGLE Deferasirox:rifampicinreducesplasmaconcentrationofDEFERASIROXlDiuretics:rifampicinreducesplasmaconcentrationoflEPLERENONE—avoidconcomitantuse TRIANGLE Fosaprepitant:rifampicinreducesplasmaconcentrationofFOSAPREPITANTlHormoneAntagonists:rifabutinpossiblyreducesplasmaconcentrationoflABIRATERONE—manufacturerofabirateroneadvisesavoidconcomitantuse;rifampicinreducesplasmaconcentrationoflABIRATERONE—manufacturerofabirateroneadvisesavoidconcomitantuse;avoidanceofrifampicinadvisedbymanufacturerofENZALUTAMIDE;rifampicinpossiblyreducesplasmaconcentrationofEXEMESTANE;rifampicinacceleratesmetabolismofTAMOXIFEN(reducedplasmaconcentration) TRIANGLE 5HT3-receptorAntagonists:rifampicinacceleratesmetabolismofONDANSETRON(reducedeffect)lIvacaftor:rifabutinpossiblyreducesplasmaconcentrationoflIVACAFTOR—manufacturerofivacaftoradvisesavoidconcomitantuse;rifampicinreducesplasmaconcentrationoflIVACAFTOR—manufacturerofivacaftoradvisesavoidconcomitantuse TRIANGLE Leflunomide:rifampicinpossiblyincreasesplasmaconcentrationofactivemetaboliteofLEFLUNOMIDE TRIANGLE Lipid-regulatingDrugs:rifampicinpossiblyreducesplasmaconcentrationofATORVASTATINandSIMVASTATIN;rifampicinacceleratesmetabolismofFLUVASTATIN(reducedeffect)lMacitentan:rifampicinreducesplasmaconcentrationoflMACITENTAN—avoidconcomitantuse TRIANGLE MuscleRelaxants:rifampicinpossiblyreducesplasmaconcentrationofTIZANIDINElMycophenolate:rifampicinreducesplasmaconcentrationofactivemetaboliteoflMYCOPHENOLATElNintedanib:rifampicinreducesplasmaconcentrationoflNINTEDANIB—avoidconcomitantuselOestrogens:rifamycinsacceleratemetabolismoflOESTROGENS(reducedcontraceptiveeffectwithcombinedoralcontraceptives,contraceptivepatches,andvaginalrings—seeContraceptiveInteractionsinBNF)lProgestogens:rifamycinsacceleratemetabolismoflPROGESTOGENS(reducedcontraceptiveeffectwithcombinedoralcontraceptives,progestogen-onlyoralcontraceptives,contraceptivepatches,vaginalrings,etonogestrel-releasingimplant,andemergencyhormonalcontraception—seeContraceptiveInteractionsinBNF)lRanolazine:rifampicinreducesplasmaconcentrationoflRANOLAZINE—manufacturerofranolazineadvisesavoidconcomitantuselRoflumilast:rifampicininhibitseffectsoflROFLUMILAST(manufacturerofroflumilastadvisesavoidconcomitantuse)lSirolimus:rifabutinandrifampicinreduceplasmaconcentrationoflSIROLIMUS—avoidconcomitantuse1236Appendix1InteractionsBNF70Interactions|Appendix1"
"Rifamycins(continued)lTacrolimus:rifabutinpossiblyreducesplasmaconcentrationofTACROLIMUS;rifampicinreducesplasmaconcentrationoflTACROLIMUSlTadalafil:rifampicinreducesplasmaconcentrationoflTADALAFIL—manufactureroftadalafiladvisesavoidconcomitantuse TRIANGLE Teriflunomide:rifampicinreducesplasmaconcentrationofTERIFLUNOMIDE TRIANGLE Theophylline:rifampicinacceleratesmetabolismofTHEOPHYLLINE(reducedplasmaconcentration) TRIANGLE ThyroidHormones:rifampicinacceleratesmetabolismofLEVOTHYROXINE(mayincreaserequirementsforlevothyroxineinhypothyroidism) TRIANGLE Tibolone:rifampicinacceleratesmetabolismofTIBOLONE(reducedplasmaconcentration)lTicagrelor:rifampicinreducesplasmaconcentrationoflTICAGRELOR TRIANGLE Tolvaptan:rifampicinreducesplasmaconcentrationofTOLVAPTAN TRIANGLE Ulcer-healingDrugs:rifampicinacceleratesmetabolismofCIMETIDINE(reducedplasmaconcentration)lUlipristal:avoidanceofrifampicinadvisedbymanufactureroflULIPRISTAL(contraceptiveeffectofulipristalpossiblyreduced) TRIANGLE Vaccines:antibacterialsinactivateORALTYPHOIDVACCINE—seeunderTyphoidVaccineinBNFRilpivirine TRIANGLE Analgesics:rilpivirinepossiblyreducesplasmaconcentrationofMETHADONE TRIANGLE Antacids:manufacturerofrilpivirineadvisesgiveANTACIDS2hoursbeforeor4hoursafterrilpivirinelAntibacterials:manufacturerofrilpivirineadvisesavoidconcomitantusewithlCLARITHROMYCINandlERYTHROMYCIN(plasmaconcentrationofrilpivirinepossiblyincreased);plasmaconcentrationofrilpivirinedecreasedbylRIFABUTIN(increasedoseofrilpivirine—consultrilpivirineproductliterature);plasmaconcentrationofrilpivirinereducedbylRIFAMPICIN—avoidconcomitantuse TRIANGLE Anticoagulants:rilpivirinepossiblyincreasesplasmaconcentrationofDABIGATRANlAntidepressants:manufacturerofrilpivirineadvisesavoidconcomitantusewithlSTJOHN’SWORT(plasmaconcentrationofrilpivirinepossiblyreduced)lAntiepileptics:manufacturerofrilpivirineadvisesavoidconcomitantusewithlCARBAMAZEPINE,lFOSPHENYTOIN,lOXCARBAZEPINE,lPHENOBARBITAL,lPHENYTOINandlPRIMIDONE(plasmaconcentrationofrilpivirinepossiblyreduced) TRIANGLE Antivirals:manufacturerofrilpivirineadvisesgiveDIDANOSINE2hoursbeforeor4hoursafterrilpivirine;avoidanceofrilpivirineadvisedbymanufacturerofNEVIRAPINE TRIANGLE CalciumSalts:manufacturerofrilpivirineadvisesgiveCALCIUMSALTS2hoursbeforeor4hoursafterrilpivirinelCorticosteroids:manufacturerofrilpivirineadvisesavoidconcomitantusewithlDEXAMETHASONE(exceptwhengivenasasingledose)lOrlistat:absorptionofrilpivirinepossiblyreducedbylORLISTATlUlcer-healingDrugs:manufacturerofrilpivirineadvisesavoidconcomitantusewithESOMEPRAZOLE,LANSOPRAZOLE,PANTOPRAZOLEandRABEPRAZOLE(plasmaconcentrationofrilpivirinepossiblyreduced);plasmaconcentrationofrilpivirinereducedbylOMEPRAZOLE—avoidconcomitantuse;manufacturerofrilpivirineadvisesavoidHISTAMINEH2-ANTAGONISTSfor12hoursbeforeor4hoursafterrilpivirine—consultproductliteratureRiociguat TRIANGLE Antacids:absorptionofriociguatreducedbyANTACIDS(giveatleast2hoursbeforeor1hourafterriociguat) TRIANGLE Antifungals:manufacturerofriociguatadvisesavoidconcomitantusewithITRACONAZOLE,KETOCONAZOLEandVORICONAZOLE TRIANGLE Antivirals:manufacturerofriociguatadvisesavoidconcomitantusewithRITONAVIRRiociguat(continued)lAvanafil:possibleenhancedhypotensiveeffectwhenriociguatgivenwithlAVANAFIL—avoidconcomitantuse TRIANGLE Bosentan:plasmaconcentrationofriociguatreducedbyBOSENTANlNitrates:possibleenhancedhypotensiveeffectwhenriociguatgivenwithlNITRATES—avoidconcomitantuselSildenafil:enhancedhypotensiveeffectwhenriociguatgivenwithlSILDENAFIL—avoidconcomitantuselTadalafil:possibleenhancedhypotensiveeffectwhenriociguatgivenwithlTADALAFIL—avoidconcomitantuselVardenafil:possibleenhancedhypotensiveeffectwhenriociguatgivenwithlVARDENAFIL—avoidconcomitantuseRisedronateSodiumseeBisphosphonatesRisperidoneseeAntipsychoticsRitonavirlAlpha-blockers:ritonavirpossiblyincreasesplasmaconcentrationoflALFUZOSIN—avoidconcomitantuselAminophylline:ritonaviracceleratesmetabolismoflAMINOPHYLLINE(reducedplasmaconcentration)lAnalgesics:ritonavirpossiblyincreasesplasmaconcentrationofNSAIDSandBUPRENORPHINE;ritonavirincreasesplasmaconcentrationoflDEXTROPROPOXYPHENEandlPIROXICAM(riskoftoxicity)—avoidconcomitantuse;ritonavirincreasesplasmaconcentrationoflALFENTANILandlFENTANYL;ritonavirreducesplasmaconcentrationofMETHADONE;ritonavirpossiblyreducesplasmaconcentrationofMORPHINE;ritonavirreducesplasmaconcentrationoflPETHIDINE,butincreasesplasmaconcentrationoftoxicmetaboliteofpethidine(avoidconcomitantuse)lAnthelmintics:ritonavirpossiblyreducesplasmaconcentrationofactivemetaboliteoflALBENDAZOLE—considerincreasingalbendazoledosewhengivenforsystemicinfectionslAnti-arrhythmics:ritonavirincreasesplasmaconcentrationoflAMIODARONEandlPROPAFENONE(increasedriskofventriculararrhythmias—avoidconcomitantuse);ritonavirpossiblyincreasesplasmaconcentrationoflDISOPYRAMIDE(increasedriskoftoxicity);avoidanceofritonaviradvisedbymanufactureroflDRONEDARONE;ritonavirpossiblyincreasesplasmaconcentrationoflFLECAINIDE(increasedriskofventriculararrhythmias—avoidconcomitantuse)lAntibacterials:ritonavirpossiblyincreasesplasmaconcentrationofAZITHROMYCINandERYTHROMYCIN;ritonavirincreasesplasmaconcentrationoflCLARITHROMYCIN(reducedoseofclarithromycininrenalimpairment);ritonavirincreasesplasmaconcentrationoflRIFABUTIN(increasedriskoftoxicity—reducerifabutindose);plasmaconcentrationofritonavirreducedbyRIFAMPICIN;ritonavirpossiblyincreasesplasmaconcentrationofBEDAQUILINE—avoidconcomitantuseifritonavirgivenformorethan14days;ritonavirincreasesplasmaconcentrationofDELAMANID;plasmaconcentrationofbothdrugsincreasedwhenritonavirgivenwithlFUSIDICACID—avoidconcomitantuse;avoidanceofconcomitantritonavirinsevererenalandhepaticimpairmentadvisedbymanufactureroflTELITHROMYCINlAnticoagulants:ritonavirmayenhanceorreduceanticoagulanteffectoflWARFARIN;avoidanceofritonaviradvisedbymanufacturerofAPIXABAN;ritonavirpossiblyenhancesanticoagulanteffectoflCOUMARINSandlPHENINDIONE;ritonavirincreasesplasmaconcentrationoflRIVAROXABAN—avoidconcomitantuselAntidepressants:ritonavirpossiblyreducesplasmaconcentrationofPAROXETINE;ritonavirincreasesplasmaconcentrationoflTRAZODONE(increasedriskoftoxicity);ritonavirpossiblyincreasesplasmaconcentrationoflSSRISandlTRICYCLICS;plasmaconcentrationofritonavirreducedbylSTJOHN’SWORT—avoidconcomitantuse TRIANGLE Antidiabetics:ritonavirpossiblyincreasesplasmaconcentrationofTOLBUTAMIDElAntiepileptics:ritonavirpossiblyincreasesplasmaconcentrationoflCARBAMAZEPINE;plasmaconcentrationofritonavirpossiblyreducedbyFOSPHENYTOINandPHENYTOIN,alsoplasmaconcentrationoffosphenytoinandphenytoinpossiblyaffected;ritonavirpossiblyreducesplasmaBNF70Appendix1Interactions1237Interactions|Appendix1"
"RitonavirlAntiepileptics(continued)concentrationofLAMOTRIGINE,SODIUMVALPROATEandVALPROICACIDlAntifungals:ritonavirincreasesplasmaconcentrationoflKETOCONAZOLE(reducedoseofketoconazole);plasmaconcentrationofritonavirincreasedbyFLUCONAZOLE;combinationofritonavirwithlITRACONAZOLEmayincreaseplasmaconcentrationofeitherdrug(orboth);ritonavirreducesplasmaconcentrationoflVORICONAZOLE—avoidconcomitantuse TRIANGLE Antihistamines:ritonavirpossiblyincreasesplasmaconcentrationofNON-SEDATINGANTIHISTAMINESlAntimalarials:cautionwithritonaviradvisedbymanufacturerofARTEMETHERWITHLUMEFANTRINE;plasmaconcentrationofritonavirpossiblyreducedbyMEFLOQUINE;ritonavirincreasesplasmaconcentrationoflQUININE(increasedriskoftoxicity)lAntimuscarinics:avoidanceofritonaviradvisedbymanufacturerofDARIFENACINandTOLTERODINE;manufactureroffesoterodineadvisesdosereductionwhenritonavirgivenwithFESOTERODINE—consultfesoterodineproductliterature;ritonavirpossiblyincreasesplasmaconcentrationoflSOLIFENACIN—seeunderSolifenacin,p670lAntipsychotics:ritonavirpossiblyincreasesplasmaconcentrationoflANTIPSYCHOTICS;ritonavirpossiblyincreasesplasmaconcentrationoflARIPIPRAZOLE(reducedoseofaripiprazole—consultaripiprazoleproductliterature);manufacturerofritonaviradvisesavoidconcomitantusewithlCLOZAPINE(increasedriskoftoxicity);ritonavirpossiblyincreasesplasmaconcentrationoflLURASIDONE—avoidconcomitantuse;ritonavirreducesplasmaconcentrationofOLANZAPINE—considerincreasingdoseofolanzapine;ritonavirincreasesplasmaconcentrationoflPIMOZIDE(increasedriskofventriculararrhythmias—avoidconcomitantuse);ritonavirpossiblyincreasesplasmaconcentrationoflQUETIAPINE—manufacturerofquetiapineadvisesavoidconcomitantuselAntivirals:plasmaconcentrationofbothdrugsreducedwhenritonavirgivenwithlBOCEPREVIR;manufacturerofritonaviradvisesritonavirandDIDANOSINEshouldbetaken25hoursapart;ritonavirincreasesthetoxicityoflEFAVIRENZ,monitorliverfunctiontests—manufacturerofAtripla®advisesavoidconcomitantusewithhigh-doseritonavir;ritonavirincreasesplasmaconcentrationofINDINAVIR,MARAVIROCandlSAQUINAVIR;ritonavirincreasesplasmaconcentrationoflSIMEPREVIR—manufacturerofsimepreviradvisesavoidconcomitantuse;ritonavirpossiblyreducesplasmaconcentrationofTELAPREVIRlAnxiolyticsandHypnotics:ritonavirpossiblyincreasesplasmaconcentrationoflANXIOLYTICSANDHYPNOTICS;ritonavirpossiblyincreasesplasmaconcentrationoflALPRAZOLAM,lDIAZEPAM,lFLURAZEPAMandlZOLPIDEM(riskofextremesedationandrespiratorydepression—avoidconcomitantuse);ritonavirpossiblyincreasesplasmaconcentrationoflMIDAZOLAM(riskofprolongedsedation—avoidconcomitantuseoforalmidazolam);ritonavirincreasesplasmaconcentrationofBUSPIRONE(increasedriskoftoxicity) TRIANGLE Aprepitant:ritonavirpossiblyincreasesplasmaconcentrationofAPREPITANT TRIANGLE Atovaquone:ritonavirpossiblyreducesplasmaconcentrationofATOVAQUONE—manufacturerofatovaquoneadvisesavoidconcomitantuselAvanafil:ritonavirsignificantlyincreasesplasmaconcentrationoflAVANAFIL—avoidconcomitantuselBosentan:ritonavirincreasesplasmaconcentrationoflBOSENTAN(considerreducingdoseofbosentan) TRIANGLE Bupropion:ritonavirreducesplasmaconcentrationofBUPROPIONlCalcium-channelBlockers:ritonavirpossiblyincreasesplasmaconcentrationoflCALCIUM-CHANNELBLOCKERS;avoidanceofritonaviradvisedbymanufacturerofLERCANIDIPINE TRIANGLE CardiacGlycosides:ritonavirpossiblyincreasesplasmaconcentrationofDIGOXINlCiclosporin:ritonavirpossiblyincreasesplasmaconcentrationoflCICLOSPORINRitonavir(continued)lCilostazol:ritonavirpossiblyincreasesplasmaconcentrationoflCILOSTAZOL(seeunderCilostazol,p206)lColchicine:ritonavirpossiblyincreasesriskoflCOLCHICINEtoxicity—suspendorreducedoseofcolchicine(avoidconcomitantuseinhepaticorrenalimpairment)lCorticosteroids:ritonavirpossiblyincreasesplasmaconcentrationoflCORTICOSTEROIDS—increasedriskofadrenalsupression;ritonavirpossiblyincreasesplasmaconcentrationoflBUDESONIDE(includinginhaled,intranasal,andrectalbudesonide)—increasedriskofadrenalsuppresion;ritonavirincreasesplasmaconcentrationofinhaledandintranasallFLUTICASONE—increasedriskofadrenalsuppressionlCytotoxics:ritonavirincreasestheplasmaconcentrationofAFATINIB—manufacturerofafatinibadvisesseparatingadministrationofritonavirby6to12hours;ritonavirpossiblyincreasesplasmaconcentrationofAXITINIB(reducedoseofaxitinib—consultaxitinibproductliterature);ritonavirpossiblyincreasestheplasmaconcentrationoflBOSUTINIBandlCABAZITAXEL—manufacturerofbosutinibandcabazitaxeladvisesavoidorconsiderreducingdoseofbosutinibandcabazitaxel;ritonavirpossiblyincreasesplasmaconcentrationofCABOZANTINIBandVINBLASTINE;ritonavirpossiblyincreasesplasmaconcentrationoflCRIZOTINIB,lEVEROLIMUS,NILOTINIBandlVINFLUNINE—manufacturerofcrizotinib,everolimus,nilotinibandvinflunineadvisesavoidconcomitantuse;avoidanceofritonaviradvisedbymanufacturerofDASATINIB(plasmaconcentrationofdasatinibpossiblyincreased);ritonavirpossiblyincreasestheplasmaconcentrationoflIBRUTINIB—reducedoseofibrutinib(seeunderIbrutinib,p809);avoidanceofritonaviradvisedbymanufactureroflLAPATINIB;ritonavirpossiblyincreasesplasmaconcentrationoflPAZOPANIB(reducedoseofpazopanib);ritonavirpossiblyincreasesplasmaconcentrationofPONATINIB—considerreducinginitialdoseofponatinib(seeunderPonatinib,p814);manufacturerofruxolitinibadvisesdosereductionwhenritonavirgivenwithlRUXOLITINIB—consultruxolitinibproductliterature;ritonavirpossiblyincreasesplasmaconcentrationoflDOCETAXEL—manufacturerofdocetaxeladvisesavoidconcomitantuseorconsiderreducingdocetaxeldose;ritonavirincreasesplasmaconcentrationofPACLITAXELlDapoxetine:avoidanceofritonaviradvisedbymanufactureroflDAPOXETINE(increasedriskoftoxicity)lDiuretics:ritonavirincreasesplasmaconcentrationoflEPLERENONE—avoidconcomitantuselDomperidone:possibleincreasedriskofventriculararrhythmiaswhenritonavirgivenwithlDOMPERIDONE—avoidconcomitantuselErgotAlkaloids:increasedriskofergotismwhenritonavirgivenwithlERGOMETRINEorlERGOTAMINE—avoidconcomitantuse TRIANGLE Fosaprepitant:ritonavirpossiblyincreasesplasmaconcentrationofFOSAPREPITANTl5HT1-receptorAgonists:ritonavirincreasesplasmaconcentrationoflELETRIPTAN(riskoftoxicity)—avoidconcomitantuselIvabradine:ritonavirpossiblyincreasesplasmaconcentrationoflIVABRADINE—avoidconcomitantuselLipid-regulatingDrugs:possibleincreasedriskofmyopathywhenritonavirgivenwithATORVASTATIN;possibleincreasedriskofmyopathywhenritonavirgivenwithlROSUVASTATIN—manufacturerofrosuvastatinadvisesavoidconcomitantuse;increasedriskofmyopathywhenritonavirgivenwithlSIMVASTATIN(avoidconcomitantuse);avoidanceofritonaviradvisedbymanufactureroflLOMITAPIDE(plasmaconcentrationoflomitapidepossiblyincreased) TRIANGLE Mirabegron:whengivenwithritonaviravoidorreducedoseofMIRABEGRONinhepaticorrenalimpairment—seeMirabegron,p671lOestrogens:ritonaviracceleratesmetabolismoflOESTROGENS(reducedcontraceptiveeffectwithcombinedoralcontraceptives,contraceptivepatches,andvaginalrings—seeContraceptiveInteractionsinBNF)1238Appendix1InteractionsBNF70Interactions|Appendix1"
"Ritonavir(continued)lOrlistat:absorptionofritonavirpossiblyreducedbylORLISTATlRanolazine:ritonavirpossiblyincreasesplasmaconcentrationoflRANOLAZINE—manufacturerofranolazineadvisesavoidconcomitantuse TRIANGLE Riociguat:avoidanceofritonaviradvisedbymanufacturerofRIOCIGUATlSildenafil:ritonavirsignificantlyincreasesplasmaconcentrationoflSILDENAFIL—avoidconcomitantuse TRIANGLE Sympathomimetics:ritonavirpossiblyincreasesplasmaconcentrationofDEXAMFETAMINE TRIANGLE Sympathomimetics,Beta2:manufacturerofritonaviradvisesavoidconcomitantusewithSALMETEROLlTacrolimus:ritonavirpossiblyincreasesplasmaconcentrationoflTACROLIMUSlTadalafil:ritonavirincreasesplasmaconcentrationoflTADALAFIL—manufactureroftadalafiladvisesavoidconcomitantuselTheophylline:ritonaviracceleratesmetabolismoflTHEOPHYLLINE(reducedplasmaconcentration)lTicagrelor:ritonavirpossiblyincreasesplasmaconcentrationoflTICAGRELOR—manufacturerofticagreloradvisesavoidconcomitantuselUlipristal:avoidanceofritonaviradvisedbymanufactureroflULIPRISTAL(contraceptiveeffectofulipristalpossiblyreduced)lVardenafil:ritonavirincreasesplasmaconcentrationoflVARDENAFIL—avoidconcomitantuseRituximablAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lVaccines:riskofgeneralisedinfectionswhenmonoclonalantibodiesgivenwithlivelVACCINES—avoidconcomitantuseRivaroxabanlAnalgesics:increasedriskofhaemorrhagewhenanticoagulantsgivenwithintravenouslDICLOFENAC(avoidconcomitantuse,includinglow-doseheparins);increasedriskofhaemorrhagewhenanticoagulantsgivenwithlKETOROLAC(avoidconcomitantuse,includinglow-doseheparins) TRIANGLE Anti-arrhythmics:manufacturerofrivaroxabanadvisesavoidconcomitantusewithDRONEDARONElAntibacterials:plasmaconcentrationofrivaroxabanreducedbylRIFAMPICIN—manufacturerofrivaroxabanadvisesmonitorforsignsofthrombosislAnticoagulants:increasedriskofhaemorrhagewhenrivaroxabangivenwithotherlANTICOAGULANTS(avoidconcomitantuseexceptwhenswitchingwithotheranticoagulantsorusingheparintomaintaincatheterpatency);increasedriskofhaemorrhagewhenotheranticoagulantsgivenwithlAPIXABANandlDABIGATRAN(avoidconcomitantuseexceptwhenswitchingwithotheranticoagulantsorusingheparintomaintaincatheterpatency)lAntidepressants:plasmaconcentrationofrivaroxabanpossiblyreducedbylSTJOHN’SWORT—manufacturerofrivaroxabanadvisesmonitorforsignsofthrombosislAntiepileptics:plasmaconcentrationofrivaroxabanpossiblyreducedbylCARBAMAZEPINE,lFOSPHENYTOIN,lPHENOBARBITAL,lPHENYTOINandlPRIMIDONE—manufacturerofrivaroxabanadvisesmonitorforsignsofthrombosislAntifungals:plasmaconcentrationofrivaroxabanincreasedbylKETOCONAZOLE—avoidconcomitantuse;manufacturerofrivaroxabanadvisesavoidconcomitantusewithITRACONAZOLE,POSACONAZOLEandVORICONAZOLElAntivirals:manufacturerofrivaroxabanadvisesavoidconcomitantusewithATAZANAVIR,DARUNAVIR,FOSAMPRENAVIR,INDINAVIR,SAQUINAVIRandTIPRANAVIR;manufacturersadviseavoidconcomitantuseofrivaroxabanwithLOPINAVIR;plasmaconcentrationofrivaroxabanincreasedbylRITONAVIR—avoidconcomitantuselCobicistat:anticoagulanteffectofrivaroxabanpossiblyenhancedbylCOBICISTAT—avoidconcomitantuseRivastigmineseeParasympathomimeticsRizatriptansee5HT1-receptorAgonists(underHT)RocuroniumseeMuscleRelaxantsRoflumilast TRIANGLE Aminophylline:manufacturerofroflumilastadvisesavoidconcomitantusewithAMINOPHYLLINElAntibacterials:effectsofroflumilastinhibitedbylRIFAMPICIN(manufacturerofroflumilastadvisesavoidconcomitantuse) TRIANGLE Antidepressants:metabolismofroflumilastinhibitedbyFLUVOXAMINE TRIANGLE Antiepileptics:effectsofroflumilastpossiblyinhibitedbyCARBAMAZEPINE,FOSPHENYTOIN,PHENOBARBITAL,PHENYTOINandPRIMIDONE(manufacturerofroflumilastadvisesavoidconcomitantuse) TRIANGLE Theophylline:manufacturerofroflumilastadvisesavoidconcomitantusewithTHEOPHYLLINE TRIANGLE Ulcer-healingDrugs:metabolismofroflumilastinhibitedbyCIMETIDINERopinirole TRIANGLE Antibacterials:metabolismofropiniroleinhibitedbyCIPROFLOXACIN(increasedplasmaconcentration) TRIANGLE Antipsychotics:manufacturerofropiniroleadvisesavoidconcomitantuseofANTIPSYCHOTICS(antagonismofeffect) TRIANGLE Memantine:effectsofdopaminergicspossiblyenhancedbyMEMANTINE TRIANGLE Methyldopa:antiparkinsonianeffectofdopaminergicsantagonisedbyMETHYLDOPA TRIANGLE Metoclopramide:manufacturerofropiniroleadvisesavoidconcomitantuseofMETOCLOPRAMIDE(antagonismofeffect) TRIANGLE Oestrogens:plasmaconcentrationofropiniroleincreasedbyOESTROGENSRopivacaine TRIANGLE Anti-arrhythmics:increasedmyocardialdepressionwhenropivacainegivenwithANTI-ARRHYTHMICS TRIANGLE Antidepressants:metabolismofropivacaineinhibitedbyFLUVOXAMINE—avoidprolongedadministrationofropivacaineRosuvastatinseeStatinsRotavirusVaccineseeVaccinesRotigotine TRIANGLE Antipsychotics:manufacturerofrotigotineadvisesavoidconcomitantuseofANTIPSYCHOTICS(antagonismofeffect) TRIANGLE Memantine:effectsofdopaminergicspossiblyenhancedbyMEMANTINE TRIANGLE Methyldopa:antiparkinsonianeffectofdopaminergicsantagonisedbyMETHYLDOPA TRIANGLE Metoclopramide:manufacturerofrotigotineadvisesavoidconcomitantuseofMETOCLOPRAMIDE(antagonismofeffect)RufinamidelAntidepressants:anticonvulsanteffectofantiepilepticspossiblyantagonisedbyMAOISandlTRICYCLIC-RELATEDANTIDEPRESSANTS(convulsivethresholdlowered);anticonvulsanteffectofantiepilepticsantagonisedbylSSRISandlTRICYCLICS(convulsivethresholdlowered) TRIANGLE Antiepileptics:plasmaconcentrationofbothdrugspossiblyreducedwhenrufinamidegivenwithCARBAMAZEPINE;plasmaconcentrationofrufinamidepossiblyreducedbyFOSPHENYTOINandPHENYTOIN,alsoplasmaconcentrationoffosphenytoinandphenytoinpossiblyincreased;plasmaconcentrationofrufinamidepossiblyreducedbyPHENOBARBITALandPRIMIDONE;plasmaconcentrationofrufinamidepossiblyincreasedbySODIUMVALPROATEandVALPROICACID(reducedoseofrufinamide)lAntimalarials:anticonvulsanteffectofantiepilepticsantagonisedbylMEFLOQUINElAntipsychotics:anticonvulsanteffectofantiepilepticsantagonisedbylANTIPSYCHOTICS(convulsivethresholdlowered)lOestrogens:rufinamideacceleratesmetabolismoflOESTROGENS(reducedcontraceptiveeffectwithcombinedoralcontraceptives,contraceptivepatches,andvaginalrings—seeContraceptiveInteractionsinBNF)lOrlistat:possibleincreasedriskofconvulsionswhenantiepilepticsgivenwithlORLISTATlProgestogens:rufinamideacceleratesmetabolismoflPROGESTOGENS(reducedcontraceptiveeffectwithcombinedoralcontraceptives,progestogen-onlyoralcontraceptives,BNF70Appendix1Interactions1239Interactions|Appendix1"
"RufinamidelProgestogens(continued)contraceptivepatches,vaginalrings,etonogestrel-releasingimplant,andemergencyhormonalcontraception—seeContraceptiveInteractionsinBNF)RuxolitiniblAntibacterials:manufacturerofruxolitinibadvisesdosereductionwhenruxolitinibgivenwithlCLARITHROMYCINandlTELITHROMYCIN—consultruxolitinibproductliterature;plasmaconcentrationofruxolitinibreducedbyRIFAMPICINlAntifungals:manufacturerofruxolitinibadvisesdosereductionwhenruxolitinibgivenwithlFLUCONAZOLE,lITRACONAZOLE,lKETOCONAZOLE,lPOSACONAZOLEandlVORICONAZOLE—consultruxolitinibproductliteraturelAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lAntivirals:manufacturerofruxolitinibadvisesdosereductionwhenruxolitinibgivenwithlBOCEPREVIR,lINDINAVIR,lLOPINAVIR,lRITONAVIR,lSAQUINAVIRandlTELAPREVIR—consultruxolitinibproductliteratureStJohn’sWort TRIANGLE Aminophylline:StJohn’swortpossiblyreducesplasmaconcentrationofAMINOPHYLLINE TRIANGLE Analgesics:StJohn’swortpossiblyreducesplasmaconcentrationofMETHADONElAnti-arrhythmics:StJohn’swortpossiblyreducesplasmaconcentrationoflDRONEDARONE—avoidconcomitantuselAntibacterials:StJohn’swortpossiblyreducesplasmaconcentrationofBEDAQUILINE—manufacturerofbedaquilineadvisesavoidconcomitantuse;StJohn’swortreducesplasmaconcentrationoflTELITHROMYCIN(avoidduringandfor2weeksafterStJohn’swort)lAnticoagulants:StJohn’swortpossiblyreducesplasmaconcentrationoflAPIXABAN—manufacturerofapixabanadvisesavoidconcomitantusewhengivenfortreatmentofdeep-veinthrombosisorpulmonaryembolism;StJohn’swortreducesanticoagulanteffectoflCOUMARINS(avoidconcomitantuse);StJohn’swortpossiblyreducesplasmaconcentrationofDABIGATRAN—manufacturerofdabigatranadvisesavoidconcomitantuse;StJohn’swortpossiblyreducesplasmaconcentrationoflRIVAROXABAN—manufacturerofrivaroxabanadvisesmonitorforsignsofthrombosislAntidepressants:possibleincreasedserotonergiceffectswhenStJohn’swortgivenwithDULOXETINEorVENLAFAXINE;StJohn’swortreducesplasmaconcentrationofAMITRIPTYLINE;increasedserotonergiceffectswhenStJohn’swortgivenwithlSSRIS—avoidconcomitantuselAntiepileptics:StJohn’swortpossiblyreducesplasmaconcentrationofCARBAMAZEPINE;StJohn’swortpossiblyreducesplasmaconcentrationoflFOSPHENYTOIN,lPHENOBARBITAL,lPHENYTOINandlPRIMIDONE—avoidconcomitantuselAntifungals:StJohn’swortreducesplasmaconcentrationoflVORICONAZOLE—avoidconcomitantuselAntimalarials:avoidanceofantidepressantsadvisedbymanufactureroflARTEMETHERWITHLUMEFANTRINEandlARTENIMOLWITHPIPERAQUINElAntipsychotics:StJohn’swortpossiblyreducesplasmaconcentrationoflARIPIPRAZOLE(avoidconcomitantuseorconsiderincreasingthedoseofaripiprazole—consultaripiprazoleproductliterature);StJohn’swortpossiblyreducesplasmaconcentrationoflLURASIDONE—avoidconcomitantuselAntivirals:StJohn’swortreducesplasmaconcentrationoflATAZANAVIR,lDARUNAVIR,lEFAVIRENZ,lFOSAMPRENAVIR,lINDINAVIR,lLOPINAVIR,lNEVIRAPINE,lRITONAVIRandlSAQUINAVIR—avoidconcomitantuse;StJohn’swortpossiblyreducesplasmaconcentrationofDACLATASVIRandlSIMEPREVIR—manufacturerofdaclatasvirandsimepreviradvisesavoidconcomitantuse;avoidanceofStJohn’swortadvisedbymanufacturerofDOLUTEGRAVIR,lELVITEGRAVIR,ETRAVIRINE,SOFOSBUVIRandlTELAPREVIR;StJohn’swortpossiblyreducesplasmaconcentrationoflMARAVIROCandlTIPRANAVIR—avoidconcomitantuse;avoidanceofStJohn’sStJohn’sWortlAntivirals(continued)wortadvisedbymanufactureroflRILPIVIRINE(plasmaconcentrationofrilpivirinepossiblyreduced) TRIANGLE AnxiolyticsandHypnotics:StJohn’swortpossiblyreducesplasmaconcentrationoforalMIDAZOLAMlAprepitant:avoidanceofStJohn’swortadvisedbymanufactureroflAPREPITANT TRIANGLE Atomoxetine:possibleincreasedriskofconvulsionswhenantidepressantsgivenwithATOMOXETINElCalcium-channelBlockers:StJohn’swortpossiblyreducesplasmaconcentrationofAMLODIPINEandFELODIPINE;StJohn’swortreducesplasmaconcentrationofNIFEDIPINE;StJohn’swortsignificantlyreducesplasmaconcentrationoflVERAPAMILlCannabisExtract:StJohn’swortpossiblyreducesplasmaconcentrationoflCANNABISEXTRACT—manufacturerofcannabisextractadvisesavoidconcomitantuselCardiacGlycosides:StJohn’swortreducesplasmaconcentrationoflDIGOXIN—avoidconcomitantuselCiclosporin:StJohn’swortreducesplasmaconcentrationoflCICLOSPORIN—avoidconcomitantuselCobicistat:StJohn’swortpossiblyreducesplasmaconcentrationoflCOBICISTAT—manufacturerofcobicistatadvisesavoidconcomitantuselCytotoxics:StJohn’swortpossiblyreducesplasmaconcentrationofAXITINIB—considerincreasingdoseofaxitinib;StJohn’swortpossiblyreducesplasmaconcentrationofBORTEZOMIB,lBOSUTINIB,CABOZANTINIB,CRIZOTINIB,EVEROLIMUS,lIBRUTINIB,lIDELALISIB,PONATINIBandlVINFLUNINE—manufacturerofbortezomib,bosutinib,cabozantinib,crizotinib,everolimus,ibrutinib,idelalisib,ponatinibandvinflunineadvisesavoidconcomitantuse;avoidanceofStJohn’swortadvisedbymanufactureroflCABAZITAXEL,DABRAFENIB,GEFITINIB,lLAPATINIBandVEMURAFENIB;StJohn’swortreducesplasmaconcentrationoflIMATINIB—avoidconcomitantuse;avoidanceofStJohn’swortadvisedbymanufacturerofVANDETANIBandlVISMODEGIB(plasmaconcentrationofvandetanibandvismodegibpossiblyreduced);StJohn’swortpossiblyreducesplasmaconcentrationofERIBULIN;StJohn’swortacceleratesmetabolismoflIRINOTECAN(reducedplasmaconcentration—avoidconcomitantuse)lDapoxetine:possibleincreasedriskofserotonergiceffectswhenStJohn’swortgivenwithlDAPOXETINE(manufacturerofdapoxetineadvisesStJohn’swortshouldnotbestarteduntil1weekafterstoppingdapoxetine,avoiddapoxetinefor2weeksafterstoppingStJohn’swort)lDiuretics:StJohn’swortreducesplasmaconcentrationoflEPLERENONE—avoidconcomitantuse TRIANGLE Fingolimod:StJohn’swortpossiblyreducesplasmaconcentrationofFINGOLIMOD—manufactureroffingolimodadvisesavoidconcomitantuselFosaprepitant:avoidanceofStJohn’swortadvisedbymanufactureroflFOSAPREPITANTlHormoneAntagonists:StJohn’swortpossiblyreducesplasmaconcentrationoflABIRATERONE—manufacturerofabirateroneadvisesavoidconcomitantusel5HT1-receptorAgonists:increasedserotonergiceffectswhenStJohn’swortgivenwithl5HT1AGONISTS—avoidconcomitantuse TRIANGLE Ivabradine:StJohn’swortreducesplasmaconcentrationofIVABRADINE—avoidconcomitantuselIvacaftor:StJohn’swortpossiblyreducesplasmaconcentrationoflIVACAFTOR—manufacturerofivacaftoradvisesavoidconcomitantuse TRIANGLE Lipid-regulatingDrugs:StJohn’swortreducesplasmaconcentrationofSIMVASTATIN TRIANGLE Macitentan:avoidanceofStJohn’swortadvisedbymanufacturerofMACITENTANlOestrogens:StJohn’swortreducescontraceptiveeffectoflOESTROGENS(avoidconcomitantuse)lProgestogens:StJohn’swortreducescontraceptiveeffectoflPROGESTOGENS(avoidconcomitantuse)lTacrolimus:StJohn’swortreducesplasmaconcentrationoflTACROLIMUS—avoidconcomitantuse1240Appendix1InteractionsBNF70Interactions|Appendix1"
"StJohn’sWort(continued) TRIANGLE Theophylline:StJohn’swortpossiblyreducesplasmaconcentrationofTHEOPHYLLINE TRIANGLE Ulcer-healingDrugs:StJohn’swortpossiblyreducesplasmaconcentrationofOMEPRAZOLElUlipristal:avoidanceofStJohn’swortadvisedbymanufactureroflULIPRISTAL(contraceptiveeffectofulipristalpossiblyreduced)SalbutamolseeSympathomimetics,Beta2SalmeterolseeSympathomimetics,Beta2SaquinavirlAnalgesics:increasedriskofventriculararrhythmiaswhensaquinavirgivenwithlALFENTANIL,lFENTANYLorlMETHADONE—avoidconcomitantuselAnti-arrhythmics:increasedriskofventriculararrhythmiaswhensaquinavirgivenwithlAMIODARONE,lDISOPYRAMIDE,lDRONEDARONE,lFLECAINIDE,lLIDOCAINEorlPROPAFENONE—avoidconcomitantuselAntibacterials:plasmaconcentrationofbothdrugspossiblyincreasedwhensaquinavirgivenwithlCLARITHROMYCIN(increasedriskofventriculararrhythmias);increasedriskofventriculararrhythmiaswhensaquinavirgivenwithlDAPSONE,lERYTHROMYCINorlMOXIFLOXACIN—avoidconcomitantuse;saquinavirincreasesplasmaconcentrationoflRIFABUTIN(alsoplasmaconcentrationofsaquinavirreduced)—reducerifabutindose;plasmaconcentrationofsaquinavirsignificantlyreducedbylRIFAMPICIN,alsoriskofhepatotoxicity—avoidconcomitantuse;increasedriskofventriculararrhythmiaswhensaquinavirgivenwithlDELAMANID;plasmaconcentrationofbothdrugsmayincreasewhensaquinavirgivenwithFUSIDICACID;avoidanceofsaquinaviradvisedbymanufactureroflTELITHROMYCIN(riskofventriculararrhythmias) TRIANGLE Anticoagulants:saquinavirpossiblyenhancesanticoagulanteffectofWARFARIN;avoidanceofsaquinaviradvisedbymanufacturerofAPIXABANandRIVAROXABANlAntidepressants:increasedriskofventriculararrhythmiaswhensaquinavirgivenwithlTRAZODONEorlTRICYCLICS—avoidconcomitantuse;plasmaconcentrationofsaquinavirreducedbylSTJOHN’SWORT—avoidconcomitantuselAntiepileptics:plasmaconcentrationofsaquinavirpossiblyreducedbyCARBAMAZEPINE,FOSPHENYTOIN,lPHENOBARBITAL,PHENYTOINandlPRIMIDONElAntifungals:plasmaconcentrationofsaquinavirincreasedbylKETOCONAZOLE—manufacturerofketoconazoleadvisesavoidconcomitantuse;plasmaconcentrationofsaquinavirpossiblyincreasedbyIMIDAZOLESandTRIAZOLESlAntihistamines:increasedriskofventriculararrhythmiaswhensaquinavirgivenwithlMIZOLASTINE—avoidconcomitantuselAntimalarials:cautionwithsaquinaviradvisedbymanufacturerofARTEMETHERWITHLUMEFANTRINE;avoidanceofsaquinaviradvisedbymanufactureroflARTENIMOLWITHPIPERAQUINE(possibleriskofventriculararrhythmias);increasedriskofventriculararrhythmiaswhensaquinavirgivenwithlQUININE—avoidconcomitantuse TRIANGLE Antimuscarinics:avoidanceofsaquinaviradvisedbymanufacturerofDARIFENACINandTOLTERODINE;manufactureroffesoterodineadvisesdosereductionwhensaquinavirgivenwithFESOTERODINE—consultfesoterodineproductliteraturelAntipsychotics:increasedriskofventriculararrhythmiaswhensaquinavirgivenwithlCLOZAPINE,lHALOPERIDOLorlPHENOTHIAZINES—avoidconcomitantuse;saquinavirpossiblyincreasesplasmaconcentrationoflARIPIPRAZOLE(reducedoseofaripiprazole—consultaripiprazoleproductliterature);saquinavirpossiblyincreasesplasmaconcentrationoflLURASIDONE—avoidconcomitantuse;saquinavirpossiblyincreasesplasmaconcentrationoflPIMOZIDE(increasedriskofventriculararrhythmias—avoidconcomitantuse);saquinavirpossiblyincreasesplasmaconcentrationoflQUETIAPINE—manufacturerofquetiapineadvisesavoidconcomitantuselAntivirals:increasedriskofventriculararrhythmiaswhensaquinavirgivenwithlATAZANAVIRorlLOPINAVIR—avoidconcomitantuse;saquinavirreducesplasmaconcentrationofDARUNAVIR;plasmaconcentrationofsaquinavirsignificantlySaquinavirlAntivirals(continued)reducedbyEFAVIRENZ;plasmaconcentrationofsaquinavirincreasedbyINDINAVIRandlRITONAVIR;saquinavirincreasesplasmaconcentrationoflMARAVIROC(considerreducingdoseofmaraviroc);plasmaconcentrationofsaquinavirreducedbylTIPRANAVIRlAnxiolyticsandHypnotics:saquinavirincreasesplasmaconcentrationoflMIDAZOLAM(riskofprolongedsedation—avoidconcomitantuseoforalmidazolam)lAvanafil:saquinavirpossiblyincreasesplasmaconcentrationoflAVANAFIL—manufacturerofavanafiladvisesavoidconcomitantuselBeta-blockers:increasedriskofventriculararrhythmiaswhensaquinavirgivenwithlSOTALOL—avoidconcomitantuselCiclosporin:plasmaconcentrationofbothdrugsincreasedwhensaquinavirgivenwithlCICLOSPORIN TRIANGLE Corticosteroids:plasmaconcentrationofsaquinavirpossiblyreducedbyDEXAMETHASONElCytotoxics:saquinavirpossiblyincreasestheplasmaconcentrationofAFATINIB—manufacturerofafatinibadvisesseparatingadministrationofsaquinavirby6to12hours;saquinavirpossiblyincreasesplasmaconcentrationofAXITINIB(reducedoseofaxitinib—consultaxitinibproductliterature);saquinavirpossiblyincreasestheplasmaconcentrationoflBOSUTINIBandlCABAZITAXEL—manufacturerofbosutinibandcabazitaxeladvisesavoidorconsiderreducingdoseofbosutinibandcabazitaxel;saquinavirpossiblyincreasesplasmaconcentrationoflCRIZOTINIBandlEVEROLIMUS—manufacturerofcrizotinibandeverolimusadvisesavoidconcomitantuse;saquinavirpossiblyincreasestheplasmaconcentrationoflIBRUTINIB—reducedoseofibrutinib(seeunderIbrutinib,p809);avoidanceofsaquinaviradvisedbymanufactureroflLAPATINIB;increasedriskofventriculararrhythmiaswhensaquinavirgivenwithlPAZOPANIB—avoidconcomitantuse;saquinavirpossiblyincreasesplasmaconcentrationofPONATINIB—considerreducinginitialdoseofponatinib(seeunderPonatinib,p814);manufacturerofruxolitinibadvisesdosereductionwhensaquinavirgivenwithlRUXOLITINIB—consultruxolitinibproductliterature;saquinavirpossiblyincreasesplasmaconcentrationoflDOCETAXEL—manufacturerofdocetaxeladvisesavoidconcomitantuseorconsiderreducingdocetaxeldoselDapoxetine:avoidanceofsaquinaviradvisedbymanufactureroflDAPOXETINE(increasedriskoftoxicity) TRIANGLE Diuretics:saquinavirincreasesplasmaconcentrationofEPLERENONE(reducedoseofeplerenone)lDomperidone:possibleincreasedriskofventriculararrhythmiaswhensaquinavirgivenwithlDOMPERIDONE—avoidconcomitantuselErgotAlkaloids:increasedriskofergotismwhensaquinavirgivenwithlERGOTAMINE—avoidconcomitantuselLipid-regulatingDrugs:possibleincreasedriskofmyopathywhensaquinavirgivenwithATORVASTATIN;possibleincreasedriskofmyopathywhensaquinavirgivenwithlROSUVASTATIN—manufacturerofrosuvastatinadvisesavoidconcomitantuse;increasedriskofmyopathywhensaquinavirgivenwithlSIMVASTATIN(avoidconcomitantuse);avoidanceofsaquinaviradvisedbymanufactureroflLOMITAPIDE(plasmaconcentrationoflomitapidepossiblyincreased)lOrlistat:absorptionofsaquinavirpossiblyreducedbylORLISTATlPentamidineIsetionate:increasedriskofventriculararrhythmiaswhensaquinavirgivenwithlPENTAMIDINEISETIONATE—avoidconcomitantuselRanolazine:saquinavirpossiblyincreasesplasmaconcentrationoflRANOLAZINE—manufacturerofranolazineadvisesavoidconcomitantuselSildenafil:increasedriskofventriculararrhythmiaswhensaquinavirgivenwithlSILDENAFIL—avoidconcomitantuselTacrolimus:saquinavirincreasesplasmaconcentrationoflTACROLIMUS(considerreducingdoseoftacrolimus)lTadalafil:increasedriskofventriculararrhythmiaswhensaquinavirgivenwithlTADALAFIL—avoidconcomitantuseBNF70Appendix1Interactions1241Interactions|Appendix1"
"Saquinavir(continued)lUlcer-healingDrugs:plasmaconcentrationofsaquinavirpossiblyincreasedbyCIMETIDINE;plasmaconcentrationofsaquinavirpossiblyincreasedbylESOMEPRAZOLE,lLANSOPRAZOLE,lPANTOPRAZOLEandlRABEPRAZOLE—manufacturerofsaquinaviradvisesavoidconcomitantuse;plasmaconcentrationofsaquinavirincreasedbylOMEPRAZOLE—manufacturerofsaquinaviradvisesavoidconcomitantuselVardenafil:increasedriskofventriculararrhythmiaswhensaquinavirgivenwithlVARDENAFIL—avoidconcomitantuseSaxagliptinseeAntidiabeticsSelegilineNOTESelegilineisaMAO-BinhibitorlAnalgesics:hyperpyrexiaandCNStoxicityreportedwhenselegilinegivenwithlPETHIDINE(avoidconcomitantuse);manufacturerofselegilineadvisesavoidconcomitantusewithOPIOIDANALGESICSlAntidepressants:manufacturerofselegilineadvisesavoidconcomitantusewithCITALOPRAMandESCITALOPRAM;increasedriskofhypertensionandCNSexcitationwhenselegilinegivenwithlFLUOXETINE(selegilineshouldnotbestarteduntil5weeksafterstoppingfluoxetine,avoidfluoxetinefor2weeksafterstoppingselegiline);increasedriskofhypertensionandCNSexcitationwhenselegilinegivenwithlFLUVOXAMINE,lSERTRALINEorlVENLAFAXINE(selegilineshouldnotbestarteduntil1weekafterstoppingfluvoxamine,sertralineorvenlafaxine,avoidfluvoxamine,sertralineorvenlafaxinefor2weeksafterstoppingselegiline);increasedriskofhypertensionandCNSexcitationwhenselegilinegivenwithlPAROXETINE(selegilineshouldnotbestarteduntil2weeksafterstoppingparoxetine,avoidparoxetinefor2weeksafterstoppingselegiline);enhancedhypotensiveeffectwhenselegilinegivenwithlMAOIS—manufacturerofselegilineadvisesavoidconcomitantuse;avoidconcomitantuseofselegilinewithlMOCLOBEMIDE;CNStoxicityreportedwhenselegilinegivenwithlTRICYCLICS TRIANGLE Dopaminergics:selegilineenhanceseffectsandincreasestoxicityofCO-BENELDOPA,CO-CARELDOPAorLEVODOPA(reducedoseofco-beneldopa,co-careldopaorlevodopa);maxdoseof10mgselegilineadvisedbymanufacturerofENTACAPONEifusedconcomitantly TRIANGLE 5HT1-receptorAgonists:manufacturerofselegilineadvisesavoidconcomitantusewith5HT1AGONISTS TRIANGLE Memantine:effectsofdopaminergicsandselegilinepossiblyenhancedbyMEMANTINE TRIANGLE Methyldopa:antiparkinsonianeffectofdopaminergicsantagonisedbyMETHYLDOPAlOestrogens:plasmaconcentrationofselegilineincreasedbylOESTROGENS—manufacturerofselegilineadvisesavoidconcomitantuselProgestogens:plasmaconcentrationofselegilineincreasedbylPROGESTOGENS—manufacturerofselegilineadvisesavoidconcomitantuselSympathomimetics:manufacturerofselegilineadvisesavoidconcomitantusewithSYMPATHOMIMETICS;riskofhypertensivecrisiswhenselegilinegivenwithlDOPAMINESelenium TRIANGLE Eltrombopag:seleniumpossiblyreducesabsorptionofELTROMBOPAG(giveatleast4hoursapart) TRIANGLE Vitamins:absorptionofseleniumpossiblyreducedbyASCORBICACID(giveatleast4hoursapart)SertralineseeAntidepressants,SSRISevelamer TRIANGLE Antibacterials:sevelamerreducesbioavailabilityofCIPROFLOXACIN TRIANGLE Ciclosporin:sevelamerpossiblyreducesplasmaconcentrationofCICLOSPORIN TRIANGLE Mycophenolate:sevelamerpossiblyreducesplasmaconcentrationofMYCOPHENOLATE TRIANGLE Tacrolimus:sevelamerpossiblyreducesplasmaconcentrationofTACROLIMUS TRIANGLE ThyroidHormones:sevelamerpossiblyreducesabsorptionofLEVOTHYROXINESevelamer(continued) TRIANGLE Vitamins:sevelamerreducesabsorptionofCALCITRIOL(giveatleast1hourbeforeor3hoursaftersevelamer)SevofluraneseeAnaesthetics,GeneralSildenafillAlpha-blockers:enhancedhypotensiveeffectwhensildenafilgivenwithlALPHA-BLOCKERS(avoidalpha-blockersfor4hoursaftersildenafil)—whenpatientisstableonthealphablockerinitiatesildenafilatthelowestpossibledose TRIANGLE Anti-arrhythmics:avoidanceofsildenafiladvisedbymanufacturerofDISOPYRAMIDE(riskofventriculararrhythmias)lAntibacterials:plasmaconcentrationofsildenafilincreasedbylCLARITHROMYCIN—considerreducinginitialdoseofsildenafilforerectiledysfunctionorreducesildenafildosefrequencytooncedailyforpulmonaryhypertension;plasmaconcentrationofsildenafilincreasedbyERYTHROMYCIN—reduceinitialdoseofsildenafilforerectiledysfunctionorreducesildenafildosefrequencytotwicedailyforpulmonaryhypertension;plasmaconcentrationofsildenafilpossiblyincreasedbylTELITHROMYCIN—considerreducinginitialdoseofsildenafilforerectiledysfunctionorreducesildenafildosefrequencytooncedailyforpulmonaryhypertensionlAntifungals:plasmaconcentrationofsildenafilincreasedbylKETOCONAZOLE—reduceinitialdoseofsildenafilforerectiledysfunctionandavoidconcomitantuseofsildenafilforpulmonaryhypertension;plasmaconcentrationofsildenafilincreasedbyITRACONAZOLE—reduceinitialdoseofsildenafillAntivirals:side-effectsofsildenafilpossiblyincreasedbylATAZANAVIR;plasmaconcentrationofsildenafilreducedbyETRAVIRINE;plasmaconcentrationofsildenafilpossiblyincreasedbyFOSAMPRENAVIR;plasmaconcentrationofsildenafilincreasedbylINDINAVIR—reduceinitialdoseofsildenafil;plasmaconcentrationofsildenafilsignificantlyincreasedbylRITONAVIR—avoidconcomitantuse;increasedriskofventriculararrhythmiaswhensildenafilgivenwithlSAQUINAVIR—avoidconcomitantuse;avoidanceofsildenafiladvisedbymanufactureroflTELAPREVIR;avoidanceofsildenafilforpulmonaryarterialhypertensionadvisedbymanufacturerofTIPRANAVIR TRIANGLE Bosentan:plasmaconcentrationofsildenafilreducedbyBOSENTAN,alsoplasmaconcentrationofbosentanincreased TRIANGLE Calcium-channelBlockers:enhancedhypotensiveeffectwhensildenafilgivenwithAMLODIPINElCobicistat:plasmaconcentrationofsildenafilpossiblyincreasedbylCOBICISTAT—manufacturerofcobicistatadvisesavoidconcomitantuseofsildenafilforpulmonaryarterialhypertensionorreducedoseofsildenafilforerectiledysfunction—consultcobicistatproductliterature TRIANGLE Cytotoxics:avoidanceofsildenafilforpulmonaryarterialhypertensionadvisedbymanufacturerofIDELALISIB TRIANGLE Dapoxetine:avoidanceofsildenafiladvisedbymanufacturerofDAPOXETINE TRIANGLE GrapefruitJuice:plasmaconcentrationofsildenafilpossiblyincreasedbyGRAPEFRUITJUICElNicorandil:sildenafilsignificantlyenhanceshypotensiveeffectoflNICORANDIL(avoidconcomitantuse)lNitrates:sildenafilsignificantlyenhanceshypotensiveeffectoflNITRATES(avoidconcomitantuse)lRiociguat:enhancedhypotensiveeffectwhensildenafilgivenwithlRIOCIGUAT—avoidconcomitantuse TRIANGLE Ulcer-healingDrugs:plasmaconcentrationofsildenafilincreasedbyCIMETIDINE—considerreducingdoseofsildenafilforerectiledysfunctionSiltuximablAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lVaccines:riskofgeneralisedinfectionswhenmonoclonalantibodiesgivenwithlivelVACCINES—avoidconcomitantuseSimeprevirlAnti-arrhythmics:possibleincreasedriskofbradycardiawhensimeprevir(withsofosbuvir)givenwithlAMIODARONE—seeunderAmiodarone,p88lAntibacterials:plasmaconcentrationofsimeprevirpossiblyincreasedbylCLARITHROMYCINandlTELITHROMYCIN—1242Appendix1InteractionsBNF70Interactions|Appendix1"
"SimeprevirlAntibacterials(continued)manufacturerofsimepreviradvisesavoidconcomitantuse;plasmaconcentrationofbothdrugsincreasedwhensimeprevirgivenwithlERYTHROMYCIN—manufacturerofsimepreviradvisesavoidconcomitantuse;plasmaconcentrationofsimeprevirpossiblyreducedbyRIFABUTIN—manufacturerofsimepreviradvisesavoidconcomitantuse;plasmaconcentrationofsimeprevirreducedbylRIFAMPICIN—manufacturerofsimepreviradvisesavoidconcomitantuselAntidepressants:plasmaconcentrationofsimeprevirpossiblyreducedbylSTJOHN’SWORT—manufacturerofsimepreviradvisesavoidconcomitantuselAntiepileptics:plasmaconcentrationofsimeprevirpossiblyreducedbylCARBAMAZEPINE,lFOSPHENYTOIN,lOXCARBAZEPINE,lPHENOBARBITAL,lPHENYTOINandlPRIMIDONE—manufacturerofsimepreviradvisesavoidconcomitantuselAntifungals:manufacturerofsimepreviradvisesavoidconcomitantusewithlKETOCONAZOLE;plasmaconcentrationofsimeprevirpossiblyincreasedbylFLUCONAZOLE,lITRACONAZOLE,lPOSACONAZOLEandlVORICONAZOLE—manufacturerofsimepreviradvisesavoidconcomitantuselAntivirals:plasmaconcentrationofbothdrugsincreasedwhensimeprevirgivenwithlDARUNAVIR—manufacturerofsimepreviradvisesavoidconcomitantuse;plasmaconcentrationofsimeprevirreducedbyEFAVIRENZ;manufacturerofsimepreviradvisesavoidconcomitantusewithETRAVIRINE;plasmaconcentrationofsimeprevirpossiblyreducedbylNEVIRAPINE—manufacturerofsimepreviradvisesavoidconcomitantuse;plasmaconcentrationofsimeprevirincreasedbylRITONAVIR—manufacturerofsimepreviradvisesavoidconcomitantuse TRIANGLE AnxiolyticsandHypnotics:simeprevirincreasesplasmaconcentrationoforalMIDAZOLAM TRIANGLE CardiacGlycosides:simeprevirincreasesplasmaconcentrationofDIGOXINlCobicistat:plasmaconcentrationofsimeprevirpossiblyincreasedbylCOBICISTAT—manufacturerofsimepreviradvisesavoidconcomitantuse TRIANGLE Corticosteroids:plasmaconcentrationofsimeprevirpossiblyreducedbyDEXAMETHASONE—manufacturerofsimepreviradvisesavoidconcomitantuse TRIANGLE Lipid-regulatingDrugs:simeprevirincreasesplasmaconcentrationofATORVASTATIN,ROSUVASTATINandSIMVASTATIN(considerreducingdoseofatorvastatin,rosuvastatinandsimvastatin)SimvastatinseeStatinsSirolimus TRIANGLE Anti-arrhythmics:cautionwithsirolimusadvisedbymanufacturerofDRONEDARONElAntibacterials:plasmaconcentrationofsirolimusincreasedbylCLARITHROMYCINandlTELITHROMYCIN—avoidconcomitantuse;plasmaconcentrationofbothdrugsincreasedwhensirolimusgivenwithlERYTHROMYCIN;plasmaconcentrationofsirolimusreducedbylRIFABUTINandlRIFAMPICIN—avoidconcomitantuselAntifungals:plasmaconcentrationofsirolimusincreasedbylITRACONAZOLE,lKETOCONAZOLEandlVORICONAZOLE—avoidconcomitantuse;plasmaconcentrationofsirolimusincreasedbyMICAFUNGINandlMICONAZOLE;plasmaconcentrationofsirolimuspossiblyincreasedbyFLUCONAZOLEandPOSACONAZOLElAntivirals:plasmaconcentrationofsirolimuspossiblyincreasedbylATAZANAVIRandLOPINAVIR;plasmaconcentrationofsirolimusincreasedbylBOCEPREVIR(increasedriskoftoxicity—reducesirolimusdose);plasmaconcentrationofbothdrugsincreasedwhensirolimusgivenwithlTELAPREVIR(reducedoseofsirolimus)lCalcium-channelBlockers:plasmaconcentrationofsirolimuspossiblyincreasedbyNICARDIPINE;plasmaconcentrationofsirolimusincreasedbylDILTIAZEM;plasmaconcentrationofbothdrugsincreasedwhensirolimusgivenwithlVERAPAMILSirolimus(continued) TRIANGLE Ciclosporin:plasmaconcentrationofsirolimusincreasedbyCICLOSPORINlCytotoxics:cautionwithsirolimusadvisedbymanufactureroflCRIZOTINIBlGrapefruitJuice:plasmaconcentrationofsirolimusincreasedbylGRAPEFRUITJUICE—avoidconcomitantuseSitagliptinseeAntidiabeticsSmallpoxVaccineseeVaccinesSodiumAurothiomalatelACEInhibitors:flushingandhypotensionreportedwhensodiumaurothiomalategivenwithlACEINHIBITORS TRIANGLE Penicillamine:avoidanceofsodiumaurothiomalateadvisedbymanufacturerofPENICILLAMINE(increasedriskoftoxicity)SodiumBenzoate TRIANGLE Antiepileptics:effectsofsodiumbenzoatepossiblyreducedbySODIUMVALPROATEandVALPROICACID TRIANGLE Antipsychotics:effectsofsodiumbenzoatepossiblyreducedbyHALOPERIDOL TRIANGLE Corticosteroids:effectsofsodiumbenzoatepossiblyreducedbyCORTICOSTEROIDSSodiumBicarbonateseeAntacidsSodiumCitrate TRIANGLE Antibacterials:avoidconcomitantuseofsodiumcitratewithMETHENAMINE TRIANGLE Ulcer-healingDrugs:avoidanceofsodiumcitrateadvisedbymanufacturerofSUCRALFATESodiumClodronateseeBisphosphonatesSodiumFerredateseeIronsaltsSodiumNitroprussideseeVasodilatorAntihypertensivesSodiumOxybatelAnalgesics:effectsofsodiumoxybateenhancedbylOPIOIDANALGESICS(avoidconcomitantuse) TRIANGLE Antidepressants:increasedriskofside-effectswhensodiumoxybategivenwithTRICYCLICSlAntiepileptics:manufacturerofsodiumoxybateadvisesavoidconcomitantusewithPHENOBARBITALandPRIMIDONE;plasmaconcentrationofsodiumoxybateincreasedbylSODIUMVALPROATEandlVALPROICACID(seeunderSodiumOxybate,p425) TRIANGLE Antipsychotics:effectsofsodiumoxybatepossiblyenhancedbyANTIPSYCHOTICSlAnxiolyticsandHypnotics:effectsofsodiumoxybateenhancedbylBENZODIAZEPINES(avoidconcomitantuse)SodiumPhenylbutyrate TRIANGLE Antiepileptics:effectsofsodiumphenylbutyratepossiblyreducedbySODIUMVALPROATEandVALPROICACID TRIANGLE Antipsychotics:effectsofsodiumphenylbutyratepossiblyreducedbyHALOPERIDOL TRIANGLE Corticosteroids:effectsofsodiumphenylbutyratepossiblyreducedbyCORTICOSTEROIDSSodiumStibogluconatelAntifungals:possibleincreasedriskofarrhythmiaswhensodiumstibogluconategivenbeforelAMPHOTERICIN—manufacturerofsodiumstibogluconateadvisesgiving14daysapartSodiumValproate TRIANGLE Analgesics:effectsofsodiumvalproateenhancedbyASPIRINlAntibacterials:metabolismofsodiumvalproatepossiblyinhibitedbyERYTHROMYCIN(increasedplasmaconcentration);avoidanceofsodiumvalproateadvisedbymanufactureroflPIVMECILLINAM;plasmaconcentrationofsodiumvalproatereducedbylCARBAPENEMS—avoidconcomitantuse TRIANGLE Anticoagulants:sodiumvalproatepossiblyenhancesanticoagulanteffectofCOUMARINSlAntidepressants:anticonvulsanteffectofantiepilepticspossiblyantagonisedbyMAOISandlTRICYCLIC-RELATEDANTIDEPRESSANTS(convulsivethresholdlowered);anticonvulsanteffectofantiepilepticsantagonisedbylSSRISandlTRICYCLICS(convulsivethresholdlowered)lAntiepileptics:plasmaconcentrationofsodiumvalproatereducedbyCARBAMAZEPINE,alsoplasmaconcentrationofactivemetaboliteofcarbamazepineincreased;sodiumvalproatepossiblyincreasesplasmaconcentrationofETHOSUXIMIDE;sodiumvalproateincreasesorpossiblyBNF70Appendix1Interactions1243Interactions|Appendix1"
"SodiumValproatelAntiepileptics(continued)decreasesplasmaconcentrationofFOSPHENYTOINandPHENYTOIN,alsoplasmaconcentrationofsodiumvalproatereduced;sodiumvalproateincreasesplasmaconcentrationoflLAMOTRIGINE(increasedriskoftoxicity—reducelamotriginedose);sodiumvalproatesometimesreducesplasmaconcentrationofanactivemetaboliteofOXCARBAZEPINE;sodiumvalproateincreasesplasmaconcentrationofPHENOBARBITALandPRIMIDONE(alsoplasmaconcentrationofsodiumvalproatereduced);sodiumvalproatepossiblyincreasesplasmaconcentrationofRUFINAMIDE(reducedoseofrufinamide);hyperammonaemiaandCNStoxicityreportedwhensodiumvalproategivenwithTOPIRAMATElAntimalarials:anticonvulsanteffectofantiepilepticsantagonisedbylMEFLOQUINElAntipsychotics:anticonvulsanteffectofantiepilepticsantagonisedbylANTIPSYCHOTICS(convulsivethresholdlowered);sodiumvalproatepossiblyincreasesordecreasesplasmaconcentrationofCLOZAPINE;increasedriskofside-effectsincludingneutropeniawhensodiumvalproategivenwithlOLANZAPINE TRIANGLE Antivirals:plasmaconcentrationofsodiumvalproatepossiblyreducedbyRITONAVIR;sodiumvalproatepossiblyincreasesplasmaconcentrationofZIDOVUDINE(increasedriskoftoxicity) TRIANGLE AnxiolyticsandHypnotics:plasmaconcentrationofsodiumvalproatepossiblyincreasedbyCLOBAZAM;increasedriskofside-effectswhensodiumvalproategivenwithCLONAZEPAM;sodiumvalproatepossiblyincreasesplasmaconcentrationofDIAZEPAMandLORAZEPAM TRIANGLE Bupropion:sodiumvalproateinhibitsthemetabolismofBUPROPION TRIANGLE Cytotoxics:sodiumvalproateincreasesplasmaconcentrationofTEMOZOLOMIDE TRIANGLE Lipid-regulatingDrugs:absorptionofsodiumvalproatepossiblyreducedbyCOLESTYRAMINE TRIANGLE Oestrogens:plasmaconcentrationofsodiumvalproatepossiblyreducedbyETHINYLESTRADIOLlOrlistat:possibleincreasedriskofconvulsionswhenantiepilepticsgivenwithlORLISTAT TRIANGLE SodiumBenzoate:sodiumvalproatepossiblyreduceseffectsofSODIUMBENZOATElSodiumOxybate:sodiumvalproateincreasestheplasmaconcentrationoflSODIUMOXYBATE(seeunderSodiumOxybate,p425) TRIANGLE SodiumPhenylbutyrate:sodiumvalproatepossiblyreduceseffectsofSODIUMPHENYLBUTYRATElUlcer-healingDrugs:metabolismofsodiumvalproateinhibitedbylCIMETIDINE(increasedplasmaconcentration)SofosbuvirlAnti-arrhythmics:possibleincreasedriskofbradycardiawhensofosbuvirgivenwithlAMIODARONE—seeunderAmiodarone,p88 TRIANGLE Antibacterials:manufacturerofsofosbuviradvisesavoidconcomitantusewithRIFABUTINandRIFAMPICIN TRIANGLE Antidepressants:manufacturerofsofosbuviradvisesavoidconcomitantusewithSTJOHN’SWORT TRIANGLE Antiepileptics:manufacturerofsofosbuviradvisesavoidconcomitantusewithCARBAMAZEPINE,FOSPHENYTOIN,OXCARBAZEPINE,PHENOBARBITAL,PHENYTOINandPRIMIDONESolifenacinseeAntimuscarinicsSomatropin TRIANGLE Corticosteroids:growth-promotingeffectofsomatropinmaybeinhibitedbyCORTICOSTEROIDS TRIANGLE Oestrogens:increaseddosesofsomatropinmaybeneededwhengivenwithOESTROGENS(whenusedasoralreplacementtherapy)Sorafenib TRIANGLE Antibacterials:bioavailabilityofsorafenibreducedbyNEOMYCIN;plasmaconcentrationofsorafenibreducedbyRIFAMPICINlAnticoagulants:sorafenibpossiblyenhancesanticoagulanteffectoflCOUMARINSSorafenib(continued)lAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lAntivirals:avoidanceofsorafenibadvisedbymanufactureroflBOCEPREVIR TRIANGLE Cytotoxics:sorafenibincreasesplasmaconcentrationofDOCETAXELandDOXORUBICIN;sorafenibpossiblyincreasesplasmaconcentrationofIRINOTECANSotalolseeBeta-blockersSpironolactoneseeDiureticsStatins TRIANGLE Antacids:absorptionofrosuvastatinreducedbyANTACIDSlAnti-arrhythmics:increasedriskofmyopathywhensimvastatingivenwithlAMIODARONE(seeunderSimvastatin,p181);plasmaconcentrationofrosuvastatinincreasedbylDRONEDARONE—adjustdoseofrosuvastatin(consultproductliterature);increasedriskofmyopathywhensimvastatingivenwithlDRONEDARONE;plasmaconcentrationofatorvastatinpossiblyincreasedbyDRONEDARONElAntibacterials:plasmaconcentrationofatorvastatinandpravastatinincreasedbylCLARITHROMYCIN;increasedriskofmyopathywhensimvastatingivenwithlCLARITHROMYCIN,lERYTHROMYCINorlTELITHROMYCIN(avoidconcomitantuse);plasmaconcentrationofrosuvastatinreducedbyERYTHROMYCIN;possibleincreasedriskofmyopathywhenatorvastatingivenwithERYTHROMYCIN;plasmaconcentrationofpravastatinincreasedbyERYTHROMYCIN;plasmaconcentrationofatorvastatinandsimvastatinpossiblyreducedbyRIFAMPICIN;metabolismoffluvastatinacceleratedbyRIFAMPICIN(reducedeffect);increasedriskofmyopathywhenstatinsgivenwithlDAPTOMYCIN(preferablyavoidconcomitantuse);riskofmyopathyandrhabdomyolysiswhenstatinsgivenwithlFUSIDICACID—avoidconcomitantuseandfor7daysafterlastfusidicaciddose;increasedriskofmyopathywhenatorvastatingivenwithlTELITHROMYCIN(avoidconcomitantuse);possibleincreasedriskofmyopathywhenpravastatingivenwithTELITHROMYCINlAnticoagulants:atorvastatinmaytransientlyreduceanticoagulanteffectofWARFARIN;rosuvastatinpossiblyenhancesanticoagulanteffectoflCOUMARINSandlPHENINDIONE;simvastatincanenhancetheanticoagulanteffectofCOUMARINS;fluvastatinenhancesanticoagulanteffectoflCOUMARINS TRIANGLE Antidepressants:plasmaconcentrationofsimvastatinreducedbySTJOHN’SWORT TRIANGLE Antidiabetics:fluvastatinpossiblyincreasesplasmaconcentrationofGLIBENCLAMIDElAntiepileptics:plasmaconcentrationofsimvastatinreducedbylCARBAMAZEPINEandESLICARBAZEPINE—considerincreasingdoseofsimvastatin;plasmaconcentrationofrosuvastatinreducedbyESLICARBAZEPINE;combinationoffluvastatinwithFOSPHENYTOINorPHENYTOINmayincreaseplasmaconcentrationofeitherdrug(orboth)lAntifungals:possibleincreasedriskofmyopathywhenatorvastatingivenwithlKETOCONAZOLE—manufacturerofketoconazoleadvisesavoidconcomitantuse;increasedriskofmyopathywhensimvastatingivenwithlITRACONAZOLE,lKETOCONAZOLEorlPOSACONAZOLE(avoidconcomitantuse);possibleincreasedriskofmyopathywhensimvastatingivenwithlFLUCONAZOLEorlMICONAZOLE;possibleincreasedriskofmyopathywhenatorvastatingivenwithlFLUCONAZOLEorIMIDAZOLES;plasmaconcentrationoffluvastatinincreasedbyFLUCONAZOLE—possibleincreasedriskofmyopathy;plasmaconcentrationofrosuvastatinincreasedbylITRACONAZOLE—adjustdoseofrosuvastatin(consultproductliterature);increasedriskofmyopathywhenatorvastatingivenwithlITRACONAZOLE,lPOSACONAZOLEorlVORICONAZOLE;increasedriskofmyopathywhensimvastatingivenwithlVORICONAZOLElAntivirals:possibleincreasedriskofmyopathywhenatorvastatinorpravastatingivenwithlATAZANAVIR;plasmaconcentrationofrosuvastatinincreasedbylATAZANAVIR,lDARUNAVIR,lLOPINAVIRandlTIPRANAVIR—adjustdoseofrosuvastatin(consultproductliterature);increasedriskofmyopathywhensimvastatingivenwithlATAZANAVIR,1244Appendix1InteractionsBNF70Interactions|Appendix1"
"StatinslAntivirals(continued)lINDINAVIR,lRITONAVIRorlSAQUINAVIR(avoidconcomitantuse);plasmaconcentrationofpravastatinincreasedbyBOCEPREVIR;plasmaconcentrationofatorvastatinincreasedbyBOCEPREVIR(reducedoseofatorvastatin);manufacturersadviseavoidconcomitantuseofsimvastatinwithlBOCEPREVIRandlTELAPREVIR;plasmaconcentrationofrosuvastatinincreasedbyDACLATASVIR;plasmaconcentrationofpravastatinpossiblyincreasedbyDARUNAVIR;possibleincreasedriskofmyopathywhenatorvastatingivenwithDARUNAVIR,FOSAMPRENAVIR,INDINAVIR,LOPINAVIR,RITONAVIRorSAQUINAVIR;plasmaconcentrationofatorvastatin,pravastatinandsimvastatinreducedbyEFAVIRENZ;plasmaconcentrationofatorvastatinpossiblyreducedbyETRAVIRINE;possibleincreasedriskofmyopathywhenrosuvastatingivenwithlFOSAMPRENAVIR,lINDINAVIR,lRITONAVIRandlSAQUINAVIR—manufacturerofrosuvastatinadvisesavoidconcomitantuse;possibleincreasedriskofmyopathywhensimvastatingivenwithlFOSAMPRENAVIRorlLOPINAVIR—avoidconcomitantuse;plasmaconcentrationofatorvastatin,rosuvastatinandsimvastatinincreasedbySIMEPREVIR(considerreducingdoseofatorvastatin,rosuvastatinandsimvastatin);avoidanceofatorvastatinadvisedbymanufactureroflTELAPREVIR;plasmaconcentrationofsimvastatinpossiblyincreasedbylTIPRANAVIR—avoidconcomitantuse;increasedriskofmyopathywhenatorvastatingivenwithlTIPRANAVIR(seeunderAtorvastatin,p179) TRIANGLE AnxiolyticsandHypnotics:atorvastatinpossiblyincreasesplasmaconcentrationofMIDAZOLAM TRIANGLE Bosentan:plasmaconcentrationofsimvastatinreducedbyBOSENTANlCalcium-channelBlockers:possibleincreasedriskofmyopathywhensimvastatingivenwithlAMLODIPINEandlDILTIAZEM(seeunderSimvastatin,p181);plasmaconcentrationofatorvastatinincreasedbyDILTIAZEM—possibleincreasedriskofmyopathy;increasedriskofmyopathywhensimvastatingivenwithlVERAPAMIL(seeunderSimvastatin,p181);atorvastatinincreasesplasmaconcentrationoflVERAPAMIL,alsopossibleincreasedriskofmyopathy(considerreducingdoseofatorvastatin) TRIANGLE CardiacGlycosides:atorvastatinpossiblyincreasesplasmaconcentrationofDIGOXINlCiclosporin:increasedriskofmyopathywhenrosuvastatinorsimvastatingivenwithlCICLOSPORIN(avoidconcomitantuse);increasedriskofmyopathywhenatorvastatingivenwithlCICLOSPORIN(seeunderAtorvastatin,p179);increasedriskofmyopathywhenfluvastatinorpravastatingivenwithlCICLOSPORINlClopidogrel:plasmaconcentrationofrosuvastatinincreasedbylCLOPIDOGREL—adjustdoseofrosuvastatin(consultproductliterature)lCobicistat:plasmaconcentrationofatorvastatinpossiblyincreasedbyCOBICISTAT—manufacturerofcobicistatadvisesreducedoseofatorvastatin;avoidanceofsimvastatinadvisedbymanufactureroflCOBICISTATlColchicine:possibleincreasedriskofmyopathywhenstatinsgivenwithlCOLCHICINE TRIANGLE Cytotoxics:plasmaconcentrationofsimvastatinpossiblyincreasedbyDASATINIB;avoidanceofsimvastatinadvisedbymanufacturerofIDELALISIB;plasmaconcentrationofsimvastatinincreasedbyIMATINIBlEltrombopag:plasmaconcentrationofrosuvastatinincreasedbylELTROMBOPAG—adjustdoseofrosuvastatin(consultproductliterature)lGrapefruitJuice:plasmaconcentrationofatorvastatinpossiblyincreasedbyGRAPEFRUITJUICE;plasmaconcentrationofsimvastatinincreasedbylGRAPEFRUITJUICE—avoidconcomitantuselHormoneAntagonists:possibleincreasedriskofmyopathywhensimvastatingivenwithlDANAZOL—avoidconcomitantuselLipid-regulatingDrugs:possibleincreasedriskofmyopathywhensimvastatingivenwithlBEZAFIBRATE(seeunderSimvastatin,p181);possibleincreasedriskofmyopathyStatinslLipid-regulatingDrugs(continued)whensimvastatingivenwithlCIPROFIBRATE(seeunderSimvastatin,p181);whengivenwithstatinsreducemaximumdoseofFENOFIBRATE—seeunderFenofibrate,p175;increasedriskofmyopathywhenatorvastatin,fluvastatinorpravastatingivenwithlGEMFIBROZIL(preferablyavoidconcomitantuse);increasedriskofmyopathywhensimvastatingivenwithlGEMFIBROZIL(avoidconcomitantuse);plasmaconcentrationofrosuvastatinincreasedbylEZETIMIBE—adjustdoseofrosuvastatin(consultproductliterature);increasedriskofmyopathywhenstatinsgivenwithlFIBRATES;increasedriskofmyopathywhenrosuvastatingivenwithlFIBRATES(seeunderRosuvastatin,p180);plasmaconcentrationofsimvastatinincreasedbylLOMITAPIDE(seeunderSimvastatin,p181);plasmaconcentrationofatorvastatinincreasedbyLOMITAPIDE—manufactureroflomitapideadvisesreducedoseofatorvastatinbyhalforseparateadministrationby12hours;increasedriskofmyopathywhenstatinsgivenwithlNICOTINICACID(appliestolipidregulatingdosesofnicotinicacid) TRIANGLE Oestrogens:atorvastatinandrosuvastatinincreaseplasmaconcentrationofETHINYLESTRADIOL TRIANGLE Progestogens:atorvastatinincreasesplasmaconcentrationofNORETHISTERONE;rosuvastatinincreasesplasmaconcentrationofactivemetaboliteofNORGESTIMATE;rosuvastatinincreasesplasmaconcentrationofNORGESTRELlRanolazine:plasmaconcentrationofsimvastatinincreasedbylRANOLAZINE(seeunderSimvastatin,p181) TRIANGLE Retinoids:plasmaconcentrationofsimvastatinreducedbyALITRETINOINlTeriflunomide:plasmaconcentrationofrosuvastatinincreasedbylTERIFLUNOMIDE(considerreducingdoseofrosuvastatin)lTicagrelor:plasmaconcentrationofsimvastatinincreasedbylTICAGRELOR(increasedriskoftoxicity)StavudinelAntivirals:increasedriskofside-effectswhenstavudinegivenwithlDIDANOSINE;increasedriskoftoxicitywhenstavudinegivenwithlRIBAVIRIN;effectsofstavudinepossiblyinhibitedbylZIDOVUDINE(manufacturersadviseavoidconcomitantuse)lCytotoxics:effectsofstavudinepossiblyinhibitedbyDOXORUBICIN;increasedriskoftoxicitywhenstavudinegivenwithlHYDROXYCARBAMIDE—avoidconcomitantuselOrlistat:absorptionofstavudinepossiblyreducedbylORLISTATStiripentollAntidepressants:anticonvulsanteffectofantiepilepticspossiblyantagonisedbyMAOISandlTRICYCLIC-RELATEDANTIDEPRESSANTS(convulsivethresholdlowered);anticonvulsanteffectofantiepilepticsantagonisedbylSSRISandlTRICYCLICS(convulsivethresholdlowered)lAntiepileptics:stiripentolincreasesplasmaconcentrationoflCARBAMAZEPINE,lFOSPHENYTOIN,lPHENOBARBITAL,lPHENYTOINandlPRIMIDONElAntimalarials:anticonvulsanteffectofantiepilepticsantagonisedbylMEFLOQUINElAntipsychotics:anticonvulsanteffectofantiepilepticsantagonisedbylANTIPSYCHOTICS(convulsivethresholdlowered) TRIANGLE AnxiolyticsandHypnotics:stiripentolincreasesplasmaconcentrationofCLOBAZAMlOrlistat:possibleincreasedriskofconvulsionswhenantiepilepticsgivenwithlORLISTATStreptomycinseeAminoglycosidesStrontiumRanelate TRIANGLE Antibacterials:strontiumranelatereducesabsorptionofQUINOLONESandTETRACYCLINES(manufacturerofstrontiumranelateadvisesavoidconcomitantuse)Sucralfate TRIANGLE Aminophylline:sucralfatepossiblyreducesabsorptionofAMINOPHYLLINE(giveatleast2hoursapart) TRIANGLE Antibacterials:sucralfatereducesabsorptionofCIPROFLOXACIN,LEVOFLOXACIN,MOXIFLOXACIN,OFLOXACINandTETRACYCLINES;BNF70Appendix1Interactions1245Interactions|Appendix1"
"SucralfateAntibacterials(continued)sucralfatereducesabsorptionofNORFLOXACIN(giveatleast2hoursapart)lAnticoagulants:sucralfatepossiblyreducesabsorptionoflCOUMARINS(reducedanticoagulanteffect)lAntiepileptics:sucralfatereducesabsorptionoflFOSPHENYTOINandlPHENYTOIN TRIANGLE Antifungals:sucralfatereducesabsorptionofKETOCONAZOLE TRIANGLE Antipsychotics:sucralfatereducesabsorptionofSULPIRIDE TRIANGLE CardiacGlycosides:sucralfatepossiblyreducesabsorptionofCARDIACGLYCOSIDES TRIANGLE PotassiumSalts:manufacturerofsucralfateadvisesavoidconcomitantusewithPOTASSIUMCITRATE TRIANGLE SodiumCitrate:manufacturerofsucralfateadvisesavoidconcomitantusewithSODIUMCITRATE TRIANGLE Theophylline:sucralfatepossiblyreducesabsorptionofTHEOPHYLLINE(giveatleast2hoursapart) TRIANGLE ThyroidHormones:sucralfatereducesabsorptionofLEVOTHYROXINE TRIANGLE Ulcer-healingDrugs:sucralfatepossiblyreducesabsorptionofLANSOPRAZOLESugammadex TRIANGLE Antibacterials:responsetosugammadexpossiblyreducedbyFUSIDICACID TRIANGLE Progestogens:sugammadexpossiblyreducesplasmaconcentrationofPROGESTOGENS—manufacturerofsugammadexadvisesadditionalcontraceptiveprecautionsSulfadiazineseeSulfonamidesSulfadoxineseeSulfonamidesSulfamethoxazoleseeSulfonamidesSulfasalazine TRIANGLE CardiacGlycosides:sulfasalazinepossiblyreducesabsorptionofDIGOXIN TRIANGLE Folates:sulfasalazinepossiblyreducesabsorptionofFOLICACIDSulfinpyrazone TRIANGLE Aminophylline:sulfinpyrazonereducesplasmaconcentrationofAMINOPHYLLINE TRIANGLE Analgesics:effectsofsulfinpyrazoneantagonisedbyASPIRIN TRIANGLE Antibacterials:sulfinpyrazonereducesexcretionofNITROFURANTOIN(increasedriskoftoxicity);sulfinpyrazonereducesexcretionofPENICILLINS;effectsofsulfinpyrazoneantagonisedbyPYRAZINAMIDElAnticoagulants:increasedriskofbleedingwhensulfinpyrazonegivenwithAPIXABAN;sulfinpyrazoneenhancesanticoagulanteffectoflCOUMARINS;possibleincreasedriskofbleedingwhensulfinpyrazonegivenwithlDABIGATRANlAntidiabetics:sulfinpyrazoneenhanceseffectsoflSULFONYLUREASlAntiepileptics:sulfinpyrazoneincreasesplasmaconcentrationoflFOSPHENYTOINandlPHENYTOIN TRIANGLE Calcium-channelBlockers:sulfinpyrazonereducesplasmaconcentrationofVERAPAMILlCiclosporin:sulfinpyrazonereducesplasmaconcentrationoflCICLOSPORIN TRIANGLE Theophylline:sulfinpyrazonereducesplasmaconcentrationofTHEOPHYLLINESulfonamides TRIANGLE Anaesthetics,General:sulfonamidesenhanceeffectsofTHIOPENTALlAnaesthetics,Local:effectsofsulfonamidespossiblyinhibitedbylCHLOROPROCAINE(manufacturerofchloroprocaineadvisesavoidconcomitantuse);increasedriskofmethaemoglobinaemiawhensulfonamidesgivenwithPRILOCAINE TRIANGLE Anti-arrhythmics:possibleincreasedriskofventriculararrhythmiaswhensulfamethoxazole(asco-trimoxazole)givenwithAMIODARONE—manufacturerofamiodaroneadvisesavoidconcomitantuseofco-trimoxazolelAntibacterials:increasedriskofcrystalluriawhensulfonamidesgivenwithlMETHENAMINESulfonamides(continued)lAnticoagulants:sulfonamidesenhanceanticoagulanteffectoflCOUMARINS;sulfonamidespossiblyinhibitmetabolismofPHENINDIONE TRIANGLE Antidiabetics:sulfonamidesrarelyenhancetheeffectsofSULFONYLUREAS TRIANGLE Antiepileptics:sulfonamidespossiblyincreaseplasmaconcentrationofFOSPHENYTOINandPHENYTOINlAntimalarials:increasedantifolateeffectwhensulfonamidesgivenwithlPYRIMETHAMINElAntipsychotics:avoidconcomitantuseofsulfonamideswithlCLOZAPINE(increasedriskofagranulocytosis)lAzathioprine:increasedriskofhaematologicaltoxicitywhensulfamethoxazole(asco-trimoxazole)givenwithlAZATHIOPRINElCiclosporin:increasedriskofnephrotoxicitywhensulfonamidesgivenwithlCICLOSPORIN;sulfadiazinepossiblyreducesplasmaconcentrationoflCICLOSPORINlCytotoxics:increasedriskofhaematologicaltoxicitywhensulfamethoxazole(asco-trimoxazole)givenwithlMERCAPTOPURINEorlMETHOTREXATE;sulfonamidesincreaseriskofMETHOTREXATEtoxicity TRIANGLE PotassiumAminobenzoate:effectsofsulfonamidesinhibitedbyPOTASSIUMAMINOBENZOATE TRIANGLE Vaccines:antibacterialsinactivateORALTYPHOIDVACCINE—seeunderTyphoidVaccineinBNFSulfonylureasseeAntidiabeticsSulindacseeNSAIDsSulpirideseeAntipsychoticsSumatriptansee5HT1-receptorAgonists(underHT)Sunitinib TRIANGLE Antibacterials:metabolismofsunitinibacceleratedbyRIFAMPICIN(reducedplasmaconcentration) TRIANGLE Antifungals:metabolismofsunitinibinhibitedbyKETOCONAZOLE(increasedplasmaconcentration)lAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lAntivirals:avoidanceofsunitinibadvisedbymanufactureroflBOCEPREVIRSuxamethoniumseeMuscleRelaxantsSympathomimeticslAdrenergicNeuroneBlockers:ephedrine,isometheptene,metaraminol,methylphenidate,noradrenaline(norepinephrine),oxymetazoline,phenylephrine,pseudoephedrineandxylometazolineantagonisehypotensiveeffectoflADRENERGICNEURONEBLOCKERS;dexamfetamineandlisdexamfetamineantagonisehypotensiveeffectoflGUANETHIDINE;increasedriskofhypertensionwhenadrenaline(epinephrine)givenwithlGUANETHIDINE TRIANGLE Alcohol:effectsofmethylphenidatepossiblyenhancedbyALCOHOL TRIANGLE Alpha2-adrenoceptorStimulants:avoidanceofsympathomimeticsadvisedbymanufacturerofAPRACLONIDINElAlpha-blockers:avoidconcomitantuseofadrenaline(epinephrine)ordopaminewithlTOLAZOLINE TRIANGLE Aminophylline:avoidanceofephedrineinchildrenadvisedbymanufacturerofAMINOPHYLLINElAnaesthetics,General:avoidanceofsympathomimeticsadvisedbymanufactureroflISOFLURANE(riskofventriculararrhythmias);increasedriskofarrhythmiaswhenadrenaline(epinephrine)ornoradrenaline(norepinephrine)givenwithlVOLATILELIQUIDGENERALANAESTHETICS;increasedriskofhypertensionwhenmethylphenidategivenwithlVOLATILELIQUIDGENERALANAESTHETICS TRIANGLE Antacids:absorptionofpseudoephedrinepossiblyincreasedbyALUMINIUMHYDROXIDElAnticoagulants:methylphenidatepossiblyenhancesanticoagulanteffectoflCOUMARINSlAntidepressants:riskofhypertensivecrisiswhenadrenaline(epinephrine),dobutamine,dopamine,noradrenaline(norepinephrine)orxylometazolinegivenwithlMAOIS;riskofhypertensivecrisiswhendexamfetamine,ephedrine,isometheptene,lisdexamfetamine,metaraminol,1246Appendix1InteractionsBNF70Interactions|Appendix1"
"SympathomimeticslAntidepressants(continued)methylphenidate,phenylephrineorpseudoephedrinegivenwithlMAOIS,avoiddexamfetamine,ephedrine,isometheptene,lisdexamfetamine,metaraminol,methylphenidate,phenylephrineorpseudoephedrineforatleast2weeksafterstoppingMAOIs;riskofhypertensivecrisiswhenoxymetazolinegivenwithlMAOIS,somemanufacturersadviseavoidoxymetazolineforatleast2weeksafterstoppingMAOIs;riskofhypertensivecrisiswhensympathomimeticsgivenwithlMOCLOBEMIDE;methylphenidatepossiblyinhibitsmetabolismofSSRISandTRICYCLICS;increasedriskofhypertensionandarrhythmiaswhenadrenaline(epinephrine)givenwithlTRICYCLICS(butlocalanaestheticswithadrenalineappeartobesafe);increasedriskofhypertensionandarrhythmiaswhennoradrenaline(norepinephrine)orphenylephrinegivenwithlTRICYCLICS TRIANGLE Antiepileptics:methylphenidateincreasesplasmaconcentrationofFOSPHENYTOINandPHENYTOIN;methylphenidatepossiblyincreasesplasmaconcentrationofPHENOBARBITALandPRIMIDONE TRIANGLE Antipsychotics:hypertensiveeffectofsympathomimeticsantagonisedbyANTIPSYCHOTICS;effectsoflisdexamfetaminepossiblyreducedbyCHLORPROMAZINE;dexamfetaminepossiblyantagonisesantipsychoticeffectsofCHLORPROMAZINE;methylphenidatepossiblyincreasesside-effectsofRISPERIDONE TRIANGLE Antivirals:plasmaconcentrationofdexamfetaminepossiblyincreasedbyRITONAVIRlBeta-blockers:increasedriskofseverehypertensionandbradycardiawhenadrenaline(epinephrine)givenwithnon-cardioselectivelBETA-BLOCKERS,alsoresponsetoadrenaline(epinephrine)maybereduced;increasedriskofseverehypertensionandbradycardiawhendobutaminegivenwithnon-cardioselectivelBETA-BLOCKERS;possibleincreasedriskofseverehypertensionandbradycardiawhennoradrenaline(norepinephrine)givenwithnon-cardioselectivelBETA-BLOCKERSlClonidine:possibleriskofhypertensionwhenadrenaline(epinephrine)ornoradrenaline(norepinephrine)givenwithCLONIDINE;seriousadverseeventsreportedwithconcomitantuseofmethylphenidateandlCLONIDINE(causalitynotestablished) TRIANGLE Corticosteroids:ephedrineacceleratesmetabolismofDEXAMETHASONElDopaminergics:riskoftoxicitywhenisometheptenegivenwithlBROMOCRIPTINE;effectsofadrenaline(epinephrine),dobutamine,dopamineandnoradrenaline(norepinephrine)possiblyenhancedbyENTACAPONE;avoidconcomitantuseofsympathomimeticswithlRASAGILINE;avoidanceofsympathomimeticsadvisedbymanufacturerofSELEGILINE;riskofhypertensivecrisiswhendopaminegivenwithlSELEGILINE TRIANGLE Doxapram:increasedriskofhypertensionwhensympathomimeticsgivenwithDOXAPRAM TRIANGLE ErgotAlkaloids:increasedriskofergotismwhensympathomimeticsgivenwithERGOTAMINE TRIANGLE Oxytocin:riskofhypertensionwhenvasoconstrictorsympathomimeticsgivenwithOXYTOCIN(duetoenhancedvasopressoreffect)lSympathomimetics:effectsofadrenaline(epinephrine)possiblyenhancedbylDOPEXAMINE;dopexaminepossiblyenhanceseffectsoflNORADRENALINE(NOREPINEPHRINE) TRIANGLE Theophylline:avoidanceofephedrineinchildrenadvisedbymanufacturerofTHEOPHYLLINE TRIANGLE Ulcer-healingDrugs:metabolismofdobutaminepossiblyinhibitedbyCIMETIDINESympathomimetics,Beta2 TRIANGLE Aminophylline:increasedriskofhypokalaemiawhenhighdosesofbeta2sympathomimeticsgivenwithAMINOPHYLLINElAntifungals:plasmaconcentrationofolodaterolincreasedbyKETOCONAZOLE;metabolismofsalmeterolinhibitedbylKETOCONAZOLE(increasedplasmaconcentration)lAntivirals:avoidanceofsalmeteroladvisedbymanufacturerofLOPINAVIR,RITONAVIRandTIPRANAVIR;avoidanceofSympathomimetics,Beta2lAntivirals(continued)salmeteroladvisedbymanufactureroflTELAPREVIR(riskofventriculararrhythmias) TRIANGLE Atomoxetine:Increasedriskofcardiovascularside-effectswhenparenteralsalbutamolgivenwithATOMOXETINE TRIANGLE CardiacGlycosides:salbutamolpossiblyreducesplasmaconcentrationofDIGOXIN TRIANGLE Cobicistat:avoidanceofsalmeteroladvisedbymanufacturerofCOBICISTAT TRIANGLE Corticosteroids:increasedriskofhypokalaemiawhenhighdosesofbeta2sympathomimeticsgivenwithCORTICOSTEROIDS TRIANGLE Cytotoxics:avoidanceofsalmeteroladvisedbymanufacturerofIDELALISIB TRIANGLE Diuretics:increasedriskofhypokalaemiawhenhighdosesofbeta2sympathomimeticsgivenwithACETAZOLAMIDE,LOOPDIURETICSorTHIAZIDESANDRELATEDDIURETICSlMethyldopa:acutehypotensionreportedwheninfusionofsalbutamolgivenwithlMETHYLDOPA TRIANGLE MuscleRelaxants:bambuterolenhanceseffectsofSUXAMETHONIUM TRIANGLE Theophylline:increasedriskofhypokalaemiawhenhighdosesofbeta2sympathomimeticsgivenwithTHEOPHYLLINETacrolimusNOTEInteractionsdonotgenerallyapplytotacrolimususedtopically;riskoffacialflushingandskinirritationwithtopicaltacrolimusonconsumptionofalcohollAnalgesics:possibleincreasedriskofnephrotoxicitywhentacrolimusgivenwithNSAIDS;increasedriskofnephrotoxicitywhentacrolimusgivenwithlIBUPROFEN TRIANGLE Angiotensin-IIReceptorAntagonists:increasedriskofhyperkalaemiawhentacrolimusgivenwithANGIOTENSIN-IIRECEPTORANTAGONISTS TRIANGLE Anti-arrhythmics:cautionwithtacrolimusadvisedbymanufacturerofDRONEDARONElAntibacterials:plasmaconcentrationoftacrolimusincreasedbylCLARITHROMYCINandlERYTHROMYCIN;plasmaconcentrationoftacrolimuspossiblyreducedbyRIFABUTIN;plasmaconcentrationoftacrolimusreducedbylRIFAMPICIN;increasedriskofnephrotoxicitywhentacrolimusgivenwithlAMINOGLYCOSIDES;plasmaconcentrationoftacrolimuspossiblyincreasedbylCHLORAMPHENICOLandlTELITHROMYCIN;possibleincreasedriskofnephrotoxicitywhentacrolimusgivenwithVANCOMYCINlAnticoagulants:tacrolimuspossiblyincreasesplasmaconcentrationoflDABIGATRAN—manufacturerofdabigatranadvisesavoidconcomitantuselAntidepressants:plasmaconcentrationoftacrolimusreducedbylSTJOHN’SWORT—avoidconcomitantuselAntiepileptics:plasmaconcentrationoftacrolimusreducedbyFOSPHENYTOINandPHENYTOIN,alsoplasmaconcentrationoffosphenytoinandphenytoinpossiblyincreased;plasmaconcentrationoftacrolimusreducedbylPHENOBARBITALandlPRIMIDONElAntifungals:plasmaconcentrationoftacrolimusincreasedbylFLUCONAZOLE,lITRACONAZOLE,lKETOCONAZOLE,lPOSACONAZOLEandlVORICONAZOLE(considerreducingdoseoftacrolimus);plasmaconcentrationoftacrolimuspossiblyincreasedbylMICONAZOLEoralgel;increasedriskofnephrotoxicitywhentacrolimusgivenwithlAMPHOTERICIN;plasmaconcentrationoftacrolimusreducedbylCASPOFUNGINlAntipsychotics:avoidanceoftacrolimusadvisedbymanufactureroflDROPERIDOL(riskofventriculararrhythmias)lAntivirals:possibleincreasedriskofnephrotoxicitywhentacrolimusgivenwithACICLOVIR,GANCICLOVIR,VALACICLOVIRorVALGANCICLOVIR;plasmaconcentrationoftacrolimuspossiblyincreasedbylATAZANAVIRandlRITONAVIR;plasmaconcentrationoftacrolimusincreasedbylBOCEPREVIR(reducedoseoftacrolimus);plasmaconcentrationoftacrolimuspossiblyaffectedbylEFAVIRENZ;plasmaconcentrationoftacrolimusincreasedbylFOSAMPRENAVIR;plasmaconcentrationoftacrolimusincreasedbylSAQUINAVIR(considerreducingdoseoftacrolimus);plasmaBNF70Appendix1Interactions1247Interactions|Appendix1"
"TacrolimuslAntivirals(continued)concentrationofbothdrugsincreasedwhentacrolimusgivenwithlTELAPREVIR(reducedoseoftacrolimus)lCalcium-channelBlockers:plasmaconcentrationoftacrolimuspossiblyincreasedbyFELODIPINEandVERAPAMIL;plasmaconcentrationoftacrolimusincreasedbylDILTIAZEM,NICARDIPINEandlNIFEDIPINElCiclosporin:tacrolimusincreasesplasmaconcentrationoflCICLOSPORIN(increasedriskofnephrotoxicity)—avoidconcomitantuse TRIANGLE Colestilan:manufacturerofcolestilanadvisesgivetacrolimusatleast1hourbeforeor3hoursafterCOLESTILANlCytotoxics:tacrolimuspossiblyincreasestheplasmaconcentrationofAFATINIB—manufacturerofafatinibadvisesseparatingadministrationoftacrolimusby6to12hours;cautionwithtacrolimusadvisedbymanufactureroflCRIZOTINIB;plasmaconcentrationoftacrolimusincreasedbyIMATINIB TRIANGLE Dexrazoxane:increasedriskofimmunosupressionwithtacrolimusadvisedbymanufacturerofDEXRAZOXANElDiuretics:increasedriskofhyperkalaemiawhentacrolimusgivenwithlPOTASSIUM-SPARINGDIURETICSANDALDOSTERONEANTAGONISTSlGrapefruitJuice:plasmaconcentrationoftacrolimusincreasedbylGRAPEFRUITJUICE TRIANGLE HormoneAntagonists:plasmaconcentrationoftacrolimuspossiblyincreasedbyDANAZOL TRIANGLE Lipid-regulatingDrugs:separatingadministrationfromtacrolimusby12hoursadvisedbymanufacturerofLOMITAPIDE TRIANGLE Mifamurtide:avoidanceoftacrolimusadvisedbymanufacturerofMIFAMURTIDE TRIANGLE Oestrogens:plasmaconcentrationoftacrolimuspossiblyincreasedbyETHINYLESTRADIOLlPotassiumSalts:increasedriskofhyperkalaemiawhentacrolimusgivenwithlPOTASSIUMSALTSlRanolazine:plasmaconcentrationoftacrolimusincreasedbylRANOLAZINE TRIANGLE Sevelamer:plasmaconcentrationoftacrolimuspossiblyreducedbySEVELAMER TRIANGLE Ulcer-healingDrugs:plasmaconcentrationoftacrolimuspossiblyincreasedbyOMEPRAZOLETadalafillAlpha-blockers:enhancedhypotensiveeffectwhentadalafilgivenwithlDOXAZOSIN—manufactureroftadalafiladvisesavoidconcomitantuse;enhancedhypotensiveeffectwhentadalafilgivenwithlALPHA-BLOCKERS—whenpatientisstableonthealphablockerinitiatetadalafilatthelowestpossibledose TRIANGLE Anti-arrhythmics:avoidanceoftadalafiladvisedbymanufacturerofDISOPYRAMIDE(riskofventriculararrhythmias)lAntibacterials:plasmaconcentrationoftadalafilpossiblyincreasedbyCLARITHROMYCINandERYTHROMYCIN;plasmaconcentrationoftadalafilreducedbylRIFAMPICIN—manufactureroftadalafiladvisesavoidconcomitantuselAntifungals:tadalafilconcentrationisincreasedbylKETOCONAZOLE—avoidconcomitantuseoftadalafilforpulmonaryhypertension;plasmaconcentrationoftadalafilpossiblyincreasedbyITRACONAZOLElAntivirals:plasmaconcentrationoftadalafilpossiblyincreasedbyFOSAMPRENAVIRandINDINAVIR;plasmaconcentrationoftadalafilincreasedbylRITONAVIR—manufactureroftadalafiladvisesavoidconcomitantuse;increasedriskofventriculararrhythmiaswhentadalafilgivenwithlSAQUINAVIR—avoidconcomitantuse;avoidanceofhighdosesoftadalafiladvisedbymanufactureroflTELAPREVIR—consultproductliterature TRIANGLE Bosentan:plasmaconcentrationoftadalafilreducedbyBOSENTANlCobicistat:plasmaconcentrationoftadalafilpossiblyincreasedbylCOBICISTAT—manufacturerofcobicistatadvisesreducedoseoftadalafil(consultcobicistatproductliterature) TRIANGLE Dapoxetine:avoidanceoftadalafiladvisedbymanufacturerofDAPOXETINETadalafil(continued) TRIANGLE GrapefruitJuice:plasmaconcentrationoftadalafilpossiblyincreasedbyGRAPEFRUITJUICElNicorandil:tadalafilsignificantlyenhanceshypotensiveeffectoflNICORANDIL(avoidconcomitantuse)lNitrates:tadalafilsignificantlyenhanceshypotensiveeffectoflNITRATES(avoidconcomitantuse)lRiociguat:possibleenhancedhypotensiveeffectwhentadalafilgivenwithlRIOCIGUAT—avoidconcomitantuseTamoxifen TRIANGLE Antibacterials:metabolismoftamoxifenacceleratedbyRIFAMPICIN(reducedplasmaconcentration)lAnticoagulants:tamoxifenenhancesanticoagulanteffectoflCOUMARINSlAntidepressants:metabolismoftamoxifentoactivemetabolitepossiblyinhibitedbylFLUOXETINEandlPAROXETINE(avoidconcomitantuse)lAntipsychotics:avoidanceoftamoxifenadvisedbymanufactureroflDROPERIDOL(riskofventriculararrhythmias)lBupropion:metabolismoftamoxifentoactivemetabolitepossiblyinhibitedbylBUPROPION(avoidconcomitantuse)lCinacalcet:metabolismoftamoxifentoactivemetabolitepossiblyinhibitedbylCINACALCET(avoidconcomitantuse)TamsulosinseeAlpha-blockersTapentadolseeOpioidAnalgesicsTaxanesseeCabazitaxel,Docetaxel,andPaclitaxelTegafur TRIANGLE Antibacterials:metabolismoftegafurinhibitedbyMETRONIDAZOLE(increasedtoxicity)lAnticoagulants:tegafurenhancesanticoagulanteffectoflCOUMARINS TRIANGLE Antiepileptics:tegafurpossiblyinhibitsmetabolismofFOSPHENYTOINandPHENYTOIN(increasedriskoftoxicity)lAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis) TRIANGLE Filgrastim:neutropeniapossiblyexacerbatedwhentegafurgivenwithFILGRASTIMlFolates:toxicityoftegafurincreasedbylFOLICACID—avoidconcomitantuse TRIANGLE Lipegfilgrastim:neutropeniapossiblyexacerbatedwhentegafurgivenwithLIPEGFILGRASTIM TRIANGLE Pegfilgrastim:neutropeniapossiblyexacerbatedwhentegafurgivenwithPEGFILGRASTIM TRIANGLE Ulcer-healingDrugs:metabolismoftegafurinhibitedbyCIMETIDINE(increasedplasmaconcentration)Teicoplanin TRIANGLE Vaccines:antibacterialsinactivateORALTYPHOIDVACCINE—seeunderTyphoidVaccineinBNFTelaprevirlAlpha-blockers:manufactureroftelapreviradvisesavoidconcomitantusewithlALFUZOSINlAnalgesics:manufactureroftelapreviradvisescautionwithlMETHADONE(riskofventriculararrhythmias)lAnti-arrhythmics:manufactureroftelapreviradvisesavoidconcomitantusewithlAMIODARONEandlDISOPYRAMIDE(riskofventriculararrhythmias);manufactureroftelapreviradvisescautionwithlFLECAINIDEandlPROPAFENONE(riskofventriculararrhythmias);manufactureroftelapreviradvisescautionwithintravenousLIDOCAINElAntibacterials:plasmaconcentrationofbothdrugspossiblyincreasedwhentelaprevirgivenwithlCLARITHROMYCIN,lERYTHROMYCINandlTELITHROMYCIN(increasedriskofventriculararrhythmias);manufactureroftelapreviradvisesavoidconcomitantusewithlRIFABUTIN;plasmaconcentrationoftelaprevirsignificantlyreducedbylRIFAMPICIN—avoidconcomitantuselAnticoagulants:telaprevirpossiblyaffectsplasmaconcentrationoflWARFARIN;avoidanceoftelapreviradvisedbymanufacturerofAPIXABAN;telaprevirpossiblyincreasesplasmaconcentrationofDABIGATRANlAntidepressants:telaprevirpossiblyincreasesplasmaconcentrationofTRAZODONE;manufactureroftelapreviradvisesavoidconcomitantusewithlSTJOHN’SWORT1248Appendix1InteractionsBNF70Interactions|Appendix1"
"Telaprevir(continued) TRIANGLE Antidiabetics:telaprevirincreasesplasmaconcentrationofMETFORMIN(considerreducingdoseofmetformin)lAntiepileptics:manufactureroftelapreviradvisesavoidconcomitantusewithlCARBAMAZEPINE,lFOSPHENYTOIN,lPHENOBARBITAL,lPHENYTOINandlPRIMIDONElAntifungals:plasmaconcentrationofbothdrugspossiblyincreasedwhentelaprevirgivenwithKETOCONAZOLE(increasedriskofventriculararrhythmias)—reducedoseofketoconazole;telaprevirpossiblyincreasesplasmaconcentrationofITRACONAZOLE;telaprevirpossiblyincreasesplasmaconcentrationoflPOSACONAZOLE(increasedriskofventriculararrhythmias);telaprevirpossiblyaffectsplasmaconcentrationoflVORICONAZOLE(possibleincreasedriskofventriculararrhythmias)lAntipsychotics:telaprevirpossiblyincreasesplasmaconcentrationoflLURASIDONE—avoidconcomitantuse;manufactureroftelapreviradvisesavoidconcomitantusewithlPIMOZIDE;telaprevirpossiblyincreasesplasmaconcentrationoflQUETIAPINE—manufacturerofquetiapineadvisesavoidconcomitantuselAntivirals:plasmaconcentrationoftelaprevirpossiblyreducedbyATAZANAVIR,alsoplasmaconcentrationofatazanavirpossiblyincreased;telaprevirincreasestheplasmaconcentrationoflDACLATASVIR—reducedoseofdaclatasvir(seeunderDaclatasvir,p544);avoidconcomitantuseoftelaprevirwithlDARUNAVIR;plasmaconcentrationoftelaprevirreducedbylEFAVIRENZ—increasedoseoftelaprevir;manufacturersadviseavoidconcomitantuseoftelaprevirwithlFOSAMPRENAVIRandlLOPINAVIR;telaprevirincreasesplasmaconcentrationofMARAVIROC(considerreducingdoseofmaraviroc);plasmaconcentrationoftelaprevirpossiblyreducedbyNEVIRAPINE—considerincreasingdoseoftelaprevir;plasmaconcentrationoftelaprevirpossiblyreducedbyRITONAVIR;telaprevirincreasesplasmaconcentrationofTENOFOVIR;avoidanceoftelapreviradvisedbymanufacturerofTIPRANAVIRlAnxiolyticsandHypnotics:telaprevirpossiblyincreasesplasmaconcentrationoflMIDAZOLAM(riskofprolongedsedation—avoidconcomitantuseoforalmidazolam)lBeta-blockers:manufactureroftelapreviradvisesavoidconcomitantusewithlSOTALOL(riskofventriculararrhythmias) TRIANGLE Bosentan:plasmaconcentrationoftelaprevirpossiblyreducedbyBOSENTAN,alsoplasmaconcentrationofbosentanpossiblyincreased TRIANGLE Calcium-channelBlockers:telaprevirincreasesplasmaconcentrationofAMLODIPINE(considerreducingdoseofamlodipine);manufactureroftelapreviradvisescautionwithDILTIAZEM,FELODIPINE,NICARDIPINE,NIFEDIPINEandVERAPAMIL TRIANGLE CardiacGlycosides:telaprevirincreasesplasmaconcentrationofDIGOXINlCiclosporin:plasmaconcentrationofbothdrugsincreasedwhentelaprevirgivenwithlCICLOSPORIN(reducedoseofciclosporin)lCilostazol:telaprevirpossiblyincreasesplasmaconcentrationoflCILOSTAZOL(seeunderCilostazol,p206)lColchicine:telaprevirpossiblyincreasesriskoflCOLCHICINEtoxicity—suspendorreducedoseofcolchicine(avoidconcomitantuseinhepaticorrenalimpairment) TRIANGLE Corticosteroids:telaprevirpossiblyincreasesplasmaconcentrationofinhaledandintranasalBUDESONIDEandFLUTICASONE;plasmaconcentrationoftelaprevirpossiblyreducedbyDEXAMETHASONElCytotoxics:telaprevirpossiblyincreasestheplasmaconcentrationoflBOSUTINIB—manufacturerofbosutinibadvisesavoidorconsiderreducingdoseofbosutinib;manufacturerofruxolitinibadvisesdosereductionwhentelaprevirgivenwithlRUXOLITINIB—consultruxolitinibproductliteraturelDomperidone:possibleincreasedriskofventriculararrhythmiaswhentelaprevirgivenwithlDOMPERIDONE—avoidconcomitantuselErgotAlkaloids:manufactureroftelapreviradvisesavoidconcomitantusewithlERGOTALKALOIDSTelaprevir(continued)lLipid-regulatingDrugs:manufactureroftelapreviradvisesavoidconcomitantusewithlATORVASTATIN;manufacturersadviseavoidconcomitantuseoftelaprevirwithlSIMVASTATIN;avoidanceoftelapreviradvisedbymanufactureroflLOMITAPIDE(plasmaconcentrationoflomitapidepossiblyincreased)lOestrogens:telaprevirpossiblyreducesplasmaconcentrationoflETHINYLESTRADIOL—manufactureroftelapreviradvisesadditionalcontraceptiveprecautionslSildenafil:manufactureroftelapreviradvisesavoidconcomitantusewithlSILDENAFILlSirolimus:plasmaconcentrationofbothdrugsincreasedwhentelaprevirgivenwithlSIROLIMUS(reducedoseofsirolimus)lSympathomimetics,Beta2:manufactureroftelapreviradvisesavoidconcomitantusewithlSALMETEROL(riskofventriculararrhythmias)lTacrolimus:plasmaconcentrationofbothdrugsincreasedwhentelaprevirgivenwithlTACROLIMUS(reducedoseoftacrolimus)lTadalafil:manufactureroftelapreviradvisesavoidconcomitantusewithhighdosesoflTADALAFIL—consultproductliteraturelVardenafil:manufactureroftelapreviradvisesavoidconcomitantusewithlVARDENAFILTelavancin TRIANGLE Vaccines:antibacterialsinactivateORALTYPHOIDVACCINE—seeunderTyphoidVaccineinBNFTelbivudinelInterferons:increasedriskofperipheralneuropathywhentelbivudinegivenwithlINTERFERONALFAandlPEGINTERFERONALFATelithromycinlAnalgesics:possibleincreasedriskofventriculararrhythmiaswhentelithromycingivenwithlMETHADONE;telithromycininhibitsthemetabolismofOXYCODONElAnti-arrhythmics:possibleincreasedriskofventriculararrhythmiaswhentelithromycingivenwithlAMIODARONEandlDISOPYRAMIDE;increasedriskofventriculararrhythmiaswhentelithromycingivenwithlDRONEDARONE—avoidconcomitantuselAntibacterials:possibleincreasedriskofventriculararrhythmiaswhentelithromycingivenwithlMOXIFLOXACIN;plasmaconcentrationoftelithromycinreducedbylRIFAMPICIN(avoidduringandfor2weeksafterrifampicin) TRIANGLE Anticoagulants:avoidanceoftelithromycinadvisedbymanufacturerofAPIXABANlAntidepressants:possibleincreasedriskofventriculararrhythmiaswhentelithromycingivenwithlCITALOPRAMandlTRICYCLICS;plasmaconcentrationoftelithromycinreducedbylSTJOHN’SWORT(avoidduringandfor2weeksafterStJohn’swort)lAntiepileptics:plasmaconcentrationoftelithromycinreducedbylCARBAMAZEPINE,lFOSPHENYTOIN,lPHENOBARBITAL,lPHENYTOINandlPRIMIDONE(avoidduringandfor2weeksaftercarbamazepine,fosphenytoin,phenobarbital,phenytoinandprimidone)lAntifungals:plasmaconcentrationoftelithromycinincreasedbylKETOCONAZOLE—avoidinsevererenalandhepaticimpairment TRIANGLE Antimuscarinics:manufactureroffesoterodineadvisesdosereductionwhentelithromycingivenwithFESOTERODINE—consultfesoterodineproductliteraturelAntipsychotics:possibleincreasedriskofventriculararrhythmiaswhentelithromycingivenwithlCHLORPROMAZINE;telithromycinpossiblyincreasesplasmaconcentrationoflLURASIDONE—avoidconcomitantuse;increasedriskofventriculararrhythmiaswhentelithromycingivenwithlPIMOZIDE—avoidconcomitantuse;telithromycinpossiblyincreasesplasmaconcentrationofQUETIAPINElAntivirals:manufactureroftelithromycinadvisesavoidconcomitantusewithlATAZANAVIR,lFOSAMPRENAVIR,lINDINAVIR,lLOPINAVIR,lRITONAVIRandlTIPRANAVIRinsevererenalandhepaticimpairment;telithromycinpossiblyincreasestheplasmaconcentrationoflDACLATASVIR—reduceBNF70Appendix1Interactions1249Interactions|Appendix1"
"TelithromycinlAntivirals(continued)doseofdaclatasvir(seeunderDaclatasvir,p544);telithromycinpossiblyincreasesplasmaconcentrationoflMARAVIROC(considerreducingdoseofmaraviroc);manufactureroftelithromycinadvisesavoidconcomitantusewithlSAQUINAVIR(riskofventriculararrhythmias);telithromycinpossiblyincreasesplasmaconcentrationoflSIMEPREVIR—manufacturerofsimepreviradvisesavoidconcomitantuse;plasmaconcentrationofbothdrugspossiblyincreasedwhentelithromycingivenwithlTELAPREVIR(increasedriskofventriculararrhythmias)lAnxiolyticsandHypnotics:telithromycininhibitsmetabolismoflMIDAZOLAM(increasedplasmaconcentrationwithincreasedsedation) TRIANGLE Aprepitant:telithromycinpossiblyincreasesplasmaconcentrationofAPREPITANTlAvanafil:telithromycinpossiblyincreasesplasmaconcentrationoflAVANAFIL—manufacturerofavanafiladvisesavoidconcomitantuselCalcium-channelBlockers:telithromycinpossiblyinhibitsmetabolismoflCALCIUM-CHANNELBLOCKERS(increasedriskofside-effects) TRIANGLE CardiacGlycosides:telithromycinpossiblyincreasesplasmaconcentrationofDIGOXINlCiclosporin:telithromycinpossiblyincreasesplasmaconcentrationoflCICLOSPORINlColchicine:telithromycinpossiblyincreasesriskoflCOLCHICINEtoxicity—suspendorreducedoseofcolchicine(avoidconcomitantuseinhepaticorrenalimpairment)lCytotoxics:telithromycinpossiblyincreasesplasmaconcentrationofAXITINIB(reducedoseofaxitinib—consultaxitinibproductliterature);telithromycinpossiblyincreasestheplasmaconcentrationoflBOSUTINIBandlCABAZITAXEL—manufacturerofbosutinibandcabazitaxeladvisesavoidorconsiderreducingdoseofbosutinibandcabazitaxel;telithromycinpossiblyincreasesplasmaconcentrationoflCRIZOTINIBandlEVEROLIMUS—manufacturerofcrizotinibandeverolimusadvisesavoidconcomitantuse;avoidanceoftelithromycinadvisedbymanufacturerofDASATINIB(plasmaconcentrationofdasatinibpossiblyincreased);telithromycinpossiblyincreasestheplasmaconcentrationoflIBRUTINIB—reducedoseofibrutinib(seeunderIbrutinib,p809);avoidanceoftelithromycinadvisedbymanufactureroflLAPATINIBandlNILOTINIB;telithromycinpossiblyincreasesplasmaconcentrationoflPAZOPANIB(reducedoseofpazopanib);telithromycinpossiblyincreasesplasmaconcentrationofPONATINIB—considerreducinginitialdoseofponatinib(seeunderPonatinib,p814);manufacturerofruxolitinibadvisesdosereductionwhentelithromycingivenwithlRUXOLITINIB—consultruxolitinibproductliterature;telithromycinpossiblyincreasesplasmaconcentrationoflDOCETAXEL—manufacturerofdocetaxeladvisesavoidconcomitantuseorconsiderreducingdocetaxeldoselDapoxetine:avoidanceoftelithromycinadvisedbymanufactureroflDAPOXETINE(increasedriskoftoxicity)lDiuretics:telithromycinincreasesplasmaconcentrationoflEPLERENONE—avoidconcomitantuselDomperidone:possibleincreasedriskofventriculararrhythmiaswhentelithromycingivenwithlDOMPERIDONE—avoidconcomitantuselErgotAlkaloids:increasedriskofergotismwhentelithromycingivenwithlERGOTAMINE—avoidconcomitantuse TRIANGLE Fosaprepitant:telithromycinpossiblyincreasesplasmaconcentrationofFOSAPREPITANTlIvabradine:telithromycinpossiblyincreasesplasmaconcentrationoflIVABRADINE—avoidconcomitantuselIvacaftor:telithromycinpossiblyincreasesplasmaconcentrationoflIVACAFTOR(seeunderIvacaftor,p257)lLipid-regulatingDrugs:increasedriskofmyopathywhentelithromycingivenwithlATORVASTATINorlSIMVASTATIN(avoidconcomitantuse);possibleincreasedriskofmyopathywhentelithromycingivenwithPRAVASTATIN;avoidanceoftelithromycinadvisedbymanufactureroflLOMITAPIDE(plasmaconcentrationoflomitapidepossiblyincreased)Telithromycin(continued)lPentamidineIsetionate:possibleincreasedriskofventriculararrhythmiaswhentelithromycingivenwithparenterallPENTAMIDINEISETIONATElRanolazine:telithromycinpossiblyincreasesplasmaconcentrationoflRANOLAZINE—manufacturerofranolazineadvisesavoidconcomitantuselSildenafil:telithromycinpossiblyincreasesplasmaconcentrationoflSILDENAFIL—considerreducinginitialdoseofsildenafilforerectiledysfunctionorreducesildenafildosefrequencytooncedailyforpulmonaryhypertensionlSirolimus:telithromycinincreasesplasmaconcentrationoflSIROLIMUS—avoidconcomitantuselTacrolimus:telithromycinpossiblyincreasesplasmaconcentrationoflTACROLIMUS TRIANGLE Ulipristal:avoidanceoftelithromycinadvisedbymanufactureroflow-doseULIPRISTAL TRIANGLE Vaccines:antibacterialsinactivateORALTYPHOIDVACCINE—seeunderTyphoidVaccineinBNFTelmisartanseeAngiotensin-IIReceptorAntagonistsTemazepamseeAnxiolyticsandHypnoticsTemocillinseePenicillinsTemoporfinlCytotoxics:increasedskinphotosensitivitywhentemoporfingivenwithtopicallFLUOROURACILTemozolomide TRIANGLE Antiepileptics:plasmaconcentrationoftemozolomideincreasedbySODIUMVALPROATEandVALPROICACIDlAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)TemsirolimusNOTEThemainactivemetaboliteoftemsirolimusissirolimus—seealsointeractionsofsirolimusandconsultproductliteraturelAntibacterials:plasmaconcentrationofactivemetaboliteoftemsirolimusreducedbylRIFAMPICIN—avoidconcomitantuselAntifungals:plasmaconcentrationofactivemetaboliteoftemsirolimusincreasedbylKETOCONAZOLE—avoidconcomitantuse;manufactureroftemsirolimusadvisesavoidconcomitantusewithlITRACONAZOLE(plasmaconcentrationoftemsirolimuspossiblyincreased)lAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)TenofovirlAntivirals:manufactureroftenofoviradvisesavoidconcomitantusewithADEFOVIR;tenofovirreducesplasmaconcentrationofATAZANAVIR,alsoplasmaconcentrationoftenofovirpossiblyincreased;tenofovirincreasesplasmaconcentrationoflDIDANOSINE(increasedriskoftoxicity)—avoidconcomitantuse;plasmaconcentrationoftenofovirincreasedbyLOPINAVIRandTELAPREVIRlOrlistat:absorptionoftenofovirpossiblyreducedbylORLISTATTenoxicamseeNSAIDsTerazosinseeAlpha-blockersTerbinafinelAntibacterials:plasmaconcentrationofterbinafinereducedbylRIFAMPICIN TRIANGLE Antidepressants:terbinafinepossiblyincreasesplasmaconcentrationofPAROXETINEandTRICYCLICS TRIANGLE Antifungals:terbinafineincreasesplasmaconcentrationofFLUCONAZOLE TRIANGLE Ciclosporin:terbinafinepossiblyreducesplasmaconcentrationofCICLOSPORIN TRIANGLE Oestrogens:occasionalreportsofbreakthroughbleedingwhenterbinafinegivenwithOESTROGENS(whenusedforcontraception) TRIANGLE Progestogens:occasionalreportsofbreakthroughbleedingwhenterbinafinegivenwithPROGESTOGENS(whenusedforcontraception) TRIANGLE Ulcer-healingDrugs:plasmaconcentrationofterbinafineincreasedbyCIMETIDINETerbutalineseeSympathomimetics,Beta21250Appendix1InteractionsBNF70Interactions|Appendix1"
"Teriflunomide TRIANGLE Antibacterials:teriflunomideincreasesplasmaconcentrationofCEFACLOR;plasmaconcentrationofteriflunomidereducedbyRIFAMPICIN TRIANGLE Antidiabetics:teriflunomideincreasesplasmaconcentrationofREPAGLINIDElLipid-regulatingDrugs:theeffectofteriflunomideissignificantlydecreasedbyCOLESTYRAMINE(enhancedelimination)—avoidunlessdrugeliminationdesired;teriflunomideincreasesplasmaconcentrationoflROSUVASTATIN(considerreducingdoseofrosuvastatin) TRIANGLE Oestrogens:teriflunomideincreasesplasmaconcentrationofETHINYLESTRADIOL TRIANGLE Progestogens:teriflunomideincreasesplasmaconcentrationofLEVONORGESTRELlVaccines:riskofgeneralisedinfectionswhenteriflunomidegivenwithlivelVACCINES—avoidconcomitantuseTestolactonelAnticoagulants:testolactoneenhancesanticoagulanteffectoflCOUMARINSandlPHENINDIONETestosteronelAnticoagulants:testosteroneenhancesanticoagulanteffectoflCOUMARINSandlPHENINDIONE TRIANGLE Antidiabetics:testosteronepossiblyenhanceshypoglycaemiceffectofANTIDIABETICSTetrabenazinelAntidepressants:riskofCNStoxicitywhentetrabenazinegivenwithlMAOIS(avoidtetrabenazinefor2weeksafterMAOIs) TRIANGLE Antipsychotics:increasedriskofextrapyramidalside-effectswhentetrabenazinegivenwithANTIPSYCHOTICS TRIANGLE Dopaminergics:increasedriskofextrapyramidalside-effectswhentetrabenazinegivenwithAMANTADINE TRIANGLE Metoclopramide:increasedriskofextrapyramidalside-effectswhentetrabenazinegivenwithMETOCLOPRAMIDETetracosactideseeCorticosteroidsTetracyclineseeTetracyclinesTetracyclines TRIANGLE ACEInhibitors:absorptionoftetracyclinesreducedbyQUINAPRILtablets(quinapriltabletscontainmagnesiumcarbonate) TRIANGLE Adsorbents:absorptionoftetracyclinespossiblyreducedbyKAOLIN TRIANGLE Antacids:absorptionoftetracyclinesreducedbyANTACIDS TRIANGLE Antibacterials:plasmaconcentrationofdoxycyclinereducedbyRIFAMPICIN—considerincreasingdoseofdoxycycline;tetracyclinespossiblyantagoniseeffectsofPENICILLINSlAnticoagulants:tetracyclinespossiblyenhanceanticoagulanteffectoflCOUMARINSandlPHENINDIONE TRIANGLE Antidiabetics:tetracyclinespossiblyenhancehypoglycaemiceffectofSULFONYLUREAS TRIANGLE Antiepileptics:metabolismofdoxycyclineacceleratedbyCARBAMAZEPINE(reducedeffect);metabolismofdoxycyclineacceleratedbyFOSPHENYTOIN,PHENOBARBITAL,PHENYTOINandPRIMIDONE(reducedplasmaconcentration) TRIANGLE Atovaquone:tetracyclinereducesplasmaconcentrationofATOVAQUONE TRIANGLE CalciumSalts:absorptionoftetracyclinereducedbyCALCIUMSALTS TRIANGLE Cytotoxics:doxycyclineortetracyclineincreaseriskofMETHOTREXATEtoxicity TRIANGLE DairyProducts:absorptionoftetracyclines(exceptdoxycyclineandminocycline)reducedbyDAIRYPRODUCTS TRIANGLE Diuretics:manufactureroflymecyclineadvisesavoidconcomitantusewithDIURETICS TRIANGLE ErgotAlkaloids:increasedriskofergotismwhentetracyclinesgivenwithERGOTAMINE TRIANGLE IronSalts:absorptionoftetracyclinesreducedbyoralIRONSALTS,alsoabsorptionoforalironsaltsreducedbytetracyclines TRIANGLE Lipid-regulatingDrugs:absorptionoftetracyclinepossiblyreducedbyCOLESTIPOLandCOLESTYRAMINElRetinoids:possibleincreasedriskofbenignintracranialhypertensionwhentetracyclinesgivenwithlRETINOIDS(avoidconcomitantuse)Tetracyclines(continued) TRIANGLE StrontiumRanelate:absorptionoftetracyclinesreducedbySTRONTIUMRANELATE(manufacturerofstrontiumranelateadvisesavoidconcomitantuse) TRIANGLE Ulcer-healingDrugs:absorptionoftetracyclinesreducedbySUCRALFATEandTRIPOTASSIUMDICITRATOBISMUTHATE TRIANGLE Vaccines:antibacterialsinactivateORALTYPHOIDVACCINE—seeunderTyphoidVaccineinBNF TRIANGLE Zinc:absorptionoftetracyclinesreducedbyZINC,alsoabsorptionofzincreducedbytetracyclinesTheophylline TRIANGLE Allopurinol:plasmaconcentrationoftheophyllinepossiblyincreasedbyALLOPURINOL TRIANGLE Anaesthetics,General:increasedriskofconvulsionswhentheophyllinegivenwithKETAMINE TRIANGLE Anti-arrhythmics:theophyllineantagonisesanti-arrhythmiceffectofADENOSINE—manufacturerofadenosineadvisesavoidtheophyllinefor24hoursbeforeadenosine;plasmaconcentrationoftheophyllineincreasedbyPROPAFENONElAntibacterials:plasmaconcentrationoftheophyllinepossiblyincreasedbyCLARITHROMYCINandISONIAZID;plasmaconcentrationoftheophyllineincreasedbylERYTHROMYCIN(alsotheophyllinemayreduceabsorptionoforalerythromycin);plasmaconcentrationoftheophyllineincreasedbylCIPROFLOXACINandlNORFLOXACIN;metabolismoftheophyllineacceleratedbyRIFAMPICIN(reducedplasmaconcentration);possibleincreasedriskofconvulsionswhentheophyllinegivenwithlQUINOLONESlAntidepressants:plasmaconcentrationoftheophyllineincreasedbylFLUVOXAMINE(concomitantuseshouldusuallybeavoided,butwherenotpossiblehalvetheophyllinedoseandmonitorplasma-theophyllineconcentration);plasmaconcentrationoftheophyllinepossiblyreducedbySTJOHN’SWORTlAntiepileptics:metabolismoftheophyllineacceleratedbyCARBAMAZEPINE,lPHENOBARBITALandlPRIMIDONE(reducedeffect);plasmaconcentrationofbothdrugsreducedwhentheophyllinegivenwithlFOSPHENYTOINandlPHENYTOINlAntifungals:plasmaconcentrationoftheophyllinepossiblyincreasedbylFLUCONAZOLEandlKETOCONAZOLElAntivirals:plasmaconcentrationoftheophyllinepossiblyincreasedbyACICLOVIRandVALACICLOVIR;metabolismoftheophyllineacceleratedbylRITONAVIR(reducedplasmaconcentration) TRIANGLE AnxiolyticsandHypnotics:theophyllinepossiblyreduceseffectsofBENZODIAZEPINES TRIANGLE Caffeinecitrate:avoidanceoftheophyllineadvisedbymanufacturerofCAFFEINECITRATElCalcium-channelBlockers:plasmaconcentrationoftheophyllinepossiblyincreasedbylCALCIUM-CHANNELBLOCKERS(enhancedeffect);plasmaconcentrationoftheophyllineincreasedbyDILTIAZEM;plasmaconcentrationoftheophyllineincreasedbylVERAPAMIL(enhancedeffect) TRIANGLE Corticosteroids:increasedriskofhypokalaemiawhentheophyllinegivenwithCORTICOSTEROIDS TRIANGLE Cytotoxics:plasmaconcentrationoftheophyllinepossiblyincreasedbyMETHOTREXATElDeferasirox:plasmaconcentrationoftheophyllineincreasedbylDEFERASIROX(considerreducingdoseoftheophylline) TRIANGLE Disulfiram:metabolismoftheophyllineinhibitedbyDISULFIRAM(increasedriskoftoxicity) TRIANGLE Diuretics:increasedriskofhypokalaemiawhentheophyllinegivenwithACETAZOLAMIDE,LOOPDIURETICSorTHIAZIDESANDRELATEDDIURETICS TRIANGLE Doxapram:increasedCNSstimulationwhentheophyllinegivenwithDOXAPRAMlInterferons:metabolismoftheophyllineinhibitedbylINTERFERONALFAandlPEGINTERFERONALFA(considerreducingdoseoftheophylline) TRIANGLE LeukotrieneReceptorAntagonists:plasmaconcentrationoftheophyllinepossiblyincreasedbyZAFIRLUKAST,alsoplasmaconcentrationofzafirlukastreduced TRIANGLE Lithium:theophyllineincreasesexcretionofLITHIUM(reducedplasmaconcentration) TRIANGLE Oestrogens:plasmaconcentrationoftheophyllineincreasedbyOESTROGENS(considerreducingdoseoftheophylline)BNF70Appendix1Interactions1251Interactions|Appendix1"
"Theophylline(continued) TRIANGLE Pentoxifylline:plasmaconcentrationoftheophyllineincreasedbyPENTOXIFYLLINE TRIANGLE Roflumilast:avoidanceoftheophyllineadvisedbymanufacturerofROFLUMILAST TRIANGLE Sulfinpyrazone:plasmaconcentrationoftheophyllinereducedbySULFINPYRAZONE TRIANGLE Sympathomimetics:manufactureroftheophyllineadvisesavoidconcomitantusewithEPHEDRINEinchildren TRIANGLE Sympathomimetics,Beta2:increasedriskofhypokalaemiawhentheophyllinegivenwithhighdosesofBETA2SYMPATHOMIMETICSlUlcer-healingDrugs:metabolismoftheophyllineinhibitedbylCIMETIDINE(increasedplasmaconcentration);absorptionoftheophyllinepossiblyreducedbySUCRALFATE(giveatleast2hoursapart) TRIANGLE Vaccines:plasmaconcentrationoftheophyllinepossiblyincreasedbyINFLUENZAVACCINEThiazolidinedionesseeAntidiabeticsThiopentalseeAnaesthetics,GeneralThiotepalAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis) TRIANGLE MuscleRelaxants:thiotepaenhanceseffectsofSUXAMETHONIUMThioxanthenesseeAntipsychoticsThyroidHormones TRIANGLE Antacids:absorptionoflevothyroxinepossiblyreducedbyANTACIDS TRIANGLE Anti-arrhythmics:serumconcentrationsofthyroidhormonescanbeaffectedbyAMIODARONE—monitorthyroidfunctionclosely TRIANGLE Antibacterials:metabolismoflevothyroxineacceleratedbyRIFAMPICIN(mayincreaserequirementsforlevothyroxineinhypothyroidism)lAnticoagulants:thyroidhormonesenhanceanticoagulanteffectoflCOUMARINSandlPHENINDIONE TRIANGLE Antidepressants:thyroidhormonesenhanceeffectsofAMITRIPTYLINEandIMIPRAMINE;thyroidhormonespossiblyenhanceeffectsofTRICYCLICS TRIANGLE Antiepileptics:metabolismofthyroidhormonesacceleratedbyCARBAMAZEPINE,PHENOBARBITALandPRIMIDONE(mayincreaserequirementsforthyroidhormonesinhypothyroidism);metabolismofthyroidhormonesacceleratedbyFOSPHENYTOINandPHENYTOIN(mayincreaserequirementsinhypothyroidism),alsoplasmaconcentrationoffosphenytoinandphenytoinpossiblyincreased TRIANGLE Beta-blockers:levothyroxineacceleratesmetabolismofPROPRANOLOL TRIANGLE CalciumSalts:absorptionoflevothyroxinereducedbyCALCIUMSALTS TRIANGLE Colestilan:manufacturerofcolestilanadvisesgivelevothyroxineatleast1hourbeforeor3hoursafterCOLESTILAN TRIANGLE Cytotoxics:plasmaconcentrationoflevothyroxinepossiblyreducedbyIMATINIB TRIANGLE IronSalts:absorptionoflevothyroxinereducedbyoralIRONSALTS(giveatleast2hoursapart) TRIANGLE Lanthanum:absorptionoflevothyroxinereducedbyLANTHANUM(giveatleast2hoursapart) TRIANGLE Lipid-regulatingDrugs:absorptionoflevothyroxinereducedbyCOLESEVELAM;absorptionofthyroidhormonesreducedbyCOLESTIPOLandCOLESTYRAMINE TRIANGLE Oestrogens:requirementsforthyroidhormonesinhypothyroidismmaybeincreasedbyOESTROGENS TRIANGLE Orlistat:possibleincreasedriskofhypothyroidismwhenlevothyroxinegivenwithORLISTAT TRIANGLE PolystyreneSulfonateResins:absorptionoflevothyroxinereducedbyPOLYSTYRENESULFONATERESINS TRIANGLE Sevelamer:absorptionoflevothyroxinepossiblyreducedbySEVELAMER TRIANGLE Ulcer-healingDrugs:absorptionoflevothyroxinereducedbyCIMETIDINEandSUCRALFATETiagabinelAntidepressants:anticonvulsanteffectofantiepilepticspossiblyantagonisedbyMAOISandlTRICYCLIC-RELATEDTiagabinelAntidepressants(continued)ANTIDEPRESSANTS(convulsivethresholdlowered);anticonvulsanteffectofantiepilepticsantagonisedbylSSRISandlTRICYCLICS(convulsivethresholdlowered) TRIANGLE Antiepileptics:plasmaconcentrationoftiagabinereducedbyCARBAMAZEPINE,FOSPHENYTOIN,PHENOBARBITAL,PHENYTOINandPRIMIDONElAntimalarials:anticonvulsanteffectofantiepilepticsantagonisedbylMEFLOQUINElAntipsychotics:anticonvulsanteffectofantiepilepticsantagonisedbylANTIPSYCHOTICS(convulsivethresholdlowered)lOrlistat:possibleincreasedriskofconvulsionswhenantiepilepticsgivenwithlORLISTATTiaprofenicAcidseeNSAIDsTibolone TRIANGLE Antibacterials:metabolismoftiboloneacceleratedbyRIFAMPICIN(reducedplasmaconcentration) TRIANGLE Antiepileptics:metabolismoftiboloneacceleratedbyCARBAMAZEPINE(reducedplasmaconcentration);metabolismoftiboloneacceleratedbyFOSPHENYTOINandPHENYTOINTicagrelorlAntibacterials:plasmaconcentrationofticagrelorpossiblyincreasedbylCLARITHROMYCIN—manufacturerofticagreloradvisesavoidconcomitantuse;plasmaconcentrationofticagrelorpossiblyincreasedbyERYTHROMYCIN;plasmaconcentrationofticagrelorreducedbylRIFAMPICINlAnticoagulants:ticagrelorincreasesplasmaconcentrationoflDABIGATRAN TRIANGLE Antidepressants:possibleincreasedriskofbleedingwhenticagrelorgivenwithCITALOPRAM,PAROXETINEorSERTRALINE TRIANGLE Antiepileptics:plasmaconcentrationofticagrelorpossiblyreducedbyCARBAMAZEPINE,FOSPHENYTOIN,PHENOBARBITAL,PHENYTOINandPRIMIDONElAntifungals:plasmaconcentrationofticagrelorincreasedbylKETOCONAZOLE—manufacturerofticagreloradvisesavoidconcomitantuselAntivirals:plasmaconcentrationofticagrelorpossiblyincreasedbylATAZANAVIRandlRITONAVIR—manufacturerofticagreloradvisesavoidconcomitantuse TRIANGLE Calcium-channelBlockers:plasmaconcentrationofticagrelorincreasedbyDILTIAZEMlCardiacGlycosides:ticagrelorincreasesplasmaconcentrationoflDIGOXIN TRIANGLE Ciclosporin:plasmaconcentrationofticagrelorincreasedbyCICLOSPORINlErgotAlkaloids:ticagrelorpossiblyincreasesplasmaconcentrationoflERGOTALKALOIDSlLipid-regulatingDrugs:ticagrelorincreasesplasmaconcentrationoflSIMVASTATIN(increasedriskoftoxicity);separatingadministrationfromticagrelorby12hoursadvisedbymanufacturerofLOMITAPIDETicarcillinseePenicillinsTick-borneEncephalitisVaccineseeVaccinesTigecycline TRIANGLE Anticoagulants:tigecyclinepossiblyenhancesanticoagulanteffectofCOUMARINS TRIANGLE Vaccines:antibacterialsinactivateORALTYPHOIDVACCINE—seeunderTyphoidVaccineinBNFTimololseeBeta-blockersTinidazole TRIANGLE Alcohol:possibilityofdisulfiram-likereactionwhentinidazolegivenwithALCOHOL TRIANGLE Antibacterials:plasmaconcentrationoftinidazolepossiblyreducedbyRIFAMPICIN TRIANGLE Vaccines:antibacterialsinactivateORALTYPHOIDVACCINE—seeunderTyphoidVaccineinBNFTinzaparinseeHeparinsTioguaninelAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis) TRIANGLE Cytotoxics:increasedriskofhepatotoxicitywhentioguaninegivenwithBUSULFANTiotropiumseeAntimuscarinics1252Appendix1InteractionsBNF70Interactions|Appendix1"
"Tipranavir TRIANGLE Analgesics:plasmaconcentrationoftipranavirpossiblyreducedbyBUPRENORPHINE TRIANGLE Antacids:absorptionoftipranavirreducedbyANTACIDS(giveatleast2hoursapart)lAntibacterials:tipranavirincreasesplasmaconcentrationoflCLARITHROMYCIN(reducedoseofclarithromycininrenalimpairment),alsoplasmaconcentrationoftipranavirincreasedbyclarithromycin;tipranavirincreasesplasmaconcentrationoflRIFABUTIN(reducedoseofrifabutin);plasmaconcentrationoftipranavirpossiblyreducedbylRIFAMPICIN—avoidconcomitantuse;avoidanceofconcomitanttipranavirinsevererenalandhepaticimpairmentadvisedbymanufactureroflTELITHROMYCIN TRIANGLE Anticoagulants:avoidanceoftipranaviradvisedbymanufacturerofAPIXABANandRIVAROXABANlAntidepressants:plasmaconcentrationoftipranavirpossiblyreducedbylSTJOHN’SWORT—avoidconcomitantuse TRIANGLE Antiepileptics:plasmaconcentrationoftipranavirpossiblyreducedbyCARBAMAZEPINE TRIANGLE Antifungals:plasmaconcentrationoftipranavirincreasedbyFLUCONAZOLElAntimalarials:cautionwithtipranaviradvisedbymanufacturerofARTEMETHERWITHLUMEFANTRINE;tipranavirpossiblyincreasesplasmaconcentrationoflQUININE(increasedriskoftoxicity) TRIANGLE Antimuscarinics:avoidanceoftipranaviradvisedbymanufacturerofDARIFENACINlAntipsychotics:tipranavirpossiblyincreasesplasmaconcentrationoflARIPIPRAZOLE(reducedoseofaripiprazole—consultaripiprazoleproductliterature);tipranavirpossiblyincreasesplasmaconcentrationoflQUETIAPINE—manufacturerofquetiapineadvisesavoidconcomitantuselAntivirals:tipranavirreducesplasmaconcentrationoflABACAVIR,lFOSAMPRENAVIR,lLOPINAVIR,lSAQUINAVIRandlZIDOVUDINE;plasmaconcentrationoftipranavirincreasedbyATAZANAVIR(alsoplasmaconcentrationofatazanavirreduced);manufactureroftipranaviradvisesavoidconcomitantusewithBOCEPREVIRandTELAPREVIR;tipranavirreducesplasmaconcentrationofDIDANOSINE—manufactureroftipranaviradvisestipranaviranddidanosinecapsulesshouldbetakenatleast2hoursapart;tipranavirreducestheplasmaconcentrationoflDOLUTEGRAVIR(seeunderDolutegravir,p557);tipranavirreducesplasmaconcentrationoflETRAVIRINE,alsoplasmaconcentrationoftipranavirincreased(avoidconcomitantuse)lBeta-blockers:manufactureroftipranaviradvisesavoidconcomitantusewithlMETOPROLOLforheartfailure TRIANGLE Bosentan:manufactureroftipranaviradvisesavoidconcomitantusewithBOSENTANlCobicistat:plasmaconcentrationofbothdrugsreducedwhentipranavirgivenwithlCOBICISTAT(avoidconcomitantuse)lLipid-regulatingDrugs:increasedriskofmyopathywhentipranavirgivenwithlATORVASTATIN(seeunderAtorvastatin,p179);tipranavirincreasesplasmaconcentrationoflROSUVASTATIN—adjustdoseofrosuvastatin(consultproductliterature);tipranavirpossiblyincreasesplasmaconcentrationoflSIMVASTATIN—avoidconcomitantuse;avoidanceoftipranaviradvisedbymanufactureroflLOMITAPIDE(plasmaconcentrationoflomitapidepossiblyincreased)lOrlistat:absorptionoftipranavirpossiblyreducedbylORLISTATlRanolazine:tipranavirpossiblyincreasesplasmaconcentrationoflRANOLAZINE—manufacturerofranolazineadvisesavoidconcomitantuse TRIANGLE Sildenafil:manufactureroftipranaviradvisesavoidconcomitantuseofSILDENAFILforpulmonaryarterialhypertension TRIANGLE Sympathomimetics,Beta2:manufactureroftipranaviradvisesavoidconcomitantusewithSALMETEROLlUlcer-healingDrugs:tipranavirreducesplasmaconcentrationoflESOMEPRAZOLEandlOMEPRAZOLE TRIANGLE Vardenafil:manufactureroftipranaviradvisescautionwithVARDENAFILTipranavir(continued) TRIANGLE Vitamins:increasedriskofbleedingwhentipranavirgivenwithhighdosesofVITAMINETirofiban TRIANGLE Iloprost:increasedriskofbleedingwhentirofibangivenwithILOPROSTTizanidineseeMuscleRelaxantsTobramycinseeAminoglycosidesTocilizumablAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lVaccines:riskofgeneralisedinfectionswhenmonoclonalantibodiesgivenwithlivelVACCINES—avoidconcomitantuseTolazolineseeAlpha-blockersTolbutamideseeAntidiabeticsTolcapone TRIANGLE Antidepressants:avoidconcomitantuseoftolcaponewithMAOIS TRIANGLE Memantine:effectsofdopaminergicspossiblyenhancedbyMEMANTINE TRIANGLE Methyldopa:antiparkinsonianeffectofdopaminergicsantagonisedbyMETHYLDOPATolfenamicAcidseeNSAIDsTolterodineseeAntimuscarinicsTolvaptan TRIANGLE Antibacterials:plasmaconcentrationoftolvaptanreducedbyRIFAMPICIN TRIANGLE Antifungals:plasmaconcentrationoftolvaptanincreasedbyKETOCONAZOLE—manufacturerofketoconazoleadvisesavoidconcomitantuse TRIANGLE CardiacGlycosides:tolvaptanincreasesplasmaconcentrationofDIGOXIN(increasedriskoftoxicity)lGrapefruitJuice:plasmaconcentrationoftolvaptanincreasedbylGRAPEFRUITJUICE—avoidconcomitantuse TRIANGLE Lipid-regulatingDrugs:separatingadministrationfromtolvaptanby12hoursadvisedbymanufacturerofLOMITAPIDETopiramatelAntidepressants:anticonvulsanteffectofantiepilepticspossiblyantagonisedbyMAOISandlTRICYCLIC-RELATEDANTIDEPRESSANTS(convulsivethresholdlowered);anticonvulsanteffectofantiepilepticsantagonisedbylSSRISandlTRICYCLICS(convulsivethresholdlowered) TRIANGLE Antidiabetics:topiramatepossiblyincreasesplasmaconcentrationofMETFORMIN;topiramatepossiblyreducesplasmaconcentrationofGLIBENCLAMIDElAntiepileptics:plasmaconcentrationoftopiramateoftenreducedbyCARBAMAZEPINE;topiramateincreasesplasmaconcentrationoflFOSPHENYTOINandlPHENYTOIN(alsoplasmaconcentrationoftopiramatereduced);topiramatereducesplasmaconcentrationofPERAMPANEL;plasmaconcentrationoftopiramatepossiblyreducedbyPHENOBARBITALandPRIMIDONE;hyperammonaemiaandCNStoxicityreportedwhentopiramategivenwithSODIUMVALPROATEandVALPROICACIDlAntimalarials:anticonvulsanteffectofantiepilepticsantagonisedbylMEFLOQUINElAntipsychotics:anticonvulsanteffectofantiepilepticsantagonisedbylANTIPSYCHOTICS(convulsivethresholdlowered) TRIANGLE Diuretics:plasmaconcentrationoftopiramatepossiblyincreasedbyHYDROCHLOROTHIAZIDE TRIANGLE Lithium:topiramatepossiblyaffectsplasmaconcentrationofLITHIUMlOestrogens:topiramateacceleratesmetabolismoflOESTROGENS(reducedcontraceptiveeffectwithcombinedoralcontraceptives,contraceptivepatches,andvaginalrings—seeContraceptiveInteractionsinBNF)lOrlistat:possibleincreasedriskofconvulsionswhenantiepilepticsgivenwithlORLISTATlProgestogens:topiramateacceleratesmetabolismoflPROGESTOGENS(reducedcontraceptiveeffectwithcombinedoralcontraceptives,progestogen-onlyoralcontraceptives,contraceptivepatches,vaginalrings,etonogestrel-releasingimplant,andemergencyhormonalcontraception—seeContraceptiveInteractionsinBNF)BNF70Appendix1Interactions1253Interactions|Appendix1"
"TorasemideseeDiureticsToremifenelAnticoagulants:toremifenepossiblyenhancesanticoagulanteffectoflCOUMARINS TRIANGLE Antiepileptics:metabolismoftoremifenepossiblyacceleratedbyCARBAMAZEPINE(reducedplasmaconcentration);metabolismoftoremifenepossiblyacceleratedbyFOSPHENYTOINandPHENYTOIN;metabolismoftoremifeneacceleratedbyPHENOBARBITALandPRIMIDONE(reducedplasmaconcentration)lCytotoxics:possibleincreasedriskofventriculararrhythmiaswhentoremifenegivenwithlVANDETANIB—avoidconcomitantuse TRIANGLE Diuretics:increasedriskofhypercalcaemiawhentoremifenegivenwithTHIAZIDESANDRELATEDDIURETICSTrabectedinlAlcohol:manufactureroftrabectedinadvisesavoidconcomitantusewithlALCOHOLlAntibacterials:plasmaconcentrationoftrabectedinreducedbylRIFAMPICINlAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lVaccines:riskofgeneralisedinfectionswhentrabectedingivenwithlivelVACCINES—avoidconcomitantuseTramadolseeOpioidAnalgesicsTrandolaprilseeACEInhibitorsTranylcypromineseeMAOIsTrastuzumablAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lVaccines:riskofgeneralisedinfectionswhenmonoclonalantibodiesgivenwithlivelVACCINES—avoidconcomitantuseTrazodoneseeAntidepressants,Tricyclic(related)TretinoinseeRetinoidsTriamcinoloneseeCorticosteroidsTriamtereneseeDiureticsTrientine TRIANGLE IronSalts:trientinereducesabsorptionoforalIRONSALTS TRIANGLE Zinc:trientinereducesabsorptionofZINC,alsoabsorptionoftrientinereducedbyzincTrifluoperazineseeAntipsychoticsTrihexyphenidylseeAntimuscarinicsTrimethoprim TRIANGLE ACEInhibitors:possibleincreasedriskofhyperkalaemiawhentrimethoprimgivenwithACEINHIBITORS TRIANGLE Angiotensin-IIReceptorAntagonists:possibleincreasedriskofhyperkalaemiawhentrimethoprimgivenwithANGIOTENSIN-IIRECEPTORANTAGONISTS TRIANGLE Anti-arrhythmics:possibleincreasedriskofventriculararrhythmiaswhentrimethoprim(asco-trimoxazole)givenwithAMIODARONE—manufacturerofamiodaroneadvisesavoidconcomitantuseofco-trimoxazole TRIANGLE Antibacterials:plasmaconcentrationoftrimethoprimpossiblyreducedbyRIFAMPICIN;plasmaconcentrationofbothdrugsmayincreasewhentrimethoprimgivenwithDAPSONE TRIANGLE Anticoagulants:trimethoprimpossiblyenhancesanticoagulanteffectofCOUMARINS TRIANGLE Antidiabetics:trimethoprimpossiblyenhanceshypoglycaemiceffectofREPAGLINIDE—manufactureradvisesavoidconcomitantuse;trimethoprimrarelyenhancestheeffectsofSULFONYLUREASlAntiepileptics:trimethoprimincreasesplasmaconcentrationoflFOSPHENYTOINandlPHENYTOIN(alsoincreasedantifolateeffect)lAntimalarials:increasedantifolateeffectwhentrimethoprimgivenwithlPYRIMETHAMINE TRIANGLE Antivirals:trimethoprim(asco-trimoxazole)increasesplasmaconcentrationofLAMIVUDINE—avoidconcomitantuseofhigh-doseco-trimoxazolelAzathioprine:increasedriskofhaematologicaltoxicitywhentrimethoprim(alsowithco-trimoxazole)givenwithlAZATHIOPRINE TRIANGLE CardiacGlycosides:trimethoprimpossiblyincreasesplasmaconcentrationofDIGOXINTrimethoprim(continued)lCiclosporin:increasedriskofnephrotoxicitywhentrimethoprimgivenwithlCICLOSPORIN,alsoplasmaconcentrationofciclosporinreducedbyintravenoustrimethoprimlCytotoxics:increasedriskofhaematologicaltoxicitywhentrimethoprim(alsowithco-trimoxazole)givenwithlMERCAPTOPURINEorlMETHOTREXATE TRIANGLE Diuretics:increasedriskofhyperkalaemiawhentrimethoprimgivenwithEPLERENONE;possibleincreasedriskofhyperkalaemiawhentrimethoprimgivenwithSPIRONOLACTONE TRIANGLE Vaccines:antibacterialsinactivateORALTYPHOIDVACCINE—seeunderTyphoidVaccineinBNFTrimipramineseeAntidepressants,TricyclicTripotassiumDicitratobismuthate TRIANGLE Antibacterials:tripotassiumdicitratobismuthatereducesabsorptionofTETRACYCLINESTropicamideseeAntimuscarinicsTrospiumseeAntimuscarinicsTyphoidVaccine(oral)seeVaccinesTyphoidVaccine(parenteral)seeVaccinesUbidecarenone TRIANGLE Anticoagulants:ubidecarenonemayenhanceorreduceanticoagulanteffectofWARFARINUlcer-healingDrugsseeHistamineH2-antagonists,ProtonPumpInhibitors,Sucralfate,andTripotassiumDicitratobismuthateUlipristallAntibacterials:manufactureroflow-doseulipristaladvisesavoidconcomitantusewithCLARITHROMYCINandTELITHROMYCIN;plasmaconcentrationoflow-doseulipristalincreasedbyERYTHROMYCIN—manufactureroflow-doseulipristaladvisesavoidconcomitantuse;manufacturerofulipristaladvisesavoidconcomitantusewithlRIFAMPICIN(contraceptiveeffectofulipristalpossiblyreduced) TRIANGLE Anticoagulants:manufacturerofulipristaladvisesgiveDABIGATRANatleast15hoursbeforeorafterulipristallAntidepressants:manufacturerofulipristaladvisesavoidconcomitantusewithlSTJOHN’SWORT(contraceptiveeffectofulipristalpossiblyreduced)lAntiepileptics:manufacturerofulipristaladvisesavoidconcomitantusewithlCARBAMAZEPINE,lFOSPHENYTOIN,lPHENOBARBITAL,lPHENYTOINandlPRIMIDONE(contraceptiveeffectofulipristalpossiblyreduced) TRIANGLE Antifungals:plasmaconcentrationoflow-doseulipristalincreasedbyKETOCONAZOLE—manufactureroflow-doseulipristaladvisesavoidconcomitantuse;manufacturerofulipristaladvisesavoidconcomitantusewithITRACONAZOLE TRIANGLE Antihistamines:manufacturerofulipristaladvisesgiveFEXOFENADINEatleast15hoursbeforeorafterulipristallAntivirals:manufacturerofulipristaladvisesavoidconcomitantusewithlRITONAVIR(contraceptiveeffectofulipristalpossiblyreduced) TRIANGLE Calcium-channelBlockers:manufactureroflow-doseulipristaladvisesavoidconcomitantusewithVERAPAMIL TRIANGLE CardiacGlycosides:manufacturerofulipristaladvisesgiveDIGOXINatleast15hoursbeforeorafterulipristal TRIANGLE GrapefruitJuice:manufactureroflow-doseulipristaladvisesavoidconcomitantusewithGRAPEFRUITJUICElProgestogens:ulipristalpossiblyreducescontraceptiveeffectoflPROGESTOGENSUmeclidiniumseeAntimuscarinicsUrsodeoxycholicAcidseeBileAcidsUstekinumablAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lVaccines:riskofgeneralisedinfectionswhenmonoclonalantibodiesgivenwithlivelVACCINES—avoidconcomitantuseVaccineslAbatacept:riskofgeneralisedinfectionswhenlivevaccinesgivenwithlABATACEPT—avoidconcomitantuse TRIANGLE Aminophylline:influenzavaccinepossiblyincreasesplasmaconcentrationofAMINOPHYLLINE1254Appendix1InteractionsBNF70Interactions|Appendix1"
"Vaccines(continued)lAnakinra:riskofgeneralisedinfectionswhenlivevaccinesgivenwithlANAKINRA—avoidconcomitantuse TRIANGLE Antibacterials:oraltyphoidvaccineinactivatedbyANTIBACTERIALS—seeunderTyphoidVaccineinBNF TRIANGLE Anticoagulants:influenzavaccinepossiblyenhancesanticoagulanteffectofWARFARIN TRIANGLE Antiepileptics:influenzavaccineenhanceseffectsofFOSPHENYTOINandPHENYTOIN TRIANGLE Antimalarials:oraltyphoidvaccineinactivatedbyANTIMALARIALS—seeunderTyphoidVaccineinBNFlCorticosteroids:immuneresponsetovaccinesimpairedbyhighdosesoflCORTICOSTEROIDS—avoidconcomitantusewithlivevaccineslCytotoxics:riskofgeneralisedinfectionswhenlivevaccinesgivenwithlDOXORUBICIN,lMONOCLONALANTIBODIES,lPIXANTRONEorlTRABECTEDIN—avoidconcomitantuselDexrazoxane:riskofgeneralisedinfectionswhenlivevaccinesgivenwithlDEXRAZOXANE—avoidconcomitantuselEtanercept:riskofgeneralisedinfectionswhenlivevaccinesgivenwithlETANERCEPT—avoidconcomitantuselImmunoglobulins:impairedimmuneresponsetooralpoliomyelitisvaccinemightoccurwithlANTI-DIMMUNOGLOBULINSandlNORMALIMMUNOGLOBULIN—giveoralpoliomyelitisvaccineatleast3weeksbeforeor3monthsafteranti-dimmunoglobulinsandnormalimmunoglobulin;impairedimmuneresponsetoBCGvaccine,MMRvaccine,oraltyphoidvaccine,rotavirusvaccine,smallpoxvaccine,varicella-zostervaccineandyellowfevervaccinemightoccurwithlANTI-DIMMUNOGLOBULINS—giveBCGvaccine,MMRvaccine,oraltyphoidvaccine,rotavirusvaccine,smallpoxvaccine,varicella-zostervaccineandyellowfevervaccineatleast3weeksbeforeor3monthsafteranti-dimmunoglobulins;impairedimmuneresponsetoliveinfluenzavaccinemightoccurwithlANTI-DIMMUNOGLOBULINSandlNORMALIMMUNOGLOBULIN—giveliveinfluenzavaccineatleast3weeksbeforeor3monthsafteranti-dimmunoglobulinsandnormalimmunoglobulin;impairedimmuneresponsetoBCGvaccine,MMRvaccine,oraltyphoidvaccine,rotavirusvaccine,smallpoxvaccine,varicella-zostervaccineandyellowfevervaccinemightoccurwithlNORMALIMMUNOGLOBULIN—giveBCGvaccine,MMRvaccine,oraltyphoidvaccine,rotavirusvaccine,smallpoxvaccine,varicella-zostervaccineandyellowfevervaccineatleast3weeksbeforeor3monthsafternormalimmunoglobulin TRIANGLE Interferons:avoidanceofvaccinesadvisedbymanufacturerofINTERFERONGAMMAlLeflunomide:riskofgeneralisedinfectionswhenlivevaccinesgivenwithlLEFLUNOMIDE—avoidconcomitantuselTeriflunomide:riskofgeneralisedinfectionswhenlivevaccinesgivenwithlTERIFLUNOMIDE—avoidconcomitantuse TRIANGLE Theophylline:influenzavaccinepossiblyincreasesplasmaconcentrationofTHEOPHYLLINEValaciclovir TRIANGLE Aminophylline:valaciclovirpossiblyincreasesplasmaconcentrationofAMINOPHYLLINE TRIANGLE Ciclosporin:increasedriskofnephrotoxicitywhenvalaciclovirgivenwithCICLOSPORIN TRIANGLE Mycophenolate:plasmaconcentrationofvalaciclovirincreasedbyMYCOPHENOLATE,alsoplasmaconcentrationofinactivemetaboliteofmycophenolateincreased TRIANGLE Tacrolimus:possibleincreasedriskofnephrotoxicitywhenvalaciclovirgivenwithTACROLIMUS TRIANGLE Theophylline:valaciclovirpossiblyincreasesplasmaconcentrationofTHEOPHYLLINEValganciclovirlAntibacterials:increasedriskofconvulsionswhenvalganciclovirgivenwithlIMIPENEMWITHCILASTATINlAntivirals:valganciclovirpossiblyincreasesplasmaconcentrationofDIDANOSINE;profoundmyelosuppressionwhenvalganciclovirgivenwithlZIDOVUDINE(ifpossibleavoidconcomitantadministration,particularlyduringinitialvalganciclovirtherapy) TRIANGLE Mycophenolate:plasmaconcentrationofvalganciclovirpossiblyincreasedbyMYCOPHENOLATE,alsoplasmaValganciclovirMycophenolate(continued)concentrationofinactivemetaboliteofmycophenolatepossiblyincreased TRIANGLE Tacrolimus:possibleincreasedriskofnephrotoxicitywhenvalganciclovirgivenwithTACROLIMUSValproicAcid TRIANGLE Analgesics:effectsofvalproicacidenhancedbyASPIRINlAntibacterials:metabolismofvalproicacidpossiblyinhibitedbyERYTHROMYCIN(increasedplasmaconcentration);avoidanceofvalproicacidadvisedbymanufactureroflPIVMECILLINAM;plasmaconcentrationofvalproicacidreducedbylCARBAPENEMS—avoidconcomitantuse TRIANGLE Anticoagulants:valproicacidpossiblyenhancesanticoagulanteffectofCOUMARINSlAntidepressants:anticonvulsanteffectofantiepilepticspossiblyantagonisedbyMAOISandlTRICYCLIC-RELATEDANTIDEPRESSANTS(convulsivethresholdlowered);anticonvulsanteffectofantiepilepticsantagonisedbylSSRISandlTRICYCLICS(convulsivethresholdlowered)lAntiepileptics:plasmaconcentrationofvalproicacidreducedbyCARBAMAZEPINE,alsoplasmaconcentrationofactivemetaboliteofcarbamazepineincreased;valproicacidpossiblyincreasesplasmaconcentrationofETHOSUXIMIDE;valproicacidincreasesorpossiblydecreasesplasmaconcentrationofFOSPHENYTOINandPHENYTOIN,alsoplasmaconcentrationofvalproicacidreduced;valproicacidincreasesplasmaconcentrationoflLAMOTRIGINE(increasedriskoftoxicity—reducelamotriginedose);valproicacidsometimesreducesplasmaconcentrationofanactivemetaboliteofOXCARBAZEPINE;valproicacidincreasesplasmaconcentrationofPHENOBARBITALandPRIMIDONE(alsoplasmaconcentrationofvalproicacidreduced);valproicacidpossiblyincreasesplasmaconcentrationofRUFINAMIDE(reducedoseofrufinamide);hyperammonaemiaandCNStoxicityreportedwhenvalproicacidgivenwithTOPIRAMATElAntimalarials:anticonvulsanteffectofantiepilepticsantagonisedbylMEFLOQUINElAntipsychotics:anticonvulsanteffectofantiepilepticsantagonisedbylANTIPSYCHOTICS(convulsivethresholdlowered);valproicacidpossiblyincreasesordecreasesplasmaconcentrationofCLOZAPINE;increasedriskofside-effectsincludingneutropeniawhenvalproicacidgivenwithlOLANZAPINE TRIANGLE Antivirals:plasmaconcentrationofvalproicacidpossiblyreducedbyRITONAVIR;valproicacidpossiblyincreasesplasmaconcentrationofZIDOVUDINE(increasedriskoftoxicity) TRIANGLE AnxiolyticsandHypnotics:plasmaconcentrationofvalproicacidpossiblyincreasedbyCLOBAZAM;increasedriskofside-effectswhenvalproicacidgivenwithCLONAZEPAM;valproicacidpossiblyincreasesplasmaconcentrationofDIAZEPAMandLORAZEPAM TRIANGLE Bupropion:valproicacidinhibitsthemetabolismofBUPROPION TRIANGLE Cytotoxics:valproicacidincreasesplasmaconcentrationofTEMOZOLOMIDE TRIANGLE Lipid-regulatingDrugs:absorptionofvalproicacidpossiblyreducedbyCOLESTYRAMINE TRIANGLE Oestrogens:plasmaconcentrationofvalproicacidpossiblyreducedbyETHINYLESTRADIOLlOrlistat:possibleincreasedriskofconvulsionswhenantiepilepticsgivenwithlORLISTAT TRIANGLE SodiumBenzoate:valproicacidpossiblyreduceseffectsofSODIUMBENZOATElSodiumOxybate:valproicacidincreasestheplasmaconcentrationoflSODIUMOXYBATE(seeunderSodiumOxybate,p425) TRIANGLE SodiumPhenylbutyrate:valproicacidpossiblyreduceseffectsofSODIUMPHENYLBUTYRATElUlcer-healingDrugs:metabolismofvalproicacidinhibitedbylCIMETIDINE(increasedplasmaconcentration)ValsartanseeAngiotensin-IIReceptorAntagonistsVancomycin TRIANGLE Anaesthetics,General:hypersensitivity-likereactionscanoccurwhenintravenousvancomycingivenwithGENERALANAESTHETICSBNF70Appendix1Interactions1255Interactions|Appendix1"
"Vancomycin(continued)lAntibacterials:increasedriskofnephrotoxicityandototoxicitywhenvancomycingivenwithlAMINOGLYCOSIDES,CAPREOMYCINorCOLISTIMETHATESODIUM;increasedriskofnephrotoxicitywhenvancomycingivenwithPOLYMYXINS TRIANGLE Antifungals:possibleincreasedriskofnephrotoxicitywhenvancomycingivenwithAMPHOTERICINlCiclosporin:increasedriskofnephrotoxicitywhenvancomycingivenwithlCICLOSPORIN TRIANGLE Cytotoxics:increasedriskofnephrotoxicityandpossiblyofototoxicitywhenvancomycingivenwithCISPLATINlDiuretics:increasedriskofotoxicitywhenvancomycingivenwithlLOOPDIURETICS TRIANGLE Lipid-regulatingDrugs:effectsoforalvancomycinantagonisedbyCOLESTYRAMINElMuscleRelaxants:vancomycinenhanceseffectsoflSUXAMETHONIUM TRIANGLE Tacrolimus:possibleincreasedriskofnephrotoxicitywhenvancomycingivenwithTACROLIMUS TRIANGLE Vaccines:antibacterialsinactivateORALTYPHOIDVACCINE—seeunderTyphoidVaccineinBNFVandetaniblAnalgesics:possibleincreasedriskofventriculararrhythmiaswhenvandetanibgivenwithlMETHADONE—avoidconcomitantuselAnti-arrhythmics:possibleincreasedriskofventriculararrhythmiaswhenvandetanibgivenwithlAMIODARONEorlDISOPYRAMIDE—avoidconcomitantuselAntibacterials:possibleincreasedriskofventriculararrhythmiaswhenvandetanibgivenwithparenterallERYTHROMYCIN—avoidconcomitantuse;possibleincreasedriskofventriculararrhythmiaswhenvandetanibgivenwithlMOXIFLOXACIN—avoidconcomitantuse;plasmaconcentrationofvandetanibreducedbylRIFAMPICIN—manufacturerofvandetanibadvisesavoidconcomitantuse TRIANGLE Antidepressants:manufacturerofvandetanibadvisesavoidconcomitantusewithSTJOHN’SWORT(plasmaconcentrationofvandetanibpossiblyreduced) TRIANGLE Antidiabetics:vandetanibpossiblyincreasesplasmaconcentrationofMETFORMIN(considerreducingdoseofmetformin) TRIANGLE Antiepileptics:manufacturerofvandetanibadvisesavoidconcomitantusewithCARBAMAZEPINE,PHENOBARBITALandPRIMIDONE(plasmaconcentrationofvandetanibpossiblyreduced)lAntihistamines:possibleincreasedriskofventriculararrhythmiaswhenvandetanibgivenwithlMIZOLASTINE—avoidconcomitantuselAntimalarials:possibleincreasedriskofventriculararrhythmiaswhenvandetanibgivenwithlARTEMETHERWITHLUMEFANTRINE—avoidconcomitantuselAntipsychotics:possibleincreasedriskofventriculararrhythmiaswhenvandetanibgivenwithlAMISULPRIDE,lCHLORPROMAZINE,lHALOPERIDOL,lPIMOZIDE,lSULPIRIDEorlZUCLOPENTHIXOL—avoidconcomitantuse;avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lBeta-blockers:possibleincreasedriskofventriculararrhythmiaswhenvandetanibgivenwithlSOTALOL—avoidconcomitantuse TRIANGLE CardiacGlycosides:vandetanibincreasesplasmaconcentrationofDIGOXIN—possibleincreasedriskofbradycardialCytotoxics:possibleincreasedriskofventriculararrhythmiaswhenvandetanibgivenwithlARSENICTRIOXIDE—avoidconcomitantuselHormoneAntagonists:possibleincreasedriskofventriculararrhythmiaswhenvandetanibgivenwithlTOREMIFENE—avoidconcomitantusel5HT3-receptorAntagonists:increasedriskofventriculararrhythmiaswhenvandetanibgivenwithlONDANSETRON—avoidconcomitantuselPentamidineIsetionate:possibleincreasedriskofventriculararrhythmiaswhenvandetanibgivenwithlPENTAMIDINEISETIONATE—avoidconcomitantuseVardenafillAlpha-blockers:enhancedhypotensiveeffectwhenvardenafilgivenwithlALPHA-BLOCKERS—whenpatientisstableonthealphablockerinitiatevardenafilatthelowestpossibledose—separatedosesby6hours(exceptwithtamsulosin) TRIANGLE Anti-arrhythmics:avoidanceofvardenafiladvisedbymanufacturerofDISOPYRAMIDE(riskofventriculararrhythmias) TRIANGLE Antibacterials:plasmaconcentrationofvardenafilpossiblyincreasedbyCLARITHROMYCIN(considerreducinginitialdoseofvardenafil);plasmaconcentrationofvardenafilincreasedbyERYTHROMYCIN(reducedoseofvardenafil)lAntifungals:plasmaconcentrationofvardenafilincreasedbylKETOCONAZOLE—avoidconcomitantuse;plasmaconcentrationofvardenafilpossiblyincreasedbylITRACONAZOLE—avoidconcomitantuselAntivirals:plasmaconcentrationofvardenafilpossiblyincreasedbyFOSAMPRENAVIR;plasmaconcentrationofvardenafilincreasedbylINDINAVIRandlRITONAVIR—avoidconcomitantuse;increasedriskofventriculararrhythmiaswhenvardenafilgivenwithlSAQUINAVIR—avoidconcomitantuse;avoidanceofvardenafiladvisedbymanufactureroflTELAPREVIR;cautionwithvardenafiladvisedbymanufacturerofTIPRANAVIR TRIANGLE Calcium-channelBlockers:enhancedhypotensiveeffectwhenvardenafilgivenwithNIFEDIPINElCobicistat:plasmaconcentrationofvardenafilpossiblyincreasedbylCOBICISTAT—manufacturerofcobicistatadvisesreducedoseofvardenafil(consultcobicistatproductliterature) TRIANGLE Dapoxetine:avoidanceofvardenafiladvisedbymanufacturerofDAPOXETINElGrapefruitJuice:plasmaconcentrationofvardenafilpossiblyincreasedbylGRAPEFRUITJUICE—avoidconcomitantuselNicorandil:possibleincreasedhypotensiveeffectwhenvardenafilgivenwithlNICORANDIL—avoidconcomitantuselNitrates:possibleincreasedhypotensiveeffectwhenvardenafilgivenwithlNITRATES—avoidconcomitantuselRiociguat:possibleenhancedhypotensiveeffectwhenvardenafilgivenwithlRIOCIGUAT—avoidconcomitantuseVaricella-zosterVaccineseeVaccinesVasodilatorAntihypertensives TRIANGLE ACEInhibitors:enhancedhypotensiveeffectwhenhydralazine,minoxidilorsodiumnitroprussidegivenwithACEINHIBITORS TRIANGLE AdrenergicNeuroneBlockers:enhancedhypotensiveeffectwhenhydralazine,minoxidilorsodiumnitroprussidegivenwithADRENERGICNEURONEBLOCKERS TRIANGLE Alcohol:enhancedhypotensiveeffectwhenhydralazine,minoxidilorsodiumnitroprussidegivenwithALCOHOL TRIANGLE Aldesleukin:enhancedhypotensiveeffectwhenhydralazine,minoxidilorsodiumnitroprussidegivenwithALDESLEUKIN TRIANGLE Alpha-blockers:enhancedhypotensiveeffectwhenhydralazine,minoxidilorsodiumnitroprussidegivenwithALPHA-BLOCKERS TRIANGLE Anaesthetics,General:enhancedhypotensiveeffectwhenhydralazine,minoxidilorsodiumnitroprussidegivenwithGENERALANAESTHETICS TRIANGLE Analgesics:hypotensiveeffectofhydralazine,minoxidilandsodiumnitroprussideantagonisedbyNSAIDS TRIANGLE Angiotensin-IIReceptorAntagonists:enhancedhypotensiveeffectwhenhydralazine,minoxidilorsodiumnitroprussidegivenwithANGIOTENSIN-IIRECEPTORANTAGONISTS TRIANGLE Antidepressants:enhancedhypotensiveeffectwhenhydralazine,minoxidilorsodiumnitroprussidegivenwithMAOIS;enhancedhypotensiveeffectwhenhydralazineorsodiumnitroprussidegivenwithTRICYCLIC-RELATEDANTIDEPRESSANTS TRIANGLE Antipsychotics:enhancedhypotensiveeffectwhenhydralazine,minoxidilorsodiumnitroprussidegivenwithPHENOTHIAZINES TRIANGLE AnxiolyticsandHypnotics:enhancedhypotensiveeffectwhenhydralazine,minoxidilorsodiumnitroprussidegivenwithANXIOLYTICSANDHYPNOTICS TRIANGLE Beta-blockers:enhancedhypotensiveeffectwhenhydralazine,minoxidilorsodiumnitroprussidegivenwithBETA-BLOCKERS1256Appendix1InteractionsBNF70Interactions|Appendix1"
"VasodilatorAntihypertensives(continued) TRIANGLE Calcium-channelBlockers:enhancedhypotensiveeffectwhenhydralazine,minoxidilorsodiumnitroprussidegivenwithCALCIUM-CHANNELBLOCKERS TRIANGLE Clonidine:enhancedhypotensiveeffectwhenhydralazine,minoxidilorsodiumnitroprussidegivenwithCLONIDINE TRIANGLE Corticosteroids:hypotensiveeffectofhydralazine,minoxidilandsodiumnitroprussideantagonisedbyCORTICOSTEROIDS TRIANGLE Diazoxide:enhancedhypotensiveeffectwhenhydralazine,minoxidilorsodiumnitroprussidegivenwithDIAZOXIDE TRIANGLE Diuretics:enhancedhypotensiveeffectwhenhydralazine,minoxidilorsodiumnitroprussidegivenwithDIURETICS TRIANGLE Dopaminergics:enhancedhypotensiveeffectwhenhydralazine,minoxidilorsodiumnitroprussidegivenwithCO-BENELDOPA;enhancedhypotensiveeffectwhenhydralazine,minoxidilorsodiumnitroprussidegivenwithCO-CARELDOPA;enhancedhypotensiveeffectwhenhydralazine,minoxidilorsodiumnitroprussidegivenwithLEVODOPA TRIANGLE Methyldopa:enhancedhypotensiveeffectwhenhydralazine,minoxidilorsodiumnitroprussidegivenwithMETHYLDOPA TRIANGLE Moxisylyte:enhancedhypotensiveeffectwhenhydralazine,minoxidilorsodiumnitroprussidegivenwithMOXISYLYTE TRIANGLE Moxonidine:enhancedhypotensiveeffectwhenhydralazine,minoxidilorsodiumnitroprussidegivenwithMOXONIDINE TRIANGLE MuscleRelaxants:enhancedhypotensiveeffectwhenhydralazine,minoxidilorsodiumnitroprussidegivenwithBACLOFEN;enhancedhypotensiveeffectwhenhydralazine,minoxidilorsodiumnitroprussidegivenwithTIZANIDINE TRIANGLE Nicorandil:possibleenhancedhypotensiveeffectwhenhydralazine,minoxidilorsodiumnitroprussidegivenwithNICORANDIL TRIANGLE Nitrates:enhancedhypotensiveeffectwhenhydralazine,minoxidilorsodiumnitroprussidegivenwithNITRATES TRIANGLE Oestrogens:hypotensiveeffectofhydralazine,minoxidilandsodiumnitroprussideantagonisedbyOESTROGENS TRIANGLE Prostaglandins:enhancedhypotensiveeffectwhenhydralazine,minoxidilorsodiumnitroprussidegivenwithALPROSTADIL TRIANGLE VasodilatorAntihypertensives:enhancedhypotensiveeffectwhenhydralazinegivenwithMINOXIDILorSODIUMNITROPRUSSIDE;enhancedhypotensiveeffectwhenminoxidilgivenwithSODIUMNITROPRUSSIDEVecuroniumseeMuscleRelaxantsVedolizumablAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lVaccines:riskofgeneralisedinfectionswhenmonoclonalantibodiesgivenwithlivelVACCINES—avoidconcomitantuseVemurafenib TRIANGLE Antibacterials:manufacturerofvemurafenibadvisesavoidconcomitantusewithRIFABUTINandRIFAMPICINlAnticoagulants:vemurafenibpossiblyenhancesanticoagulanteffectoflWARFARIN TRIANGLE Antidepressants:manufacturerofvemurafenibadvisesavoidconcomitantusewithSTJOHN’SWORT TRIANGLE Antiepileptics:manufacturerofvemurafenibadvisesavoidconcomitantusewithCARBAMAZEPINE,FOSPHENYTOINandPHENYTOINlAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis) TRIANGLE Cytotoxics:avoidanceofvemurafenibadvisedbymanufacturerofIPILIMUMABlOestrogens:manufacturerofvemurafenibadvisescontraceptiveeffectoflOESTROGENSpossiblyreducedlProgestogens:manufacturerofvemurafenibadvisescontraceptiveeffectoflPROGESTOGENSpossiblyreducedVenlafaxinelAnalgesics:increasedriskofbleedingwhenvenlafaxinegivenwithlNSAIDSorlASPIRIN;possibleincreasedserotonergiceffectswhenSSRI-relatedantidepressantsgivenwithFENTANYL;possibleincreasedserotonergiceffectswhenvenlafaxinegivenwithTRAMADOLlAnticoagulants:venlafaxinepossiblyenhancesanticoagulanteffectoflWARFARIN;possibleincreasedriskofbleedingwhenSSRI-relatedantidepressantsgivenwithlDABIGATRANVenlafaxine(continued)lAntidepressants:possibleincreasedserotonergiceffectswhenvenlafaxinegivenwithSTJOHN’SWORT,DULOXETINEorMIRTAZAPINE;enhancedCNSeffectsandtoxicitywhenvenlafaxinegivenwithlMAOIS(venlafaxineshouldnotbestarteduntil2weeksafterstoppingMAOIs,avoidMAOIsfor1weekafterstoppingvenlafaxine);afterstoppingSSRI-relatedantidepressantsdonotstartlMOCLOBEMIDEforatleast1weeklAntimalarials:avoidanceofantidepressantsadvisedbymanufactureroflARTEMETHERWITHLUMEFANTRINEandlARTENIMOLWITHPIPERAQUINE TRIANGLE Antipsychotics:venlafaxineincreasesplasmaconcentrationofHALOPERIDOL TRIANGLE Atomoxetine:possibleincreasedriskofconvulsionswhenantidepressantsgivenwithATOMOXETINElDapoxetine:possibleincreasedriskofserotonergiceffectswhenvenlafaxinegivenwithlDAPOXETINE(manufacturerofdapoxetineadvisesvenlafaxineshouldnotbestarteduntil1weekafterstoppingdapoxetine,avoiddapoxetinefor2weeksafterstoppingvenlafaxine)lDopaminergics:cautionwithvenlafaxineadvisedbymanufacturerofENTACAPONE;increasedriskofhypertensionandCNSexcitationwhenvenlafaxinegivenwithlSELEGILINE(selegilineshouldnotbestarteduntil1weekafterstoppingvenlafaxine,avoidvenlafaxinefor2weeksafterstoppingselegiline) TRIANGLE 5HT1-receptorAgonists:possibleincreasedserotonergiceffectswhenvenlafaxinegivenwith5HT1AGONISTS TRIANGLE 5HT3-receptorAntagonists:possibleincreasedserotonergiceffectswhenSSRI-relatedantidepressantsgivenwith5HT3ANTAGONISTS TRIANGLE Lithium:possibleincreasedserotonergiceffectswhenvenlafaxinegivenwithLITHIUMlMethylthioninium:riskofCNStoxicitywhenSSRI-relatedantidepressantsgivenwithlMETHYLTHIONINIUM—avoidconcomitantuse(ifavoidancenotpossible,uselowestpossibledoseofmethylthioniniumandobservepatientforupto4hoursafteradministration)VerapamilseeCalcium-channelBlockersVigabatrinlAntidepressants:anticonvulsanteffectofantiepilepticspossiblyantagonisedbyMAOISandlTRICYCLIC-RELATEDANTIDEPRESSANTS(convulsivethresholdlowered);anticonvulsanteffectofantiepilepticsantagonisedbylSSRISandlTRICYCLICS(convulsivethresholdlowered) TRIANGLE Antiepileptics:vigabatrinreducesplasmaconcentrationofFOSPHENYTOINandPHENYTOINlAntimalarials:anticonvulsanteffectofantiepilepticsantagonisedbylMEFLOQUINElAntipsychotics:anticonvulsanteffectofantiepilepticsantagonisedbylANTIPSYCHOTICS(convulsivethresholdlowered)lOrlistat:possibleincreasedriskofconvulsionswhenantiepilepticsgivenwithlORLISTATVilanterolseeSympathomimetics,Beta2VildagliptinseeAntidiabeticsVinblastinelAldesleukin:avoidanceofvinblastineadvisedbymanufactureroflALDESLEUKINlAntibacterials:toxicityofvinblastineincreasedbylERYTHROMYCIN—avoidconcomitantuse;possibleincreasedriskofventriculararrhythmiaswhenvinblastinegivenwithlDELAMANIDlAntifungals:possibleincreasedriskofvinblastinetoxicitywhengivenwithlITRACONAZOLE;metabolismofvinblastinepossiblyinhibitedbylPOSACONAZOLE(increasedriskofneurotoxicity)lAntimalarials:avoidanceofvinblastineadvisedbymanufactureroflARTENIMOLWITHPIPERAQUINElAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis) TRIANGLE Antivirals:plasmaconcentrationofvinblastinepossiblyincreasedbyRITONAVIRBNF70Appendix1Interactions1257Interactions|Appendix1"
"VincristinelAntibacterials:possibleincreasedriskofventriculararrhythmiaswhenvincristinegivenwithlDELAMANIDlAntifungals:increasedriskofvincristinetoxicitywhengivenwithlITRACONAZOLE;metabolismofvincristinepossiblyinhibitedbylPOSACONAZOLE(increasedriskofneurotoxicity)lAntimalarials:avoidanceofvincristineadvisedbymanufactureroflARTENIMOLWITHPIPERAQUINElAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis) TRIANGLE Calcium-channelBlockers:metabolismofvincristinepossiblyinhibitedbyNIFEDIPINE TRIANGLE CardiacGlycosides:vincristinepossiblyreducesabsorptionofDIGOXINtabletsVindesinelAntibacterials:possibleincreasedriskofventriculararrhythmiaswhenvindesinegivenwithlDELAMANIDlAntifungals:possibleincreasedriskofvindesinetoxicitywhengivenwithlITRACONAZOLElAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)VinfluninelAntibacterials:plasmaconcentrationofvinfluninepossiblyreducedbylRIFAMPICIN—manufacturerofvinflunineadvisesavoidconcomitantuse;increasedriskofventriculararrhythmiaswhenvinfluninegivenwithlDELAMANIDlAntidepressants:plasmaconcentrationofvinfluninepossiblyreducedbylSTJOHN’SWORT—manufacturerofvinflunineadvisesavoidconcomitantuselAntifungals:plasmaconcentrationofvinflunineincreasedbylKETOCONAZOLE—manufacturerofvinflunineadvisesavoidconcomitantuse;possibleincreasedriskofvinfluninetoxicitywhengivenwithlITRACONAZOLElAntimalarials:avoidanceofvinflunineadvisedbymanufactureroflARTENIMOLWITHPIPERAQUINElAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lAntivirals:plasmaconcentrationofvinfluninepossiblyincreasedbylRITONAVIR—manufacturerofvinflunineadvisesavoidconcomitantuse TRIANGLE GrapefruitJuice:plasmaconcentrationofvinfluninepossiblyincreasedbyGRAPEFRUITJUICE—manufacturerofvinflunineadvisesavoidconcomitantuseVinorelbinelAntibacterials:possibleincreasedriskofneutropeniawhenvinorelbinegivenwithlCLARITHROMYCIN;possibleincreasedriskofventriculararrhythmiaswhenvinorelbinegivenwithlDELAMANIDlAntifungals:possibleincreasedriskofvinorelbinetoxicitywhengivenwithlITRACONAZOLElAntimalarials:avoidanceofvinorelbineadvisedbymanufactureroflARTENIMOLWITHPIPERAQUINElAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)VismodegiblAntibacterials:manufacturerofvismodegibadvisesavoidconcomitantusewithlRIFAMPICIN(plasmaconcentrationofvismodegibpossiblyreduced)lAntidepressants:manufacturerofvismodegibadvisesavoidconcomitantusewithlSTJOHN’SWORT(plasmaconcentrationofvismodegibpossiblyreduced)lAntiepileptics:manufacturerofvismodegibadvisesavoidconcomitantusewithlCARBAMAZEPINE,lFOSPHENYTOINandlPHENYTOIN(plasmaconcentrationofvismodegibpossiblyreduced)lAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)VitaminAseeVitaminsVitaminDseeVitaminsVitaminEseeVitaminsVitaminK(Phytomenadione)seeVitaminsVitamins TRIANGLE Antibacterials:absorptionofvitaminApossiblyreducedbyNEOMYCINVitamins(continued)lAnticoagulants:vitaminEpossiblyenhancesanticoagulanteffectoflCOUMARINS;vitaminKantagonisesanticoagulanteffectoflCOUMARINSandlPHENINDIONE TRIANGLE Antiepileptics:alfacalcidol,calcitriol,colecalciferol,dihydrotachysterol,ergocalciferol,paricalcitolorvitaminDrequirementspossiblyincreasedwhengivenwithCARBAMAZEPINE;alfacalcidol,calcitriol,colecalciferol,dihydrotachysterol,ergocalciferol,paricalcitolorvitaminDrequirementspossiblyincreasedwhengivenwithFOSPHENYTOIN;alfacalcidol,calcitriol,colecalciferol,dihydrotachysterol,ergocalciferol,paricalcitolorvitaminDrequirementspossiblyincreasedwhengivenwithPHENOBARBITAL;alfacalcidol,calcitriol,colecalciferol,dihydrotachysterol,ergocalciferol,paricalcitolorvitaminDrequirementspossiblyincreasedwhengivenwithPHENYTOIN;alfacalcidol,calcitriol,colecalciferol,dihydrotachysterol,ergocalciferol,paricalcitolorvitaminDrequirementspossiblyincreasedwhengivenwithPRIMIDONE TRIANGLE Antifungals:plasmaconcentrationofparicalcitolpossiblyincreasedbyKETOCONAZOLE;effectsofalfacalcidol,calcitriol,colecalciferol,dihydrotachysterol,ergocalciferol,paricalcitolandvitaminDpossiblyreducedbyMICONAZOLE TRIANGLE Antivirals:increasedriskofbleedingwhenhighdosesofvitaminEgivenwithTIPRANAVIR TRIANGLE Ciclosporin:vitaminEpossiblyaffectsplasmaconcentrationofCICLOSPORIN TRIANGLE Cytotoxics:effectsofalfacalcidol,calcitriol,colecalciferol,dihydrotachysterol,ergocalciferol,paricalcitolandvitaminDpossiblyreducedbyDACTINOMYCIN;avoidanceofvitaminEadvisedbymanufacturerofIBRUTINIB TRIANGLE Diuretics:increasedriskofhypercalcaemiawhenalfacalcidol,calcitriol,colecalciferol,dihydrotachysterol,ergocalciferol,paricalcitolorvitaminDgivenwithTHIAZIDESANDRELATEDDIURETICS TRIANGLE Dopaminergics:pyridoxinereduceseffectsofLEVODOPAwhengivenwithoutdopa-decarboxylaseinhibitor TRIANGLE Lipid-regulatingDrugs:absorptionofcalcitriolpossiblyreducedbyCOLESTYRAMINE(giveatleast1hourbeforeor4to6hoursaftercolestyramine)lRetinoids:riskofhypervitaminosisAwhenvitaminAgivenwithlRETINOIDS—avoidconcomitantuse TRIANGLE Selenium:ascorbicacidpossiblyreducesabsorptionofSELENIUM(giveatleast4hoursapart) TRIANGLE Sevelamer:absorptionofcalcitriolreducedbySEVELAMER(giveatleast1hourbeforeor3hoursaftersevelamer)VoriconazoleseeAntifungals,TriazoleWarfarinseeCoumarinsWaspVenomExtractslACEInhibitors:possiblesevereanaphylactoidreactionwhenwaspvenomextractsgivenwithlACEINHIBITORSXipamideseeDiureticsXylometazolineseeSympathomimeticsYellowFeverVaccineseeVaccinesZafirlukastseeLeukotrieneReceptorAntagonistsZaleplonseeAnxiolyticsandHypnoticsZidovudineNOTEIncreasedriskoftoxicitywithnephrotoxicandmyelosuppressivedrugs—forfurtherdetailsconsultproductliterature TRIANGLE Analgesics:increasedriskofhaematologicaltoxicitywhenzidovudinegivenwithNSAIDS;plasmaconcentrationofzidovudinepossiblyincreasedbyMETHADONE TRIANGLE Antibacterials:absorptionofzidovudinereducedbyCLARITHROMYCINtablets(giveatleast2hoursapart);manufacturerofzidovudineadvisesavoidconcomitantusewithRIFAMPICIN TRIANGLE Antiepileptics:zidovudineincreasesordecreasesplasmaconcentrationofFOSPHENYTOINandPHENYTOIN;plasmaconcentrationofzidovudinepossiblyincreasedbySODIUMVALPROATEandVALPROICACID(increasedriskoftoxicity)lAntifungals:plasmaconcentrationofzidovudineincreasedbylFLUCONAZOLE(increasedriskoftoxicity) TRIANGLE Antimalarials:increasedantifolateeffectwhenzidovudinegivenwithPYRIMETHAMINE1258Appendix1InteractionsBNF70Interactions|Appendix1"
"Zidovudine(continued)lAntivirals:profoundmyelosuppressionwhenzidovudinegivenwithlGANCICLOVIRorlVALGANCICLOVIR(ifpossibleavoidconcomitantadministration,particularlyduringinitialganciclovirorvalganciclovirtherapy);increasedriskofgranulocytopeniawhenzidovudinegivenwithlNEVIRAPINE;increasedriskofanaemiawhenzidovudinegivenwithlRIBAVIRIN—avoidconcomitantuse;zidovudinepossiblyinhibitseffectsoflSTAVUDINE(manufacturersadviseavoidconcomitantuse);plasmaconcentrationofzidovudinereducedbylTIPRANAVIR TRIANGLE Atovaquone:plasmaconcentrationofzidovudineincreasedbyATOVAQUONE(increasedriskoftoxicity)lOrlistat:absorptionofzidovudinepossiblyreducedbylORLISTATZinc TRIANGLE Antibacterials:zincreducesabsorptionofCIPROFLOXACIN,LEVOFLOXACIN,MOXIFLOXACINandOFLOXACIN;zincreducesabsorptionofNORFLOXACIN(giveatleast2hoursapart);zincreducesabsorptionofTETRACYCLINES,alsoabsorptionofzincreducedbytetracyclines TRIANGLE CalciumSalts:absorptionofzincreducedbyCALCIUMSALTS TRIANGLE Eltrombopag:zincpossiblyreducesabsorptionofELTROMBOPAG(giveatleast4hoursapart) TRIANGLE IronSalts:absorptionofzincreducedbyoralIRONSALTS,alsoabsorptionoforalironsaltsreducedbyzinc TRIANGLE Penicillamine:absorptionofzincreducedbyPENICILLAMINE,alsoabsorptionofpenicillaminereducedbyzinc TRIANGLE Trientine:absorptionofzincreducedbyTRIENTINE,alsoabsorptionoftrientinereducedbyzincZoledronicAcidseeBisphosphonatesZolmitriptansee5HT1-receptorAgonists(underHT)ZolpidemseeAnxiolyticsandHypnoticsZonisamidelAntidepressants:anticonvulsanteffectofantiepilepticspossiblyantagonisedbyMAOISandlTRICYCLIC-RELATEDANTIDEPRESSANTS(convulsivethresholdlowered);anticonvulsanteffectofantiepilepticsantagonisedbylSSRISandlTRICYCLICS(convulsivethresholdlowered) TRIANGLE Antiepileptics:plasmaconcentrationofzonisamidereducedbyCARBAMAZEPINE,FOSPHENYTOIN,PHENOBARBITAL,PHENYTOINandPRIMIDONElAntimalarials:anticonvulsanteffectofantiepilepticsantagonisedbylMEFLOQUINElAntipsychotics:anticonvulsanteffectofantiepilepticsantagonisedbylANTIPSYCHOTICS(convulsivethresholdlowered) TRIANGLE Diuretics:manufacturerofzonisamideadvisesavoidconcomitantusewithCARBONICANHYDRASEINHIBITORSinchildrenlOrlistat:possibleincreasedriskofconvulsionswhenantiepilepticsgivenwithlORLISTATZopicloneseeAnxiolyticsandHypnoticsZuclopenthixolseeAntipsychoticsBNF70Appendix1Interactions1259Interactions|Appendix1"
[]
